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Dyslipidemia has a complex pathophysiology consisting of various genetic, lifestyle, and 
environmental factors. It has many adverse health impacts, notably in the development 
of chronic non-communicable diseases. Significant ethnic differences exist due to the 
prevalence and types of lipid disorders. While elevated serum total- and LDL-cholesterol 
are the main concern in Western populations, in other countries hypertriglyceridemia 
and low HDL-cholesterol are more prevalent. The latter types of lipid disorders are 
considered as components of the metabolic syndrome. The escalating trend of obesity, as 
well as changes in lifestyle and environmental factors will make dyslipidemia a global 
medical and public health threat, not only for adults but for the pediatric age group as 
well. Several experimental and clinical studies are still being conducted regarding the 
underlying mechanisms and treatment of dyslipidemia. The current book is providing 
a general overview of dyslipidemia from diverse aspects of pathophysiology, ethnic 
differences, prevention, health hazards, and treatment.
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Preface 
The term dyslipidemia origins from dys- + lipid (fat) + -emia (in the blood), and
essentially refers to serum lipid disorders. By definition, dyslipidemia is a disorder
of lipoprotein metabolism in terms of either lipoprotein overproduction or
deficiency. It may be expressed by increased serum total cholesterol, low-density
lipoprotein cholesterol and/or triglycerides, a decrease in high-density lipoprotein
cholesterol concentration, and/or various combinations of such disorders.
Lipoproteins, which contain lipids and proteins (apolipoproteins), are mainly
responsible for transporting plasma lipids from the intestines and liver to peripheral
tissues.
Dyslipidemia has a complex pathophysiology consisting of various genetic, lifestyle,
and environmental factors. It has many adverse health impacts, and has a pivotal role
in the development of chronic non-communicable diseases.
Significant ethnic differences exist due to the prevalence and types of lipid
disorders. While elevated serum total and LDL-cholesterol are the main concern in
Western populations, in other countries hypertriglyceridemia and low HDL-
cholesterol are more prevalent. The latter types of lipid disorders are considered as
components of the metabolic syndrome, which is a clustering of dyslipidemia, 
hypertension, dysglycemia, and obesity. The rapid escalating trend of obesity at 
global level, which is associated with obesogenic milieus through high-calorie intake
and sedentary lifestyle, as well as the environmental factors, will result in increasing
prevalence of dyslipidemia, and will make it a global medical and public health
threat. 
This situation is not limited to adults, and the pediatric age group is being involved 
more and more. The results of longitudinal studies support the association of risk
factors cluster in children and adolescents with future chronic diseases.
However, the processes by which lipids and lipoproteins participate in the
development of non-communicable diseases at different life stages continue to be an 
area of controversy. Several experimental and clinical research studies are being 
conducted regarding issues related to the underlying mechanisms and therapeutic
modalities.
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Obesity Related Lipid Profile and Altered  
Insulin Incretion in Adolescent with  
Policystic Ovary Syndrome  
Annamaria Fulghesu and Roberta Magnini 
Department of Obstetrics and Gynecology, University of Cagliari, Cagliari,  
Italy 
1. Introduction 
Polycystic ovary syndrome (PCOS) is the most common female endocrine disorder, present in 
5 – 7% of women of reproductive age. The diagnosis of PCOS was made according to 
Rotterdam criteria in presence of at least two of the following: 1) oligomenorrhea and/or 
anovulation; 2) hyperandrogenism (clinical and/or biochemical); 3) polycystic ovaries with the 
exclusion of other etiologies (1). The disorder is characterized by irregular menstrual cycle, 
chronic anovulation and hyperandrogenism. Women with PCOS demonstrate marked clinical 
heterogeneity: the commonly associated features of hirsutism, acne, polycystic-appearing 
ovaries, obesity and acanthosis nigricans are neither uniform nor universal (2-3). In time the 
disorder may lead to onset of hyperinsulinemia, insulin resistance, gestational diabetes, early 
onset of type 2 diabetes mellitus (DM), dyslipidemia and cardiovascular disease (CVD) (4-5). 
PCOS is characterized by a complex physiology implicating an interaction with 
environmental and genetic factors, resulting in a broad spectrum of reproductive and 
metabolic disorders. (6-7) Adult females with PCOS may be at increased risk for 
atherosclerotic cardiovascular disease (CVD) due to increased prevalence of obesity and 
central adiposity as well as to hypertension, hyperinsulinemia, type 2 DM, and dyslipidemia 
in these patients (8).The prevalence of obesity and consequently the presence of metabolic 
abnormalities reported in Italian and American published studies differs considerably, 
underlining the presence of important ethnic differences. (9, 10, 11, 12). 
A percentage ranging from 30-75% of women with PCOS are obese, European women 
generally weighing less than their American counterparts (20,21). Hyperinsulemia and/or 
insulin resistance (IR) are frequently manifested in obese, and to a lesser extent (50%) in 
lean, PCOS patients (3, 13, 14). Hyperandrogenaemia, hyperinsulemia and obesity are 
considered as risk factors for the development of hypertension and dyslipidemia, diabetes 
mellitus and coronary disease in PCOS (15-16). The causes of metabolic disorders in PCOS 
remain to be clarified, but include obesity-related IR, an intrinsic abnormality of 
postreceptor insulin signaling (e.g. excess serine phosphorylation), and abnormal insulin 
secretion. On the other hand, increased resistance to insulin is a hallmark of the onset of 
normal pubertal development with natural to pre-pubertal values at the end of puberty in 
non-obese subjects. Consequently, in early adolescence a physiological resistance to insulin 
should be taken into account (12). 
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Dyslipidemia in PCOS is frequently manifested and is characterized by elevated plasma 
levels of low- density lipoproteins (LDL), very-low-density lipoproteins (VLDL) and 
triglycerides with concomitantly reduced concentration of high-density lipoproteins (HDL) 
in obese subjects (17, 18). A decrease in HDL, rise in triglyceride, VLDL, and LDL levels, as 
well as qualitative disorders of the LDL have all been described in young and adult PCOS 
(19). Moreover, recent data have shown a higher prevalence of metabolic syndrome in 
adolescent PCOS compared to controls (20) as well as an early impairment of endothelial 
structure and function even in non-dyslipidemic subjects with PCOS syndrome (21). 
Nevertheless, metabolic disorders in PCOS have not been extensively studied in the 
adolescent population. Several studies have shown how both lean and obese adolescents 
with PCOS appear to present an increased risk of both metabolic disorders and impaired 
glucose tolerance and diabetes (22), similar to their adult counterparts. A previous study 
carried out by our group demonstrated that the Italian young PCOS population is 
characterized by a high incidence of insulin alterations also in presence of normal weight 
and normal peripheral insulin resistance (12). Although the prevalence of dyslipidemia 
differs between PCOS subjects and young healthy girls, it however remains to be clarified 
whether dissimilarities in dyslipidemia occur in relation only to BMI or also to alterations to 
the insulinmetabolism and/or hyperandrogenemia. 
Carmina recently demonstrated that MBS in women with PCOS is less common in Southern 
Italy compared to rates reported in the USA, the former reaching only 8.2% compared to a 
prevalence of 43-46% reported by US authors (23). The prevalence of MBS in the adult 
Italian PCOS population is higher than in control population matched for BMI, suggesting 
that body weight may be only in part responsible for this metabolic disorder (24). 
Although few studies have investigated the latter condition in adolescents, it could prove to 
be of considerable importance in view of the health implications involved, requiring medical 
counseling to implement an adequate change in lifestyle. Likewise, obesity rate in 
adolescent PCOS subjects differs between Europe and the USA. In Sardinia, the incidence of 
obesity is lower than throughout the rest of Italy, with only 3-4% of high school female 
population presenting a BMI >25 (25). A combination of genetic factors, different lifestyle 
and diet are likely involved. In view therefore of the regional peculiarity, the patient 
population attending our Clinic was deemed to be of interest. 
Therefore it is important to understand the relationship between lipid pattern and BMI, 
hyperinsulinemia and/or insulin resistance and circulating androgens in adolescent PCOS. 
In a study carried out in July 2005 to the Adolescent Center for gynecological diseases of the 
Department of Obstetrics and Gynecology, University of Cagliari, San Giovanni di Dio 
Hospital seventy-one adolescent (age 13-18) subjects affected by PCOS were recruited for 
this study. On the basis of the various aspects linking PCOS dyslipidemia and CVD risk, the 
present study was designed to investigate the influence of BMI and insulin metabolism 
derangement on lipid levels. All subjects were screened for other causes of 
hyperandrogenism, such as androgen secreting tumors and congenital adrenal hyperplasia 
(tested by evaluation of 17- dydroxyprogesterone). All subjects were euthyroid and devoid 
of hyperprolactinemia, diabetes mellitus and cardiovascular disease. No subjects had taken 
hormonal contraceptives or other type of medication or been on a diet that may have 
affected lipid profile, carbohydrate metabolism or insulin levels for at least 3 months 
preceding the study. No subjects were either smokers or drinkers. No subjects practiced 
sports on a regular basis (3 or more 20-min sessions of aerobic exercise per week). 
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These patients were linked with a control group consisting of healthy patients referred to 
the Adolescent centre for ultrasound screening of ovarian disease. 
Control subjects and PCOS were studied 5 to 8 days following menstrual bleeding, which 
was progestin-induced in amenorrhoic patients. All patients were studied at least 15 days 
following Medrossi-Progesteron-Acetate administration (MAP 10 mg for 5 days). At the 
time of admittance to the study the presence of a dominant follicle, recent ovulation, or 
luteal phase was excluded by ultrasound examination and serum P evaluation. Height and 
weight were measured on the morning of testing. Waist and hip circumference were 
measured as previously referred. Blood pressure was measured in the second position and 
in the right arm (26) after 15 minutes resting.The hormonal study (after 12 hours overnight) 
included baseline plasma determination of LH, FSH, Estradiol (E2), Androstenedione (A), 
Testosterone (T), Dehydroepiandrosteronesulphate (DHEAS), 17hydroxyprogesterone (17-
OHP) and Sex-hormone-binding globulin (SHBG). Lipid assay was performed to measure 
total cholesterol level, high-density lipoprotein cholesterol level (HDL), low-density 
lipoprotein cholesterol level (LDL) and triglyceride level. Homocysteine levels were also 
determined. 
Adolescents meeting three or more of the following criteria were diagnosed with MBS: waist 
circumference of at least 90th percentile for age and gender; systolic or diastolic blood 
pressure at least 90th percentile for age, height and gender; fasting TG at least 110mg/dl 
(90th percentile for age); fasting HDL not exceeding 40mg/dl (10th percentile for age); and 
fasting glucose at least 110mg/dl. 
Subsequently, patients underwent a 75-g oral glucose tolerance test (OGTT). Insulin, C-
peptide, and glucose serum concentrations were analyzed prior to (time 0) and 30, 60, 90, 
120 and 180 min after oral glucose load. A normal glycemic response to OGTT was defined 
according to the criteria of the National Diabetes Data Group (27). Insulin, C-peptide and 
glucose response to glucose load were expressed as area below the curve (AUC), calculated 
according to the trapezoidal rule. The homeostatic index of IR (HOMA) was calculated as 
follows: HOMA = [fasting insulin (μU/ml) x fasting glucose (mmol/L/22, 5)]. (28) The body 
mass index (BMI) was calculated according to the following formula: body weight in 
kilograms/ height in m2. Normal weight was considered as 18 ≤ BMI ≥ 25. The degree of 
hirsutism was quantified using Ferriman and Gallwey (F-G) score (28). 
No differences were observed with regard to the presence of overweight and obese subjects 
between PCOS and controls (30% vs. 23%); a similar finding was obtained also for waist 
measurement and WHR, confirming that obesity is not a common finding in young PCOS 
subjects in the population studied.Moreover, no subjects affected by metabolic Syndrome or 
diabetes either among PCOS or in the control group were detected. No differences were 
revealed in lipid levels between PCOS and controls. In addition, no differences were 
reported for any of the fasting metabolic parameters (i.e. Glucose fasting insulin, HOMA 
ratio), whilst a higher insulin response under OGTT was obtained for PCOS subjects. On the 
other hand, statistical correlations clearly demonstrated the influence produced by BMI and 
waist measurement on HDL, triglyceride and LDL levels. However, dividing the population 
into tertiles for BMI and waist measurement significant differences were revealed for both 
HDL and LDL levels in lean overweight and obese subjects and in relation to the presence of 
visceral fat.The above features have also been reported by several authors carrying out 
studies on young subjects. 
Glueck published a study regarding PCOS and regular cycling adolescents in USA 
demonstrating a higher prevalence of obesity and dyslipidemia in PCOS. 
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These patients were linked with a control group consisting of healthy patients referred to 
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HDL and LDL levels in lean overweight and obese subjects and in relation to the presence of 
visceral fat.The above features have also been reported by several authors carrying out 
studies on young subjects. 
Glueck published a study regarding PCOS and regular cycling adolescents in USA 
demonstrating a higher prevalence of obesity and dyslipidemia in PCOS. 
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However, when subjects were matched one-by-one for BMI and age, differences in lipids 
were no longer significant. In a recent paper on young obese subjects Shroff failed to 
demonstrate any difference in lipid as well as traditional CV factors in PCOS and control 
populations, but demonstrated a higher BMI in subjects presenting subclincal coronary 
atherosclerosis (CAC) (10). In young subjects from southern Italy, Orio demonstrated 
normal lipid levels in lean PCOS even in the presence of increased dimensions of heart 
ventricles.The above findings all seem to indicate that rather than being an insulin-
correlated factor BMI may well be implicated in lipid alteration. On the other hand, the 
presence of increased waist measurements in PCOS population suggests that the presence of 
visceral fat may represent an additional risk factor, independent from BMI in PCOS. The 
influence of insulin on lipid profile was also determined. 
Indeed, to date very few authors have investigated this aspect: Mather found a significant 
increase in traditional CV risk factors in PCOS women with fasting hyperinsulinemia in 
respect to their normoinsulinemic counterparts; this difference persisted when BMI was 
included as covariate. (29) Through reduction of hyperinsulinemia by means of metformin 
treatment Banazewska obtained a significant increase of HDL and reduction of triglycerides 
in a group of 43 adult PCOS. Our group recently published a paper on the peculiar insulin 
derangement observed in a population of normal weight young PCOS demonstrating a low 
incidence of insulin resistance but high incidence of hyperinsulinemia under OGTT (30). 
This peculiar metabolic alteration was confirmed in the present sample, thus allowing the 
separation of hyperinsulinemia from peripheral insulin resistance in data analysis. 
Ibanez et al. also demonstrated higher serum insulin levels after OGTT with normal insulin 
sensitivity in a population of adolescent girls with PCOS. The causes underlying the 
increased response of β-cells in these subjects are, as yet, unknown. It is not clear whether 
high levels of insulin necessarily indicate the presence of a disorder although it may be 
hypothesized that adaptation to the chronic risk of hypoglycemia in hyperinsulinemic 
subjects could lead to IR after some time. Moreover, our group recently demonstrated that a 
normal HOMA score is not sufficient to exclude earlymetabolic abnormalities such as 
hyperinsulinemia in young lean PCOS subjects. Hyperinsulinemia per se could contribute 
toward onset of hyperandrogenism independently of peripheral IR.(12) 
In this study was found a significant negative correlation between HDL and fasting insulin 
and HOMA, but this correlation was no longer significant when the influence of BMI was 
excluded, whereas insulin AUC was not related to any lipid parameters. 
Furthermore, although the PCOS sample studied here was divided into tertiles on the basis 
of both insulin resistance and insulin AUC levels, the data obtained clearly indicate the 
failure to detect any relationship between insulin levels and lipid profile. Nevertheless, 
surprisingly a positive correlation was observed between A levels and HDL and a negative 
correlation between A and triglycerides. Reports present in literature did not afford any 
explanation for this result. A negative effect of A on HDL levels has previously been 
reported in males to whom A supplements had been administered (31). Moreover, 
exogenous T is reported to influence negatively HDL via hepatic lipase (HL) (31) an enzyme 
that increases the clearance of HDL. Less is known about the regulation of HDL by 
endogenally-derived androgens. A study performed in women with PCOS was not able to 
demonstrate any correlation between T and HDL. Considerable controversy exists as to the 
effect of androgens on lipoprotein lipase (LPL) activity. 
In obese women LPL activity correlated positively with plasma free testosterone (32), 
whereas in women with PCOS a correlation with LPL activity was demonstrated. 
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Other authors have attributed to coexisting (29) insulin resistance the negative effect of 
androgen observed on lipid profile. In this case, the low incidence of insulin resistant 
subjects in a population may explain this unexpected result. 
In conclusion, no lipid differences were revealed between our population of adolescent 
PCOS from southern Italy and controls. 
Anthropometric characteristics (BMI, waist measurement and WHR) are the main 
parameters correlated to lipid derangement, confirming the importance of treating obesity at 
an early age to prevent onset of complex metabolic syndromes in the future. The latter may 
be of particular importance in PCOS populations in which insulin alterations 
(hyperinsulinemia and insulin resistance) are well known peculiarities potentially capable of 
influencing the long-term evolution of this endocrine disorder towards CVD and diabetes 
mellitus. A targeted support program should be set up for these young patients aimed at 








Age (years) (M±ES) (range 13-19) 18,61 ± 0,4 18,10 ± 0,38 NS 
BMI (kg\m2) (M±ES) 23,97 ± 0,72 22,56 ± 0,50 NS 
Overweight (BMI 25 - 29) (%) 10% 11%  
Obesity (BMI > 29) (%) 20% 13%  
Waist (cm) (M±ES) 78,60 ± 1,79 75,56 ± 1,18 NS 
WHR (M±ES) 0,77 ± 0 0,77 ± 0 NS 
Hirsutism (score F&G) (M±ES) 11,24 ± 0,67 6,7 ± 0,45 0,005° 
LH (IU/L)(M±ES) 5,21 ± 0,55 4,19 ± 0,36 NS 
FSH (IU/L)(M±ES) 6,42 ± 0,63 5,96 ± 0,19 NS 
E2 (pmol/L)(M±ES) 129,30 ± 20,58 136,81 ± 13,25 NS 
A (nmol/L)(M±ES) 0,08 ± 0 0,05 ± 0 0,005° 
Tot T(nmol/L)(M±ES) 0,02 ± 0 0,01 ± 0 0,005° 
17OHP (ng/mL)(M±ES) 1,49 ± 0,18 1,18 ± 0,07 NS 
DHEAS (μmol/L)(M±ES) 2,05 ± 0,12 1,6 ± 0,09 NS 
SHBG (nmol/L)(M±ES) 65,83 ± 4,54 71,18 ± 3,35 NS 
°P < 0,05 
Table 1. Shows the clinical and hormonal characteristics of PCOS population vs. Control 
group. No significant differences were revealed in age, body weight, waist and WHR 
between PCOS and control group. Likewise, no differences were observed in the incidence 
of overweight or obesity in the two groups. As expected, the prevalence of hirsutism and 
circulating androgen levels were higher amongst PCOS. 
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Table 1. Shows the clinical and hormonal characteristics of PCOS population vs. Control 
group. No significant differences were revealed in age, body weight, waist and WHR 
between PCOS and control group. Likewise, no differences were observed in the incidence 
of overweight or obesity in the two groups. As expected, the prevalence of hirsutism and 
circulating androgen levels were higher amongst PCOS. 
 








(mmol/L)(M±ES) 81,13 ± 0,65 88,00 ± 3,27 NS 
Fasting Insulin  
(pmol/L)(M±ES) 119,98 ± 6,14 96,68 ± 4,73 NS 
HOMA (M±ES) 61,02 ± 3,09 57,81 ± 2,41 NS 
I-AUC 180 min 
(UI/ml)(M±ES) 21069 ± 978,39 16578 ± 729,37 0,05 
Cholesterol  
(mg/dl)(M±ES) 166,48 ± 3,53 169,51 ± 2,62 NS 
HDL-Cholesterol 
(mg/dl)(M±ES) 54,26 ± 1,44 51,25 ± 0,89 NS 
LDL-Cholesterol  
(mg/dl)(M±ES) 96,78 ± 3,08 104,55 ± 2,34 NS 
Cholesterol/ HDL 
(mg/dl)(M±ES) 3,16 ± 0,09 3,37 ± 0,07 NS 
Triglycerides  
(mg/dl)(M±ES) 73,91 ± 3,75 78,35 ± 3,86 NS 
Homocysteine  
(mol/L) (M±ES) 8,16 ± 0,20 7,68 ± 0,25 NS 
PCR (M±ES) 2,04 ± 0,36 0,89 ± 0,11 NS 
 
° P < 0,05 
Table 2. Reports the metabolic features of PCOS and control group. Fasting metabolic 
indexes detected for glucose, insulin and HOMA were similar between the two groups. On 
the contrary, insulin secretion after glucose load (I-AUC) was significantly higher in PCOS 
subjects. Total cholesterol, HDL, LDL, triglycerides and homocysteine levels did not differ 
between PCOS and control groups 
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BMI (kg\m2) R = 0,0727 R = 0,2579٠ R = - 0,404▪ R = 0,1576 
WAIST (cm) R = 0,0869 R = 0,2960٠ R = - 0,5934▪ R = 0,1704 
WHR (cm) R = 0,1645 R = 0,2872٠ R = - 0,1853 R = 0,1362 
A (nmol/L) R = 0,0136 R = - 0,0523 R = 0,3705▪ R = -0,2948٠ 
Tot T (nmol/L) R = - 0,1016 R = - 0,0948 R = 0,0012 R = - 0,0157 
FSH (mIU/L) R = - 0,0134 R = - 0,0143 R = 0,0623 R = - 0,0687 
E2(pmol/L) R = - 0,1011 R = - 0,0895 R = 0,0698 R = - 0,1984 
DHEAS (μmol/L) R = - 0,0498 R = - 0,0022 R = - 0,0447 R = - 0,0441 
HOMA R = 0,0762 R = 0,1770 R = -0,3335 R = - 0,0214 
I-AUC 180 min(UI/ml) R = - 0,0098 R = - 0,0272 R = - 0,0701 R = - 0,0287 
SHBG (nmol/L) R = - 0,0689 R = - 0,1514 R = 0,1102 R = 0,1013 
17OHP (nmol/L) R = 0,0418 R = 0,0582 R = 0,0854 R = - 0,1720 
Homocysteine (mol/L) R = - 0,0670 R = - 0,0786 R = 0,0463 R = - 0,1108▪ 
Fasting Glucose R = 0,0049 R = 0,0260 R = -0,0829 R = 0,0643 
Fasting Insulin R = 0,0586 R = 0,1557 R = -0,3314 R = -0,0174 
P < 0,05 
P < 0,01 
P < 0,001 
Table 3. Illustrates linear regression relationship featured between lipid and physical, 
hormonal and metabolic parameters. Total cholesterol levels were significantly related to 
WHR but not to other antropometric parameters. On analyzing cholesterol fractions LDL 
levels were found to correlate positively with BMI, Waist, WHR and HOMA but not with I-
AUC. HDL results correlated in a markedly negative manner with the same physical 
parameters as BMI, WHR and waist circumference. Moreover, HDL was negatively 
correlated with both fasting insulin and HOMA but not I-AUC. Finally, HDL was positively 
correlated with circulating A and negatively with circulating T levels. 
Triglycerides appeared to correlate positively with BMI, Waist and WHR, and negatively 
with A levels. Homocysteine levels correlated positively with plasma triglyceride content. In 
view of the potential capacity of BMI to affect insulin sensitivity, conditional regression 
analysis was performed on HOMA and lipid assays to exclude any possible influence of 
BMI: HOMA resulted as being no longer correlated with any lipid parameter.To determine 
whether lipid alterations were primarily caused by increased BMI, lipid assay was repeated 
stratifying the population into 3 weight categories: normal weight, overweight and obese, 
and waist measurements were classified (normal and excessive). 
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Fig. 1. Shows the lipid levels in relation to the BMI and the waist of PCOS group.Normal 
weight and normal waist subjects featured lower LDL and Higher HDL compared to 
increased waist overweight or obese counterparts. On the other hand, in order to evaluate 
the influence of metabolic alteration subjects were also stratified on the basis of both HOMA 
and Insulin AUC values (fig.2). 
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Fig. 2. Shows lipid levels in subjects divided into tertiles for both HOMA and Insulin AUC 
levels. Similar lipid values were demonstrated in all subjects. 
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Fig. 1. Shows the lipid levels in relation to the BMI and the waist of PCOS group.Normal 
weight and normal waist subjects featured lower LDL and Higher HDL compared to 
increased waist overweight or obese counterparts. On the other hand, in order to evaluate 
the influence of metabolic alteration subjects were also stratified on the basis of both HOMA 
and Insulin AUC values (fig.2). 
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 Cholesterol LDL-Cholesterol 
HDL-
Cholesterol Triglycerides 
BMI (kg\m2) R = 0,0800 R = - 0,0017 R = - 0,4762▪ R = 0,6962 
WAIST (cm) R = 0,1410 R = 0,0753 R = - 0,4253▪ R = 0,6765 
WHR (cm) R = 0,0326 R = - 0,1535 R = - 0,1878 R = 0,4262 
A (nmol/L) R = - 0,1921 R = - 0,0280 R = - 0,1845 R = 0,0007 
Tot T (nmol/L) R = - 0,3425 R = - 0,4544▪ R = - 0,1377 R = 0,3692 
FSH (IU/L) R = 0,3094 R = 0,3909▪ R = 0,3711▪ R = - 0,1603 
E2(pmol/L) R = 0,0150 R = 0,0124 R = - 0,0264 R = - 0,0876 
DHEAS (μmol/L) R = 0,1230 R = 0,1925 R = - 0,1793 R = 0,2206 
SHBG (nmol/L) R = - 0,2226 R = - 0,2834 R = 0,0655 R = - 0,0942 
17OHP (nmol/L) R = - 0,0925 R = - 0,0586 R = 0,1667 R = - 0,3703▪ 
HOMA R = 0,4724 R = 0,5140 R = 0,2293 R = - 0,0123 
I-AUC 180 
min(UI/ml) R = - 0,0021 R = 0,0331 R = - 0,3391 R = 0,2882 
Homocysteine 
(mol/L) R = 0,2148 R = 0,1214 R = - 0,2604 R = 0,5656▪ 
Fasting Glucose R = 0,0440 R = 0,1325 R = - 0,1952 R = - 0,0396 
Fasting Insulin R = 0,1226 R = 0,1315 R = 0,0435 R = 0,0972 
 
P < 0,05 
P < 0,01 
P < 0,001 
Table 4. Linear relationships between lipid assays and phisical endocrine and metabolic 
parameters in CONTROLS. 
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BMI (kg\m2) R = 0,1058 R = 0,2252 R = - 0,3930 R = 0,2933 
WAIST (cm) R = 0,1298 R = 0,2624 R = -0,3756 R = 0,2856 
WHR (cm) R = 0,2174 R = 0,3039 R = - 0,1924 R = 0,2063 
E2(pmol/L) R = - 0,0912 R = - 0,0912 R = 0,0541 R = - 0,1495 
A (nmol/L) R = - 0,0401 R = - 0,0953 R = 0,2933 R = -0,2400 
Tot T (nmol/L) R = - 0,1848 R = - 0,2191 R = 0,0181 R = 0,0085 
SHBG (nmol/L) R = - 0,1260 R = -0,1973 R = 0,1038 R = 0,0368 
Fasting Glucose R = 0,0107 R = 0.0800 R = - 0,1425 R = -0,0092 
Fasting Insulin R = 0,0773 R = 0,1239 R = - 0,1960 R = 0,0109 
HOMA R = 0,1349 R = 0,2269 R = - 0,2800▪ R = 0,0021 
I-AUC 180 min(UI/ml) R = 0,0324 R = 0,0550 R = - 0,0930 R = 0,0123 
Homocysteine (mol/L) R = 0,0764 R = 0,0209 R = - 0,0656 R = 0,2863▪ 
P < 0,05 
P < 0,01 
P < 0,001 
Table 5. Linear relationships between lipid assays and phisical endocrine and metabolic 
parameters in all patients. 
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Dyslipidaemia is a major cardiovascular disease (CVD) risk factor that plays an important 
role in the progress of atherosclerosis, the underlying pathology of CVD. To keep lipids and 
lipoproteins levels within ideal range has been recommended by different national, regional, 
or global (2001; Graham et al. 2007; World Health Organization 2007) guidelines on the 
prevention and management of CVD. The prevalence and pattern of lipid disorder, 
however, differ between ethnicities and populations. 
As a component of the metabolic syndrome, dyslipidaemia often coexists with diabetes, 
the coronary heart disease (CHD) risk equivalent. An atherogenic lipid profiles consists of 
high triglycerides (TG) and small dense low-density lipoprotein cholesterol (LDL-C) and 
low high-density lipoprotein cholesterol (HDL-C). The importance of dyslipidaemia on 
risk of CVD in patients with diabetes has been extensively studied in numerous studies. 
Reduced HDL-C is well documented as an independent predictor of CVD events (Wilson 
et al. 1988; Cooney et al. 2009). In contrast, the role of TG as an independent risk factor for 
CVD is more controversial (Patel et al. 2004; Psaty et al. 2004; Barzi et al. 2005; Sarwar et 
al. 2007; Wang et al. 2007). Recently, the interest to use novel parameters such as total 
cholesterol (TC) to HDL ratio (TC/HDL-C), non-HDL-cholesterol (non-HDL-C), 
apolipoprotein B (apoB) and apolipoprotein A (apoA) to assess CVD risk has increased 
(Barzi et al. 2005; Pischon et al. 2005; Charlton-Menys et al. 2009). As a CVD risk predictor, 
the non-HDL-C has been considered to be superior to LDL-C (Cui et al. 2001; Schulze et 
al. 2004; Liu et al. 2005; Ridker et al. 2005). However, there are racial and geographic 
disparities in lipid profiles not only in general populations but also in individuals with 
different glucose categories. The Third Report of the National Cholesterol Education 
Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol 
in Adults (NCEP-ATP III) has recommended that certain factors be recognized when 
clinicians evaluate the lipid profile of different population groups (Adult Treatment Panel 
III 2002). Although management of lipids using NCEP-ATP III guidelines is applicable to 
all populations, unique aspects of risk factor profile call for special attention to certain 
features in different racial/ethnic groups. 
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2. Ethnic differences in lipid profiles in general populations 
The prevalence of dyslipidaemia varies depending on the population studied, geographic 
location, socioeconomic development and the definition used (Wood et al. 1972; Mann et al. 
1988; Onat et al. 1992; Berrios et al. 1997; Ezenwaka et al. 2000; Foucan et al. 2000; Hanh et al. 
2001; Zaman et al. 2001; Azizi et al. 2003; Florez et al. 2005; Li et al. 2005; Hertz et al. 2006; Pang 
et al. 2006; Pongchaiyakul et al. 2006; Tekes-Manova et al. 2006; Zhao et al. 2007; Erem et al. 
2008; Steinhagen-Thiessen et al. 2008). Caucasians generally have higher mean TC 
concentrations than do populations of Asian or African origin (Fuentes et al. 2003; Tolonen et 
al. 2005). In general populations, the highest prevalence of hypercholesterolaemia (TC ≥ 
6.5mmol/l) has been seen in Malta (up to 50% in women) and the lowest in China (2.7% in 
men) in the World Health Orgnization (WHO) Inter-Health Programme (Berrios et al. 1997). 
However, inhabitants of the developing world now have had access to more fats in their diets 
and more sedentary lives; therefore the disease is becoming an increasing problem there. 
Ethnic differences in the risk of CVD and type 2 diabetes have consistently been identified, 
with the most studies comparing the risk between African-Americans and Whites. African-
Americans usually display a more favorable lipid profile compared with Whites, despite 
having the highest overall mortality rates from CVD. In general, African-American men 
have similar or lower LDL-C and TG but higher HDL-C levels compared with White men. 
There is evidence that the difference in HDL-C between African-American and White men 
may be due to a relatively lower hepatic lipase activity in African-Americans (Vega GL 
1998). The difference in TG may be related to increased activity of lipoprotein lipase in 
African-Americans (Sumner AE 2005). However, compared with Whites, Hispanics and 
Asians, African-Americans have less favorable levels of lipoprotein(a) (Lp[a]), which is 
structurally similar to LDL-C, with an additional disulfide linked glycoprotein termed 
ApoA. A number of studies have suggested that Lp(a) may be an important risk factor for 
CVD (Danesh J 2000; The Emerging Risk Factors C 2009).  
Compared to non-Hispanic Whites, Hispanics, specifically Mexican-Americans, have 
demonstrated lower HDL-C and higher TG levels (Sundquist J 1999). Data from the Dallas 
Heart Study and a smaller cross-sectional analysis of healthy individuals confirm that levels 
of Lp(a) are likely similar or even lower in Hispanics compared with Whites (Tsimikas S 
2009). Although Lp(a) levels have been associated with endothelial dysfunction in 
Hispanics, the relationship with coronary artery disease in this population is less clear.  
Asian Indians exhibit a higher prevalence of diabetes mellitus than Chinese and Malays 
(Tan et al. 1999). They also have higher serum TG concentrations and lower HDL-C 
concentrations than Chinese (Gupta M 2006). In the HeartSCORE and IndiaSCORE studies 
(Mulukutla et al. 2008) where lipids were measured with the same assay procedures for 
Asian Indians as for Whites and Blacks, Asian Indians had lowest TC and HDL-C and 
highest TG among all the ethnic groups studied. In another multi-ethnic study of the 1992 
Singapore National Health Survey (Tan et al. 1999), Asian Indians appeared to have lower 
HDL-C but higher TG levels compared with the Chinese group. Data in other racial/ethnic 
groups are somewhat limited. Mean total cholesterol and LDL-C levels are lower in 
American Indians compared with the US average, and levels of Lp(a) are reported to be 
lower than in Whites (Wang W 2002). East Asians tend to have lower LDL-C, HDL-C and 
TG as compared with non-Asians (Karthikeyan et al. 2009). East Asians have been reported 
to have low Lp(a) levels, whereas south Asians have higher mean Lp(a) levels (Geethanjali 
FS 2003; Berglund L 2004). 
 
Ethnic Difference in Lipid Profiles 
 
17 
Globalization of the western lifestyle contribute to worldwide increases of adiposity and 
type 2 diabetes not only in adults but also in children and adolescents (Kelishadi et al. 2006; 
Schwandt et al. 2010). In the BIG Study comparing the prevalence of the metabolic 
syndrome components in children and adolescents of European, Asian and South-American 
ethnicities, Iranian and Brazilian youths had considerably higher prevalence of 
dyslipidaemia than German youths. The most remarkable ethnic difference detected in this 
study is the high prevalence of low HDL-C levels in Iranian children and adolescents (38%) 
compared with German youths (7%) (Schwandt et al. 2010). Future longitudinal studies 
should seek the clinical importance of these ethnic differences. 
3. Ethnic differences in lipid profiles in the state of hyperglycaemia 
3.1 Lipid disorder and CVD risk in individuals with hyperglycaemia 
Lipids and lipoproteins abnormalities are major metabolic disorders, commonly including 
elevated levels of TC, LDL-C, Lp(a) and TG and reduced levels of HDL-C. In patients with 
type 2 diabetes, a CHD equivalent (Juutilainen et al. 2005), it is most commonly 
characterized by elevated TG and reduced HDL-C (Goldberg, I. J. 2001; Krauss 2004; 
Kendall 2005). There is increasing evidence that the diabetic dyslipidaemia pattern is 
common not only in patients with overt diabetes (Barrett-Connor et al. 1982) but also in 
individuals with different glucose categories, i.e., impaired glucose tolerance (IGT) or 
impaired fasting glucose (IFG) (Meigs et al. 2002; Novoa et al. 2005; Chen et al. 2006; 
Pankow et al. 2007). These abnormalities can be present alone or in combination with other 
metabolic disorders. It is well known that the risk of morbidity and mortality from CVD is 
increased by two- to four-fold in diabetic patients compared with the general population 
(Kannel 1985; Morrish et al. 1991; Almdal et al. 2004). A number of studies have determined 
the association of dyslipidaemia with cardiovascular risk in people with hyperglycaemia, 
and most of them were conducted in patients with diabetes. There is a large body of 
evidence linking dyslipidaemia and cardiovascular risk in patients with diabetes against 
quite few negative reports (Vlajinac et al. 1992; Roselli della Rovere et al. 2003) on this issue. 
Cross-sectional studies have found positive associations of atherosclerotic vascular disease 
with TC (Ronnemaa et al. 1989; Jurado et al. 2009), LDL-C (Reckless et al. 1978; Agarwal et 
al. 2009; Jurado et al. 2009), non-HDL-C (Jurado et al. 2009), TG (Santen et al. 1972; 
Ronnemaa et al. 1989; Gomes et al. 2009), apoB (Ronnemaa et al. 1989) and Lp(a) (Mohan et 
al. 1998; Murakami et al. 1998; Smaoui et al. 2004), but inverse associations with HDL-C 
(Reckless et al. 1978; Ronnemaa et al. 1989; Smaoui et al. 2004; Grant and Meigs 2007; Gomes 
et al. 2009; Jurado et al. 2009) and apoA-I (Seviour et al. 1988; Ronnemaa et al. 1989).  
Prospective data have provided with further evidence. The UKPDS study (Turner et al. 
1998) has demonstrated that high LDL-C and low HDL-C are potentially modifiable risk 
factors for coronary artery disease (CAD) in patients with type 2 diabetes. TG, however, was 
not independently associated with CAD risk in this study, possibly because of its close 
inverse relationship with HDL-C. Results from the MRFIT (Stamler et al. 1993), in which 
356,499 nondiabetic and 5163 diabetic men without CHD at baseline were followed for 12 
years, indicated that serum cholesterol is an independent predictor of CHD mortality in men 
with diabetes. Rosengren et al. (Rosengren et al. 1989) showed similar results in a 
prospective study of 6897 middle aged diabetic men. Patients with TC > 7.3 mmol/l had a 
significantly higher incidence of CHD during the 7-year follow up than those with TC ≤ 5.5 
mmol/l (28.3% vs. 5.4%, p<0.05). Long term follow-up of the London cohort of the WHO 
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Multinational Study of Vascular Disease in Diabetics, consisting of 254 type 2 diabetic 
patients, has showed that TC was associated with incidence of MI (Morrish et al. 1991) and 
overall cardiovascular mortality (Morrish et al. 1990). The role of TC in predicting CHD was 
also confirmed in women patients with diabetes (Schulze et al. 2004). 
3.2 Ethnic difference in lipid profiles across glucose categories 
Although the ethnic variation in lipid patterns has been wided studied in general 
populations, the ethnic differences in lipid profiles given the same glucose levels have not 
been well investigated. This issue has been recently studied in the DECODE (Diabetes 
Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe) and DECODA 
(Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Asia) study, which 
consisted of 64 cohorts of mainly population-based from 24 countries and regions around 
the world, with about 84 000 Europeans and 84 207 Asians of Chinese, Japanese, Indians, 
Mongolians and Filipinos.  
In the collaborative analysis of seven ethnic groups of European and Asian populations 
(studies included see Appendix 1), considerable ethnic differences in lipid profiles were 
observed within each glucose category. Asian Indians exhibited an adverse lipid pattern 
consisting of low HDL-C and high TG across all glucose categories as compared with other 
ethnic groups. Reduced HDL-C is prevalent even in Asian Indians with desirable LDL-C 
levels regardless of the diabetic status. In addition, in most of the ethnic groups, individuals 
detected with undiagnosed diabetes had a worse lipid profile than did diagnosed cases. 
Age-, cohort- and BMI adjusted mean TC, LDL-C and TG increased while the mean HDL-C 
decreased with more pronounced glucose intolerance in most of the ethnic groups in 
individuals without a prior history of diabetes (Fig. 1 a-h). Subjects with undiagnosed 
diabetes, however, had a worse lipid profile than those with known disease. Within 
individuals with normoglycaemia, mean lipid and lipoprotein concentrations differed 
among the ethnic groups. The Europeans had highest TC (Fig. 1 a-b) and LDL-C (Fig. 1 c-d), 
while Qingdao Chinese had highest HDL-C levels among all ethnic groups (Fig. 1 e-f). In 
contrast, Asian Indians had the lowest TC (Fig. 1 a-b), LDL-C (Fig. 1 c-d) and HDL-C (Fig. 1 
e-f) but the highest TG (Fig. 1 g-h) among the ethnic groups (p <0.05 for all comparisons). 
These ethnic differences were consistently found in all glucose categories. 
The multivariate-adjusted odds ratio (95% CI) of having low HDL-C was significantly 
higher for Asian Indians, Mauritian Indians, Hong Kong Chinese and Southern Europeans 
but lower for Qingdao Chinese compared with Central & North (C&N) Europeans, across 
all glucose categories from normal to diabetes (Table 1). Asian Indians and Mauritian 
Indians tended to have higher but Southern Europeans lower odds ratios for having high-
TG compared with the reference group. Unlike that for HDL-C or TG, the odds ratio for 
having high LDL-C was consistently lower in all Asian ethnic groups compared with the 
reference, across most of the glucose categories.  
In the HeartSCORE and IndiaSCORE studies (Mulukutla et al. 2008) where lipids were 
measured with the same assay procedures for Asian Indians as for whites and blacks, Asian 
Indians had lowest TC and HDL-C and highest TG among all the ethnic groups studied. In 
another multi-ethnic study of the 1992 Singapore National Health Survey (Tan et al. 1999), 
Asian Indians appeared to have lower HDL-C but higher TG levels compared with Chinese. 
The findings of these previous studies are consistent with ours although glucose status was 
not controlled in the previous studies.  
 
Ethnic Difference in Lipid Profiles 
 
19 
Similar to others (Harris and Eastman 2000; Hadaegh et al. 2008), we observed a worse lipid 
profile in individuals with undiagnosed diabetes than that of previously diagnosed patients 
in most of the ethnic groups, indicating individuals with undiagnosed diabetes are at 
increased CVD risk and need to be identified and treated early. On the other hand, 
glycaemic control is shown to be an important determinant of diabetic dyslipidaemia (Ismail 
et al. 2001). The better lipid profile in diagnosed diabetes as compared with undiagnosed 
diabetes might imply a benefit of lifestyle intervention or drug treatment targeting favorable 
metabolic profiles and hemoglobin A1c (HbA1c), a surrogate measure for average blood 
glucose. However, to what extent the levels of HbA1c have contributed to the differences is 
unknown due to the lack of information in the current study. In addition, the data on lipid-
lowering treatment is not available for most of the earlier studies conducted in the 1990s 
because the statins were not widely prescribed at that time. These deserve further 
investigation in future studies. 
In contrast to the lower HDL-C and higher TG profiles, Asian Indians had considerably 
lower TC and LDL-C concentrations than others. As shown in Table 2, 71% non-diabetic and 
57.6% diabetic Asian Indians had low LDL-C (< 3.0 mmol/l), while the corresponding 
figures were 19.2% and 24.6% (p < 0.01) for C&N Europeans and 46.6% and 38.8% (p < 0.01) 
for Qingdao Chinese. However, even within the low LDL-C category, there was still a 
higher proportion of Asian Indians having low HDL-C compared with others (Table 2). The 
results were confirmed in the same analysis conducted separately for men and women. 
There is a large body of evidence showing that diabetes is associated with a high prevalence 
of dyslipidaemia (Kannel 1985; Cowie et al. 1994; 1997; Jacobs et al. 2005; Bruckert et al. 
2007; Abdel-Aal et al. 2008; Ahmed et al. 2008; Okafor et al. 2008; Surana et al. 2008; Agarwal 
et al. 2009; Jurado et al. 2009; Papazafiropoulou et al. 2009; Roberto Robles et al. 2009; 
Temelkova-Kurktschiev et al. 2009; Zhang et al. 2009; Seyum et al. 2010). In the Framingham 
Heart Study (Kannel 1985), the prevalence of low HDL-C (21% vs. 12% in men and 25% vs. 
10% in women, respectively) and high TG levels (19% vs. 9% in men and 17% vs. 8% in 
women, respectively) in people with diabetes was almost twice as high as the prevalence in 
non-diabetic individuals. By contrast, TC and LDL-C levels did not differ from those of non-
diabetic counterparts. A similar pattern of lipid profiles was observed in the UK Prospective 
Diabetes Study (UKPDS) (1997). In this study, the plasma TG levels were substantially 
increased whereas HDL-C levels were markedly reduced in both men and women with 
diabetes compared with the non-diabetic controls. Higher prevalence has been reported in 
other studies. Data from a primary care-based 7692 patients with type 2 diabetes in the 
United States showed nearly half of the patients had low HDL-C (Grant and Meigs 2007). 
The figure was even worse in an urban Indian cohort of 5088 type 2 diabetes patients, with 
more than half having low HDL-C (52.3%) or high TG (57.9%) (Surana et al. 2008). In 
addition to the traditional lipid measurement, increased levels of apoB were also seen in 
patients with diabetes compared with non-diabetic individuals (Bangou-Bredent et al. 1999). 
It has been shown that the prevalence of lipid and/or glucose abnormality differs between 
ethnic groups. It is clear that certain ethnic groups have differences in lipid profiles in 
general. Elevated TG and reduced HDL-C, as the components of the metabolic syndrome 
and atherogenic dyslipidaemia, was seen more common in Asian Indians than in the Whites 
(Anand et al. 2000; Razak et al. 2005; Chandalia et al. 2008; Mulukutla et al. 2008), Chinese 
(Tan et al. 1999; Anand et al. 2000; Razak et al. 2005; The DECODA Study Group 2007; 
Karthikeyan et al. 2009), Japanese (The DECODA Study Group 2007; Karthikeyan et al. 
2009) or Africans (Mulukutla et al. 2008). In a nationally representative sample of seven 
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Heart Study (Kannel 1985), the prevalence of low HDL-C (21% vs. 12% in men and 25% vs. 
10% in women, respectively) and high TG levels (19% vs. 9% in men and 17% vs. 8% in 
women, respectively) in people with diabetes was almost twice as high as the prevalence in 
non-diabetic individuals. By contrast, TC and LDL-C levels did not differ from those of non-
diabetic counterparts. A similar pattern of lipid profiles was observed in the UK Prospective 
Diabetes Study (UKPDS) (1997). In this study, the plasma TG levels were substantially 
increased whereas HDL-C levels were markedly reduced in both men and women with 
diabetes compared with the non-diabetic controls. Higher prevalence has been reported in 
other studies. Data from a primary care-based 7692 patients with type 2 diabetes in the 
United States showed nearly half of the patients had low HDL-C (Grant and Meigs 2007). 
The figure was even worse in an urban Indian cohort of 5088 type 2 diabetes patients, with 
more than half having low HDL-C (52.3%) or high TG (57.9%) (Surana et al. 2008). In 
addition to the traditional lipid measurement, increased levels of apoB were also seen in 
patients with diabetes compared with non-diabetic individuals (Bangou-Bredent et al. 1999). 
It has been shown that the prevalence of lipid and/or glucose abnormality differs between 
ethnic groups. It is clear that certain ethnic groups have differences in lipid profiles in 
general. Elevated TG and reduced HDL-C, as the components of the metabolic syndrome 
and atherogenic dyslipidaemia, was seen more common in Asian Indians than in the Whites 
(Anand et al. 2000; Razak et al. 2005; Chandalia et al. 2008; Mulukutla et al. 2008), Chinese 
(Tan et al. 1999; Anand et al. 2000; Razak et al. 2005; The DECODA Study Group 2007; 
Karthikeyan et al. 2009), Japanese (The DECODA Study Group 2007; Karthikeyan et al. 
2009) or Africans (Mulukutla et al. 2008). In a nationally representative sample of seven 
 




ethnic groups in the UK (Zaninotto et al. 2007), the prevalence of low HDL-C was highest in 
south Asian groups such as Bangladeshi, Indian and Pakistani, followed by Chinese, Irish 
and those from the general population living in private households; In contrast, the lowest 
prevalence was seen in Black Caribbean. Similar finding was reported in another study 
where the comparison was made between non-South-Asians and South Asians (France et al. 
2003). In addition, African Americans have been reported to have less adverse lipid profiles 
than Whites or Hispanics despite the presence of diabetes (Werk et al. 1993; Cowie et al. 
1994; Sharma and Pavlik 2001). The causes of ethnic difference in levels of CVD risk factor 
are complex and may include genetic, environmental and cultural factors (Zaninotto et al. 
2007). However, little is known about such ethnic differences in lipid profiles at comparable 
glucose tolerance status. 
4. Causes of ethnic differences 
There are several factors that contribute to the development of dyslipidaemia (2001), 
including genetic factors (Cohen et al. 1994) and acquired factors (Chait and Brunzell 1990; 
Devroey et al. 2004; Ruixing et al. 2008) such as overweight and obesity (Denke et al. 1993; 
Denke et al. 1994; Brown et al. 2000), physical inactivity (Berg et al. 1997; Hardman 1999), 
cigarette smoking (Criqui et al. 1980; Cade and Margetts 1989; Umeda et al. 1998; Fisher et 
al. 2000; Wu et al. 2001; Maeda et al. 2003; Mammas et al. 2003; Venkatesan et al. 2006; Grant 
and Meigs 2007; Arslan et al. 2008; Batic-Mujanovic et al. 2008), high fat intake (Hennig et al. 
2001; Millen et al. 2002; Tanasescu et al. 2004), very high carbohydrate diets (> 60 percent of 
total energy) (McNamara and Howell 1992) and certain drugs (Lehtonen 1985; Fogari et al. 
1988; Roberts 1989; Middeke et al. 1990; Stone 1994) (such as beta-blockers, anabolic steroids, 
progestational agents, et al.). Excess alcohol intake is also documented as a risk factor 
(Umeda et al. 1998; Wu et al. 2001; Mammas et al. 2003) despite that moderate alcohol 
consumption may have a beneficial effect on improving HDL-C concentrations (De Oliveira 
et al. 2000; Shai et al. 2004). In addition, glycaemic control is an important determinant of 
dyslipidaemia in patients with diabetes (Ismail et al. 2001; Grant and Meigs 2007; Ahmed et 
al. 2008; Gatti et al. 2009). Among these acquired factors, overweight, obesity and physical 
inactivity appear to be most important (Denke et al. 1993; Denke et al. 1994; Berg et al. 1997; 
Hardman 1999; Brown et al. 2000). They are also the most important lifestyle variables that 
decrease insulin action and increase the risk of diabetes. 
The causes of ethnic difference in cardiovascular risk profile are complex. Possible 
contributors include genetic, environmental, psychosocial, cultural and unmeasured factors 
and many are not well clarified (Zaninotto et al. 2007). It is clear that the observed ethnic 
differences in lipid profiles cannot be explained by genetics alone and may be more 
indicative of lifestyle-related factors such as dietary pattern and physical activity (Ruixing et 
al. 2008; McNaughton et al. 2009; Sisson et al. 2009). To what extent is ethnic-specific lifestyle 
pattern associated with different lipid profiles deserves further investigation.  
4.1 Genetic factors 
An adverse lipid profile in Asian Indians has been reported to be associated with the greater 
susceptibility to insulin resistance (Tan et al. 1999; Anand et al. 2000; Bhalodkar et al. 2005; 
Palaniappan et al. 2007), and a higher percentage of body fat for the same BMI as compared 
with Whites (McKeigue et al. 1991), which may contribute to the high prevalence of CVD 
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(Kuller 2004) and diabetes (Ramachandran et al. 2008; Snehalatha and Ramachandran 2009) 
in this ethnic group. In addition, it may also reflect the genetic variation, for example, at the 
apoE locus (Tan et al. 2003) and an excess of other risk factors such as homocysteine, Lp(a) 
or dietary fat (France et al. 2003). 
4.2 Environmental factors 
As suggested by previous research, dietary factors may play a role in both lipid and insulin 
profiles, although these patterns may be mediated by body fat content (Ku CY 1998). Total 
fat (and saturated fat) intake has been shown to adversely affect total cholesterol 
concentrations in children, adolescents, and young adults (Post GB 1997). The difference in 
HDL-C concentrations between Qingdao and Hong Kong Chinese subgroups observed in 
the DECODA study cannot be simply explained by the difference in assay methods. It may 
largely attribute to the differences in dietary structure and preference, geographic and 
environmental factors. Shellfish and beer, for example, are commonly consumed all the year 
round in Qingdao. Nevertheless, whether other factors exist and contribute to the high 
HDL-C in Qingdao needs to be further investigated.  
Mexican Americans have been previously reported to have greater adiposity, higher TG 
levels and lower HDL-C levels than Anglos. The relationship between behavioral variables 
(caloric balance, cigarette and alcohol consumption, exercise, post-menopausal estrogen or 
oral contraceptive use) and lipid pattern has been investigated in the San Antonio Heart 
Study (1979–1982) (n=2,102) to explain the ethnic difference in lipids and lipoproteins. 
Adjustment for caloric balance (as reflected by body mass index) narrowed the ethnic 
difference in TG and HDL-C levels for both sexes, while adjustment for smoking widened 
the ethnic difference. For females, the ethnic difference was also decreased by adjustment 
for alcohol and estrogen use. However, adjustment for these behavioral variables did not 
completely eliminate the ethnic difference in lipids and lipoproteins in either sex. Increased 
central adiposity, more characteristic of Mexican Americans than Anglos, was positively 
associated with triglycerides and negatively associated with HDL-C levels, especially in 
females. Fat patterning made a more important contribution to the prediction of TG and 
HDL-C levels than did the other behavioral variables (except for caloric balance) and, in 
general, eliminated ethnic differences in lipids and lipoproteins (Steven H 1986). 
Epidemiologists should consider the use of a centrality index to distinguish different types 
of adiposity since it is easy and inexpensive to measure.  
5. Implications for management and prevention of dyslipidaemia 
Epidemiological investigations of human populations have revealed a robust relationship 
between lipids and CVD risk. Furthermore, the benefit of lipid-modifying strategy on 
cardiovascular events has been demonstrated from a large number of randomized clinical 
trials (Thavendiranathan et al. 2006; Mills et al. 2008), especially from those using 3-
hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (i.e., statins) (Goldberg, R. 
B. et al. 1998; Collins et al. 2003; Colhoun et al. 2004; Pyorala et al. 2004; Sever et al. 2005; 
Knopp et al. 2006; Shepherd et al. 2006). Intensive control of dyslipidaemia has been  
greatly emphasized in the prevention and management of CVD. Current guidelines from 
the National Cholesterol Education Program Adult Treatment Panel III (ATP III) (Adult 
Treatment Panel III 2002), the European Society of Cardiology (Graham et al. 2007) and  
the American Diabetes Association (American Diabetes Association 2009) consistently  
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Fig. 1. Age-, study cohort- and body mass index-adjusted mean lipid (geometric means for 
triglycerides) and lipoprotein concentrations and 95% CIs (vertical bars) in men (figure 1-a, 
c, e and g) and women (figure 1-b, d, f and h) by ethnicities and glucose categories.* p for 
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Model adjusted for age, study cohort, body mass index, systolic blood pressure and smoking status. 
NFG, normal fasting glucose; NGT, normal glucose tolerance. a Reference group 
Table 1. Odds ratio (95% confidence interval) of having dyslipidaemia in relation to 
ethnicity by glucose categories. 
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NFG, normal fasting glucose; NGT, normal glucose tolerance. a Reference group 
Table 1. Odds ratio (95% confidence interval) of having dyslipidaemia in relation to 
ethnicity by glucose categories. 
 






































29.3 9.9 1.6 4.2 32.1 12.9 3.7 6.2 
Qingdao Chinese 31.0 5.4 8.3 1.9 40.5 2.4 9.8  0.7  
Asian Indian 23.2 33.6 3.2 11.0 9.2 10.7 2.8  6.4 
Mauritian Indian 23.9 15.8 5.0 4.7 23.2 14.7 5.7 7.0 




13.3 2.3 2.0 1.6 48.6 9.7 12.6 10.0 
Southern 
European 






12.4 9.6 1.4 11.0 22.6 18.1 7.6 17.2 
Qingdao Chinese 21.1 3.5 11.1 3.1 37.9 2.7 19.1 1.5 
Asian Indian 12.8 17.4 6.0 21.4 8.1 12.4 7.2 14.7 
Mauritian Indian 12.4 8.6 6.4 10.2 21.2 15.5 10.2 15.5 




10.5 2.8 4.9 6.4 30.4 9.3 16.4 19.4 
Southern 
European 
7.5 3.3 6.0 10.2 24.4 11.2 12.8 14.8 
a < 1.03 mmol/l in men and < 1.29 mmol/l in women 
b ≥ 1.70 mmol/l 
Table 2. Proportions (%) of individuals according to lipid levels stratified by diabetic status 
in each ethnic group. 
recommend that LDL-C should be the primary target of therapy not only in patients with 
CHD or diabetes but also in individuals with increased cardiovascular risk. In addition, 
non-HDL-C is set by ATP III as a secondary target of therapy and HDL-C and TG as 
potential target. The Current guideline, mainly based on the data of Whites, consistently 
recommend that LDL-C < 2.6 mmol/l should be the primary target of therapy in patients 
with diabetes. As shown in our study and others’ (Mulukutla et al. 2008; Karthikeyan et al. 
2009), the Asian Indian population had significantly lower TC and LDL-C than did Whites. 
The threshold of LDL-C for treatment target for Whites may be too high for Asian Indians. 
Further studies are warranted to verify this hypothesis and determine the threshold 
applicable to this ethnic group. 
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In contrast to LDL-C, HDL-C has been either dropped from (Graham et al. 2007) or set as a 
secondary (American Diabetes Association 2010) or tertiary (Expert Panel on Detection 2001) 
target in the major guidelines despite the strong evidence of reduced HDL-C as an 
independent risk factor for CVD (Boden 2000). This may change if more therapy choices 
developed to increase HDL-C levels and improve HDL function are shown to prevent CVD 
(Singh et al. 2007; Duffy and Rader 2009; Sorrentino et al. 2010) or reduce the residual 
cardiovascular risk (Fruchart J 2008). Most recently, the ARBITER 6-HALTS (Arterial 
Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and 
LDL Treatment Strategies in Atherosclerosis) trial has shown a significant improvement in 
serum HDL-C levels and regression of carotid intima-media thickness when ERN was 
conbined with statin therapy in patients with CHD or CHD equivalent (Taylor et al. 2009; 
Villines et al. 2010). Considering the high proportion of Asian Indians with adverse HDL-C 
levels, appropriate approaches to increasing HDL-C and/or improving HDL function may 
become an important treatment target in Asian Indians in order to reduce their excess CVD 
risks. 






Total cholesterol High-density lipoprotein 
cholesterol 
Triglycerides 







Plasma Cholesterol oxidase 
(CHOD) method; 




pitation of very-low density 
lipoprotein (VLDL) and 
low-density lipoprotein 
(LDL) by polyethylene 





Survey on CVD 




with reagents (Baker 
Instruments 
Corporation, 
Allentown, PA 18103, 
USA) with Cobas Mira 
analyzer (Hoffman-La 
Roche and Co., Basle 
Switzerland).  
Enzymatic method after 
precipitation with dextran 
sulphate-MgCl2 on Cobas 
Mira analyzer (Hoffman-







18103, USA) with 
Cobas Mira 
analyzer (Hoffman-











Enzymatic method after 
precipitation (AMS 
Analyzer Medical System, 


































































29.3 9.9 1.6 4.2 32.1 12.9 3.7 6.2 
Qingdao Chinese 31.0 5.4 8.3 1.9 40.5 2.4 9.8  0.7  
Asian Indian 23.2 33.6 3.2 11.0 9.2 10.7 2.8  6.4 
Mauritian Indian 23.9 15.8 5.0 4.7 23.2 14.7 5.7 7.0 




13.3 2.3 2.0 1.6 48.6 9.7 12.6 10.0 
Southern 
European 






12.4 9.6 1.4 11.0 22.6 18.1 7.6 17.2 
Qingdao Chinese 21.1 3.5 11.1 3.1 37.9 2.7 19.1 1.5 
Asian Indian 12.8 17.4 6.0 21.4 8.1 12.4 7.2 14.7 
Mauritian Indian 12.4 8.6 6.4 10.2 21.2 15.5 10.2 15.5 




10.5 2.8 4.9 6.4 30.4 9.3 16.4 19.4 
Southern 
European 
7.5 3.3 6.0 10.2 24.4 11.2 12.8 14.8 
a < 1.03 mmol/l in men and < 1.29 mmol/l in women 
b ≥ 1.70 mmol/l 
Table 2. Proportions (%) of individuals according to lipid levels stratified by diabetic status 
in each ethnic group. 
recommend that LDL-C should be the primary target of therapy not only in patients with 
CHD or diabetes but also in individuals with increased cardiovascular risk. In addition, 
non-HDL-C is set by ATP III as a secondary target of therapy and HDL-C and TG as 
potential target. The Current guideline, mainly based on the data of Whites, consistently 
recommend that LDL-C < 2.6 mmol/l should be the primary target of therapy in patients 
with diabetes. As shown in our study and others’ (Mulukutla et al. 2008; Karthikeyan et al. 
2009), the Asian Indian population had significantly lower TC and LDL-C than did Whites. 
The threshold of LDL-C for treatment target for Whites may be too high for Asian Indians. 
Further studies are warranted to verify this hypothesis and determine the threshold 
applicable to this ethnic group. 
 
Ethnic Difference in Lipid Profiles 
 
25 
In contrast to LDL-C, HDL-C has been either dropped from (Graham et al. 2007) or set as a 
secondary (American Diabetes Association 2010) or tertiary (Expert Panel on Detection 2001) 
target in the major guidelines despite the strong evidence of reduced HDL-C as an 
independent risk factor for CVD (Boden 2000). This may change if more therapy choices 
developed to increase HDL-C levels and improve HDL function are shown to prevent CVD 
(Singh et al. 2007; Duffy and Rader 2009; Sorrentino et al. 2010) or reduce the residual 
cardiovascular risk (Fruchart J 2008). Most recently, the ARBITER 6-HALTS (Arterial 
Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and 
LDL Treatment Strategies in Atherosclerosis) trial has shown a significant improvement in 
serum HDL-C levels and regression of carotid intima-media thickness when ERN was 
conbined with statin therapy in patients with CHD or CHD equivalent (Taylor et al. 2009; 
Villines et al. 2010). Considering the high proportion of Asian Indians with adverse HDL-C 
levels, appropriate approaches to increasing HDL-C and/or improving HDL function may 
become an important treatment target in Asian Indians in order to reduce their excess CVD 
risks. 






Total cholesterol High-density lipoprotein 
cholesterol 
Triglycerides 







Plasma Cholesterol oxidase 
(CHOD) method; 




pitation of very-low density 
lipoprotein (VLDL) and 
low-density lipoprotein 
(LDL) by polyethylene 





Survey on CVD 




with reagents (Baker 
Instruments 
Corporation, 
Allentown, PA 18103, 
USA) with Cobas Mira 
analyzer (Hoffman-La 
Roche and Co., Basle 
Switzerland).  
Enzymatic method after 
precipitation with dextran 
sulphate-MgCl2 on Cobas 
Mira analyzer (Hoffman-







18103, USA) with 
Cobas Mira 
analyzer (Hoffman-











Enzymatic method after 
precipitation (AMS 
Analyzer Medical System, 
































Finland     




Olli C3000 photometer 
(Kone Oy, Finland) 
 
Enzymetic method after 
precipitation of VLDL 
and LDL by means of 
dextran-magnesium-
chloride, with Olli C3000 










































Elektron Oy, Finland) 
















method after precipitation 
of LDL and VLDL with a 
reagent containing 











Plasma Enzymatic colorimetric 
method (CHOD-PAP) 









PAP) Cobas  
Integra 400/700 
analyzer 
Vantaa Study Serum Enzymatic techniques 
(Boehringer-
Mannheim) 







India     






















Ethnic Difference in Lipid Profiles 
 
27 










method after  




Corning Express Plus 
Auto Analyser (Corning, 






Plus Auto Analyser 
(Corning, medfied, 
MA, USA) 















using kits supplied by 
Roche Diagnostics 























Italy     




with CIBA Corning 
550 Express Auto-
analyser  
Precipitation with PEG 









CIBA Corning 550 
Express Auto-
analyser 
Japan     
Funagata Study Plasma Cholesterol oxidase 
method (L-type Wako 
CHO-H [Wako Pure 
Chemical Industries, 
Osaka, Japan])  





(Cholesterol N HDL 
[Daiichi Pure Chemicals, 
Tokyo, Japan]) with TBA 





S TG-N [Daiichi 
Pure Chemicals, 
Tokyo, Japan]) with 
TBA 80FR (Toshiba 
medical system 
corporation, Tokyo) 
Hisayama Study Serum Enzymatic techniques 
(TBA-80S; Toshiba 
Inc., Tokyo, Japan) 
Enzymatic method after 
precipitation of of VLDL 
and LDL with dextran 
sulfate and magnesium 




80S; Toshiba Inc., 
Tokyo, Japan) 
Mauritius     
 




Finland     




Olli C3000 photometer 
(Kone Oy, Finland) 
 
Enzymetic method after 
precipitation of VLDL 
and LDL by means of 
dextran-magnesium-
chloride, with Olli C3000 










































Elektron Oy, Finland) 
















method after precipitation 
of LDL and VLDL with a 
reagent containing 











Plasma Enzymatic colorimetric 
method (CHOD-PAP) 









PAP) Cobas  
Integra 400/700 
analyzer 
Vantaa Study Serum Enzymatic techniques 
(Boehringer-
Mannheim) 







India     






















Ethnic Difference in Lipid Profiles 
 
27 










method after  




Corning Express Plus 
Auto Analyser (Corning, 






Plus Auto Analyser 
(Corning, medfied, 
MA, USA) 















using kits supplied by 
Roche Diagnostics 























Italy     




with CIBA Corning 
550 Express Auto-
analyser  
Precipitation with PEG 









CIBA Corning 550 
Express Auto-
analyser 
Japan     
Funagata Study Plasma Cholesterol oxidase 
method (L-type Wako 
CHO-H [Wako Pure 
Chemical Industries, 
Osaka, Japan])  





(Cholesterol N HDL 
[Daiichi Pure Chemicals, 
Tokyo, Japan]) with TBA 





S TG-N [Daiichi 
Pure Chemicals, 
Tokyo, Japan]) with 
TBA 80FR (Toshiba 
medical system 
corporation, Tokyo) 
Hisayama Study Serum Enzymatic techniques 
(TBA-80S; Toshiba 
Inc., Tokyo, Japan) 
Enzymatic method after 
precipitation of of VLDL 
and LDL with dextran 
sulfate and magnesium 




80S; Toshiba Inc., 
Tokyo, Japan) 
Mauritius     
 


























(Boeringer Cat nr 
400971) 

















Model LS (Coulter- 
France) 
Mauritius 1998 Venous 
plasma 
Automated enzymatic 















Poland     




Determined in the 
supernatant after 









   
Nicosia Diabetes 
Study Whole Blood
Cobas Micra Plus 
Roche 
Cobas Micra Plus Roche Cobas Micra Plus 
Roche 
Spain     
The Guía Study Plasma Standard enzymatic 
methods 
(Boehringer-























Sweden     














Study of Adult 
Serum Enzymatic techniques 
using IL Test 
Cholesterol Trinders's 




techniques using IL 
Test Cholesterol 
 
Ethnic Difference in Lipid Profiles 
 
29 
Men (ULSAM) Method and IL Test 
Enzymatic-
colorimetric Method 








phosphotumgstate. Trinders's Method 
and IL Test 
Enzymatic-
colorimetric 





The Netherlands     
The Hoorn 
Study 






after precipitation of the 















Enzymatic method after 
precipitation of apoB-
containing particles by 







U.K.     
Isle of ELY 
Diabetes Project  
Plasma Enzymatic techniques, 
















method with Cobas 
Bio centrifugal 
analyzer (Roche 
Products Ltd, Welwyn 






with heparin and 
manganese. 
Cobas Bio centrifugal 
analyzer (Roche Products 






















Herts, U.K.) after 
precipitation of LDL by 
the addition of 
phosphotungstic acid in 









Measures of lipid components in each study. 
 


























(Boeringer Cat nr 
400971) 

















Model LS (Coulter- 
France) 
Mauritius 1998 Venous 
plasma 
Automated enzymatic 















Poland     




Determined in the 
supernatant after 









   
Nicosia Diabetes 
Study Whole Blood
Cobas Micra Plus 
Roche 
Cobas Micra Plus Roche Cobas Micra Plus 
Roche 
Spain     
The Guía Study Plasma Standard enzymatic 
methods 
(Boehringer-























Sweden     














Study of Adult 
Serum Enzymatic techniques 
using IL Test 
Cholesterol Trinders's 




techniques using IL 
Test Cholesterol 
 
Ethnic Difference in Lipid Profiles 
 
29 
Men (ULSAM) Method and IL Test 
Enzymatic-
colorimetric Method 








phosphotumgstate. Trinders's Method 
and IL Test 
Enzymatic-
colorimetric 





The Netherlands     
The Hoorn 
Study 






after precipitation of the 















Enzymatic method after 
precipitation of apoB-
containing particles by 







U.K.     
Isle of ELY 
Diabetes Project  
Plasma Enzymatic techniques, 
















method with Cobas 
Bio centrifugal 
analyzer (Roche 
Products Ltd, Welwyn 






with heparin and 
manganese. 
Cobas Bio centrifugal 
analyzer (Roche Products 






















Herts, U.K.) after 
precipitation of LDL by 
the addition of 
phosphotungstic acid in 









Measures of lipid components in each study. 
 





Abdel-Aal, N. M., A. T. Ahmad, E. S. Froelicher, A. M. Batieha, M. M. Hamza, et al. (2008). 
"Prevalence of dyslipidemia in patients with type 2 diabetes in Jordan." Saudi Med 
J 29(10): 1423-1428. 
Adult Treatment panel III (2002). "Third Report of the National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III) final report." Circulation 
106(25): 3143-3421. 
Agarwal, A. K., S. Singla, R. Singla, A. Lal, H. Wardhan, et al. (2009). "Prevalence of 
coronary risk factors in type 2 diabetics without manifestations of overt coronary 
heart disease." J Assoc Physicians India 57: 135-142. 
Ahmed, N., J. Khan and T. S. Siddiqui (2008). "Frequency of dyslipidaemia in type 2 diabetes 
mellitus in patients of Hazara division." J Ayub Med Coll Abbottabad 20(2): 51-54. 
Almdal, T., H. Scharling, J. S. Jensen and H. Vestergaard (2004). "The independent effect of 
type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-
based study of 13,000 men and women with 20 years of follow-up." Arch Intern 
Med 164(13): 1422-1426. 
American Diabetes Association (2009). "Standards of medical care in diabetes--2009." 
Diabetes Care 32 Suppl 1: S13-61. 
American Diabetes Association (2010). "Standards of medical care in diabetes--2010." 
Diabetes Care 33 Suppl 1: S11-61. 
Anand, S. S., S. Yusuf, V. Vuksan, S. Devanesen, K. K. Teo, et al. (2000). "Differences in risk 
factors, atherosclerosis, and cardiovascular disease between ethnic groups in 
Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE)." 
Lancet 356(9226): 279-284. 
Arslan, E., T. Yakar and I. Yavasoglu (2008). "The effect of smoking on mean platelet volume 
and lipid profile in young male subjects." Anadolu Kardiyol Derg 8(6): 422-425. 
Azizi, F., M. Rahmani, A. Ghanbarian, H. Emami, P. Salehi, et al. (2003). "Serum lipid levels 
in an Iranian adults population: Tehran Lipid and Glucose Study." Eur J Epidemiol 
18(4): 311-319. 
Bangou-Bredent, J., V. Szmidt-Adjide, P. Kangambega-Nouvier, L. Foucan, A. Campier, et 
al. (1999). "Cardiovascular risk factors associated with diabetes in an Indian 
community of Guadeloupe. A case control study." Diabetes Metab 25(5): 393-398. 
Barrett-Connor, E., S. M. Grundy and M. J. Holdbrook (1982). "Plasma lipids and diabetes 
mellitus in an adult community." Am J Epidemiol 115(5): 657-663. 
Barzi, F., A. Patel, M. Woodward, C. M. Lawes, T. Ohkubo, et al. (2005). "A comparison of 
lipid variables as predictors of cardiovascular disease in the Asia Pacific region." 
Ann Epidemiol 15(5): 405-413. 
Batic-Mujanovic, O., A. Beganlic, N. Salihefendic, N. Pranjic and Z. Kusljugic (2008). 
"Influence of smoking on serum lipid and lipoprotein levels among family 
medicine patients." Med Arh 62(5-6): 264-267. 
Berg, A., M. Halle, I. Franz and J. Keul (1997). "Physical activity and lipoprotein metabolism: 
epidemiological evidence and clinical trials." Eur J Med Res 2(6): 259-264. 
Berglund L, R. R. (2004). "Lipoprotein(a): an elusive cardiovascular risk factor." Arterioscler. 
Thromb. Vasc. Biol 24(12): 2219-2226. 
 
Ethnic Difference in Lipid Profiles 
 
31 
Berrios, X., T. Koponen, T. Huiguang, N. Khaltaev, P. Puska, et al. (1997). "Distribution and 
prevalence of major risk factors of noncommunicable diseases in selected countries: 
the WHO Inter-Health Programme." Bull World Health Organ 75(2): 99-108. 
Bhalodkar, N. C., S. Blum, T. Rana, R. Kitchappa, A. N. Bhalodkar, et al. (2005). 
"Comparison of high-density and low-density lipoprotein cholesterol subclasses 
and sizes in Asian Indian women with Caucasian women from the Framingham 
Offspring Study." Clin Cardiol 28(5): 247-251. 
Boden, W. E. (2000). "High-density lipoprotein cholesterol as an independent risk factor in 
cardiovascular disease: assessing the data from Framingham to the Veterans Affairs 
High--Density Lipoprotein Intervention Trial." Am J Cardiol 86(12A): 19L-22L. 
Brown, C. D., M. Higgins, K. A. Donato, F. C. Rohde, R. Garrison, et al. (2000). "Body mass 
index and the prevalence of hypertension and dyslipidemia." Obes Res 8(9): 605-619. 
Bruckert, E., M. Baccara-Dinet and E. Eschwege (2007). "Low HDL-cholesterol is common in 
European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from 
a pan-European survey." Diabet Med 24(4): 388-391. 
Cade, J. and B. Margetts (1989). "Cigarette smoking and serum lipid and lipoprotein 
concentrations." Bmj 298(6683): 1312. 
Chait, A. and J. D. Brunzell (1990). "Acquired hyperlipidemia (secondary 
dyslipoproteinemias)." Endocrinol Metab Clin North Am 19(2): 259-278. 
Chandalia, M., V. Mohan, B. Adams-Huet, R. Deepa and N. Abate (2008). "Ethnic difference 
in sex gap in high-density lipoprotein cholesterol between Asian Indians and 
Whites." J Investig Med 56(3): 574-580. 
Charlton-Menys, V., D. J. Betteridge, H. Colhoun, J. Fuller, M. France, et al. (2009). 
"Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the 
Collaborative Atorvastatin Diabetes Study (CARDS)." Diabetologia 52(2): 218-225. 
Chen, L. K., M. H. Lin, Z. J. Chen, S. J. Hwang, S. T. Tsai, et al. (2006). "Metabolic 
characteristics and insulin resistance of impaired fasting glucose among the 
middle-aged and elderly Taiwanese." Diabetes Res Clin Pract 71(2): 170-176. 
Cohen, J. C., Z. Wang, S. M. Grundy, M. R. Stoesz and R. Guerra (1994). "Variation at the 
hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically 
determined variation in plasma HDL cholesterol levels." J Clin Invest 94(6): 2377-
2384. 
Colhoun, H. M., D. J. Betteridge, P. N. Durrington, G. A. Hitman, H. A. Neil, et al. (2004). 
"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes 
in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre 
randomised placebo-controlled trial." Lancet 364(9435): 685-696. 
Collins, R., J. Armitage, S. Parish, P. Sleigh and R. Peto (2003). "MRC/BHF Heart Protection 
Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a 
randomised placebo-controlled trial." Lancet 361(9374): 2005-2016. 
Cooney, M. T., A. Dudina, D. De Bacquer, L. Wilhelmsen, S. Sans, et al. (2009). "HDL 
cholesterol protects against cardiovascular disease in both genders, at all ages and 
at all levels of risk." Atherosclerosis 206(2): 611-616. 
Cowie, C. C., B. V. Howard and M. I. Harris (1994). "Serum lipoproteins in African 
Americans and whites with non-insulin-dependent diabetes in the US population." 
Circulation 90(3): 1185-1193. 
Criqui, M. H., R. B. Wallace, G. Heiss, M. Mishkel, G. Schonfeld, et al. (1980). "Cigarette 
smoking and plasma high-density lipoprotein cholesterol. The Lipid Research 
Clinics Program Prevalence Study." Circulation 62(4 Pt 2): IV70-76. 
 





Abdel-Aal, N. M., A. T. Ahmad, E. S. Froelicher, A. M. Batieha, M. M. Hamza, et al. (2008). 
"Prevalence of dyslipidemia in patients with type 2 diabetes in Jordan." Saudi Med 
J 29(10): 1423-1428. 
Adult Treatment panel III (2002). "Third Report of the National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III) final report." Circulation 
106(25): 3143-3421. 
Agarwal, A. K., S. Singla, R. Singla, A. Lal, H. Wardhan, et al. (2009). "Prevalence of 
coronary risk factors in type 2 diabetics without manifestations of overt coronary 
heart disease." J Assoc Physicians India 57: 135-142. 
Ahmed, N., J. Khan and T. S. Siddiqui (2008). "Frequency of dyslipidaemia in type 2 diabetes 
mellitus in patients of Hazara division." J Ayub Med Coll Abbottabad 20(2): 51-54. 
Almdal, T., H. Scharling, J. S. Jensen and H. Vestergaard (2004). "The independent effect of 
type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-
based study of 13,000 men and women with 20 years of follow-up." Arch Intern 
Med 164(13): 1422-1426. 
American Diabetes Association (2009). "Standards of medical care in diabetes--2009." 
Diabetes Care 32 Suppl 1: S13-61. 
American Diabetes Association (2010). "Standards of medical care in diabetes--2010." 
Diabetes Care 33 Suppl 1: S11-61. 
Anand, S. S., S. Yusuf, V. Vuksan, S. Devanesen, K. K. Teo, et al. (2000). "Differences in risk 
factors, atherosclerosis, and cardiovascular disease between ethnic groups in 
Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE)." 
Lancet 356(9226): 279-284. 
Arslan, E., T. Yakar and I. Yavasoglu (2008). "The effect of smoking on mean platelet volume 
and lipid profile in young male subjects." Anadolu Kardiyol Derg 8(6): 422-425. 
Azizi, F., M. Rahmani, A. Ghanbarian, H. Emami, P. Salehi, et al. (2003). "Serum lipid levels 
in an Iranian adults population: Tehran Lipid and Glucose Study." Eur J Epidemiol 
18(4): 311-319. 
Bangou-Bredent, J., V. Szmidt-Adjide, P. Kangambega-Nouvier, L. Foucan, A. Campier, et 
al. (1999). "Cardiovascular risk factors associated with diabetes in an Indian 
community of Guadeloupe. A case control study." Diabetes Metab 25(5): 393-398. 
Barrett-Connor, E., S. M. Grundy and M. J. Holdbrook (1982). "Plasma lipids and diabetes 
mellitus in an adult community." Am J Epidemiol 115(5): 657-663. 
Barzi, F., A. Patel, M. Woodward, C. M. Lawes, T. Ohkubo, et al. (2005). "A comparison of 
lipid variables as predictors of cardiovascular disease in the Asia Pacific region." 
Ann Epidemiol 15(5): 405-413. 
Batic-Mujanovic, O., A. Beganlic, N. Salihefendic, N. Pranjic and Z. Kusljugic (2008). 
"Influence of smoking on serum lipid and lipoprotein levels among family 
medicine patients." Med Arh 62(5-6): 264-267. 
Berg, A., M. Halle, I. Franz and J. Keul (1997). "Physical activity and lipoprotein metabolism: 
epidemiological evidence and clinical trials." Eur J Med Res 2(6): 259-264. 
Berglund L, R. R. (2004). "Lipoprotein(a): an elusive cardiovascular risk factor." Arterioscler. 
Thromb. Vasc. Biol 24(12): 2219-2226. 
 
Ethnic Difference in Lipid Profiles 
 
31 
Berrios, X., T. Koponen, T. Huiguang, N. Khaltaev, P. Puska, et al. (1997). "Distribution and 
prevalence of major risk factors of noncommunicable diseases in selected countries: 
the WHO Inter-Health Programme." Bull World Health Organ 75(2): 99-108. 
Bhalodkar, N. C., S. Blum, T. Rana, R. Kitchappa, A. N. Bhalodkar, et al. (2005). 
"Comparison of high-density and low-density lipoprotein cholesterol subclasses 
and sizes in Asian Indian women with Caucasian women from the Framingham 
Offspring Study." Clin Cardiol 28(5): 247-251. 
Boden, W. E. (2000). "High-density lipoprotein cholesterol as an independent risk factor in 
cardiovascular disease: assessing the data from Framingham to the Veterans Affairs 
High--Density Lipoprotein Intervention Trial." Am J Cardiol 86(12A): 19L-22L. 
Brown, C. D., M. Higgins, K. A. Donato, F. C. Rohde, R. Garrison, et al. (2000). "Body mass 
index and the prevalence of hypertension and dyslipidemia." Obes Res 8(9): 605-619. 
Bruckert, E., M. Baccara-Dinet and E. Eschwege (2007). "Low HDL-cholesterol is common in 
European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from 
a pan-European survey." Diabet Med 24(4): 388-391. 
Cade, J. and B. Margetts (1989). "Cigarette smoking and serum lipid and lipoprotein 
concentrations." Bmj 298(6683): 1312. 
Chait, A. and J. D. Brunzell (1990). "Acquired hyperlipidemia (secondary 
dyslipoproteinemias)." Endocrinol Metab Clin North Am 19(2): 259-278. 
Chandalia, M., V. Mohan, B. Adams-Huet, R. Deepa and N. Abate (2008). "Ethnic difference 
in sex gap in high-density lipoprotein cholesterol between Asian Indians and 
Whites." J Investig Med 56(3): 574-580. 
Charlton-Menys, V., D. J. Betteridge, H. Colhoun, J. Fuller, M. France, et al. (2009). 
"Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the 
Collaborative Atorvastatin Diabetes Study (CARDS)." Diabetologia 52(2): 218-225. 
Chen, L. K., M. H. Lin, Z. J. Chen, S. J. Hwang, S. T. Tsai, et al. (2006). "Metabolic 
characteristics and insulin resistance of impaired fasting glucose among the 
middle-aged and elderly Taiwanese." Diabetes Res Clin Pract 71(2): 170-176. 
Cohen, J. C., Z. Wang, S. M. Grundy, M. R. Stoesz and R. Guerra (1994). "Variation at the 
hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically 
determined variation in plasma HDL cholesterol levels." J Clin Invest 94(6): 2377-
2384. 
Colhoun, H. M., D. J. Betteridge, P. N. Durrington, G. A. Hitman, H. A. Neil, et al. (2004). 
"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes 
in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre 
randomised placebo-controlled trial." Lancet 364(9435): 685-696. 
Collins, R., J. Armitage, S. Parish, P. Sleigh and R. Peto (2003). "MRC/BHF Heart Protection 
Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a 
randomised placebo-controlled trial." Lancet 361(9374): 2005-2016. 
Cooney, M. T., A. Dudina, D. De Bacquer, L. Wilhelmsen, S. Sans, et al. (2009). "HDL 
cholesterol protects against cardiovascular disease in both genders, at all ages and 
at all levels of risk." Atherosclerosis 206(2): 611-616. 
Cowie, C. C., B. V. Howard and M. I. Harris (1994). "Serum lipoproteins in African 
Americans and whites with non-insulin-dependent diabetes in the US population." 
Circulation 90(3): 1185-1193. 
Criqui, M. H., R. B. Wallace, G. Heiss, M. Mishkel, G. Schonfeld, et al. (1980). "Cigarette 
smoking and plasma high-density lipoprotein cholesterol. The Lipid Research 
Clinics Program Prevalence Study." Circulation 62(4 Pt 2): IV70-76. 
 




Cui, Y., R. S. Blumenthal, J. A. Flaws, M. K. Whiteman, P. Langenberg, et al. (2001). "Non-
high-density lipoprotein cholesterol level as a predictor of cardiovascular disease 
mortality." Arch Intern Med 161(11): 1413-1419. 
Danesh J, C. R., Peto R. (2000). "Lipoprotein(a) and coronary heart disease: meta-analysis of 
prospective studies." Circulation 102(10): 1082-1085. 
De Oliveira, E. S. E. R., D. Foster, M. McGee Harper, C. E. Seidman, J. D. Smith, et al. (2000). 
"Alcohol consumption raises HDL cholesterol levels by increasing the transport 
rate of apolipoproteins A-I and A-II." Circulation 102(19): 2347-2352. 
Denke, M. A., C. T. Sempos and S. M. Grundy (1993). "Excess body weight. An 
underrecognized contributor to high blood cholesterol levels in white American 
men." Arch Intern Med 153(9): 1093-1103. 
Denke, M. A., C. T. Sempos and S. M. Grundy (1994). "Excess body weight. An under-
recognized contributor to dyslipidemia in white American women." Arch Intern 
Med 154(4): 401-410. 
Devroey, D., N. De Swaef, P. Coigniez, J. Vandevoorde, J. Kartounian, et al. (2004). 
"Correlations between lipid levels and age, gender, glycemia, obesity, diabetes, and 
smoking." Endocr Res 30(1): 83-93. 
Duffy, D. and D. J. Rader (2009). "Update on strategies to increase HDL quantity and 
function." Nat Rev Cardiol 6(7): 455-463. 
Erem, C., A. Hacihasanoglu, O. Deger, M. Kocak and M. Topbas (2008). "Prevalence of 
dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid 
study." Endocrine 34(1-3): 36-51. 
Expert Panel on Detection, E., and Treatment of High Blood Cholesterol in Adults (2001). 
"Executive Summary of The Third Report of The National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High 
Blood Cholesterol In Adults (Adult Treatment Panel III)." Jama 285(19): 2486-2497. 
Ezenwaka, C. E., N. Premanand and F. A. Orrett (2000). "Studies on plasma lipids in industrial 
workers in central Trinidad and Tobago." J Natl Med Assoc 92(8): 375-381. 
Fisher, S. D., W. Zareba, A. J. Moss, V. J. Marder, C. E. Sparks, et al. (2000). "Effect of 
smoking on lipid and thrombogenic factors two months after acute myocardial 
infarction." Am J Cardiol 86(8): 813-818. 
Florez, H., E. Silva, V. Fernandez, E. Ryder, T. Sulbaran, et al. (2005). "Prevalence and risk 
factors associated with the metabolic syndrome and dyslipidemia in White, Black, 
Amerindian and Mixed Hispanics in Zulia State, Venezuela." Diabetes Res Clin 
Pract 69(1): 63-77. 
Fogari, R., A. Zoppi, C. Pasotti, L. Poletti, F. Tettamanti, et al. (1988). "Effects of different 
beta-blockers on lipid metabolism in chronic therapy of hypertension." Int J Clin 
Pharmacol Ther Toxicol 26(12): 597-604. 
Foucan, L., P. Kangambega, D. Koumavi Ekouevi, J. Rozet and J. Bangou-Bredent (2000). 
"Lipid profile in an adult population in Guadeloupe." Diabetes Metab 26(6): 473-
480. 
France, M. W., S. Kwok, P. McElduff and C. J. Seneviratne (2003). "Ethnic trends in lipid tests 
in general practice." QJM 96(12): 919-923. 
Fruchart J, S. F., Hermans M, Assmann, G, Brown W, Ceska R, Chapman M, Dodson P, 
Fioretto P, Ginsberg H (2008). "The residual risk reduction initiative: a call to action 
to reduce residual vascular risk in dyslipidaemic patients." Diabetes&Vascular 
Disease Research 5(4): 319-335. 
 
Ethnic Difference in Lipid Profiles 
 
33 
Fuentes, R., T. Uusitalo, P. Puska, J. Tuomilehto and A. Nissinen (2003). "Blood cholesterol 
level and prevalence of hypercholesterolaemia in developing countries: a review of 
population-based studies carried out from 1979 to 2002." Eur J Cardiovasc Prev 
Rehabil 10(6): 411-419. 
Gatti, A., M. Maranghi, S. Bacci, C. Carallo, A. Gnasso, et al. (2009). "Poor glycemic control is 
an independent risk factor for low HDL cholesterol in patients with type 2 
diabetes." Diabetes Care 32(8): 1550-1552. 
Geethanjali FS, L. K., Lingenhel A. (2003). "Analysis of the apo(a) size polymorphism in 
Asian Indian populations: association with Lp(a) concentration and coronary heart 
disease." Atherosclerosis 169(1): 121-130. 
Goldberg, I. J. (2001). "Clinical review 124: Diabetic dyslipidemia: causes and consequences." 
J Clin Endocrinol Metab 86(3): 965-971. 
Goldberg, R. B., M. J. Mellies, F. M. Sacks, L. A. Moye, B. V. Howard, et al. (1998). 
"Cardiovascular events and their reduction with pravastatin in diabetic and 
glucose-intolerant myocardial infarction survivors with average cholesterol levels: 
subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care 
Investigators." Circulation 98(23): 2513-2519. 
Gomes, M. B., D. Giannella-Neto, M. Faria, M. Tambascia, R. M. Fonseca, et al. (2009). 
"Estimating cardiovascular risk in patients with type 2 diabetes: a national 
multicenter study in Brazil." Diabetol Metab Syndr 1(1): 22. 
Graham, I., D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, et al. (2007). "European 
guidelines on cardiovascular disease prevention in clinical practice: executive 
summary. Fourth Joint Task Force of the European Society of Cardiology and other 
societies on cardiovascular disease prevention in clinical practice (constituted by 
representatives of nine societies and by invited experts)." Eur J Cardiovasc Prev 
Rehabil 14 Suppl 2: E1-40. 
Grant, R. W. and J. B. Meigs (2007). "Prevalence and treatment of low HDL cholesterol 
among primary care patients with type 2 diabetes: an unmet challenge for 
cardiovascular risk reduction." Diabetes Care 30(3): 479-484. 
Gupta M, S. N., Verma S. (2006). "South Asians and cardiovascular risk: what clinicians 
should know." Circulation 113(25): E924-E929. 
Hadaegh, F., M. R. Bozorgmanesh, A. Ghasemi, H. Harati, N. Saadat, et al. (2008). "High 
prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian 
urban population: Tehran Lipid and Glucose Study." BMC Public Health 8: 176. 
Hanh, T. T. M., T. Komatsu, N. T. Hung, V. N. Chuyen, Y. Yoshimura, et al. (2001). 
"Nutritional status of middle-aged Vietnamese in Ho Chi Minh City." J Am Coll 
Nutr 20(6): 616-622. 
Hardman, A. E. (1999). "Physical activity, obesity and blood lipids." Int J Obes Relat Metab 
Disord 23 Suppl 3: S64-71. 
Harris, M. I. and R. C. Eastman (2000). "Early detection of undiagnosed diabetes mellitus: a 
US perspective." Diabetes Metab Res Rev 16(4): 230-236. 
Hennig, B., M. Toborek and C. J. McClain (2001). "High-energy diets, fatty acids and 
endothelial cell function: implications for atherosclerosis." J Am Coll Nutr 20(2 
Suppl): 97-105. 
Hertz, R. P., A. N. Unger and C. M. Ferrario (2006). "Diabetes, hypertension, and 
dyslipidemia in Mexican Americans and non-Hispanic whites." Am J Prev Med 
30(2): 103-110. 
 




Cui, Y., R. S. Blumenthal, J. A. Flaws, M. K. Whiteman, P. Langenberg, et al. (2001). "Non-
high-density lipoprotein cholesterol level as a predictor of cardiovascular disease 
mortality." Arch Intern Med 161(11): 1413-1419. 
Danesh J, C. R., Peto R. (2000). "Lipoprotein(a) and coronary heart disease: meta-analysis of 
prospective studies." Circulation 102(10): 1082-1085. 
De Oliveira, E. S. E. R., D. Foster, M. McGee Harper, C. E. Seidman, J. D. Smith, et al. (2000). 
"Alcohol consumption raises HDL cholesterol levels by increasing the transport 
rate of apolipoproteins A-I and A-II." Circulation 102(19): 2347-2352. 
Denke, M. A., C. T. Sempos and S. M. Grundy (1993). "Excess body weight. An 
underrecognized contributor to high blood cholesterol levels in white American 
men." Arch Intern Med 153(9): 1093-1103. 
Denke, M. A., C. T. Sempos and S. M. Grundy (1994). "Excess body weight. An under-
recognized contributor to dyslipidemia in white American women." Arch Intern 
Med 154(4): 401-410. 
Devroey, D., N. De Swaef, P. Coigniez, J. Vandevoorde, J. Kartounian, et al. (2004). 
"Correlations between lipid levels and age, gender, glycemia, obesity, diabetes, and 
smoking." Endocr Res 30(1): 83-93. 
Duffy, D. and D. J. Rader (2009). "Update on strategies to increase HDL quantity and 
function." Nat Rev Cardiol 6(7): 455-463. 
Erem, C., A. Hacihasanoglu, O. Deger, M. Kocak and M. Topbas (2008). "Prevalence of 
dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid 
study." Endocrine 34(1-3): 36-51. 
Expert Panel on Detection, E., and Treatment of High Blood Cholesterol in Adults (2001). 
"Executive Summary of The Third Report of The National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High 
Blood Cholesterol In Adults (Adult Treatment Panel III)." Jama 285(19): 2486-2497. 
Ezenwaka, C. E., N. Premanand and F. A. Orrett (2000). "Studies on plasma lipids in industrial 
workers in central Trinidad and Tobago." J Natl Med Assoc 92(8): 375-381. 
Fisher, S. D., W. Zareba, A. J. Moss, V. J. Marder, C. E. Sparks, et al. (2000). "Effect of 
smoking on lipid and thrombogenic factors two months after acute myocardial 
infarction." Am J Cardiol 86(8): 813-818. 
Florez, H., E. Silva, V. Fernandez, E. Ryder, T. Sulbaran, et al. (2005). "Prevalence and risk 
factors associated with the metabolic syndrome and dyslipidemia in White, Black, 
Amerindian and Mixed Hispanics in Zulia State, Venezuela." Diabetes Res Clin 
Pract 69(1): 63-77. 
Fogari, R., A. Zoppi, C. Pasotti, L. Poletti, F. Tettamanti, et al. (1988). "Effects of different 
beta-blockers on lipid metabolism in chronic therapy of hypertension." Int J Clin 
Pharmacol Ther Toxicol 26(12): 597-604. 
Foucan, L., P. Kangambega, D. Koumavi Ekouevi, J. Rozet and J. Bangou-Bredent (2000). 
"Lipid profile in an adult population in Guadeloupe." Diabetes Metab 26(6): 473-
480. 
France, M. W., S. Kwok, P. McElduff and C. J. Seneviratne (2003). "Ethnic trends in lipid tests 
in general practice." QJM 96(12): 919-923. 
Fruchart J, S. F., Hermans M, Assmann, G, Brown W, Ceska R, Chapman M, Dodson P, 
Fioretto P, Ginsberg H (2008). "The residual risk reduction initiative: a call to action 
to reduce residual vascular risk in dyslipidaemic patients." Diabetes&Vascular 
Disease Research 5(4): 319-335. 
 
Ethnic Difference in Lipid Profiles 
 
33 
Fuentes, R., T. Uusitalo, P. Puska, J. Tuomilehto and A. Nissinen (2003). "Blood cholesterol 
level and prevalence of hypercholesterolaemia in developing countries: a review of 
population-based studies carried out from 1979 to 2002." Eur J Cardiovasc Prev 
Rehabil 10(6): 411-419. 
Gatti, A., M. Maranghi, S. Bacci, C. Carallo, A. Gnasso, et al. (2009). "Poor glycemic control is 
an independent risk factor for low HDL cholesterol in patients with type 2 
diabetes." Diabetes Care 32(8): 1550-1552. 
Geethanjali FS, L. K., Lingenhel A. (2003). "Analysis of the apo(a) size polymorphism in 
Asian Indian populations: association with Lp(a) concentration and coronary heart 
disease." Atherosclerosis 169(1): 121-130. 
Goldberg, I. J. (2001). "Clinical review 124: Diabetic dyslipidemia: causes and consequences." 
J Clin Endocrinol Metab 86(3): 965-971. 
Goldberg, R. B., M. J. Mellies, F. M. Sacks, L. A. Moye, B. V. Howard, et al. (1998). 
"Cardiovascular events and their reduction with pravastatin in diabetic and 
glucose-intolerant myocardial infarction survivors with average cholesterol levels: 
subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care 
Investigators." Circulation 98(23): 2513-2519. 
Gomes, M. B., D. Giannella-Neto, M. Faria, M. Tambascia, R. M. Fonseca, et al. (2009). 
"Estimating cardiovascular risk in patients with type 2 diabetes: a national 
multicenter study in Brazil." Diabetol Metab Syndr 1(1): 22. 
Graham, I., D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, et al. (2007). "European 
guidelines on cardiovascular disease prevention in clinical practice: executive 
summary. Fourth Joint Task Force of the European Society of Cardiology and other 
societies on cardiovascular disease prevention in clinical practice (constituted by 
representatives of nine societies and by invited experts)." Eur J Cardiovasc Prev 
Rehabil 14 Suppl 2: E1-40. 
Grant, R. W. and J. B. Meigs (2007). "Prevalence and treatment of low HDL cholesterol 
among primary care patients with type 2 diabetes: an unmet challenge for 
cardiovascular risk reduction." Diabetes Care 30(3): 479-484. 
Gupta M, S. N., Verma S. (2006). "South Asians and cardiovascular risk: what clinicians 
should know." Circulation 113(25): E924-E929. 
Hadaegh, F., M. R. Bozorgmanesh, A. Ghasemi, H. Harati, N. Saadat, et al. (2008). "High 
prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian 
urban population: Tehran Lipid and Glucose Study." BMC Public Health 8: 176. 
Hanh, T. T. M., T. Komatsu, N. T. Hung, V. N. Chuyen, Y. Yoshimura, et al. (2001). 
"Nutritional status of middle-aged Vietnamese in Ho Chi Minh City." J Am Coll 
Nutr 20(6): 616-622. 
Hardman, A. E. (1999). "Physical activity, obesity and blood lipids." Int J Obes Relat Metab 
Disord 23 Suppl 3: S64-71. 
Harris, M. I. and R. C. Eastman (2000). "Early detection of undiagnosed diabetes mellitus: a 
US perspective." Diabetes Metab Res Rev 16(4): 230-236. 
Hennig, B., M. Toborek and C. J. McClain (2001). "High-energy diets, fatty acids and 
endothelial cell function: implications for atherosclerosis." J Am Coll Nutr 20(2 
Suppl): 97-105. 
Hertz, R. P., A. N. Unger and C. M. Ferrario (2006). "Diabetes, hypertension, and 
dyslipidemia in Mexican Americans and non-Hispanic whites." Am J Prev Med 
30(2): 103-110. 
 




Ismail, I. S., W. Nazaimoon, W. Mohamad, R. Letchuman, M. Singaraveloo, et al. (2001). 
"Ethnicity and glycaemic control are major determinants of diabetic dyslipidaemia 
in Malaysia." Diabet Med 18(6): 501-508. 
Jacobs, M. J., T. Kleisli, J. R. Pio, S. Malik, G. J. L'Italien, et al. (2005). "Prevalence and control 
of dyslipidemia among persons with diabetes in the United States." Diabetes Res 
Clin Pract 70(3): 263-269. 
Jurado, J., J. Ybarra, P. Solanas, J. Caula, I. Gich, et al. (2009). "Prevalence of cardiovascular 
disease and risk factors in a type 2 diabetic population of the North Catalonia 
diabetes study." J Am Acad Nurse Pract 21(3): 140-148. 
Juutilainen, A., S. Lehto, T. Ronnemaa, K. Pyorala and M. Laakso (2005). "Type 2 diabetes as 
a "coronary heart disease equivalent": an 18-year prospective population-based 
study in Finnish subjects." Diabetes Care 28(12): 2901-2907. 
Kannel, W. B. (1985). "Lipids, diabetes, and coronary heart disease: insights from the 
Framingham Study." Am Heart J 110(5): 1100-1107. 
Karthikeyan, G., K. K. Teo, S. Islam, M. J. McQueen, P. Pais, et al. (2009). "Lipid profile, 
plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an 
analysis from the INTERHEART Study." J Am Coll Cardiol 53(3): 244-253. 
Kelishadi, R., G. Ardalan, R. Gheiratmand and A. Ramezani (2006). "Is family history of 
premature cardiovascular diseases appropriate for detection of dyslipidemic 
children in population-based preventive medicine programs? CASPIAN study." 
Pediatr Cardiol 27(6): 729-736. 
Kendall, D. M. (2005). "The dyslipidemia of diabetes mellitus: giving triglycerides and high-
density lipoprotein cholesterol a higher priority?" Endocrinol Metab Clin North 
Am 34(1): 27-48. 
Knopp, R. H., M. d'Emden, J. G. Smilde and S. J. Pocock (2006). "Efficacy and safety of 
atorvastatin in the prevention of cardiovascular end points in subjects with type 2 
diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease 
Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)." Diabetes Care 
29(7): 1478-1485. 
Krauss, R. M. (2004). "Lipids and lipoproteins in patients with type 2 diabetes." Diabetes 
Care 27(6): 1496-1504. 
Ku CY, G. B., Nagy TR, Goran MI. (1998). "Relationships between dietary fat, body fat, and 
serum lipid profile in prepubertal children." Obes Res(6): 400-407. 
Kuller, L. H. (2004). "Ethnic differences in atherosclerosis, cardiovascular disease and lipid 
metabolism." Curr Opin Lipidol 15(2): 109-113. 
Lehtonen, A. (1985). "Effect of beta blockers on blood lipid profile." Am Heart J 109(5 Pt 2): 
1192-1196. 
Li, Z., R. Yang, G. Xu and T. Xia (2005). "Serum lipid concentrations and prevalence of 
dyslipidemia in a large professional population in Beijing." Clin Chem 51(1): 144-
150. 
Liu, J., C. Sempos, R. P. Donahue, J. Dorn, M. Trevisan, et al. (2005). "Joint distribution of 
non-HDL and LDL cholesterol and coronary heart disease risk prediction among 
individuals with and without diabetes." Diabetes Care 28(8): 1916-1921. 
Maeda, K., Y. Noguchi and T. Fukui (2003). "The effects of cessation from cigarette smoking 
on the lipid and lipoprotein profiles: a meta-analysis." Prev Med 37(4): 283-290. 
Mammas, I. N., G. K. Bertsias, M. Linardakis, N. E. Tzanakis, D. N. Labadarios, et al. (2003). 
"Cigarette smoking, alcohol consumption, and serum lipid profile among medical 
students in Greece." Eur J Public Health 13(3): 278-282. 
 
Ethnic Difference in Lipid Profiles 
 
35 
Mann, J. I., B. Lewis, J. Shepherd, A. F. Winder, S. Fenster, et al. (1988). "Blood lipid 
concentrations and other cardiovascular risk factors: distribution, prevalence, and 
detection in Britain." Br Med J (Clin Res Ed) 296(6638): 1702-1706. 
McKeigue, P. M., B. Shah and M. G. Marmot (1991). "Relation of central obesity and insulin 
resistance with high diabetes prevalence and cardiovascular risk in South Asians." 
Lancet 337(8738): 382-386. 
McNamara, D. J. and W. H. Howell (1992). "Epidemiologic data linking diet to 
hyperlipidemia and arteriosclerosis." Semin Liver Dis 12(4): 347-355. 
McNaughton, S. A., G. D. Mishra and E. J. Brunner (2009). "Food patterns associated with 
blood lipids are predictive of coronary heart disease: the Whitehall II study." Br J 
Nutr 102(4): 619-624. 
Meigs, J. B., D. M. Nathan, R. B. D'Agostino, Sr. and P. W. Wilson (2002). "Fasting and 
postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring 
Study." Diabetes Care 25(10): 1845-1850. 
Middeke, M., W. O. Richter, P. Schwandt, B. Beck and H. Holzgreve (1990). "Normalization 
of lipid metabolism after withdrawal from antihypertensive long-term therapy 
with beta blockers and diuretics." Arteriosclerosis 10(1): 145-147. 
Millen, B. E., P. A. Quatromoni, B. H. Nam, C. E. O'Horo, J. F. Polak, et al. (2002). "Dietary 
patterns and the odds of carotid atherosclerosis in women: the Framingham 
Nutrition Studies." Prev Med 35(6): 540-547. 
Mills, E. J., B. Rachlis, P. Wu, P. J. Devereaux, P. Arora, et al. (2008). "Primary prevention of 
cardiovascular mortality and events with statin treatments: a network meta-
analysis involving more than 65,000 patients." J Am Coll Cardiol 52(22): 1769-1781. 
Mohan, V., R. Deepa, S. P. Haranath, G. Premalatha, M. Rema, et al. (1998). "Lipoprotein(a) 
is an independent risk factor for coronary artery disease in NIDDM patients in 
South India." Diabetes Care 21(11): 1819-1823. 
Morrish, N. J., L. K. Stevens, J. H. Fuller, R. J. Jarrett and H. Keen (1991). "Risk factors for 
macrovascular disease in diabetes mellitus: the London follow-up to the WHO 
Multinational Study of Vascular Disease in Diabetics." Diabetologia 34(8): 590-594. 
Morrish, N. J., L. K. Stevens, J. H. Fuller, H. Keen and R. J. Jarrett (1991). "Incidence of 
macrovascular disease in diabetes mellitus: the London cohort of the WHO 
Multinational Study of Vascular Disease in Diabetics." Diabetologia 34(8): 584-589. 
Morrish, N. J., L. K. Stevens, J. Head, J. H. Fuller, R. J. Jarrett, et al. (1990). "A prospective 
study of mortality among middle-aged diabetic patients (the London Cohort of the 
WHO Multinational Study of Vascular Disease in Diabetics) II: Associated risk 
factors." Diabetologia 33(9): 542-548. 
Mulukutla, S. R., L. Venkitachalam, O. C. Marroquin, K. C. Kip, A. Aiyer, et al. (2008). 
"Population variation in atherogenic dyslipidemia: A report from the HeartSCORE 
and IndiaSCORE Studies." Journal of Clinical Lipidology 2(6): 410-417. 
Murakami, K., S. Ishibashi, Y. Yoshida, N. Yamada and Y. Akanuma (1998). "Lipoprotein(a) 
as a coronary risk factor in Japanese patients with Type II (non-insulin-dependent) 
diabetes mellitus. Relation with apolipoprotein(a) phenotypes." Diabetologia 
41(11): 1397-1398. 
Novoa, F. J., M. Boronat, P. Saavedra, J. M. Diaz-Cremades, V. F. Varillas, et al. (2005). 
"Differences in cardiovascular risk factors, insulin resistance, and insulin secretion 
in individuals with normal glucose tolerance and in subjects with impaired glucose 
regulation: the Telde Study." Diabetes Care 28(10): 2388-2393. 
 




Ismail, I. S., W. Nazaimoon, W. Mohamad, R. Letchuman, M. Singaraveloo, et al. (2001). 
"Ethnicity and glycaemic control are major determinants of diabetic dyslipidaemia 
in Malaysia." Diabet Med 18(6): 501-508. 
Jacobs, M. J., T. Kleisli, J. R. Pio, S. Malik, G. J. L'Italien, et al. (2005). "Prevalence and control 
of dyslipidemia among persons with diabetes in the United States." Diabetes Res 
Clin Pract 70(3): 263-269. 
Jurado, J., J. Ybarra, P. Solanas, J. Caula, I. Gich, et al. (2009). "Prevalence of cardiovascular 
disease and risk factors in a type 2 diabetic population of the North Catalonia 
diabetes study." J Am Acad Nurse Pract 21(3): 140-148. 
Juutilainen, A., S. Lehto, T. Ronnemaa, K. Pyorala and M. Laakso (2005). "Type 2 diabetes as 
a "coronary heart disease equivalent": an 18-year prospective population-based 
study in Finnish subjects." Diabetes Care 28(12): 2901-2907. 
Kannel, W. B. (1985). "Lipids, diabetes, and coronary heart disease: insights from the 
Framingham Study." Am Heart J 110(5): 1100-1107. 
Karthikeyan, G., K. K. Teo, S. Islam, M. J. McQueen, P. Pais, et al. (2009). "Lipid profile, 
plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an 
analysis from the INTERHEART Study." J Am Coll Cardiol 53(3): 244-253. 
Kelishadi, R., G. Ardalan, R. Gheiratmand and A. Ramezani (2006). "Is family history of 
premature cardiovascular diseases appropriate for detection of dyslipidemic 
children in population-based preventive medicine programs? CASPIAN study." 
Pediatr Cardiol 27(6): 729-736. 
Kendall, D. M. (2005). "The dyslipidemia of diabetes mellitus: giving triglycerides and high-
density lipoprotein cholesterol a higher priority?" Endocrinol Metab Clin North 
Am 34(1): 27-48. 
Knopp, R. H., M. d'Emden, J. G. Smilde and S. J. Pocock (2006). "Efficacy and safety of 
atorvastatin in the prevention of cardiovascular end points in subjects with type 2 
diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease 
Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)." Diabetes Care 
29(7): 1478-1485. 
Krauss, R. M. (2004). "Lipids and lipoproteins in patients with type 2 diabetes." Diabetes 
Care 27(6): 1496-1504. 
Ku CY, G. B., Nagy TR, Goran MI. (1998). "Relationships between dietary fat, body fat, and 
serum lipid profile in prepubertal children." Obes Res(6): 400-407. 
Kuller, L. H. (2004). "Ethnic differences in atherosclerosis, cardiovascular disease and lipid 
metabolism." Curr Opin Lipidol 15(2): 109-113. 
Lehtonen, A. (1985). "Effect of beta blockers on blood lipid profile." Am Heart J 109(5 Pt 2): 
1192-1196. 
Li, Z., R. Yang, G. Xu and T. Xia (2005). "Serum lipid concentrations and prevalence of 
dyslipidemia in a large professional population in Beijing." Clin Chem 51(1): 144-
150. 
Liu, J., C. Sempos, R. P. Donahue, J. Dorn, M. Trevisan, et al. (2005). "Joint distribution of 
non-HDL and LDL cholesterol and coronary heart disease risk prediction among 
individuals with and without diabetes." Diabetes Care 28(8): 1916-1921. 
Maeda, K., Y. Noguchi and T. Fukui (2003). "The effects of cessation from cigarette smoking 
on the lipid and lipoprotein profiles: a meta-analysis." Prev Med 37(4): 283-290. 
Mammas, I. N., G. K. Bertsias, M. Linardakis, N. E. Tzanakis, D. N. Labadarios, et al. (2003). 
"Cigarette smoking, alcohol consumption, and serum lipid profile among medical 
students in Greece." Eur J Public Health 13(3): 278-282. 
 
Ethnic Difference in Lipid Profiles 
 
35 
Mann, J. I., B. Lewis, J. Shepherd, A. F. Winder, S. Fenster, et al. (1988). "Blood lipid 
concentrations and other cardiovascular risk factors: distribution, prevalence, and 
detection in Britain." Br Med J (Clin Res Ed) 296(6638): 1702-1706. 
McKeigue, P. M., B. Shah and M. G. Marmot (1991). "Relation of central obesity and insulin 
resistance with high diabetes prevalence and cardiovascular risk in South Asians." 
Lancet 337(8738): 382-386. 
McNamara, D. J. and W. H. Howell (1992). "Epidemiologic data linking diet to 
hyperlipidemia and arteriosclerosis." Semin Liver Dis 12(4): 347-355. 
McNaughton, S. A., G. D. Mishra and E. J. Brunner (2009). "Food patterns associated with 
blood lipids are predictive of coronary heart disease: the Whitehall II study." Br J 
Nutr 102(4): 619-624. 
Meigs, J. B., D. M. Nathan, R. B. D'Agostino, Sr. and P. W. Wilson (2002). "Fasting and 
postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring 
Study." Diabetes Care 25(10): 1845-1850. 
Middeke, M., W. O. Richter, P. Schwandt, B. Beck and H. Holzgreve (1990). "Normalization 
of lipid metabolism after withdrawal from antihypertensive long-term therapy 
with beta blockers and diuretics." Arteriosclerosis 10(1): 145-147. 
Millen, B. E., P. A. Quatromoni, B. H. Nam, C. E. O'Horo, J. F. Polak, et al. (2002). "Dietary 
patterns and the odds of carotid atherosclerosis in women: the Framingham 
Nutrition Studies." Prev Med 35(6): 540-547. 
Mills, E. J., B. Rachlis, P. Wu, P. J. Devereaux, P. Arora, et al. (2008). "Primary prevention of 
cardiovascular mortality and events with statin treatments: a network meta-
analysis involving more than 65,000 patients." J Am Coll Cardiol 52(22): 1769-1781. 
Mohan, V., R. Deepa, S. P. Haranath, G. Premalatha, M. Rema, et al. (1998). "Lipoprotein(a) 
is an independent risk factor for coronary artery disease in NIDDM patients in 
South India." Diabetes Care 21(11): 1819-1823. 
Morrish, N. J., L. K. Stevens, J. H. Fuller, R. J. Jarrett and H. Keen (1991). "Risk factors for 
macrovascular disease in diabetes mellitus: the London follow-up to the WHO 
Multinational Study of Vascular Disease in Diabetics." Diabetologia 34(8): 590-594. 
Morrish, N. J., L. K. Stevens, J. H. Fuller, H. Keen and R. J. Jarrett (1991). "Incidence of 
macrovascular disease in diabetes mellitus: the London cohort of the WHO 
Multinational Study of Vascular Disease in Diabetics." Diabetologia 34(8): 584-589. 
Morrish, N. J., L. K. Stevens, J. Head, J. H. Fuller, R. J. Jarrett, et al. (1990). "A prospective 
study of mortality among middle-aged diabetic patients (the London Cohort of the 
WHO Multinational Study of Vascular Disease in Diabetics) II: Associated risk 
factors." Diabetologia 33(9): 542-548. 
Mulukutla, S. R., L. Venkitachalam, O. C. Marroquin, K. C. Kip, A. Aiyer, et al. (2008). 
"Population variation in atherogenic dyslipidemia: A report from the HeartSCORE 
and IndiaSCORE Studies." Journal of Clinical Lipidology 2(6): 410-417. 
Murakami, K., S. Ishibashi, Y. Yoshida, N. Yamada and Y. Akanuma (1998). "Lipoprotein(a) 
as a coronary risk factor in Japanese patients with Type II (non-insulin-dependent) 
diabetes mellitus. Relation with apolipoprotein(a) phenotypes." Diabetologia 
41(11): 1397-1398. 
Novoa, F. J., M. Boronat, P. Saavedra, J. M. Diaz-Cremades, V. F. Varillas, et al. (2005). 
"Differences in cardiovascular risk factors, insulin resistance, and insulin secretion 
in individuals with normal glucose tolerance and in subjects with impaired glucose 
regulation: the Telde Study." Diabetes Care 28(10): 2388-2393. 
 




Okafor, C. I., O. A. Fasanmade and D. A. Oke (2008). "Pattern of dyslipidaemia among 
Nigerians with type 2 diabetes mellitus." Niger J Clin Pract 11(1): 25-31. 
Onat, A., G. Surdum-Avci, M. Senocak, E. Ornek and Y. Gozukara (1992). "Plasma lipids and 
their interrelationship in Turkish adults." J Epidemiol Community Health 46(5): 
470-476. 
Palaniappan, L. P., A. C. Kwan, F. Abbasi, C. Lamendola, T. L. McLaughlin, et al. (2007). 
"Lipoprotein abnormalities are associated with insulin resistance in South Asian 
Indian women." Metabolism 56(7): 899-904. 
Pang, R. W., S. Tam, E. D. Janus, S. T. Siu, O. C. Ma, et al. (2006). "Plasma lipid, lipoprotein 
and apolipoprotein levels in a random population sample of 2875 Hong Kong 
Chinese adults and their implications (NCEP ATP-III, 2001 guidelines) on 
cardiovascular risk assessment." Atherosclerosis 184(2): 438-445. 
Pankow, J. S., D. K. Kwan, B. B. Duncan, M. I. Schmidt, D. J. Couper, et al. (2007). 
"Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: 
the Atherosclerosis Risk in Communities Study." Diabetes Care 30(2): 325-331. 
Papazafiropoulou, A., A. Sotiropoulos, E. Skliros, M. Kardara, A. Kokolaki, et al. (2009). 
"Familial history of diabetes and clinical characteristics in Greek subjects with type 
2 diabetes." BMC Endocr Disord 9: 12. 
Patel, A., F. Barzi, K. Jamrozik, T. H. Lam, H. Ueshima, et al. (2004). "Serum triglycerides as 
a risk factor for cardiovascular diseases in the Asia-Pacific region." Circulation 
110(17): 2678-2686. 
Pischon, T., C. J. Girman, F. M. Sacks, N. Rifai, M. J. Stampfer, et al. (2005). "Non-high-
density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary 
heart disease in men." Circulation 112(22): 3375-3383. 
Pongchaiyakul, C., P. Hongsprabhas and V. Pisprasert (2006). "Rural-urban difference in 
lipid levels and prevalence of dyslipidemia: a population-based study in Khon 
Kaen province, Thailand." J Med Assoc Thai 89(11): 1835-1844. 
Post GB, K. H., Twisk J, van Mechelen W. (1997). "The association between dietary patterns 
and cardiovascular disease risk indicators in healthy youngsters: results covering 
fifteen years of longitudinal development." Eur J Clin Nutr 51: 387-393. 
Psaty, B. M., M. Anderson, R. A. Kronmal, R. P. Tracy, T. Orchard, et al. (2004). "The 
association between lipid levels and the risks of incident myocardial infarction, 
stroke, and total mortality: The Cardiovascular Health Study." J Am Geriatr Soc 
52(10): 1639-1647. 
Pyorala, K., C. M. Ballantyne, B. Gumbiner, M. W. Lee, A. Shah, et al. (2004). "Reduction of 
cardiovascular events by simvastatin in nondiabetic coronary heart disease patients 
with and without the metabolic syndrome: subgroup analyses of the Scandinavian 
Simvastatin Survival Study (4S)." Diabetes Care 27(7): 1735-1740. 
Ramachandran, A., S. Mary, A. Yamuna, N. Murugesan and C. Snehalatha (2008). "High 
prevalence of diabetes and cardiovascular risk factors associated with urbanization 
in India." Diabetes Care 31(5): 893-898. 
Razak, F., S. Anand, V. Vuksan, B. Davis, R. Jacobs, et al. (2005). "Ethnic differences in the 
relationships between obesity and glucose-metabolic abnormalities: a cross-
sectional population-based study." Int J Obes (Lond) 29(6): 656-667. 
Reckless, J. P., D. J. Betteridge, P. Wu, B. Payne and D. J. Galton (1978). "High-density and 
low-density lipoproteins and prevalence of vascular disease in diabetes mellitus." 
Br Med J 1(6117): 883-886. 
 
Ethnic Difference in Lipid Profiles 
 
37 
Ridker, P. M., N. Rifai, N. R. Cook, G. Bradwin and J. E. Buring (2005). "Non-HDL 
cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, 
and CRP as risk factors for cardiovascular disease in women." Jama 294(3): 326-333. 
Roberto Robles, N., S. Barroso, G. Marcos and J. F. Sanchez Munoz-Torrero (2009). "[Lipid 
control in diabetic patients in Extremadura (Spain)]." Endocrinol Nutr 56(3): 112-
117. 
Roberts, W. C. (1989). "Recent studies on the effects of beta blockers on blood lipid levels." 
Am Heart J 117(3): 709-714. 
Ronnemaa, T., M. Laakso, V. Kallio, K. Pyorala, J. Marniemi, et al. (1989). "Serum lipids, 
lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart 
disease in non-insulin-dependent diabetic patients." Am J Epidemiol 130(4): 632-645. 
Roselli della Rovere, G., A. Lapolla, G. Sartore, C. Rossetti, S. Zambon, et al. (2003). "Plasma 
lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A 
nine-year follow-up study." Nutr Metab Cardiovasc Dis 13(1): 46-51. 
Rosengren, A., L. Welin, A. Tsipogianni and L. Wilhelmsen (1989). "Impact of cardiovascular 
risk factors on coronary heart disease and mortality among middle aged diabetic 
men: a general population study." Bmj 299(6708): 1127-1131. 
Ruixing, Y., W. Jinzhen, H. Yaoheng, T. Jing, W. Hai, et al. (2008). "Associations of diet and 
lifestyle with hyperlipidemia for middle-aged and elderly persons among the 
Guangxi Bai Ku Yao and Han populations." J Am Diet Assoc 108(6): 970-976. 
Santen, R. J., P. W. Willis, 3rd and S. S. Fajans (1972). "Atherosclerosis in diabetes mellitus. 
Correlations with serum lipid levels, adiposity, and serum insulin level." Arch 
Intern Med 130(6): 833-843. 
Sarwar, N., J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, et al. (2007). 
"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 
262,525 participants in 29 Western prospective studies." Circulation 115(4): 450-458. 
Schulze, M. B., I. Shai, J. E. Manson, T. Li, N. Rifai, et al. (2004). "Joint role of non-HDL 
cholesterol and glycated haemoglobin in predicting future coronary heart disease 
events among women with type 2 diabetes." Diabetologia 47(12): 2129-2136. 
Schwandt, P., R. Kelishadi and G. M. Haas (2010). "Ethnic disparities of the metabolic 
syndrome in population-based samples of german and Iranian adolescents." Metab 
Syndr Relat Disord 8(2): 189-192. 
Schwandt, P., R. Kelishadi, R. Q. Ribeiro, G. M. Haas and P. Poursafa (2010). "A three-
country study on the components of the metabolic syndrome in youths: the BIG 
Study." Int J Pediatr Obes 5(4): 334-341. 
Sever, P. S., N. R. Poulter, B. Dahlof, H. Wedel, R. Collins, et al. (2005). "Reduction in 
cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: 
Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)." 
Diabetes Care 28(5): 1151-1157. 
Seviour, P. W., T. K. Teal, W. Richmond and R. S. Elkeles (1988). "Serum lipids, lipoproteins 
and macrovascular disease in non-insulin-dependent diabetics: a possible new 
approach to prevention." Diabet Med 5(2): 166-171. 
Seyum, B., G. Mebrahtu, A. Usman, J. Mufunda, B. Tewolde, et al. (2010). "Profile of patients 
with diabetes in Eritrea: results of first phase registry analyses." Acta Diabetol 
47(1): 23-27. 
Shai, I., E. B. Rimm, M. B. Schulze, N. Rifai, M. J. Stampfer, et al. (2004). "Moderate alcohol 
intake and markers of inflammation and endothelial dysfunction among diabetic 
men." Diabetologia 47(10): 1760-1767. 
 




Okafor, C. I., O. A. Fasanmade and D. A. Oke (2008). "Pattern of dyslipidaemia among 
Nigerians with type 2 diabetes mellitus." Niger J Clin Pract 11(1): 25-31. 
Onat, A., G. Surdum-Avci, M. Senocak, E. Ornek and Y. Gozukara (1992). "Plasma lipids and 
their interrelationship in Turkish adults." J Epidemiol Community Health 46(5): 
470-476. 
Palaniappan, L. P., A. C. Kwan, F. Abbasi, C. Lamendola, T. L. McLaughlin, et al. (2007). 
"Lipoprotein abnormalities are associated with insulin resistance in South Asian 
Indian women." Metabolism 56(7): 899-904. 
Pang, R. W., S. Tam, E. D. Janus, S. T. Siu, O. C. Ma, et al. (2006). "Plasma lipid, lipoprotein 
and apolipoprotein levels in a random population sample of 2875 Hong Kong 
Chinese adults and their implications (NCEP ATP-III, 2001 guidelines) on 
cardiovascular risk assessment." Atherosclerosis 184(2): 438-445. 
Pankow, J. S., D. K. Kwan, B. B. Duncan, M. I. Schmidt, D. J. Couper, et al. (2007). 
"Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: 
the Atherosclerosis Risk in Communities Study." Diabetes Care 30(2): 325-331. 
Papazafiropoulou, A., A. Sotiropoulos, E. Skliros, M. Kardara, A. Kokolaki, et al. (2009). 
"Familial history of diabetes and clinical characteristics in Greek subjects with type 
2 diabetes." BMC Endocr Disord 9: 12. 
Patel, A., F. Barzi, K. Jamrozik, T. H. Lam, H. Ueshima, et al. (2004). "Serum triglycerides as 
a risk factor for cardiovascular diseases in the Asia-Pacific region." Circulation 
110(17): 2678-2686. 
Pischon, T., C. J. Girman, F. M. Sacks, N. Rifai, M. J. Stampfer, et al. (2005). "Non-high-
density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary 
heart disease in men." Circulation 112(22): 3375-3383. 
Pongchaiyakul, C., P. Hongsprabhas and V. Pisprasert (2006). "Rural-urban difference in 
lipid levels and prevalence of dyslipidemia: a population-based study in Khon 
Kaen province, Thailand." J Med Assoc Thai 89(11): 1835-1844. 
Post GB, K. H., Twisk J, van Mechelen W. (1997). "The association between dietary patterns 
and cardiovascular disease risk indicators in healthy youngsters: results covering 
fifteen years of longitudinal development." Eur J Clin Nutr 51: 387-393. 
Psaty, B. M., M. Anderson, R. A. Kronmal, R. P. Tracy, T. Orchard, et al. (2004). "The 
association between lipid levels and the risks of incident myocardial infarction, 
stroke, and total mortality: The Cardiovascular Health Study." J Am Geriatr Soc 
52(10): 1639-1647. 
Pyorala, K., C. M. Ballantyne, B. Gumbiner, M. W. Lee, A. Shah, et al. (2004). "Reduction of 
cardiovascular events by simvastatin in nondiabetic coronary heart disease patients 
with and without the metabolic syndrome: subgroup analyses of the Scandinavian 
Simvastatin Survival Study (4S)." Diabetes Care 27(7): 1735-1740. 
Ramachandran, A., S. Mary, A. Yamuna, N. Murugesan and C. Snehalatha (2008). "High 
prevalence of diabetes and cardiovascular risk factors associated with urbanization 
in India." Diabetes Care 31(5): 893-898. 
Razak, F., S. Anand, V. Vuksan, B. Davis, R. Jacobs, et al. (2005). "Ethnic differences in the 
relationships between obesity and glucose-metabolic abnormalities: a cross-
sectional population-based study." Int J Obes (Lond) 29(6): 656-667. 
Reckless, J. P., D. J. Betteridge, P. Wu, B. Payne and D. J. Galton (1978). "High-density and 
low-density lipoproteins and prevalence of vascular disease in diabetes mellitus." 
Br Med J 1(6117): 883-886. 
 
Ethnic Difference in Lipid Profiles 
 
37 
Ridker, P. M., N. Rifai, N. R. Cook, G. Bradwin and J. E. Buring (2005). "Non-HDL 
cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, 
and CRP as risk factors for cardiovascular disease in women." Jama 294(3): 326-333. 
Roberto Robles, N., S. Barroso, G. Marcos and J. F. Sanchez Munoz-Torrero (2009). "[Lipid 
control in diabetic patients in Extremadura (Spain)]." Endocrinol Nutr 56(3): 112-
117. 
Roberts, W. C. (1989). "Recent studies on the effects of beta blockers on blood lipid levels." 
Am Heart J 117(3): 709-714. 
Ronnemaa, T., M. Laakso, V. Kallio, K. Pyorala, J. Marniemi, et al. (1989). "Serum lipids, 
lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart 
disease in non-insulin-dependent diabetic patients." Am J Epidemiol 130(4): 632-645. 
Roselli della Rovere, G., A. Lapolla, G. Sartore, C. Rossetti, S. Zambon, et al. (2003). "Plasma 
lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A 
nine-year follow-up study." Nutr Metab Cardiovasc Dis 13(1): 46-51. 
Rosengren, A., L. Welin, A. Tsipogianni and L. Wilhelmsen (1989). "Impact of cardiovascular 
risk factors on coronary heart disease and mortality among middle aged diabetic 
men: a general population study." Bmj 299(6708): 1127-1131. 
Ruixing, Y., W. Jinzhen, H. Yaoheng, T. Jing, W. Hai, et al. (2008). "Associations of diet and 
lifestyle with hyperlipidemia for middle-aged and elderly persons among the 
Guangxi Bai Ku Yao and Han populations." J Am Diet Assoc 108(6): 970-976. 
Santen, R. J., P. W. Willis, 3rd and S. S. Fajans (1972). "Atherosclerosis in diabetes mellitus. 
Correlations with serum lipid levels, adiposity, and serum insulin level." Arch 
Intern Med 130(6): 833-843. 
Sarwar, N., J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, et al. (2007). 
"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 
262,525 participants in 29 Western prospective studies." Circulation 115(4): 450-458. 
Schulze, M. B., I. Shai, J. E. Manson, T. Li, N. Rifai, et al. (2004). "Joint role of non-HDL 
cholesterol and glycated haemoglobin in predicting future coronary heart disease 
events among women with type 2 diabetes." Diabetologia 47(12): 2129-2136. 
Schwandt, P., R. Kelishadi and G. M. Haas (2010). "Ethnic disparities of the metabolic 
syndrome in population-based samples of german and Iranian adolescents." Metab 
Syndr Relat Disord 8(2): 189-192. 
Schwandt, P., R. Kelishadi, R. Q. Ribeiro, G. M. Haas and P. Poursafa (2010). "A three-
country study on the components of the metabolic syndrome in youths: the BIG 
Study." Int J Pediatr Obes 5(4): 334-341. 
Sever, P. S., N. R. Poulter, B. Dahlof, H. Wedel, R. Collins, et al. (2005). "Reduction in 
cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: 
Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)." 
Diabetes Care 28(5): 1151-1157. 
Seviour, P. W., T. K. Teal, W. Richmond and R. S. Elkeles (1988). "Serum lipids, lipoproteins 
and macrovascular disease in non-insulin-dependent diabetics: a possible new 
approach to prevention." Diabet Med 5(2): 166-171. 
Seyum, B., G. Mebrahtu, A. Usman, J. Mufunda, B. Tewolde, et al. (2010). "Profile of patients 
with diabetes in Eritrea: results of first phase registry analyses." Acta Diabetol 
47(1): 23-27. 
Shai, I., E. B. Rimm, M. B. Schulze, N. Rifai, M. J. Stampfer, et al. (2004). "Moderate alcohol 
intake and markers of inflammation and endothelial dysfunction among diabetic 
men." Diabetologia 47(10): 1760-1767. 
 




Sharma, M. D. and V. N. Pavlik (2001). "Dyslipidaemia in African Americans, Hispanics and 
whites with type 2 diabetes mellitus and hypertension." Diabetes Obes Metab 3(1): 
41-45. 
Shepherd, J., P. Barter, R. Carmena, P. Deedwania, J. C. Fruchart, et al. (2006). "Effect of 
lowering LDL cholesterol substantially below currently recommended levels in 
patients with coronary heart disease and diabetes: the Treating to New Targets 
(TNT) study." Diabetes Care 29(6): 1220-1226. 
Singh, I. M., M. H. Shishehbor and B. J. Ansell (2007). "High-density lipoprotein as a 
therapeutic target: a systematic review." Jama 298(7): 786-798. 
Sisson, S. B., S. M. Camhi, T. S. Church, C. K. Martin, C. Tudor-Locke, et al. (2009). "Leisure 
time sedentary behavior, occupational/domestic physical activity, and metabolic 
syndrome in U.S. men and women." Metab Syndr Relat Disord 7(6): 529-536. 
Smaoui, M., S. Hammami, R. Chaaba, N. Attia, K. B. Hamda, et al. (2004). "Lipids and 
lipoprotein(a) concentrations in Tunisian type 2 diabetic patients; Relationship to 
glycemic control and coronary heart disease." J Diabetes Complications 18(5): 258-
263. 
Snehalatha, C. and A. Ramachandran (2009). "Cardiovascular risk factors in the 
normoglycaemic Asian-Indian population--influence of urbanisation." Diabetologia 
52(4): 596-599. 
Sorrentino, S. A., C. Besler, L. Rohrer, M. Meyer, K. Heinrich, et al. (2010). "Endothelial-
vasoprotective effects of high-density lipoprotein are impaired in patients with 
type 2 diabetes mellitus but are improved after extended-release niacin therapy." 
Circulation 121(1): 110-122. 
Stamler, J., O. Vaccaro, J. D. Neaton and D. Wentworth (1993). "Diabetes, other risk factors, 
and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor 
Intervention Trial." Diabetes Care 16(2): 434-444. 
Steinhagen-Thiessen, E., P. Bramlage, C. Losch, H. Hauner, H. Schunkert, et al. (2008). 
"Dyslipidemia in primary care--prevalence, recognition, treatment and control: data 
from the German Metabolic and Cardiovascular Risk Project (GEMCAS)." 
Cardiovasc Diabetol 7: 31. 
Steven H, M. M., Helen H, Marc R, J.AVA K. (1986). "The role of behavioral variables and fat 
patterning in explaining ethnic differences in serum lipids and lipoproteins." Am. J. 
Epidemiol 123(5): 830-839. 
Stone, N. J. (1994). "Secondary causes of hyperlipidemia." Med Clin North Am 78(1): 117-
141. 
Sumner AE, V. G., Genovese DJ, Finley KB, Bergman RN, Boston RC. (2005). "Normal 
triglyceride levels despite insulin resistance in African Americans: role of 
lipoprotein lipase." Metabolism 54(7): 902-909. 
Sundquist J, W. M. (1999). "Cardiovascular risk factors in mexican american adults: a 
transcultural analysis of NHANES III, 1988-1994." Am. J. Public Health 89(5): 723-
730. 
Surana, S. P., D. B. Shah, K. Gala, S. Susheja, S. S. Hoskote, et al. (2008). "Prevalence of 
metabolic syndrome in an urban Indian diabetic population using the NCEP ATP 
III guidelines." J Assoc Physicians India 56: 865-868. 
Tan, C. E., S. C. Emmanuel, B. Y. Tan and E. Jacob (1999). "Prevalence of diabetes and ethnic 
differences in cardiovascular risk factors. The 1992 Singapore National Health 
Survey." Diabetes Care 22(2): 241-247. 
 
Ethnic Difference in Lipid Profiles 
 
39 
Tan, C. E., E. S. Tai, C. S. Tan, K. S. Chia, J. Lee, et al. (2003). "APOE polymorphism and lipid 
profile in three ethnic groups in the Singapore population." Atherosclerosis 170(2): 
253-260. 
Tanasescu, M., E. Cho, J. E. Manson and F. B. Hu (2004). "Dietary fat and cholesterol and the 
risk of cardiovascular disease among women with type 2 diabetes." Am J Clin Nutr 
79(6): 999-1005. 
Taylor, A. J., T. C. Villines, E. J. Stanek, P. J. Devine, L. Griffen, et al. (2009). "Extended-
release niacin or ezetimibe and carotid intima-media thickness." N Engl J Med 
361(22): 2113-2122. 
Tekes-Manova, D., E. Israeli, T. Shochat, M. Swartzon, S. Gordon, et al. (2006). "The 
prevalence of reversible cardiovascular risk factors in Israelis aged 25-55 years." Isr 
Med Assoc J 8(8): 527-531. 
Temelkova-Kurktschiev, T. S., D. P. Kurktschiev, L. G. Vladimirova-Kitova, I. Vaklinova and 
B. R. Todorova (2009). "Prevalence and type of dyslipidaemia in a population at 
risk for cardiovascular death in Bulgaria." Folia Med (Plovdiv) 51(2): 26-32. 
Thavendiranathan, P., A. Bagai, M. A. Brookhart and N. K. Choudhry (2006). "Primary 
prevention of cardiovascular diseases with statin therapy: a meta-analysis of 
randomized controlled trials." Arch Intern Med 166(21): 2307-2313. 
The DECODA Study Group (2007). "Prevalence of the metabolic syndrome in populations of 
Asian origin. Comparison of the IDF definition with the NCEP definition." Diabetes 
Res Clin Pract 76(1): 57-67. 
The Emerging Risk Factors C (2009). "Lipoprotein(a) concentration and the risk of coronary 
heart disease, stroke, and nonvascular mortality." Jama 302(4): 412-423. 
Tolonen, H., U. Keil, M. Ferrario and A. Evans (2005). "Prevalence, awareness and treatment 
of hypercholesterolaemia in 32 populations: results from the WHO MONICA 
Project." Int J Epidemiol 34(1): 181-192. 
Tsimikas S, C. P., Brilakis ES. (2009). "Relationship of oxidized phospholipids on 
apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, 
and cardiovascular risk factors: results from the Dallas Heart Study." Circulation 
119(13): 1711-1719. 
Turner, R. C., H. Millns, H. A. Neil, I. M. Stratton, S. E. Manley, et al. (1998). "Risk factors for 
coronary artery disease in non-insulin dependent diabetes mellitus: United 
Kingdom Prospective Diabetes Study (UKPDS: 23)." Bmj 316(7134): 823-828. 
U.K. Prospective Diabetes Study Investigators (1997). "U.K. Prospective Diabetes Study 27. 
Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex." Diabetes 
Care 20(11): 1683-1687. 
Umeda, T., S. Kono, Y. Sakurai, K. Shinchi, K. Imanishi, et al. (1998). "Relationship of 
cigarette smoking, alcohol use, recreational exercise and obesity with serum lipid 
atherogenicity: a study of self-defense officials in Japan." J Epidemiol 8(4): 227-234. 
Vega GL, C. L., Tang A, Marcovina S, Grundy SM, Cohen JC. (1998). "Hepatic lipase activity 
is lower in African-American men than in white American men: effects of 5' 
flanking polymorphism in the hepatic lipase gene (LIPC)." J Lipid Res 39(1): 228-
232. 
Venkatesan, A., A. Hemalatha, Z. Bobby, N. Selvaraj and V. Sathiyapriya (2006). "Effect of 
smoking on lipid profile and lipid peroxidation in normal subjects." Indian J 
Physiol Pharmacol 50(3): 273-278. 
 




Sharma, M. D. and V. N. Pavlik (2001). "Dyslipidaemia in African Americans, Hispanics and 
whites with type 2 diabetes mellitus and hypertension." Diabetes Obes Metab 3(1): 
41-45. 
Shepherd, J., P. Barter, R. Carmena, P. Deedwania, J. C. Fruchart, et al. (2006). "Effect of 
lowering LDL cholesterol substantially below currently recommended levels in 
patients with coronary heart disease and diabetes: the Treating to New Targets 
(TNT) study." Diabetes Care 29(6): 1220-1226. 
Singh, I. M., M. H. Shishehbor and B. J. Ansell (2007). "High-density lipoprotein as a 
therapeutic target: a systematic review." Jama 298(7): 786-798. 
Sisson, S. B., S. M. Camhi, T. S. Church, C. K. Martin, C. Tudor-Locke, et al. (2009). "Leisure 
time sedentary behavior, occupational/domestic physical activity, and metabolic 
syndrome in U.S. men and women." Metab Syndr Relat Disord 7(6): 529-536. 
Smaoui, M., S. Hammami, R. Chaaba, N. Attia, K. B. Hamda, et al. (2004). "Lipids and 
lipoprotein(a) concentrations in Tunisian type 2 diabetic patients; Relationship to 
glycemic control and coronary heart disease." J Diabetes Complications 18(5): 258-
263. 
Snehalatha, C. and A. Ramachandran (2009). "Cardiovascular risk factors in the 
normoglycaemic Asian-Indian population--influence of urbanisation." Diabetologia 
52(4): 596-599. 
Sorrentino, S. A., C. Besler, L. Rohrer, M. Meyer, K. Heinrich, et al. (2010). "Endothelial-
vasoprotective effects of high-density lipoprotein are impaired in patients with 
type 2 diabetes mellitus but are improved after extended-release niacin therapy." 
Circulation 121(1): 110-122. 
Stamler, J., O. Vaccaro, J. D. Neaton and D. Wentworth (1993). "Diabetes, other risk factors, 
and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor 
Intervention Trial." Diabetes Care 16(2): 434-444. 
Steinhagen-Thiessen, E., P. Bramlage, C. Losch, H. Hauner, H. Schunkert, et al. (2008). 
"Dyslipidemia in primary care--prevalence, recognition, treatment and control: data 
from the German Metabolic and Cardiovascular Risk Project (GEMCAS)." 
Cardiovasc Diabetol 7: 31. 
Steven H, M. M., Helen H, Marc R, J.AVA K. (1986). "The role of behavioral variables and fat 
patterning in explaining ethnic differences in serum lipids and lipoproteins." Am. J. 
Epidemiol 123(5): 830-839. 
Stone, N. J. (1994). "Secondary causes of hyperlipidemia." Med Clin North Am 78(1): 117-
141. 
Sumner AE, V. G., Genovese DJ, Finley KB, Bergman RN, Boston RC. (2005). "Normal 
triglyceride levels despite insulin resistance in African Americans: role of 
lipoprotein lipase." Metabolism 54(7): 902-909. 
Sundquist J, W. M. (1999). "Cardiovascular risk factors in mexican american adults: a 
transcultural analysis of NHANES III, 1988-1994." Am. J. Public Health 89(5): 723-
730. 
Surana, S. P., D. B. Shah, K. Gala, S. Susheja, S. S. Hoskote, et al. (2008). "Prevalence of 
metabolic syndrome in an urban Indian diabetic population using the NCEP ATP 
III guidelines." J Assoc Physicians India 56: 865-868. 
Tan, C. E., S. C. Emmanuel, B. Y. Tan and E. Jacob (1999). "Prevalence of diabetes and ethnic 
differences in cardiovascular risk factors. The 1992 Singapore National Health 
Survey." Diabetes Care 22(2): 241-247. 
 
Ethnic Difference in Lipid Profiles 
 
39 
Tan, C. E., E. S. Tai, C. S. Tan, K. S. Chia, J. Lee, et al. (2003). "APOE polymorphism and lipid 
profile in three ethnic groups in the Singapore population." Atherosclerosis 170(2): 
253-260. 
Tanasescu, M., E. Cho, J. E. Manson and F. B. Hu (2004). "Dietary fat and cholesterol and the 
risk of cardiovascular disease among women with type 2 diabetes." Am J Clin Nutr 
79(6): 999-1005. 
Taylor, A. J., T. C. Villines, E. J. Stanek, P. J. Devine, L. Griffen, et al. (2009). "Extended-
release niacin or ezetimibe and carotid intima-media thickness." N Engl J Med 
361(22): 2113-2122. 
Tekes-Manova, D., E. Israeli, T. Shochat, M. Swartzon, S. Gordon, et al. (2006). "The 
prevalence of reversible cardiovascular risk factors in Israelis aged 25-55 years." Isr 
Med Assoc J 8(8): 527-531. 
Temelkova-Kurktschiev, T. S., D. P. Kurktschiev, L. G. Vladimirova-Kitova, I. Vaklinova and 
B. R. Todorova (2009). "Prevalence and type of dyslipidaemia in a population at 
risk for cardiovascular death in Bulgaria." Folia Med (Plovdiv) 51(2): 26-32. 
Thavendiranathan, P., A. Bagai, M. A. Brookhart and N. K. Choudhry (2006). "Primary 
prevention of cardiovascular diseases with statin therapy: a meta-analysis of 
randomized controlled trials." Arch Intern Med 166(21): 2307-2313. 
The DECODA Study Group (2007). "Prevalence of the metabolic syndrome in populations of 
Asian origin. Comparison of the IDF definition with the NCEP definition." Diabetes 
Res Clin Pract 76(1): 57-67. 
The Emerging Risk Factors C (2009). "Lipoprotein(a) concentration and the risk of coronary 
heart disease, stroke, and nonvascular mortality." Jama 302(4): 412-423. 
Tolonen, H., U. Keil, M. Ferrario and A. Evans (2005). "Prevalence, awareness and treatment 
of hypercholesterolaemia in 32 populations: results from the WHO MONICA 
Project." Int J Epidemiol 34(1): 181-192. 
Tsimikas S, C. P., Brilakis ES. (2009). "Relationship of oxidized phospholipids on 
apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, 
and cardiovascular risk factors: results from the Dallas Heart Study." Circulation 
119(13): 1711-1719. 
Turner, R. C., H. Millns, H. A. Neil, I. M. Stratton, S. E. Manley, et al. (1998). "Risk factors for 
coronary artery disease in non-insulin dependent diabetes mellitus: United 
Kingdom Prospective Diabetes Study (UKPDS: 23)." Bmj 316(7134): 823-828. 
U.K. Prospective Diabetes Study Investigators (1997). "U.K. Prospective Diabetes Study 27. 
Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex." Diabetes 
Care 20(11): 1683-1687. 
Umeda, T., S. Kono, Y. Sakurai, K. Shinchi, K. Imanishi, et al. (1998). "Relationship of 
cigarette smoking, alcohol use, recreational exercise and obesity with serum lipid 
atherogenicity: a study of self-defense officials in Japan." J Epidemiol 8(4): 227-234. 
Vega GL, C. L., Tang A, Marcovina S, Grundy SM, Cohen JC. (1998). "Hepatic lipase activity 
is lower in African-American men than in white American men: effects of 5' 
flanking polymorphism in the hepatic lipase gene (LIPC)." J Lipid Res 39(1): 228-
232. 
Venkatesan, A., A. Hemalatha, Z. Bobby, N. Selvaraj and V. Sathiyapriya (2006). "Effect of 
smoking on lipid profile and lipid peroxidation in normal subjects." Indian J 
Physiol Pharmacol 50(3): 273-278. 
 




Villines, T. C., E. J. Stanek, P. J. Devine, M. Turco, M. Miller, et al. (2010). "The ARBITER 6-
HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of 
Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) 
Final Results and the Impact of Medication Adherence, Dose, and Treatment 
Duration." J Am Coll Cardiol: doi:10.1016/j.jacc.2010.1003.1017. 
Vlajinac, H., M. Ilic and J. Marinkovic (1992). "Cardiovascular risk factors and prevalence of 
coronary heart disease in type 2 (non-insulin-dependent) diabetes." Eur J Epidemiol 
8(6): 783-788. 
Wang, J., S. Ruotsalainen, L. Moilanen, P. Lepisto, M. Laakso, et al. (2007). "The metabolic 
syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly 
non-diabetic Finns." Eur Heart J 28(7): 857-864. 
Wang W, H. D., Lee ET. (2002). "Lipoprotein(a) in American Indians is low and not 
independently associated with cardiovascular disease: the Strong Heart Study." 
Ann. Epidemiol. 12(2): 107-114. 
Werk, E. E., Jr., J. J. Gonzalez and J. E. Ranney (1993). "Lipid level differences and 
hypertension effect in blacks and whites with type II diabetes." Ethn Dis 3(3): 242-
249. 
Wilson, P. W., R. D. Abbott and W. P. Castelli (1988). "High density lipoprotein cholesterol 
and mortality. The Framingham Heart Study." Arteriosclerosis 8(6): 737-741. 
Wood, P. D., M. P. Stern, A. Silvers, G. M. Reaven and J. von der Groeben (1972). 
"Prevalence of plasma lipoprotein abnormalities in a free-living population of the 
Central Valley, California." Circulation 45(1): 114-126. 
World Health Organization (2007). "Prevention of cardiovascular disease: guideline for 
assessment and management of cardiovascular risk." WHO Press. 
Wu, D. M., L. Pai, P. K. Sun, L. L. Hsu and C. A. Sun (2001). "Joint effects of alcohol 
consumption and cigarette smoking on atherogenic lipid and lipoprotein profiles: 
results from a study of Chinese male population in Taiwan." Eur J Epidemiol 17(7): 
629-635. 
Zaman, M. M., N. Yoshiike, M. A. Rouf, M. H. Syeed, M. R. Khan, et al. (2001). 
"Cardiovascular risk factors: distribution and prevalence in a rural population of 
Bangladesh." J Cardiovasc Risk 8(2): 103-108. 
Zaninotto, P., J. Mindell and V. Hirani (2007). "Prevalence of cardiovascular risk factors 
among ethnic groups: results from the Health Surveys for England." 
Atherosclerosis 195(1): e48-57. 
Zhang, X., Z. Sun, D. Zhang, L. Zheng, J. Li, et al. (2009). "Prevalence and association with 
diabetes and obesity of lipid phenotypes among the hypertensive Chinese rural 
adults." Heart Lung 38(1): 17-24. 
Zhao, W. H., J. Zhang, Y. Zhai, Y. You, Q. Q. Man, et al. (2007). "Blood lipid profile and 
prevalence of dyslipidemia in Chinese adults." Biomed Environ Sci 20(4): 329-335. 
3 
Nutrigenetics and Dyslipidemia  
Maryam Shalileh 
Islamic Azad University of Hamedan Branch 
Iran 
1. Introduction 
Dyslipidemia is an abnormal amount of lipids (abnormality in any of the lipoprotein 
fractions), especially elevated Low Density Lipoprotein (LDLs) and decreased High Density 
Lipoprotein (HDLs) in the blood (Shalileh et al., 2009). In developed countries, most 
dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood, are often due 
to diet and lifestyle (Wikipedia., 2011; Shalileh et al., 2009). According to the Katharina 
studie’s, elevated cholesterol levels and dyslipoproteinemia are metabolic abnormalities that 
are becoming increasingly significant in industrialized countries, but also worldwide 
(Shalileh et al., 2009).  
There is a proportional increase in the risk of Coronary Heart Disease (CHD) with rising 
serum cholesterol levels (Shalileh et al., 2009). Dyslipidaemia is an important risk factor for 
Cardiovascular Disease (CVD) (Masson & McNeili., 2005).  
CVD is a common killer in both the Western and the developing world and is the leading 
cause of death globally (Lovegrove & Gitau., 2008).  
More people die annually from CVDs than from any other cause. An estimated 17. 1 
million people died from CVDs in 2004, representing 29%of all global deaths. Of these 
deaths, an estimated 7. 2 million were due to CHD and 5. 7 million were due to stroke. By 
2030, almost 23. 6 million people will die from CVDs, mainly from heart disease and 
stroke (WHO. 2011).  
Atherosclerosis is the most common cause of CHD and related mortality (Debra., 2008; 
Shalileh et al., 2009) .Endothelial dysfunction initiates atherosclerosis (Shalileh et al., 2009) .
The first observable event in the process of atherosclerosis is the accumulation of plaque 
(cholesterol from low-density lipoproteins, calcium, and fibrin) in the endothelium in large 
and medium arteries (Debra., 2008).  
One of the factors that causes endothelial dysfunction is dyslipidemia (Shalileh et al., 2009).  
2. Treatment 
CVD represents the paradigm of multi factorial disorders encompassing multiple genetic 
and non modifiable risk factors, for example older age and modifiable risk factors such as 
elevated total and LDL-cholesteroland and triglycerides concentrations, reduced HDL-
cholesterol concentrations (Ordovas & Corella., 2004; Ordovas., 2009; Perez-Martinez et al, 
2011; Lovegrove & Gitau, 2008). The interactions of those modulate plasma lipid 
concentrations and potentially CVD risk (Ordovas., 2009; Lovegrove & Gitau., 2008).  
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The link between serum cholesterol and the development of atherosclerosis was established 
a few decades ago and is now widely accepted. The National Cholesterol Education 
Program (NCEP) Adult Treatment Panel (ATP) publishes updated guidelines for treating 
lipid disorders. The latest version is the ATP III (Ordovas & Corella., 2004; Debra., 2008).  
The current recommendations aim to reduce the classical modifiable risk factors, and much 
emphasis has been placed on controlling high-plasma cholesterol levels (Ordovas & 
Corella., 004).  
Physicians are encouraged to refer patients to Registered Dietitians (RDs) to help patients 
meet goals for therapy (NCEP) based on LDL cholesterol levels. So the ATP III 
recommended the therapeutic lifestyle change (TLC) dietary pattern as the cornerstone for 
primary and secondary prevention of CHD. These guidelines consider dietary modification 
of treatment with emphasis on reducing the high saturated fat atherogenic diet and 
increased content of polyunsaturated fatty acid (PUFA) as well as controlling other 
behavioral factors. These therapies are used primarily to lower elevated blood levels of LDL-
C, raise HDL –C and lower triglycerides (TGs) (Rubin & Berglund., 2002; Debra., 2008; 
Ordovas & Orella., 2004).  
3. Response to the diet therapy 
Although dietary recommendations have been implemented to improve health and 
diminish the risk of CVD, type 2 diabetes and obesity, these recommendations have been 
established based on populations and not the individual. On the other hand the approach 
has been surprisingly unsuccessful in reducing CVD risk and the drastically different inter 
individual responses to a diet (Ordovas & Corella., 2004).  
So this clearly highlights the limitations of population-based nutritional recommendations 
and suggests that our understanding of the mechanisms responsible for inter-individual 
differences are far from being understood (Much et al., 2005).  
Recent clinical evidence suggests dramatic inter-individual differences and existence  
of consistent hypo- and hyperresponders in response of plasma lipids to dietary 
manipulations, ranging from reduced LDL-C levels and TGs in some, to decreased HDL-C 
levels to elevated TGs. So in some, a low-fat diet has caused a shift to a lipid pattern that is 
more atherogenic than the original one. This supports the hypothesis that responsiveness is 
related to genetic variation and existence of nutrient–gene interactions or personsۥ genotype 
(defined by the term ‘nutrigenetics’) (DeBusk, 2008; Perez-Martinez et al., 2011; Masson et 
al., 2003; Rideout., 2011; Ordovas et al., 2007).  
A classic example of this is the large variation in the concentration of serum low-density 
lipoprotein-cholesterol (LDL-C) in response to fish oil supplementation. The cardio 
protective effects of the fatty acids in fish oil, Eicosapentaenoic Acid (EPA) and 
Docosahexaenoic Acid (DHA) are well recognized. However, a potentially deleterious 
increase in LDL-C (5–10%) has been consistently reported after moderate to high doses of 
fish oil (>2 g day−1 EPA + DHA) (Lovegrove & Gitau., 2008).  
Despite this small, but significant increase in LDL-C, closer examination of the responses 
revealed a noticeable inter-individual variation. There was a mean increase in LDL-C of 4. 
1%, yet the spread of individual responses was substantial, with 33 of the 74 subjects 
demonstrating a lower serum LDL-C and the remaining 41 demonstrating a higher LDL-C 
(range −40 to +113%) following fish oil intervention. This heterogeneous response to a 
change in dietary fat, may be attributed to a number of factors; including age, gender, 
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baseline LDL-C levels, disease status and drug use. However, recent evidence strongly 
suggests that variations in a number of key genes may also be important (Lovegrove & 
Gitau., 2008). For example, individuals with specific of genetic variants in a gene may 
experience different type of lipoprotein changes when placed on a particular diet, whereas 
individuals with other variants in the gene may be resistant to the effects of the same diet. 
Although data is sparse in regard to whether such interactions exist, some limited work 
suggests that interactions may play an important role in determining lipoprotein profiles 
and may thus be informative for CVD risk prediction. For example, knowledge of a patient’s 
genetic information may allow medical providers and nutritional counselors to predict what 
lipoprotein changes are likely to occur if the patient starts a particular dietary intervention 
and, thus, better advise the patient regarding lifestyle changes (Musunuru., 2010; Ordovas & 
Corella., 2004).  
Lipoproteins are macromolecular complexes of lipids and proteins that originate mainly in 
the liver and intestine and are involved in transporting and redistributing lipids in the body. 
Lipid homeostasis is achieved by the coordinated action of numerous nuclear factors, 
enzymes, apolipoproteins, binding proteins, and receptors. Lipid metabolism is also 
linked with energy metabolism and is subject to many hormonal controls essential for 
adjusting to environmental and internal conditions. Genetic variability exists in humans 
for most of these components, and some of these mutations result in abnormal lipid 
metabolism and plasma lipoprotein profiles that may contribute to the pathogenesis of 
atherosclerosis. Many of these genes have been explored in terms of gene-diet interactions 
(Ordovas & Corella., 2004).  
So the shift towards personalized nutritional advice is a very attractive proposition, where, 
in principle, an individual can be given dietary advice specifically tailored to their genotype. 
However, the evidence-base for the impact of interactions between nutrients and fixed 
genetic variants on biomarkers of CVD risk is still very limited (Lovegrove & Gitau., 2008; 
Ordovas., 2006; Masson et al., 2003; Masson & Mc Neil., 2005; Fisler & Warden., 2005).  
With the advent of nutritional genomics, it's becoming clear that an individual's genetic 
makeup (genotype) is an important factor in this response and that dietary interventions 
must be matched to genotypes to effect the intended lipid-lowering responses (DeBusk., 
2008).  
A number of such genes have already been identified and include those involved with 
postprandial lipoprotein and triglyceride responses, homocysteine metabolism, 
hypertension, blood-clotting, and inflammation (Ordovas & Corella., 2004; DeBusk., 2008).  
Genetic polymorphism in human populations is part of the evolutionary process that results 
from the interaction between the environment and the human genome. Recent changes in 
diet have upset this equilibrium, potentially influencing the risk of most common 
morbidities such as cardiovascular diseases, diabetes, and cancer. Reduction of these 
conditions is a major public health concern, and such a reduction could be achieved by 
improving our ability to detect disease predisposition early in life and by providing more 
personalized behavioral recommendations for successful primary prevention. In terms of 
cardiovascular diseases, polymorphisms at multiple genes have been associated with 
differential effects in terms of lipid metabolism. The integration of genetic and 
environmental complexity into current and future research will drive the field toward the 
implementation of clinical tools aimed at providing dietary advice optimized for the 
individual's genome (Ordovas., 2009; Engler., 2009).  
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The recognition that nutrients have the ability to interact and modulate molecular 
mechanisms underlying an organism’s physiological functions has prompted a revolution in 
the field of nutrition (Much et al., 2005).  
For the field of nutrition, this would encompass the ongoing efforts to understand the 
relationships between the genome and diet, currently termed nutrigenomics and 
nutrigenetics (Much et al., 2005; Ommen., 2004) 
4. Nutritional genomics 
Nutrigenetics and nutrigenomics are promising multidisciplinary fields that focus on 
studying the interactions between nutritional factors, genetic factors and health outcomes. 
Their goal is to achieve more efficient individual dietary intervention strategies aimed at 
preventing disease, improving quality of life and achieving healthy aging (Ordovas., 2004).  
In contrast to most single gene disorders, chronic disorders (e. g., cardiovascular disease, 
cancer, diabetes) are far more complex. First, they involve multiple genes, each of which 
comes in more than one variation, that likely contribute in small ways to the overall 
condition rather than have the dramatic impact that is more typical with single gene 
disorders. Second, the genes are more likely to be influenced by environmental factors, 
which make the resulting phenotype murkier than with single-gene disorders. An 
individual might have gene variants that predispose to a particular chronic disorder but, 
depending on that individual's nutritional and other lifestyle choices, the disorder may or 
may not develop (DeBusk., 2008).  
Nutritional genomics or nutrigenomics is the newly developing field of science that focuses 
on the complex interaction among genes and environmental factors, specifically bioactive 
components in food and how a person’s diet interacts with his or her genotype to  
influence the balance between health and disease (DeBusk., 2009; Much et al., 2005; Fisler & 
Warden., 2005).  
Nutritional genomics is the umbrella term (Ryan-Harshman., 2008). There are two major 
subcategories of nutritional genomics: nutrigenetics and nutrigenomics (Much et al., 2005).  
The creation of nutrigenomics and nutrigenetics, two fields with distinct approaches to 
elucidate the interaction between diet and genes but with a common ultimate goal to 
optimize health through the personalization of diet, provide powerful approaches to 
unravel the complex relationship between nutritional molecules, genetic polymorphisms, 
and the biological system as a whole (Much et al., 2005).  
Thus, nutrition in the 21st century is poised to be an exciting and highly relevant field of 
research, as each new day is accompanied by advances in our understanding of how the 
interactions between lifestyle and genotype contribute to health and disease, taking us one 
step closer to achieving the highly desirable goal of personalized nutrition (Much et  
al., 2005).  
4.1 Nutrigenetics 
Nutrigenetics term was used first time by Dr R. O Brennan in 1975 (Farhud et al., 2010). 
Nutrigenetics is concerned with the effect of gene variations or gene variant or individual’s 
genetic make-up on the organism's functional ability, specifically its ability  
to digest, absorb, and use food (DeBusk., 2009; Ordovas & Corella., 2004; Lovegrove & 
Gitau., 2008). Nutrigenetics embodies the science of identifying and characterizing gene 
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variants associated with differential responses to nutrients or dietary pattern, functional 
food or supplement on a specific health outcome, and relating this variation to disease states 
(Much et al., 2005; Michael., 2008). The particular gene variants a person has to determine 
the nutritional requirements for that person and the gene-based differences in response to 
dietary components and developing nutraceuticals that are most compatible with health 
based on individual genetic makeup (DeBusk., 2009; Subbiah., 2007). Nutrigenetics will 
assist clinicians in identifying the optimal diet for a given individual, i. e., personalized 
nutrition (Much et al., 2005; Svacina., 2007; Zak & Slaby., 2007; Gillies., 2003).  
Furthermore, the concept is that if an individual is genotyped at various genes for disease-
associated risk alleles, a genotype-based diet or nutritional supplement regimen may be 
useful to overcome the genetic variation and reduce risk or prevent the disease altogether 
(Wood., 2008; Xacur-GarcAa et al., 2008; Kussmann & Fay., 2008).  
4.2 Nutrigenomics 
Nutrigenomics, is concerned with how bioactive components within food affect genes. The 
field of nutritional genomics is still evolving, and it is common to see "nutrigenomics" used 
as a shorthand version of "nutritional genomics ". However, keeping the concepts separate 
can be helpful when sorting out the underlying mechanisms involved (DeBusk., 2009). 
Nutrigenomics will unravel the optimal diet from within a series of nutritional alternatives, 
whereas nutrigenetics will help clinicians in identifying the optimal diet for a given 
individual, i. e., personalized nutrition (Much et al., 2005).  
Although these two concepts are intimately associated, they take a fundamentally different 
approach to understanding the relationship between genes and diet. Despite the immediate 
goals differing, the long-term goal of improving health and preventing disease with 
nutrition requires the amalgamation of both disciplines (Much et al., 2005)  
Nutrigenetics is the more familiar of the two subtypes of nutritional genomics (DeBusk., 
2009) At one end of the spectrum of nutritional genomics are the highly penetrant 
monogenic disorders that give rise to inborn errors of metabolism such as phenylketonuria 
(DeBusk., 2009). More recently less penetrant, more subtle variations have been identified 
that also affect the gene-encoded protein's function. However, such variations do not in 
themselves cause disease. Instead, they alter a person's susceptibility for developing a 
disease. Depending on the specific gene variant, the person's likelihood of developing a 
disorder may be increased or reduced. These genes are the primary focus of nutritional 
genomics, because they are common within the global population, they affect dietary 
recommendations about the types and amounts of food that best fit a person, and 
practical interventions are possible. These interventions can potentially improve the 
health potential of individual people and, by extrapolation, the populations in which they 
live (DeBusk., 2009).  
Current nutrition recommendations, directed towards populations, are based on estimated 
average nutrient requirements for a target population and intend to meet the needs of most 
individuals within that population. They also aim at preventing common diseases such as 
obesity, diabetes and cardiovascular disease. So diet has been reported as a major 
contributor to alarming prevalence of obesity (Shalileh et al, 2010). For infants with specific 
genetic polymorphisms, e. g. some inborn errors of metabolism such as phenylketonuria, 
adherence to current recommendations will cause disease symptoms and they need 
personalized nutrition recommendations (Hernell & West., 2008; Farhud & Shalileh., 2008).  
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variants associated with differential responses to nutrients or dietary pattern, functional 
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Some other monogenic polymorphisms, e. g. adult hypolactasia, are common but with 
varying prevalence between ethnic groups and within populations. Ages at onset as well as 
the degree of the resulting lactose intolerance also vary, making population-based as well as 
personalized recommendations difficult. The tolerable intake is best set by each individual 
based on symptoms. For polygenetic diseases such as celiac disease, and allergic disease, 
current knowledge is insufficient to suggest personalized recommendations aiming at 
primary prevention for all high-risk infants, although it may be justified to provide such 
recommendations on an individual level should the parents ask for them.  
New technologies such as nutrigenetics and nutrigenomics are promising tools with which 
current nutrition recommendations can possibly be refined and the potential of 
individualized nutrition be explored. It seems likely that in the future it will be possible  
to offer more subgroups within a population personalized recommendations (hernell & 
West., 2008).  
The possibility of offering personalized nutritional advice to the individual is an attractive 
option for dietitians and nutrition scientists and is becoming practicable with the emergence 
of nutritional genomics. This developing field promises to revolutionize dietetic practice, 
with dietary advice prescribed according to an individual’s genetic makeup to prevent, 
mitigate or cure chronic disease (Lovegrove & Gitau., 2008). It has been also termed 
“personalized nutrition” or “individualized nutrition” (Ordovas & Corella., 2004; Perez-
Martinez et al., 2011). The practical applications of this research include a new set of tools 
that nutrition professionals can use to identify disease susceptibilities and a growing body 
of knowledge that will form the basis for developing strategies for disease prevention and 
intervention that are specifically targeted to the underlying genetic mechanisms (DeBusk., 
2008).  
Nutrigenetics and personalized nutrition are components of the concept that in the future 
genotyping will be used as a means of defining dietary recommendations to suit the 
individual. Over the last two decades there has been an explosion of research in this area, 
with often conflicting findings reported in the literature (Rimbach & Minihane., 2009).  
According to WHO reports, diet factors influence occurrence of more than 2/3 of diseases. 
Most of these factors belong to the categories of nutrigenetics and nutrigenomics. In the 
future both, nutrigenetics and nutrigenomics, will induce many changes in preventive 
medicine and also in clinical medicine (Svacina., 2007).  
Nutrients interact with the human genome to modulate molecular pathways that may 
become disrupted, resulting in an increased risk of developing various chronic diseases. 
Understanding how genetic variations influence nutrient digestion, absorption, transport, 
biotransformation, uptake and elimination will provide a more accurate measure of 
exposure to the bioactive food ingredients ingested. Furthermore, genetic polymorphisms in 
the targets of nutrient action such as receptors, enzymes or transporters could alter 
molecular pathways that influence the physiological response to dietary interventions. 
Knowledge of the genetic basis for the variability in response to these dietary factors should 
result in a more accurate measure of exposure of target tissues of interest to these 
compounds and their metabolites. Examples of how 'slow' and 'fast' metabolizers respond 
differently to the same dietary exposures will be discussed. Identifying relevant diet-gene 
interactions will benefit individuals seeking personalized dietary advice as well as improve 
public health recommendations by providing sound scientific evidence linking diet and 
health (EL-Sohemy, 2007; Amouyel., 2000).  
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A really personalized diet will be a diet considering the nutritional status, the nutritional 
needs based on age, body composition, work and physical activities, but also considering 
the genotype. That is, define the "nutritional phenotype (Perez-Martinez et al., 2011; 
Miggiano   & De Sanctis., 2006). It is clear that integrating knowledge of gene variants into 
dietary recommendations for populations and individuals will increasingly play a role in 
nutrition counseling and policy making (DeBusk., 2008).  
Nutrigenetics will provide the basis for personalized dietary recommendations based on the 
individual's genetic makeup. This approach has been used for decades for certain single 
gene diseases; such as phenylketonuria, however, the challenge is to implement a similar 
concept for common multi factorial disorders and to develop tools to detect genetic 
predisposition and to prevent common disorders decades before their manifestation. The 
preliminary results involving gene-diet interactions for cardiovascular diseases and cancer 
are promising, but mostly inconclusive. Success in this area will require the integration of 
different disciplines and investigators working on large population studies designed to 
adequately investigate gene-environment interactions (Ordovas & Corella., 2004; Ordovas & 
Mooser., 2004).  
4.3 Nutritional genomics and lipid metabolism 
From a health perspective, the major concerns regarding genes and lipid metabolism center 
on susceptibility to vascular disease. Genes involved with cholesterol homeostasis offer 
examples of how genetic variations affect lipid metabolism and, thereby, disease risk 
(DeBusk., 2009).  
The blood lipid response to diet is influenced by polymorphisms within genes for the 
apolipoproteins as well as within those for enzymes, such as hepatic lipase, that are 
involved in lipid metabolism (fisler & Warden., 2005).  
The major focus of nutritional genomics research is on identifying (1) gene-disease 
associations, (2) the dietary components that influence these associations, (3) the 
mechanisms by which dietary components exert their effects, and (4) the genotypes that 
benefit most from particular dietary choices (DeBusk., 2008).  
The following section takes a brief look at some of the key diet-related genes and their 
known variants and how these variants affect the person's response to diet. Keep in mind 
that chronic diseases involve complex interactions among genes and bioactive food 
components, and unraveling the details will require population and intervention studies 
large enough to have the statistical power needed to draw meaningful conclusions. 
Although what is known today is but the tip of the iceberg compared to what will come in 
the years ahead (DeBusk., 2008).  
Over the last two decades there has been an explosion of research in this area, with often 
conflicting findings reported in the literature (Rimbach & Minihan., 2009).  
5. Candidate gene approach 
The candidate gene approach involves the selection and study of biologically relevant genes. 
Genetic polymorphisms in these genes, known as Single-Nucleotide Polymorphism (SNPs), 
can alter susceptibility to a disease. Candidate or "susceptibility" genes should meet one or 
more of the following conditions: genes that are chronically activated during a disease state 
and have been previously demonstrated to be sensitive to dietary intervention; genes with 
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molecular pathways that influence the physiological response to dietary interventions. 
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functionally important variations; genes that have an important hierarchical role in 
biological cascades; polymorphisms that are highly prevalent in the population (usually 
>10% for public health relevance); and/or genes with associated biomarkers, rendering 
clinical trials useful (Lovegrove & Gitau., 2008).  
Many studies have investigated this possibility and have largely focused on genes whose 
products affect lipoprotein metabolism, eg, apolipoproteins, enzymes, and receptors. 
Although there have been several reviews of such studies, many of them may have led to 
articles being omitted and introduced bias toward positive findings (Ordovas., 2006).  
5.1 Apolipoprotein A-I (Apo AI)  
The Apo AI gene, codes for apolipoprotein A-I, is a major structural and functional 
component of HDL constituting about 70% to 80% of HDL protein mass, and is the main 
activator of the enzyme lecithin cholesterol acyl transferase (LCAT) (Ordovas & Corella., 
2004; Lovegrove & Gitau., 2008; Much et al., 2005; DeBusk., 2008).  
Plasma HDL-cholesterol plays a protective role for CVD (Lovegrove & Gitau., 2008; Much et 
al., 2005). Its gene product Apo A-I plays a central role in lipid metabolism and CVD risk. 
Pedigree studies have reported associations between genetic variation at the Apo A1 locus 
and plasma lipid and lipoprotein levels (Ordovas & Corella., 2004). One of the variants that 
has been identified to be diet-related is -75G>A, in which the typical guanine has been 
replaced with an adenine at position 75 within the regulatory region of the Apo A-I gene 
(DeBusk., 2008).  
It was reported that this polymorphism was associated with Apo A-I and HDL-C 
concentrations, and individuals carrying the A-allele presented with the highest levels, 
compared with subjects homozygotes for the G allele (G/G) but many studies have had 
contradictory results (Lovegrove & Gitau., 2008; Ordovas & Corella., 2004).  
In the context of the Framingham Heart Study, individuals with a polymorphism in the Apo 
A1 gene promoter region (–75 G/A) were found to respond differently to dietary PUFA 
(Much et al., 2005; Lovegrove & Gitau., 2008).  
The inconsistencies in reported studies outcomes are not necessarily a result of inherent 
differences, but are a result of a nutrient–gene interaction, i. e. a classic example of where 
individualized dietary advice could be important in relation to exerting a positive influence 
on HDL-C levels and CVD risk (Lovegrove & Gitau., 2008; Much et al., 2005). In brief, that 
individuals with the A allele showed an increase in HDL levels following an increased 
consumption of PUFA. In contrast, those with the more common G allele showed an inverse 
relationship between HDL levels and PUFA consumption. This study revealed that 
differences in sex also mediate the response. Indeed, men did not show a relationship 
between HDL and PUFA consumption, irrespective of their Apo A1 polymorphism 
(Lovegrove & Gitau., 2008; Much et al., 2005).  
A common practice in treating dyslipidemia is to reduce the saturated fat content of the diet 
and increase the polyunsaturated fat content. Typically, HDL levels fall in women with the 
more common G allele as the polyunsaturated content of the diet increases, an effect counter 
to the desired one. These women would benefit from a fat modified diet that keeps amounts 
of both saturated and polyunsaturated fat low and increases amounts of monounsaturated 
fat. Women with the A allele, increasing polyunsaturated dietary fat leads to increased HDL 
levels, and the effect is "dose-dependent; so in women with the more common G allele, 
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increasing dietary Polyunsaturated Fat (PUFA) levels from less than 4% of total energy to 
4% to 8% to greater than 8% resulted in a corresponding decline in HDL levels as PUFA 
levels increase. However, in women with the A allele, increasing PUFA concentrations (>8% 
of energy derived from PUFA) increased HDL levels and the increase is more dramatic in 
the presence of two copies of the A alleles than it is with just one. For these women, a diet 
low in saturated fat, moderate in polyunsaturated fat (8% or greater of total calories), and 
supplying the rest in monounsaturated fat has the greatest benefit in raising HDL levels. 
Clearly, whether a person has the -75G>A Apo AI variant, and how many copies are 
present, will affect any therapeutic intervention developed to correct dyslipidemia (DeBusk., 
2009; Much et al., 2005; Debra., 2008).  
Juo et al (Hank Juo., 1999) used a meta analysis approach to show the lack of consistency 
between the less common A-allele and higher HDL-cholesterol concentrations. In view of 
the significant gene-diet interaction observed for those intervention studies, they 
examined whether these results could be extrapolated to a free living population, 
consisting of about 1600 Framingham Offspring Study participants (Ordovas et al., 2002). 
The results from the straightforward association between genotype and phenotype were 
disappointing and suggested that the G/A polymorphism was not associated with HDL- 
cholesterol, Apo A-I concentrations, nor with any other anthropometrical or plasma lipid 
variable examined. To examine the potential modifying effect of dietary fat on these 
associations, they fitted multivariate linear regression models, including interaction terms 
for fat intake [total, Saturated Fatty Acid (SFA), Monounsaturated Fat (MUFA), and PUFA 
fat]. No significant interactions were observed between the G/A polymorphism, total, 
SFA, and MUFA fat intakes. However, in women, HDL-cholesterol concentrations were 
associated with a significant interaction between PUFA intake and Apo A1 genotype  
 (p = 0. 005). Using PUFA as a dichotomous variable, their data show that G/G women 
consuming <6% PUFA/day had higher HDL-cholesterol (1. 48 ± 0. 40 m mol/L) than A-
carriers (1. 43 ± 0. 40 m mol/L). Conversely, when consuming ≥6% PUFA/day, G/G had 
lower HDL-cholesterol concentrations (1. 44 ± 0. 39 m mol/L) than A-carriers (1. 49 ± 0. 39 
m mol/L). In men, the situation was more complex because the effects were observed 
using three-way interactions, including smoking and alcohol consumption, in the 
analyzes (Ordovas & Corella., 2004).  
The most evident application of these results may be to help us make more efficacious 
dietary recommendations based on genetic profile. It is clear that subjects with the A-allele 
at this Apo A1–75 (G/A) polymorphism will benefit from diets containing a high percentage 
(it is important to underscore that we are talking about percent in the diet and not about 
total amounts) of PUFA (i. e., vegetable oils, fish, nuts, and so on). According to their data, 
this should result in higher HDL-cholesterol concentrations, which in turn should lower 
CVD risk. These findings suggest that the expression of the Apo A1 gene may be regulated 
by PUFA (Ordovas & Corella., 2004).  
On the other hand, of 13 reports, 5 found that the presence of the Apo A-I–75 (G/A) A allele 
instead of the common G allele resulted in greater LDL-cholesterol responses to changes in 
dietary. In addition, significant interactions between the G/A genotype and diet were found 
for changes in total and LDL cholesterol when subjects changed from a low-fat diet to a diet 
high in MUFAs. No significant interactions between diet and other polymorphisms in the 
Apo A-I gene were shown (Ordovas & Corella., 2004).  
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5.2 Apolipoprotein A-IV (APOA4) 
Apo A-IV is a 46-Kd plasma glycoprotein that is synthesized by intestinal enterocytes 
during lipid absorption and is incorporated into nascent chylomicrons. Apo A-IV enters 
circulation on lymph chylomicrons, but then dissociates from their surface and circulates 
primarily as a lipid-free protein. Several genetically determined isoforms of Apo A-IV have 
been detected; amino acid positions 360 and 347 of the mature protein are the most 
common. The polymorphism at position 360 is due to a CAG → CAT substitution at codon 
360 in the Apo A4 gene and encodes a Q360H (Gln → His) substitution in the carboxyl 
terminus, and produces an isoform, originally known as Apo A-IV-2, one charge unit more 
basic than the common isoform, Apo A-IV-. In some population studies the Apo A-IV-2 
allele is associated with higher levels of HDL-cholesterol and or Apo A-I and/or lower 
triglyceride (TG) levels, as well as lower LDL-cholesterol, lower Lp (a), and higher fasting 
glucose and insulin levels, but no associations have been observed in other studies (Ordovas 
& Corella., 2004).  
The other common mutation (Thr347→Ser) is due to an ACT→TCT substitution at codon 
347 in the human Apo A-IV gene, it is found within subjects with the apoA-IV-1 isoform. 
Several population studies note that carriers of the 347S allele have lower plasma, total, 
LDL-cholesterol, Apo B levels, and Lp (a) levels, than 347T/T homozygotes. The results of 
many reports showing that male carriers of the less common allele at the Gln360His 
polymorphism were less responsive to changes in dietary fat and cholesterol or cholesterol 
alone (Ordovas & Corella., 2004).  
Several studies have focused on the interaction between the Apo A4 locus and dietary 
factors, both in the fasting and postprandial states. Similar to the findings for other genes, 
the data are conflicting when it comes to the effect of Apo A-IV polymorphisms on the LDL 
response to dietary cholesterol. However, according to Weinberg (Weinberg., 2002), the 
results from different studies can be partially reconciled if one assumes that the dietary fatty 
acid effects dominate over the allele effects. Therefore, if dietary cholesterol intake is the 
principal variable, and total fat intake is moderate and constant, Q/H subjects display an 
attenuated response of LDL-cholesterol. However, when dietary cholesterol intake is 
changed in the setting of a higher baseline dietary fat intake or with a change in fat 
saturation, the fatty acid effects on LDL levels predominate and overrule the allele effect. 
The impact of the Q360H polymorphism on cholesterol absorption may be greater on a high 
PUFAs intake. However, dietary PUFA counteract the effect of dietary cholesterol on the 
expression of hepatic LDL receptors. Thus, the final effect of Apo AIV alleles on the LDL 
response to dietary cholesterol may be determined by the relative amounts of cholesterol, 
saturated fatty acids (SAFAs), and PUFAs in the diet (winberg et al., 2000; Weggemans., 
2000; Lopez-Miranda., 1998; Ordovas & Corella., 2004; Hockey., 2001).  
There is more consistency and probably less complexity regarding the impact of Apo A-IV 
polymorphisms on HDL-cholesterol: When total fat intake is raised or lowered, Q/H 
subjects have an exaggerated, and Threonine /Serine (T/S) subjects an attenuated, response 
in plasma HDL levels. It has been suggested, and Weinberg demonstrated, that a high-
PUFA intake may amplify this effect (Ordovas & Corella., 2004; Winberg et al., 2000).  
Given the relationships between plasma TG and plasma HDL-cholesterol levels, it is 
possible that the response of plasma HDL-cholesterol levels to changes in dietary fat is 
mediated by Apo A-IV allele effects on postprandial triglyceride-rich lipoprotein 
metabolism. These studies clearly illustrate the extreme complexity associated with the 
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interpretation of results from studies involving gene-diet interactions (Ordovas & Corella., 
2004).  
The presence of serine instead of threonine at position 347 in the Apo A-IV gene was 
associated with increased total and LDL-cholesterol responsiveness when subjects switched 
from a high-SFA diet to a National Cholesterol Education Program Step I diet. When the 
same subjects changed from the National Cholesterol Education Program Step I diet to a 
high-MUFA diet, subjects with the Thr /Thr genotype had a 1% decrease in total cholesterol 
concentrations, whereas subjects with the Ser allele had a 5% increase in total cholesterol 
concentrations. When the Thr347Ser and the Apo A-I–75 (G/A) genotypes were combined, 
carriers of the A and Ser alleles showed greater LDL-cholesterol responses to changes in 
dietary fat. However, Carmena-Ramon et al (Carmena-Ramon et al., 1998) investigated both 
the Gln360His and Thr347Ser polymorphisms and found no gene-diet or haplotype-diet 
interactions (Masson et al., 2003). The evidence that exists for an interaction between diet 
and the Apo A-IV glutamine-histidine mutation at position 360 (Gln360His) suggests that 
Gln / Gln subjects show significantly greater total and LDL-cholesterol responses and that 
Gln /His subjects show greater HDL-cholesterol responses to changes in dietary fat, 
cholesterol, or both. Although Wallace et al found no significant differences in LDL-
cholesterol responses between genotypes, dense LDL cholesterol decreased more in subjects 
carrying the His allele when polyunsaturated fatty acids (PUFAs) replaced SFAs in the diet 
(Wallace et al, 2000). In the same study, there was a significant difference in HDL-cholesterol 
responses between genotype groups such that concentrations decreased in Gln /Gln subjects 
and increased in Gln /His subjects (Masson et al., 2003).  
5.3 Apolipoprotein B (Apo B)  
Apolipoprotein B is the main protein component of low-density-lipoprotein (LDL) and 
contains several domains. The human Apo B is 43 kb in length with 81 bp signal sequence. 
Numerous polymorphisms have been identified on this gene (Heilbronn et al., 2000).  
The evidence for an interaction between the XbaI polymorphism and diet is inconsistent. In 
2 studies, X-X- subjects showed greater LDL-cholesterol responses, whereas Tikkanen et al, 
found that subjects carrying the X+ allele had greater total, LDL-, and HDL-cholesterol 
responses. However in, analysis of these data, the XbaI polymorphism only explained a 
significant proportion of variance of the change in HDL cholesterol (Tikkanen et al., 1995). 
In one research they found no significant effect on LDL-cholesterol responsiveness, although 
X-X-subjects showed the greatest HDL2- and VLDL-cholesterol responses. Finally, in 
another study researchers studied the effect of the XbaI polymorphism in subjects with the 
common Apo E3/3 genotype and found that X-X- subjects showed the greatest 
triacylglycerol response. Rantala et al conducted a meta-analysis of all published dietary 
trials. In their analysis of 8 studies, X-X+ subjects had greater LDL responses than did X+X+ 
subjects and no significant differences in the responses of total or HDL cholesterol or 
triacylglycerol were found between genotypes (Masson et al., 2003; Rantala., 2000). Two of 7 
intervention studies found that the EcoRI R- allele was associated with significantly greater 
total and LDL-cholesterol responses to changes in dietary fat and cholesterol. Only one 
study found an interaction between the MspI polymorphism and response to diet. Ten 
intervention studies found no significant effects of the Apo B signal peptide 
insertion/deletion (I/D) polymorphism on dietary responsiveness; however, 2 studies 
reported a significantly greater responsiveness in subjects homozygous for the I allele. In a 
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interpretation of results from studies involving gene-diet interactions (Ordovas & Corella., 
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reported a significantly greater responsiveness in subjects homozygous for the I allele. In a 
 
Dyslipidemia - From Prevention to Treatment 
 
52
study, 43 men and women were observed to compare the effects of insoluble and soluble 
fiber on plasma lipids. Their statistical model identified gene-diet interactions. However, 
they did not look specifically at differences between genotype groups. It was found that D/D 
subjects had similar decreases in HDL cholesterol after consumption of the insoluble- and 
soluble-fiber diets. However, I/I subjects had larger HDL-cholesterol decreases with the 
soluble-fiber diet, whereas I/D subjects had larger HDL-cholesterol decreases with the 
insoluble-fiber diet. The gene-diet interaction was significant (P = 0. 021) (Masson et al., 
2003; Rantala., 2000).  
In response, low-fat, low-cholesterol diet, I/I subjects showed the greatest decrease in HDL2. 
In addition, I/I and I/D subjects showed increased VLDL-cholesterol and decreased LDL-
cholesterol concentrations, whereas D/D subjects showed decreased VLDL-cholesterol and 
increased LDL-cholesterol concentrations. The I/D polymorphism showed no significant 
effect on the responsiveness of total, LDL, or HDL cholesterol or triacylglycerol in a meta-
analysis of 7 studies (Masson et al., 2003).  
5.4 Apolipoprotein E (APO E) 
Apo E gene variants have implications for nutrition therapy related to preventing and 
treating CVD and the responses to dietary fat, soluble fiber, and alcohol. The impact of Apo 
E genotype on individual variability in its LDL cholesterol response to diet interventions 
and CVD risk has been extensively investigated over the past 30 years. Apo E contains 299 
amino acids, considering Apo E’s key role in lipoprotein metabolism, being involved in 
chylomicron metabolism, very low-density lipoprotein synthesis and secretion, and in the 
cellular removal of lipoprotein remnants from the circulation. Apo E serves as a ligand for 
multiple lipoprotein receptors. This gene locus is polymorphic, with 84 gene variants being 
characterized to date. The prevalence of this SNP varies in different populations (Lovegrove 
& Gitau., 2008; Rubin & Berglund., 2002; Ordovas & Corella., 2004; DeBusk., 2009).  
Apo E is present in a subfraction of lipoprotein (a). The receptor-binding properties reside in 
the N-terminal part of Apo E, whereas the lipid-binding domain resides in the C-terminal 
portion. It was recognized that Apo E was present as three different Apo E isoforms (E2, E3, 
and E4), coded by three different alleles (e2, e3, and e4), resulting in six homo and 
heterozygous genotypes (e2/e2, e2/e3, e2/e4, e3/e3, e3/e4, e4/e4). Apo E2 differs from the 
wild type, Apo E3, by a substitution of arginine for cysteine at amino acid 158, and Apo E4 
differs from Apo E3 by a substitution of cysteine for arginine at amino acid 112. In addition, 
several other genetic variants have been described at the Apo E locus (Rubin & Berglund., 
2002; Lovegrove & Gitau., 2008; Masson et al., 2003; Farhud et al., 2010).  
Persons with E4 variant respond to a high-fat diet negatively with an increased risk for 
coronary heart disease (CHD). In these individuals, low-fat diet should be useful (Farhud et 
al., 2010; Sheweta et al., 2011).  
Population studies show that plasma cholesterol, LDL cholesterol, and Apo B levels are 
highest in subjects carrying the Apo E4, intermediate in those with the Apo E3, and lowest 
in those with the Apo E2 isoform. An initial observation was that the association of the  
Apo E4 isoform with elevated serum cholesterol levels was greater in populations 
consuming diets rich in saturated fat and cholesterol than in other populations (Ordovas & 
Corella., 2004).  
Corella and Ordovas reviewed the numerous studies that have investigated the diet-gene 
interaction for Apo E variants. People with at least one E4 allele have the highest basal levels 
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of various lipids and show the greatest lipid-lowering response to a low-fat diet. Taking into 
account which Apo E alleles a person has is helpful in developing diet and lifestyle 
interventions for improving serum lipid levels (DeBusk., 2009).  
In 46 studies that examined the Apo E locus and alterations in dietary fat content, 
significantly different responses in total and LDL cholesterol by Apo E genotype were 
reported in 8 and 11 studies, respectively, with the Apo E4 individuals generally being the 
most responsive (Lovegrove & Gitau., 2008; Masson et al., 2003).  
Note that despite the numerous studies examining the relation between Apo E genetic 
variability and LDL-cholesterol response to diet intervention, there is considerable 
inconsistency regarding the magnitude and significance of the reported associations, and 
this locus continues to be the subject of intense research (Ordovas & Corella., 2004).  
In a study, there are 29 intervention studies that examine Apo E-diet interactions. A total of 
3224 subjects participated in these studies, ranging from 16 to 420 subjects per study. Of the 
29 studies, 12 demonstrated no significant Apo E-diet interactions, 15 reported significant 
interactions (E4 was usually associated with increased dietary response), and 2 were 
undefined. Using the same available literature, but different selection criteria, Masson, 
reviewed 62 dietary intervention periods, including 3223 subject-by-diet interventions 
(Masson et al., 2003). Again, the range of the studies varied between 8 and 210 subjects per 
dietary intervention. According to this review, 42 of the diet interventions did not 
demonstrate significant Apo E-diet interactions, and only 19 provided evidence for 
significant interactions, clearly demonstrating the diversity of the results presented in the 
original papers as well as those obtained from review papers (Ordovas & Corella., 2004; 
Masson et al., 2003).  
The heterogeneous response to changes in dietary fat may be attributed to a number of 
factors including age, gender, baseline LDL-C levels, disease status and drug use 
(Lovegrove & Gitau., 2008).  
One difference between the negative studies and those reporting significant Apo E  
gene–diet interactions relates to the baseline lipid levels of the subjects. Studies  
reporting significant associations often included subjects who were moderately 
hypercholesterolemic and/or had significant differences in base total cholesterol and 
LDL-cholesterol among the Apo E genotype groups. This suggests that the significant 
gene-diet interaction is apparent only in subjects susceptible to hypercholesterolemia. 
Concerning differences in dietary interventions, there were significant interactions in 
studies in which total dietary fat and cholesterol were modified. Several mechanisms are 
proposed to explain these Apo E-related differences in individual response to dietary 
therapy. Some studies show that intestinal cholesterol absorption is related to Apo E 
phenotype, with Apo E4 carriers absorbing more cholesterol than non-Apo E4 carriers. 
Other mechanisms such as different distribution of Apo E on the lipoprotein fractions, 
LDL Apo B production, bile acid, and cholesterol synthesis, and postprandial lipoprotein 
clearance may also be involved (Ordovas & Corella., 2004).  
On the other hand although the obvious dietary factors implicated in gene-diet interactions 
affecting plasma lipid levels are dietary fats and cholesterol, other dietary components have 
revealed significant interactions. This is the case for alcohol intake.  
Although the raising effect of alcohol consumption on high-density lipoprotein (HDL)-
cholesterol levels is well established, the effect on LDL-cholesterol is still unclear. It is 
possible that the reported variability will be due to interactions between genetic factors and 
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alcohol consumption. Using cross-sectional analysis, researcher examined whether variation 
at the Apo E locus modulates the association between alcohol consumption and LDL-
cholesterol levels in a healthy population based sample of 1014 male and 1133 female 
participants in the Framingham Offspring Study (Corella et al., 2001). In male nondrinkers, 
LDL-cholesterol levels were not different across Apo E groups; however, in male drinkers, 
there were differences in LDL-cholesterol, with Apo E2 subjects displaying the lowest levels. 
When LDL cholesterol levels were compared among the Apo E subgroups by drinking 
status, LDL-cholesterol levels in Apo E2 male drinkers were lower than in Apo E2 non 
drinkers. Conversely, in Apo E4 males, LDL-cholesterol was higher in drinkers than in 
nondrinkers. This Apo E-alcohol interaction remained significant after controlling for age, 
BMI, smoking, fat, and energy intake. In women, the expected effect of Apo E alleles on 
LDL-cholesterol levels was present in both drinkers and nondrinkers. Multiple linear 
regression models showed a negative association between alcohol and LDL-cholesterol 
levels in Apo E2 men, with alcohol intake a continuous variable. Conversely, in Apo E4 
men, this association was positive. There were no statistically significant associations in 
either Apo E3 men or in women. These data suggest that in men, variability at the Apo E 
locus partially modulates the effects of consuming alcoholic beverages on LDL-cholesterol 
levels (Ordovas & Corella., 2004).  
The effect of alcohol was also investigated in the Copenhagen City Heart Study (Frikke-
Schmidt., 2000). In that study, there was an interaction between alcohol and Apo E among 
women, in which higher triglyceride levels were associated with both the E2 and E4 alleles 
among women who regularly consumed alcohol. For men, increased triglyceride levels 
among E2 and E4 carriers were seen across the entire alcohol distribution spectrum, perhaps 
because of some degree of alcohol consumption among all men. Overall, the results 
suggested that metabolic stresses, such as the postprandial situation or alcohol 
consumption, might contribute to uncover underlying differences between Apo E genotypes 
in cholesterol, triglyceride or lipoprotein metabolism (Frikke-Schmidt., 2000).  
The effect of the Apo E gene on lipoproteins may differ with age. In elderly individuals as 
well as in children, there is less difference in LDL cholesterol levels in individuals carrying 
the E4 allele versus non-E4 carriers. Interestingly, in both of these age groups, the presence 
of the Apo E2 allele was associated with lower LDL cholesterol levels. An age-dependent 
variation between Apo E and plasma lipids was also seen by Jarvik et al (Jarvik et al, 1997). 
By longitudinally following male Caucasian twins, the authors demonstrated that whereas 
E4 carriers initially had higher triglyceride and cholesterol levels compared with E3 
homozygotes, this difference disappeared over an 18-year period (Rubin & Berglund., 2002).  
A sex-specific association between Apo E2 and HDL cholesterol levels has been described in 
Turkish individuals. In Turkish women, but not men, the frequency of the Apo E2 allele 
increased almost six fold from the lowest to the highest HDL cholesterol tertiary (Rubin & 
Berglund., 2002). The available information show, significant diet–Apo E gene interactions 
occurred in male-only studies. In studies including men and women, significant effects were 
noted only in men, suggesting a significant gene-sex interaction (Ordovas & Corella., 2004).  
As pointed out above, in studies in which an Apo E gene nutrient interaction was found, it 
was generally more common among men than women, suggesting a modulation by sex. 
Interestingly, in the study by Mahley et al, on HDL levels in Turkish individuals, the 
authors suggested that the association of Apo E2 with higher HDL cholesterol levels found 
in women but not in men may be caused by a sex difference in hepatic lipase. Among 
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women, a lower hepatic lipase activity might allow the detection of the modulating effect of 
Apo E genotypes, whereas this effect might be overwhelmed by a higher enzyme activity in 
men (Mahley et al., 2000). This is an analogous situation to the suggestion above that 
differences in susceptibility might be uncovered by a metabolic challenge (Rubin & 
Berglund., 2002).  
Other causes for the observed differences between studies may be the presence of 
confounders, the type of dietary intervention used, the population studied and, importantly, 
the number of subjects in the respective studies. A small number of subjects limits the 
possibility of detecting differences, or could alternatively lead to spurious associations. 
Although the number of studies addressing the gene nutrient interaction for Apo E is 
growing, in most studies so far this has been a secondary endpoint, usually analyzed post 
hoc. Perhaps the most likely possibility is that a number of dietary interventions will elicit 
variable responses across Apo E genotypes, but that the ability to detect such differences 
will depend on the strength and type of intervention as well as on specific recipient factors 
(type of population, presence of hyperlipidemia, etc. ). In the end, however, our ability  
to confirm or refute the presence of Apo E gene nutrient interactions as well as to 
understand their metabolic basis fully will require larger and more detailed studies (Rubin 
& Berglund., 2002).  
Inconsistency in nutrient–gene interactions in relation to Apo E polymorphisms may be a 
result, in part, of retrospective genotyping of small study cohorts, for which the genotype–
diet–LDL-C interactions were not the primary outcome. This factor has resulted in the 
under-representation of the less-frequent genotypes and, although trends may have been 
evident, many of the studies were clearly under-powered to detect significant genotype–
treatment effects. The prospective genotyping of larger study cohorts has been used as an 
alternative approach to increase statistical power (Lovegrove & Gitau., 2008).  
 However, recent evidence strongly suggests that variations in a number of key genes may 
also be important, including common variants of the Apo E gene. The most convincing 
evidence to date for genotypic effects on dietary response comes from the extensively 
studied Apo E gene variant (Lovegrove & Gitau., 2008).  
A metaanalysis has been published recently that summarizes the overall findings from 
studies using a variety of end-point measures. A mean 40–50% increase in CHD risk was 
observed in E4 carriers (overall OR 1. 42) relative to the wild-type E3/E3 genotype, with no 
apparent differences for either the E2 and E3 subgroups (OR 0. 98). Although a causal 
mechanism to link E4 with increased CHD risk has not been fully elucidated, the association 
has been ascribed to a higher concentration of LDL-C. This higher LDL-C is believed to arise 
from the Apo E4 isoform having a relatively higher affinity for its membrane 
(LDL/chylomicron remnant) receptor and feedback inhibition of receptor activity in E4 
carriers Other mechanisms relating to reduced antioxidant status may also be operative 
(Lovegrove & Gitau., 2008).  
There is the large variation that is observed in the concentration of serum LDL-cholesterol 
(LDL-C) in response to fish oil supplementation. The cardioprotective effects of the fatty 
acids in fish oil include eicosapantanoiec acid (EPA) and docosahesanoiec acid (DHA) are 
well recognized. However, a potentially deleterious increase in LDL-C (5–10%) has been 
consistently reported after moderate to high doses of fish oil (>2 g EPA+ DHA/d). These 
data showed the DHA rather than the EPA in fish oils that is responsible for the LDL-C 
raising effects in E4 individuals (Lovegrove & Gitau., 2008).  
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at the Apo E locus modulates the association between alcohol consumption and LDL-
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participants in the Framingham Offspring Study (Corella et al., 2001). In male nondrinkers, 
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well as in children, there is less difference in LDL cholesterol levels in individuals carrying 
the E4 allele versus non-E4 carriers. Interestingly, in both of these age groups, the presence 
of the Apo E2 allele was associated with lower LDL cholesterol levels. An age-dependent 
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By longitudinally following male Caucasian twins, the authors demonstrated that whereas 
E4 carriers initially had higher triglyceride and cholesterol levels compared with E3 
homozygotes, this difference disappeared over an 18-year period (Rubin & Berglund., 2002).  
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Turkish individuals. In Turkish women, but not men, the frequency of the Apo E2 allele 
increased almost six fold from the lowest to the highest HDL cholesterol tertiary (Rubin & 
Berglund., 2002). The available information show, significant diet–Apo E gene interactions 
occurred in male-only studies. In studies including men and women, significant effects were 
noted only in men, suggesting a significant gene-sex interaction (Ordovas & Corella., 2004).  
As pointed out above, in studies in which an Apo E gene nutrient interaction was found, it 
was generally more common among men than women, suggesting a modulation by sex. 
Interestingly, in the study by Mahley et al, on HDL levels in Turkish individuals, the 
authors suggested that the association of Apo E2 with higher HDL cholesterol levels found 
in women but not in men may be caused by a sex difference in hepatic lipase. Among 
 
Nutrigenetics and Dyslipidemia 
 
55 
women, a lower hepatic lipase activity might allow the detection of the modulating effect of 
Apo E genotypes, whereas this effect might be overwhelmed by a higher enzyme activity in 
men (Mahley et al., 2000). This is an analogous situation to the suggestion above that 
differences in susceptibility might be uncovered by a metabolic challenge (Rubin & 
Berglund., 2002).  
Other causes for the observed differences between studies may be the presence of 
confounders, the type of dietary intervention used, the population studied and, importantly, 
the number of subjects in the respective studies. A small number of subjects limits the 
possibility of detecting differences, or could alternatively lead to spurious associations. 
Although the number of studies addressing the gene nutrient interaction for Apo E is 
growing, in most studies so far this has been a secondary endpoint, usually analyzed post 
hoc. Perhaps the most likely possibility is that a number of dietary interventions will elicit 
variable responses across Apo E genotypes, but that the ability to detect such differences 
will depend on the strength and type of intervention as well as on specific recipient factors 
(type of population, presence of hyperlipidemia, etc. ). In the end, however, our ability  
to confirm or refute the presence of Apo E gene nutrient interactions as well as to 
understand their metabolic basis fully will require larger and more detailed studies (Rubin 
& Berglund., 2002).  
Inconsistency in nutrient–gene interactions in relation to Apo E polymorphisms may be a 
result, in part, of retrospective genotyping of small study cohorts, for which the genotype–
diet–LDL-C interactions were not the primary outcome. This factor has resulted in the 
under-representation of the less-frequent genotypes and, although trends may have been 
evident, many of the studies were clearly under-powered to detect significant genotype–
treatment effects. The prospective genotyping of larger study cohorts has been used as an 
alternative approach to increase statistical power (Lovegrove & Gitau., 2008).  
 However, recent evidence strongly suggests that variations in a number of key genes may 
also be important, including common variants of the Apo E gene. The most convincing 
evidence to date for genotypic effects on dietary response comes from the extensively 
studied Apo E gene variant (Lovegrove & Gitau., 2008).  
A metaanalysis has been published recently that summarizes the overall findings from 
studies using a variety of end-point measures. A mean 40–50% increase in CHD risk was 
observed in E4 carriers (overall OR 1. 42) relative to the wild-type E3/E3 genotype, with no 
apparent differences for either the E2 and E3 subgroups (OR 0. 98). Although a causal 
mechanism to link E4 with increased CHD risk has not been fully elucidated, the association 
has been ascribed to a higher concentration of LDL-C. This higher LDL-C is believed to arise 
from the Apo E4 isoform having a relatively higher affinity for its membrane 
(LDL/chylomicron remnant) receptor and feedback inhibition of receptor activity in E4 
carriers Other mechanisms relating to reduced antioxidant status may also be operative 
(Lovegrove & Gitau., 2008).  
There is the large variation that is observed in the concentration of serum LDL-cholesterol 
(LDL-C) in response to fish oil supplementation. The cardioprotective effects of the fatty 
acids in fish oil include eicosapantanoiec acid (EPA) and docosahesanoiec acid (DHA) are 
well recognized. However, a potentially deleterious increase in LDL-C (5–10%) has been 
consistently reported after moderate to high doses of fish oil (>2 g EPA+ DHA/d). These 
data showed the DHA rather than the EPA in fish oils that is responsible for the LDL-C 
raising effects in E4 individuals (Lovegrove & Gitau., 2008).  
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In contrast, those with one or more E4 alleles have the highest serum total cholesterol, LDL-, 
and Apo B levels, the lowest HDL-C levels, and have elevated fasting and postprandial 
triglyceride levels. They respond best to a low-fat diet but are the least responsive to soluble 
fiber for lowering serum lipids or to exercise for increasing HDL levels. Fish oil 
supplementation in these people increases total cholesterol and reduces HDL. Whether a 
person has the U allele or the E4 allele appears to make a difference in the diet and lifestyle 
recommendations that would be appropriate for improving vascular health (DeBusk., 2009).  
Two prospectively genotyped studies designed to test the hypothesis that Apo E 
polymorphism has a significant effect on the LDL-C response to EPA and DHA have 
recently been completed (Lovegrove & Gitau., 2008).  
Overall, the triglyceride response to the fat load was lower during fish oil supplementation, 
and interestingly the decrease in the incremental area under the curve for triglyceride levels 
was significantly higher for E2 carriers compared with E3 homozygotes and E4 carriers 
(Rubin & Berglund., 2002).  
Although a number of previous studies have observed effects of Apo E genotype in 
response to dietary total fat and saturated fatty acid (SFA) manipulation, only one study to 
date has examined the Apo E genotype–dietary fat-LDL-C association using prospective 
recruitment by genotype. A study reported a significant effect of Apo E genotype on the 
plasma lipid response to a low fat diet, with a 5%, 13% and 16% reduction in LDL-C in 
E3/E3, E3/E4 and E4/E4 males, respectively. Other studies have examined the association 
between Apo E genotype and fish oil (EPA/DHA) on LDL-C responses. In a retrospectively 
genotyped study it was observed that a mean increase of 7. 1% in LDL-C for the group as a 
whole was solely attributable to a 16% rise in LDL-C in the Apo E4 participants, and it was 
speculated that Apo E genotype may, in part, predict the blood lipid response to fish oil 
intervention. Variable effects of EPA and DHA on LDL-C have been reported previously 
(Kobayashi et al., 2001; Lovegrove & Gitau., 2008).  
The ApoE gene locus accounts for approximately 7% of the population variance in total and 
LDL cholesterol levels; in general, E4 carriers have higher and E2 carriers have lower LDL 
cholesterol levels. It has also been suggested that Apo E variations impact triglyceride levels, 
as higher triglyceride levels have been reported for both E4 and E2 carriers compared with 
E3 homozygotes (Rubin & Berglund, 2002).  
In a recent study of more than 9000 individuals from the Copenhagen City Heart Study, 
Frikke-Schmidt and colleagues demonstrated that the association between the Apo E locus 
and cholesterol or plasma Apo B levels was invariant, i. e. present in most contexts (e. g. 
present in both men and women), whereas associations between Apo E and other 
lipoproteins such as triglycerides, Apo A-I, HDL cholesterol and lipoprotein (a) were found 
to be context dependent (Frikke-Schmidt., 2000). As the associations of Apo E with Apo B 
remained significant when adjusting for cholesterol but not the other way around, this 
suggested that Apo B is the factor primarily associated with Apo E genotype. It should be 
pointed out, however, that in their study triglyceride levels represented nonfasting 
conditions, and LDL cholesterol was not included in the analysis (Rubin & Berglund., 2002).  
Furthermore, the Apo E2 allele was more common in individuals with high LpA-I levels,  
i. e. HDL with Apo AI but not Apo A-II. This HDL subfraction generally corresponds to the 
larger HDL2 subpopulation, which interestingly, in a study by Isasi et al, was associated 
with Apo E2 in children (Isasi et al., 2000). In view of their results, Mahley et al, suggest that 
HDL containing Apo E2 might be a poorer substrate for hepatic lipase compared with HDL 
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with Apo E3 or E4, leading to an accumulation of HDL in plasma. In addition, there might 
be a difference in the clearing mechanisms between HDL containing Apo E2 compared with 
Apo E3 or E4 (Mahley et al., 2000).  
This mixed pattern was recently addressed by Weggemans et al, who performed a meta-
analysis of 26 controlled clinical diet trials conducted. The effect of Apo E genotypes on 
response to dietary change in 395 healthy subjects, well balanced for sex, was evaluated. The 
authors pooled data in the response of LDL and HDL cholesterol from four types of trials; 
replacement of cis-unsaturated fat for saturated fat (n = 7 studies), replacement of cis-
unsaturated fat for trans unsaturated fat (n = 2), changes in dietary cholesterol (n = 8) and 
changes in coffee diterpenes (n = 9). Overall, there were small, non-significant differences 
between Apo E genotypes in the response of LDL cholesterol, and results were unchanged 
after adjusting for age, sex and body mass index. For HDL cholesterol, a sex difference was 
noted, as the response to trans fat and cholesterol differed across Apo E genotypes in men 
but not in women (Weggemans et al., 2001).  
Appropriately, the authors caution against the over interpretation of this result because of 
chance associations (Rubin & Berglund., 2002).  
Friedlander et al, compared plasma levels across Apo E genotypes in response to two diets, 
a high saturated fat/high cholesterol and a low saturated fat/low cholesterol diet, in 214 
free-living individuals in two kibbutz settlements in Israel. Although the baseline total and 
LDL cholesterol levels were higher among E4 carriers and lower among E2 carriers 
compared with E3 homozygotes, the plasma lipid response to the diet intervention did not 
differ across Apo E genotypes (Friedlander et al., 2000).  
Loktionov et al, investigated 132 free-living healthy individuals participating in the 
European Prospective Investigation of Cancer study, a cohort study with approximately 25 
000 subjects. The reported subgroup was part of a quality control study on the dietary 
methods used. In the 132 subjects, serum cholesterol levels correlated with the intake of total 
and saturated fat. For LDL cholesterol, a significant correlation with relative saturated fat 
intake was seen only for Apo E 4/3, and not for Apo E3/3 or 3/2 (Loktionov et al., 2000).  
In another recent study, researchers analyzed lipid levels in relation to Apo E genotypes in 
420 randomly selected free-living Costa Rican individuals consuming a low fat intake (53% 
of energy). In accordance with most previous studies, E2 carriers had lower, and E4 carriers 
higher LDL cholesterol and Apo B levels compared with E3 homozygotes. The population 
was dichotomized in two groups depending on the intake of saturated fat. High saturated 
fat intake (mean intake 13. 5% of energy) was associated with increased VLDL cholesterol, 
decreased HDL cholesterol and smaller LDL sizes in Apo E2 carriers, whereas the opposite 
was found for Apo E4 carriers. Effects on LDL size had previously been noted by Dreon et 
al, in which a more pronounced decrease in large, buoyant LDL particles during reduced fat 
intake was seen for Apo E4 carriers (Dreon et al, 1995). The findings of Campos et al 
suggested, as pointed out by the authors, that in E2 carriers, a high saturated fat intake may 
result in increased VLDL production and delayed clearance. Such a metabolic challenge 
might thus unmask a relative susceptibility in E2 carriers (Campos et al, 2001).  
Finally, the study on plasma lipid response to dietary fat and carbohydrate in men and 
women with coronary heart disease provided further support for the association of 
triglyceride metabolism with Apo E2. Overall, E2 carriers had lower LDL cholesterol as well 
as a tendency to higher triglyceride levels than E3 and E4 carriers. In addition, there was a 
positive association between dietary sucrose (6±7% of the total energy intake) and plasma 
triglyceride levels among E2 carriers (Rubin & Berglund., 2002).  
 
Dyslipidemia - From Prevention to Treatment 
 
56
In contrast, those with one or more E4 alleles have the highest serum total cholesterol, LDL-, 
and Apo B levels, the lowest HDL-C levels, and have elevated fasting and postprandial 
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fiber for lowering serum lipids or to exercise for increasing HDL levels. Fish oil 
supplementation in these people increases total cholesterol and reduces HDL. Whether a 
person has the U allele or the E4 allele appears to make a difference in the diet and lifestyle 
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E3/E3, E3/E4 and E4/E4 males, respectively. Other studies have examined the association 
between Apo E genotype and fish oil (EPA/DHA) on LDL-C responses. In a retrospectively 
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with Apo E3 or E4, leading to an accumulation of HDL in plasma. In addition, there might 
be a difference in the clearing mechanisms between HDL containing Apo E2 compared with 
Apo E3 or E4 (Mahley et al., 2000).  
This mixed pattern was recently addressed by Weggemans et al, who performed a meta-
analysis of 26 controlled clinical diet trials conducted. The effect of Apo E genotypes on 
response to dietary change in 395 healthy subjects, well balanced for sex, was evaluated. The 
authors pooled data in the response of LDL and HDL cholesterol from four types of trials; 
replacement of cis-unsaturated fat for saturated fat (n = 7 studies), replacement of cis-
unsaturated fat for trans unsaturated fat (n = 2), changes in dietary cholesterol (n = 8) and 
changes in coffee diterpenes (n = 9). Overall, there were small, non-significant differences 
between Apo E genotypes in the response of LDL cholesterol, and results were unchanged 
after adjusting for age, sex and body mass index. For HDL cholesterol, a sex difference was 
noted, as the response to trans fat and cholesterol differed across Apo E genotypes in men 
but not in women (Weggemans et al., 2001).  
Appropriately, the authors caution against the over interpretation of this result because of 
chance associations (Rubin & Berglund., 2002).  
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free-living individuals in two kibbutz settlements in Israel. Although the baseline total and 
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suggested, as pointed out by the authors, that in E2 carriers, a high saturated fat intake may 
result in increased VLDL production and delayed clearance. Such a metabolic challenge 
might thus unmask a relative susceptibility in E2 carriers (Campos et al, 2001).  
Finally, the study on plasma lipid response to dietary fat and carbohydrate in men and 
women with coronary heart disease provided further support for the association of 
triglyceride metabolism with Apo E2. Overall, E2 carriers had lower LDL cholesterol as well 
as a tendency to higher triglyceride levels than E3 and E4 carriers. In addition, there was a 
positive association between dietary sucrose (6±7% of the total energy intake) and plasma 
triglyceride levels among E2 carriers (Rubin & Berglund., 2002).  
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Postprandial studies as Apo E have important functions in chylomicron remnant 
metabolism, there has been substantial interest in the role of Apo E genotypes in the 
postprandial setting. Furthermore, a postprandial challenge could serve as a tool to uncover 
more precisely the differences between different Apo E alleles (Rubin & Berglund., 2002).  
In a study of normolipidemic adults by Rubin & Berglund, the Apo E2 allele was associated 
with an increased postprandial triglyceride response. A similar response has also been 
demonstrated in other studies. Regarding the Apo E4 allele, more controversial results have 
been obtained (Rubin & Berglund., 2002).  
However, although such studies are compatible with a faster clearance of VLDL and 
chylomicron remnants in E4 compared with E3 carriers, the meta-analysis showed higher 
triglyceride and lower HDL cholesterol levels among E4/3 individuals compared with E3 
homozygotes. This would perhaps suggest an impaired postprandial clearance among E4 
carriers (Rubin & Berglund., 2002). In support of this, another study found an impaired 
clearance of chylomicron and VLDL remnants in normolipidemic male E4 carriers compared 
with E3/3. Furthermore, several recent studies have also reported an increased postprandial 
triglyceride excursion in E4 carriers. In children, they did not observe any difference in 
triglyceride or retinyl palmitate response between E3/3 and E4 carriers, although a non-
significant trend towards higher baseline triglyceride levels as well as higher triglyceride 
and retinyl palmitate levels 3 h postprandially among E4 carriers was seen (Couch et al., 
2000). Another research found no significant effects of the Apo E4 allele on the postprandial 
triglyceride response after adjusting for baseline triglyceride levels, although a delayed 
retinyl palmitate clearance in E2 carriers was observed (Rubin & Berglund., 2002). In a 
recent study by Kobayashi et al, individuals with the E3/3 and E3/4 genotypes were 
matched for intra-abdominal visceral fat accumulation. Postprandial triglyceride levels did 
not differ between the two genotypes when adjusting for baseline levels, whereas retinyl 
palmitate levels among lipoproteins with Sf 5400 were higher among male E3/4 subjects, 
indicating a slower remnant clearance. As pointed out by the authors, there were fewer 
women in the study, which might contribute to the non-significant finding in this sex group 
(Kobayashi et al., 2001).  
In a study, the researchers investigated postprandial fat load tolerance in 55 healthy 
volunteers with an atherogenic lipid profile, defined as triglyceride levels of 1. 5±4 m M, 
cholesterol 5±8 m M and HDL cholesterol less than 1. 1 m M, as part of a double-blind 
placebo-controlled crossover study with the consumption of either 6 g of fish oil or 6 g of 
olive oil supplements for 6 weeks. At the end of each period, a postprandial study was 
carried out. The difference in LDL cholesterol levels among Apo E genotypes is associated 
with differences in LDL receptor activity, with Apo E2 carriers having higher and Apo E4 
carriers lower activity compared with Apo E3 homozygotes. Conditions with increased 
stress of this system, such as the increased intake of cholesterol and saturated fat, could 
therefore result in a variable response in LDL cholesterol levels across Apo E genotypes. In 
addition, E2 carriers may have decreased lipolytic function with an inhibition of the 
conversion of VLDL to LDL, as well as a compromised clearance system for triglyceride-rich 
lipoproteins. Therefore, even a modestly increased VLDL production in response to 
increased precursor availability might result in differences in plasma triglyceride levels 
across Apo E genotypes (Rubin & Berglund., 2002).  
Although the results from postprandial studies are generally in agreement with the 
established metabolic differences between Apo E2 and E3, it is currently more difficult to 
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explain the reduced postprandial clearance in E4 carriers. However, it is possible that a 
differential distribution of the varying Apo E isoforms over different lipoprotein fractions, 
as well as variations in Apo E levels, could play a role. In addition, a lower LDL receptor 
activity in E4 carriers may contribute to a decreased postprandial clearance (Rubin & 
Berglund., 2002).  
How could we reconcile these varying results? Even if most studies have established 
associations between Apo E and baseline lipoprotein levels, the absolute differences 
between the Apo E genotypes are relatively modest. It might thus be expected that inter-
genotype differences in response to nutrient variations may generally be even smaller in 
magnitude, and thus more difficult to detect, although they might be enhanced by metabolic 
challenges affecting the synthetic or clearance systems in lipoprotein metabolism described 
above. Examples of such metabolic stresses in which Apo E gene nutrient interactions may 
be more readily detectable may be hyperlipidemia, an increased intake of saturated fat or 
cholesterol, the postprandial state, or alcohol intake. In agreement with this, studies 
indicating Apo E gene nutrient interactions have been more common in hyperlipidemic 
settings, whereas it has been more difficult to detect differences across Apo E genotypes in 
normolipidemic individuals or populations. However, Apo E gene± nutrient interaction has 
not been seen in all hyperlipidemic states. In familial heperlipidemia heterozygotes, no 
difference in plasma lipid response to a step 1 diet was seen across Apo E genotypes, 
indicating that the modulating effects of Apo E may be overwhelmed by other genetic 
defects, such as LDL receptor deficiency (Rubin & Berglund., 2002).  
In conclusion, Apo E has important functions in lipoprotein metabolism and the Apo E 
polymorphism is associated with plasma lipoprotein levels. Although a large number of 
studies have addressed whether there is an interaction between Apo E genotypes and diet in 
affecting plasma lipid levels, this issue is presently unresolved. Most studies to date have 
involved a small number of subjects, analyzed the Apo E polymorphism post hoc, or 
included populations in which the effects might be modest, making discrepancies difficult 
to detect. Studies conducted with conditions representing a metabolic challenge have 
generally been more successful in finding differential effects across Apo E genotypes, and 
such studies may be helpful in the future to clarify Apo E gene nutrient relationships. The 
mixed results obtained indicate that, at present, it is premature to suggest the use of 
genotyping of Apo E in the design of therapeutic diet interventions (Rubin & Berglund., 
2002).  
All studies have demonstrated a strong association between plasma cholesterol and Apo E 
phenotypes in the following order: E4/E4 > E4/E3 > E3/E3 > E3/E2. It has been thought 
possible that the Apo E gene might be involved in the modulation of dietary plasma 
cholesterol responses, perhaps explaining the differences in cholesterol concentrations. 
Some dietary intervention studies have suggested that Apo E4 individuals react to dietary 
change with exaggerated cholesterol responses. In one study, Apo E4/E4 individuals 
responded by increased cholesterol reductions during low fat intake, and by increased 
cholesterol elevations during a switchback to high fat diet. Plausible mechanisms have been 
postulated which could explain such differences. However, other studies have reported no 
differences in plasma lipid responses among Apo E phenotypes. The studies cannot be 
directly compared because of different designs and study populations with differing Apo E 
allele frequencies (Tikkanen., 1995).  
Although Tikkanen et al, found that subjects with the E4/4 phenotype showed the greatest 
total and LDL-cholesterol responses to dietary change (Tikkanen et al., 1995) Xu et al 
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Postprandial studies as Apo E have important functions in chylomicron remnant 
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not differ between the two genotypes when adjusting for baseline levels, whereas retinyl 
palmitate levels among lipoproteins with Sf 5400 were higher among male E3/4 subjects, 
indicating a slower remnant clearance. As pointed out by the authors, there were fewer 
women in the study, which might contribute to the non-significant finding in this sex group 
(Kobayashi et al., 2001).  
In a study, the researchers investigated postprandial fat load tolerance in 55 healthy 
volunteers with an atherogenic lipid profile, defined as triglyceride levels of 1. 5±4 m M, 
cholesterol 5±8 m M and HDL cholesterol less than 1. 1 m M, as part of a double-blind 
placebo-controlled crossover study with the consumption of either 6 g of fish oil or 6 g of 
olive oil supplements for 6 weeks. At the end of each period, a postprandial study was 
carried out. The difference in LDL cholesterol levels among Apo E genotypes is associated 
with differences in LDL receptor activity, with Apo E2 carriers having higher and Apo E4 
carriers lower activity compared with Apo E3 homozygotes. Conditions with increased 
stress of this system, such as the increased intake of cholesterol and saturated fat, could 
therefore result in a variable response in LDL cholesterol levels across Apo E genotypes. In 
addition, E2 carriers may have decreased lipolytic function with an inhibition of the 
conversion of VLDL to LDL, as well as a compromised clearance system for triglyceride-rich 
lipoproteins. Therefore, even a modestly increased VLDL production in response to 
increased precursor availability might result in differences in plasma triglyceride levels 
across Apo E genotypes (Rubin & Berglund., 2002).  
Although the results from postprandial studies are generally in agreement with the 
established metabolic differences between Apo E2 and E3, it is currently more difficult to 
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explain the reduced postprandial clearance in E4 carriers. However, it is possible that a 
differential distribution of the varying Apo E isoforms over different lipoprotein fractions, 
as well as variations in Apo E levels, could play a role. In addition, a lower LDL receptor 
activity in E4 carriers may contribute to a decreased postprandial clearance (Rubin & 
Berglund., 2002).  
How could we reconcile these varying results? Even if most studies have established 
associations between Apo E and baseline lipoprotein levels, the absolute differences 
between the Apo E genotypes are relatively modest. It might thus be expected that inter-
genotype differences in response to nutrient variations may generally be even smaller in 
magnitude, and thus more difficult to detect, although they might be enhanced by metabolic 
challenges affecting the synthetic or clearance systems in lipoprotein metabolism described 
above. Examples of such metabolic stresses in which Apo E gene nutrient interactions may 
be more readily detectable may be hyperlipidemia, an increased intake of saturated fat or 
cholesterol, the postprandial state, or alcohol intake. In agreement with this, studies 
indicating Apo E gene nutrient interactions have been more common in hyperlipidemic 
settings, whereas it has been more difficult to detect differences across Apo E genotypes in 
normolipidemic individuals or populations. However, Apo E gene± nutrient interaction has 
not been seen in all hyperlipidemic states. In familial heperlipidemia heterozygotes, no 
difference in plasma lipid response to a step 1 diet was seen across Apo E genotypes, 
indicating that the modulating effects of Apo E may be overwhelmed by other genetic 
defects, such as LDL receptor deficiency (Rubin & Berglund., 2002).  
In conclusion, Apo E has important functions in lipoprotein metabolism and the Apo E 
polymorphism is associated with plasma lipoprotein levels. Although a large number of 
studies have addressed whether there is an interaction between Apo E genotypes and diet in 
affecting plasma lipid levels, this issue is presently unresolved. Most studies to date have 
involved a small number of subjects, analyzed the Apo E polymorphism post hoc, or 
included populations in which the effects might be modest, making discrepancies difficult 
to detect. Studies conducted with conditions representing a metabolic challenge have 
generally been more successful in finding differential effects across Apo E genotypes, and 
such studies may be helpful in the future to clarify Apo E gene nutrient relationships. The 
mixed results obtained indicate that, at present, it is premature to suggest the use of 
genotyping of Apo E in the design of therapeutic diet interventions (Rubin & Berglund., 
2002).  
All studies have demonstrated a strong association between plasma cholesterol and Apo E 
phenotypes in the following order: E4/E4 > E4/E3 > E3/E3 > E3/E2. It has been thought 
possible that the Apo E gene might be involved in the modulation of dietary plasma 
cholesterol responses, perhaps explaining the differences in cholesterol concentrations. 
Some dietary intervention studies have suggested that Apo E4 individuals react to dietary 
change with exaggerated cholesterol responses. In one study, Apo E4/E4 individuals 
responded by increased cholesterol reductions during low fat intake, and by increased 
cholesterol elevations during a switchback to high fat diet. Plausible mechanisms have been 
postulated which could explain such differences. However, other studies have reported no 
differences in plasma lipid responses among Apo E phenotypes. The studies cannot be 
directly compared because of different designs and study populations with differing Apo E 
allele frequencies (Tikkanen., 1995).  
Although Tikkanen et al, found that subjects with the E4/4 phenotype showed the greatest 
total and LDL-cholesterol responses to dietary change (Tikkanen et al., 1995) Xu et al 
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analyzed the same data and concluded that the Apo E polymorphism did not explain a 
significant proportion of the variation of the response (Xu et al., 1990). In a meta-analysis of 
9 studies involving 612 subjects and found that the presence of the E4 allele was associated 
with a significantly greater LDL response to dietary intervention (Masson et al, 2003).  
Four studies found significantly different HDL-cholesterol responses between genotype 
groups: one study found that carriers of the E4 allele had the smallest HDL-cholesterol 
response, whereas the other 3 studies found that carriers of the E4 allele had the largest 
response (Masson et al., 2003).  
However, recent evidence strongly suggests that variations in a number of key genes may 
also be important, including common variants of the Apo E gene. The most convincing 
evidence to date for genotypic effects on dietary response comes from the extensively 
studied Apo E gene variant (Lovegrove & Gitau., 2008).  
5.5 Cholesteryl ester transfer protein (CETP) 
Another gene that affects HDL levels is CETP, encoding for the cholesteryl ester transfer 
protein that exchanges cholesteryl esters and triglycerids from HDL to other lipoproteins. 
This protein is also called the "lipid transfer protein:' People with two copies of a common 
allele at position 279 of this gene tend to have low HDL levels and elevated levels of LDL 
and VLDL. A variation (279G>A) that decreases plasma levels of CETP is associated with 
increased HDL levels, decreased LDL and VLDL levels, and a lower risk of cardiovascular 
disease than the more common (GG) form (DeBusk, 2009; Musunuru., 2010).  
A recent meta-analysis which confirms that the I405V and TaqIB variants are indeed 
associated with lower CETP activity and higher high-density lipoprotein-cholesterol levels 
(Boekholdt., 2004).  
The currently available evidence suggests that several genetic variants in the CETP gene are 
associated with altered CETP plasma levels and activity, high-density lipoprotein-
cholesterol plasma levels, low-density lipoprotein and high-density lipoprotein particle size, 
and perhaps the risk of coronary heart disease (Boekholdt., 2004).  
5.6 Hepatic lipase (LIPC) 
Hepatic lipase (HL) is a lipolytic enzyme involved in the hydrolysis of triacylglycerols 
present in circulating chylomicrons providing nonesterified fatty acids and 2-
monoacylglycerol for tissue utilization and phospholipids from plasma lipoproteins that 
participates in metabolizing intermediate-density lipoprotein and large LDL into smaller, 
denser LDL particles, and in converting HDL2 to HDL3 during reverse cholesterol transport 
(Ordovas & Corella., 2004; Fisler, Warden, 2005; Ordovas., 2006; Much et al., 2005). It may 
suggest a role to play as a ligand for cell-surface proteoglycans in the uptake of lipoproteins 
by cell-surface receptors (Fisler & Warden., 2005; Ordovas & Corella., 2004).  
Given the wide spectrum of effects that HL exerts on lipoprotein metabolism, and the 
significance of the promoter variant (s), it is reasonable to hypothesize that genetic variation 
at this locus may also be involved in variability in the response to dietary therapy (Ordovas 
& Corella., 2004). HL deficiency is characterized by mildly elevated concentrations of 
triglyceride-rich LDL and HDL particles, as well as impaired metabolism of postprandial 
triglyceride-rich lipoproteins, which may result in premature atherosclerosis. Conversely, 
increased HL activity is associated with increased small, dense LDL particles and decreased 
HDL2 concentrations, which may also result in increased CAD risk. Four common single 
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nucleotide polymorphisms (SNPs) on the 5_-flanking region of the HL gene (LIPC) [−763 
(A/G), −710 (T/C), −514 (C/T), and –250 (G/A)] are in total linkage disequilibrium and 
define a unique haplotype that is associated with variation in HL activity and HDL-
cholesterol levels (Fisler & Warden., 2005; Ordovas & Corella., 2004).  
The less common A-allele of the SNP at position−250 is associated with lower HL activity 
and buoyant LDL particles. Normal and CAD subjects heterozygous for the A-allele have 
lower HL activity and significantly more buoyant LDL particles. Homozygosity for this 
allele (AA) is associated with an even lower HL activity. The A-allele is associated with 
higher HDL2-cholesterol (Ordovas & Corella., 2004).  
An early intervention study with a low-saturated-fat, low-cholesterol diet found that, 
although significant improvements in fasting lipids occurred, there was no difference in 
response between genotypes at the hepatic lipase gene (LIPC) polymorphism measured. 
However, the study of 83 subjects may not have had adequate power to detect a modest 
effect of genotype (Fisler & Warden., 2005; Masson & McNeill., 2005; Ordovas., 2006).  
Dietary information collected from Framingham Heart Study participants shows that 
subjects carrying the CC genotype react to higher contents of fat in their diets by increasing 
the concentrations of HDL-cholesterol, which could be interpreted as a “defense 
mechanism” to maintain the homeostasis of lipoprotein metabolism. Conversely, carriers of 
the TT genotype cannot compensate, and experience decreases on the HDL-cholesterol 
levels. These data could identify a segment of the population especially susceptible to diet-
induced atherosclerosis. Considering the higher frequency of the T allele among certain 
ethnic groups (i. e., African-Americans), these data could shed some light on the impaired 
ability of certain ethnic groups to adapt to new nutritional environments, as clearly seen for 
Native Americans and Asian Indians. In this regard, they replicated the significant gene-diet 
interaction demonstrated in the Caucasian population of Framingham in another 
multiethnic cohort that consisted of Chinese, Malays, and Indians representing the 
population of Singapore. In addition to the significant gene-diet interactions reported in 
these papers, these data provides clues about the reasons why genotype-phenotype 
association studies fail to show consistent results. In theory, this polymorphism at the 
hepatic lipase gene will show dramatically different outcomes in association studies 
depending on the dietary environment of the population studies. The impact of these 
interactions will be magnified in populations with a high prevalence of the T-allele, as it is 
with Asians and African-Americans (Ordovas & Corella., 2004).  
Three larger observational studies on the effect of a common polymorphism in the LIPC 
promoter gene –514C→T on the response of HDL cholesterol to dietary fat intake have been 
published. In examining the effects of the –514C→T LIPC polymorphism x dietary fat 
interaction on HDL in 2130 men and women participating in the Framingham Study, 
Ordovas et al found that the rarer TT genotype was associated with significantly higher 
HDL-cholesterol concentrations only in subjects consuming <30% of energy from fat. This 
same interaction was found for saturated and monounsaturated fats but not for 
polyunsaturated fat. A second association study, in an Asian population of 2170 subjects, 
found that Asian Indian subjects with a total fat intake of <30% of energy and with TT 
genotype at the –514C→T polymorphism had the highest HDL-cholesterol concentrations. 
This interaction, however, did not apply to the Chinese or Malay subjects in that study, and 
the significant interactions found for saturated or monounsaturated fats found by Ordovas 
et al were not found in the study by Tai et al. However, these 2 studies are consistent with 
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analyzed the same data and concluded that the Apo E polymorphism did not explain a 
significant proportion of the variation of the response (Xu et al., 1990). In a meta-analysis of 
9 studies involving 612 subjects and found that the presence of the E4 allele was associated 
with a significantly greater LDL response to dietary intervention (Masson et al, 2003).  
Four studies found significantly different HDL-cholesterol responses between genotype 
groups: one study found that carriers of the E4 allele had the smallest HDL-cholesterol 
response, whereas the other 3 studies found that carriers of the E4 allele had the largest 
response (Masson et al., 2003).  
However, recent evidence strongly suggests that variations in a number of key genes may 
also be important, including common variants of the Apo E gene. The most convincing 
evidence to date for genotypic effects on dietary response comes from the extensively 
studied Apo E gene variant (Lovegrove & Gitau., 2008).  
5.5 Cholesteryl ester transfer protein (CETP) 
Another gene that affects HDL levels is CETP, encoding for the cholesteryl ester transfer 
protein that exchanges cholesteryl esters and triglycerids from HDL to other lipoproteins. 
This protein is also called the "lipid transfer protein:' People with two copies of a common 
allele at position 279 of this gene tend to have low HDL levels and elevated levels of LDL 
and VLDL. A variation (279G>A) that decreases plasma levels of CETP is associated with 
increased HDL levels, decreased LDL and VLDL levels, and a lower risk of cardiovascular 
disease than the more common (GG) form (DeBusk, 2009; Musunuru., 2010).  
A recent meta-analysis which confirms that the I405V and TaqIB variants are indeed 
associated with lower CETP activity and higher high-density lipoprotein-cholesterol levels 
(Boekholdt., 2004).  
The currently available evidence suggests that several genetic variants in the CETP gene are 
associated with altered CETP plasma levels and activity, high-density lipoprotein-
cholesterol plasma levels, low-density lipoprotein and high-density lipoprotein particle size, 
and perhaps the risk of coronary heart disease (Boekholdt., 2004).  
5.6 Hepatic lipase (LIPC) 
Hepatic lipase (HL) is a lipolytic enzyme involved in the hydrolysis of triacylglycerols 
present in circulating chylomicrons providing nonesterified fatty acids and 2-
monoacylglycerol for tissue utilization and phospholipids from plasma lipoproteins that 
participates in metabolizing intermediate-density lipoprotein and large LDL into smaller, 
denser LDL particles, and in converting HDL2 to HDL3 during reverse cholesterol transport 
(Ordovas & Corella., 2004; Fisler, Warden, 2005; Ordovas., 2006; Much et al., 2005). It may 
suggest a role to play as a ligand for cell-surface proteoglycans in the uptake of lipoproteins 
by cell-surface receptors (Fisler & Warden., 2005; Ordovas & Corella., 2004).  
Given the wide spectrum of effects that HL exerts on lipoprotein metabolism, and the 
significance of the promoter variant (s), it is reasonable to hypothesize that genetic variation 
at this locus may also be involved in variability in the response to dietary therapy (Ordovas 
& Corella., 2004). HL deficiency is characterized by mildly elevated concentrations of 
triglyceride-rich LDL and HDL particles, as well as impaired metabolism of postprandial 
triglyceride-rich lipoproteins, which may result in premature atherosclerosis. Conversely, 
increased HL activity is associated with increased small, dense LDL particles and decreased 
HDL2 concentrations, which may also result in increased CAD risk. Four common single 
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nucleotide polymorphisms (SNPs) on the 5_-flanking region of the HL gene (LIPC) [−763 
(A/G), −710 (T/C), −514 (C/T), and –250 (G/A)] are in total linkage disequilibrium and 
define a unique haplotype that is associated with variation in HL activity and HDL-
cholesterol levels (Fisler & Warden., 2005; Ordovas & Corella., 2004).  
The less common A-allele of the SNP at position−250 is associated with lower HL activity 
and buoyant LDL particles. Normal and CAD subjects heterozygous for the A-allele have 
lower HL activity and significantly more buoyant LDL particles. Homozygosity for this 
allele (AA) is associated with an even lower HL activity. The A-allele is associated with 
higher HDL2-cholesterol (Ordovas & Corella., 2004).  
An early intervention study with a low-saturated-fat, low-cholesterol diet found that, 
although significant improvements in fasting lipids occurred, there was no difference in 
response between genotypes at the hepatic lipase gene (LIPC) polymorphism measured. 
However, the study of 83 subjects may not have had adequate power to detect a modest 
effect of genotype (Fisler & Warden., 2005; Masson & McNeill., 2005; Ordovas., 2006).  
Dietary information collected from Framingham Heart Study participants shows that 
subjects carrying the CC genotype react to higher contents of fat in their diets by increasing 
the concentrations of HDL-cholesterol, which could be interpreted as a “defense 
mechanism” to maintain the homeostasis of lipoprotein metabolism. Conversely, carriers of 
the TT genotype cannot compensate, and experience decreases on the HDL-cholesterol 
levels. These data could identify a segment of the population especially susceptible to diet-
induced atherosclerosis. Considering the higher frequency of the T allele among certain 
ethnic groups (i. e., African-Americans), these data could shed some light on the impaired 
ability of certain ethnic groups to adapt to new nutritional environments, as clearly seen for 
Native Americans and Asian Indians. In this regard, they replicated the significant gene-diet 
interaction demonstrated in the Caucasian population of Framingham in another 
multiethnic cohort that consisted of Chinese, Malays, and Indians representing the 
population of Singapore. In addition to the significant gene-diet interactions reported in 
these papers, these data provides clues about the reasons why genotype-phenotype 
association studies fail to show consistent results. In theory, this polymorphism at the 
hepatic lipase gene will show dramatically different outcomes in association studies 
depending on the dietary environment of the population studies. The impact of these 
interactions will be magnified in populations with a high prevalence of the T-allele, as it is 
with Asians and African-Americans (Ordovas & Corella., 2004).  
Three larger observational studies on the effect of a common polymorphism in the LIPC 
promoter gene –514C→T on the response of HDL cholesterol to dietary fat intake have been 
published. In examining the effects of the –514C→T LIPC polymorphism x dietary fat 
interaction on HDL in 2130 men and women participating in the Framingham Study, 
Ordovas et al found that the rarer TT genotype was associated with significantly higher 
HDL-cholesterol concentrations only in subjects consuming <30% of energy from fat. This 
same interaction was found for saturated and monounsaturated fats but not for 
polyunsaturated fat. A second association study, in an Asian population of 2170 subjects, 
found that Asian Indian subjects with a total fat intake of <30% of energy and with TT 
genotype at the –514C→T polymorphism had the highest HDL-cholesterol concentrations. 
This interaction, however, did not apply to the Chinese or Malay subjects in that study, and 
the significant interactions found for saturated or monounsaturated fats found by Ordovas 
et al were not found in the study by Tai et al. However, these 2 studies are consistent with 
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other studies showing that the TT genotype at –514C→T is associated with higher HDL 
concentrations, although, in 1 of those studies, this effect was attenuated by visceral obesity 
(Fisler & Warden., 2005).  
The third association study of the interaction between dietary fat and the –514C→T 
polymorphism, by Zhang et al that, from a study population of 18159 men, Zhang et al 
selected 780 men with confirmed type 2 diabetes. After adjustment for age, smoking, alcohol 
intake, exercise, and BMI, higher HDL-cholesterol concentrations were found in men with 
the CT or TT genotype, which is consistent with previous studies. However, they found 
significantly higher HDL-cholesterol concentrations in men with the CT/TT genotype who 
consumed large amounts of dietary fat (≥32% of energy), saturated fat, and 
monounsaturated fat, a result that is apparently opposite to the findings of the other 2 
association studies. Thus, the interaction effect of dietary fat with the –514C→T 
polymorphism was not replicated (Zhang et al., 2005).  
Two researcher discussed causes of nonreplication of genetic association studies in obesity 
and diabetes research that should apply to studies of dyslipidemias as well. An important 
cause of nonreplication is a lack of statistical power. For any polygenic model, such as 
models with complex phenotypes (eg, obesity, dyslipidemia, or type 2 diabetes), the effect 
size for any marker will be small to moderate. Thus, larger sample sizes are needed to 
ensure adequate power to observe an effect. In the study of Zhang et al, the problem of 
small sample size (despite the fact that >18000 men were screened to identify ≈800 men with 
type 2 diabetes) is compounded by the fact that the TT genotype is rare, especially in a white 
population. Thus, only 30 subjects in that study had homozygous TT genotype at –514C→T 
LIPC, and subjects with either the CT or TT genotype were pooled for analysis. Examination 
of the data of Ordovas et al and Tai et al found that the slope of predicted values for HDL 
cholesterol versus total fat intake as a percentage of energy is steeply negative in persons 
with the TT genotype, whereas it is positive for persons with the CT genotype (Ordovas, et 
al, 2002; Tai et al, 2003). Assuming that the data of Zhang et al followed the same pattern, 
combining the smaller number (n = 30) of persons with the TT genotype with the larger 
number (n = 247) of persons with the CT genotype would mask the effects of percentage of 
dietary fat and the TT genotype on HDL-cholesterol concentrations. An additional 
complexity is that BMI and obesity phenotypes may also interact with dietary fat and LIPC 
genotype to modulate HDL-cholesterol concentrations (Tai et al., 2003; Zhang., 2005). Thus, 
the nonreplication in the study by Zhang et al of the findings of Ordovas et al and Tai et al is 
likely due to the small number of persons with the TT genotype who were available in the 
study of Zhang et al (Fisler & Warden., 2005).  
5.7 Lipoprotein lipase (LPL)  
LPL, encoding lipoprotein lipase, which hydrolyzes triglycerides in chylomicrons and VLDL 
particles, converting the latter to LDL particles, as well facilitating cellular lipoprotein 
uptake (Musunuru, 2010).  
Several polymorphisms have been described that disrupt normal LPL function and 
contribute to the premature development of CHD, primarily through the increased levels of 
circulating TGs (Much et al., 2005).  
Indeed, several of the common LPL polymorphisms described by Merkel et al have recently 
been established to influence circulating lipid levels in pregnant women, whom are often 
characterized with high levels of circulating TGs and increased total cholesterol (Merkel et 
 
Nutrigenetics and Dyslipidemia 
 
63 
al., 2011). Although TG levels were unaffected, certain LPL SNPs modulated HDL levels and 
may alter the susceptibility of pregnant women to developing CHD. However, further 
studies are required to definitively define a relationship between lipid levels, CHD, and 
pregnant women. Therefore, the importance of LPL in the whole-body regulation of lipid 
metabolism has been avidly demonstrated and merits further exploration.  
One common LPL polymorphism, known as T495G Hind III, has been extensively examined 
and demonstrates the complexity of disease prediction associated with a single SNP. Indeed, 
preliminary indications suggest that this polymorphism may play a role in the onset of 
several important diseases, such as CHD, diabetes and obesity. This SNP has been 
associated with the higher plasma TG and lower HDL levels characteristic with the early 
onset of diabetes. Preliminary results have also suggested a positive association between the 
Hind III polymorphism and a predisposition to developing obesity. Finally, this 
polymorphism has been associated with variations in lipid levels and heart disease, and that 
these alterations were attenuated by such environmental factors as physical exercise and 
low calorie diets, reiterating the important interactions arising between lifestyle, nutrition, 
and disease. Although these associations are not conclusive, they do suggest that LPL 
variants play a critically important role in the regulation of whole-body lipid metabolism 
that may predispose an individual to the onset of several metabolic diseases.  
A relationship was established between a low calorie diet and the circulating lipid profile in 
obese individuals with the Hind III polymorphism. Homozygotes (H2H2) were found to 
have significantly higher levels of plasma VLDL-TG and Apo B than heterozygotes. Caloric 
restriction reduced lipid levels in both H2H2 and H1 individuals to a point where no 
difference was observed between the groups. Although H2H2 individuals responded more 
strongly (larger decreases in plasma lipids) to the low calorie diet, these preliminary results 
identify an important relationship between LPL polymorphisms, function, and diet (Much 
et al., 2005).  
As such, it is difficult to draw any firm conclusions from any one gene-diet study in the 
absence of replication by another study that examined the same question using similar 
methodologies. For example, one study demonstrated that a Mediterranean-style, MUFA-
rich diet compared to a high-carbohydrate diet increased LDL size in individuals with 
certain Apo E gene variants but decreased LDL size in those with other Apo E variants; this 
is potentially a clinically important observation, but no confirmatory study has yet emerged, 
calling this observation into doubt. As pointed out by others, the field would greatly benefit 
from increased collaboration and coordination of studies among international nutrition 
researchers (Musunuru., 2010).  
6. Magnitude of the response 
Because of the heterogeneity in the type and duration of the interventions described the 
magnitude of the lipid response to dietary interventions varied widely: in one study the 
change in LDL cholesterol in the Apo B EcoRI R-R- genotype group was as large as 59% of 
the baseline concentration. In the studies that showed a significant difference in response 
between genotype groups, the results also varied widely: in some studies, the difference in 
response between 2 genotype groups was ≈20% of the baseline lipid concentration (Rantala 
et al., 2000; Clitfon., 1997). However, the magnitude of these differences cannot be estimated 
with any accuracy, largely because most studies had only a small number of subjects in the 
rare genotype group (Masson et al, 2003). The proportion of variance in the lipid response 
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other studies showing that the TT genotype at –514C→T is associated with higher HDL 
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al., 2011). Although TG levels were unaffected, certain LPL SNPs modulated HDL levels and 
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attributable to a single polymorphism is not likely to be > 10% (Xu et sal., 1990). Therefore, 
individual genes contribute only a small part to the variation in the lipid response; however, 
when several genes are considered, the proportion of variance explained could be larger 
(Masson et al, 2003).  
7. Evidence for a gene-diet interaction 
Evidence suggests that variation in the genes for apolipoproteins A-I, A-IV, B, and E may 
contribute to the heterogeneity in the lipid response to dietary intervention. Many studies 
were unable to show significantly different responses between these genotype groups, and 
the genotypes showing the greatest response are not necessarily consistent between studies. 
There was insufficient evidence to assess whether lipid responsiveness is affected by 
variation in the genes for Apo C-III, lipoprotein lipase, hepatic lipase, the cholesteryl ester 
transfer protein. Although each of these gene products is essential in lipid metabolism, only 
a handful of studies have investigated variation in these genes, and most of these studies 
were unable to show significant gene-diet interactions (Masson et al, 2003).  
8. Publication bias 
Publication bias is a problem with any review because "studies with results that are 
significant, interesting, from large well-funded studies, or of higher quality are more likely 
to be submitted, published, or published more rapidly than work without such 
characteristics" (Sutton, 2000). Therefore, it is possible that other relevant dietary 
intervention studies with genotype information exist but were not included in this review 
because they have not been published. It is possible that the literature strategy for this 
review missed studies because the genotype analyses were not mentioned in their title, 
abstract, or subject headings (Masson et al, 2003).  
In the search for explanations for the heterogeneity in lipid responses, reviewers may tend 
to highlight studies showing significant effects of genetic variation while ignoring a large 
proportion of studies that found no such results. Studies showing nonsignificant or 
conflicting results cannot be ignored, especially because they outnumber the studies 
showing significant effects, notwithstanding the unpublished studies that could have 
nonsignificant and uninteresting results. Therefore, one has to ask the question "If genetic 
variability plays a role in the heterogeneity of lipid and lipoprotein responses to dietary 
change, why have so many studies been unable to demonstrate this with statistical 
significance?" (Masson et al, 2003).  
9. Possible reasons for conflicting results 
There are many possible reasons why studies have been unable to show statistically 
significant gene-diet interactions. First, it is highly probable that lipid responses to dietary 
change are under polygenic control, with each gene contributing a relatively small effect. 
However, most studies have attempted to find only single-gene effects (Masson et al, 2003). 
Most of the studies summarized in this review lacked sufficient statistical power to detect 
any but a very strong effect because the sample sizes were too small, particularly for 
genotypes with low frequencies of the rare allele. However, many of the studies were 
retrospective and were not designed to examine gene-diet interactions, but data were 
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reexamined after the availability of new information from genotype analyses. Therefore, it is 
perhaps not surprising that significant effects were not found in many studies because the 
numbers of individuals in each genotype group were so small. In many studies there were 
too few subjects homozygous for the rare allele to allow an analysis that would take into 
account differences in the response between heterozygote's and homozygote's. For Apo E, 
where there are 6 possible genotypes, differences in the grouping of these could also lead to 
differences in results between studies. This illustrates that meta-analyses are important 
because they can detect effects with greater power and greater precision because of their 
inflated sample size (Rantala et al., 2000; Lopez-Miranda et al., 1994). In addition, in studies 
with small sample sizes, genotype misclassification of one individual may significantly 
affect the interpretation and validity of the results. Conflicting results may also occur 
because of the different dietary protocols that were followed. The studies reviewed varied 
widely in the composition and length of the baseline and experimental diets. The dietary 
factors responsible for the changes seen in each genotype group are not clear because many 
studies modified several dietary factors, and so the dietary content in future studies should 
be tightly controlled and compliance must be strictly measured not only for cholesterol and 
the amount and type of fatty acids but also for other influential dietary components such as 
fiber and plant sterols. In addition, these studies investigated fasting lipid and lipoprotein 
concentrations; however, the effect of genetic variation may be more evident in the 
postprandial state than in the less-common fasting state). Differences in the age, sex, body 
mass index, menopausal status, dietary backgrounds, and baseline lipid values of the 
participants could also have contributed to the discrepancies between the results. For 
instance, subjects with the E4 allele tend to have higher baseline total and LDL-cholesterol 
concentrations, and so greater responses in these subjects could reflect the regression to the 
mean phenomenon. It is also possible that weight change could account for differences in 
lipid and lipoprotein changes. In addition, a significant effect may not reflect a causal 
relation but the allele may be in linkage disequilibrium with another one that does. For 
example, the base change that results in the Xba I site in the gene for Apo B does not alter 
the amino acid, and so it may be in linkage disequilibrium with another functional mutation 
(Masson et al., 2003).  
The studies varied widely in terms of the number and type of study participants, the 
composition and duration of the dietary interventions, the nutrients studied and dietary 
assessment methods used in the observational studies, and the polymorphisms analyzed - 
some of which had not been studied before with regard to the lipid response to diet (Masson 
et al., 2005).  
10. Conclusion 
Evidence suggests that genetic variation may contribute to the heterogeneity in lipid 
responsiveness. At present, the evidence is limited but suggestive and justifies the need 
for future studies with much larger sample sizes based on power calculations, with 
carefully controlled dietary interventions, and that investigate the effects of 
polymorphisms in multiple genes rather than in single genes. Investigating gene-diet 
interactions will increase our knowledge of the mechanisms involved in lipid metabolism 
and improve our understanding of the role of diet in reducing cardiovascular disease risk 
(Masson et al., 2003).  
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Future studies will have to be large in order to assess the effects of multiple polymorphisms, 
and will have to control for many factors other than diet. At present, it is premature to 
recommend the use of genotyping in the design of therapeutic diets. However, such studies 
may be useful in identifying the mechanisms by which dietary components influence lipid 
levels (Masson & McNeill., 2005).  
However, current knowledge is still very limited and so is the potential benefit of its 
application to clinical practice. Thinking needs to evolve from simple scenarios (e. g., one 
single dietary component, a single nucleotide polymorphism and risk factor) to more 
realistic situations involving multiple interactions. One of the first situations where 
personalized nutrition is likely to be beneficial is in patients with dyslipidemia who require 
special intervention with dietary treatment. This process could be more efficient if the 
recommendations were carried out based on genetic and molecular knowledge. Moreover, 
adherence to dietary advice may increase when it is supported with information based on 
nutritional genomics, and a patient believes the advice is personalized. However, a number 
of important changes in the provision of health care are needed to achieve the potential 
benefits associated with this concept, including a teamwork  
approach with greater integration among physicians, food and nutrition professionals, and 
genetic counselors (Ordovas., 2006).  
The ultimate goal of nutritional genomics is to provide sufficient knowledge to allow 
diagnosis and nutritional treatment recommendations based on an individual’s genotype. 
Defining the interaction effects of nutrients and genes on complex phenotypes will be the 
challenge of this field of nutrition research for some time to come (Fisler & Warden, 2005; 
Gregori et al, 2011; Ordovas & Corella., 2004).  
11. Ethic 
Although an increased understanding of how these and other genes influence response to 
nutrients should facilitate the progression of personalized nutrition, the ethical issues 
surrounding its routine use need careful consideration (Lovegrove & Gitau., 2008).  
The study of nutrigenetics is in its infancy. Many studies published in this area have only 
considered one SNP in a single gene, with little consideration being given to multiple 
nutrient–gene–environmental interactions. Although this is scientifically valid, and 
invaluable for the elucidation of causative mechanisms in disease, multiple gene–nutrient–
environment–gender interactions will be required for developing specific personalized 
nutritional advice. The collation of data in haplotype databases and biobanks is expensive 
and difficult to establish, but is a necessity if nutrigenetic research is to progress (Lovegrove 
& Gitau., 2008).  
Standardized protocols in nutrigenetics are not yet established, the comparison of studies is 
challenging and conclusions are often difficult to draw. As discussed previously, studies are 
often retrospective in design and thus of insufficient power to detect nutrient–gene 
associations. Prospective genotyping increases the power to resolve these associations and 
should be used whenever possible. With any research, publication bias results in positive 
associations being reported more often than negative associations. This has applied to 
nutrigentic studies and created a false impression of the level of significance of many 
nutrient–gene interactions (Lovegrove & Gitau., 2008).  
There are numerous ethical issues and unavoidable assumptions that need to be considered 
before personalized nutritional can become routine practice. First, it is important to consider 
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whether the genetic tests and personalized food products would be affordable, cost-effective 
and socially acceptable. It is also of concern that only the well educated and affluent would 
benefit. The open accessibility of genetic information to third parties has major implications 
for the availability of health insurance and increased premiums (Lovegrove, Gitau, 2008).  
Moreover, it is still unknown whether people will want to undertake genetic tests or even 
understand the concept of such technology. A survey was conducted by Cogent Research in 
2003 on 1000 Americans in which 62% of respondents reported they had never heard of 
‘nutrigenomics’. However, if specific products did arise from nutrigenomic research, those 
interviewed did express interest in an in-depth well-being assessment and also a strong 
interest in vitamins, fortified foods and natural foods. More research is required to 
determine whether individuals would want to undergo such tests, and for understanding 
the value to the individual of an increased awareness of personalized nutrition regimens. 
There is already a large gap between the existing dietary guidelines and what people 
actually eat. Knowledge of being at higher than average risk of CVD may motivate people to 
actually make positive changes to their diets. However, genetic testing could undermine 
current healthy eating messages, by implying that only those with the ‘risky gene’ need to 
eat a healthy diet. These are important unanswered questions that must be addressed if 
personalized nutritional advice is ever to become part of mainstream disease prevention and 
treatment. It may be that the interactions between genotype–phenotype and the 
environment are just too complex to be properly understood from human dietary 
intervention studies (Lovegrove, Gitau, 2008).  
There is resistance to the use and perceived effectiveness of personalized nutrition that is 
based on genomics, and whether this can offer a solution to diseases caused by a diet that is 
inappropriate for health (Canon & Leitzmann, 2005). It has been suggested that it may be 
more beneficial to use current risk factors as a basis for population screening and the 
management of CVD (McCluskey et al., 2007). There has also been dialogue on the social, 
economic and environmental causes of CVD, shifting the emphasis away from dietary 
intake to food manufacturing as being more effective in disease management (Canon & 
Leitzmann, 2005; Lovegrove & Gitau., 2008).  
Progression of knowledge in the fields of nutrient–gene interactions promises a future 
revolution in preventative health care. However, although there is increasing evidence for 
interactions between diets/nutrients, genes and environmental factors, there are 
inconsistencies in the evidence that will limit the application of nutrigenetics in diet-related 
disease in the immediate future. In addition to the need for adequately powered 
intervention studies, greater attention should be given to ethical issues, such as the public’s 
acceptance of genetic testing and the economics of this relatively new science (Lovegrove & 
Gitau., 2008).  
Ethical issues fall into a number of categories: (1) why nutrigenomics? Will it have 
important public health benefits? (2) questions about research, e. g. concerning the 
acquisition of information about individual genetic variation; (3) questions about who has 
access to this information, and its possible misuse; (4) the applications of this information in 
terms of public health policy, and the negotiation of the potential tension between the 
interests of the individual in relation to, for example, prevention of conditions such as 
obesity and allergy; (5) the appropriate ethical approach to the issues, e. g. the moral 
difference, if any, between therapy and enhancement in relation to individualised diets; 
whether the 'technological fix' is always appropriate, especially in the wider context of the 
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current healthy eating messages, by implying that only those with the ‘risky gene’ need to 
eat a healthy diet. These are important unanswered questions that must be addressed if 
personalized nutritional advice is ever to become part of mainstream disease prevention and 
treatment. It may be that the interactions between genotype–phenotype and the 
environment are just too complex to be properly understood from human dietary 
intervention studies (Lovegrove, Gitau, 2008).  
There is resistance to the use and perceived effectiveness of personalized nutrition that is 
based on genomics, and whether this can offer a solution to diseases caused by a diet that is 
inappropriate for health (Canon & Leitzmann, 2005). It has been suggested that it may be 
more beneficial to use current risk factors as a basis for population screening and the 
management of CVD (McCluskey et al., 2007). There has also been dialogue on the social, 
economic and environmental causes of CVD, shifting the emphasis away from dietary 
intake to food manufacturing as being more effective in disease management (Canon & 
Leitzmann, 2005; Lovegrove & Gitau., 2008).  
Progression of knowledge in the fields of nutrient–gene interactions promises a future 
revolution in preventative health care. However, although there is increasing evidence for 
interactions between diets/nutrients, genes and environmental factors, there are 
inconsistencies in the evidence that will limit the application of nutrigenetics in diet-related 
disease in the immediate future. In addition to the need for adequately powered 
intervention studies, greater attention should be given to ethical issues, such as the public’s 
acceptance of genetic testing and the economics of this relatively new science (Lovegrove & 
Gitau., 2008).  
Ethical issues fall into a number of categories: (1) why nutrigenomics? Will it have 
important public health benefits? (2) questions about research, e. g. concerning the 
acquisition of information about individual genetic variation; (3) questions about who has 
access to this information, and its possible misuse; (4) the applications of this information in 
terms of public health policy, and the negotiation of the potential tension between the 
interests of the individual in relation to, for example, prevention of conditions such as 
obesity and allergy; (5) the appropriate ethical approach to the issues, e. g. the moral 
difference, if any, between therapy and enhancement in relation to individualised diets; 
whether the 'technological fix' is always appropriate, especially in the wider context of the 
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purported lack of public confidence in science, which has special resonance in the sphere of 
nutrition (Chadwick., 2004).  
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1. Introduction 
Environmental factors, notably climate change and air pollution influence health before 
conception, and continue during pregnancy, childhood, and adolescence. Experts have 
suggested that such health hazards may represent the greatest public health challenge 
humanity has faced. The accumulation of greenhouse gases such as carbon dioxide, 
primarily from burning fossil fuels results in warming, which has an impact on air 
pollution, particularly on levels of ozone and particulates. Heat-related health effects 
include increased rates of pregnancy complications, pre-eclampsia, eclampsia, low birth 
weight, renal effects, vector-borne diseases as malaria and dengue; increased diarrheal and 
respiratory disease, food insecurity, decreased quality of foods (notably grains), 
malnutrition, water scarcity, exposures to toxic chemicals, worsened poverty, natural 
disasters, and population displacement. Air pollution has many adverse health effects, 
which would have long-term impact on the components of the metabolic syndrome. In 
addition to short-term effects as premature labor, intrauterine growth retardation, neonatal 
and infant mortality rate, malignancies (notably leukemia and Hodgkin lymphoma), 
respiratory diseases, allergic disorders and anemia, exposure to criteria air pollutants from 
early life might be associated with dyslipidemia, increase in stress oxidative, inflammation 
and endothelial dysfunction which in turn might have long-term effects on chronic non-
communicable diseases.  
2. Environmental factors: Climate change and air pollution 
2.1 Air pollutants 
Air pollution is a mixture of solid particles and gases in the air. The six common and 
hazardous air pollutants consist of particulate matter, ground-level ozone, carbon 
monoxide, sulfur oxides, nitrogen oxides, and lead; of which, particle pollution and ground-
level ozone are the most widespread health hazards (Samet & Krewski, 2007; Chen & Kan, 
2008).  
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Particulate matter or PM consists of a diverse mixture of very small particles and liquid 
droplets suspended in air. The PM size is directly related to their potential for affecting 
health. Particles with diameter < 10 micrometers are the particles that usually pass through 
the throat and nose to enter the lungs. Then, they can affect different body organs especially 
the heart and lungs, and may cause serious health effects. According to the size, the particle 
pollution is grouped into: "inhalable coarse particles" which have a diameter of 2.5 to 10 
micrometers, and are found near roadways and industries, and "fine particles" < 2.5 
micrometers in diameter such as those found in smoke and haze; they can form when gases 
emitted from power plants, industries and automobiles react in the air. Ozone (O3) is a gas 
composed of three oxygen atoms. In the presence of sunlight, it is created at ground-level by 
a chemical reaction between oxides of nitrogen and volatile organic compounds. Ozone 
might have harmful effects when formed in the earth's lower atmosphere, i.e. at ground-
level. Hot weather and sunlight cause ground-level ozone to form in harmful concentrations 
in the air. Carbon monoxide (CO) is an odorless and colorless gas formed by incomplete 
carbon combustion. It is mainly emitted from the motor vehicle exhaust followed by non-
road engines as construction equipment, industrial processes and wood burning. The 
increasing number of cars has an important role in the increase in CO emission worldwide. 
Sulfur Dioxide (SO2) is a gas formed when fuel containing sulfur, such as coal and oil, is 
burned, and when gasoline is extracted from oil or metals are extracted from ore. Nitrogen 
oxides (Nox) are a group of highly reactive gases containing various levels of nitrogen and 
oxygen. Lead is usually emitted from motor vehicles and industrial sources (Chen & Kan, 
2008; Brook et al., 2004). Other stationary sources are waste incinerators, utilities, and lead-
acid battery manufacturers. In addition to exposure to lead in air, other major exposure 
pathways include ingestion of lead in drinking water and lead-contaminated food as well as 
incidental ingestion of lead-contaminated soil and dust. Lead-based paint remains a major 
exposure pathway in older homes. Some toys might contain considerable amounts of lead 
that would be harmful for children’s health (Samet & Krewski, 2007; Han & Naeher, 2006).   
2.2 Climate change 
Climate change and global warming have various health hazards (Poursafa & Kelishadi 
2011). 
Climate change has an impact on levels of ozone and particulate matters, which are both 
associated with various health hazards. The accumulation of greenhouse gases such as 
carbon dioxide, primarily from burning fossil fuels results in warming. Heat increases 
ground level ozone production, which in turn augments morbidity and mortality (Bell et al., 
2007). Moreover, warming increases water vapor and ground-level ozone formation, and 
will result in harmful ozone levels (Jacob & Winner, 2009). Warming modify the risk of 
forest fires, and may generate massive amounts of carcinogens, as formaldehyde and 
benzene, potent lung irritants, as acrolein and other aldehydes, carbon monoxide, and 
particulates (Wegesser et al., 2009).  
3. Association of environmental factors and dyslipidemia 
Environmental factors are associated with many chronic diseases. Air pollution and climate 
change are associated with risk factors of non-communicable diseases in children and 
adolescents (Kelishadi et al., 2009; Sheffield & Landrigan, 2011; Kelishadi & Poursafa, 2010; 
Mansourian et al., 2010; Poursafa et al., 2011; Kargarfard et al., 2011). 
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The effects of environmental factors on intrauterine growth retardation and preterm labor 
are well documented. In turn, low birth weight (Sinclair et al., 2007) and prematurity 
(Evensen et al., 2008) would increase the risk of chronic non-communicable diseases and 
their risk factors. Exposure to air pollutants is reported to be associated with stress oxidative 
and markers of insulin resistance (Kelishadi et al., 2010) as well as with diabetes mellitus 
(Brook et al., 2008). These systemic responses to environmental factors can potentially 
increase the risk for dyslipidemia, development of the metabolic syndrome, hypertension, 
and other chronic diseases.Moreover, it is documented that some environmental factors as 
increased humidity are associated with preeclampsia and eclampsia, and their related 
consequences (Subramaniam, 2007).  
Several reports exist on the association of environmental factors with dyslipidemia and the 
components of metabolic syndrome. By applying generalized additive models, Secondary 
analyses of a Taiwanese survey in 2002 demonstrated that increased particulate matter with 
aerodynamic diameters <10 microm was associated with elevated systolic blood pressure, 
triglycerides, apolipoprotein B, hemoglobin A1c, and reduced high-density lipoprotein 
(HDL) cholesterol. Elevated ozone was associated with increased diastolic blood pressure, 
apolipoprotein B, and hemoglobin A1c (Chuang et al., 2010). Genetic-environment 
interactions may have a role in this regard (Eisenberg et al., 2010). 
The associations of both obesity and air pollution with several age-related diseases remain 
poorly understood with regard to causality and underlying mechanisms. Exposure to both, 
excess body fat and particulate matter, is accompanied by systemic low-grade inflammation 
as well as alterations in insulin/insulin-like growth factor signaling and cell cycle control. 
Understanding the causality of exposure disease associations and differences in 
susceptibilities to environment and lifestyle is an important aspect for effective prevention 
(Probst-Hensch, 2010). 
A case-control study evaluated the effects of urban pollution on the lipid balance of 
members of a municipal police force in comparison with controls. Mean and frequency 
distributions of HDL-cholesterol and triglycerides had significant difference between the 
exposed traffic police group and controls. This study suggested that some chemical agents, 
as carbon dioxide, of the urban pollution could cause dyslipidemia among exposed people 
(Tomao et al., 2002). 
A study among asthmatic patients showed that with a 1-microg/m3 increase in coarse PM, 
triglycerides increased 4.8% (p = 0.02), and very low-density lipoprotein increased 1.15%  
(p = 0.01). This study suggested that small temporal increases in ambient coarse PM are 
sufficient to affect lipid profile in adults with asthma (Yeatts et al., 2007).  
Hypercholesterolemia may potentiate diesel exhaust-related endothelial gene regulation. 
These regulated transcripts may implicate pathways involved in the acceleration of 
atherosclerosis by air pollution (Maresh et al., 2011). The systemic pro-inflammatory and 
pro-thrombotic response to the inhalation of fine and ultrafine particulate matters may be 
associated with platelet activation (Poursafa & Kelishadi, 2010 platelets).  
A study conducted in Greece, explored the relations between ambient environmental factors 
and arterial stiffness, peripheral and central hemodynamics in a cohort of 1222 
participants.It found that the exposure to lower environmental temperatures is related to 
impaired hemodynamics not only to the periphery but also to the aorta. In men, PM10 levels 
were associated with intensified amplitude of the reflection wave resulting in significant 
alterations in central-pulse pressure (Adamopoulos et al., 2010). 
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A study examined the associations of PM2.5 with heart rate variability, a marker of 
autonomic function, and whether metabolic syndrome modified these associations. It found 
significant correlations; which were stronger among individuals with metabolic syndrome 
than among those without it. This study proposed that autonomic dysfunction may be a 
mechanism through which PM exposure affects cardiovascular risk, especially among 
persons with metabolic syndrome (Park et al., 2010). 
Exposure to high and low air temperatures are associated with cardiovascular mortality, the 
underlying mechanisms are still under investigation. In a cohort in the US, 478 men with a 
mean age of 74.2 years were followed up from 1995 to 2008. Associations of three 
temperature variables, i.e. ambient, apparent, and dew point temperature with serum lipid 
profile were studied with linear mixed models by including possible confounders such as 
air pollution and a random intercept for each individual. HDL decreased -1.76%, and -5.58% 
for each 5°C increase in mean ambient temperature. For the same increase in mean ambient 
temperature, LDL increased by 1.74% and 1.87%. Similar results were also found for 
apparent and dew point temperatures. No changes were found in total cholesterol or 
triglycerides in relation to temperature increase. This study suggested that changes in HDL 
and LDL levels, which are associated with an increase in ambient temperature, may be 
among the underlying mechanisms of temperature-related cardiovascular mortality 
(Halonen et al., 2011). 
A study in Taiwan found that increased 1-year average ozone, PM and nitrogen dioxide 
were associated with elevated blood pressure, total cholesterol, fasting glucose, and HbA1c. 
PM2.5 was more significantly associated with end-point variables than other gaseous 
pollutants (Chuang et al., 2011). A study on the association of blood markers of 
cardiovascular risk and air pollution in a national sample of the U.S. population found that 
PM10, but not gaseous air pollutants, is associated with blood markers of cardiovascular risk 
(Schwartz, 2001). In a study in Italy, the carboxyhaemoglobin concentration had an inverse 
correlation with HDL-C (Biava et al., 1992). In addition to the outdoor environment, the 
health hazards of indoor pollution should be considered (Kaplan, 2010). 
In recent years, global climate change has affected many biological and environmental 
factors. Of its most important effects are the increasing levels of atmospheric carbon dioxide, 
ultraviolet radiation, and ocean temperatures. In turn, they have resulted in decreased 
marine phytoplankton growth and reduced synthesis of omega-3 polyunsaturated fatty 
acids. It is suggested that the detrimental effects of climate change on the oceans may reduce 
the availability of dietary omega-3, which may have detrimental effects on serum lipid 
profile (Kang, 2011).  
4. Conclusion 
Climate change may alter concentrations of air pollutants or alterations in mechanisms of 
pollutant transport and thus influence individual and public health. The potential impacts 
of climate change and air pollution on lipid disorders is considered as an important area of 
investigation. This is of special concern for low- and middle-income countries, where the 
burden of air pollution and climate-related health disorders, and the burden of non-
communicable diseases are emerging. Effects of environmental factors on dyslipidemia 
should be considered in primordial and primary prevention of chronic diseases from early 
life. 
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1. Introduction 
Dyslipidemia is the major risk factors for macrovascular complications leading to 
cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM). In addition to this, 
endothelial dysfunction, platelet hyperactivity, impaired fibrinolytic balance and abnormal 
blood flow may accelerate atherosclerosis and increased risk of thrombotic vascular events 
(Colwell & Nesto, 2003). Macrovascular disease is the most common cause of morbidity and 
mortality in T2DM (Koskinen, 1998). Macrovascular disease is defined as illnesses affecting 
the larger arteries supplying the heart, brain, and the legs, thereby causing ischemic heart 
disease, cerebrovascular disease, and peripheral vascular disease (Thompson, 1999). In 
patients with diabetes, alteration in distribution of lipid increased risk of atherosclerosis. 
Specifically, insulin resistance and insulin deficiency was identified as phenotype of 
dyslipidemia in diabetes mellitus (Taskinen, 2003; Krauss & Siri, 2004; Chahil & Ginsberg, 
2006). This was characterized with high plasma triglyceride level, low HDL cholesterol level 
and increased level of small dense LDL-cholesterol (Mooradian, 2008). In these patient also, 
the increment of free fatty-acid release is due to insulin resistance. With the presence of 
adequate glycogen stores in the liver, this will promote triglyceride production, which 
stimulates the secretion of apolipoprotein B (Apo B) and VLDL cholesterol (Mooradian, 
2008). Hepatic production of VLDL cholesterol is enhanced due to disability of insulin to 
inhibit the release of free fatty-acid. Low HDL cholesterol levels were also associated with 
hyperinsulinemia. There are several associations between dyslipidemia and the increased 
risk of cardiovascular disease in patients with type 2 diabetes mellitus. Low HDL cholesterol 
and increased triglyceride levels may contribute to the increased risk of cardiovascular 
disease. In conjunction with increased small dense LDL cholesterol and low HDL cholesterol 
levels, further evidence suggests that acceleration of atherosclerosis in diabetes mellitus and 
insulin-resistant conditions is regulated by hypertriglyceridemia. Nevertheless, the 
association between LDL cholesterol and CHD risk is stronger compared to the association 
between hypertriglyceridemia and CHD risk. Type 2 diabetes is also associated with insulin 
resistance and hyperinsulinemia or syndrome X comprises hypertension, dyslipidemia, 
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decreased fibrinolysis and increased procoagulation factors (Serrano Rios, 1998). Besides 
dyslipidemia, platelet abnormalities contributed significantly to increased risk of CVD in 
these patients. In patients with type 2 diabetes, the platelet abnormalities are due to 
increased platelet aggregability and adhesiveness (Colwell & Nesto, 2003) and enhanced 
platelet aggregation activity may precede development of CVD (Halushka et al. 1981, 
Mandal et al. 1993). It has been well known that management of dyslipidemia in diabetes 
mellitus includes lifestyle changes such as increased physical activity and dietary 
modifications. Besides, various antihyperlipidemic agents have been utilized for this 
purpose. In contrast, antiplatelet agents are recommended mainly for primary and 
secondary prevention for cardiovascular disease in T2DM. Dyslipidemia is categorized as 
one of the cardiovascular risk factors besides others (family history CHD, hypertension, 
smoking, albuminuria) (American Diabetes Association, 2011). Patients with T2DM and 
having dyslipidemia are eligible for primary prevention of CVD with antiplatelet agents. 
This chapter will discuss on different types of antiplatelet agents used as primary 
prevention of cardiovascular disease in patients with T2DM. It will also emphasize 
appropriate selection of antiplatelet agents pertaining to clinical conditions of patients with 
T2DM and dyslipidemia. 
2. Pathophysiology of dyslipidemia and platelet abnormalities in type 2 
diabetes mellitus 
Atherogenic dyslipidemia is characterized by three lipoprotein abnormalities: elevated 
VLDL, small LDL and decreased HDL cholesterol levels, named as atherogenic lipoprotein 
phenotype (Grundy, 1998). In patients with type 2 diabetes, the prothrombotic state is 
characterized by increased fibrinogen levels (Imperatore et al 1998), increased plasminogen 
activator inhibitor (PAI)-1 (Byberg et al., 1998) and abnormalities in platelet function 
(Trovati et al., 1988). The reason for three aforementioned phenotypes in athrogenic 
dyslipidemia is the increased free fatty-acid release from insulin-resistant fat cells (Taskinen, 
2003; Krauss & Siri, 2004; Chahil & Ginsberg, 2006). The increased flux of free fatty acids 
into the liver in the presence of adequate glycogen stores promotes triglyceride production, 
which in turn stimulates the secretion of apolipoprotein B (ApoB) and VLDL cholesterol 
(Mooradian, 2008). The impaired ability of insulin to inhibit free fatty-acid release leads to 
enhanced hepatic VLDL cholesterol production (Frayn, 2001) which correlates with the 
degree of hepatic fat accumulation (Adiels et al., 2007). The increased number of plasma 
VLDL cholesterol and triglyceride levels decrease the level of HDL cholesterol and increase 
the concentration of small dense LDL cholesterol (Mooradian, 2008).  
Platelet activation commenced with binding of thrombogenic substances (collagen, 
thrombin, components of atheromatous plaque) to receptors located on the platelet surface 
(Colwell & Nesto, 2003). Receptor binding triggers a series of events that include hydrolysis 
of membrane phospholipids, mobilization of intracellular calcium, and phosphorylation of 
important intracellular proteins (Colwell & Nesto, 2003). There are several platelet 
abnormalities seen in diabetes patients. Abnormalities of thromboxane A2 (TXA2) 
production were among the earliest abnormalities in platelets of diabetes patients. TXA2 is a 
potent activator and its synthesis is suppressed by aspirin (Natarajan et al., 2008). Platelets 
from patients with type 2 diabetes mellitus found to have increased expression of adhesion 
molecules CD31, CD36, CD49b, CD62P and CD63 (Eibl et al., 2004). Glycemic control 
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improvement led to a significant decline in their expression (Eibl et al., 2004). In type 2 
diabetes patients, platelets increased surface expressionof GP Ib and GP IIb/IIIa (Vinik et al., 
2001). GP Ib mediates binding to von Willebrand factor (vWf) which is important in platelet-
dependent thrombogenesis (Natarajan et al., 2008). Increased expression of GP IIb/IIIa on 
platelet surfaces leads to enhanced fibrinogen binding, platelet cross-linking and 
thrombogenesis (Colwell & Nesto, 2003). In patients with type 2 diabetes, decreased platelet 
insulin receptor number and affinity responsible for platelet hyperactivity (Vinik et al., 
2001). Platelets have been shown to be targets of insulin action as they act as functional 
insulin receptor for insulin binding and autophosphorylation (Vinik et al., 2001). Insulin 
reduces platelet responses to the agonists’ adenosine diphosphate (ADP), collagen, 
thrombin, arachidonate and platelet-activating factor. (Natarajan et al., 2008). In patients 
with type 2 diabetes also, platelets show disordered calcium homeostasis (Li et al., 2001). 
This may cause hyperactivity including platelet shape change, secretion, aggregation and 
thromboxane formation (Beckman et al., 2002). Furthermore, the deficiency of magnesium in 
diabetes has been associated with platelet hyperaggregability and adhesiveness (Gawaz et 
al., 1994). In type 2 diabetes patients, the reduced vascular synthesis of the anti-aggregants 
prostacyclin and nitric oxide by endothelium, shift the balance towards aggregation and 
vasoconstriction (Vinik et al., 2001; Ferroni et al., 2004). In type 2 diabetes patients with 
acute hyperglycaemia, shear stress-induced platelet activation and P-selection expression 
(Natarajan et al., 2008). Hyperglycaemia also causes non-enzymatic glycation of platelet 
membrane proteins resulting in changes in protein structure and conformation, as well as 
alterations of membrane lipid dynamics (Brownlee et al., 1988; Winocour et al., 1992). This 
could result in enhanced expression of certain crucial platelet receptors, for instance,  
P-selectin and GP IIb/IIIa, thus altering platelet activity (Ferroni et al., 2004). Glycated LDL 
causes an increase in intracellular calcium concentration and platelet nitric oxide (NO) 
production, as well as inhibition of the platelet membrane Na+/K+-adenosine 
triphosphatase (Na+/K+-ATPase) activity (Ferroni et al., 2004). 
3. Implications of dyslipidemia and platelet abnormality in type 2 diabetes 
mellitus 
In patients with type 2 diabetes mellitus, low HDL cholesterol and high triglyceride levels 
might contribute to the increased risk of cardiovascular disease (Mooradian, 2008). Based on 
the Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in 
Adults (2011), hypertriglyceridemia, increased small dense LDL cholesterol and low HDL 
cholesterol found to be important in accelerating atherosclerosis in diabetes mellitus and 
insulin-resistant conditions. Abnormal platelet function is another important risk factors for 
cardiovascular disease in patients with diabetes (Colwell & Nesto, 2003). Atherosclerosis 
and thrombosis contribute significantly to the increased cardiovascular risk of diabetic 
patients (Colwell, 1997). The majority of ischemic coronary and cerebrovascular events are 
precipitated by vessel occlusion caused by atherosclerotic plaque disruption, platelet 
aggregation, platelet adhesion and thrombosis (Colwell & Nesto, 2003). Several systems that 
involved vasculature such as platelet, endothelial function, coagulation and fibrinolysis are 
impaired in patients with diabetes (Jokl & Colwell, 1997). Furthermore, increased platelet 
aggregability and adhesiveness are due to reduce membrane fluidity, increased intracellular 
Ca2+ and decreased intracellular Mg2+, increased arachidonic acid metabolism, increased 
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might contribute to the increased risk of cardiovascular disease (Mooradian, 2008). Based on 
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TXA2 synthesis, decreased prostacyclin production, decreased NO production, decreased 
antioxidant levels and increased expression of activation-dependent adhesion molecules 
(Halushka et al., 1981; Mayfield et al., 1985; Watala et al., 1998; Martina et al., 1998; Trovati 
et al., 1997; Sarji et al., 1979; Tschoepe, et al., 1997; Leet et al., 1981). For patients with T2DM, 
the presence of dyslipidemia and platelet hyperactivity justifies the use of antiplatelet agents 
as primary prevention strategy of CVD. 
4. Role of antiplatelet agents in primary prevention of CVD 
Increased physical activity, dietary modifications and pharmacologic interventions are the 
key methods in management of dyslipidemia in type 2 diabetes mellitus (Mooradian, 2008). 
The Antithrombotic Trialists’ Collaboration meta-analysis found that antiplatelet therapy 
reduces the relative risk of any serious vascular event by 25% in patients at high risk for a 
cardiovascular (CV) event (Antithrombotic Trialist’ Collaboration, 2002). Antiplatelet agents 
are used for primary and secondary prevention of CVD in type 2 diabetes mellitus patients. 
Antiplatelet therapy is needed in the management of diabetes mellitus because there is an 
increase of platelet aggregability and adhesiveness due to platelet and endothelial 
dysfunction, impaired coagulation cascade, and fibrinolysis process among diabetic 
individuals compared to nondiabetic individuals (Colwell & Nesto, 2003). Consequently, the 
balance in normal hemostasis is shifted to favor thrombosis and accelerated atherosclerosis 
and results in increasing CVD (Colwell & Nesto, 2003). For primary prevention of 
cardiovascular diseases, type 2 diabetes mellitus patients with high risk acquiring 
cardiovascular events such as those with family history of cardiovascular disease, 
hypertension, obesity (BMI > 30 kg/m2), smoking, dyslipidemia and albuminuria (Colwell, 
2004). Several types of antiplatelet agents is being utilized for prevention of CVD which 
including aspirin, ticlopidine, clopidogrel and glycoprotein (Gp) IIb-IIIa antagonist such as 
abciximab, eptifibatide and tirofiban (Patrono et al., 2004; American Diabetes Association, 
2006; Colwell & Nesto, 2003). Aspirin is one of the most common antiplatelet that been 
suggested in prevention of CVD in diabetes. Clopidogrel and ticlopidine are theinopyridine 
antiplatelet agents that generally suggested if patients are contraindicated to aspirin 
(American Diabetes Association, 2006). In contrast, Gp IIb-IIIa antagonist is usually given to 
diabetes patients who undergo precutaneous coronary intervention in order to intensify the 
antiplatelet therapy and to reduce the risk of procedure related thrombotic complication and 
reoccurrence of CV event (Patrono et al., 2004). 
5. Types of antiplatelet 
5.1 Aspirin 
Aspirin selectively and irreversibly acetylates the COX-1 enzyme, thereby blocking the 
formation of thromboxane A2 in platelets and leads to inability of platelet to resynthesize 
COX-1 (Patrono et al., 2005). Aspirin has been used as a primary strategy to prevent CVD in 
type 2 diabetes due to its effectiveness in atherosclerosis prevention is well established. 
Various meta-analyses studies and large scale randomized controlled trials in T2DM 
support that low-dose aspirin therapy should be prescribed as prevention strategy in T2DM, 
if the contraindication is not exist (Colwell, 2004). Low dose of aspirin inhibits thromboxane 
production by platelets but has little or no effects on other sites of platelet activity (Colwell 
& Nesto, 2003). Several randomized controlled trials had been designed to assess the 
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efficacy of aspirin in primary prevention of CVD which included Primary Prevention Project 
(PPP), US physicians’ Health Study (USPHS), Early Treatment of Diabetes Retinopathy 
Study (ETDRS), Hypertension Optimal Treatment Trial (HOT), British Male Doctors’ Trial 
(BMD) and the Thrombosis Prevention Trial (TPT) (Colwell & Nesto, 2003; Hayden et al., 
2002). In Primary Prevention Project (PPP), a low dose aspirin (100 mg/day) was evaluated 
for the prevention of cardiovascular events in individuals with one or more of the following 
conditions such as hypertension, hypercholesterolemia, diabetes, obese, family history of 
premature myocardial infarction or being elderly. After a mean of 3.6 years follow-up, 
aspirin was found to significantly lower the frequency of cardiovascular death (from 1.4 % 
to 0.8 %); relative risk (RR) 0.56 [confidence interval (CI) 0.31-.99] and total cardiovascular 
events (from 8.2 to 6.3% ; RR 0.77 [ 0.62-0.95] ). This trial involved large sample size (n = 
4495) with the largest proportion of patients with diabetes mellitus (17%) (Collaborative 
Group of the Primary Prevention Project, 2001). Overall, PPP provides evidence to prove the 
efficacy of aspirin in diabetes; though participants were not blinded and were not given 
placebo pills. Additionally, a meta-analysis done by Hayden et al., (2002) also rated the 
quality of PPP as “fair” if compared to the rest of studies. In addition to PPP, a 5 years 
primary prevention trial in 22 701 healthy men; included 533 men with diabetes was 
conducted in US Physicians’ Health Study (USPHS) in which a low-dose aspirin regimen 
(325 mg every other day) was given to treated group compared with placebo. A total of 44% 
significant risk reduction in CVD treated group was noted and the subgroup analyses in the 
diabetes reveals a reduction in myocardial infarction from 10.1 % (placebo) to 4.0 % 
(aspirin), yield a relative risk reduction of 0.39 for the diabetes men on aspirin therapy 
(Steering Committee of the Physicians’ Health Study Research Group, 1989). Researcher and 
participants were blinded in this trial. In contrast with PPP, women were included in the 
study populations (2583 out of 4495 sample sizes). Hence, this study was more reliable 
compared to previous ones even though only 2% of the study population was diagnosed 
with diabetes. The Hypertension Optimal Treatment Trial (HOT) also examined the effects 
of low dose of aspirin (75 mg/day) versus placebo in 18 790 hypertension patients and 8% of 
them had diabetes. Results showed that aspirin significantly reduce cardiovascular event by 
15% and myocardial infarction by 36% (Hansson et al., 1998). The HOT trial was another 
primary prevention study that included women, which was 46.6 % from total study 
population. Colwell (2004) commended that this study provided further evidence for the 
efficacy and safety of aspirin therapy in diabetes with systolic blood pressure less than 160 
mmHg. Hayden et al., (2002) was in agreement with Colwell (2004) and concluded that HOT 
was a “good” quality of trial in their meta-analysis. Despite that, these findings were 
mirrored by Early Treatment of Diabetes Retinopathy Study (ETDRS) where they reported 
that although aspirin did not prevent progression of retinopathy but it did produce a 
significant reduction in risk for myocardial infarction (28%) over 5 years (P=0.038). This 
study may viewed as mixed primary and secondary prevention trials since those enrolled 
had a history of myocardial infarction and less than 50% had elevated blood pressure and 
history of CVD (ETDRS Investigators 1992). Conversely, the British Male Doctors’ Trial 
(BMD) had conflicting results regarding aspirin effects in reducing the risk for myocardial 
infarction and adverse effects such as gastrointestinal bleeding and hemorrhagic stroke to 
diabetes patients. A total of 39 % of participants were discontinued therapy during the study 
due to adverse effect of aspirin (Hayden et al., 2002). Similar to PPP trial, participants in this 
study were not blinded thus results may be varies. Following this, a meta-analysis of these 
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five randomized clinical trials (except ETDRS) was performed by Hayden et al., (2002) and 
systematic reviews on nine articles about the effect of aspirin on gastrointestinal bleeding 
and hemorrhagic stroke were conducted. They concluded that the net benefit of aspirin 
increase with CV risk. Nonetheless, this meta-analysis was found to have selection bias due 
to exclusion of 2 large trials that examined the effects of aspirin in patients with diabetes or 
stable angina. Sanmuganathan et al., (2001) also reached similar estimates of the beneficial 
effects of aspirin in primary prevention of CVD. The Japanese Primary Prevention of 
Atherosclerosis With Aspirin for Diabetes (JPAD) trial was the first prospectively designed 
trial to evaluate the use of aspirin (81 mg or 100 mg) in the primary prevention of 
cardiovascular events in patients with type 2 diabetes (n = 2539) aged 30–85 years in Japan 
(Ogawa et al., 2008). Among patients aged > 65 years (n =1363), aspirin was associated with 
a 32% reduction in the risk of the primary end point (6.3 vs. 9.2%; P = 0.047). Furthermore, in 
aspirin-treated patients, the incidence of fatal coronary and cerebrovascular events was 
significantly lower by 90% (0.08 vs. 0.8%; P = 0.0037). Paradoxically, there were no 
differences in nonfatal coronary and cerebrovascular events. Aspirin was well tolerated, 
with no significant increase in the composite of hemorrhagic stroke and severe 
gastrointestinal bleeding (Angiolillo, 2009). The outcome of this study was in opposite with 
the current recommendations on aspirin usage in primary prevention of CVD in diabetes 
patients (Angiolillo, 2009). However, the ASCEND and ACCEPT-D study are two ongoing 
trials will provide further insights to the appropriateness of aspirin usage in primary 
prevention of CVD in patients with diabetes. Another recent trial (POPADAD), failed to 
show any benefit with aspirin or antioxidants in primary prevention of cardiovascular 
events (Belch, 2008). The outcome of the study could be due to small number of patients 
with low event rates. A study on the utilization of antiplatelet therapy in type 2 diabetes 
patients revealed that many of the eligible patients did not receive the drugs as primary 
prevention strategy for CVD (Huri et al., 2008). Therefore, the recommendations on aspirin 
usage in primary prevention of CVD in type 2 diabetes patients must be fully justified after 
taking consideration against the benefit versus risk of its use. In another words, the 
recommendations should be base on individual patients’ assessment and clinical judgment. 
Proper use of aspirin in primary prevention of CVD in type 2 diabetes patients may result in 
long-term benefits.  
5.2 Clopidogrel  
Clopidogrel is another type of antiplatelet agents used in primary prevention of CVD in 
type 2 diabetes when patients are intolerant to aspirin. It inhibits ADP-induced platelet 
aggregation by blocking the purinergic receptors and therefore prevents the activation of the 
GpIIb-IIIa receptor and subsequent binding to fibrinogen (Colwell & Nesto, 2003). 
Clopidogrel is preferable compared to ticlopidine because of its safety profile (Savi & 
Herbert, 2005; Bertrand et al., 2000). Nevertheless, the information regarding the usage of 
clopidogrel in primary prevention of CVD is limited than for secondary prevention of CVD 
in diabetes patients. Even though clopidogrel may be slightly more effective than aspirin, 
the size of any additional benefits is statistically uncertain and it has not been granted a 
claim of superiority against aspirin (Patrono et al., 2004). However, the publication of the 
Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) recently had led to 
FDA approval of a new indication for clopidogrel in patients with acute coronary 
syndromes without ST-segment elevation (Patrono et al., 2004).The CURE trial examined CV 
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outcomes with clopidogrel plus aspirin versus aspirin alone in patients with acute ischemic 
heart disease (IHD) (CURE Steering Committee, 2001). These findings demonstrated that 
clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-
segment elevation thus can be generalized as the study sample size (n =12,562) was large 
and patients were recruited from 482 centers in 28 countries. This trial also showed that 
3.7% of patients in this combination therapy group had major bleeding and it was 
significant more compared with those solely on aspirin but there was no increase in life-
threatening bleeds (CURE Steering Committee, 2001). Hence, a loading dose of 300mg 
clopidogrel should be used in this setting followed by 75 mg daily (Patrono et al., 2004). 
Bhatt et al., (2002) concluded that clopidogrel is an effective drug for secondary prevention 
in diabetes. Therefore, previous studies clearly justified the use of dual anti platelet therapy 
with aspirin and clopidogrel for secondary prevention of CVD in diabetes patients. Its role 
in primary prevention of CVD in diabetes patients is vague since no study has directly 
measure the outcome for this purpose.  
5.3 Ticlopidine 
Ticlopidine also inhibit ADP-induced platelet aggregation with no direct effects on the 
metabolism of arachidonic acid (Patrono, 1998). It has slower antiplatelet effect compared 
with clopidogrel (Patrono et al., 2004). Ticlopidine in Microangiopathy of Diabetes (TIMAD) 
study was conducted by involving 435 patients with nonproliferative diabetes retinopathy 
to evaluate for its effects on macrovascular disease in diabetes patients. Patients were 
randomized to receive ticlopidine, 250 mg twice daily and were followed up to 3 years. 
Ticlopidine was found significantly reduced annual microaneurysm progression by 67% 
and overall progression of retinopathy was significantly less severe with ticlopidine 
(TIMAD Study Group, 1990). However, this study was not designed to evaluate effect of 
ticlopidine on cardiovascular events. There are limited studies done on effect of ticlopidine 
in prevention of CVD in diabetes. In contrast to clopidogrel, ticlopidine does not have an 
approved indication for patients with a recent myocardial infarction (Patrono et al., 2004). 
Even though ticlopidine has lower cost compared to clopidogrel, (Drug Formulary 
University Malaya Medical Centre, 2005; Patrono et al., 2004), its role in primary prevention 
of CVD in type 2 diabetes patients have not been established. 
5.4 Dipyridamole  
Dipyridamole inhibits platelet cyclic-3’,5’-adenosine monophosphate and cyclic-3’, 5’-
guanosine monophosphate phosphodiesterase (Natarajan et al. 2008). Overview of 25 trials 
among approximately 10000 high risks of CVD patients with the use of dipyridamole and 
aspirin, it was found that the addition of dipyridamole to aspirin has not been shown clearly 
to produce additional reductions in serious vascular events (Patrono et al., 2004). However, 
one of 25 trials suggested that there may be a worthwhile further reduction in stroke 
(Patrono et al. 2004). Patrono et al., (2004) also suggested that the combination of low dose 
aspirin and extended release dipyridamole (200 mg twice daily) is considered an acceptable 
option for initial therapy of patients with non-cardioembolic cerebral ischemic events and 
not in patients with ischemic heart attack. The benefits of dipyridamole in patients with 
diabetes have not been reported (Natarajan et al., 2008). Specifically, there are limited 
studies or trials conducted to examine the role of dipyridamole for primary and secondary 
prevention of CVD amongst T2DM patients.  
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studies or trials conducted to examine the role of dipyridamole for primary and secondary 
prevention of CVD amongst T2DM patients.  
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5.5 GP IIb/IIIa inhibitors 
The platelet glycoprotein (GP) IIb/IIIa complex receptor antagonists block activity at the 
fibrinogen binding site on platelet (Colwell & Nesto, 2003). These agents are useful in type 2 
diabetes patients with acute coronary syndrome and in those undergoing percutaneous 
coronary interventions (Colwell & Nesto, 2003). These agents are administered intravenously 
with a rapid onset of action and short half-life (Natarajan et al., 2008). Numerous studies have 
been performed comparing various GP IIb/IIIa inhibitors. Currently, three different GP 
IIb/IIIa inhibitors (abciximab, eptifibatide, and tirofiban) are approved for clinical use. This 
group of drugs was mainly study for secondary prevention of CVD in diabetes patients. 
Evidence from three trials revealed that among 1,262 diabetes patients, use of these agents was 
associated with reduction in mortality from 4.5% to 2.5% (p=0.031) (Bhatt et al., 2000). In 
another meta-analysis of six large trials, with 6,458 patients with diabetes and acute coronary 
syndromes, GP IIb/IIIa inhibitor therapy was associated with a significant mortality reduction 
at 30 days, from 6.2% to 4.6% CI(0.59-0.92, p=0.007) (Roffi et al., 2001). Nonetheless, the role of 
GP IIb/IIIa inhibitors in primary prevention of CVD in type 2 diabetes mellitus has not been 
justified; therefore it is not recommended for this purpose. 
6. Appropriate selection of antiplatelet agents for primary prevention of CVD 
in type 2 diabetes patients 
Among all choices, there are considerations to be taken into account before types of 
antiplatelet agents chosen. According to American Diabetes Association (2011), aspirin (75-
162mg/day) should be considered for primary prevention of cardiovascular disease in type 
2 diabetes patients for men (>50 years) and women (>60 years) with at least one additional 
major risk factor (family history of cardiovascular disease, hypertension, smoking, 
dyslipidemia or albuminuria). The other types of antiplatelet agents either alone or 
combination with aspirin therapy has no established role in primary prevention of 
cardiovascular disease in type 2 diabetes patients. In contrast, aspirin should not be 
recommended for CVD prevention for diabetes patients with low CVD risk (10-year CVD 
risk <5%, such as in men <50 and women <60 years of age with no additional CVD risk 
factors, since the potential adverse effects from bleeding likely outweigh the potential 
benefits (ADA, 2011). A same recommendation goes to type 2 diabetes patients with 
multiple other risk factors (e.g. 10-year risk 5-10%), in which clinical judgment is required 
(American Diabetes Association, 2011).  
7. Monitoring of aspirin efficacy and adverse effects 
Aspirin once daily (75-100 mg) is recommended in primary prevention of CVD in type 2 
diabetes patients when antiplatelet prophylaxis has a favorable benefit/risk profile (Patrono 
et al., 2004). For effectiveness of primary prevention strategy, patients should be followed on 
a regular basis and examined for signs and symptoms of any cardiovascular diseases. In 
consideration of dose-dependent GI toxicity and its potential impact on compliance, 
physicians are encouraged to use the lowest dose of aspirin that was shown to be effective in 
each clinical setting (Patrono et al., 2001). Aspirin should not be given to patients with 
gastrointestinal ulcerations; best tolerated after food. In conclusion, bleeding and gastrointestinal 
complications are the most common adverse effects of aspirin. Thus, the patients on aspirin 
should be monitored for stomach pain, heartburn, nausea and bleeding tendency.  
Dyslipidemia and Type 2 Diabetes Mellitus:  




Dyslipidemia is one of the risk factors for acquiring cardiovascular disease in patients 
with type 2 diabetes. In absent for contraindication, type 2 diabetes patients with 
dyslipidemia are eligible for primary prevention of cardiovascular disease although the 
routine use has not been documented. Aspirin plays a key role in primary prevention 
strategy of cardiovascular disease in type 2 diabetes patients. With limited studies and 
evidence for other antiplatelet agents, their role in primary prevention has not been 
established. 
9. Summary 
Dyslipidemia is one of the major risk factors for macrovascular disease leading to CVD in 
type 2 diabetes. 
In type 2 diabetes patients with dyslipidemia, alteration in lipid distribution and platelet 
abnormalities increased risk of acquiring CVD. 
Patients with type 2 diabetes with one of the following; dyslipidemia, family history of 
coronary heart disease, hypertension, smoking and albuminuria are at increased risk of 
CVD, thus eligible for primary prevention strategy of CVD. 
With limited evidence, proper justification and clinical judgments of benefit versus risk, 
aspirin plays a key role as antiplatelet agent in primary prevention of CVD in patients with 
type 2 diabetes with dyslipidemia. 
Patients with type 2 diabetes and dyslipidemia receiving aspirin for primary prevention 
strategy should be monitored for effectiveness of treatment (sign and symptoms of CVD) 
and adverse effects (stomach pain, heartburn, nausea and bleeding tendency). 
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1. Introduction 
Dyslipidemia is characterized by an aggregation of lipoprotein abnormalities including low 
high density lipoprotein cholesterol (HDL-C), high serum triglycerides (TG) and increased 
small low density lipoprotein cholesterol (LDL-C). Lipoproteins, which contain lipids and 
proteins (apolipoproteins, APO) are responsible, primarily, for transporting water insoluble 
lipids (cholesterol, TG) in plasma from the intestines and liver, where they are absorbed and 
synthesized, respectively, to peripheral tissues (muscle, adipose) for utilization, processing 
and/or storage (Kwan et al., 2007). There are several subtypes of lipoproteins with specific 
functions including, from smallest to largest: 1) chylomicrons, which transport dietary TG 
from the intestines to the peripheral tissue and liver; 2) very LDL (VLDL) particles, which 
transport TG from the liver to peripheral tissues; 3) intermediate density lipoproteins (IDL), 
which are produced from VLDL particle metabolism and may be taken up by the liver or 
further hydrolyzed to LDL; and, 4) HDL, which is key in ‘reverse cholesterol transport’ or 
shuttling cholesterol from peripheral cells to the liver (Kwan et al., 2007). 
The Metabolic Syndrome (MetSyn) is a clustering of traits including dyslipidemia as well as 
hypertension (raised systolic and/or diastolic blood pressure), dysglycemia (high fasting 
glucose) and obesity (high body mass index (BMI) and/or waist circumference). 
Dyslipidemia is formally defined within the context of MetSyn. Various diagnostic 
definitions have been proposed for MetSyn by several organizations including the World 
Health Organization (WHO) (Alberti and Zimmet, 1998), European Group Insulin 
Resistance (EGIR) (Balkau and Charles, 1999), National Cholesterol Education Program 
Adult Treatment Panel III (NCEP ATP III, (2001), International Diabetes Federation (IDF, 
(Alberti et al., 2005), American Heart Association/National Heart, Lung, and Blood Institute 
(AHA/NHLBI) (Grundy et al., 2006) and, with the most recent joint interim statement 
proposed by the AHA/NHLBI, IDF and other organizations (Alberti et al., 2009). Although 
the recommendations differ widely on the obesity component, the dyslipidemia component 
has been fairly consistently defined as having TG ≥ 150 mg/l, HDL-C <40 mg/dL (1.03 
mmol/l, in males) or <50 mg/dL (1.29 mmol/l in females) or drug treatment for elevated 
TG or low HDL-C (NCEP ATP III: (2001), IDF: (Alberti et al., 2005), Joint Statement: (Alberti 
et al., 2009)). However, the WHO (Alberti and Zimmet, 1998) proposed slightly lower limits 
for HDL-C (male: < 0.9 mmol/l (35 mg/dl); female: < 1.0 mmol/l (39 mg/dl)) and the EGIR 
(Balkau and Charles, 1999) recommended dyslipidemia be defined by HDL-C < 1.0 mmol/l 
(39 mg/dl) or TG > 2.0 mmol/l (177 mg/dl). There is currently no recommended value for 
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LDL-C levels in the context of MetSyn yet LDL-C remains the primary target of therapy for 
the management of high blood cholesterol per the most recent guidelines from the NCEP 
ATPIII, which recommended drug therapy for LDL-C values ranging from ≥100 mg/dl to 
≥190 mg/dl depending on the presence/absence of other coronary heart disease (CHD) risk 
factors (Grundy et al., 2004). When LDL becomes lipid depleted, small dense LDL (sdLDL) 
particles are formed, which have a lower affinity for the LDL receptor (LDLR), more 
susceptibility to oxidation and a higher affinity for macrophages; and, thus, sdLDL particles 
contribute to the atherosclerotic process (Austin et al., 1990; Littlewood and Bennett, 2003) 
and likely MetSyn (Kruit et al., 2010). 
Dyslipidemia and MetSyn are common in developed nations and the prevalence of both are 
rising worldwide, which may be attributed, in part, to the rising rates of overweight and 
obesity (Alberti et al., 2009; Halpern et al., 2010). According to the National Health and 
Nutrition Examination Survey (NHANES) III (1988-1994) in the United States (U.S.), which 
used the NCEP ATP III criteria, the age-adjusted prevalence of dyslipidemia defined by 
high TG or low HDL-C, was approximately 30.0% and 37.1%, respectively; and, the 
prevalence of MetSyn was approximately 23.7% (Ford et al., 2002). The prevalence of 
dyslipidemia and MetSyn generally increase with increasing age (Ford et al., 2002). 
However, in a more recent study that used the Health Survey for England (HSE) (2003-2006) 
survey data and NHANES (1999-2006) data with exclusion of persons over 80 years old, the 
prevalence of low HDL-C (defined in both males and females as <40 mg/dL) was 10.0% in 
England and 19.2% in the U.S. (Martinson et al., 2010). Thus, the prevalence can vary markedly 
depending on how these traits are defined (Cook et al., 2008). Interestingly, trends in the U.S. 
and England indicate during the past two decades an increase in the proportion of individuals 
diagnosed with high cholesterol (≥240 mg/dL) but who achieved therapeutic control (Roth et 
al., 2010). For example, in the U.S. in 2006, 54.0% of men (95% CI: 47.6–60.4) and 49.7% of 
women (95% CI: 44.3–55.0) with high total serum cholesterol were on cholesterol-lowering 
medication, as opposed to 10.8% of men (95% CI: 8.0–13.6) and 8.6% (95% CI: 6.7–10.6) of 
women in 1993 (Roth et al., 2010). In England, in 2006, 35.5% of men (95% CI: 32.8–38.3) and 
25.7% of women (95% CI: 23.4–28.1) were on cholesterol-lowering medication as opposed to 
0.6% of men (95% CI: 0.3–1.3) and 0.4% of women (95% CI: 0.1–0.7%) in 1993 (Roth et al., 2010). 
Thus, prevalence rates will also vary by whether or not relevant drug treatments have been 
considered and, perhaps, the list of relevant drugs should include cholesterol lowering 
therapies (e.g., statins) as well as other drugs (e.g., tamoxifen, glucocorticoids) known to alter 
TG and cholesterol levels (Garg and Simha, 2007). 
Both dyslipidemia and MetSyn increase the risk of Type II diabetes mellitus (T2DM) (Adiels 
et al., 2006; Kruit et al., 2010) and cardiovascular disease (CVD) morbidity (Alberti et al., 
2009; Linsel-Nitschke and Tall, 2005) and CVD mortality (Lewington et al., 2007). Patients 
with MetSyn have a five-fold increase in the risk of developing T2DM and are at twice the 
risk of developing CVD over the next 5 to 10 years compared to individuals without the 
syndrome (Alberti et al., 2009). In the presence of both MetSyn and T2DM, the prevalence of 
CVD is markedly increased with an odds ratio (OR) of 3.04 [95% confidence interval (CI) of 
OR: 1.98-4.11] in comparison to those with none of these conditions (Athyros et al., 2004). 
The importance of MetSyn is exemplified by its ICD-9 code (277.7), which was initially 
established as a diagnosis of “Dysmetabolic Syndrome X” (Einhorn et al., 2003; Kahn et al., 
2005). In summary, both dyslipidemia and MetSyn are substantial public health problems, 
which require a better understanding of their respective etiologies to develop more effective 
lifestyle and therapeutic interventions. 
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Heritability estimates suggest there is a strong genetic component to dyslipidemia and 
MetSyn. Heritability estimates for dyslipidemia range from 0.20 to 0.60 (Edwards et al., 
1997; Goode et al., 2007; Herbeth et al., 2010; Kronenberg et al., 2002; Wang and Paigen, 
2005) and from 0.24 to 0.63 for MetSyn (Lin et al., 2005; Sung et al., 2009).  
Multiple genetic variants in the form of single nucleotide polymorphisms (SNPs) (i.e., single 
DNA base changes) have been associated with manifestation of dyslipidemia and MetSyn. 
In this chapter, we review and summarize associations between common SNPs (i.e., those 
with a minor allele frequency (MAF) ≥0.05) in the most biologically plausible candidate 
genes and HDL-C, LDL-C and TG levels as well as MetSyn as a single, unifying trait. 
Previous estimates suggest all common variants together explain less than 10 percent of 
HDL-C levels in the general population (Kronenberg et al., 2002); however, more elegant 
statistical modeling methods that combine SNPs in a more biologically meaningful way may 
be needed to better understand the collective role of genetic variants in manifestation of 
dyslipidemia, MetSyn and other complex metabolic traits. As a result, at the end of this 
chapter, we review studies that have undertaken more complex modeling strategies to 
understand the aggregate effects of SNPs in manifestation of dyslipidemia and MetSyn and 
provide our insights for future directions in this field. 
2. Genetic variants in lipid metabolism and HDL-C levels 
As mentioned above, HDL-C is important for “reverse cholesterol transport” or the 
shuttling of cholesterol from peripheral cells to the liver. Many of the genetic variants 
associated with HDL-C levels have been summarized nicely in a recent comprehensive 
review by Boes et al. (Boes et al., 2009). In Table 1, we include common SNPs tabulated in 
Boes et al. (2009) review of large studies (ethnic group sample sizes ≥500) as well as common 
SNPs in large studies that have been identified since their review.  
 
Gene Polym. rs Number MAF Ethn. Sample 
Size 
Results 
(Effect Size,  
p-value) 
Reference 
ABCA1 C (-297)T rs2246298 0.25 (T) A 1625 
(GP) 
p=0.0455 (Shioji et al. 
2004b) 






+1.9 /+5.0 mg/dl 
(1/2 copies); p=0.03
(Shioji et al. 
2004b) 







ABCA1 G378C rs1800978 0.13 (C) W 5040 
(GP) 
-1.2/- 2.7 mg/dl 
(1/2 copies); 
p=0.03 
(Porchay et al. 
2006) 
ABCA1  rs3890182 0.13 (A) W 5287 
(GP) 
-1/-3 mg/dl (1/2 
copies) ; p=0.003 
(Kathiresan et 
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(GP) 
p=0.006 (Shioji et al. 
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LDL-C levels in the context of MetSyn yet LDL-C remains the primary target of therapy for 
the management of high blood cholesterol per the most recent guidelines from the NCEP 
ATPIII, which recommended drug therapy for LDL-C values ranging from ≥100 mg/dl to 
≥190 mg/dl depending on the presence/absence of other coronary heart disease (CHD) risk 
factors (Grundy et al., 2004). When LDL becomes lipid depleted, small dense LDL (sdLDL) 
particles are formed, which have a lower affinity for the LDL receptor (LDLR), more 
susceptibility to oxidation and a higher affinity for macrophages; and, thus, sdLDL particles 
contribute to the atherosclerotic process (Austin et al., 1990; Littlewood and Bennett, 2003) 
and likely MetSyn (Kruit et al., 2010). 
Dyslipidemia and MetSyn are common in developed nations and the prevalence of both are 
rising worldwide, which may be attributed, in part, to the rising rates of overweight and 
obesity (Alberti et al., 2009; Halpern et al., 2010). According to the National Health and 
Nutrition Examination Survey (NHANES) III (1988-1994) in the United States (U.S.), which 
used the NCEP ATP III criteria, the age-adjusted prevalence of dyslipidemia defined by 
high TG or low HDL-C, was approximately 30.0% and 37.1%, respectively; and, the 
prevalence of MetSyn was approximately 23.7% (Ford et al., 2002). The prevalence of 
dyslipidemia and MetSyn generally increase with increasing age (Ford et al., 2002). 
However, in a more recent study that used the Health Survey for England (HSE) (2003-2006) 
survey data and NHANES (1999-2006) data with exclusion of persons over 80 years old, the 
prevalence of low HDL-C (defined in both males and females as <40 mg/dL) was 10.0% in 
England and 19.2% in the U.S. (Martinson et al., 2010). Thus, the prevalence can vary markedly 
depending on how these traits are defined (Cook et al., 2008). Interestingly, trends in the U.S. 
and England indicate during the past two decades an increase in the proportion of individuals 
diagnosed with high cholesterol (≥240 mg/dL) but who achieved therapeutic control (Roth et 
al., 2010). For example, in the U.S. in 2006, 54.0% of men (95% CI: 47.6–60.4) and 49.7% of 
women (95% CI: 44.3–55.0) with high total serum cholesterol were on cholesterol-lowering 
medication, as opposed to 10.8% of men (95% CI: 8.0–13.6) and 8.6% (95% CI: 6.7–10.6) of 
women in 1993 (Roth et al., 2010). In England, in 2006, 35.5% of men (95% CI: 32.8–38.3) and 
25.7% of women (95% CI: 23.4–28.1) were on cholesterol-lowering medication as opposed to 
0.6% of men (95% CI: 0.3–1.3) and 0.4% of women (95% CI: 0.1–0.7%) in 1993 (Roth et al., 2010). 
Thus, prevalence rates will also vary by whether or not relevant drug treatments have been 
considered and, perhaps, the list of relevant drugs should include cholesterol lowering 
therapies (e.g., statins) as well as other drugs (e.g., tamoxifen, glucocorticoids) known to alter 
TG and cholesterol levels (Garg and Simha, 2007). 
Both dyslipidemia and MetSyn increase the risk of Type II diabetes mellitus (T2DM) (Adiels 
et al., 2006; Kruit et al., 2010) and cardiovascular disease (CVD) morbidity (Alberti et al., 
2009; Linsel-Nitschke and Tall, 2005) and CVD mortality (Lewington et al., 2007). Patients 
with MetSyn have a five-fold increase in the risk of developing T2DM and are at twice the 
risk of developing CVD over the next 5 to 10 years compared to individuals without the 
syndrome (Alberti et al., 2009). In the presence of both MetSyn and T2DM, the prevalence of 
CVD is markedly increased with an odds ratio (OR) of 3.04 [95% confidence interval (CI) of 
OR: 1.98-4.11] in comparison to those with none of these conditions (Athyros et al., 2004). 
The importance of MetSyn is exemplified by its ICD-9 code (277.7), which was initially 
established as a diagnosis of “Dysmetabolic Syndrome X” (Einhorn et al., 2003; Kahn et al., 
2005). In summary, both dyslipidemia and MetSyn are substantial public health problems, 
which require a better understanding of their respective etiologies to develop more effective 
lifestyle and therapeutic interventions. 
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Heritability estimates suggest there is a strong genetic component to dyslipidemia and 
MetSyn. Heritability estimates for dyslipidemia range from 0.20 to 0.60 (Edwards et al., 
1997; Goode et al., 2007; Herbeth et al., 2010; Kronenberg et al., 2002; Wang and Paigen, 
2005) and from 0.24 to 0.63 for MetSyn (Lin et al., 2005; Sung et al., 2009).  
Multiple genetic variants in the form of single nucleotide polymorphisms (SNPs) (i.e., single 
DNA base changes) have been associated with manifestation of dyslipidemia and MetSyn. 
In this chapter, we review and summarize associations between common SNPs (i.e., those 
with a minor allele frequency (MAF) ≥0.05) in the most biologically plausible candidate 
genes and HDL-C, LDL-C and TG levels as well as MetSyn as a single, unifying trait. 
Previous estimates suggest all common variants together explain less than 10 percent of 
HDL-C levels in the general population (Kronenberg et al., 2002); however, more elegant 
statistical modeling methods that combine SNPs in a more biologically meaningful way may 
be needed to better understand the collective role of genetic variants in manifestation of 
dyslipidemia, MetSyn and other complex metabolic traits. As a result, at the end of this 
chapter, we review studies that have undertaken more complex modeling strategies to 
understand the aggregate effects of SNPs in manifestation of dyslipidemia and MetSyn and 
provide our insights for future directions in this field. 
2. Genetic variants in lipid metabolism and HDL-C levels 
As mentioned above, HDL-C is important for “reverse cholesterol transport” or the 
shuttling of cholesterol from peripheral cells to the liver. Many of the genetic variants 
associated with HDL-C levels have been summarized nicely in a recent comprehensive 
review by Boes et al. (Boes et al., 2009). In Table 1, we include common SNPs tabulated in 
Boes et al. (2009) review of large studies (ethnic group sample sizes ≥500) as well as common 
SNPs in large studies that have been identified since their review.  
 
Gene Polym. rs Number MAF Ethn. Sample 
Size 
Results 
(Effect Size,  
p-value) 
Reference 
ABCA1 C (-297)T rs2246298 0.25 (T) A 1625 
(GP) 
p=0.0455 (Shioji et al. 
2004b) 






+1.9 /+5.0 mg/dl 
(1/2 copies); p=0.03
(Shioji et al. 
2004b) 







ABCA1 G378C rs1800978 0.13 (C) W 5040 
(GP) 
-1.2/- 2.7 mg/dl 
(1/2 copies); 
p=0.03 
(Porchay et al. 
2006) 
ABCA1  rs3890182 0.13 (A) W 5287 
(GP) 
-1/-3 mg/dl (1/2 
copies) ; p=0.003 
(Kathiresan et 
al. 2008) 
ABCA1  rs2275542  A <1880 
(GP) 
p=0.006 (Shioji et al. 
2004b) 
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ABCA1  rs2515602 0.27 B 1943 (P) M; p=0.034;
F; p<0.001
(Klos et al. 
2006a) 
ABCA1 G596A rs2853578 0.28 (A) W 2468 
CVD 
834 (Co)
0.2 /+2.8 mg/dl 
(1/2 copies); 
p=0.02 
(Whiting et al. 
2005) 
ABCA1 2310G>A rs2066718 0.03 (A) W 9123 (P) F: higher levels in 
carriers; p=0.02 
(Frikke-
Schmidt et al. 
2004) 
ABCA1 G2706A rs2066718 0.05 (A) Tu 2458 
(GP) 







rs2066718 0.06 (A) Tu 2105 
(GP) 




ABCA1 1883M rs4149313 0.12 (G) W 9123 (P) F: + heterozygotes; 
p=0.05 
(Frikke-












Schmidt et al. 
2004) 
ABCA1 4759G > A rs2230808 0.26 (K) W 779 
(CVD) 
-1.5 mg/dl for 
carriers; p=0.03 












rs5070 0.23 (C) A 1637 
(GP) 
+1.9 /+5.4 mg/dl 
(1/2copies); 
p=0.0005




rs5069 0.31 (C) B 3831 (P) M/F; p=n.s/0.022 (Brown et al. 
2006) 
APOA1  rs28927680 0.93 (G) EA 25,167 p= 8.61E-09 (Dumitrescu et 
al. 2011) 
APOA1  rs964184 0.86 (C) EA 25,167 p= 6.08E-10 (Dumitrescu et 
al. 2011) 
APOA5 - 1131T > 
C 
rs662799 0.06 (C) UK 1696 (P) -1.5 mg/dl /-5.4 
mg/dl (1/2 
copies) ; p=0.04 
(Talmud et al. 
2002a) 
APOA5 - 1131T > 
C 
rs662799 0.07 (C) W 1596(SA
PHIR) 
-3.5 mg/dl per 
copy; p=0.00038 
(Grallert et al. 
2007) 









- 1.2 /- 8.1 mg/dl 
1/2 copies; 
p<0.0001
(Lai et al. 2003) 
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APOA5 - 1131T > C rs662799 0.34 (C) A 521 
HoCo 
-3.3 mg/dl per 
copy; p<0.001 
(Yamada et al. 
2007) 
APOA5 -3A > G rs651821 0.07 W 2056 (P) M; p=0.30; F; 
p=0.26 
(Klos et al. 
2006a) 
APOA5 -3A > G rs651821 0.18 (G) C 2711 
(GP) 
-2.3/-5.8 mg/dl 
1/2 copies ; 
p<0.0001 
(Lai et al. 2003) 
APOA5 -3A > G rs651821 0.34 (C) A 5207 
(Ho Co, 
P) 
-2.7 mg/dl per 
copy; p<0.001 
(Yamada et al. 
2007) 
APOA5 -3A > G rs651821 0.36 (G) A 2417 
(Ho Co)
-3.9 /- 7.0 mg/dl 
1/2 copies ; 
p<0.001 
(Yamada et al. 
2008) 
APOA5 S19W rs3135506 0.06 (W) UK 1660 (P) -1.9 /+1.2 mg/dl 
(1/2 copies); 
p=0.02 
(Talmud et al. 
2002a) 
APOA5 56C>G rs3135506 0.06 (G) W 2347 (P) -2.0 mg/dl for 
carriers; p=0.008 
(Lai et al. 2004) 
APOA5  rs2072560 0.16 (A) C 2711 
(GP) 
-1.9 /-3.9 mg/dl 
(1/2 copies) ; 
p=0.003 
(Lai et al. 2003) 
APOA5 IVS3+476
G>A 
rs2072560  Ma 707 (P) -0.4 /9.3 mg/dl 
(1/2 copies) ; 
p=0.004 
(Qi et al. 2007) 




APOA5 +553 rs2075291 0.07 (T) A 5206 
HoCo 
-4.6 mg/dl per 
copy; p<0.001 
(Yamada et al. 
2007) 
APOA5 Gly185Cys rs2075291 0.08 (T) A 2417 
HoCo 
-5.0 /-11.2 mg/dl 
(1/2 copies); 
p<0.001 
(Yamada et al. 
2008) 




-2.3 /-3.1 mg/dl 
1/2 copies; 
p<0.0001 
(Lai et al. 2003) 
APOB  rs11902417 0.78 (G) E 17723 p= 3.7x10-7 (Waterworth 
et al. 2010) 
APOC3 C455T rs2854116 0.41 (C) In 1308 (P) -3.1/-5.4 mg/dl 
(1/2 copies) ; 
p<0.05 
(Lahiry et al. 
2007) 
APOC3 PvuIl rs618354 0.49 A F:291 
(GP) 
F: +0.1/-4.2 mg/dl 
1/2 copies;p=0.029
(Kamboh et al. 
1999) 
APOC3 Sst1 RFLP rs5128 0.09 (S2) W M:1219 
(P) 
M: -1.8 mg/dl for 
carriers; p=0.04. 
(Russo et al. 
2001) 
APOC3 3‘-utr/Sac I rs5128 0.09 (+) Hu 713 (P) -5.0 mg/dl for 
heteroz.;  
p=0.0014 
(Hegele et al. 
1995) 
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p<0.05 
(Lahiry et al. 
2007) 
APOC3 PvuIl rs618354 0.49 A F:291 
(GP) 
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1999) 
APOC3 Sst1 RFLP rs5128 0.09 (S2) W M:1219 
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M: -1.8 mg/dl for 
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APOC3 3‘-utr/Sac I rs5128 0.09 (+) Hu 713 (P) -5.0 mg/dl for 
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APOC3 3238C > G rs5128 0.07 (S2) W 906 (GP) +1.9 mg/dl for 
carriers; p=0.079 
(Corella et al. 
2002) 
APOE Cys112Arg rs429358 0.16 (A) N 3575 p=0.001 (Povel et al. 
2011) 
CETP G2708A rs12149545 0.30 (A) W 2683 GP 
556 Cvd




CETP G2708A rs12149545 0.31 (A) W 709 
(CVD) 
+1.5 /+3.5 mg/dl 
(1/2 copies) 
;p=0.0016 
(Klerkx et al. 
2003) 
CETP  rs3764261 0.14 (T) C 4192 +0.07 mg/dl; 
p=4.3x10-14 
(Liu et al. 
2011) 
CETP G971A rs4783961 0.49 (A) W 709 
(CVD) 
+1.2/+1.9 mg/dl 
(1/2 copies) ; 
p=0.09 
(Klerkx et al. 
2003) 





CETP C629A rs1800775 0.51 (A) W 847 M, 
873 F (P)




CETP C629A rs1800775 0.49 (A) W 5287 
(GP) 
+3 /+5 mg/dl 









(Tai et al. 
2003b) 
CETP C629A rs1800775 0.48 (A) W 2683 GP
556 Cvd














copies) ; p=0.05 
(Blankenberg 
et al. 2004) 
CETP C629A rs1800775 0.44 (A) W 709 
(CVD) 
+0.8/3.9 mg/dl 
(1/2 copies) ; 
p<0.0001 
(Klerkx et al. 
2003) 
CETP C629A rs1800775 0.50 (A) W 309 (MI)
757 (Co)
+1.9/6.1 mg/dl 








(1/2 copies) ; 
p<0.001 
(Freeman et al. 
2003) 
CETP Taq1B rs708272 0.40 (B2)  13,677 
(Meta)
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CETP Taq1B rs708272   >10,000 
(Meta)





CETP Taq1B rs708272 0.42 (B2) W 7083 (P) +2.7/5.0 mg/dl 




CETP Taq1B rs708272 0.44 (B2) W 2916 (P) +2.5/4.7 mg/dl 
(1/2 copies) ; 
p<0.001 
(Ordovas et al. 
2000) 








(Klos et al. 
2006b) 





8764 (P) +2.3/5.8 mg/dl 
(1/2 copies) ; 
p<0.001 
+3.8/9.8 mg/dl 




CETP Taq1B rs708272 0.41 (A) W 1503 (P) +2 /+5 mg/dl 




CETP Taq1B rs708272 0.33 (A) A 4207 
(GP) 
+2.5/4.4 mg/dl 
(1/2 copies ; 
p=1.25x10-10 
(Tai et al. 
2003b) 
CETP Taq1B rs708272 0.40 (A) A 1729 
(GP) 
M: +1.2/3.5 mg/dl 
(1/2 copies); 
p=0.096 
F: +1.9/6.2 mg/dl 
(1/2 copies); 
p<0.001 
(Tsujita et al. 
2007) 
CETP Taq1B rs708272 0.42 (A) W 2683 GP 
556 CVd








(1/2 copies) ; 
p<0.001 
(Whiting et al. 
2005) 
CETP Taq1B rs708272 0.40 (A) W 1464 
CVD 
+2.1/3.0 mg/dl 





CETP Taq1B rs708272 0.41 (A) W 1200 CV
571 (Co)
+2.6 /+4.3 mg/dl 
(1/2 copies) ; 
p<0.02 
(Blankenberg 
et al. 2004) 




(1/2 copies) ; 
p<0.001 
(Freeman et al. 
2003) 
CETP +784CCC rs34145065 0.39 (A) W 709 
(CVD) 
+1.2/3.5 mg/dl 
(1/2 copies) ; 
p=0.0009 
(Klerkx et al. 
2003) 
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CETP Taq1B rs708272 0.41 (A) W 1200 CV
571 (Co)
+2.6 /+4.3 mg/dl 
(1/2 copies) ; 
p<0.02 
(Blankenberg 
et al. 2004) 




(1/2 copies) ; 
p<0.001 
(Freeman et al. 
2003) 
CETP +784CCC rs34145065 0.39 (A) W 709 
(CVD) 
+1.2/3.5 mg/dl 
(1/2 copies) ; 
p=0.0009 
(Klerkx et al. 
2003) 
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CETP A373P rs5880 0.05 (A) W 8467 P 
1636 CV
5.4 mg/dl for 
heteroz.; p<0.0001
(Agerholm-
Larsen et al. 
2000) 
CETP Ile405Val rs5882 >10,000 
(Meta)






CETP A + 
16G/Ex.14






(Isaacs et al. 
2007) 
CETP  rs61212082 0.30 (A) W 1208 
(CVD)
572 (Co)
+1.4 /+3.1 mg/dl 
(1/2 copies) ; 
p=0.08 




et al. 2004) 




+1.2 /+3.5 mg/dl 
(1/2 copies); 
p<0.05 
+1.5 /+1.5 mg/dl 
(1/2 copies); 
p<0.05
(Freeman et al. 
2003) 
CETP D442G rs2303790b 0.03 (A) A 3469
(He Ex)
+4.9 mg/dl for 
heteroz.; p<0.001
(Zhong et al. 
1996) 
CETP R451Q rs1800777 0.04 (A) W 8467 (P) 
1636 
(CVD) 




Larsen et al. 
2000) 
CETP G + 
82A/Ex15
rs1800777 0.03 (A) W 1071 CV
532 Co





















 W 156 low
160 high
Variant sig. only 
in low HDL group
(Miettinen et 
al. 1998) 
LCAT 608C/T rs5922 . A 203 
(CVD) 
Increase in HDL; 
p=0.015 
(Zhang et al. 
2003) 
LCAT  rs5922 A 150 Str 
122 Co
Lower HDL-C in 
heteroz.; p<0.05 









(Zhang et al. 
2004) 
LCAT  rs2292318 0.12 (A) W 1442 
CVD,Co
Increases HDLC; 
p=2 x 10 -5 
(Pare et al. 
2007) 
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0.12 (T) A 2417 
(Ho Co)
+1.5 /+8.5 mg/dl 
(1/2 copies) ; 
p=0.0155 






0.39 (+) Hu 713 (P) 2.3 / 4.3 mg/dl 
(1/2 copies) ; 
p=0.047 






0.17 (C) A 2417 
HoCo 
+1.2/+5.4 (1/2 
copies) ; p=0.043 
(Yamada et al. 
2008) 




LIPC C-514Ta rs1800588 0.25 (T) Va >24,000 
(Meta)
+1.5 /+3.5 mg/dl 
(1/2 copies); 
p<0.001 
(Isaacs et al. 
2004) 














LIPC  rs1800588 0.21 (T) W 6239 (P) +1.3/+4.3 mg/dl 
(1/2 copies); 
p<0.001 
(Isaacs et al. 
2007) 
LIPC  rs1800588 0.38 (T) A 2170 (P) +2.3 /+2.7 mg/dl 
(1/2 copies); 
p=0.001 
(Tai et al. 
2003a) 
LIPC  rs1800588 0.21 (T) W 5287 
(GP) 
+1 /+4 mg/dl 




LIPC  rs1800588 0.25 (T) W 2773 
(GP) 
+1.5 mg/dl per 
copy; p=0.04 
(Talmud et al. 
2002b) 
LIPC  rs1800588 0.24 (T) W 3319 CV 
1385 Co
+1.0 /+3.8 mg/dl 
(1/2 copies); 
p=0.001 
(Whiting et al. 
2005) 
LIPC  rs1800588 0.51 (T) A 5207 
Ho Co 
+2.5 mg/dl per 
copy; p<0.001 
(Yamada et al. 
2007) 
















LIPC  rs2070895 0.32 (A) W 514 (P) M; p=0.001 (de Andrade 
et al. 2004) 
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LIPC  rs2070895 0.23 (A) W 5585 (P) +3.9/3.9 mg/dl 
(1/2 copies); 
p=8x10-10 
(Grarup et al. 
2008) 




+2.7 mg/dl per 
copy; p<0.001 
(Yamada et al. 
2007) 
LIPC  rs2070895 0.39 (A) A 716 
HeEx 
+2.1 mg/dl for 
carriers; 
 p=0.026 
(Ko et al. 2004) 
LIPC  rs12594375 0.37 (A) A 2970 
(GP) 
p=0.00003 (Iijima et al. 
2008) 
LIPC  rs8023503 0.38 (T) A 2970 
(GP) 
p=0.0001 (Iijima et al. 
2008) 
LIPC +1075C rs3829462 0.05 (C) A 823 +8.0 mg/dl for 
heterozygotes; 
p<0.05 
(Fang & Liu 
2002) 
LIPC  rs4775041 0.29C EA 25,167 p=1.03E-16 (Dumitrescu et 
al. 2011) 
LIPC  rs261332 0.20 (A) EA 25,167 p=1.99E-13 (Dumitrescu et 
al. 2011) 
LPC  rs261334 0.20 (T) E 17723 p= 4.9×10-22 (Waterworth 
et al. 2010) 
LIPG -384A > C rs3813082 0.12 (C) A 541 (Co) +1.3/+10.2 mg/dl 
(1/2 copies) ; 
p=0.021 
(Hutter et al. 
2006) 








LIPG 584 C/T 
T111l 
rs2000813 0.32 (I) W 495 (GP) M: 1.2 /+2.7 
mg/dl (1/2 
copies) ; p=0.82 
F: 0.4 /+1.9 mg/dl 
(1/2 copies) ; 
p=0.09 
(Paradis et al. 
2003) 
LIPG  rs2000813 0.24 (T) A 541 (Co) +0.5/+6.1 mg/dl 
(1/2 copies) ; 
p=0.048 
(Hutter et al. 
2006) 
LIPG  rs2000813 0.30 (T) A 265 
CVD 
265 Co
+3.7 for carries; 
p=<0.02 (Tang et al. 2008) 




+1.6 /+6.0 mg/dl 
(1/2 copies) ; 
p=0.035 









Seymour et al. 
2004) 
 










Seymour et al. 
2004) 
LIPG 2237G > A rs3744841 0.36 (A) A 340 
(Kids) 
4.0 mg/dl /-4.3 
mg/dl (1/2 






rs1801177  – 5067 
(Meta)
-3.1 mg/dl for 
heteroz.; p=0.002
(Wittrup et al. 
1999) 
LPL Gly188Glu   – 10,434 
(Meta)
- 9.7 mg/dl for 
heteroz.; p<0.001
(Wittrup et al. 
1999) 
LPL N291S rs268  – 14,912 
(Meta)
-4.6 mg/dl for 
heteroz.; p<0.001




rs320 0.30 (H) W 520 (P) +5.5 mg/dl in H –
H- vs. H+H+; 
p=0.025 






W 1361 (P) M: +3.5 mg/dl for 
heteroz. ; p=0.0018
F : +4.2 mg/dl for 
heteroz. ; p=0.0212




rs320 0.32 (H) W 906 (GP) +1.9 mg/dl; 
p=0.003 








NGT: +3.0 mg/dl 
for carriers; p<0.05
DM: +1.0 mg/dl 
for carriers; p<0.05










p=0.005 (Ahn et al. 
1993) 
LPL  rs326 0.44 B 1943 (P) M; p=0.013; 
F; p=0.004 




rs328   4388 
(Meta)
+1.5 mg/dl for 
heteroz.; p<0.001















LPL S447X rs328 0.11 (X) A 4058 (P) +3.1 mg/dl; 
p<0.001 
(Lee et al. 
2004) 




LPL  rs328   25,167 P=5.6E-22 (Dumitrescu et 
al. 2011) 
LPL  rs328 0.09 (G) W 5287 
(GP) 
+3 /+5 mg/dl 
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LPL  rs325 0.89 (T) E 17723 p= 7.8×10-25 (Waterworth 
et al. 2010) 
MLXIP
L 
 rs17145738 0.12 (T) EA 25,167 p=1.64E-05 (Dumitrescu et 
al. 2011) 
PON1 Q192R rs662 = 
rs60480675
0.30 (G) W 1232 (P)
 
W: +0.1 /+2.3 
mg/dl (1/2 







0.67 B 554 -5.4 /- 6.7 mg/dl 
(1/2 copies) ; 
p=0.008 
“ 
PON1  rs662 = 
rs60480675
0.29 (R) Hu 738 (P) -3.1 mg/dl /- 3.1 
mg/dl (1/2 
copies) ; p=0.001 
(Hegele et al. 
1995) 







M: +1.5 /+2.7 
mg/dl (1/2 
copies) ; p=0.035 
(Rios et al. 
2007) 
PON1 C -107T rs705379 0.48 (C) W 710 
(CVD) 
-3.1/- 2.3 mg/dl 
(1/2 copies) ; 
p=0.006 
(Blatter Garin 
et al. 2006) 














C1050T rs5888 0.49 (T) W 546 
(CVD) 





Table 1. Genetic Polymorphisms Associated With HDL-C. MAF=Minor Allele Frequency; 
Ethn.: A=Asians; AA=African Americans; Am=Amish; A-I=Asian Indian; B=Blacks; 
C=Chinese; CH=Caribbean Hispanics; In=Inuit; Ma= Malays; N=Netherlands; NHW=Non-
Hispanic Whites; H=Hispanics; Hu=Hutteries; Tu=Turks; UK=United Kingdom; W-
Bra=Caucasian Brazilians; W= Whites; Va=Various; Non-DM C0=Non diabetic control 
subjects; MI=Myocardial infarction; NGT=Normal glucose tolerance; DM= Diabetes 
mellitus; Ho Sta= Hospital staff; HBP= Hypertensive patients; He Ex=Health examination; 
Cor Ang=coronary angiography; hyperCH=hypercholesterolemia patients; CVD= 
Cardiovascular Disease; Co=Controls; Ho Co=Hospital based controls; GP=General 
Population; Meta= Meta Analysis; P=Population based; M= Males; F= females; + =increase; 
- = decrease; n.s.=not significant; see text for full gene names. Adapted from Boes et al. 
(2009) with permission from Elsevier. 
2.1 Genetic variation in enzymes involved in lipid metabolism and HDL-C levels  
Perhaps, the most notable gene in the HDL-C synthesis and metabolism pathways, whose 
variants have been consistently associated with HDL-C, is the cholesterol ester transfer 
protein (CETP), which is a key plasma protein that mediates the transfer of esterfied 
cholesterol from HDL to APOB containing particles in exchange for TG. Although complete 
loss of CETP function is rare and can yield HDL-C levels up to five times higher than 
normal (Klos and Kullo, 2007), three common polymorphisms (Table 1: TaqIB (rs708272); -
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629C>A (rs1800775); Ile405Val (rs5882)) can all modestly inhibit CETP activity and have 
been consistently associated with higher HDL-C levels (Bernstein et al., 2003; Blankenberg et 
al., 2004; Boekholdt et al., 2005; Boekholdt and Thompson, 2003; Borggreve et al., 2005; 
Eiriksdottir et al., 2001; Freeman et al., 2003; Kathiresan et al., 2008a; Klerkx et al., 2003; Tai 
et al., 2003b; Thompson et al., 2008). The CETP gene is located on chromosome 16 (16q21).  
Lipoprotein lipase (LPL) is an enzyme involved in lipolysis of TG-containing lipoproteins 
such as VLDL and chlyomicrons (Miller and Zhan, 2004), which generate free fatty acids 
(FFA) that can be taken up by the liver, muscle and adipose tissues (Kwan et al., 2007). Thus, 
LPL affects LDL levels directly (see Section 3.2) may only affect HDL-C levels indirectly 
(Lewis and Rader, 2005). The human LPL gene is located on chromosome 8 (8p22). Several 
LPL SNPs have been associated with HDL-C (Table 1) (Ahn et al., 1993; Corella et al., 2002; 
Holmer et al., 2000; Klos and Kullo, 2007; Klos et al., 2006; Komurcu-Bayrak et al., 2007; Lee 
et al., 2004; Nettleton et al., 2007; Senti et al., 2001; Wittrup et al., 1999); however, many of 
them are in strong linkage disequilibrium with each other (e.g., rs320, rs326, rs13702, 
rs10105606) (Boes et al., 2009; Heid et al., 2008).  
Hepatic lipase (HL; LIPC) is a glycoprotein that is synthesized by liver cells (hepatocytes) 
and catalyzes the hydrolysis of TG and phospholipids (Miller et al., 2003). For example, after 
hydrolysis of TG by LPL, VLDL particles are reduced to IDL particles and can be further 
hydrolyzed by HL/LIPC to LDL or taken up by the liver (Kwan et al., 2007). The human 
HL/LIPC gene is located on chromosome 15 (15q21). Several HL/LIPC SNPs have been 
associated with HDL-C levels (Table 1) (Andersen et al., 2003; Costanza et al., 2005; de 
Andrade et al., 2004; Fang and Liu, 2002; Grarup et al., 2008; Iijima et al., 2008; Isaacs et al., 
2007; Kathiresan et al., 2008b; Ko et al., 2004; McCaskie et al., 2006; Nettleton et al., 2007; Tai 
et al., 2003a; Talmud et al., 2002b; Whiting et al., 2005; Yamada et al., 2007). However, the 
most consistent associations have been observed for rs1800588 and rs2070895 and, several 
SNPs in the promoter region are in strong LD (Boes et al., 2009).  
Endothelial lipase (EL; LIPG) is an enzyme expressed in endothelial cells that, in the 
presence of HL/LIPC, metabolizes larger (HDL3) to smaller (HDL2) HDL-C particles and 
increases the catabolism of APOA-I (see Section 2.3) (Jaye and Krawiec, 2004). EL/LIPG 
plays a role in the dyslipidemia component and, possibly, the yet to be established, 
proinflammatrory component of MetSyn (Lamarche and Paradis, 2007) (see Section 5.0). The 
human EL/LIPG gene is located on chromosome 18 (18q21.1). Several polymorphisms in 
EL/LPIG have been associated with HDL-C levels (Table 1) (Hutter et al., 2006; Ma et al., 
2003; Mank-Seymour et al., 2004; Paradis et al., 2003; Tang et al., 2008; Yamakawa-
Kobayashi et al., 2003). However, most of these SNPs have not been as well studied as those 
in CETP, LPL and EL; and, only the nonsynonymous SNP, rs2000813, has been consistently 
associated with HDL-C levels in African-American populations (Hutter et al., 2006; Tang et 
al., 2008; Yamakawa-Kobayashi et al., 2003).  
In the presence of cofactor, APOA-I (see Section 2.3), lecithin-cholesteryl acyltransferase 
(LCAT), catalyzes the esterification of free cholesterol and, can metabolize larger HDL-C 
particles to smaller HDL-C particles (Klos and Kullo, 2007; Miller and Zhan, 2004). The 
human LCAT is located on chromosome 16 (16q22.1). Although mutations leading to 
complete loss of LCAT and marked (5-10%) reduction in HDL-C levels are rare and can 
cause cornea opacifications (fish eye disease) and renal disease (Garg and Simha, 2007), 
several common polymorphisms in LCAT have been associated, albeit inconsistently, with 
much more modest changes in HDL-C levels (Table 1) (Boekholdt et al., 2006; Miettinen et 
al., 1998; Pare et al., 2007; Zhang et al., 2004; Zhu et al., 2006).  
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loss of CETP function is rare and can yield HDL-C levels up to five times higher than 
normal (Klos and Kullo, 2007), three common polymorphisms (Table 1: TaqIB (rs708272); -
 
Dyslipidemia: Genetics and Role in the Metabolic Syndrome 
 
105 
629C>A (rs1800775); Ile405Val (rs5882)) can all modestly inhibit CETP activity and have 
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hydrolysis of TG by LPL, VLDL particles are reduced to IDL particles and can be further 
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human LCAT is located on chromosome 16 (16q22.1). Although mutations leading to 
complete loss of LCAT and marked (5-10%) reduction in HDL-C levels are rare and can 
cause cornea opacifications (fish eye disease) and renal disease (Garg and Simha, 2007), 
several common polymorphisms in LCAT have been associated, albeit inconsistently, with 
much more modest changes in HDL-C levels (Table 1) (Boekholdt et al., 2006; Miettinen et 
al., 1998; Pare et al., 2007; Zhang et al., 2004; Zhu et al., 2006).  
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Parroxanonase 1 (PON1), inhibits the oxidation of LDL (Mackness et al., 1991) and, 
therefore, may only indirectly affect antioxidant properties of HDL-C. The human PON1 
gene is located on chromosome 7 (7q21.3). Several SNPs in PON1 have been associated 
with HDL-C levels, most notably, two nonsynonymous SNPs, rs662 and rs3202100, which 
are in strong LD, but results are inconsistent across studies (Table 1) (Blatter Garin et al., 
2006; Hegele et al., 1995; Manresa et al., 2006; Rios et al., 2007; van Aalst-Cohen et al., 
2005).  
2.2 Genetic variation in receptors and transporters and HDL-C levels 
Scavenger receptor class B, type 1 (SCARB1; SR-B1), which is highly expressed in liver 
and steroidogenic tissues (testes, ovaries, adrenal) (Cao et al., 1997), has been shown to 
participate in the uptake of HDL in animals by transferring cholesterol from the HDL-C 
particle and releasing the lipid-depleted HDL particle into the circulation (Acton et al., 
1996; Miller et al., 2003). The human SCARB1 gene is located on chromosome 12 
(12q24.31). Only a few studies have examined potential associations between SCARB1 
polymorphisms and HDL-C levels (Table 1) (Boekholdt et al., 2006; Costanza et al., 2005; 
Hsu et al., 2003; Morabia et al., 2004; Osgood et al., 2003; Roberts et al., 2007). The most 
well studied polymorphism has been rs5888; however, the association with rs5888 and 
HDL-C levels was only significant among Caucasian (White, W) males in one study 
(Morabia et al., 2004), Amish females (Roberts et al., 2007) and Caucasian CVD patients 
(Boekholdt et al., 2006).  
The LDL receptor (LDLR) and LDLR-related protein participate in the uptake of LDL and 
chylomicron remnants by hepatocytes (Kwan et al., 2007) and, therefore, may only indirectly 
affect HDL-C levels. The human LDLR is located on chromosome 19 (19p13.2). Although 
some common polymorphisms in LDLR have been associated with HDL-C levels (Table 1: 
(Costanza et al., 2005; Hegele et al., 1995; Yamada et al., 2008), their impact is likely greater 
on LDL-C levels (see Section 3.1).  
The ATP-binding cassette transporter A1 (ABCA1), which is highly expressed in the liver, 
steroidogenic tissues and macrophages, plays a key role in ‘reverse cholesterol transport’ 
by mediating the efflux of cholesterol and phospholipids from macrophages to the 
nascent lipid-free, APOA-1 HDL particle (Cavelier et al., 2006; Miller et al., 2003). The 
human ABCA1 gene is located on chromosome 9 (9q31.1). Due to its functional 
importance, genetic variants in this gene have been well investigated but many of them 
are quite rare including the homozygous deletion that leads to Tangier’s disease that is 
characterized by very low HDL-C levels (~5 mg/dl), orange colored tonsils, peripheral 
neuropathy and, sometimes, premature CHD (Garg and Simha, 2007). Several common 
polymorphisms have been fairly consistently associated with more modest changes in 
HDL-C levels but different variants appear to drive this association in different ethnic 
groups (Table 1) (Clee et al., 2001; Costanza et al., 2005; Frikke-Schmidt et al., 2004; 
Hodoglugil et al., 2005; Kathiresan et al., 2008b; Klos et al., 2006; Porchay et al., 2006; 
Shioji et al., 2004b; Whiting et al., 2005).  
2.3 Genetic variation in apolipoproteins and HDL-C levels  
Apolipoprotein A-1 (APOA1; APOA-I) is a ligand required for HDL-C binding to its 
receptors including SCARB1 and ABCA1 and, is an important cofactor in ‘reverse 
cholesterol transport’ (Miller et al., 2003; Remaley et al., 2001; Rigotti et al., 1997). The 
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human APOA1 gene is located on chromosome 11 (11q23-24). APOA-I is a major constituent 
of HDL particles and deletions leading to complete APOA-I deficiency are rare but lead to 
HDL deficiency (HDL-C <10 mg/dl) and sometimes CHD (Garg and Simha, 2007). Several 
common polymorphisms in APOA-I have been associated with more modest reductions in 
HDL-C but results across studies are inconsistent (Table 1) (Brown et al., 2006; Kamboh et 
al., 1999b; Larson et al., 2002; Shioji et al., 2004a). 
Apolipoprotein A-4 (APOA4; APOA-IV) is a potent activator of LCAT and modulates the 
activation of LPL and transfer of cholestryl esters from HDL to LDL (Kwan et al., 2007). 
The human APOA4 gene is located on chromosome 11 near APOA1 (11q23) and is part of 
what is known as the APOA1/C3/A4/A5 gene cluster. Polymorphisms in APOA4 have 
not been as well studied; however, the nonsynonymous SNP, rs5110 (Gln360His), has 
recently been associated with reduced HDL-C levels in Brazilian elderly (Ota et al., 2011) 
and coronary artery calcification (CAC) progression, a marker of subclinical 
atherosclerosis, in patients with Type I Diabetes Mellitus (T1DM) (Kretowski et al., 2006). 
The rs675 polymorphism has been associated with reduced HDL-C levels in females with 
T2DM (Qi et al., 2007).  
Apolipoprotein A-5 (APOA5; APOA-V) is located predominantly on TG-rich chylomicrons 
and VLDL and activates LPL (Hubacek, 2005). The human APOA5 gene is located on 
chromosome 11 (11q23) in the APOA1/C3/A4/A5 gene cluster. Several APOA5 SNPs have 
been associated with reduced HDL-C levels; and, perhaps, the most well studied and 
consistent associations have been observed for rs651821 and rs662799 (Table 1) (Grallert et 
al., 2007; Hubacek, 2005; Klos et al., 2006; Lai et al., 2003; Qi et al., 2007; Talmud et al., 2002a; 
Yamada et al., 2008; Yamada et al., 2007).  
Apolipoprotein C-3 (APOC3; APOC-III) is an inhibitor of LPL and is transferred to HDL 
during the hydrolysis of TG-rich lipoproteins (Kwan et al., 2007; Miller and Zhan, 2004). The 
human APOC3 gene is located on chromosome 11 (11q23) in the APOA1/C3/A4/A5 gene 
cluster. Although several APOC3 SNPs have been identified and investigated, associations 
between these SNPs and HDL-C levels have been quite inconsistent (Table 1) (Arai and 
Hirose, 2004; Brown et al., 2006; Corella et al., 2002; Hegele et al., 1995; Kamboh et al., 1999a; 
Lahiry et al., 2007; Pallaud et al., 2001; Qi et al., 2007; Russo et al., 2001).  
Chylomicron remnants, VLDL and IDL particles are rich in apolipoprotein E (APOE) and 
APOE is a critical ligand for binding to hepatic receptors that remove these particles from 
the circulation (Kwan et al., 2007). Mutations in APOE are well known to modify LDL-C 
levels; however, their independent influence on HDL-C levels remains controversial 
(Sviridov and Nestel, 2007). Nevertheless, associations between APOE SNPs and HDL-C 
levels in large scale studies have been fairly consistent (Costanza et al., 2005; Frikke-Schmidt 
et al., 2000; Gronroos et al., 2008; Kataoka et al., 1996; Srinivasan et al., 1999; Volcik et al., 
2006; Wilson et al., 1994; Wu et al., 2007). 
2.4 GWAS and HDL-C Levels  
Results from genomewide association studies (GWAS) have confirmed associations between 
polymorphisms in viable candidate genes including CETP, LPL, HL/LIPIC, EL/LIPG, 
ABCA1, LCAT and the APOA1/C3/A4/A5 gene cluster and HDL-C levels (Boes et al., 
2009). GWAS have also identified several novel putative loci, which are discussed in detail 
in a recent review (Teslovich et al., 2010). 
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3. Genetic variants in lipid metabolism and LDL-C levels 
3.1 Genetic variation in enzymes, receptors and transporters and LDL-C levels  
LDL-C is a widely accepted risk factor for atherosclerotic cardiovascular diseases. The most 
marketed drugs for lowering LDL-C are statins, which inhibit hydroxy-3-methylglutaryl 
coenzyme A reductase (HMGCR), the rate limiting enzyme in cholesterol synthesis that is 
normally suppressed (Endo, 1992). The human HMGCR gene is located on chromosome 5 
(5q13.3-14). Only a few common HMGCR polymorphisms have been associated with LDL-C 
levels including rs3846662, which was identified through GWAS (Table 2) (Burkhardt et al., 
2008; Hiura et al., 2010; Polisecki et al., 2008; Teslovich et al., 2010). 
As mentioned above, the LDL receptor (LDLR) regulates the uptake of LDL and chylomicron 
remnants by hepatocytes (Kwan et al., 2007) and, the human LDLR gene is located on 
chromosome 19 (19p13.2). Familial (or monogenic) hypercholesterolemia (FH: OMIM No. 
143890), which is due to mutations in LDLR occurring at a frequency of approximately 1 in 500 
(heterozygotes) to 1 in 1,000,000 (homozygotes), is one of the most common inherited 
metabolic diseases and results in a reduced number of LDL receptors and, in heterozygotes, a 
2- to 3-fold increase in LDL–C levels and, in homozygotes, complete loss of LDLR function and 
a greater than 5-fold increase in LDL-C (Garg and Simha, 2007). A few common 
polymorphisms in LDLR have been identified and associated with more modest changes in 
LDL-C levels, most notably, rs6511720, which was highly significantly associated with LDL-C 
in a recent meta analysis (Table 2) (Teslovich et al., 2010; Willer et al., 2008).  
ATP-binding cassette transporters G5 and G8 (ABCG5/8) regulate the efflux of cholesterol 
back into the intestinal lumen and, in hepatocytes, the efflux of cholesterol into bile (Graf et 
al., 2003). The human ABCG5/8 gene cluster is located on chromosome 2 (2p21). A rare 
autosomal recessive mutation in ABCG5/8 leads to sitosterolemia characterized by 
xanthomas, premature atherosclerosis and other features (Berge et al., 2000). Only a couple 
of common variants in ABCG5/8 have been associated with LDL-C levels and a recent 
meta-analysis failed to find associations between ABCG5/G8 polymorphisms including, 
ABCG8 rs6544718, and plasma lipid levels (Table 2) (Jakulj et al., 2010; Teslovich et al., 2010) 
3.2 Genetic variation in lipoproteins and LDL-C levels  
Apolipoprotein B (APOB; main isoform: ApoB-100) is responsible for the recognition and 
uptake of LDL by LDLR, which clears approximately 60-80% of the LDL in ‘normal’ 
individuals with the remaining taken up by LRP or SCARB1 (Kwan et al., 2007). The human 
APOB gene is located on chromosome 2 (2p23-24). Familial defective APOB (FDB: OMIM 
No. 144010) is an autosomal codominant disorder due to mutations in APOB that are a bit 
more rare than FH mutations at approximately 1 in 500 to 1 in 700 resulting in lower LDL-C 
levels than in FH patients (Garg and Simha, 2007). Common polymorphisms have also been 
identified and associated with more modest changes in LDL-C (Table 2) (Haas et al., 2011; 
Teslovich et al., 2010; Waterworth et al., 2010; Willer et al., 2008). 
As mentioned above, APOE is a critical ligand for binding chylomicron remnants, VLDL 
and IDL particles to hepatic receptors to remove these particles from the circulation (Kwan 
et al., 2007). The human APOE gene is located on chromosome 19 (19q13.2). The structural 
APOE gene is polymorphic with three common alleles, designated as ε2, ε3 and ε4 which 
encode for E2, E3 and E4 proteins, respectively. Although several APOE polymorphisms 
have been identified, the APOE ε4 allele has been the most consistently associated with 
CHD and LDL-C levels (Table 2) (Anoop et al., 2010; Chang et al., 2010; Eichner et al., 2002; 
Teslovich et al., 2010; Willer et al., 2008).  
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ABCG8 A632V rs6544718 Va 982 p=0.02 (Jakuljl et al. 
2010) 
APOB  rs562338 0.18 (A) Va 10,849 +4.89 mg/dl;
p=3.6 X 10-12
(Willer et al. 
2008) 
APOB  rs754523 0.28 (A) Va 6,542 +2.78 mg/dl;
p=1.3 X10-6
(Willer et al. 
2008) 
APOB  rs693 0.42 (G) Va 3,222 +2.44 mg/dl; 
p=0.0034
(Willer et al. 
2008) 






APOB  rs7575840 0.28 (T) F 5054 0.131
p= 3.88x10 -9
(Haas et al. 
2011) 
APOB  rs515135 0.19 (A) Va 982 p=2.4X10-20 Waterworth 
et al. (2010) 








rs7412 0.06 (T) N-HB 683 -22.52mg/dl;
p< 0.0001




rs429358 0.076 (T) M-A 739 10.54mg/dl;
p< 0.0001
(Chang et al. 
2010) 
APOC1  rs4420638 0.82 (A) Va 10,806 +6.61 mg/dl;
p = 4.9 X10-24




 rs10402271 0.67 (T) Va 6,519 +2.62 mg/dl; p 
=1.5 X 10-5
(Willer et al. 
2008) 






LDLR  rs6511720 0.90 (T) Va 7,442 +9.17 mg/dl; p 
=3.3 X 10-19
(Willer et al. 
2008) 
PCSK9  rs11206510 0.81 (C) Va 10,805 +3.04 mg/dl; 
p=5.4 X 10-7
(Willer et al. 
2008) 
















PCSK9 E670G rs505151 0.11 (G) W 691 P=0.001 (Chen et al. 
2005) 
PCSK9  rs11206510 0.81 (T) EA 21,986 
(Meta)
p=1.44E-05 (Dumitrescu 
et al. 2011) 






Table 2. Genetic Polymorphisms Associated with LDL-C. See Table 1 legend.  
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Apolipoprotein B (APOB; main isoform: ApoB-100) is responsible for the recognition and 
uptake of LDL by LDLR, which clears approximately 60-80% of the LDL in ‘normal’ 
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Teslovich et al., 2010; Willer et al., 2008).  
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ABCG8 A632V rs6544718 Va 982 p=0.02 (Jakuljl et al. 
2010) 
APOB  rs562338 0.18 (A) Va 10,849 +4.89 mg/dl;
p=3.6 X 10-12
(Willer et al. 
2008) 
APOB  rs754523 0.28 (A) Va 6,542 +2.78 mg/dl;
p=1.3 X10-6
(Willer et al. 
2008) 
APOB  rs693 0.42 (G) Va 3,222 +2.44 mg/dl; 
p=0.0034
(Willer et al. 
2008) 






APOB  rs7575840 0.28 (T) F 5054 0.131
p= 3.88x10 -9
(Haas et al. 
2011) 
APOB  rs515135 0.19 (A) Va 982 p=2.4X10-20 Waterworth 
et al. (2010) 








rs7412 0.06 (T) N-HB 683 -22.52mg/dl;
p< 0.0001




rs429358 0.076 (T) M-A 739 10.54mg/dl;
p< 0.0001
(Chang et al. 
2010) 
APOC1  rs4420638 0.82 (A) Va 10,806 +6.61 mg/dl;
p = 4.9 X10-24




 rs10402271 0.67 (T) Va 6,519 +2.62 mg/dl; p 
=1.5 X 10-5
(Willer et al. 
2008) 






LDLR  rs6511720 0.90 (T) Va 7,442 +9.17 mg/dl; p 
=3.3 X 10-19
(Willer et al. 
2008) 
PCSK9  rs11206510 0.81 (C) Va 10,805 +3.04 mg/dl; 
p=5.4 X 10-7
(Willer et al. 
2008) 
















PCSK9 E670G rs505151 0.11 (G) W 691 P=0.001 (Chen et al. 
2005) 
PCSK9  rs11206510 0.81 (T) EA 21,986 
(Meta)
p=1.44E-05 (Dumitrescu 
et al. 2011) 






Table 2. Genetic Polymorphisms Associated with LDL-C. See Table 1 legend.  
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3.3 Genetic variation in proteases and LDL-C levels  
Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a serine protease that degrades 
hepatic LDLR in endosomes (Maxwell et al., 2005). The human PCSK9 gene is located on 
chromosome 1 (1p32.3). A mutation in PCSK9 results in an autosomal dominant form of 
hypercholesterolemia (OMIM No. 607786) with clinical features similar to FH patients (Garg 
and Simha, 2007). Over 50 variants in PCSK9 have been shown to affect circulating levels of 
cholesterol; however, most of these are relatively rare (see Davignon et al., 2010) for a 
complete list). The number of common polymorphisms in PCSK9 is substantially less with 
only a few SNPs having been associated with changes in LDL-C levels (Table 2) (Chen et al., 
2005; Evans and Beil, 2006; Huang et al., 2009; Teslovich et al., 2010; Willer et al., 2008).  
3.4 GWAS and LDL-C Levels  
GWAS have confirmed associations between polymorphisms in viable candidate genes 
including APOB, APOE, LDLR and PCSK9, and have identified novel SNPs associated with 
LDL-C levels with strong biological plausibility including an inhibitor of lipase (ANGPTL3), 
see Section 4.1 and a transcription factor activating triglyceride synthesis (MLXIPL) see 
Section 4.2 (Teslovich et al., 2010).  
4. Genetic variants in lipid metabolism and TG levels 
Plasma triglycerides (TG) integrate multiple TG-rich lipoprotein particles, predominantly, 
intestinally synthesized chylomicrons in the postprandial state and hepatically synthesized 
VLDL in the fasted state. Therefore, not surprisingly, there is considerable overlap between 
genetic variants associated with HDL-C and LDL-C levels as well as TG levels. For example, 
the Global Lipids Genetics Consortium (GLGC) found that 15 of the 32 loci associated with TG 
levels were also jointly associated with HDL-C levels, explaining 9.6% of the total variation in 
plasma TG, which corresponded to 25–30% of the total genetic contribution to TG variability 
(Teslovich et al., 2010). However, the joint associations reported do not appear additionally 
adjusted for the other lipid phenotype. Furthermore, certain loci appear to be more strongly 
associated with one lipid phenotype over the other while others have similar effect sizes; and, 
genetic heterogeneity between loci clearly exists between major ethnic groups.   
4.1 Genetic variation in aolipoproteins and TG levels  
As mentioned above (see Section 3.2), APOB is the backbone of atherogenic lipoproteins and 
is located on chromosome 2 (2p23-24). A rare monogenic autosomal recessive disorder 
called homozygous hypobetalipoproteinemia and rare autosomal codominant disorder 
called familial hypobetalipoproteinaemia (HHBL and FHBL, respectively: OMIM No. 
107730), characterized by very low (<5th percentile of age- and sex-specific values) of 
plasma TG (and LDL-C) levels, which are caused by rare mutations in APOB (Burnett and 
Hooper, 2008; Di et al., 2009). Although common APOB polymorphisms have primarily 
been associated with LDL-C levels (Benn, 2009), GWAS has revealed that a common SNP in 
APOB, rs1042034, is associated with TG (Johansen and Hegele, 2011; Teslovich et al., 2010). 
Common polymorphisms in the APOA1/C3/A4/A5 gene cluster, located on chromosome 
11 (11q23), have been associated with HDL-C levels (see Section 2.3) as well as TG levels 
(Teslovich et al., 2010; Willer et al., 2008). A SNP in the APOE gene, rs439401, has also been 
shown to be strongly associated with TG levels in a recent GWAS meta analyses (Johansen 
and Hegele, 2011; Teslovich et al., 2010). 
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z Polym. rs Number MAF Ethn. Sample Size
Results (Effect 
Size, p-value) Reference 






ANGPTL3 rs1748195 0.70 (G) Va 9,559 7.12 mg/dl; 
p=5.4x10-8
(Willer et al. 
2008) 








rs12286037 0.94 (C) Va 9,738 25.82 mg/dl; 
p=1.6x10-22
(Willer et al. 
2008) 
APOA5 rs662799 0.05 (A) Va 3,248 16.88 mg/dl 
p=2.7x10-10




rs2000571 0.17 (G) Va 3,209 6.93 mg/dl; 
p=8.7x10-5




rs486394 0.28 (A) Va 3,597 1.50 mg/dl; 
p=0.0073
(Willer et al. 
2008) 
APOE rs439401 0.40 (C) C 4.192 p=2.2×10-5 (Liu et al. 2011) 
APOE rs439401 0.64 (C) Va Meta p=5.5x10-30 Johansen et al. 
(2010) 
LIPC/HL rs4775041 0.67 (G) Va 8,462 3.62 mg/dl; 
p=2.9x10-5
(Willer et al. 
2008) 
LIPC/HL rs261342 0.22 (G) Va Meta p=2.0x10-13 Johansen et al. 
(2010) 






LPL rs10503669 0.90 (A) Va 9,711 11.57 mg/dl; 
p=1.6x10-14
(Willer et al. 
2008) 
LPL rs2197089 0.58 (A) Va 3,202 3.38 mg/dl; 
p=0.0029
(Willer et al. 
2008) 
LPL rs6586891 0.66 (A) Va 3,622 4.60 mg/dl; 
p=5x10-4
(Willer et al. 
2008) 
LPL S447X rs328 0.90 (C) EA 24,258 p=4.16E-30 (Dumitrescu 
et al. 2011) 
LPL S447X rs328 0.10 (X) Va 43,242 -0.15 (-0.12- -
0.19) mmol/l
(Sagoo et al. 
2008) 
LPL D9N rs1801177 0.03 (N) Va 21,040 0.14 (0.08-0.20) 
mmol/l
(Sagoo et al. 
2008) 
LPL N291S rs368 0.03 (S) Va 27,204 0.19 (0.12-0.26)
mmol/l
(Sagoo et al. 
2008) 
LPL rs326 0.18 (G) C 4,192 p=2.3×10-6 (Liu et al. 2011) 












MLXIPL rs17145738 0.84 (T) Va 9,741 8.21 mg/dl; 
p=5x10-8
(Willer et al. 
2008) 




Table 3. Genetic Polymorphisms Associated With TG Levels. See Table 1 legend. 
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only a few SNPs having been associated with changes in LDL-C levels (Table 2) (Chen et al., 
2005; Evans and Beil, 2006; Huang et al., 2009; Teslovich et al., 2010; Willer et al., 2008).  
3.4 GWAS and LDL-C Levels  
GWAS have confirmed associations between polymorphisms in viable candidate genes 
including APOB, APOE, LDLR and PCSK9, and have identified novel SNPs associated with 
LDL-C levels with strong biological plausibility including an inhibitor of lipase (ANGPTL3), 
see Section 4.1 and a transcription factor activating triglyceride synthesis (MLXIPL) see 
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4. Genetic variants in lipid metabolism and TG levels 
Plasma triglycerides (TG) integrate multiple TG-rich lipoprotein particles, predominantly, 
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VLDL in the fasted state. Therefore, not surprisingly, there is considerable overlap between 
genetic variants associated with HDL-C and LDL-C levels as well as TG levels. For example, 
the Global Lipids Genetics Consortium (GLGC) found that 15 of the 32 loci associated with TG 
levels were also jointly associated with HDL-C levels, explaining 9.6% of the total variation in 
plasma TG, which corresponded to 25–30% of the total genetic contribution to TG variability 
(Teslovich et al., 2010). However, the joint associations reported do not appear additionally 
adjusted for the other lipid phenotype. Furthermore, certain loci appear to be more strongly 
associated with one lipid phenotype over the other while others have similar effect sizes; and, 
genetic heterogeneity between loci clearly exists between major ethnic groups.   
4.1 Genetic variation in aolipoproteins and TG levels  
As mentioned above (see Section 3.2), APOB is the backbone of atherogenic lipoproteins and 
is located on chromosome 2 (2p23-24). A rare monogenic autosomal recessive disorder 
called homozygous hypobetalipoproteinemia and rare autosomal codominant disorder 
called familial hypobetalipoproteinaemia (HHBL and FHBL, respectively: OMIM No. 
107730), characterized by very low (<5th percentile of age- and sex-specific values) of 
plasma TG (and LDL-C) levels, which are caused by rare mutations in APOB (Burnett and 
Hooper, 2008; Di et al., 2009). Although common APOB polymorphisms have primarily 
been associated with LDL-C levels (Benn, 2009), GWAS has revealed that a common SNP in 
APOB, rs1042034, is associated with TG (Johansen and Hegele, 2011; Teslovich et al., 2010). 
Common polymorphisms in the APOA1/C3/A4/A5 gene cluster, located on chromosome 
11 (11q23), have been associated with HDL-C levels (see Section 2.3) as well as TG levels 
(Teslovich et al., 2010; Willer et al., 2008). A SNP in the APOE gene, rs439401, has also been 
shown to be strongly associated with TG levels in a recent GWAS meta analyses (Johansen 
and Hegele, 2011; Teslovich et al., 2010). 
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Table 3. Genetic Polymorphisms Associated With TG Levels. See Table 1 legend. 
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Angiopoietin-like 3 protein (ANGPTL3) inhibits LPL catalytic activity but this process is 
reversible (Shan et al., 2009; Shimizugawa et al., 2002). A monogenic autosomal recessive 
disorder called familial combined hypolipidemia (FCH: OMIM No. 605019), characterized 
by very low TG levels, is genetically complex and poorly understood; however, mutations in 
ANGPTL3 are believed to play a role. Common polymorphisms in ANGPTL3, most notably, 
rs2131925, have been associated with more modest changes in TG levels (Johansen and 
Hegele, 2011; Keebler et al., 2009; Lanktree et al., 2009; Teslovich et al., 2010; Willer et al., 
2008). Sequencing individuals in the Dallas Heart Study has identified several additional 
nonsynonymous ANGPTL3 variants affecting TG levels (Musunuru et al., 2010); however, 
these SNPs require further investigation in other populations.  
4.2 Genetic variation in enzymes and transcription factors and TG levels 
As mentioned above (see Section 2.1), LPL is an enzyme that hydrolyzes TG-rich particles in 
peripheral tissues (muscle, macrophages, adipose) generating FFA and glycerol for energy 
metabolism and storage (Goldberg, 1996). More than 100 mutations in LPL have been 
identified (Murthy et al., 1996); however, only a few common nonsynonymous SNPs have 
been consistently associated with TG levels including rs1801177, rs328 and rs268 (Mailly et 
al., 1995; Rip et al., 2006; Sagoo et al., 2008; Teslovich et al., 2010; Willer et al., 2008). Two 
SNPs, rs1801177 and rs328, have also been consistently associated with CHD; however, 
there is fairly strong LD between these SNPs, at least in Caucasians (Sagoo et al., 2008).  
MLX interacting protein like (MLXIPL) locus encodes a transcription factor of the 
Myc/Max/Mad superfamily which activates, in a glucose-dependent manner, carbohydrate 
response element binding protein (CREBP) that is expressed in lipogenic tissues 
coordinating the subsequent activation of lipogenic enzymes such as fatty acid synthase 
(FAS) to convert dietary carbohydrate to TG (Iizuka and Horikawa, 2008). The human 
MLXIPL gene is located on chromosome 7 (7q11.23). Although initially identified through 
GWAS, the rs1745738 polymorphism has been replicated in other studies (Johansen and 
Hegele, 2011; Teslovich et al., 2010; Wang et al., 2008; Willer et al., 2008). 
5. Genetic variants in dyslipidemia and the Metabolic Syndrome (MetSyn) 
As mentioned in the Introduction (see Section 1.0), MetSyn is a clustering of traits including 
dyslipidemia as well as obesity, hypertension and insulin resistance/dysglycemia. 
Undoubtedly, there is complex interplay between genetic determinants of each of these 
traits and ‘environmental’ factors including those related to lifestyle (diet, exercise, sleep) 
and those related to toxin exposure. Due to space limitations, we focus only on the genetic 
determinants of dyslipidemia that overlap with MetSyn defined as a single, unifying trait 
and refer the reader to other reviews for genetic determinants of the other traits involved in 
MetSyn (Joy et al., 2008; Monda et al., 2010; Pollex and Hegele, 2006; Sharma and McNeill, 
2006) and their interactions with lifestyle factors (Adamo and Tesson, 2008; Garaulet et al., 
2009; Ordovas and Shen, 2008; Phillips et al., 2008) and toxins (Andreassi, 2009).  
Lipoprotein related genes with common SNPs associated with MetSyn (as defined by NCEP 
ATP III and AHA/NHLBI criteria) and HDL-C, LDL-C or TG levels include APOA5 and 
APOC3 (Table 4) (Grallert et al., 2007; Joy et al., 2008; Miller et al., 2007; Pollex et al., 2006; 
Pollex and Hegele, 2006; Yamada et al., 2008). Enzymes involved in lipid metabolism with 
genetic polymorphisms that have also been associated with MetSyn (using the NCEP ATPIII 
criteria) appear limited to the nonsynonymous SNP in LPL, rs328 (Table 4) (Joy et al., 2008; 
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Komurcu-Bayrak et al., 2007). Several SNPs in the LDLR have been associated with MetSyn 
(using AHA/NHLBI criteria) and LDL-C or HDL-C (Joy et al., 2008; Yamada et al., 2008).  
 















APOA5 -3A→G J 2417 p< 0.0001 (Yamada 
et al. 2008)
AHA/NHLBI 







LDLR 2052TmC J 2417 p=0.0005 (Yamada 
et al. 2008)
AHA/NHLBI 











Table 4. Genetic Polymorphisms in Lipid Metabolism Associated with MetSyn. See Table 1 
legend. WHO= World Health Organization; NCEP ATP III=National Cholesterol Education 
Program Adult Treatment Panel III, IDF=International Diabetes Federation; 
AHA=American Heart Association; NHLBI=National Heart, Lung, and Blood institute. 
6. Genetic variants in dyslipidemia and MetSyn: Future directions 
Given the polygenic nature and multi-level complexity of Dyslipidemia and MetSyn, a 
better understanding of the genetic determinants of each intermediate (lower level) 
phenotype as well as the collective integration of these traits as unifying syndromes 
(higher/hierarchical level) is needed, which will require more elegant statistical modeling 
methods and, perhaps, a paradigm shift in the way in which we think about dissecting 
genetic and environmental factors in complex traits. As stated throughout this chapter, there 
is considerable overlap between genetic variants associated with HDL-C, LDL-C and TG 
levels as well MetSyn as a unifying trait. As a result, there is great need to understand not 
only the aggregate effects of multiple variants in each of these genes but to also understand 
how the effects of variation in one gene are modified in the presence of other genes. 
Aggregate effects of multiple variants in genes affecting dyslipidemia and MetSyn related 
traits have included calculation of ‘risk scores’, which simply add the number of ‘risk alleles’ 
in a weighted or unweighted manner. For example, unweighted risk scores were 
constructed by summing the number of ‘TG-raising’ alleles at 32 loci and placed in ‘risk 
bins’ (categories) to show that higher risk scores were significantly associated with patients 
with hypertriglyceridemia (HTG) compared to controls (Johansen and Hegele, 2011; 
Teslovich et al., 2010). Increasing genotype risk scores comprised by summing risk alleles in 
9 common SNPs were associated with decreasing HDL-C levels (Kathiresan et al., 2008a). 
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nonsynonymous ANGPTL3 variants affecting TG levels (Musunuru et al., 2010); however, 
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dyslipidemia as well as obesity, hypertension and insulin resistance/dysglycemia. 
Undoubtedly, there is complex interplay between genetic determinants of each of these 
traits and ‘environmental’ factors including those related to lifestyle (diet, exercise, sleep) 
and those related to toxin exposure. Due to space limitations, we focus only on the genetic 
determinants of dyslipidemia that overlap with MetSyn defined as a single, unifying trait 
and refer the reader to other reviews for genetic determinants of the other traits involved in 
MetSyn (Joy et al., 2008; Monda et al., 2010; Pollex and Hegele, 2006; Sharma and McNeill, 
2006) and their interactions with lifestyle factors (Adamo and Tesson, 2008; Garaulet et al., 
2009; Ordovas and Shen, 2008; Phillips et al., 2008) and toxins (Andreassi, 2009).  
Lipoprotein related genes with common SNPs associated with MetSyn (as defined by NCEP 
ATP III and AHA/NHLBI criteria) and HDL-C, LDL-C or TG levels include APOA5 and 
APOC3 (Table 4) (Grallert et al., 2007; Joy et al., 2008; Miller et al., 2007; Pollex et al., 2006; 
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genetic polymorphisms that have also been associated with MetSyn (using the NCEP ATPIII 
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Komurcu-Bayrak et al., 2007). Several SNPs in the LDLR have been associated with MetSyn 
(using AHA/NHLBI criteria) and LDL-C or HDL-C (Joy et al., 2008; Yamada et al., 2008).  
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Table 4. Genetic Polymorphisms in Lipid Metabolism Associated with MetSyn. See Table 1 
legend. WHO= World Health Organization; NCEP ATP III=National Cholesterol Education 
Program Adult Treatment Panel III, IDF=International Diabetes Federation; 
AHA=American Heart Association; NHLBI=National Heart, Lung, and Blood institute. 
6. Genetic variants in dyslipidemia and MetSyn: Future directions 
Given the polygenic nature and multi-level complexity of Dyslipidemia and MetSyn, a 
better understanding of the genetic determinants of each intermediate (lower level) 
phenotype as well as the collective integration of these traits as unifying syndromes 
(higher/hierarchical level) is needed, which will require more elegant statistical modeling 
methods and, perhaps, a paradigm shift in the way in which we think about dissecting 
genetic and environmental factors in complex traits. As stated throughout this chapter, there 
is considerable overlap between genetic variants associated with HDL-C, LDL-C and TG 
levels as well MetSyn as a unifying trait. As a result, there is great need to understand not 
only the aggregate effects of multiple variants in each of these genes but to also understand 
how the effects of variation in one gene are modified in the presence of other genes. 
Aggregate effects of multiple variants in genes affecting dyslipidemia and MetSyn related 
traits have included calculation of ‘risk scores’, which simply add the number of ‘risk alleles’ 
in a weighted or unweighted manner. For example, unweighted risk scores were 
constructed by summing the number of ‘TG-raising’ alleles at 32 loci and placed in ‘risk 
bins’ (categories) to show that higher risk scores were significantly associated with patients 
with hypertriglyceridemia (HTG) compared to controls (Johansen and Hegele, 2011; 
Teslovich et al., 2010). Increasing genotype risk scores comprised by summing risk alleles in 
9 common SNPs were associated with decreasing HDL-C levels (Kathiresan et al., 2008a). 
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We have used the multivariate statistical framework of structural equation modeling (SEM) 
to evaluate multiple genetic determinants of MetSyn and aggregate effects of individual 
genes by modeling MetSyn as a second-order factor together with multiple putative 
candidate genes represented by latent constructs, which we mathematically defined by 
multiple SNPs in each gene (Nock et al., 2009b). Using this approach with the Framingham 
Heart Study (Offspring Cohort, Exam 7; Affymetrix 50k Human Gene Panel) data, we found 
that the CETP gene had a very strong association with the Dyslipidemia factor but little 
effect on MetSyn directly. Furthermore, we found that the effects of the CSMD1 gene 
diminished when modeled simultaneously with six other candidate genes, most notably 
CETP and STARD13. Work to identify the genetic determinants of ‘Syndrome Z’, modeled 
as a higher-order, unifying syndrome defined by 5 first-order factors (dyslipidemia, insulin 
resistance, obesity, hypertension, sleep disturbance) (Nock et al., 2009a) using the latent 
gene construct SEM approach is underway.  
The use of other forms of ‘causal modeling’ (edge/node; integrative genetics) has been 
proposed (Lusis et al., 2008), particularly, to improve our understanding of differential 
effects by gender as well as to better understand how maternal nutrition and epigenetics 
affect MetSyn. Furthermore, a complex model for the genetic determinants of MetSyn 
associated phenotypes was recently proposed and, using gene enrichment analysis and 
protein-protein interaction network approaches, the retinoid X receptor and farnesoid X 
receptor (FXR) were identified as key players in MetSyn given their multiple interactions 
with metabolism, cell proliferation and oxidative stress (Sookoian and Pirola, 2011). 
However, more elegant kinetic models may be required to understand the true influence of 
genetic variants on Dsylipidemia and MetSyn given the presence of multiple feedback loops 
and reversible reactions (Bakker et al., 2010; Gutierrez-Cirlos et al., 2011). 
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The pathway of intracellular cholesterol synthesis, uptake and efflux is much affected by 
both the positive and the negative feedbacks from direct interaction between cholesterol and 
its oxygenated derivatives (oxysterols) as well as the regulatory factors such as the sterol-
regulatory-element-binding protein (SREBP)– cleavage-activating protein–Insig complex 
(Radhakrishnan, Ikeda et al. 2007), 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase 
(Sever, Song et al. 2003) and liver X receptors (LXRs) (Chen, Chen et al. 2007). Since these 
regulatory factors are located in the compartments with comparatively low cholesterol 
density, they can react promptly on acute changes in local cholesterol or oxysterol density. 
While much is known about the interaction between these regulatory factors and 
cholesterol, only little has been studied about the mechanism to deliver the cholesterol or 
oxysterol to its appropriate compartments. 
Therefore, there arises a possibility that oxysterol-binding protein/oxysterol-binding 
protein-related protein (OSBP/ORP) family may regulate such processes by binding 
oxyterol and/or cholesterol and by functioning as a cholesterol sensor or cholesterol 
transporter. According to the study about the family members, it is now becoming clear that 
they affect the regulation such as the cholesterol or triglyceride level. 
For comprehensive information on OSBP/ORP family, please refer to several good reviews 
already published (Fairn and McMaster 2008; Ngo, Colbourne et al. 2010; Raychaudhuri and 
Prinz 2010; Vihervaara, Jansen et al. 2011). This review focuses more on the family’s 
association with dyslipidemia from a perspective of the individual features of the structure, 
the expression, the cellular localization, the molecular functions, and the epidemiologial 
study-based information of each member. 
2. Overview of functions of OSBP/ORP family proteins and their relation to 
dyslipidemia 
It has become widely known that each member of OSBP/ORP family respectively affects 
diverse processes considered to have an association with dyslipidemia, such as intracellular 
trafficking of cholesterol or neutral lipid. The first presented is a brief overview of the 
members as a whole before the individual explanation of each member. 
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OSBP negatively regulates ATP-binding cassette transporter A1 (ABCA1) protein stability 
(Bowden and Ridgway 2008). OSBP induces upregulation of SREBP-1c and enhances hepatic 
lipogenesis (Yan, Lehto et al. 2007).  
ORP1L forms a RILP-Rab7-ORP1L complex (Johansson, Rocha et al. 2007) and is involved in 
both protein and lipid transport functions of the late endocytic compartments (Vihervaara, 
Uronen et al. 2011). 
ORP1S and ORP2 enhance plasma membrane (PM)-to-lipid droplet (LD) sterol transport 
(Jansen, Ohsaki et al. 2011). ORP2 presents on LD and has a functional role in the regulation 
of neutral lipid metabolism, possibly as a factor that integrates the cellular metabolism of 
triglycerides (TG) with that of cholesterol (Hynynen, Suchanek et al. 2009). 
ORP3 may play an important role in efficient directed membrane trafficking (Lehto, 
Mayranpaa et al. 2008). But the direct evidence that ORP3 functions to regulate dyslipidemia 
is yet to be reported. 
ORP4 in an interaction with intermediate filaments inhibits an intracellular cholesterol-
transport pathway mediated by vimentin (Wang, JeBailey et al. 2002). 
ORP5 may cooperate with Niemann-Pick C1 (NPC1) to mediate the exit of cholesterol from 
endosomes/lysosomes (Du, Kumar et al. 2011). 
ORP6 is identified as one of the candidate genes that are possibly involved in the regulation 
of high-density lipoprotein (HDL) cholesterol levels (North, Martin et al. 2003). 
SNPs near ORP7 gene show a genome-wide significant association with low-density 
lipoprotein (LDL) cholesterol (Teslovich, Musunuru et al. 2010). 
ORP8 negatively regulates ABCA1 expression and macrophage cholesterol efflux (Yan, 
Mayranpaa et al. 2008). ORP8 has the capacity to modulate lipid homeostasis and SREBP 
activity, probably through an indirect mechanism required Nup62 (Zhou, Li et al. 2011). The 
OSBPL8-ZDHHC17 region (chr12) is detected for HDL cholesterol identified by one new 
SNP with genome-wide significance (Ma, Yang et al. 2010). 
ORP9 and ORP11 are dimerized and may act as an intracellular lipid sensor or transporter 
(Zhou, Li et al. 2010). 
ORP10 suppresses hepatic lipogenesis and very-low-density lipoprotein production 
(Perttila, Merikanto et al. 2009). ORP10 is genetically associated with both TG (Perttila, 
Merikanto et al. 2009) and LDL cholesterol level (Koriyama, Nakagami et al. 2010). 
SNPs in the ORP11 gene is associated with LDL cholesterol levels, hyperglycemia /diabetes as 
well as with metabolic syndrome per se (Bouchard, Faucher et al. 2009). 
2.1 Phylogenetic distribution and molecular structure of OSBP/ORP family 
As a result of differential promoter usage and splicing, there are 16 major OSBP/ORP family 
members. The human ORP family is divided into six subfamilies based on the gene 
structure and amino acid sequence homology (Fig. 1). Some of the proteins, for example 
ORP1 and ORP4, have both short (S) and long (L) variants.  
A feature in common for all ORPs is a conserved C-terminal OSBP-related domain (ORD), 
which contains the highly conserved “OSBP-fingerprint (OF)” sequence EQVSHHPP (Fig. 
1). Most of the human ORPs belong to the long subtype have a pleckstrin homology domain 
(PH domain), which bind phosphoinositides (PIPs). This interaction controls the subcellular 
localization of the proteins. 12 out of the 16 major mammalian OSBP/ORP family members 
contain a FFAT motif, which is a short sequence that binds VAMP associated proteins 
(VAPs), integral membrane proteins of the ER. Instead of an ER targeting FFAT motif, ORP5 
and ORP8 contain a putative C-terminal transmembrane segment, which anchors these 
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proteins in the ER. The human ORP1L have at their N-terminus ankyrin repeats, which 
interacts with the active GTP-bound form of Rab7 on late endosomes, and thus mediates 
targeting of the protein to late endosomes.  
 
 
Fig. 1. Domain organization of the humam OSBP/ORP family. 
Human OSBP/ORP family members are arranged into subfamilies I-VI. The color codes are: 
red, OSBP-related domain (ORD); yellow, OSBP-fingerprint (OF) motif; green, pleckstrin 
homology (PH) domain; Blue, ankirin repeats; black, VAP targeting motif (FFAT motif); 
Orange, transmembrane domain. L and S in the protein names indicate long and short 
variants, respectively. 
2.2 OSBP 
Structure, Tissue distribution and Intracellular localization: OSBP belongs to the 
subfamily I of OSBP/ORP homologues. OSBP has an ORD, a PH domain and an FFAT 
motif. OSBP shares the highest degree of similarity with ORP4 and dimerizes with ORP4. In 
the transfected cells, some of the OSBP was distributed diffusely in the cytoplasm, and some 
was bound to small vesicles near the nucleus. Upon addition of 25-hydroxycholesterol, most 
of the OSBP became concentrated in the Golgi apparatus (Ridgway, Dawson et al. 1992). 
Molecular functions related to dyslipidemia: OSBP is the founding member of the 
OSBP/ORP family. Human OSBP was cloned in 1990 (Levanon, Hsieh et al. 1990) and was 
studied intensively (Ridgway, Dawson et al. 1992; Lagace, Byers et al. 1997; Ridgway, 
Badiani et al. 1998; Ridgway, Lagace et al. 1998; Storey, Byers et al. 1998; Lagace, Byers et al. 
1999; Mohammadi, Perry et al. 2001; Levine and Munro 2002).  
Yan et al. reported that adenovirus-mediated hepatic overexpression of OSBP induced a 
marked increase of VLDL TG. Also, the liver tissue TG were elevated in the AdOSBP-
injected mice, and their TG secretion rate was increased by 70%. The messenger RNAs for 
enzymes of fatty acid synthesis and their transcriptional regulator, SREBP-1c, as well as the 
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injected mice, and their TG secretion rate was increased by 70%. The messenger RNAs for 
enzymes of fatty acid synthesis and their transcriptional regulator, SREBP-1c, as well as the 
 
Dyslipidemia - From Prevention to Treatment 
 
130 
Insig-1 mRNA, were upregulated two-fold in the OSBP expressing livers. Silencing of OSBP 
in hepatocytes suppressed the induction of SREBP1-c by insulin and resulted in a reduction 
of TG synthesis. These results demonstrate that OSBP regulates hepatic TG metabolism and 
suggest the involvement of OSBP in the insulin signaling pathways that control hepatic 
lipogenesis (Yan, Lehto et al. 2007). 
 Bowden et al. revealed that suppression of OSBP in Chinese hamster ovary cells by RNA 
interference resulted in increased ABCA1 protein expression and cholesterol efflux activity 
following induction with oxysterols or the synthetic LXR agonist TO901317. OSBP 
knockdown in J774 macrophages also increased ABCA1 expression in the presence and 
absence of LXR agonists. Their results demonstrate that OSBP opposes the activity of LXR 
by negatively regulating ABCA1 activity in the cytoplasm by sterol-binding domain-
dependent protein destabilization (Bowden and Ridgway 2008). 
Cephalostatin 1, OSW-1, ritterazine B and schweinfurthin A are natural products that 
potently, and in some cases selectively, inhibit the growth of cultured human cancer cell 
lines. Recently, Burgett et al. have discovered that these molecules target OSBP and its 
closest paralog, ORP4L, and have named these natural products ORPphilins (Burgett, 
Poulsen et al. 2011). By uncovering the cellular targets of the ORPphilins, they have revealed 
that OSBP and ORP4L are involved in cancer cell survival. 
They also show that ORPphilins perturb the cellular localization of OSBP and affect 
sphingomyelin biosynthesis. The ORPphilins are powerful probes of OSBP and ORP4L that 
will be useful in uncovering their cellular functions and their roles in human diseases.  
Epidemiological study: Epidemiological study of OSBP is not reported yet. 
2.3 OSBPL1B (ORP1L) 
Structure, Tissue distribution and Intracellular localization: ORP1L belongs to the 
subfamily II of OSBP/ORP homologues. ORP1L has an ORD, an FFAT motif, a PH domain 
and three ankyrin repeats.  
While macrophages, brain, and lung are the areas where ORP1L is expressed most 
predominantly, it is also found in colon, kidney, and liver (Johansson, Bocher et al. 2003). 
ORP1L localizes to late endosomes.  
Molecular functions related to dyslipidemia: Johansson et al. reported that ORP1L binds to 
Rab7, modifies its functional cycle, and can interfere with LE/lysosome organization and 
endocytic membrane trafficking (Johansson, Lehto et al. 2005).  
They show that the GTPase Rab7, when bound to GTP, simultaneously binds to ORP1L and 
RILP to form a RILP-Rab7-ORP1L complex, which is required for the perinuclear 
localization of late endosomes/lysosomes (Johansson, Rocha et al. 2007). The later study of 
Rocha et al., went deeper in examining these processes more in detail. They found that the 
cholesterol levels in late endosomes are sensed by ORP1L and are lower in peripheral 
vesicles. Under low cholesterol conditions, ORP1L conformation induces the formation of 
endoplasmic reticulum (ER)- late endosome membrane contact sites. At these sites, the ER 
protein VAP (VAMP [vesicle-associated membrane protein]-associated ER protein) can 
interact in trans with the Rab7-RILP complex to remove p150 (Glued) and associated motors. 
late endosomes then move to the microtubule plus end. Under high cholesterol conditions, as 
in Niemann-Pick type C disease, this process is prevented, and late endosomes accumulate at 
the microtubule minus end as the result of dynein motor activity. These data explain how the 
ER and cholesterol control the association of late endosomes with motor proteins and their 
positioning in cells (Rocha, Kuijl et al. 2009).  
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Recently, Vihervaara et al. have shown that ORP1L silencing in macrophage foam cells 
inhibits the efflux of lipoprotein-derived endocytosed cholesterol to apolipoprotein A-I, 
providing evidence for the involvement of ORP1L in both protein and lipid transport 
functions of the late endocytic compartments (Vihervaara, Uronen et al. 2011). 
The multivesicular body(MVB) sorting pathway is known to be involved in many processes, 
including growth factor receptor down-regulation, exosome secretion, antigen presentation, 
the budding of enveloped viruses, and cytokinesis. Recently, Kobuna et al. have shown that 
knockdown of ORP1L induces the formation of enlarged MVBs in HeLa cells. They suggest 
that the proper cholesterol level of late endosomes/lysosomes generated by ORPs is 
required for normal MVB formation and MVB–mediated membrane protein degradation 
(Kobuna, Inoue et al. 2010). 
Epidemiological study: Epidemiological study of ORP1L is not reported yet. 
2.4 OSBPL1A (ORP1S) and OSBPL2 (ORP2) 
Structure, Tissue distribution and Intracellular localization: ORP1S and ORP2 belong to 
the subfamily II of OSBP/ORP homologues. ORP1S and ORP2 have an ORD and an FFAT 
motif but lack PH domain.  
ORP1S is expressed predominantly in skeletal muscle and heart (Johansson, Bocher et al. 
2003). ORP2 is expressed ubiquitously in mammalian tissues. Highest mRNA levels of ORP2 
are present in specific parts of the central nervous system (cerebellum, pituitary gland, pons, 
and putamen) as well as in leukocytes, placenta, and pancreas (Laitinen, Lehto et al. 2002).  
ORP1S has been reported to be largely cytosolic (Johansson, Bocher et al. 2003) and ORP2 
localizes, in addition to a cytosolic fraction, on the surface of lipid droplets (LDs) and also 
the plasma membrane (PM) (Hynynen, Suchanek et al. 2009). 
Molecular functions related to dyslipidemia: In the earlier study of Hynynen et al., 
overexpression of ORP2 induces enhancement of [14C]cholesterol efflux to all extracellular 
acceptors, which results in a reduction of cellular free cholesterol. They also show that ORP2 
binds PtdIns(3,4,5)P(3) and enhances endocytosis.  
In their recent study, Hynynen et al. discover that ORP2 localizes not only cytosolic fraction 
but also on cytoplasmic LDs and reveal its function in neutral lipid metabolism. They show 
that the ORP2 LD association depends on sterol binding: Treatment with 5 mM 22(R)OHC 
inhibits the LD association, while a mutant defective in sterol binding is constitutively LD 
bound. Silencing of ORP2 using RNA interference slows down cellular TG hydrolysis. 
Furthermore, ORP2 silencing increases the amount of [14C]cholesteryl esters but only under 
conditions in which lipogenesis and LD formation are enhanced by treatment with oleic acid 
(Hynynen, Suchanek et al. 2009). These results identify ORP2 as a sterol receptor present on 
LD and provide an evidence for its role in the regulation of neutral lipid metabolism, 
possibly as a factor that integrates the cellular metabolism of TG with that of cholesterol.  
By overexpressing all mammalian ORPs, Jansen et al. found that especially ORP1S and 
ORP2 enhanced PM-to-LD sterol transport. This reflected the stimulation of transport from 
the PM to the ER, rather than from the ER to LDs. Double knockdown of ORP1S and ORP2 
inhibited sterol transport from the PM to the ER and LDs, suggesting a physiological role for 
these ORPs in the process (Jansen, Ohsaki et al. 2011). These findings suggest that ORP1S 
and ORP2 are essential in controlling cellular neutral lipid and cholesterol and has a strong 
association with the pathophysiology of dyslipidemia.  
Epidemiological study: Epidemiological studies of ORP1S or ORP2 are not reported yet. 
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Insig-1 mRNA, were upregulated two-fold in the OSBP expressing livers. Silencing of OSBP 
in hepatocytes suppressed the induction of SREBP1-c by insulin and resulted in a reduction 
of TG synthesis. These results demonstrate that OSBP regulates hepatic TG metabolism and 
suggest the involvement of OSBP in the insulin signaling pathways that control hepatic 
lipogenesis (Yan, Lehto et al. 2007). 
 Bowden et al. revealed that suppression of OSBP in Chinese hamster ovary cells by RNA 
interference resulted in increased ABCA1 protein expression and cholesterol efflux activity 
following induction with oxysterols or the synthetic LXR agonist TO901317. OSBP 
knockdown in J774 macrophages also increased ABCA1 expression in the presence and 
absence of LXR agonists. Their results demonstrate that OSBP opposes the activity of LXR 
by negatively regulating ABCA1 activity in the cytoplasm by sterol-binding domain-
dependent protein destabilization (Bowden and Ridgway 2008). 
Cephalostatin 1, OSW-1, ritterazine B and schweinfurthin A are natural products that 
potently, and in some cases selectively, inhibit the growth of cultured human cancer cell 
lines. Recently, Burgett et al. have discovered that these molecules target OSBP and its 
closest paralog, ORP4L, and have named these natural products ORPphilins (Burgett, 
Poulsen et al. 2011). By uncovering the cellular targets of the ORPphilins, they have revealed 
that OSBP and ORP4L are involved in cancer cell survival. 
They also show that ORPphilins perturb the cellular localization of OSBP and affect 
sphingomyelin biosynthesis. The ORPphilins are powerful probes of OSBP and ORP4L that 
will be useful in uncovering their cellular functions and their roles in human diseases.  
Epidemiological study: Epidemiological study of OSBP is not reported yet. 
2.3 OSBPL1B (ORP1L) 
Structure, Tissue distribution and Intracellular localization: ORP1L belongs to the 
subfamily II of OSBP/ORP homologues. ORP1L has an ORD, an FFAT motif, a PH domain 
and three ankyrin repeats.  
While macrophages, brain, and lung are the areas where ORP1L is expressed most 
predominantly, it is also found in colon, kidney, and liver (Johansson, Bocher et al. 2003). 
ORP1L localizes to late endosomes.  
Molecular functions related to dyslipidemia: Johansson et al. reported that ORP1L binds to 
Rab7, modifies its functional cycle, and can interfere with LE/lysosome organization and 
endocytic membrane trafficking (Johansson, Lehto et al. 2005).  
They show that the GTPase Rab7, when bound to GTP, simultaneously binds to ORP1L and 
RILP to form a RILP-Rab7-ORP1L complex, which is required for the perinuclear 
localization of late endosomes/lysosomes (Johansson, Rocha et al. 2007). The later study of 
Rocha et al., went deeper in examining these processes more in detail. They found that the 
cholesterol levels in late endosomes are sensed by ORP1L and are lower in peripheral 
vesicles. Under low cholesterol conditions, ORP1L conformation induces the formation of 
endoplasmic reticulum (ER)- late endosome membrane contact sites. At these sites, the ER 
protein VAP (VAMP [vesicle-associated membrane protein]-associated ER protein) can 
interact in trans with the Rab7-RILP complex to remove p150 (Glued) and associated motors. 
late endosomes then move to the microtubule plus end. Under high cholesterol conditions, as 
in Niemann-Pick type C disease, this process is prevented, and late endosomes accumulate at 
the microtubule minus end as the result of dynein motor activity. These data explain how the 
ER and cholesterol control the association of late endosomes with motor proteins and their 
positioning in cells (Rocha, Kuijl et al. 2009).  
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Recently, Vihervaara et al. have shown that ORP1L silencing in macrophage foam cells 
inhibits the efflux of lipoprotein-derived endocytosed cholesterol to apolipoprotein A-I, 
providing evidence for the involvement of ORP1L in both protein and lipid transport 
functions of the late endocytic compartments (Vihervaara, Uronen et al. 2011). 
The multivesicular body(MVB) sorting pathway is known to be involved in many processes, 
including growth factor receptor down-regulation, exosome secretion, antigen presentation, 
the budding of enveloped viruses, and cytokinesis. Recently, Kobuna et al. have shown that 
knockdown of ORP1L induces the formation of enlarged MVBs in HeLa cells. They suggest 
that the proper cholesterol level of late endosomes/lysosomes generated by ORPs is 
required for normal MVB formation and MVB–mediated membrane protein degradation 
(Kobuna, Inoue et al. 2010). 
Epidemiological study: Epidemiological study of ORP1L is not reported yet. 
2.4 OSBPL1A (ORP1S) and OSBPL2 (ORP2) 
Structure, Tissue distribution and Intracellular localization: ORP1S and ORP2 belong to 
the subfamily II of OSBP/ORP homologues. ORP1S and ORP2 have an ORD and an FFAT 
motif but lack PH domain.  
ORP1S is expressed predominantly in skeletal muscle and heart (Johansson, Bocher et al. 
2003). ORP2 is expressed ubiquitously in mammalian tissues. Highest mRNA levels of ORP2 
are present in specific parts of the central nervous system (cerebellum, pituitary gland, pons, 
and putamen) as well as in leukocytes, placenta, and pancreas (Laitinen, Lehto et al. 2002).  
ORP1S has been reported to be largely cytosolic (Johansson, Bocher et al. 2003) and ORP2 
localizes, in addition to a cytosolic fraction, on the surface of lipid droplets (LDs) and also 
the plasma membrane (PM) (Hynynen, Suchanek et al. 2009). 
Molecular functions related to dyslipidemia: In the earlier study of Hynynen et al., 
overexpression of ORP2 induces enhancement of [14C]cholesterol efflux to all extracellular 
acceptors, which results in a reduction of cellular free cholesterol. They also show that ORP2 
binds PtdIns(3,4,5)P(3) and enhances endocytosis.  
In their recent study, Hynynen et al. discover that ORP2 localizes not only cytosolic fraction 
but also on cytoplasmic LDs and reveal its function in neutral lipid metabolism. They show 
that the ORP2 LD association depends on sterol binding: Treatment with 5 mM 22(R)OHC 
inhibits the LD association, while a mutant defective in sterol binding is constitutively LD 
bound. Silencing of ORP2 using RNA interference slows down cellular TG hydrolysis. 
Furthermore, ORP2 silencing increases the amount of [14C]cholesteryl esters but only under 
conditions in which lipogenesis and LD formation are enhanced by treatment with oleic acid 
(Hynynen, Suchanek et al. 2009). These results identify ORP2 as a sterol receptor present on 
LD and provide an evidence for its role in the regulation of neutral lipid metabolism, 
possibly as a factor that integrates the cellular metabolism of TG with that of cholesterol.  
By overexpressing all mammalian ORPs, Jansen et al. found that especially ORP1S and 
ORP2 enhanced PM-to-LD sterol transport. This reflected the stimulation of transport from 
the PM to the ER, rather than from the ER to LDs. Double knockdown of ORP1S and ORP2 
inhibited sterol transport from the PM to the ER and LDs, suggesting a physiological role for 
these ORPs in the process (Jansen, Ohsaki et al. 2011). These findings suggest that ORP1S 
and ORP2 are essential in controlling cellular neutral lipid and cholesterol and has a strong 
association with the pathophysiology of dyslipidemia.  
Epidemiological study: Epidemiological studies of ORP1S or ORP2 are not reported yet. 
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2.5 OSBPL3 (ORP3) 
Structure, Tissue distribution and Intracellular localization: ORP3 belongs to the 
subfamily III of OSBP/ORP homologues. ORP3 has an ORD, a PH domain and an FFAT 
motif. A total of eight isoforms of ORP3 were demonstrated with alternative splicing 
(Collier, Gregorio-King et al. 2003). In human tissues there was specific isoform distribution, 
with most tissues expressing varied levels of isoforms with the complete ORD; while only 
whole brain, kidney, spleen, thymus, and thyroid expressed high levels of the isoforms 
associated with the truncated ORD. The expression in cerebellum, heart, and liver of most 
isoforms was negligible. Lehto et al described that ORP3 was expressed at high levels in 
kidney tubule epithelia and in the human embryonic kidney cell line HEK293 (Lehto, 
Mayranpaa et al. 2008).  
They also described that the endogenous ORP3 protein in HEK293 cells localized at the ER 
and the PM, especially thin filopodial cell-surface projections.  
Molecular functions related to dyslipidemia: The direct evidence that ORP3 functions to 
regulate Dyslipidemia is yet to be reported.  
ORP3 interacts with R-Ras, a small GTPase regulating cell adhesion, spreading and 
migration (Lehto, Mayranpaa et al. 2008). Gene silencing of ORP3 and overexpression of 
ORP3 in HEK293 cells or primary macrophages demonstrate the function of ORP3 as part of 
the machinery that controls the actin cytoskeleton, cell polarity and cell adhesion. These 
functional evidences, together with the abundant expression of ORP3 in polarized cell types, 
suggest that ORP3 may play an important role in efficient directed membrane trafficking.  
Epidemiological study: Epidemiological study of ORP3 is not reported yet. 
2.6 OSBPL4 (ORP4, OSBP2, HLM)  
Structure, Tissue distribution and Intracellular localization: ORP4 belongs to the 
subfamily I of OSBP/ORP homologues. ORP4 has an ORD, a PH domain and an FFAT 
motif. ORP4 shares the highest degree of similarity with OSBP and dimerizes with OSBP.  
Two ORP4 cDNAs were identified: a full-length ORP4 containing a PH domain and an ORD 
(designated ORP4-L), and a splice variant in which the PH domain and part of the ORD 
were deleted (designated ORP4-S). ORP4 mRNA and protein expression overlapped 
partially with OSBP and were restricted to brain, heart, muscle and kidney(Wang, JeBailey 
et al. 2002).  
Immunofluorescence localization in stably transfected Chinese hamster ovary cells showed 
that ORP4-S co-localized with vimentin and caused the intermediate filament network to 
bundle or aggregate. ORP4-L displayed a diffuse staining pattern that did not overlap with 
vimentin except when the microtubule network was disrupted with nocodazole.  
Molecular functions related to dyslipidemia: Cells overexpressing ORP4S had a 40% 
reduction in the esterification of low-density-lipoprotein-derived cholesterol, demonstrating 
that ORP4 in an interaction with intermediate filaments inhibits an intracellular cholesterol-
transport pathway mediated by vimentin (Wang, JeBailey et al. 2002).  
ORP4L bound [3H]25-hydroxycholesterol with high affinity and specificity. However, 
sterol-binding or a mutation that ablated sterol-binding did not influence the interaction of 
GST-ORP4 with vimentin (Wyles, Perry et al. 2007). Thus the precise mechanism about what 
ORP4L senses to regulate intracellular cholesterol-transport pathway still remains 
unidentified. 
Epidemiological study: Epidemiological study of ORP4 is not reported yet. 
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2.7 OSBPL5 (ORP5) 
Structure, Tissue distribution and Intracellular localization: ORP5 belongs to the 
subfamily IV of OSBP/ORP homologues. ORP5 has an ORD, a PH domain and a 
transmembrane domain. ORP5 localizes to the ER.  
Molecular functions related to dyslipidemia: Knocking down ORP5 causes cholesterol 
accumulation in late endosomes and lysosomes, which is reminiscent of the cholesterol 
trafficking defect in Niemann Pick C (NPC) fibroblasts (Du, Kumar et al. 2011). Cholesterol 
appears to accumulate in the limiting membranes of endosomal compartments in ORP5-
depleted cells, whereas depletion of NPC1 or both ORP5 and NPC1 results in luminal 
accumulation of cholesterol. Moreover, trans-Golgi resident proteins mislocalize to 
endosomal compartments upon ORP5 depletion, which depends on a functional NPC1.  
Niemann-Pick type C (NPC) disease is most often caused by mutations in the NPC1 gene, 
whose protein product is believed to facilitate the egress of cholesterol and other lipids from 
late endosomes and lysosomes to other cellular compartments (Boadu and Francis 2006). 
The results of the research by Du et al. establish the first link between NPC1 and a 
cytoplasmic sterol carrier, and suggest that ORP5 may cooperate with NPC1 to mediate the 
exit of cholesterol from endosomes/lysosomes.  
Epidemiological study: Epidemiological study of ORP5 is not reported yet. 
2.8 OSBPL6 (ORP6) 
Structure, Tissue distribution and Intracellular localization: ORP6 belongs to the 
subfamily III of OSBP/ORP homologues. ORP6 has an ORD, a PH domain and an FFAT 
motif. ORP6 shows the highest expression in brain and skeletal muscle (Lehto, Tienari et al. 
2004). Endogenous ORP6 associated predominantly with the nuclear envelope. When 
expressed from the cDNA in cultured cells, ORP6 was distributed between the cytosol and 
ER membranes, with a minor portion found at the PM.  
Molecular functions related to dyslipidemia: The direct evidence that ORP6 functions to 
regulate Dyslipidemia is yet to be reported. 
Epidemiological study: Using the Framingham Heart Study data set, a quantitative trait locus 
in the chromosome 2q was found to be significantly involved in variations of HDL cholesterol 
levels. ORP6 is identified as one of the candidate genes that are possibly involved in the 
regulation of HDL cholesterol levels in this region (North, Martin et al. 2003).  
2.9 OSBPL7 (ORP7) 
Structure, Tissue distribution and Intracellular localization: ORP7 belongs to the 
subfamily III of OSBP/ORP homologues. ORP7 has an ORD, a PH domain and a an FFAT 
motif. ORP7 shows the highest expression in the gastrointestinal tract (Lehto, Tienari et al. 
2004). When expressed from the cDNA in cultured cells, ORP7 was distributed between the 
cytosol and ER membranes, with a minor portion found at the PM. The N-terminal portion 
of the proteins, containing a PH domain, has markedly strong PM targeting specificity, 
while the C-terminal half remains largely cytosolic. The dual targeting of the proteins 
indicates a putative role in communication between the ER and the PM.  
Molecular functions related to dyslipidemia: Recently, Zhong et al. identified by yeast two-
hybrid screening an interaction partner of ORP7, GATE-16, which (i) regulates the function 
and stability of Golgi SNARE of 28kDa (GS28), and (ii) plays a role in autophagosome 
biogenesis (Zhong, Zhou et al. 2011).  
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2.5 OSBPL3 (ORP3) 
Structure, Tissue distribution and Intracellular localization: ORP3 belongs to the 
subfamily III of OSBP/ORP homologues. ORP3 has an ORD, a PH domain and an FFAT 
motif. A total of eight isoforms of ORP3 were demonstrated with alternative splicing 
(Collier, Gregorio-King et al. 2003). In human tissues there was specific isoform distribution, 
with most tissues expressing varied levels of isoforms with the complete ORD; while only 
whole brain, kidney, spleen, thymus, and thyroid expressed high levels of the isoforms 
associated with the truncated ORD. The expression in cerebellum, heart, and liver of most 
isoforms was negligible. Lehto et al described that ORP3 was expressed at high levels in 
kidney tubule epithelia and in the human embryonic kidney cell line HEK293 (Lehto, 
Mayranpaa et al. 2008).  
They also described that the endogenous ORP3 protein in HEK293 cells localized at the ER 
and the PM, especially thin filopodial cell-surface projections.  
Molecular functions related to dyslipidemia: The direct evidence that ORP3 functions to 
regulate Dyslipidemia is yet to be reported.  
ORP3 interacts with R-Ras, a small GTPase regulating cell adhesion, spreading and 
migration (Lehto, Mayranpaa et al. 2008). Gene silencing of ORP3 and overexpression of 
ORP3 in HEK293 cells or primary macrophages demonstrate the function of ORP3 as part of 
the machinery that controls the actin cytoskeleton, cell polarity and cell adhesion. These 
functional evidences, together with the abundant expression of ORP3 in polarized cell types, 
suggest that ORP3 may play an important role in efficient directed membrane trafficking.  
Epidemiological study: Epidemiological study of ORP3 is not reported yet. 
2.6 OSBPL4 (ORP4, OSBP2, HLM)  
Structure, Tissue distribution and Intracellular localization: ORP4 belongs to the 
subfamily I of OSBP/ORP homologues. ORP4 has an ORD, a PH domain and an FFAT 
motif. ORP4 shares the highest degree of similarity with OSBP and dimerizes with OSBP.  
Two ORP4 cDNAs were identified: a full-length ORP4 containing a PH domain and an ORD 
(designated ORP4-L), and a splice variant in which the PH domain and part of the ORD 
were deleted (designated ORP4-S). ORP4 mRNA and protein expression overlapped 
partially with OSBP and were restricted to brain, heart, muscle and kidney(Wang, JeBailey 
et al. 2002).  
Immunofluorescence localization in stably transfected Chinese hamster ovary cells showed 
that ORP4-S co-localized with vimentin and caused the intermediate filament network to 
bundle or aggregate. ORP4-L displayed a diffuse staining pattern that did not overlap with 
vimentin except when the microtubule network was disrupted with nocodazole.  
Molecular functions related to dyslipidemia: Cells overexpressing ORP4S had a 40% 
reduction in the esterification of low-density-lipoprotein-derived cholesterol, demonstrating 
that ORP4 in an interaction with intermediate filaments inhibits an intracellular cholesterol-
transport pathway mediated by vimentin (Wang, JeBailey et al. 2002).  
ORP4L bound [3H]25-hydroxycholesterol with high affinity and specificity. However, 
sterol-binding or a mutation that ablated sterol-binding did not influence the interaction of 
GST-ORP4 with vimentin (Wyles, Perry et al. 2007). Thus the precise mechanism about what 
ORP4L senses to regulate intracellular cholesterol-transport pathway still remains 
unidentified. 
Epidemiological study: Epidemiological study of ORP4 is not reported yet. 
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2.7 OSBPL5 (ORP5) 
Structure, Tissue distribution and Intracellular localization: ORP5 belongs to the 
subfamily IV of OSBP/ORP homologues. ORP5 has an ORD, a PH domain and a 
transmembrane domain. ORP5 localizes to the ER.  
Molecular functions related to dyslipidemia: Knocking down ORP5 causes cholesterol 
accumulation in late endosomes and lysosomes, which is reminiscent of the cholesterol 
trafficking defect in Niemann Pick C (NPC) fibroblasts (Du, Kumar et al. 2011). Cholesterol 
appears to accumulate in the limiting membranes of endosomal compartments in ORP5-
depleted cells, whereas depletion of NPC1 or both ORP5 and NPC1 results in luminal 
accumulation of cholesterol. Moreover, trans-Golgi resident proteins mislocalize to 
endosomal compartments upon ORP5 depletion, which depends on a functional NPC1.  
Niemann-Pick type C (NPC) disease is most often caused by mutations in the NPC1 gene, 
whose protein product is believed to facilitate the egress of cholesterol and other lipids from 
late endosomes and lysosomes to other cellular compartments (Boadu and Francis 2006). 
The results of the research by Du et al. establish the first link between NPC1 and a 
cytoplasmic sterol carrier, and suggest that ORP5 may cooperate with NPC1 to mediate the 
exit of cholesterol from endosomes/lysosomes.  
Epidemiological study: Epidemiological study of ORP5 is not reported yet. 
2.8 OSBPL6 (ORP6) 
Structure, Tissue distribution and Intracellular localization: ORP6 belongs to the 
subfamily III of OSBP/ORP homologues. ORP6 has an ORD, a PH domain and an FFAT 
motif. ORP6 shows the highest expression in brain and skeletal muscle (Lehto, Tienari et al. 
2004). Endogenous ORP6 associated predominantly with the nuclear envelope. When 
expressed from the cDNA in cultured cells, ORP6 was distributed between the cytosol and 
ER membranes, with a minor portion found at the PM.  
Molecular functions related to dyslipidemia: The direct evidence that ORP6 functions to 
regulate Dyslipidemia is yet to be reported. 
Epidemiological study: Using the Framingham Heart Study data set, a quantitative trait locus 
in the chromosome 2q was found to be significantly involved in variations of HDL cholesterol 
levels. ORP6 is identified as one of the candidate genes that are possibly involved in the 
regulation of HDL cholesterol levels in this region (North, Martin et al. 2003).  
2.9 OSBPL7 (ORP7) 
Structure, Tissue distribution and Intracellular localization: ORP7 belongs to the 
subfamily III of OSBP/ORP homologues. ORP7 has an ORD, a PH domain and a an FFAT 
motif. ORP7 shows the highest expression in the gastrointestinal tract (Lehto, Tienari et al. 
2004). When expressed from the cDNA in cultured cells, ORP7 was distributed between the 
cytosol and ER membranes, with a minor portion found at the PM. The N-terminal portion 
of the proteins, containing a PH domain, has markedly strong PM targeting specificity, 
while the C-terminal half remains largely cytosolic. The dual targeting of the proteins 
indicates a putative role in communication between the ER and the PM.  
Molecular functions related to dyslipidemia: Recently, Zhong et al. identified by yeast two-
hybrid screening an interaction partner of ORP7, GATE-16, which (i) regulates the function 
and stability of Golgi SNARE of 28kDa (GS28), and (ii) plays a role in autophagosome 
biogenesis (Zhong, Zhou et al. 2011).  
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GATE-16 is a ubiquitin-like low molecular weight peripheral membrane protein which was 
initially reported to localize at the Golgi complex and to regulate docking/fusing reactions 
in intra-Golgi traffic and Golgi assembly from mitotic fragments via interactions with NSF 
and the Golgi v-SNARE GS28 (Sagiv, Legesse-Miller et al. 2000). GS28 was identified as a 
SNARE protein, the majority of which is associated with the cis-Golgi, and is implicated in 
both ER-Golgi and intra-Golgi transport (Subramaniam, Peter et al. 1996). In the presence of 
NSF, SNAP and ATP, GATE-16 interacts with GS28, apparently maintaining GS28 in a 
transport competent form and protecting it from proteolysis.  
Zhong et al. revealed that ORP7 knockdown in 293A cells resulted in a 40% increase of GS28 
protein while ORP7 overexpression had the opposite effect. Similar to ORP7 overexpression, 
treatment of cells with 25-hydroxycholesterol (25-OH) resulted in GS28 destabilization, 
which was potentiated by excess ORP7 and inhibited by ORP7 silencing. Their results 
suggest that ORP7 negatively regulates GS28 protein stability via sequestration of GATE-16, 
and may mediate the effect of 25-OH on GS28 and Golgi function. 
Epidemiological study: It is reported that SNPs near ORP7 gene show genome-wide 
significant association with LDL cholesterol (Teslovich, Musunuru et al. 2010). 
2.10 OSBPL8 (ORP8) 
Structure, Tissue distribution and Intracellular localization: ORP8 belongs to the 
subfamily IV of OSBP/ORP homologues. ORP8 has an ORD, a PH domain and a 
transmembrane domain. ORP8 is expressed at the highest levels in macrophages, liver, 
spleen, kidney, and brain (Yan, Mayranpaa et al. 2008). ORP8 is localized in the ER via its C-
terminal transmembrane domain. 
Molecular functions related to dyslipidemia: It is reported that silencing of ORP8 by RNA 
interference in THP-1 macrophages increased the expression of ABCA1 and concomitantly 
cholesterol efflux to lipid-free apolipoprotein A-I. Experiments employing an ABCA1 
promoter-luciferase reporter confirmed that ORP8 silencing enhances ABCA1 transcription. 
These data identify ORP8 as a negative regulator of ABCA1 expression and macrophage 
cholesterol efflux. But the precise mechanism to regulate the expression of ABCA1 has not 
been revealed.  
Recently, Zhou et al. investigated the action of ORP8 in hepatic cells in vivo and in vitro. 
They found that adenoviral overexpression of ORP8 in mouse liver induced a decrease of 
cholesterol, phospholipids, and triglycerides in serum (-34%, -26%, -37%, respectively) and 
liver tissue (-40%, -12%, -24%), coinciding with reduction of nuclear (n)SREBP-1 and -2 and 
mRNA levels of their target genes. Consistently, excess ORP8 reduced nSREBPs in HuH7 
cells, and ORP8 overexpression or silencing by RNA interference moderately suppressed or 
induced the expression of SREBP-1 and SREBP-2 target genes, respectively. In accordance, 
cholesterol biosynthesis was reduced by ORP8 overexpression and enhanced by ORP8 
silencing in [(3)H]acetate pulse-labeling experiments. 
They also performed yeast two-hybrid, bimolecular fluorescence complementation (BiFC), 
and co-immunoprecipitation analyses, and revealed the nuclear pore component Nup62 as 
an interaction partner of ORP8. They showed that the impact of overexpressed ORP8 on 
nSREBPs and their target mRNAs was inhibited in cells depleted of Nup62.  
These results reveal that ORP8 has the capacity to modulate lipid homeostasis and SREBP 
activity, probably through an indirect mechanism required Nup62. 
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Epidemiological study: Ma et al. performed a genome-wide association analysis of total 
cholesterol and HDL cholesterol levels using the Framingham heart study data. In that 
study, single-locus effects and pairwise epistasis effects of 432,096 SNP markers were tested 
for their significance on log-transformed total cholesterol and HDL cholesterol levels. 
As a result, the OSBPL8-ZDHHC17 region (chr12) was detected for HDL cholesterol 
identified by one new SNP with genome-wide significance (Ma, Yang et al. 2010). 
2.11 OSBPL9 (ORP9) 
Structure, Tissue distribution and Intracellular localization: ORP9 belongs to the 
subfamily V of OSBP/ORP homologues. ORP9 has an ORD, a PH domain and an FFAT 
motif. VAP binding FFAT motif and PH domains target ORP9 to the ER and a Golgi-COPII 
compartment, respectively (Wyles and Ridgway 2004).  
Molecular functions related to dyslipidemia: Ngo et al. demonstrate that ORP9L 
partitioning between the trans-Golgi/trans-Golgi network (TGN), and the ER is mediated 
by a phosphatidylinositol 4-phosphate (PI-4P)-specific PH domain and VAP, respectively 
(Ngo and Ridgway 2009). In vitro, ORP9L mediates PI-4P-dependent cholesterol transport 
between liposomes, suggesting that its primary function in vivo is sterol transfer between 
the Golgi and ER. Depletion of ORP9L by RNAi caused Golgi fragmentation, inhibition of 
vesicular somatitus virus glycoprotein transport from the ER and accumulation of 
cholesterol in endosomes/lysosomes. These findings indicate that ORP9 maintains the 
integrity of the early secretory pathway by mediating transport of sterols between the ER 
and trans-Golgi/TGN. 
It is also reported that ORP9, in interaction with ORP11, may act as an intracellular lipid 
sensor or transporter (Zhou, Li et al. 2010). (see also ORP11.) 
Epidemiological study: Epidemiological study of ORP9 is not reported yet. 
2.12 OSBPL10 (ORP10) 
Structure, Tissue distribution and Intracellular localization: ORP10 belongs to the 
subfamily VI of OSBP/ORP homologues. ORP10 has an ORD and a PH domain but does not 
have an FFAT motif or a transmembrane domain.  
ORP10 was shown to associate dynamically with microtubules, being consistent with its 
involvement in intracellular transport or organelle positioning (Perttila, Merikanto et al. 
2009).  
Immunofluorescence localization in transiently transfected bovine aorta endothelial cells 
showed that EGFP-ORP10 co-localized with alpha-tubulin (Fig. 2 c, g) and not with actin 
(Fig. 2 a, e) or vimentin (Fig. 2 b, f). The microtubules co-localize with EGFP-ORP10 show 
the aberrant bundled structures. These structures were disrupted by treatment with 
nocodazol (Fig. 2 d, h). 
Molecular functions related to dyslipidemia: Silencing of ORP10 increased the 
incorporation of [(3)H]acetate into cholesterol and both [(3)H]acetate and [(3)H]oleate into 
triglycerides and enhanced the accumulation of secreted apolipoprotein B100 in growth 
medium, suggesting that ORP10 suppresses hepatic lipogenesis and very-low-density 
lipoprotein production. 
Epidemiological study: We examined the association between polymorphisms in the 
ORP10 gene and risk factors for the metabolic syndrome in the Tanno and Sobetsu Study in 
Japan (Koriyama, Nakagami et al. 2010). 
 
Dyslipidemia - From Prevention to Treatment 
 
134 
GATE-16 is a ubiquitin-like low molecular weight peripheral membrane protein which was 
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NSF, SNAP and ATP, GATE-16 interacts with GS28, apparently maintaining GS28 in a 
transport competent form and protecting it from proteolysis.  
Zhong et al. revealed that ORP7 knockdown in 293A cells resulted in a 40% increase of GS28 
protein while ORP7 overexpression had the opposite effect. Similar to ORP7 overexpression, 
treatment of cells with 25-hydroxycholesterol (25-OH) resulted in GS28 destabilization, 
which was potentiated by excess ORP7 and inhibited by ORP7 silencing. Their results 
suggest that ORP7 negatively regulates GS28 protein stability via sequestration of GATE-16, 
and may mediate the effect of 25-OH on GS28 and Golgi function. 
Epidemiological study: It is reported that SNPs near ORP7 gene show genome-wide 
significant association with LDL cholesterol (Teslovich, Musunuru et al. 2010). 
2.10 OSBPL8 (ORP8) 
Structure, Tissue distribution and Intracellular localization: ORP8 belongs to the 
subfamily IV of OSBP/ORP homologues. ORP8 has an ORD, a PH domain and a 
transmembrane domain. ORP8 is expressed at the highest levels in macrophages, liver, 
spleen, kidney, and brain (Yan, Mayranpaa et al. 2008). ORP8 is localized in the ER via its C-
terminal transmembrane domain. 
Molecular functions related to dyslipidemia: It is reported that silencing of ORP8 by RNA 
interference in THP-1 macrophages increased the expression of ABCA1 and concomitantly 
cholesterol efflux to lipid-free apolipoprotein A-I. Experiments employing an ABCA1 
promoter-luciferase reporter confirmed that ORP8 silencing enhances ABCA1 transcription. 
These data identify ORP8 as a negative regulator of ABCA1 expression and macrophage 
cholesterol efflux. But the precise mechanism to regulate the expression of ABCA1 has not 
been revealed.  
Recently, Zhou et al. investigated the action of ORP8 in hepatic cells in vivo and in vitro. 
They found that adenoviral overexpression of ORP8 in mouse liver induced a decrease of 
cholesterol, phospholipids, and triglycerides in serum (-34%, -26%, -37%, respectively) and 
liver tissue (-40%, -12%, -24%), coinciding with reduction of nuclear (n)SREBP-1 and -2 and 
mRNA levels of their target genes. Consistently, excess ORP8 reduced nSREBPs in HuH7 
cells, and ORP8 overexpression or silencing by RNA interference moderately suppressed or 
induced the expression of SREBP-1 and SREBP-2 target genes, respectively. In accordance, 
cholesterol biosynthesis was reduced by ORP8 overexpression and enhanced by ORP8 
silencing in [(3)H]acetate pulse-labeling experiments. 
They also performed yeast two-hybrid, bimolecular fluorescence complementation (BiFC), 
and co-immunoprecipitation analyses, and revealed the nuclear pore component Nup62 as 
an interaction partner of ORP8. They showed that the impact of overexpressed ORP8 on 
nSREBPs and their target mRNAs was inhibited in cells depleted of Nup62.  
These results reveal that ORP8 has the capacity to modulate lipid homeostasis and SREBP 
activity, probably through an indirect mechanism required Nup62. 
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Epidemiological study: Ma et al. performed a genome-wide association analysis of total 
cholesterol and HDL cholesterol levels using the Framingham heart study data. In that 
study, single-locus effects and pairwise epistasis effects of 432,096 SNP markers were tested 
for their significance on log-transformed total cholesterol and HDL cholesterol levels. 
As a result, the OSBPL8-ZDHHC17 region (chr12) was detected for HDL cholesterol 
identified by one new SNP with genome-wide significance (Ma, Yang et al. 2010). 
2.11 OSBPL9 (ORP9) 
Structure, Tissue distribution and Intracellular localization: ORP9 belongs to the 
subfamily V of OSBP/ORP homologues. ORP9 has an ORD, a PH domain and an FFAT 
motif. VAP binding FFAT motif and PH domains target ORP9 to the ER and a Golgi-COPII 
compartment, respectively (Wyles and Ridgway 2004).  
Molecular functions related to dyslipidemia: Ngo et al. demonstrate that ORP9L 
partitioning between the trans-Golgi/trans-Golgi network (TGN), and the ER is mediated 
by a phosphatidylinositol 4-phosphate (PI-4P)-specific PH domain and VAP, respectively 
(Ngo and Ridgway 2009). In vitro, ORP9L mediates PI-4P-dependent cholesterol transport 
between liposomes, suggesting that its primary function in vivo is sterol transfer between 
the Golgi and ER. Depletion of ORP9L by RNAi caused Golgi fragmentation, inhibition of 
vesicular somatitus virus glycoprotein transport from the ER and accumulation of 
cholesterol in endosomes/lysosomes. These findings indicate that ORP9 maintains the 
integrity of the early secretory pathway by mediating transport of sterols between the ER 
and trans-Golgi/TGN. 
It is also reported that ORP9, in interaction with ORP11, may act as an intracellular lipid 
sensor or transporter (Zhou, Li et al. 2010). (see also ORP11.) 
Epidemiological study: Epidemiological study of ORP9 is not reported yet. 
2.12 OSBPL10 (ORP10) 
Structure, Tissue distribution and Intracellular localization: ORP10 belongs to the 
subfamily VI of OSBP/ORP homologues. ORP10 has an ORD and a PH domain but does not 
have an FFAT motif or a transmembrane domain.  
ORP10 was shown to associate dynamically with microtubules, being consistent with its 
involvement in intracellular transport or organelle positioning (Perttila, Merikanto et al. 
2009).  
Immunofluorescence localization in transiently transfected bovine aorta endothelial cells 
showed that EGFP-ORP10 co-localized with alpha-tubulin (Fig. 2 c, g) and not with actin 
(Fig. 2 a, e) or vimentin (Fig. 2 b, f). The microtubules co-localize with EGFP-ORP10 show 
the aberrant bundled structures. These structures were disrupted by treatment with 
nocodazol (Fig. 2 d, h). 
Molecular functions related to dyslipidemia: Silencing of ORP10 increased the 
incorporation of [(3)H]acetate into cholesterol and both [(3)H]acetate and [(3)H]oleate into 
triglycerides and enhanced the accumulation of secreted apolipoprotein B100 in growth 
medium, suggesting that ORP10 suppresses hepatic lipogenesis and very-low-density 
lipoprotein production. 
Epidemiological study: We examined the association between polymorphisms in the 
ORP10 gene and risk factors for the metabolic syndrome in the Tanno and Sobetsu Study in 
Japan (Koriyama, Nakagami et al. 2010). 
 




Fig. 2. Intracellular localization of ORP10. 
As a result, we found that the LDL cholesterol of individuals with the rs2290532 (D254N) 
polymorphism was significantly greater in subjects with the CC+CT genotype than in 
subjects with the TT genotype (124.3+/-1.3 vs. 111.6+/-4.1 mg per 100 ml, P=0.009) (Fig. 3). 
Comparison of the genotype frequency in both groups indicated that the genotype 
associated with low risk (TT) reduced the risk of hyper-LDL cholesterolemia significantly 
(P=0.003), with an odds ratio of 0.35 (95% confidence interval=0.17-0.76). These findings 
suggest that the rs2290532 (D254N) polymorphism in OSBPL10 may predispose individuals 
with this SNP to hyper-LDL cholesterolemia.  
 
 
Fig. 3. Relation of rs2290532 of ORP10 with serum LDL cholesterol. 
Perttila et al. also reported that the analysis of variants in ORP10 gene revealed suggestive 
linkage of ORP10 single-nucleotide polymorphisms (SNPs) with extreme end high TG 
(>90th percentile) trait. They carried out an association analysis in a metabolic syndrome 
subcohort (Genmets) of Health2000 examination survey (N = 2,138), revealing an association 
of multiple ORP10 SNPs with high serum TG levels (>95th percentile). 
The result proves that ORP10 is genetically associated with both TG and LDL cholesterol 
levels. Though it is estimated that microtubule dependent intracellular transport of vesicles 
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plays an important role in that process, the mechanism to control TG and LDL cholesterol 
levels is yet to be explained. A further analysis is highly expected. 
2.13 OSBPL11 (ORP11) 
Structure, Tissue distribution and Intracellular localization: ORP11 belongs to the 
subfamily VI of OSBP/ORP homologues. ORP11 has an ORD and a PH domain but does not 
have an FFAT motif or a transmembrane domain. ORP11 is present at the highest levels in 
human ovary, testis, kidney, liver, stomach, brain, and adipose tissue. 
Immunohistochemistry demonstrates abundant ORP11 in the epithelial cells of kidney 
tubules, testicular tubules, caecum, and skin. ORP11 dimerizes with ORP9 and localizes at 
the Golgi-late endosome interface (Zhou, Li et al. 2010).  
Molecular functions related to dyslipidemia: Cells overexpressing ORP11 displayed 
lamellar lipid bodies associated with vacuolar structures or the Golgi complex, indicating a 
disturbance of lipid trafficking. Similar multilamellar membranes arise in endo-lysosomal 
compartments in phospholipidosis occurring, for instance, upon incubation of macrophage 
with oxidized low-density lipoprotein, or associated with inheritable lysosomal storage 
disorders, situations in which normal lipid transport is disturbed. These findings indicate 
that ORP11, in interaction with ORP9, may act as an intracellular lipid sensor or transporter.  
Epidemiological study: it is reported that ORP11 is significantly overexpressed in the 
visceral adipose tissue of obese men with metabolic syndrome (Bouchard, Faucher et al. 
2009). Furthermore, they found SNPs in the ORP11 gene to be associated with several 
cardiovascular risk factors in obese individuals. IVS12+95 T>C, a newly discovered SNP  
of the study, was associated with LDL cholesterol levels (OR = 1.63; P < 0.001), 
hyperglycemia/diabetes (OR = 1.48; P < 0.004) as well as with metabolic syndrome per se 
(OR = 1.56; P < 0.01). These results suggest that ORP11 is involved in cholesterol and 
glucose metabolism in obese individuals. 
3. Conclusion 
Since OSBP/ORP family involves functional redundancy as well as overlap tissue 
expression and intracellular localization, the function of each family member has been 
mostly left unrevealed. Various studies including the genome-wide association study, 
however, have succeeded to prove the direct association between the individual members 
and dyslipidemia. Analyses on the individual members have also made it clear that the 
members affect the regulation of cholesterol and triglyceride level in interaction with 
diverse molecules.  
Nevertheless, the precise molecular mechanism of the process still remains unascertained. 
The recent findings such as the identification of the small molecule which associates with 
OSBP are expected to act as a convenient tool to clarify the more detailed functions of 
OSBP/ORP family in future.  
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1. Introduction 
Obesity and lack of physical activity are two major factors contributing considerably to the 
pathogenesis of many chronic diseases so prevalent in contemporary human population. 
Adipose tissue and skeletal muscle are therefore the primary organs one would immediately 
suggest to target in an attempt to battle metabolic disease progression. Fine tuning of the 
physiological processes within the two organs have a large potential to modulate (i) energy 
balance, (ii) lipid storage-utilization efficiency as well as (iii) central and peripheral actions 
in the brain, gastrointestinal system or liver which are integrated by the endocrine activity 
of the two energy balance maintaining tissues.  
2. Adipose tissue in metabolic health and disease  
Despite the fact that the primary role of adipose tissue is an effective lipid storage and 
timely regulation of its release and that these processes could, in a simplified adipocentric 
view, be the primary determinants of the dyslipidemia and metabolic disease progression, 
adipose tissue has a broad range of other regulatory functions exerted via its autocrine, 
paracrine and endocrine actions. Adipose tissue secretory products, “adipokines”, could 
modulate food intake, energy expenditure, or tissue oxidative capacity (Trayhurn et al. 1998; 
Ukropec et al. 2001; Ahima & Lazar 2008; Henry & Clarke 2008; Friedman 2011). In addition, 
adipose tissue dynamically changes its structure (tissue remodeling, lipid composition), 
function (lipid storage & lipolysis) as well as endocrine action in response to different 
physiological (fasting / refeeding, exercise, microgravity) and pathophysiological (obesity, 
prediabetes, diabetes, cachexia, lipodystrophy, growth hormone deficiency) conditions (Ukropec et 
al. 2008; Itoh et al. 2011; Pietilainen et al. 2011). It is important to understand that adipose 
tissue is a mixture of very different cell-types. Apart from approximately 50% of mature 
lipid-laden adipocytes it contains various stromal cells including preadipocytes, endothelial 
cells, fibroblasts, pluripotent stem cells and immune cells which substantially influence its 
function (Bjorntorp 1974; Sethi & Vidal-Puig 2007; Divoux & Clement 2011). Extreme 
enlargement of the fat cell size, such as we have recently observed in individuals with 
growth hormone deficiency, is perhaps the best early marker of the obesity related - 
metabolic disease development (Ukropec et al. 2008a) (Fig. 1.). Adipose tissue with enlarged 
adipocytes, expressing markers of the local tissue microhypoxia but not responding to it 
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properly and attracting large amount of activated immunocompetent cells, has recently been 
termed “pathogenic adipose tissue” (Bays et al. 2008; Ukropec et al. 2008b). 
 
 
Fig. 1. Fat cell size in obesity and in growth hormone deficiency (GHD), percentage of 
cumulative frequency (Y axis), (Ukropec et al. 2008a).  
The tissue damage due to overwhelming adipocytes with lipids, largely exceeding their lipid 
storage capacity, changes the adipokine secretory profile and leads to uncontrolled release of a 
large amount of lipids into circulation while the capacity of the adipose tissue adaptive 
remodeling is compromised. This is followed by the accumulation of lipids in tissues not 
designed for the lipid storage such as liver, skeletal muscle, pancreatic beta cells or lung which 
largely interferes with their physiological functions and accelerates the development of 
metabolic disease (Bays et al. 2008; Foster et al. 2010; Unger et al. 2010). Limited expandability 
of the adipose tissue seems to determine individual propensity to the development of 
metabolic disease (Arner, P. et al. 2011). Adaptive expansion of the adipose tissue is enabled by 
combination of adipocyte hypertrophy and hyperplasia. Expansion of adipose tissue requires 
quite extensive tissue remodeling, in order to maintain adequate energy and oxygen supply, 
active neuronal network as well as integrity and functional properties of cellular membranes 
(Itoh et al. 2011; Pietilainen et al. 2011). Broader knowledge of the fat cell life-cycle dynamics is 
critical for our understanding the pathophysiological mechanisms limiting adipose tissue 
hyperplastic expansion. In 2008, Arner’s group analyzed the adipocyte turnover by detecting 
the genomic DNA incorporation of atmospheric 14C derived from above-ground nuclear bomb 
tests in period between 1955 and 1963. This work revealed that approximately 10% of fat cells 
are renewed per year at all adult ages and levels of BMI and that neither adipocyte death nor 
generation rate is altered in early onset obesity. It seemed that the steady production of 
adipocytes in adults results in a stable size of the constantly turning over adipocyte population 
(Spalding et al. 2008). More recent work by these authors examining morphology of the 
subcutaneous adipose tissue from 764 individuals with broad range of BMI (18-60 kg.m2) 
defines hyperplasia and hypertrophy as a difference between measured adipocyte volume and 
volume predicted by the curve-like fit, for adipocyte volume and body fat mass (Fig. 2.). In this 
analysis occurrence of hyperplasia or hypertrophy correlated with fasting plasma insulin and 
insulin sensitivity. In addition, total adipocyte number was greatest in individuals with 
pronounced hyperplasia, and smallest in those with pronounced hypertrophy. The absolute 
number of new adipocytes generated each year was 70% lower in patients with hypertrophy 
than with hyperplasia. Whereas the relative death rate (~ 10% per year) or mean age of 
adipocytes (~ 10 years) was not correlated with adipocyte morphology (Arner, E. et al. 2010).   
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Fig. 2. (A) Graph depicts large variability in adipose tissue morphology in individuals with 
identical body fat mass (764 subjects). (B) Level of hyperplasia is represented by adequately 
lowered morphology value while hypertrophy is associated with parallel increase in 
morphology value defined as a difference between measured and expected adipocyte 
volume given by the curve-like fit , for given body fat mass (Arner, E. et al. 2010).    
Insulin sensitivity could therefore govern adipose tissue morphology towards beneficial 
hyperplastic state at the population level. Conversely, defects in insulin action are 
interconnected with the hypertrophic adipocytes, and higher risk of lipid flooding the 
nonadipose tissues. Absolute numbers of adipocytes as well as their capacity to expand and 
store lipids are quite difficult to modulate. Morbid obesity and lipodystrophy represent the 
two medical conditions associated with excessive hypertriglyceridemia, hepatic steatosis, 
and disordered muscle glucose metabolism, due to defected ability of adipose tissue to store 
lipids or the selective loss of adipose tissue respectively. Activation of adipogenic 
programme by PPAR agonists or chronic leptin treatment improves insulin-stimulated 
hepatic and peripheral glucose metabolism in obese and lipodystrophic patients 
respectively (Petersen et al. 2002; Rieusset et al. 2002; Van Gaal et al. 2003). Adipogenesis is 
necessary to increase the adipose tissue cellularity (hyperplastic adaptive change) and lipid 
storage capacity; it is largely dependent on the signal transducers and activators of 
transcription (STAT) pathway. In brief, transcription factors C/EBP, C/EBP, and PPAR 
control adipogenesis by regulating STAT5B and STAT5A. Regulation of PPAR-STAT5 by 
C/EBP signaling seems to be the crucial adipogenesis - initiating cascade of the various 
adipogenic genes (Jung et al. 2011). Activation of adipogenic program should be paralleled 
with the extracellular matrix remodeling. As mentioned above, adipocytes are embedded in 
a unique extracellular matrix which main function is to provide mechanical support, in 
addition to participating in a variety of signaling events. Extracellular matrix requires 
remodeling to accommodate growing adipocytes in the expanding adipose tissue. We have 
recently participated in the research by Christian Wolfrum’s laboratory investigating 
regulatory processes related to adipose tissue hyperplasia. In this work, the transcription 
factor retinoid-related orphan receptor γ (RORγ) was identified as an important regulator of 
adipocyte development through regulation of its newly identified target gene matrix 
metallopeptidase-3. RORγ might serve as a novel predictor for the risk of metabolic 
complications in obesity as well as a pharmaceutical target for the treatment of obesity-
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Khan et al., recently proposed that "adipose tissue fibrosis" is a hallmark of metabolically 
challenged adipocytes. Authors observed that the absence of collagen VI, the highly enriched 
extracellular matrix component of adipose tissue, results in the uninhibited expansion of 
individual adipocytes, which is paradoxically associated with substantial improvements in 
whole-body energy homeostasis, both with high-fat diet exposure and in the ob/ob 
background. Weakening the extracellular scaffold of adipocytes seems to enable their stress-
free expansion during states of positive energy balance, which is consequently associated with 
an improved inflammatory profile (Khan et al. 2009). Further support to the notion that 
metabolic deregulation is rather due to lipid-leakage than the adipocyte hypertrophy per se 
comes from the experiment where mice lacking leptin were made to overexpress adiponectin. 
This led to the modest increase in circulating levels of full-length adiponectin and to 
subsequent normalization of glucose and insulin levels, dramatic improvement of glucose 
tolerance and positive effect on serum triglyceride levels. Adiponectin in fact completely 
rescued the diabetic phenotype in ob/ob mice. These mice displayed increased expression of 
PPAR target genes and a reduction in macrophage infiltration in adipose tissue and systemic 
inflammation. Adiponectin expressing ob/ob mice, however, were morbidly obese, with 
significantly higher levels of adiposity and adipocyte hypertrophy than their ob/ob 
littermates. Adiponectin seems to act as a peripheral "starvation" signal promoting the storage 
of triglycerides preferentially in adipose tissue. As a consequence, reduced triglyceride levels 
in the liver and muscle convey improved systemic insulin sensitivity despite adipocyte 
hypertrophy (Kim et al. 2007).  
2.1 Specificities of subcutaneous and visceral adipose tissue  
In contrast to visceral adipose tissue, which is often blamed from inducing detrimental 
metabolic effects, subcutaneous adipose tissue has the potential to benefit lipid and glucose 
metabolism. It has been repeatedly shown that differences in regional body fat distribution 
determine the propensity for the development of obesity related metabolic complications 
(Tchernof 2007). Accumulation of fat in the visceral region (mesentery, omentum, 
retroperitoneum), that in fact corresponds to central obesity (determined by increased waist 
circumference) is associated with cardiovascular disease and type 2 diabetes, independently 
on overall obesity (Wajchenberg 2000; Hamdy et al. 2006; Pischon et al. 2008). The amount of 
visceral fat increases with age in both genders but man in general have greater visceral 
adiposity than women (Wajchenberg 2000). Consistent with this notion, removal of visceral 
adipose tissue (omentectomy) decreases glucose and insulin levels in humans (Thorne et al. 
2002). By contrast peripheral obesity – increased subcutaneous adipose tissue mass, mainly 
in the region of buttock and thighs seem to be associated with improved insulin sensitivity 
and lower risk for type 2 diabetes mellitus (Snijder et al. 2003; Koska et al. 2008). One 
possible explanation for the detrimental effect of visceral fat accumulation comes from its 
unfortunate anatomical location (Arner, P. 1998; Bergman et al. 2006), but second theory 
based on adipose tissue transplantation experiments blames rather the tissue internal 
properties such as unfavorable secretory profile (Matsuzawa et al. 1999).   
Adipose tissue transplantation experiments have been primarily used as a tool to study 
physiology for human reconstructive surgery, but they provide important information on 
differences between visceral and subcutaneous adipose tissue which opens the vision of the 
adipose tissue or adipose tissue derived stem cells transplantation for the treatment of 
obesity and metabolic disorders.   
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2.2 Brown adipose tissue in human physiology  
Humans and other mammals have two types of adipose tissue that contribute to control of 
the whole body energy metabolism. The above discussed white adipose tissue, “the bad 
guy” associated with obesity, is necessary for energy storage. Brown adipose, “the good 
guy”, contains a lots of mitochondria and is ready to burn energy to generate heat in 
response to cold or dietary intake, keeping the body warm and slim (Cannon & Nedergaard 
2004). Until recently, physiologically relevant amount of brown fat was only found in 
newborns. However, accumulating evidence indicates that adult humans – or at least 
significant portion of us retain physiologically relevant amount of brown fat (van Marken 
Lichtenbelt et al. 2009; Vijgen et al. 2011; Virtanen & Nuutila 2011). This provides an exciting 
possibility to precisely regulate the adaptive thermogenic process in humans, which could 
dissipate energy and lower the obesity related metabolic burden. Brown adipose tissue 
activity in humans was determined with the aid of 18F-fluorodeoxyglucose positron-
emission tomography and computing tomography mainly in the supraclavicular region of 
cold-exposed individuals. Importantly, specimens of the adipose tissue from the 
supraclavicular region of adult humans with active brown adipose tissue were positive for 
UCP1 protein (Fig. 3.) (van Marken Lichtenbelt et al. 2009; Zingaretti et al. 2009). Vision of 
translating this knowledge into the clinical practice is quite reachable (Nedergaard & 
Cannon 2010; Tseng et al. 2010). Clinical importance could be significant, despite the fact 
that the volume of active brown adipose tissue tends to be lower in the overweight or obese 
than in the lean individuals (van Marken Lichtenbelt et al. 2009), and that it decreases with 
age (Cypess et al. 2009). Interestingly, applying the personalized cooling protocol for 
maximal nonshivering conditions to morbidly obese individuals could still increase brown 
adipose tissue activity (Vijgen et al. 2011).  
 
 
Fig. 3. Metabolically activated brown adipose tissue in supraclavicular region (arrows, B) in 
morbidly obese individuals after personalized cooling protocol (Vijgen et al. 2011). 
2.3 Metabolic activation of the white adipose tissue 
It has recently been shown that brown adipocytes and muscle cells share the common origin 
and in this respect they are quite distinct from white adipocytes (Tseng et al. 2008; Seale & 
Lazar 2009). The question remains, what is the origin of “brown fat-like white (brite) ” 
adipocytes containing UCP1 which could be induced in white fat depots under certain 
pohysiological (cold exposure) (Fig. 4.) or pharmacological (activation of SNS, agonists of 
PPAR) conditions (Granneman et al. 2005; Li et al. 2005; Ukropec et al. 2006). Nedegaard`s 
laboratory had recently reported that chronic treatment with the PPAR agonist 
rosiglitazone promotes not only the expression of PGC1 and mitochondriogenesis but also 
a catecholamine – inducible UCP1 gene expression in a significant subset of the white 
adipocytes, giving them the genuine, thermogenic capacity.  
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2.2 Brown adipose tissue in human physiology  
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response to cold or dietary intake, keeping the body warm and slim (Cannon & Nedergaard 
2004). Until recently, physiologically relevant amount of brown fat was only found in 
newborns. However, accumulating evidence indicates that adult humans – or at least 
significant portion of us retain physiologically relevant amount of brown fat (van Marken 
Lichtenbelt et al. 2009; Vijgen et al. 2011; Virtanen & Nuutila 2011). This provides an exciting 
possibility to precisely regulate the adaptive thermogenic process in humans, which could 
dissipate energy and lower the obesity related metabolic burden. Brown adipose tissue 
activity in humans was determined with the aid of 18F-fluorodeoxyglucose positron-
emission tomography and computing tomography mainly in the supraclavicular region of 
cold-exposed individuals. Importantly, specimens of the adipose tissue from the 
supraclavicular region of adult humans with active brown adipose tissue were positive for 
UCP1 protein (Fig. 3.) (van Marken Lichtenbelt et al. 2009; Zingaretti et al. 2009). Vision of 
translating this knowledge into the clinical practice is quite reachable (Nedergaard & 
Cannon 2010; Tseng et al. 2010). Clinical importance could be significant, despite the fact 
that the volume of active brown adipose tissue tends to be lower in the overweight or obese 
than in the lean individuals (van Marken Lichtenbelt et al. 2009), and that it decreases with 
age (Cypess et al. 2009). Interestingly, applying the personalized cooling protocol for 
maximal nonshivering conditions to morbidly obese individuals could still increase brown 
adipose tissue activity (Vijgen et al. 2011).  
 
 
Fig. 3. Metabolically activated brown adipose tissue in supraclavicular region (arrows, B) in 
morbidly obese individuals after personalized cooling protocol (Vijgen et al. 2011). 
2.3 Metabolic activation of the white adipose tissue 
It has recently been shown that brown adipocytes and muscle cells share the common origin 
and in this respect they are quite distinct from white adipocytes (Tseng et al. 2008; Seale & 
Lazar 2009). The question remains, what is the origin of “brown fat-like white (brite) ” 
adipocytes containing UCP1 which could be induced in white fat depots under certain 
pohysiological (cold exposure) (Fig. 4.) or pharmacological (activation of SNS, agonists of 
PPAR) conditions (Granneman et al. 2005; Li et al. 2005; Ukropec et al. 2006). Nedegaard`s 
laboratory had recently reported that chronic treatment with the PPAR agonist 
rosiglitazone promotes not only the expression of PGC1 and mitochondriogenesis but also 
a catecholamine – inducible UCP1 gene expression in a significant subset of the white 
adipocytes, giving them the genuine, thermogenic capacity.  
 




Fig. 4. Metabolically activated “brite adipocytes” as found in inguinal white adipose tissue 
of mice lacking the UCP1-thermogenesis after gradual exposure to cold.  
(A) histomorphology, (B) O2 consumption by oxymetry, (C) adipose tissue ex vivo  
palmitate oxidation, (D&E) evidence for AMPK activation (Ukropec et al. 2006). 
In collaboration with laboratory of dr. Kvatnansky we have recently observed that 
catecholamines, important regulators of lipolysis in adipose tissue, could be produced 
within adipocytes. Adipocytes isolated from mesenteric adipose tissue expressed genes 
encoding the catecholamine biosynthetic enzymes and produced catecholamines de novo. 
Administration of tyrosine hydroxylase inhibitor, alpha-methyl-p-tyrosine, significantly 
reduced concentration of catecholamines in isolated adipocytes in vitro (Fig. 5.). We 
therefore hypothesized that the sympathetic innervation of adipose tissue is not the only 
source of catecholamines and that adipocyte-derived catecholamines could dynamically 
modulate metabolic or thermogenic properties of the white adipose tissue perhaps by 
enhancing ”brite adipocyte” function (Vargovic et al. 2011). 
3. Adipocentric view on the pathophysiology of metabolic disease  
The prevalence of obesity and its consequent pathologies in modern society is of serious 
health concern. Although the expansion of adipose tissue mass during pathological obesity 
is in itself not a grave problem, rather it is the ensuing pathologies resultant of this state, 
including development of hypertension, type 2 diabetes and cardiac myopathies, that 
impacts peoples lives and health services worldwide.  
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Clearly not all obese individuals develop metabolic and cardiovascular complications; here 
we discuss several regulatory mechanisms representing a base for the strategies to prevent 
metabolic disease development.  
 
            d 
Fig. 5. Adipocytes have internal catecholamine production capacity. Adipose tissue contains 
mRNA and proteins specific for tyrosine hydroxylase (TH) and phenylethanolamine N-
methyltransferase PNMT as shown on histological sections probed with specific PNMT (a,b) 
and TH (c) antibodies, scale bar: 20 µm. (d) Adipocytes freshly isolated from mesenteric 
adipose tissue produce dopamine (DA), norepinephrine (NE) and epinephrine (EPI) into the 
media. Production of catecholamines is largely inhibited by addition of alpha-methyl-p-
tyrosine (AMPT) – competitive inhibitor of TH activity (Vargovic et al. 2011).  
3.1 Hypoxia  
Hypothesis that adipose tissue populated by large adipocytes contains the local 
microhypoxia suffering areas, which has a profound effect on the tissue metabolic and 
inflammatory phenotype, has been largely accepted. Hypoxia is one of the major triggers 
strongly inhibiting adipocyte differentiation. Tissue hypoxia in obesity is associated with the 
defects in the nutrient and oxygen supply into the tissue, related to a defective blood flow 
regulation which might be perpetuated by the increased fat cell size (Yun et al. 2002). This is 
happening in spite of the almost unlimited capacity of adipose tissue to expand in a non-
transformed form, which is a very unique property of adipose tissue that cannot be seen in 
any other organ. To accomplish this adipose tissue requires potent mechanisms to remodel, 
acutely and chronically, as it can rapidly reach the diffusional limit of oxygen; molecular 
response to hypoxia is therefore an early determinant that limits healthy adipose tissue 
expansion. Proper expansion requires a highly coordinated response among many different 
cell types, including endothelial precursor cells, immune cells, and preadipocytes (Sun et al. 
2011). It has also been demonstrated that mitochondrial oxidative apparatus is essential for 
the white fat adipocyte differentiation (De Pauw et al. 2009). Beside their key role in ATP 
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production, mitochondria constitute the primary source of reactive oxygen species (ROS), 
which have a great potential to influence the tissue plasticity.  
ROS are not only considered a negative factors contributing to degenerative processes and 
ageing, but also a physiological signal molecules participating in the oxygen sensing 
mechanisms (Chandel & Budinger 2007). Mitochondrial ROS production influences the size 
of the white adipocytes, and ROS are in fact antiadipogenic signaling molecules triggering 
the hypoxia-dependent inhibition of adipocyte differentiation (Carriere et al. 2004). In 
addition, decreased oxygen availability stimulates the programming of cellular metabolism 
towards increased glycolysis and fatty acid and triacylglyceride synthesis (Halperin et al. 
1969; Kinnula et al. 1978). Hypoxia-inducible factor (HIF), dimers composed of HIF1, 
HIF2 or HIF3 (collectively HIF) and HIF1/ARNT subunits, play a key role in the 
coordination of these metabolic adaptations (Trayhurn et al. 2008; Krishnan et al. 2009). 
HIF subunits are constitutively expressed but degraded under normoxia due to prolyl 
hydroxylase activity, which marks them for recognition by the von Hippel-Lindau (VHL) 
tumor suppressor protein pVHL, that acts as part of an E3 ubiquitin ligase complex to target 
HIF subunit for proteasomal degradation. Loss of pVHL function or hypoxia leads to 
accumulation of HIF, dimerization with HIF/ARNT and the activation of numerous 
hypoxia-inducible genes (Krek 2000; Semenza 2001). Previous work by Krek`s laboratory 
provided the seminal observation that hypoxia activated pVHL and HIF1 oxygen sensing 
system affects normal physiological function of heart and pancreatic beta cells by triggering 
the changes in the glucose and fatty acid metabolism (Zehetner et al. 2008; Krishnan et al. 
2009). Interestingly, hypoxia present in atherosclerotic lesions contributes to the pro-
inflammatory lipid-loaded foam cells formation, as it decreases expression of enzymes 
involved in -oxidation and increases expression of enzymes related to fatty acid synthesis 
and lipid droplet formation. The aforementioned processes possibly stimulate progression 
of the atherosclerotic plaque formation (Bostrom et al. 2007). Finally, tissue hypoxia largely 
modulates adipocytokine production and possibly contributes to the adipose tissue 
inflammation in obesity (Hosogai et al. 2007; Wang et al. 2007; Ukropec et al. 2008). 
3.2 Inflammation – Macrophage, adipocyte and preadipocyte plasticity  
Chronic low level of inflammation present in the “pathogenic” adipose tissue has been 
found to have adverse effects on the adipose tissue physiological functions contributing thus 
to the metabolic disease. It has been shown that increase in both body fat mass and 
adipocyte cell size are directly related to the number of macrophages found in the adipose 
tissue (Wellen & Hotamisligil 2005; Weisberg et al. 2006; Goossens 2008). A net pro-
inflammatory response of the adipose tissue may result from adipose tissue secretion of pro-
inflammatory factors; adipose tissue secretion of factors that stimulate other tissues to 
produce inflammatory factors; and decreased production of anti-inflammatory factors. 
Although the contribution of specific cell types to inflammation is uncertain, evidence is 
mounting that implicates adipose tissue macrophages as the significant contributor to 
inflammation in insulin resistant adipose tissue (Kanda et al. 2006; Neels & Olefsky 2006). 
There are controversial reports related to the importance of the CC chemokine ligand 2 
(CCL2, monocyte chemoattractant protein-1) for the macrophage-recruitment and activation 
in obesity (Kamei et al. 2006; Inouye et al. 2007). Interestingly CCL2 has also been proposed 
to affect metabolism independently of its macrophage-recruiting capabilities (Inouye et al. 
2007). There is also preliminary data indicating that the tissue infiltration by macrophages 
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depends upon the expression of osteopontin, an extracellular matrix protein and pro-
inflammatory cytokine which promotes the monocyte chemotaxis and cell motility. Mice 
exposed to a high-fat diet exhibited increased plasma osteopontin level, and elevated 
expression of osteopontin in macrophages recruited into adipose tissue. In addition, obese 
mice lacking osteopontin displayed improved insulin sensitivity in the absence of an effect 
on the diet-induced obesity, body composition or energy expenditure. These mice further 
demonstrated decreased macrophage infiltration into adipose tissue, which may reflect both 
impaired macrophage motility and attenuated monocyte recruitment by stromal vascular 
cells. Finally, obese osteopontin-deficient mice exhibited decreased markers of 
inflammation, both in adipose tissue and systemically (Nomiyama et al. 2007).  
Adipose tissue resident macrophages show significant heterogeneity in their properties and 
activation state, reflecting the local metabolic and immune microenvironment (Gordon & 
Taylor 2005). Different stimuli activate macrophages to express distinct patterns of 
chemokines, surface markers and enzymes that ultimately generate the diversity of 
macrophage function seen in inflammatory and non-inflammatory settings. It has recently 
been proposed that adipose tissue macrophages, which accumulate with obesity and are 
implicated in insulin resistance switch their phenotype from one of an alternatively 
activated (M2) to pro-inflammatory (M1) cells (Lumeng et al. 2007). Characteristic features 
of the IFN- induced pro-inflammatory (M1) macrophages include enhanced MHC class II 
expression, but distinctive up-regulation of i-NOS. Alternative activation of macrophages 
(M2) is strongly associated with extracellular parasitic infections, allergy, humoral 
immunity, and fibrosis. It is characterized by up-regulation of the endocytic lecithin-like 
receptors and arginase rather than i-NOS (Gordon 2007). Therefore, the alternatively 
activated (M2) macrophages seem to have high capacity for the tissue remodeling and 
repair.  
It had been recently proposed that PPARγ is required for maturation of alternatively 
activated macrophages (M2), which could also participate to its insulin sensitizing effect 
(Odegaard et al. 2007). Disruption of PPAR in myeloid cells impaired alternative 
macrophage activation and predisposed to the development of diet-induced obesity, insulin 
resistance, and glucose intolerance. This might be related to the concomitant down-
regulation of oxidative phosphorylation gene expression in skeletal muscle and liver 
(Odegaard et al. 2007). Phenotype of macrophages in the pathogenic-hypoxic adipose tissue 
might also be regulated by HIF-1 since the functional loss of HIF-1α resulted in a dramatic 
reduction of the intracellular ATP stores in macrophages to approximately 15-20%, most 
likely due to the inhibition of the HIF-1α regulated glycolytic energy generation (Cramer & 
Johnson 2003; Cramer et al. 2003). It could be hypothesized that resident alternatively 
activated macrophages have a beneficial role in regulating nutrient homeostasis and suggest 
that macrophage polarization towards the alternative state might be a useful strategy for 
treating type 2 diabetes, by modulating adipose tissue phenotype.  
Fatty acid binding proteins (FABPs), which are common to adipocytes and macrophages, 
could also play an important role in metabolic and inflammatory disease, and might 
therefore represent desirable therapeutic targets for metabolic syndrome (Erbay et al. 2007). 
Macrophage-derived foam cells express the adipocyte fatty acid-binding protein (FABP) aP2 
that plays an important role in regulating the development of insulin resistance in obesity. It 
has been shown that macrophages deficient in aP2 display alterations in the inflammatory 
cytokine production. Through its distinct actions in adipocytes and macrophages, aP2 links 
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together the features of the metabolic syndrome including insulin resistance, obesity, 
inflammation, and atherosclerosis (Linton & Fazio 2003). 
3.3 Phospholipid membrane composition  
In the last decades, free radical processes delineated an interdisciplinary field linking 
chemistry to biology and medicine. Free radical mechanisms became of importance as 
molecular basis of physiological and pathological conditions. Lipids, in particular 
unsaturated fatty acids, are susceptible to free radical attack. The reactivity of the double 
bond toward free radicals is well known; in particular the reversible addition of radical 
species to this functionality determines the cis-trans double bond isomerization. Since the 
prevalent geometry displayed by unsaturated fatty acids in eukaryotes is cis, the occurrence 
of the cis-trans isomerization by free radicals corresponds to the loss of an important 
structural information linked to biological activity (Ferreri & Chatgilialoglu 2009). 
Formation of trans isomers of unsaturated fatty acid in biological membranes can have 
important meaning and consequences connected to radical stress associated with nutritional 
overload and mitochondrial defects. It might, together with changes in membrane lipid 
composition (Pietilainen et al. 2011), substantially modulate lipid membrane biophysical 
characteristics such as thickness, fluidity, protein lateral diffusion capacity, permeability to 
small molecules in expanding adipocytes and contribute thus to the development of 
metabolic disease in obesity.  
3.4 Pollutants and metabolic health  
Physical inactivity and unhealthy diet are well recognized environmental influences largely 
increasing the risk for metabolic disease development. Recent advances in detecting the 
presence of various persistent organic pollutants in the surrounding world as well as within 
our bodies, prompted us to evaluate its possible role in pathogenesis of different endocrine 
and metabolic pathological states (Langer et al. 2003; Langer et al. 2007; Langer 2010; Langer 
et al. 2010; Ukropec et al. 2010; Langer et al. 2011).  
A heavily polluted area of Eastern Slovakia was targeted by the PCBrisk cross-sectional 
survey to search for possible links between environmental pollution and both prediabetes 
and diabetes. Associations of serum levels of five persistent organic pollutants (POPs), 
namely polychlorinated biphenyls (PCBs), 2,2'-bis(4-chlorophenyl)-1,1-dichloroethylene 
(p,p'-DDE), 2,2'-bis(4-chlorophenyl)-1,1,1-trichloro-ethane (p,p'-DDT), hexachlorobenzene 
(HCB) and beta-hexachlorocyclohexane (-HCH), with prediabetes and diabetes were 
investigated in 2,047 adults. Prevalence of prediabetes and diabetes increased in a dose-
dependent manner, with individuals in upper quintiles of individual POPs showing striking 
increases in prevalence of prediabetes (Fig. 6.) Interestingly, unlike PCBs, DDT and DDE, 
increased levels of HCB and -HCH seemed not to be associated with increased prevalence 
of diabetes (Ukropec et al. 2010). Cumulative effect of all five persistent organic pollutants 
(sum of orders) more than tripled the prevalence of prediabetes while that of diabetes was 
increased more than six times as compared to the referent quintile composed of individuals 
with lowest levels of pollutants in serum. We as well as the others have clearly shown that 
increasing serum concentrations of individual persistent organic pollutants considerably 
increased prevalence of prediabetes and diabetes in a dose-dependent manner. Interaction 
of industrial and agricultural pollutants in increasing prevalence of prediabetes or diabetes 
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is likely (Hong et al. 2010; Ukropec et al. 2010; Howard & Lee 2011; Lee, D. H. et al. 2011; 
Lee, D. H. et al. 2011; Lee, H. K. 2011). 
 
 
Fig. 6. The prevalence of prediabetes increases with increased circulating levels of PCBs 
(sum 15 congeners of polychlorinated biphenyls); DDE (2,2'-bis(4-chlorophenyl)-1,1-
dichloroethylene); DDT (2,2'-bis(4-chlorophenyl)-1,1,1-trichloro-ethane); HCB 
(hexachlorobenzene) and b-HCH (beta-hexachlorocyclohexane); POLL5 represents the sum 
of orders for all 5 pollutants. Odds ratios were adjusted for age, gender and BMI.  
4. Skeletal muscle in metabolic health and disease  
Skeletal muscle represents a large mass of tissue, and its primary function is to use 
energy, though quite inefficiently, to enable us the 3D life, voluntary positioning and 
moving our bodies in a surrounding space. This makes an active muscle to be the most 
effective energy burner. In addition to obvious metabolic consequences, regular exercise 
activates central reward mechanisms and makes us happy (Figure 7.) (Sher 1998; Boecker 
et al. 2008). 
 
A      B 
 
Fig. 7. Correlation of opidergic ligand 6-O-(2-[18F]fluoroethyl)-6-O-desmethyldiprenorphine 
binding in right orbitofrontal cortex (OFC) with the visual analog mood scale (for euphoria) 
in runners (A) and effect of exercise on the individual’s mood expressed in the visual analog 
mood scale (B) (Boecker et al. 2008).  
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is likely (Hong et al. 2010; Ukropec et al. 2010; Howard & Lee 2011; Lee, D. H. et al. 2011; 
Lee, D. H. et al. 2011; Lee, H. K. 2011). 
 
 
Fig. 6. The prevalence of prediabetes increases with increased circulating levels of PCBs 
(sum 15 congeners of polychlorinated biphenyls); DDE (2,2'-bis(4-chlorophenyl)-1,1-
dichloroethylene); DDT (2,2'-bis(4-chlorophenyl)-1,1,1-trichloro-ethane); HCB 
(hexachlorobenzene) and b-HCH (beta-hexachlorocyclohexane); POLL5 represents the sum 
of orders for all 5 pollutants. Odds ratios were adjusted for age, gender and BMI.  
4. Skeletal muscle in metabolic health and disease  
Skeletal muscle represents a large mass of tissue, and its primary function is to use 
energy, though quite inefficiently, to enable us the 3D life, voluntary positioning and 
moving our bodies in a surrounding space. This makes an active muscle to be the most 
effective energy burner. In addition to obvious metabolic consequences, regular exercise 
activates central reward mechanisms and makes us happy (Figure 7.) (Sher 1998; Boecker 
et al. 2008). 
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Fig. 7. Correlation of opidergic ligand 6-O-(2-[18F]fluoroethyl)-6-O-desmethyldiprenorphine 
binding in right orbitofrontal cortex (OFC) with the visual analog mood scale (for euphoria) 
in runners (A) and effect of exercise on the individual’s mood expressed in the visual analog 
mood scale (B) (Boecker et al. 2008).  
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More importantly, inadequate physical activity, associated with defects in mitochondrial 
function and changes in ultrastructure as well as muscle endocrine properties, largely 
contributes to the imbalance between energy intake and energy expenditure and is tightly 
associated with many chronic metabolic and cardiovascular diseases (Bluher & Zimmer 
2010; Pedersen 2011). Physical activity is a key factor to bring individuals living in a 
modern society with plenty of palatable food choices to energy balance. The mechanisms 
that tie muscle activity to health are unclear. Generation of “exercise pill” targeting organ 
systems involved in facultative thermogenesis had been envisaged (Himms-Hagen 2004). 
And results of studies aimed at identifying the endocrine properties of exercising muscle 
are encouraging our thinking in this respect. In our recent study we observed on the 
sample of 71 individuals with a broad range of BMI that overweight and obesity is 
associated with decreased physical activity. This might be not so surprising. But low 
physical activity level was also associated with decreased insulin sensitivity, increased fat 
cell size and expanded visceral adiposity all independent on BMI (Fig. 8.). In addition, the 
basic metabolic rate was positively and respiratory quotient negatively associated with 
the duration of the daily physical activity representing thus a direct link between physical 




Fig. 8. Free-living ambulatory activity (number of steps in 24h) correlates with insulin 
sensitivity, modulates adipocyte diameter as well as visceral adiposity (Ukropcova et al., 
unpublished observations).    
This complements the previous observations by others indicating that inactivity initiates 
unique cellular processes that are qualitatively different from the exercise responses. 
Inactivity physiology studies are beginning to raise a new concern with potentially major 
clinical and public health significance. Sedentary lifestyle threatens our society. The average 
nonexercising person may become even more metabolically unfit in the coming years if they 
sit too much and thereby lower the normally high volume of intermittent nonexercise 
physical activity in everyday life (Fig. 8) (Hamilton et al. 2007; Levine et al. 2008). Dynamic 
interrelations of skeletal muscle and adipose tissue during exercise are necessary to support 
muscle performance. This requires precise spacio-temporal management of the adipose 
tissue metabolic flux. The transcriptional coactivator PGC1 has recently been shown to 
regulate several exercise-associated aspects of muscle function. There is mounting evidence 
suggesting that this transcription factor controls muscle plasticity, suppresses a broad 
inflammatory response and integrates many beneficial effects of exercise on metabolic 
health (Handschin & Spiegelman 2008).  
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4.1 Exercise and skeletal muscle endocrinology  
The recent identification of skeletal muscle as an endocrine organ that produces and releases 
biologically active substances, ”myokines”, expands our knowledge on how the endocrine, 
immune and nervous systems contribute to the maintenance of homeostasis, especially 
when energy demands are increased (Pedersen & Febbraio 2008). To date, only a few muscle 
cell-secreted proteins with auto-, para-, or endocrine functions have been identified. It could 
be hypothesized that skeletal muscle releases a large number of biologically active 
substances which participate to cell-to-cell and organ-to-organ cross-talk. It also has to be 
noted that specific biological functions of known myokines are very incompletely 
understood.  
Certain myokines, such as calprotectin (Mortensen et al. 2008), IL15 (Nielsen & Pedersen 
2007) and IL6 (Jonsdottir et al. 2000), are acutely induced by muscle contraction but might 
not necessarily be increased in response to muscle training (Pedersen & Febbraio 2008; 
Haugen et al. 2010). Exercise training involves multiple adaptations including increased pre-
exercise skeletal muscle glycogen content (Kirwan et al. 1990), enhanced activity of key 
enzymes involved in -oxidation (Schantz 1986), increased sensitivity of adipose tissue to 
epinephrine-induced lipolysis (Crampes et al. 1986), and increased muscle capacity to 
oxidize fat (Holloszy & Booth 1976; Phillips et al. 1996). It could therefore be hypothesized 
that secretory activity of muscle subjected to inadequate physical activity would be 
qualitatively and quantitatively distinct from that of the trained athlete, and that it could 
simply be regulated by e.g. the glycogen level (Keller et al. 2001; Steensberg et al. 2001), 
reactive oxygen species production (Kosmidou et al. 2002; Steensberg et al. 2007) or by 
modulating biological availability of various forms of lipids (Peter et al. 2009), such as found 
in obesity.  
Previous reports indicate that calprotectin, IL6 and IL15 might contribute to homeostatic 
control of glucose and lipid metabolism (Van Hall et al. 2003; Febbraio et al. 2004). In 
addition, fibroblast growth factor-21 (FGF-21), the potent metabolic regulator, shown to 
improve glucose metabolism and insulin sensitivity in animal models, had recently been 
found to be expressed and secreted in vitro from murine muscle cells and in vivo from 
human muscle in response to insulin stimulation (hyperinsulinemic-euglycemic clamp) 
(Hojman et al. 2009). Follistatin-like 1 (Fstl-1) is another myokine whose functional 
significance in physiological and pathological processes is incompletely understood. 
Preliminary evidence indicates that Fstl-1 promotes endothelial cell function and stimulates 
revascularization in response to ischemic insult through its ability to activate Akt-eNOS 
signaling in muscle (Ouchi et al. 2008). Interleukin-8 is a CXC family chemokine increased in 
human muscle in response to concentric exercise (Akerstrom et al. 2005), which has also 
been shown to have angiogenic actions associated with activation of CXCR2 receptors in the 
human microvascular endothelial cells (Bek et al. 2002; Frydelund-Larsen et al. 2007). Recent 
report by Drevon’s laboratory describes interleukin-7 as a novel myokine affecting 
myogenesis in vitro in human primary muscle cells. Interleukin-7 is up-regulated by exercise 
training in male individuals undergoing a strength training program (Haugen et al. 2010). 
4.2 Mitochondrial biogenesis in skeletal muscle – Energetic remodeling of muscle 
phenotype in obesity, insulin resistance and exercise  
Mitochondria are energy power plants of the cells, believed to have evolved over billions of 
years from invading prokaryotic oxygen utilizing “quite energizing” eubacterium to early 
eucaryotic cells, giving the life on earth new energy spark (Lanza & Nair 2010). Their 
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structure and function is orchestrated by a strict coordination of nuclear and mitochondrial 
genome. Of ~1.000 mitochondrial proteins, only 13 are encoded by the mitochondrial 
genome, remaining proteins are translated from nuclear genome and transported across the 
inner mitochondrial membrane (Lanza & Nair 2010). Mitochondria cover majority of 
energetic needs of cells by coupling substrate oxidation with ATP formation, the process 
known as oxidative phosphorylation. This process also generates reactive oxygen species 
(ROS). It has been estimated that 0.2 – 2% of oxygen taken up by the cell is converted into 
ROS (Harper et al. 2004). Mechanisms for detoxifying the ROS are quite well developed in a 
eukaryotic cell which is another reason for their long lasting partnership with “dangerous” 
mitochondria. Sustained excessive production may accumulate amount of ROS exceeding 
the antioxidant capacity of the specific cell, eventually leading to cell damage and death 
(Harman 1956). During recent years, mitochondria , though not only those found in skeletal 
muscle, were put on the spot as organelles involved in aging and associated chronic 
civilization diseases such as Alzheimer’s disease (Reddy 2009), some forms of cancer, 
obesity and type 2 diabetes (Johannsen & Ravussin 2009).  
4.2.1 Mitochondria in obesity, insulin resistance and type 2 diabetes  
Recent evidence indicates that insulin resistance in skeletal muscle might develop due to the 
reduced capacity of mitochondria to oxidize lipids (Bjorntorp et al. 1967; Kelley et al. 2002; 
Petersen et al. 2004; Ukropcova et al. 2007) and reduced capacity for insulin-stimulated ATP-
synthesis (Petersen et al. 2005). Obese individuals and subjects with type 2 diabetes are 
characterized also by reduced adiponectin signaling (Kern et al. 2003; Civitarese et al. 2004; 
Rasmussen et al. 2006), lower rates of fasting lipid utilization and impaired switch to 
carbohydrate oxidation in response to insulin (Kelley et al. 1999; Kelley & Mandarino 2000; 
Ukropcova et al. 2005; Ukropcova et al. 2007). Recent studies using microarray expression 
analysis reported a decrease in the expression of genes involved in mitochondrial biogenesis 
in skeletal muscle of individuals with insulin resistance (Patti et al. 2003) and T2D (Mootha 
et al. 2003). Further studies in insulin resistant subjects and individuals with type 2 diabetes 
have shown reduced mitochondrial content, lower electron transport chain activity in total 
mitochondria and in intramyofibrilar and subsarcolemal mitochondrial fractions (Kelley et 
al. 2002; Ritov et al. 2005). Taken together, these data support the hypothesis that insulin 
resistance in human skeletal muscle arises from lowering mitochondrial number and 
functional capacity. Another hypothesis challenges this paradigm; it is supported by 
observations that increased fatty acid availability is associated with increased mitochondrial 
fat oxidation. However, mitochondrial overload with energy rich substrates highlights the 
pathophysiological role of ROS and that of products of incomplete mitochondrial oxidation 
rather than simple lowering of mitochondrial functional capacity (Koves et al. 2008; 
Holloszy 2009). The importance of mitochondria for energy homeostasis makes this 
organelle an exciting target for investigation and better understanding to regulation of 
mitochondrial biogenesis and function would help us to understand its putative role in the 
pathogenesis of obesity and insulin resistance.  
4.2.2 Exercise and ageing keep constant battle for healthy mitochondria 
Exercise is one of the two physiological stimuli known to increase production of new 
mitochondria and to improve mitochondrial efficiency. In our work, we have shown that 
caloric restriction, the only officially acknowledged physiological stimulus demonstrated to 
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prolong lifespan, is also inducing mitochondrial biogenesis in human skeletal muscle 
(Civitarese et al. 2007). Many scientists are on a quest, pursuing the vision of exercise 
mimicking pill, capable of induction of mitochondrial biogenesis in vivo. „Exercise in a pill“ 
(another option would be a pill mimicking caloric restriction) is by many considered a 
putatively great tool to combat obesity and civilization diseases. However, healthy lifestyle 
intervention, with sufficient physical activity and matching caloric intake still proves to be 
the most natural and effective way how to stay fit, healthy and with increased chances to 
live up to be a hundred.  
4.2.3 Adipose tissue and skeletal muscle interplay  
Our organism can be viewed as a very complex society of tissues that need to communicate 
with one another in order to maintain metabolic health. Tissue cross-talk plays the central 
role in the regulation of food intake, energy expenditure, oxidative capacity, adaptation to 
changes in physical activity, nutritional status etc. As mentioned above, adipose tissue (as 
well as many other tissues in our body) is (are) a (the) source of many biologically active 
substances with autocrine, paracrine and endocrine activities, exerting effects over many 
different neighboring as well as distant tissues and organs. 
Adiponectin is the most studied adipocytokine which is in relatively high quantities 
secreted from adipose tissue into the bloodstream. Adiponectin has very positive effects on 
our metabolic health as it activates glucose and fatty acid metabolism and improves insulin 
sensitivity. Adiponectin levels are inversely correlated with body fat mass and positively 
with insulin sensitivity (Hara et al. 2005) and it also displays anti-atherogenic and anti-
inflammatory effects (Antoniades et al. 2009). This hormone was first characterized in mice 
as a transcript overexpressed in preadipocytes (precursors of fat cells) differentiating into 
adipocytes. The human homologue was identified as the most abundant transcript in 
adipose tissue. Contrary to expectations and despite being produced in adipose tissue, 
adiponectin was found to be decreased in obesity. The gene was localized to chromosome 
3p27, a region highlighted as affecting genetic susceptibility to T2D and obesity. 
Supplementation by differing forms of adiponectin was able to improve insulin control, 
blood glucose and triglyceride levels in mouse models. The question remains what are the 
mechanisms underlying positive effects of adiponectin on metabolism? 
The molecular mechanisms leading to mitochondrial dysfunction in obesity and T2D remain 
largely unknown. Bergeron et al (Bergeron et al. 2001) demonstrated that activation of 
cAMP-activated protein kinase (AMPK) increases both mitochondrial biogenesis and 
oxidative capacity in skeletal muscle of rodents. In animal models of T2D, the activation of 
AMPK by adiponectin increases muscle and hepatic fat oxidation and improves insulin 
sensitivity (Yamauchi et al. 2001). Studies in obese and diabetic rhesus monkey demonstrate 
that plasma adiponectin level declines in the early phases of obesity and in parallel to the 
progressive development of insulin resistance (Hotta et al. 2001). Furthermore, circulating 
plasma adiponectin levels and the expression of both adiponectin receptors are reduced in 
subjects with a family history of diabetes (Civitarese et al. 2004), while prospective studies in 
Pima Indians show that high concentrations of adiponectin is protective against the 
development of T2D (Lindsay et al. 2002). Collectively, these data define a pathway in 
skeletal muscle by which adiponectin contributes to energy homeostasis by modulating 
mitochondrial number and function (Civitarese et al. 2006). Early defects in the secretion of 
adiponectin or in adiponectin signaling might contribute to the lower mitochondrial content 
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and/or function in the prediabetic state. Interestingly and in accordance with our results, it 
has been recently demonstrated that an adiponectin-like molecule, a recombinant globular 
domain of adiponectin (rgAd110-244), has a significant therapeutic potential to treat insulin 
resistance in mice fed a high fat diet for 3 months (Sulpice et al. 2009). This makes 
adiponectin derivatives a promising new treatment for T2D.  
It appears that adiponectin is also produced by skeletal muscle and that globular 
adiponectin is capable of inducing the differentiation and fusion of muscle cells in vitro 
(Fiaschi et al. 2009). Mimicking of pro-inflammatory settings or exposure to oxidative stress 
strongly increases the production of adiponectin from differentiating primary muscle cells. 
These data suggest a novel function of adiponectin, coordinating the myogenic 
differentiation program. 
4.2.4 Mitochondrial biogenesis in muscle cells – Lipids and exercise  
Fatty acids are known to be the ligands of various transcription factors involved in the 
regulation of metabolism and mitochondrial biogenesis (Gilde & Van Bilsen 2003). It has 
been shown previously that fatty acids as well as a diet with an increased fat content is 
capable of inducing mitochondrial biogenesis both in vitro and in vivo (Watt et al. 2006; 
Hancock et al. 2008). In our work, we have tested the effect of chronic, 4-day long exposure 
to palmitate on metabolic phenotypes of human primary skeletal muscle cells. We observed 
an increase in number of active mitochondria as measured by incorporation of mitotracker 
(fluorescencent dye selectively activated within respiring mitochondria) as well as increased 
expression of genes involved in mitochondrial biogenesis, increase in the capacity for fatty 
acid oxidation (Ukropcova et al. 2005, Ukropcova et al, unpublished observation). At this 
moment we can only speculate on the mechanisms behind this oxidation boosting effect of 
palmitate. However, it has been shown that fatty acids are capable of activating AMP 
activated protein kinase (AMPK) in skeletal muscle (Watt et al. 2006). AMPK signaling is 
activated in energy deficit states and it primarily saves the cell by inducing de novo 
mitochondrial biogenesis. It cooperates with transcription factor PGC1, overexpression of 
which has been demonstrated to enhance both lipid oxidation and synthesis (Espinoza et al. 
2010). Another possibility is that palmitate is a ligand for the transcription factors involved 
in the regulation of cell´s oxidative capacity, such as PPARδ (Gilde & Van Bilsen 2003). 
Animal (Hancock et al. 2008) as well as clinical studies (Bajaj et al. 2007) also support the 
role of fatty acids for PGC1 regulation at the level of gene expression. We and others have 
indicated that saturated fatty acids (e.g. palmitate) contribute to the regulation of 
metabolism by self-promoting their utilization via increased oxidative capacity of the 
skeletal muscle cell.  
In addition, dynamic interrelations of skeletal muscle and adipose tissue during exercise are 
necessary to support muscle performance and adipose tissue energy fluxes management. 
The transcriptional coactivator PGC1 has also been shown to regulate several exercise-
associated aspects of muscle function. It could be hypothesized that this protein controls 
muscle plasticity, suppresses a broad inflammatory response and mediates the beneficial 
effects of exercise on metabolic health (Handschin and Spiegelman 2008).  
4.2.5 Caloric restriction induces mitochondrial biogenesis in skeletal muscle 
Caloric restriction is a non-genetic manipulation that results in the lifespan extension of 
many different species, from yeasts to dogs, and even primates, and it is accompanied by 
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delayed onset of chronic civilization diseases (Ball et al. 1947; Anderson et al. 2009). There 
are also hints that people who eat a calorie-restricted diet might live longer than those 
who overeat. People living in Okinawa, Japan, have a lower energy intake than the rest of 
the Japanese population and an extremely long life span (Willcox et al. 2007). In addition, 
calorie-restricted diets beneficially affect several biomarkers of aging, including decreased 
insulin sensitivity. Based on combined favorable changes in lipid and blood pressure, 
caloric restriction with or without exercise induces weight loss and favorably reduces risk 
for cardiovascular disease even in healthy non-obese individuals (Lefevre et al. 2009) and 
ameliorates the age-related loss of muscle mass, sarcopenia, in a variety a species 
(Marzetti et al. 2009). But how might caloric restriction slow aging? Some of the theories 
behind the lifespan extending effect of caloric restriction include (i) decreased oxidative 
damage, (ii) altered glucose utilization, (iii) increased insulin sensitivity, (iv) 
neuroendocrine changes and (v) enhanced stress responsiveness (Allard et al. 2009). 
Reduction of oxidative damage to proteins, lipids, and DNA is one of the leading theories, 
although the underlying mechanisms of this process are unclear. Cellular nutrient sensing 
systems seem to mediate many of the metabolic responses to caloric restriction, including 
the regulation of free radical production and oxidative stress. Mitochondria are the major 
consumers of cellular oxygen (~85%) and the predominant production site of free radicals, 
a by-product of oxidative phosphorylation. Studies in mammals have shown that caloric 
restriction reduces the generation of free radicals by mitochondria, in parallel to 
reductions in mitochondrial proton leak and whole-body energy expenditure. 
Paradoxically, caloric restriction induces mitochondrial proliferation in rodents (Lanza & 
Nair 2010), and either lowers (Handschin & Spiegelman 2008) or does not affect 
mitochondrial oxygen consumption (Lanza & Nair 2010). Low mitochondrial content 
seems to contribute to increased ROS production. When mitochondrial mass is reduced, 
mitochondria have increased “workload,” leading to higher membrane potential and 
increased ROS production (Handschin & Spiegelman 2008; Lanza & Nair 2009; Lanza & 
Nair 2010). It has also been demonstrated that caloric restriction is strongly associated 
with an increased level and activation of sirtuins, namely the Sir2 histone deacetylase and 
its mammalian ortholog Sirt1. Sirtuins are members of the silent information regulator 2 
(Sir2) family, a family of Class III histone/protein deacetylases. The enzymatic activity of 
most sirtuins has been shown to be dependent on nicotinamide dinucleotide, suggesting 
that the activity of these enzymes is dependent on the nutritive state of the organism 
(Allard et al. 2009). Specific Sirt1 activation mimics low energy levels and protects against 
diet-induced metabolic disorders by enhancing fat oxidation (Feige et al. 2008). PGC1α is 
a transcriptional coactivator playing a pivotal role in the regulation of mitochondrial 
biogenesis, which is known to be induced in response to exercise and caloric restriction 
(Fig. 8.). Research strongly supports the health benefits of exercise in humans of all ages. 
Increased exercise in the absence of other behavioral changes prevents the onset of many 
chronic diseases (Elbekai & El-Kadi 2005).  
In our study we showed that short-term caloric deficit (caloric restriction with or without 
exercise) coordinately up-regulated the expression of genes involved in mitochondrial 
biogenesis in skeletal muscle resulting in increased mitochondrial content, improved whole 
body energy efficiency, and decreased DNA fragmentation in non-obese humans (Civitarese 
et al. 2007). Our results suggest that caloric restriction induces biogenesis of “efficient” 
mitochondria as an adaptive mechanism, which in turn lowers oxidative stress.  
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and/or function in the prediabetic state. Interestingly and in accordance with our results, it 
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Fig. 9. The free radical theory of aging posits that a senescent phenotype is induced by 
accumulation of oxidative damage resulting from reactive oxygen species. Exercise and 
caloric restriction (CR) are two interventions that induce mitochondrial biogenesis through 
PGC-1α. Although exercise and CR increase average life expectancy by protecting against 
age-related comorbidities, only CR has been shown to increase maximal life span; an effect 
that seems to require the activation of sirtuins (Lanza & Nair 2010).  
 
Fig. 10. Determinants of metabolic health and disease (Ukropec et al. 2008) 
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situations determines the overall metabolic health. Increased adipose tissue mass but mainly 
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phenotype, characteristic by extra-large unilocular adipocytes, further promotes tissue 
hypoxia and development of chronic persistent inflammation and metabolic stress. 
Pathogenic modification of the adipocyte modulates its metabolic, secretory and 
immunologic function leading to the development of metabolic disease (Fig. 10.). Inactive 
skeletal muscle, overloaded with fat could also contribute to metabolic imbalance by 
switching the fiber type towards less oxidative (less insulin sensitive) fibers, by lack of anti-
inflammatory and insulin-sensitizing myokine production as well as by chronic 
inflammation associated with mitochondrial stress and stress of endoplasmic reticulum (Fig. 
10.). Our environment greatly modifies our metabolic health by means of dietary influences 
and exercise activity which together with pathologies associated with hyperlipidemia, 
chronic systemic hypoxia and tissue inflammation determines adipose tissue and skeletal 
muscle metabolic and secretory phenotype and subsequently our metabolic health.  
It is generally accepted that regular physical activity prevents metabolic and cardiovascular 
disease development, and supports healthy aging. Skeletal muscle has been shown to 
produce and secrete several bioactive factors (hormones) termed “myokines”. Different 
spectra of myokines originating from either active ”trained” or inactive “sedentary” skeletal 
muscles elicit distinct adaptive changes in immune system, metabolic balance and processes 
of cellular growth and differentiation in order to maintain the whole body homeostasis. This 
requires extensive communication of skeletal muscle with many different cells and organs 
but the nature of mechanisms that tie muscle activity to metabolic health is not completely 
understood. It seems to be essential (i) to identify myokines differentially expressed and 
secreted from muscle cells derived from healthy and obese individuals, and individuals 
with type 2 diabetes; to (ii) determine basic principles of the muscle cross-communication 
with adipocytes (differentiation) and endothelial cells (angiogenesis) in fostering tissue 
plasticity necessary for adaptation to obesity and type 2 diabetes; and (iii) to discover novel 
myokines and to investigate their physiological significance in cell culture models and in 
vivo in genetically modified animal models as well as in humans. Myokines may be involved 
in mediating the health beneficial effects of exercise and play important roles in the 
protection against chronic diseases associated with low-grade inflammation, insulin 
resistance, hyperlipidemia, such as cardiovascular disease, type-2-diabetes, and cancer. 
Extension of the knowledge on the mechanisms whereby regular exercise offers protection 
against chronic diseases in combination with clinical research serves as a foundation for the 
development of public health guidelines with regard to exercise. Moreover, identification of 
new myokines and understanding basic principles and mechanisms of their action will 
potentially provide pharmacological targets for the treatment of metabolic and 
cardiovascular disorders. 
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High density lipoprotein (HDL) is a macromolecular complex of proteins and lipids that is 
produced primarily by the liver through a complex pathway that requires initially the 
functions of apolipoprotein A-I (apoA-I), ATP binding cassette transporter A1 (ABCA1) 
and lecithin:cholesterol acetyl transferase (LCAT) (Zannis et al., 2006b). Following 
synthesis, HDL affects the functions of the arterial wall cells through signaling 
mechanisms mediated by scavenger receptor class B type-I (SR-BI) and other cell surface 
proteins. The impetus for studying HDL has been the inverse correlation that exists 
between plasma HDL levels and the risk for coronary artery disease (CAD) (Gordon et al., 
1989). HDL promotes cholesterol efflux (Gu et al., 2000; Nakamura et al., 2004), prevents 
oxidation of low density lipoprotein (LDL) (Navab et al., 2000a; Navab et al., 2000b), 
inhibits expression of proinflammatory cytokines by macrophages (Okura et al., 2010) as 
well as expression of adhesion molecules by endothelial cells (Cockerill et al., 1995; 
Nicholls et al,. 2005b). HDL inhibits cell apoptosis (Nofer et al., 2001) and promotes 
endothelial cell proliferation and migration (Seetharam et al., 2006). HDL stimulates 
release of nitric oxide (NO) from endothelial cells thus promoting vasodilation (Mineo et 
al., 2003). HDL also inhibits platelet aggregation and thrombosis (Dole et al., 2008) and 
has antibacterial, antiparasitic and antiviral activities (Parker et al., 1995; Singh et al., 1999; 
Vanhollebeke and Pays, 2010). Due to these properties HDL is thought to protect the 
endothelium and inhibit several steps in the cascade of events that lead to the 
pathogenesis of atherosclerosis and various other human diseases.  
This review focuses on two important aspects of contemporary HDL research. The first 
part considers briefly the structure of apoA-I and HDL and the key proteins that 
participate in the pathway of the biogenesis of HDL as well as clinical phenotypes 
associated with HDL abnormalities. The second part considers various physiological 
functions of HDL and apoA-I and the protective role of HDL against atherosclerosis and 
other diseases.  
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synthesis, HDL affects the functions of the arterial wall cells through signaling 
mechanisms mediated by scavenger receptor class B type-I (SR-BI) and other cell surface 
proteins. The impetus for studying HDL has been the inverse correlation that exists 
between plasma HDL levels and the risk for coronary artery disease (CAD) (Gordon et al., 
1989). HDL promotes cholesterol efflux (Gu et al., 2000; Nakamura et al., 2004), prevents 
oxidation of low density lipoprotein (LDL) (Navab et al., 2000a; Navab et al., 2000b), 
inhibits expression of proinflammatory cytokines by macrophages (Okura et al., 2010) as 
well as expression of adhesion molecules by endothelial cells (Cockerill et al., 1995; 
Nicholls et al,. 2005b). HDL inhibits cell apoptosis (Nofer et al., 2001) and promotes 
endothelial cell proliferation and migration (Seetharam et al., 2006). HDL stimulates 
release of nitric oxide (NO) from endothelial cells thus promoting vasodilation (Mineo et 
al., 2003). HDL also inhibits platelet aggregation and thrombosis (Dole et al., 2008) and 
has antibacterial, antiparasitic and antiviral activities (Parker et al., 1995; Singh et al., 1999; 
Vanhollebeke and Pays, 2010). Due to these properties HDL is thought to protect the 
endothelium and inhibit several steps in the cascade of events that lead to the 
pathogenesis of atherosclerosis and various other human diseases.  
This review focuses on two important aspects of contemporary HDL research. The first 
part considers briefly the structure of apoA-I and HDL and the key proteins that 
participate in the pathway of the biogenesis of HDL as well as clinical phenotypes 
associated with HDL abnormalities. The second part considers various physiological 
functions of HDL and apoA-I and the protective role of HDL against atherosclerosis and 
other diseases.  
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2. Biogenesis of HDL  
HDL is synthesized through a complex pathway (Zannis et al., 2004a). The first step 
involves an ABCA1 mediated transfer of cellular phospholipids and cholesterol to lipid poor 
apoA-I extracellularly. The lipidated apoA-I is gradually converted to discoidal particles 
that are remodelled in the plasma compartment by the esterification of cholesterol by the 
enzyme LCAT (Zannis et al., 2006a) and are converted to spherical HDL particles. The 
cholesteryl esters formed are transferred to very low-density lipoproteins/intermediate-
density lipoproteins/low density lipoproteins (VLDL/IDL/LDL) by the cholesteryl ester 
transfer protein (CETP) (Barter et al., 2003). Additional remodelling of HDL involves 
transfer of phospholipids from VLDL/LDL to HDL by the phospholipid transfer protein 
(PLTP) (Lusa et al., 1996), cholesterol efflux from cells or delivery of cholesteryl esters to 
cells mediated by the SR-BI (Krieger, 2001) as well as cholesterol efflux mediated by the cell 
surface transporter ATP binding cassette transporter G1 (ABCG1) (Wang et al., 2004). 
Finally hydrolysis of lipids of HDL is mediated by various lipases [lipoprotein lipase (LpL), 
hepatic lipase (HL), endothelial lipase (EL)] (Breckenridge et al., 1982; Brunzell and Deeb, 
2001; Ishida et al., 2003; Krauss et al., 1974). Mutations in any of these proteins may affect 
the biogenesis, maturation and the functions of HDL (Fig. 1). 
 
 
Fig. 1. Schematic representation of the pathway of the biogenesis and catabolism of HDL 
Numbers 1-11 indicate key cell membrane or plasma proteins shown to influence HDL 
levels or composition as follows: 1) apoA-I; 2) ABCA1; 3) LCAT; 4) CETP; 5) HL; 6) EL; 7) 
PLTP; 8) lipoproteins lipase; 9) SR-BI; 10) LDL receptor; 11) ABCG1. The figure is modified 
from ref. (Zannis et al., 2004b; Zannis et al., 2006b). 
3. Proteins involved in the biogenesis, remodeling and signaling of HDL 
3.1 Apolipoprotein A-I and its structure in solution and in discoidal and spherical HDL 
ApoA-I is synthesized by the liver and the intestine in humans (Williamson et al., 1992) and it 
is the major protein component of the HDL. ApoA-I along with several other proteins 
participate in the biogenesis and remodeling of HDL as well as in signaling pathways induced 
by apoA-I and HDL (Yuhanna et al., 2001; Zannis et al., 2004a). ApoA-I contains 22 or 11 
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amino acid repeats which are organized in amphipathic a-helices (Nolte and Atkinson, 1992). 
Based on the crystal structure of apoA-I in solution (Borhani et al., 1997) a belt model was 
proposed to explain the structure of apoA-I on discoidal HDL particles. In this model, two 
antiparallel molecules of apoA-I are wrapped like a belt around a discoidal bilayer containing 
160 phospholipid molecules and shields the hydrophobic fatty acid chains of the 
phospholipids. Analysis of the 93 Å spherical HDL in solution by small angle neutron 
scattering (SANS) showed that three molecules of apoA-I fold around a central lipid core that 
has 88.4 Å x 62.8 Å dimensions to form a spheroidal HDL (sHDL) particle (Wu et al., 2011). 
3.2 Interactions of ApoA-I with ABCA1 are the first step in the biogenesis of HDL  
ABCA1 is a ubiquitous protein that belongs to the ABC family of transporters and is 
expressed abundantly in the liver, macrophages, brain and various other tissues (Kielar et 
al., 2001). ABCA1 was shown to promote the efflux of cellular phospholipids and cholesterol 
to lipid free or minimally lipidated apoA-I and other apolipoproteins and amphipathic 
peptides, but it does not promote efflux to spherical HDL particles (Remaley et al., 2001; 
Wang et al., 2000). The functional interactions between apoA-I and ABCA-1 are important 
for the biogenesis of HDL. In the abscence of either apoA-I (Matsunaga et al., 1991) or 
ABCA-1 (Brunham et al., 2006) HDL is not formed. Adenovirus mediated gene transfer of 
apoA-I mutants in apoA-I-/- mice showed that deletion of the C-terminal region of apoA-I 
prevented the formation of HDL (Chroni et al., 2007). The ability of ABCA1 to promote 
cholesterol efflux from macrophages is very important for the prevention of formation of 
foam cells in the atherosclerotic lesions (Van Eck et al., 2002). Mutations resulting in 
inactivation of ABCA1 are present in patients with Tangier disease (Brunham et al., 2006). 
The deficiency is associated with very low levels of total plasma and HDL cholesterol and 
abnormal lipid deposition in various tissues (Christiansen-Weber et al., 2000; McNeish et al., 
2000). The ABCA1 deficiency in humans or experimental animals may contribute to 
accelerated atherosclerosis (Joyce et al., 2002; Singaraja et al., 2003). Inactivation of the 
ABCA1 gene in macrophages increases the susceptibility to atherosclerosis (Van Eck et al., 
2002; Van Eck et al., 2006). Specific amino acid substitutions found in the Danish general 
population were predictors of ischemic heart disease and reduced life expectancy (Frikke-
Schmidt et al., 2008). 
3.3 Interactions of lipid-bound ApoA-I with LCAT stabilize the nascent HDL  
Plasma LCAT is a 416 amino acid long enzyme that is synthesized and secreted by the liver 
and esterifies the free cholesterol of HDL and LDL. ApoA-I is a potent activator of LCAT 
(Fielding et al., 1972). Following esterification, the cholesteryl esters formed become part of 
the lipid core and the discoidal HDL is converted to mature spherical HDL (Chroni et al., 
2005a). 
Mutations in LCAT are associated with two phenotypes in humans. The familiar LCAT 
deficiency (FLD) is characterized by the inability of the mutant LCAT to esterify cholesterol 
on HDL and LDL and causes accumulation of discoidal HDL in the plasma. The fish eye 
disease (FED) is characterized by the inability of mutant LCAT to esterify cholesterol on 
HDL only. Both diseases are characterized by low HDL levels due to the inability of LCAT 
to convert the nascent immature pre-β and discoidal particles to mature spherical HDL 
(Santamarina-Fojo et al., 2001).  
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3.4 Interactions of lipid-bound ApoA-I with SR-BI 
SR-BI is an 82 kDa membrane glycoprotein primarily expressed in the liver, steroidogenic 
tissues and endothelial cells but is also found in other tissues. The most important 
property of SR-BI is considered to be its ability to act as the HDL receptor (Acton et al., 
1996). SR-BI mediates both selective uptake of cholesteryl esters and other lipids from 
HDL to cells (Acton et al., 1996; Stangl et al., 1999; Thuahnai et al., 2001), as well as efflux 
of unesterified cholesterol (Gu et al., 2000). Transgenic mice expressing SR-BI in the liver 
had greatly decreased apoA-I and HDL levels as well as increased clearance of VLDL and 
LDL (Ueda et al., 1999) and were protected from atherosclerosis (Arai et al., 1999). SR-BI 
deficient mice had decreased HDL cholesterol clearance (Out et al., 2004), two fold 
increased plasma cholesterol and presence of large size abnormal apolipoprotein E (apoE) 
enriched particles that were distributed in the HDL/IDL/LDL region (Rigotti et al., 1997). 
The SR-BI deficiency in the background of LDL receptor (LDLr) deficient or apoE 
deficient mice accelerated dramatically the development of atherosclerosis (Huszar et al., 
2000; Trigatti et al., 1999). The double deficient mice for apoE and SR-BI developed 
occlusive coronary atherosclerosis, cardiac hypertrophy, myocardial infarctions, cardiac 
dysfunction and died prematurely (mean age of death ~6 weeks) (Braun et al., 2002; 
Trigatti et al., 1999). The SR-BI deficiency reduced greatly cholesteryl ester levels in the 
steroidogenic tissues that utilize HDL cholesterol for synthesis of steroid hormones (Ji et 
al., 1999). It also decreased secretion of biliary cholesterol by approximately 50% 
(Mardones et al., 2001; Rigotti et al., 1997). The SR-BI deficiency also caused defective 
maturation of oocytes and red blood cells due to accumulation of cholesterol in the 
plasma membrane of progenitor cells (Holm et al., 2002; Trigatti et al., 1999) and caused 
infertility in the female but not the male mice (Trigatti et al., 1999; Yesilaltay et al., 2006). 
Interactions of HDL with SR-BI in endothelial cells triggers signaling mechanisms 
discussed below that involve activation of endothelial nitric oxide synthase (eNOS) and 
release of NO that causes vasodilation (Mineo et al., 2003; Yuhanna et al., 2001). Human 
subjects have been identified with a P297S substitution in SR-BI. Heterozygote carriers for 
this mutation had increased HDL levels, decreased adrenal stereoidogenesis and 
dysfunctional platelets but did not develop atherosclerosis (Vergeer et al., 2011).  
A [Gly2Ser]SR-BI substitution in humans is associated with decreased follicular 
progesterone levels in Caucasian women and non viable fetuses 42 days post embryo 
transfer. Another single nucleotide polymorphism (SNP) (rs10846744) was associated with 
gestational sacs and fetal heart beats and with poor fetal viability in African-American 
women (Yates et al., 2011). 
3.5 Interactions of HDL with ABCG1 
ABCG1 is a 67 kDa protein which is a member of ABC family of half transporters. ABCG1 
is expressed in the spleen, thymus, lung, brain, endothelial cells and other tissues (Savary 
et al., 1996) and promotes cholesterol efflux from cells to HDL but not to lipid free apoA-I 
(Nakamura et al., 2004; Vaughan and Oram, 2005). The absence of ABCG1 in mice causes 
cholesterol accumulation in various tissues (Kennedy et al., 2005) and selective deletion of 
both ABCA1 and ABCG1 genes in macrophages further increases cholesterol 
accumulation and results in severe atherosclerosis (Out et al., 2008; Yvan-Charvet et al., 
2007). 
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4. Phenotypes of humans and experimental animals having apoA-I mutations 
4.1 Natural apoA-I mutations 
Several apoA-I mutations have been described in the general population that are associated 
with low plasma HDL levels. Most of the mutations affect the interaction of apoA-I with 
LCAT. Eight mutations between residues 26 and 107 and one on residue 173, have been 
associated with amyloidosis and low HDL levels (Sorci-Thomas and Thomas, 2002; Zannis 
et al., 1993) and one mutation on residue 164 is associated with increased risk for ischemic 
heart disease and reduced life expectancy (Haase et al., 2011). The in vivo interactions of 
representative naturally occurring apoA-I mutants with LCAT were studied by adenovirus-
mediated gene transfer in apoA-I deficient mice. The mutants apoA-I(Leu141Arg)Pisa and 
apoA-I(Leu159Arg)FIN produced only small amounts of HDL that formed mostly preβ1 and 
small size α4 HDL particles. The apoA-I(Arg151Cys)Paris and apoA-I(arg160Leu)Oslo formed 
discoidal HDL particles. These studies indicated that apoA-I(Leu141Arg)Pisa and apoA-
I(Leu159Arg)FIN mutation may inhibit an early step in the biogenesis of HDL due to 
insufficient esterification of the cholesterol of the preβ1-HDL particles by the endogenous 
LCAT. The LCAT insufficiency appears to result from depletion of the plasma LCAT mass 
(Koukos et al., 2007). A remarkable finding of these studies was that all the aberrant 
phenotypes were corrected by treatment with exogenous LCAT. This indicates that LCAT 
administration could be a potential therapeutic intervention to correct low-HDL conditions 
in humans that are caused by these and other unidentified mutations (Amar et al., 2009). 
4.2 Specific bioengineered mutations in ApoA-I may cause dyslipidemia 
Four bioengineered mutations in apoA-I have been studied by adenovirus-mediated gene 
transfer in apoA-I deficient mice. Mutants apoA-I[Δ(62-78)], apoA-I [Glu110Ala/Glu111Ala] 
and apoA-I[Asp89Ala/Glu90Ala/Glu92Ala], caused combined hyperlipidemia, 
characterized by elevated plasma cholesterol and severe hypertriglyceridemia (Chroni et al., 
2004; Chroni et al., 2005b; Kateifides et al., 2011). An apoA-I[Δ89-99] mutant induced high 
plasma cholesterol, but did not affect plasma triglyceride levels (Chroni et al., 2005b).  
 
 
Fig. 2. The pathway of HDL biogenesis and functions of HDL. a-e represent sites of possible 
disruption of the HDL biogenesis pathway. Different subpopulations of HDL that have been 
generated due to these defects may have different functions. 
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The systematic study of the functions of apoA-I by adenovirus mediated gene transfer as 
well as the phenotypes of naturally occurring apoA-I mutants identified the following five 
steps where the pathway of biogenesis and/or catabolism of HDL can be disrupted: a) Lack 
of synthesis of HDL due to mutations in ABCA1 or mutations in apoA-I that affect the 
ABCA1/apoA-I interaction, b) Failure to convert efficiently the lipidated pre-β HDL to 
discoidal HDL. This defect most likely results from fast catabolism of apoA-I following its 
lipidation by ABCA1, c) Accumulation of discoidal HDL. This phenotype has been 
generated by the mutations in the 149-160 region of apoA-I that affect LCAT activation, d) 
Accumulation of discoidal HDL and induction of hypercholesterolemia. This condition has 
been observed in the case of the apoA-I[Δ(89-99)] mutant, e) Induction of 
hypertriglyceridemia. This defect has been observed in the case of apoA-I[Δ(62-78)], apoA-
I[Glu110Ala/Glu111Ala] and apoA-I[Asp89Ala/Glu90Ala/Glu92Ala] mutants (Fig. 2). 
5. Physiological functions of ApoA-I and HDL that may be relevant to its 
atheroprotective properties 
5.1 Cell signaling pathways mediated by HDL and apoA-I 
Various studies have shown that increased HDL levels are associated with greater 
vasodilator effects in humans and this effect is impaired in patients with coronary heart 
disease (CHD) (Li et al., 2000; Zeiher et al., 1994). Treatment with HDL increased eNOS 
protein levels in cultured human aortic endothelial cells (HAECs) (Ramet et al., 2003). Other 
studies in endothelial cells and Chinese hamster ovary (CHO) cells that express SR-BI, 
showed that SR-BI-HDL interactions lead to the phosphorylation and activation of eNOS. 
The HDL-induced eNOS activation occurs in the caveolae. The HDL-mediated NO-
dependent relaxation is lost in aortic rings of SR-BI-/- mice (Yuhanna et al., 2001). 
Experiments in cultures of endothelial cells and COS M6 cells transfected with eNOS and 
SR-BI showed that interaction of HDL with SR-BI triggered signalling mechanisms which 
led to phosphorylation of eNOS at Ser1179 and increased its activity. On the other hand 
phosphorylation of Thr 497 of eNOS attenuated its activity. The signalling cascade initially 
involves the nonreceptor tyrosine kinase Src which phosphorylated PI3 kinase (PI3K). 
Inhibition of Src by specific inhibitors prevented eNOS phosphorylation. PI3K activation led 
to phosphorylation of Akt and mitogen-activated protein kinase (MAPK) which 
independently phosphorylated eNOS. Inhibitors of MAPK did not affect HDL-mediated Akt 
activation and a dominant negative Akt did not affect HDL-mediated MAPK activation and 
eNOS phosphorylation (Mineo et al., 2003) (figure 3A). 
The mechanism of the SR-BI mediated activation of eNOS was studied in detail (Assanasen 
et al., 2005). HDL and cholesterol-free reconstituted HDL (rHDL) particles containing apoA-
I and phosphatidylocholine (Lp2A-I) as well as cyclodextrin stimulated eNOS activity 
whereas rHDL particles that contain cholesterol did not. Blocking of cholesterol efflux with 
a monoclonal antibody to SR-BI abolished the activation of eNOS. Experiments were 
performed using SR-BII, a splice variant of SR-BI as well as a SR-BI mutant that lacks the 
carboxyterminal amino acid 509 [SR-BI(Δ509)] and chimeric receptors where the 
transmembrane and the C-terminal domains of SR-BI were replaced by the corresponding 
domains of CD36. These studies established that the C-terminal cytoplasmic PDZ-
interacting domain and the C-terminal transmembrane domain of SR-BI were both required 
for eNOS activation (Assanasen et al., 2005). The cytoplasmic PDZK1 interacting domain of 
SR-BI binds adaptor proteins such as PDZK1 that may participate in cell signalling (Kocher 
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et al., 2003). A photoactive derivative of cholesterol binds in the transmembrane region of 
SR-BI indicating that this region serves as a cholesterol sensor on the plasma membrane 
(Assanasen et al., 2005). HDL and lysophospholipids that are components of HDL including 
sphingosylphosphorylcholine, sphingosine-1-phospate (S1P) and lysosulphatide cause 
eNOS dependent relaxation of mouse aortic rings via intracellular Ca2+ mobilization and 
eNOS phosphorylation mediated by Akt (Nofer et al., 2004). Another study however, 
indicated that interactions of HDL with SR-BI stimulate eNOS by increasing intracellular 
ceramide levels without affecting intracellular calcium levels and Akt phosphorylation (Li et 
al., 2002). The proposed role of HDL-associated estradiol in the stimulation of eNOS activity 
is unclear (Gong et al., 2003). 5’ AMP-activated protein kinase (AMPK) may also play a role 
in the HDL-mediated phosphorylation of eNOS at multiple sites (Ser116, Ser635, and 
Ser1179) (Drew et al., 2004). It was suggested that activation by AMPK may involve physical 
interactions between the apoA-I component of HDL and eNOS. Such interactions may be 
possible following SR-BI mediated endocytosis of HDL (Silver et al., 2001). HDL also 
affected the signaling in endothelial cells by the bone morphogenetic protein 4 (BMP4) and 
increased expression of the activin-like kinase receptor 1 and 2 (Yao et al., 2008). This 
resulted in increased expression of vascular endothelial growth factor (VEGF) and matrix 
gla protein (MGP). VEGF promotes endothelial cell survival and MGP prevents vascular 
calcification and thus contribute to the maintenance, the integrity and the preservation of 
the functions of the endothelium (Yao et al., 2008). 
 
 
Fig. 3. A) Schematic representation of SR-BI signaling that can lead to vasodilation, cell 
migration and inhibition of inflammation and apoptosis. B) Schematic representation of 
PKC-dependent SR-BI-dependent signalling pathway that promote cell proliferation (Drew 
et al., 2004; Grewal et al., 2003; Kimura et al., 2003; Mineo et al., 2003). 
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The systematic study of the functions of apoA-I by adenovirus mediated gene transfer as 
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dependent relaxation is lost in aortic rings of SR-BI-/- mice (Yuhanna et al., 2001). 
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domains of CD36. These studies established that the C-terminal cytoplasmic PDZ-
interacting domain and the C-terminal transmembrane domain of SR-BI were both required 
for eNOS activation (Assanasen et al., 2005). The cytoplasmic PDZK1 interacting domain of 
SR-BI binds adaptor proteins such as PDZK1 that may participate in cell signalling (Kocher 
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5.2 Effect of HDL and apoA-I on inflammation 
An initial step in the pathogenesis of atherosclerosis is the association of the monocytes to 
adhesion molecules of the endothelial cells that facilitates their entry in the sub-endothelial 
space (Zannis et al., 2004b). Induction of adhesion molecules is promoted by pro-
inflammatory stimuli (Cybulsky and Gimbrone, Jr., 1991). Recruitment and migration of 
monocytes into sub-endothelial space is promoted by the monocyte chemoattractant factor 
(MCP-1) as well as by oxidized LDL (Peters and Charo, 2001). HDL has anti-oxidant 
properties and can prevent the oxidation of LDL (Navab et al., 2000a; Navab et al., 2000b). 
Interactions of HDL or apoA-I with cells of the vascular wall were shown to prevent the 
expression of pro-inflammatory cytokines and chemokines that induce the expression of 
adhesion molecules (Bursill et al., 2010; Cockerill et al., 1995; Nobecourt et al., 2010). The 
anti-inflammatory functions of HDL were manifested in several ways. HDL binds via its 
apoA-I moiety to progranulin produced by macrophages. This prevents conversion of 
progranulin to inflammatory granulins which were shown to induce expression of tumor 
necrosis factor α (TNFα) and interleukin (IL) 1β in monocyte macrophages (Okura et al., 
2010). HDL and rHDL were shown to inhibit the cytokine induced expression of vascular 
cell adhesion molecule-1 (VCAM-1) and inter-cellular adhesion molecule-1 (ICAM-1) by 
endothelial cells (Cockerill et al., 1995). In addition, HDL promoted the expression of anti-
inflammatory cytokines in endothelial cells. Thus treatment of endothelial cells (HUVEC) 
with HDL and lysosphingolipids present in HDL, increased the expression of TGF-β2 
through mechanisms that involve the activation of Akt and extracellular signal regulated 
kinases (ERK) 1/2. Consistent with cell culture studies, the expression of transforming 
growth factor-β2 (TGF-β2) and the phosphorylation of ERK1/2, Akt and Smad2/3 were 
increased in apoA-I transgenic mice and diminished in apoA-I deficient mice (Norata et al., 
2005). In vivo studies also showed that infusion of rHDL inhibited the pro-oxidant and pro-
inflammatory events that occurred following implantation of non occlusive periarteral 
collars in rabbits that induce acute arterial inflammation. In these studies the rHDL 
inhibited neutrofil infiltration, production of reactive oxygen species (ROS) and the 
expression of VCAM-1, ICAM-1, MCP-1 and E-selectin (Nicholls et al., 2005b). The carotid 
vascular inflammation and neutrofil infiltration could be inhibited by rHDL containing 
normal apoA-I but not by apoA-I obtained from diabetic patients (Nobecourt et al., 2010). 
The beneficial effects of rHDL containing apoA-I in vivo and in cell cultures could be 
duplicated using synthetic apoA-I mimetics such as 5A, L37pA and D37pA (Gomaraschi et 
al., 2008; Tabet et al., 2010). The 5A/PLPC complexes reduced the vascular inflammation 
that is associated with collar insertion in a rabbit model by reducing the ICAM-1 and 
VCAM-1 expression, the infiltration of neutrofils and the Nox4 activity. In cultures of 
human carotid endothelial cells (HCEC) 5A/PLPC and rHDL containing apoA-I inhibited 
the TNF-α induced VCAM-1 and ICAM-1 expression as well as the activation of  
nuclear factor κB (NF-κΒ) pathway and these effects were abolished by ABCA1 silencing  
(Tabet et al., 2010). Complexes of L37pA or D37pA with β-oleoyl-γ-palmitoyl-L-α-
phosphatidylcholine reduced the postischemic cardiac contractile dysfunction in a rat heart 
model of ischemia/reperfusion. They also reduced TNF-α levels and increased prostacyclin 
levels in the perfusate and inhibited the TNF-α mediated VCAM-1 expression in endothelial 
cell cultures (Gomaraschi et al., 2008). In monocyte and endothelial cell cultures HDL also 
suppressed expression of chemokines CCL2, CCL5 and CX3CL1 and chemokine receptors 
CCR2, CCR5 and CX3CR1 (Bursill et al., 2010). This effect was mediated by inhibition of Iκ-
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Bα phosphorylation and NF-κB(p65) expression and in some cases by peroxisome 
proliferator-activated receptor γ (PPARγ) activation. Consistent with cell culture studies, in 
vivo infusion of apoA-I in cholesterol fed apoE deficient mice reduced expression of 
chemokines and chemokine receptors (Bursill et al., 2010). HDL and its protein moiety 
apoA-I have been shown to inhibit the expression of CD11b of human monocytes that is 
induced by phorbol myristate acetate (PMA) and promote cell adhesion. Inhibition of the 
ABCA1-mediated and to a lesser extent SR-BI mediated cholesterol efflux by monoclonal 
antibodies attenuated the inhibitory effect of apoA-I and HDL respectively. Expression of 
CD11b was also affected by depletion of the membrane cholesterol by treatment of the cells 
with cyclodextrin (Murphy et al., 2008), pointing out to a potential role of cholesterol efflux 
in the inhibition of inflammation. Consistent with the ex vivo studies infusion of rHDL in 
patients with type 2 diabetes mellitus, reduced the expression of CD11b of the peripheral 
monocytes and reduced the adhesion of the patients’ neutrophils to a fibrinogen matrix. 
Plasma HDL isolated 4 to 72 hours post rHDL infusion suppressed the expression of 
VCAM-1 in cultures of HAECs and had increased ability to promote cholesterol efflux from 
THP-1 macrophages (Patel et al., 2009). In cultures of smooth muscle cells, HDL 
downregulated the NADPH-oxidase mediated generation of reactive oxygen species (ROS) 
and inhibited production of MCP-1. The inhibitory effect was attenuated by antagonists of 
S1P1 and S1P3 receptors. The data showed that free S1P or S3P alone or as components of 
HDL could attenuate production of MCP-1. Consistent with these findings, MCP-1 
production and ROS generation in the aortas of S1P3-/- receptor and SR-BI-/- mice were not 
affected by treatment with HDL, S1P and sphingosylphosphorylcholine (SPC) (Tolle et al., 
2008). ApoA-I induced the expression of the adhesion molecule CD31, and changed the 
morphology and size distribution of lineage negative bone marrow cells. The treatment also 
increased the ability of the cells to bind to fibronectin and to cultured endothelial cells. 
Deletion of the C-terminal helix 10 of apoA-I abolished the effects of apoA-I on bone 
marrow cells (Mythreye et al., 2008). 
5.3 Effect of HDL and apoA-I on endothelial cell apoptosis 
Exposure of endothelial cells to inflammatory stimuli may disturb the endothelial 
monolayer integrity (Dimmeler et al., 2002). Numerous factors that promote endothelial 
apoptosis have been described and include OxLDL (Li et al., 1998), TNF-a (Dimmeler et al., 
1999), homocysteine (Welch and Loscalzo, 1998), and angiotensin II (Strawn and Ferrario, 
2002). HDL also can reverse the TNF-a induced and growth deprivation induced endothelial 
cell apoptosis (Nofer et al., 2001; Sugano et al., 2000). OxLDL increased intracellular calcium 
and resulted in apoptosis that could be inhibited by HDL and apoA-I (Suc et al., 1997). 
ApoA-I interacts with ABCA1 and F1-ATPase (Chroni et al., 2003; Vantourout et al., 2010), 
whereas HDL interacts with SR-BI and ABCG1 (Liadaki et al., 2000; Wang et al., 2004) 
respectively and the sphingolipid components of HDL interact with the S1P receptors 
(Kimura et al., 2003; Okajima et al., 2009). HDL protected endothelial cells from apoptosis 
induced by oxLDL by preventing the generation of intracellular ROS. The anti-apoptotic 
activity was highest for HDL3 and diminished as the size of HDL increased. It was 
suggested that approximately 70% of the anti-apoptotic activity of HDL was attributed to 
apoA-I which has the capacity to accept through its methionine residues the phospholipid 
hydroperoxides (PLOOH) of oxLDL (de Souza et al., 2010). The anti-apoptotic functions of 
small size HDL3 was reduced by 35% in subjects with metabolic syndrome and this 
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Bα phosphorylation and NF-κB(p65) expression and in some cases by peroxisome 
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reduction was correlated with the clinical phenotype of the human subjects. Compared to 
normal HDL the HDL3 fractions of the diabetic subjects had increased total triglyceride 
levels and decreased cholesteryl esters/triglycerides ratio suggesting that the lipid core of 
HDL3 was enriched with triglycerides (de Souza et al., 2008). HDL3 also inhibited apoptotic 
cell death induced by oxLDL and preserved lysosomal integrity of an osteoblastic cell line 
(Brodeur et al., 2008). The anti-apoptotic effects were attributed to the increased expression 
of SR-BI that is mediated by HDL3, combined with the ability of HDL to compete for the 
binding of oxLDL to osteoblasts as well as increased selective uptake of the cholesterol of 
the oxLDL by these cells (Brodeur et al., 2008). 
Interactions of apoA-I with cell surface F1-ATPase inhibited apoptosis of HUVEC and 
stimulated cell proliferation (Radojkovic et al., 2009). In the absence of apoA-I, specific 
inhibitors for F1-ATPase (IF1-H49K) and angiostatin or specific antibodies to F1-ATPase 
promoted apoptosis and inhibited cell proliferation. In the presence of apoA-I, F1-ATPase 
inhibitors and antibodies diminished its anti-apoptotic and anti-proliferative effects. Down-
regulation of the ABCA1 by siRNA did not affect the anti-apoptotic and proliferative 
functions of apoA-I whereas inhibition of SR-BI by a specific antibody diminished the anti-
apoptotic and proliferative functions of HDL3 (Radojkovic et al., 2009). The findings suggest 
that interactions of lipid free apoA-I with F1-ATPase and of HDL with SR-BI contribute to 
their anti-apoptotic and proliferative effects on endothelial cells. The antiapoptotic effects of 
HDL on endothelial cells could be mimicked by the lysosphingolipid components of HDL 
(Nofer et al., 2001). The SR-BI mediated signalling that leads to activation of eNOS, also 
promotes cell growth and migration and protects cells from apoptosis (Mineo et al., 2006; 
Noor et al., 2007). Activation of eNOS required its localization in the caveolae, where 
caveolin SR-BI and CD36 are also found (Uittenbogaard et al., 2000). It has been proposed 
that oxLDL acting through CD36 depletes the cholesterol content of caveolae and leads to 
eNOS redistribution to intracellular sites thus resulting in decreased eNOS activity (Blair et 
al., 1999; Uittenbogaard et al., 2000). HDL acting through SR-BI maintains the concentration 
of caveolae-associated cholesterol, inhibits the actions of oxLDL and maintains eNOS in the 
caveolae (Uittenbogaard et al., 2000). This interpretation implies that strong interactions 
between eNOS and caveolin-1 (Cav-1) stimulate eNOS activity. Other studies provided the 
opposite mechanism of modulation of eNOS activity by interactions of eNOS with Cav-1 
(Terasaka et al., 2010). It was shown that these interactions were enhanced by loading cells 
with cholesterol or oxysterols and decreased by cholesterol depletion in endothelial cells as 
a result of ABCG1-mediated cholesterol efflux. Studies in murine lung endothelial cells 
(MLEC) also showed that HDL could reverse the inhibition of eNOS activity caused by 
cholesterol loading in the normal but not the Cav-1 deficient cells (Terasaka et al., 2010). It 
was proposed that diminished interactions between eNOS and Cav-1 caused by ABCG1-
mediated efflux stimulated eNOS activity. It has been shown that oxidized phospholipids 
uncouple eNOS activity and lead to the generation of oxygen radicals which induces the 
expression of sterol regulatory element binding protein (SREBP) and IL-8 (Gharavi et al., 
2006; Yeh et al., 2004). ApoA-I mimetic peptides also prevent LDL from uncoupling eNOS 
activity to favour O2.- anion production as opposed to normal production of NO (Ou et al., 
2003). Finally it has been shown that SR-BI via a highly conserved redox motif CXXS 
between residues 323-326 can promote a ligant independent apoptosis via a caspase 8 
pathway and this effect could be reversed by HDL and eNOS (Li et al., 2005). It was 
proposed that at low HDL levels oxitative stress causes relocation of eNOS away from the 
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caveolae and this results in SR-BI induced apoptosis (Li et al., 2005). The picture that 
emerges from these studies is that HDL promotes survival and migration of endothelial cells 
by signalling mechanisms that originate from the interactions of HDL with SR-BI, the 
interactions of S1P with S1P1 and S1P3 receptors and the interactions of lipid-free apoA-I 
with F1-ATPase. 
5.4 Effect of HDL on endothelial cell proliferation and migration 
Damage of the endothelium is associated with vascular disease which can be blunted by re-
endothelialization (Werner et al., 2003). HDL promoted proliferation of HUVEC via 
mechanisms that increased intracellular Ca2+ and upregulated the production of 
prostacyclin (Tamagaki et al., 1996). HDL also promoted endothelial cell migration 
(Murugesan et al., 1994). Migration was promoted by signalling cascades mediated by 
interaction of S1P with S1P1 and S1P3 receptors that led to the activation of PI3 kinase, 
p38MAP kinase and Rho kinases (Kimura et al., 2003). Other studies showed that HDL can 
activate the MAPK pathway either through processes that involve protein kinase C (PKC), 
Raf-1, MEK and ERK1/2 or PKC independent pathways. This latter pathway leads to the 
activation of Ras and can be inhibited by pertussis toxin and neutralizing antibodies against 
SR-BI (Grewal et al., 2003). The data suggest that interactions of HDL with SR-BI activate 
Ras in a PKC independent manner and this leads to subsequent activation of MAPK 
signalling cascade (Grewal et al., 2003) (Fig.3B). Another beneficial effect of HDL is its 
capacity to promote capillary tube formation in vitro. This function is pertussis toxin 
sensitive and requires p44/42MAP kinase which is downstream of Ras (Miura et al., 2003). 
Other studies showed that interaction of SR-BI with HDL or rHDL, activated Src kinases 
and Rac GTPases and stimulated endothelial cell migration. In vivo experiments have also 
shown that re-endothelialization of carotid artery following injury is promoted by apoA-I 
expression and is inhibited in apoA-I deficient in mice (Seetharam et al., 2006). 
5.5 Effect of HDL on thrombosis 
Increased HDL cholesterol levels are associated with decreased risk of venous thrombosis 
(Doggen et al., 2004). In contrast low HDL levels are associated with increased risk of 
venous thrombosis (Deguchi et al., 2005). The ability of HDL to inhibit endothelial cell 
apoptosis (Dimmeler et al., 2002; Mineo et al., 2006) prevents vessel denudation and 
formation of microparticles that may contribute to thrombosis (Durand et al., 2004). It has 
been shown that thrombogenic membrane microparticles that may originate from apoptotic 
endothelial cells are increased in the plasma of patients with acute coronary syndrome 
(ACS) (Mallat et al., 2000). Infusion of rHDL in volunteers that received low levels of 
endotoxin limited the prothrombotic and procoagulant effect of endotoxin (Pajkrt et al., 
1997). Furthermore infusion of apoA-IMILANO in a rat model of acute arterial thrombosis 
increased the time of thrombus formation and decreased the weight of the thrombus (Li et 
al., 1999). HDL may affect thrombosis via a variety of mechanisms: Early studies showed 
that HDL causes increased synthesis of prostacyclin in cultured endothelial cells (Fleisher et 
al., 1983; Tamagaki et al., 1996). Prostacyclin in combination with NO promote smooth 
muscle cells relaxation, inhibit platelet activation and local smooth muscle cell proliferation 
(Vane and Botting, 1995). It has been reported that HDL3 induced expression of 
cyclooxygenase-2 (Cox-2) by smooth muscle cells and promoted release of prostacyclin 
(PGI2) via a signalling pathway that involves p38MAP kinase and c-Jun N terminal kinase 
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reduction was correlated with the clinical phenotype of the human subjects. Compared to 
normal HDL the HDL3 fractions of the diabetic subjects had increased total triglyceride 
levels and decreased cholesteryl esters/triglycerides ratio suggesting that the lipid core of 
HDL3 was enriched with triglycerides (de Souza et al., 2008). HDL3 also inhibited apoptotic 
cell death induced by oxLDL and preserved lysosomal integrity of an osteoblastic cell line 
(Brodeur et al., 2008). The anti-apoptotic effects were attributed to the increased expression 
of SR-BI that is mediated by HDL3, combined with the ability of HDL to compete for the 
binding of oxLDL to osteoblasts as well as increased selective uptake of the cholesterol of 
the oxLDL by these cells (Brodeur et al., 2008). 
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inhibitors and antibodies diminished its anti-apoptotic and anti-proliferative effects. Down-
regulation of the ABCA1 by siRNA did not affect the anti-apoptotic and proliferative 
functions of apoA-I whereas inhibition of SR-BI by a specific antibody diminished the anti-
apoptotic and proliferative functions of HDL3 (Radojkovic et al., 2009). The findings suggest 
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their anti-apoptotic and proliferative effects on endothelial cells. The antiapoptotic effects of 
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(Terasaka et al., 2010). It was shown that these interactions were enhanced by loading cells 
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cholesterol loading in the normal but not the Cav-1 deficient cells (Terasaka et al., 2010). It 
was proposed that diminished interactions between eNOS and Cav-1 caused by ABCG1-
mediated efflux stimulated eNOS activity. It has been shown that oxidized phospholipids 
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expression of sterol regulatory element binding protein (SREBP) and IL-8 (Gharavi et al., 
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caveolae and this results in SR-BI induced apoptosis (Li et al., 2005). The picture that 
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with F1-ATPase. 
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activation of Ras and can be inhibited by pertussis toxin and neutralizing antibodies against 
SR-BI (Grewal et al., 2003). The data suggest that interactions of HDL with SR-BI activate 
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endotoxin limited the prothrombotic and procoagulant effect of endotoxin (Pajkrt et al., 
1997). Furthermore infusion of apoA-IMILANO in a rat model of acute arterial thrombosis 
increased the time of thrombus formation and decreased the weight of the thrombus (Li et 
al., 1999). HDL may affect thrombosis via a variety of mechanisms: Early studies showed 
that HDL causes increased synthesis of prostacyclin in cultured endothelial cells (Fleisher et 
al., 1983; Tamagaki et al., 1996). Prostacyclin in combination with NO promote smooth 
muscle cells relaxation, inhibit platelet activation and local smooth muscle cell proliferation 
(Vane and Botting, 1995). It has been reported that HDL3 induced expression of 
cyclooxygenase-2 (Cox-2) by smooth muscle cells and promoted release of prostacyclin 
(PGI2) via a signalling pathway that involves p38MAP kinase and c-Jun N terminal kinase 
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(JNK-1) (Escudero et al., 2003; Vinals et al., 1997). PGI2 synthesis was enhanced by 
HMGCoA reductase inhibitors (Martinez-Gonzalez et al., 2004). It has been shown that there 
is a positive correlation between plasma HDL levels and anticoagulant response to activated 
protein C (APC)/protein S in vitro (Griffin et al., 1999) and negative correlation with the 
plasma thrombin activation markers such as prothrombin fragments F1.2 and D-dimer 
(MacCallum et al., 2000). APC inactivates, by proteolysis, factors Va and VIIIa in plasma and 
thus it can downregulate thrombin formation. Administration of HDL to cholesterol-fed 
rabbits also increased endothelial cell thrombomodulin levels, promoted generation of APC 
and inhibited formation of thrombin (Nicholls et al., 2005a). Glucosylceramide and 
glycosphingolipids which are present in HDL are lipid cofactors for the anticoagulant 
activity of APC and in a significant number of patients with venous thrombosis the levels of 
glucosylceramides are low (Deguchi et al., 2002; Deguchi et al., 2001). Shpingosine, another 
molecule present in HDL, has been shown to inhibit prothrombin activation on platelets’ 
surface by disrupting procoagulant interactions between factors Xa and Va (Deguchi et al., 
2004). HDL also downregulated expression of plasminogen activator inhibitor-1 (PAI-1) and 
upregulated tissue plasminogen activator (t-PA) in endothelial cell cultures (Eren et al., 
2002). Transgenic mice expressing the human PAI-1 developed age-dependent coronary 
arterial thrombosis (Eren et al., 2002). In contrast oxidized HDL3 induced the expression of 
PAI-1 in endothelial cells through signalling mechanisms that involve activation of ERK1/2 
and p38MAPK and mRNA stabilization (Norata et al., 2004).  
5.6 Effects of HDL on diabetes mellitus 
In vivo and in vitro studies have provided evidence that HDL may have beneficial effects on 
glucose metabolism (Koseki et al., 2009; Rutti et al., 2009). Ex vivo studies showed that HDL 
and delipidated apoA-I or S1P decreased IL-1β and glucose-mediated apoptosis and thus 
increased the survival of human and murine islets. HDL treatment down-regulated the 
expression of iNOS and its downstream target Fas which is pro-apoptotic and up-regulated 
the expression of FLICE-like inhibitory protein (FLIP) which is anti-apoptotic (Rutti et al., 
2009). HDL also reversed the toxic effects of oxidized LDL on beta cells that are associated 
with apoptosis and cJNK mediated transcriptional repression of the insulin gene caused 
cJNK mediated (Abderrahmani et al., 2007).  
Oral glucose tolerance test in a limited number of patients with Tangier disease (that lack or 
have dysfunctional ABCA1) showed that they had glucose intolerance as compared to 
controls (Koseki et al., 2009), thus implicating ABCA1, apoA-I and HDL in glucose 
metabolism. Cell culture studies using primary pancreatic islets cells and a pancreatic β-cell 
line (Min6), showed that lipid free apoA-I or apoA-II or reconstituted HDL increased insulin 
secretion up to 5-fold in a Ca2+ dependant manner (Fryirs et al., 2010). The free 
apolipoproteins also increased insulin mRNA levels. HDL mediated insulin secretion has 
also been observed in cultures of mouse pancreatic β-cells (MIN6N8) (Drew et al., 2009). The 
increase in insulin secretion mediated by lipid-free apoproteins and rHDL required the 
functions of ABCA1 and SRBI or ABCG1 respectively. These functions may be different 
from those involved in cholesterol efflux. For high glucose concentrations enhanced insulin 
secretion required the action of KATP channel and glucose catabolism in the pancreatic cell, 
but this did not occur for low glucose concentrations (Fryirs et al., 2010).  
Further insight on the role of ABCA1 in diabetes was obtained by studies in mice with 
selective deficiency of ABCA1 in the pancreas (ABCA1-P/-P). These mice accumulated 
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cholesterol in their islets and were characterized by impaired acute phase insulin secretion 
and glucose intolerance. The ABCA1-P/-P mice exhibited normal insulin sensitivity indicating 
normal response of the peripheral tissues to insulin. The impairment in insulin secretion 
was verified in cell culture experiments using islets isolated from the ABCA1-P/-P mice. In 
contrast, whole ABCA1 deficient mice had normal glucose tolerance and displayed only 
small impairment in the islet function and did not accumulate significant amount of 
cholesterol in the islets (Brunham et al., 2007). Pancreatic islets isolated from apoE deficient 
mice had increased cholesterol content and reduced insulin secretion as compared to islets 
obtained from WT mice. The reduced insulin secretion in the pancreatic islets or cultures of 
β-cells could be restored by depletion of the cellular cholesterol using mevastatin or methyl-
β-cyclodextrin (MβCD) (Hao et al., 2007). Experiments in cell lines of pancreatic β-cell origin 
indicated that cholesterol loading or cholesterol depletion affect the activity of glucokinase 
(GK) which is known to regulate insulin secretion (Rizzo and Piston, 2003). The experiments 
showed that under normal cholesterol levels GK is associated with a dimeric form of nNOS on 
insulin containing granules in the cytoplasm and is inactive (Rizzo and Piston, 2003). Increase 
in plasma cholesterol enhanced dimerization of nNOS and its association with GK whereas 
reduction in the cholesterol levels or increase in the extracellular glucose levels promoted 
monomerization of nNOS and release of active GK in the cytoplasm (Hao et al., 2007). The role 
of the increase in the cholesterol content of β-cells in insulin secretion was tested in transgenic 
mice expressing SREBP-2 in β-cells under the control of insulin promoter. These mice had 
normal plasma cholesterol levels but developed severe diabetes characterized by 5-fold 
increase in gluco-hemoglobin and defects in glucose and potassium-stimulated insulin 
secretion and were characterized by glucose intolerance. The islets were fewer, smaller and 
deformed and had increased levels of total and esterified cholesterol (Ishikawa et al., 2008). It 
was proposed that the loss of β-cell mass could be related to the down regulation of genes such 
as PDX-1 and BETA2 that are involved in β-cell differentiation.  
A recent comprehensive study has measured the properties of HDL isolated from patients 
with type 2 diabetes mellitus and their functions on endothelial cells in vitro and in vivo. 
HDL isolated from patients with low HDL and type 2 diabetes mellitus contained increased 
levels of lipid peroxides and increased myeloperoxidase activity. In endothelial cell cultures 
diabetic HDL had reduced production of NO and increased NADPH oxidase activity that 
resulted in increased oxidant stress. Diabetic HDL had diminished endothelium dependent 
relaxation of aortic rings and endothelial progenitor cells obtained from diabetic subjects 
had diminished capacity to promote reendothelialization in vivo. A remarkable finding in 
this study was that extended release niacin treatment of the diabetic patients restored the 
properties and functions of HDL. The HDL obtained after treatment had normal levels of 
peroxides and normal myeloperoxidase (MPO) activity. Studies with endothelial cultures 
showed that following treatment of the diabetic patients their HDL could induce normal NO 
production and NADPH oxidase activity and could promote normal relaxation of aortic 
rings. Endothelial progenitor cells obtained from diabetic patients following niacin 
treatment had normal ability to promote reendothelialization in vivo (Sorrentino et al., 
2010). In another study intravenous infusion of rHDL (80 mg/kg over 4 hours) in type 2 
diabetic human subjects decreased plasma glucose level, increased plasma insulin level and 
increased β-cell functions as compared to patients receiving placebo (Drew et al., 2009). 
HDL and apoA-I increased glucose uptake of primary human skeletal muscle cultures 
established from patients with type 2 diabetes mellitus. HDL induced glucose uptake and 
fatty acid oxidation and increased AMPKα2 activity and phosphorylation. These effects 
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(JNK-1) (Escudero et al., 2003; Vinals et al., 1997). PGI2 synthesis was enhanced by 
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is a positive correlation between plasma HDL levels and anticoagulant response to activated 
protein C (APC)/protein S in vitro (Griffin et al., 1999) and negative correlation with the 
plasma thrombin activation markers such as prothrombin fragments F1.2 and D-dimer 
(MacCallum et al., 2000). APC inactivates, by proteolysis, factors Va and VIIIa in plasma and 
thus it can downregulate thrombin formation. Administration of HDL to cholesterol-fed 
rabbits also increased endothelial cell thrombomodulin levels, promoted generation of APC 
and inhibited formation of thrombin (Nicholls et al., 2005a). Glucosylceramide and 
glycosphingolipids which are present in HDL are lipid cofactors for the anticoagulant 
activity of APC and in a significant number of patients with venous thrombosis the levels of 
glucosylceramides are low (Deguchi et al., 2002; Deguchi et al., 2001). Shpingosine, another 
molecule present in HDL, has been shown to inhibit prothrombin activation on platelets’ 
surface by disrupting procoagulant interactions between factors Xa and Va (Deguchi et al., 
2004). HDL also downregulated expression of plasminogen activator inhibitor-1 (PAI-1) and 
upregulated tissue plasminogen activator (t-PA) in endothelial cell cultures (Eren et al., 
2002). Transgenic mice expressing the human PAI-1 developed age-dependent coronary 
arterial thrombosis (Eren et al., 2002). In contrast oxidized HDL3 induced the expression of 
PAI-1 in endothelial cells through signalling mechanisms that involve activation of ERK1/2 
and p38MAPK and mRNA stabilization (Norata et al., 2004).  
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In vivo and in vitro studies have provided evidence that HDL may have beneficial effects on 
glucose metabolism (Koseki et al., 2009; Rutti et al., 2009). Ex vivo studies showed that HDL 
and delipidated apoA-I or S1P decreased IL-1β and glucose-mediated apoptosis and thus 
increased the survival of human and murine islets. HDL treatment down-regulated the 
expression of iNOS and its downstream target Fas which is pro-apoptotic and up-regulated 
the expression of FLICE-like inhibitory protein (FLIP) which is anti-apoptotic (Rutti et al., 
2009). HDL also reversed the toxic effects of oxidized LDL on beta cells that are associated 
with apoptosis and cJNK mediated transcriptional repression of the insulin gene caused 
cJNK mediated (Abderrahmani et al., 2007).  
Oral glucose tolerance test in a limited number of patients with Tangier disease (that lack or 
have dysfunctional ABCA1) showed that they had glucose intolerance as compared to 
controls (Koseki et al., 2009), thus implicating ABCA1, apoA-I and HDL in glucose 
metabolism. Cell culture studies using primary pancreatic islets cells and a pancreatic β-cell 
line (Min6), showed that lipid free apoA-I or apoA-II or reconstituted HDL increased insulin 
secretion up to 5-fold in a Ca2+ dependant manner (Fryirs et al., 2010). The free 
apolipoproteins also increased insulin mRNA levels. HDL mediated insulin secretion has 
also been observed in cultures of mouse pancreatic β-cells (MIN6N8) (Drew et al., 2009). The 
increase in insulin secretion mediated by lipid-free apoproteins and rHDL required the 
functions of ABCA1 and SRBI or ABCG1 respectively. These functions may be different 
from those involved in cholesterol efflux. For high glucose concentrations enhanced insulin 
secretion required the action of KATP channel and glucose catabolism in the pancreatic cell, 
but this did not occur for low glucose concentrations (Fryirs et al., 2010).  
Further insight on the role of ABCA1 in diabetes was obtained by studies in mice with 
selective deficiency of ABCA1 in the pancreas (ABCA1-P/-P). These mice accumulated 
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cholesterol in their islets and were characterized by impaired acute phase insulin secretion 
and glucose intolerance. The ABCA1-P/-P mice exhibited normal insulin sensitivity indicating 
normal response of the peripheral tissues to insulin. The impairment in insulin secretion 
was verified in cell culture experiments using islets isolated from the ABCA1-P/-P mice. In 
contrast, whole ABCA1 deficient mice had normal glucose tolerance and displayed only 
small impairment in the islet function and did not accumulate significant amount of 
cholesterol in the islets (Brunham et al., 2007). Pancreatic islets isolated from apoE deficient 
mice had increased cholesterol content and reduced insulin secretion as compared to islets 
obtained from WT mice. The reduced insulin secretion in the pancreatic islets or cultures of 
β-cells could be restored by depletion of the cellular cholesterol using mevastatin or methyl-
β-cyclodextrin (MβCD) (Hao et al., 2007). Experiments in cell lines of pancreatic β-cell origin 
indicated that cholesterol loading or cholesterol depletion affect the activity of glucokinase 
(GK) which is known to regulate insulin secretion (Rizzo and Piston, 2003). The experiments 
showed that under normal cholesterol levels GK is associated with a dimeric form of nNOS on 
insulin containing granules in the cytoplasm and is inactive (Rizzo and Piston, 2003). Increase 
in plasma cholesterol enhanced dimerization of nNOS and its association with GK whereas 
reduction in the cholesterol levels or increase in the extracellular glucose levels promoted 
monomerization of nNOS and release of active GK in the cytoplasm (Hao et al., 2007). The role 
of the increase in the cholesterol content of β-cells in insulin secretion was tested in transgenic 
mice expressing SREBP-2 in β-cells under the control of insulin promoter. These mice had 
normal plasma cholesterol levels but developed severe diabetes characterized by 5-fold 
increase in gluco-hemoglobin and defects in glucose and potassium-stimulated insulin 
secretion and were characterized by glucose intolerance. The islets were fewer, smaller and 
deformed and had increased levels of total and esterified cholesterol (Ishikawa et al., 2008). It 
was proposed that the loss of β-cell mass could be related to the down regulation of genes such 
as PDX-1 and BETA2 that are involved in β-cell differentiation.  
A recent comprehensive study has measured the properties of HDL isolated from patients 
with type 2 diabetes mellitus and their functions on endothelial cells in vitro and in vivo. 
HDL isolated from patients with low HDL and type 2 diabetes mellitus contained increased 
levels of lipid peroxides and increased myeloperoxidase activity. In endothelial cell cultures 
diabetic HDL had reduced production of NO and increased NADPH oxidase activity that 
resulted in increased oxidant stress. Diabetic HDL had diminished endothelium dependent 
relaxation of aortic rings and endothelial progenitor cells obtained from diabetic subjects 
had diminished capacity to promote reendothelialization in vivo. A remarkable finding in 
this study was that extended release niacin treatment of the diabetic patients restored the 
properties and functions of HDL. The HDL obtained after treatment had normal levels of 
peroxides and normal myeloperoxidase (MPO) activity. Studies with endothelial cultures 
showed that following treatment of the diabetic patients their HDL could induce normal NO 
production and NADPH oxidase activity and could promote normal relaxation of aortic 
rings. Endothelial progenitor cells obtained from diabetic patients following niacin 
treatment had normal ability to promote reendothelialization in vivo (Sorrentino et al., 
2010). In another study intravenous infusion of rHDL (80 mg/kg over 4 hours) in type 2 
diabetic human subjects decreased plasma glucose level, increased plasma insulin level and 
increased β-cell functions as compared to patients receiving placebo (Drew et al., 2009). 
HDL and apoA-I increased glucose uptake of primary human skeletal muscle cultures 
established from patients with type 2 diabetes mellitus. HDL induced glucose uptake and 
fatty acid oxidation and increased AMPKα2 activity and phosphorylation. These effects 
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were modulated through a Ca2+ dependent pathway. Subsequent in vitro and in vivo studies 
showed that rHDL inhibited lipolysis in 3T3-L1 adipocytes partially via activation of AMPK 
pathway (Drew et al., 2011). Infusion of rHDL also inhibited fasting induced lipolysis and fatty 
acid oxidation but increased the circulating non essential fatty acids possibly due to the action 
of phospholipase on the rHDL phospholipids (Drew et al., 2011). The HDL dependent glucose 
uptake by the skeletal muscle cells was abrogated by inhibition of ABCA1 with a blocking 
antibody suggesting that ABCA1 functions not related to cholesterol efflux, may contribute to 
the increased glucose uptake and β-oxidation by skeletal muscle cells obtained from patients 
with type 2 diabetic mellitus (Drew et al., 2011). The effect of apoA-I on glucose metabolism 
was also studied in C2C12 myocytes and apoA-I deficient mice. Consistent with the studies 
with primary human skeletal muscle cultures, apoA-I stimulated AMPK and acetyl-CoA 
carboxylase (ACC) phosphorylation and glucose uptake and endocytosis into C2C12 cells. The 
apoA-I deficient mice had increased fat content decreased glucose tolerance and increased 
expression of gluconeogenic enzymes in the liver and decreased AMPK-dependent 
phosphorylation in skeletal muscle and the liver (Han et al., 2007).  
5.7 Role of apoA-I and HDL in atheroprotection 
Atherosclerosis is associated with lipid and lipoprotein abnormalities (Zannis et al., 2004b). 
Low HDL levels (Gordon et al., 1989) and decreased concentration of the largest size HDL 
subpopulations (Asztalos et al., 2004) are associated with increased risk of CAD. The anti-
atherogenic functions of HDL and apoA-I have been, to a large extent, attributed to the 
beneficial effects that HDL exerts on cells of the arterial wall as well as their ability to 
promote efflux from macrophages and other cells of the arterial wall via ABCA1, ABCG1 
and SR-BI (Wang et al., 2007). Hepatic overexpression of apoA-I gene in the background of 
apoE or LDLr deficient mice reduced the atherosclerosis burden of these mice following an 
atherogenic diet (Tangirala et al., 1999). These findings demonstrate the importance of 
apoA-I and HDL for atheroprotection. In contrast, double deficient mice for apoA-I and the 
LDLr fed an atherogenic diet developed atherosclerosis and had increased concentration of 
circulating auto-anibodies, increased population of T, B, dendritic cells and macrophages, as 
well as increased T cell proliferation and activation. The abnormal phenotype was corrected 
by adenovirus mediated gene expression of apoA-I (Wilhelm et al., 2010). Similarly apoA-I 
transgenic rabbits were resistant to diet induced atherosclerosis (Duverger et al., 1996).  
Two clinical trials showed that intravenous administration of 15 mg/kg of apoA-
IMILANO/phospholipid complexes in five weekly doses in patients with acute coronary 
syndrome resulted in significant regression of atherosclerosis as it was shown by intravascular 
ultrasound (Nicholls et al., 2006; Nissen et al., 2003). The epidemiological studies (Gordon et 
al., 1989), combined with studies of experimental animals (Duverger et al., 1996; Tangirala et 
al., 1999) and clinical intervention studies (Barter et al., 2007; Sorrentino et al., 2010) highlight 
the importance of increased HDL levels for atheroprotection. However, human subjects have 
been identified with high HDL levels and CAD (Ansell et al., 2003). In addition, increased 
HDL levels in humans treated with the CETP inhibitor torcetrapib, increased cardiovascular, 
and non-cardiovascular deaths (Barter et al., 2007). These findings suggest that high HDL 
levels are not always synonymous with atheroprotection. The concept that emerges from all 
the studies is that the most important factor for atheroprotection is the functionality of HDL. 
Understanding of the structure-function and the cell signaling associated with HDL and apoA-
I will provide molecular explanations for their beneficial effects for atherosclerosis and other 
human diseases and apoA-I. 
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6. Conclusion  
Numerous prospective epidemiological studies have established an inverse correlation 
between HDL cholesterol levels and the risk for CAD. However, the discovery of human 
subjects with high HDL cholesterol levels and CAD, combined with clinical intervention 
studies designed to raise HDL levels and studies of animal models, led to the realization 
that high levels of HDL cholesterol alone are not sufficient to prevent atherosclerosis. HDL 
via its protein and/or lipid components participates in numerous interactions with the 
endothelium, other cells of the vascular wall, as well as with β pancreatic cells, and has a 
protective effect against atherothrombosis and other diseases. The key proteins that 
participate in the biogenesis, remodeling and signaling of HDL are of great importance for 
the functionality of HDL. Mutations in apoA-I, ABCA1 and LCAT affect the biogenesis of 
HDL and either prevent formation of HDL or generate aberrant HDL subpopulations which 
may have altered functions. The ability of HDL to inhibit the oxidation of LDL, prevents the 
induction of pro-inflammatory and pro-apoptotic pathways that are detrimental to the 
endothelium. HDL interacts directly with the endothelial cells via SR-BI and the ABCG1. 
These interactions lead to NO release and vasodilatation, promote reendothelialization and 
suppress expression of adhesion molecules on endothelial cells in response to pro-
inflammatory cytokines. As a result of these and other interactions of the sphingolipid 
components of HDL with S1P receptors, HDL protects from apoptosis and inflammation 
and promotes endothelial cell growth and migration. Understanding the complexity and the 
functions of HDL may facilitate in the near future the development of new HDL-based 
therapies to prevent or treat atherosclerosis and other human diseases. 
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expression of gluconeogenic enzymes in the liver and decreased AMPK-dependent 
phosphorylation in skeletal muscle and the liver (Han et al., 2007).  
5.7 Role of apoA-I and HDL in atheroprotection 
Atherosclerosis is associated with lipid and lipoprotein abnormalities (Zannis et al., 2004b). 
Low HDL levels (Gordon et al., 1989) and decreased concentration of the largest size HDL 
subpopulations (Asztalos et al., 2004) are associated with increased risk of CAD. The anti-
atherogenic functions of HDL and apoA-I have been, to a large extent, attributed to the 
beneficial effects that HDL exerts on cells of the arterial wall as well as their ability to 
promote efflux from macrophages and other cells of the arterial wall via ABCA1, ABCG1 
and SR-BI (Wang et al., 2007). Hepatic overexpression of apoA-I gene in the background of 
apoE or LDLr deficient mice reduced the atherosclerosis burden of these mice following an 
atherogenic diet (Tangirala et al., 1999). These findings demonstrate the importance of 
apoA-I and HDL for atheroprotection. In contrast, double deficient mice for apoA-I and the 
LDLr fed an atherogenic diet developed atherosclerosis and had increased concentration of 
circulating auto-anibodies, increased population of T, B, dendritic cells and macrophages, as 
well as increased T cell proliferation and activation. The abnormal phenotype was corrected 
by adenovirus mediated gene expression of apoA-I (Wilhelm et al., 2010). Similarly apoA-I 
transgenic rabbits were resistant to diet induced atherosclerosis (Duverger et al., 1996).  
Two clinical trials showed that intravenous administration of 15 mg/kg of apoA-
IMILANO/phospholipid complexes in five weekly doses in patients with acute coronary 
syndrome resulted in significant regression of atherosclerosis as it was shown by intravascular 
ultrasound (Nicholls et al., 2006; Nissen et al., 2003). The epidemiological studies (Gordon et 
al., 1989), combined with studies of experimental animals (Duverger et al., 1996; Tangirala et 
al., 1999) and clinical intervention studies (Barter et al., 2007; Sorrentino et al., 2010) highlight 
the importance of increased HDL levels for atheroprotection. However, human subjects have 
been identified with high HDL levels and CAD (Ansell et al., 2003). In addition, increased 
HDL levels in humans treated with the CETP inhibitor torcetrapib, increased cardiovascular, 
and non-cardiovascular deaths (Barter et al., 2007). These findings suggest that high HDL 
levels are not always synonymous with atheroprotection. The concept that emerges from all 
the studies is that the most important factor for atheroprotection is the functionality of HDL. 
Understanding of the structure-function and the cell signaling associated with HDL and apoA-
I will provide molecular explanations for their beneficial effects for atherosclerosis and other 
human diseases and apoA-I. 
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6. Conclusion  
Numerous prospective epidemiological studies have established an inverse correlation 
between HDL cholesterol levels and the risk for CAD. However, the discovery of human 
subjects with high HDL cholesterol levels and CAD, combined with clinical intervention 
studies designed to raise HDL levels and studies of animal models, led to the realization 
that high levels of HDL cholesterol alone are not sufficient to prevent atherosclerosis. HDL 
via its protein and/or lipid components participates in numerous interactions with the 
endothelium, other cells of the vascular wall, as well as with β pancreatic cells, and has a 
protective effect against atherothrombosis and other diseases. The key proteins that 
participate in the biogenesis, remodeling and signaling of HDL are of great importance for 
the functionality of HDL. Mutations in apoA-I, ABCA1 and LCAT affect the biogenesis of 
HDL and either prevent formation of HDL or generate aberrant HDL subpopulations which 
may have altered functions. The ability of HDL to inhibit the oxidation of LDL, prevents the 
induction of pro-inflammatory and pro-apoptotic pathways that are detrimental to the 
endothelium. HDL interacts directly with the endothelial cells via SR-BI and the ABCG1. 
These interactions lead to NO release and vasodilatation, promote reendothelialization and 
suppress expression of adhesion molecules on endothelial cells in response to pro-
inflammatory cytokines. As a result of these and other interactions of the sphingolipid 
components of HDL with S1P receptors, HDL protects from apoptosis and inflammation 
and promotes endothelial cell growth and migration. Understanding the complexity and the 
functions of HDL may facilitate in the near future the development of new HDL-based 
therapies to prevent or treat atherosclerosis and other human diseases. 
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1. Introduction 
Gram-negative sepsis is an increasingly clinical syndrome triggered by exposure to bacterial 
lipopolysaccharide (LPS) or endotoxin. It is associated with a plethora of physiological and 
biochemical changes, known as acute-phase response (APR), including disturbances in 
serum lipid and lipoprotein levels (Khovidhunkit et al., 2004). Within the blood, LPS is 
extracted by the acute phase reactant LPS-binding protein (LBP) and transferred to CD14 
receptor on monocytes and macrophages. The CD14 associates with Toll like receptor 4, 
myeloid differentiation-2 and other proteins forming a receptor cluster that leads to LPS-
induced activation (Triantafilou & Triantafilou, 2005), resulting in the release of soluble 
mediators, such as proinflammatory cytokines. 
Kupffer cells (KC), the resident machrophages in the liver, secrete cytokines, particularly 
tumor necrosis factor α (TNF-α) and the interleukins (IL) IL-6 and IL-1β, that act as 
paracrine factors on neighboring hepatocytes and promote many of the metabolic changes 
that accompany the acute-phase response. One of the most striking changes associated to 
sepsis is the accumulation of triglycerides (TG) within very low density lipoprotein (VLDL) 
in the plasma, partly ascribed to an increased hepatic VLDL production and a decreased 
peripheral metabolism driven by pro-inflammatory cytokines. These metabolic alterations, 
clinically termed as the “lipemia of sepsis”, have been postulated to be components of the 
innate defensive reaction against infection (Harris et al., 2000).  
In this chapter we summarize the actual knowledge on sepsis induced alterations in VLDL 
metabolism, lipids and apoB availability and the involvement of inflammatory mediators.  
2. Hiperlipemia of sepsis 
Elevation of plasma lipid levels is an early hallmark of sepsis, clinically defined as lipemia of 
sepsis. The rise in circulating lipids is mainly caused by a rapid accumulation of 
triglycerides within very low density lipoproteins (Esteve et al., 2005; Khovidhunkit et al., 
2004), although other lipids such as non-esterified fatty acids coming from peripheral tissue 
lipolysis (Khovidhunkit et al., 2004), or cholesterol, in the case of rodents, can also be 
elevated (Feingold et al., 1993). However, decreases in cholesterol associated to high density 
lipoproteins (HDL) have been reported as a characteristic associated to sepsis in primates 
and rodents (Khovidhunkit et al., 2004).  
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The accumulation of VLDL particles in plasma is attributable to complex disturbances in 
their metabolism, including increased hepatic production (Feingold et al., 1992; 
Khovidhunkit et al., 2004; Lanza-Jacoby et al., 1998) and depressed peripheral clearance in 
the bloodstream by lipoprotein lipase (LPL) depending upon the dose (Feingold et al., 1992; 
Khovidhunkit et al., 2004; Lanza-Jacoby et al., 1998). Initially, the sepsis-induced 
hypertriglyceridemia was thought to constitute a mechanism for supplying high-energy 
substrates to cells involved in host defence (Hardardottir et al., 1994). However, it is 
increasingly believed that TG-rich lipoproteins are also components of an innate, non-
adaptive host immune reaction against infection in humans and animal models (Barcia & 
Harris, 2005; Harris et al., 2000; Harris et al., 2002).  
Both in vitro (Levels et al., 2001; Van Lenten et al., 1986) and in vivo (Kitchens et al., 2003) 
studies have demonstrated that all lipoprotein classes are able to bind LPS, through their 
phospholipid (Kitchens et al., 2003) or apolipoprotein (Levels et al., 2001; Vreugdenhil et al., 
2001) components, in such a way that lipoprotein-bound LPS is subsequently cleared from 
the circulation by hepatic parenchymal cells (Harris et al., 2002). Most of the LPS-binding 
ability corresponds to HDL particles (Levels et al., 2001); however, when levels of VLDL are 
increased and HDL diminished, as may occur in endotoxemia, the binding appears to shift 
towards VLDL (Kitchens & Thompson, 2003; Vreugdenhil et al., 2001) and partially depends 
on interacting with apolipoprotein B (apoB) (Vreugdenhil et al., 2001). Therefore, higher 
secretion levels of VLDL may be regarded as a protective mechanism against infection. We 
have shown in LPS-treated rats that plasma VLDL-apoB is rapidly elevated, and this can 
represent a defence mechanism to neutralize and remove LPS from the circulation (Fig. 1).  
 
 
Fig. 1. Proposed role of VLDL in the host inflammatory response. Inflammatory mediators 
released from Kupffer cells act on hepatocytes inducing the production of VLDL and the 
synthesis of APR proteins, among them LBP. LBP mediates the binding of LPS to VLDL, the 
complex is taken up by the hepatocyte and LPS is eliminated through the bile. 
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Notwithstanding the beneficial role of VLDL, many of the sepsis-associated changes in 
lipoprotein characteristics and metabolism are similar to those promoting atherogenesis, 
and has been proposed that the APR associated changes in lipoproteins can be one possible 
link between infection/inflammation and atherosclerosis. During acute phase reaction, 
apart from changes in HDL-cholesterol, alterations in HDL associated proteins have been 
reported. These changes alter cholesterol reverse transport, leading to diminished HDL-
cholesterol, and reduce their antioxidant properties (Esteve et al., 2005; Khovidhunkit et al., 
2004). In fact, following acute infection low density lipoproteins (LDL) become more 
susceptible to oxidation (Memon et al., 2000).  
One factor that may influence lipoprotein metabolism and is known to be altered during 
sepsis is food intake (Grunfeld et al., 1996). In order to avoid this variability, animals are 
food-deprived from the time of administration of endotoxin.  
We have shown that endotoxin administration to fasted rats induced hipertriglyceridemia in 
a time-dependent pattern, related to different systemic fuels (Bartolome et al., 2010). 
Metabolic background is an important factor contributing to the sepsis-promoted VLDL 
abundance. We have demonstrated a biphasic response to endotoxin in systemic fuels of 
fasted rats, with two 12 h differentiated phases. We found that during the first phase serum 
fatty acids were markedly increased and glucose levels decreased, whereas in the second 
period hyperglycemia was recorded and fatty acid levels were bellow controls. Impaired 
glucose metabolism has been reported (McGuinness, 2005). During the second phase of the 
response we detected increased levels of insulin, that together with the high glucose levels 
indicate the reported sepsis induced insulin resistance (Andersen et al., 2004). It is well 
known that overproduction of VLDL is a characteristic of insulin-resistant states (Adeli et 
al., 2001).  
 
 mean diamenter (nm)
Triglycerides Cholesterol 
8 h 18 h 8 h 18 h 
VLDL 31,3-64 8,21** 3,16** 3,29*** 2,24* 
large 44,5-64 9,21*** 2,74* 4,69*** 2,37* 
medium 36,8 6,62*** 4,26** 2,89*** 2,27* 
small 31,3 5,83** 4,18** 1,76 2,00 
LDL 16,7-28,6 3,66** 2,88** 0,97 1,36 
large 28,6 4,37** 3,49* 1,37 1,78 
medium 26,5 3,35** 2,87* 1,19 1,63 
small 23 3,08** 2,61* 1,05 1,48 
very small 16,7-20,7 3,82** 2,42** 0,83 1,21 
HDL 7,6-15 4,64** 1,53* 0,98 0,72* 
very large 13,5-15 7,28** 1,93** 1,11 0,72 
large 12,1 5,78** 1,80** 1,03 0,69** 
medium 10,9 4,15** 1,50** 0,79* 0,75** 
small 9,8 4,84*** 2,13** 0,83 0,76** 
very small 7,6-8,8 4,12** 1,24 0,93 0,79* 
Table 1. Fold-changes induced by LPS administration in triglyceride and cholesterol 
concentration in lipoprotein classes. Rats were injected with LPS and blood collected for 
lipoprotein triglyceride and total cholesterol measurements.  
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We analyzed the lipoprotein lipid profile in serum of rats after 8 or 18 h of LPS treatment 
(Table 1). We found that hypertriglyceridemia was associated with different VLDL, LDL 
and HDL subclasses depending on the metabolic background of the APR. Although TG 
increased in all lipoprotein classes, VLDL particles were the major contributors. We did find 
transient proatherogenic changes in VLDL particles. During the first phase of the APR 
hypertriglyceridemia was predominantly associated to large VLDL, which were increased 8 
fold after 8 h (Bartolome et al., 2010). These large TG-rich VLDL particles, more than normal 
VLDL, are able to cross the endothelial barrier and interact with lipoprotein receptors in 
macrophages, initiating a sequence of events that result in the atherosclerotic lesion and, in 
addition they give rise to small-dense atherogenic LDL (Gianturco et al., 1998; Ginsberg, 
2002; Taskinen, 2003). In addition, large TG-rich VLDL were also enriched in cholesterol, 
making them more proatherogenic.  
In the second phase, the rise in serum VLDL-TG corresponded mainly to medium and small 
VLDL particles. Endotoxin did not affected serum total cholesterol, however changes occurs 
in lipoprotein subclasses. Total cholesterol increased in large and medium VLDL and HDL-
cholesterol levels fell in all HDL subclasses. 
3. Altered VLDL metabolism in sepsis 
The assembly of VLDL particles is a complex and highly regulated process that occurs in 
the secretory pathway of hepatocytes. It represents an active export process of fuel 
carbons, mainly in the form of TG, and is an important route for cholesteryl ester and 
phospholipid secretion to the circulation. The biogenesis of VLDL has been mostly 
described as a two step process depending on the cellular availability of lipids, such as 
triglycerides, phospholipids, cholesterol, and cholesteryl esters, and it is absolutely 
dependent on the provision of functional apoB, which, in rodents, may be either the full 
length apoB-100 or the truncated form of apoB-48 (Davidson & Shelness, 2000). Firstly, 
during translocation to the lumen across the endoplasmic reticulum (ER) membrane, 
nascent apoB is lipidated by the essential chaperone microsomal triglyceride transfer 
protein (MTP) (Gordon & Jamil, 2000; Hussain et al., 2003; Liang & Ginsberg, 2001), 
originating a relatively small, dense, TG-poor lipoprotein particle. In the second stage, 
bulk of lipidation and final maturation of lipoprotein precursor occur in the ER and post-
ER compartments to form mature VLDL (Gusarova et al., 2003; Kulinski et al., 2002). It is 
known that when MTP activity is low, or when lipid availability or synthesis is reduced, 
apoB is cotranslationally targeted for ER-associated degradation by both proteasome-
dependent and non-dependent pathways (Fisher et al., 2001; Fisher & Ginsberg, 2002; 
Ginsberg & Fisher, 2009). 
The apoB gene has been considered to be constitutively expressed (Pullinger et al., 1989) and 
VLDL assembly regulation as a post-transcriptional event. However, increasing evidence 
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1998a) and that endotoxin and cytokines suppressed mitochondrial acyl-CoA synthetase 
expression and activity (Memon et al., 1998b) but enhanced microsomal acyl-CoA 
synthetase. In addition, LPS administration to rats led to reduced carnitine acyltransferase I, 
lower ketogenic capacity (Takeyama et al., 1990) and decreased levels of serum ketone 
bodies (Bartolome et al., 2010). Evidences also established a relationship between increased 
de novo fatty acid synthesis and enhanced secretion of VLDL-TG in rodents treated with 
LPS or cytokines (Feingold et al., 1992; Lanza-Jacoby & Tabares, 1990). Taken all together, 
high amounts of fatty acids are directed away from mitochondrial oxidation and are 
available for their esterification into TG and secreted within VLDL. However, previous 
works done in our laboratory did not support the proposed hypothesis since levels of fatty 
acid synthase mRNA or rate of TG synthesis measured as the incorporation of [3H]acetate or 
[3H]oleate did not change after 18 h of LPS treatment (Aspichueta et al., 2006). 
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we detected an elevation of 5 fold in the number of circulating VLDL particles, measured as 
apoB quantities, at 8 h from LPS administration, without any modification in apoB transcript 
level. The increment in VLDL-TG is of greater magnitude (8 fold), indicating that during the 
first phase of the septic response TG-rich VLDL particles accumulate in the circulation 
(Bartolome et al., 2010).  
Different mechanisms seem to be involved in the second phase of septic response. The 
serum fatty levels drop below controls, which would suggest a lower availability of fatty 
acids of extrahepatic origin for hepatic VLDL-TG secretion. 
Endotoxic rats showed a higher number (10 fold) of circulating VLDL particles in rats at 18 h, 
but the content of the lipid in each VLDL is reduced (Aspichueta et al., 2006; Bartolome et al., 
2010). This was accompanied by high levels of apob gene transcript, which could provide for 
high apoB availability increasing the secretion of lipid poor VLDL particles. Using intact rats in 
the fasted state, injected with the LPL inhibitor Triton WR-1339, we have shown that the TG 
and cholesterol secreted into VLDL released by the liver to the blood in 2 h was not enhanced 
by LPS administration to the same extent as the VLDL-apoB production was (Aspichueta et al., 
2005). In this way, hepatocytes isolated from 18 hour LPS-treated rats secreted TG-poor VLDL, 
and although secretion was highly stimulated, global triglyceride secretion in VLDL remained 
unchanged. This was related to unchanged rates of fatty acid esterification, measured as 
[3H]oleate incorporation into TG (Aspichueta et al., 2005; Aspichueta et al., 2006).  
In septic hypertriglyceridemic rats, 24 h after sepsis induction, the increase in plasma TG was 
associated to a decrease in VLDL-TG clearance rate, due to suppressed mRNA levels, protein 
mass and activity of LPL in peripheral tissues (Lanza-Jacoby et al., 1997; Lanza-Jacoby & 
Tabares, 1990). Thus, in the early phase of the septic reaction hypertriglyceridemia is mostly 
due to high VLDL secretion driven by availability of lipids in the hepatocyte; and during the 
second phase, hypertriglyceridemia would be the result of LPL inhibition, and the increase in 
apoB transcription would be responsible for the increased secretion of VLDL particles (Fig.3). 
4. Zonation of VLDL secretion during sepsis 
It has been suggested that parenchymal capacity for VLDL secretion is zonated. Zonation 
refers to a phenotypic heterogeneity that is well established in many essential liver functions 
(Jungermann & Katz, 1989). While some authors suggested that VLDL secretion might be 
higher in perivenous (PV) hepatocytes because of their higher capacity for fatty acid synthesis 
(Guzman & Castro, 1989), others proposed that it could be concentrated in the periportal (PP) 
area (Kang & Davis, 2000) since higher expression of the cholesterol synthesis rate-limiting 
enzyme 3-hydroxy-3-methylglutaryl-CoA reductase was found (Singer et al., 1984).  
Zonation has also been evidenced in non parenchymal liver cells. Kupffer cells are more 
abundant and larger in the PP than in the PV zone (Bouwens et al., 1992), and expression of 
IL-6, a key cytokine acting on hepatocytes in response to endotoxin, occur preferentially in 
the PP region (Fang et al., 1998). 
After 18 h of endotoxin treatment, highly pure rat PP and PV hepatocyte subpopulations, 
assessed by cytometry, were maintained in suspension for 2 h. Endotoxin treatment 
provoked zonation of VLDL secretion. The induction in VLDL-apoB secretion was markedly 
higher in PP hepatocytes (~90%) than in PV cells (~38%). In addition, the increase in the 
VLDL associated lipid, particularly in triglycerides, was lower than the enhance in apoB 
output, consequently producing changes in VLDL features which were triglyceride poor 
(Aspichueta et al., 2005). Endotoxin doubled apoB mRNA and increased by 50% MTP 
mRNA in PP hepatocytes when compared to their fasted controls, the increase in apoB 
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genetic expression was of a lesser extend in PV cells. Regarding to de novo synthesis of 
lipids for VLDL assembly, the incorporation of [3H]acetate into TG and cholesterol did not 
change by endotoxin challenge. 
We concluded that periportal and perivenous hepatocytes exhibited similar capabilities for 
VLDL assembly and secretion in normal conditions; and, only the endotoxic condition led 
PP hepatocytes to a marked increase in TG-poor VLDL secretion (Fig 4). 
 
 
Fig. 3. Proposed model for the biphasic response to endotoxin in VLDL metabolism. In the 
first phase the stimulation of lipolysis provides fatty acids that are taken by the liver and 
esterified to be secreted into TG-rich VLDL. In the second phase apoB mRNA levels are 
increased providing the apolipoprotein for secretion of TG-poor VLDL. 
 
Fig. 4. Model of VLDL secretion by periportal and perivenous hepatocytes in fed state and 
18 h after fasting or endotoxin treatment. Endotoxin effect when compared with the fasted 
state is marked with  
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5. Kupffer cell mediators and VLDL secretion 
During the acute phase of the septic response, Kupffer cells, the resident macrophages in the 
liver, release a plethora of soluble bioactive molecules, among them soluble pro-
inflammatory mediators as cytokines, particularly TNF-, IL-6 and IL-1. These cytokines 
would act locally on nearby hepatocytes as paracrine factors promoting VLDL secretion and 
many other metabolic changes that accompany the inflammatory reaction. 
We confirmed a rapid release of TNF- and IL-6 into the bloodstream in rats after 2 h of LPS 
injection (1 mg/Kg bw), whereas the IL-1 maximum level was observed at 6 h and the rise 
was less accentuated. Basal levels were recovered in all cases at 12 h from the LPS treatment 
(Bartolome et al., 2008).  
Administration of cytokines to animals has been shown to mimic the sepsis induced 
alterations in lipid metabolism. TNF-, IL-6 and IL-1 administered to rodents induce 
triglyceride synthesis and promote rises in VLDL-TG (Khovidhunkit et al., 2004). In the case 
of TNF- and IL-6 administration, the hypertriglyceridemia has been reported to be 
secondary to higher lipolysis in peripheral tissues; consequently more fatty acids in blood 
are available and can be recruited by liver. In some studies, the three cytokines have been 
shown to stimulate hepatic de novo fatty acid synthesis (Feingold et al., 1989) and TG 
secretion (Feingold et al., 1991; Nonogaki et al., 1995), and decrease adipose tissue LPL 
activity (Feingold et al., 1994; Popa et al., 2007). Nevertheless, the reduction in LPL was 
delayed several hours with respect to hypertriglyceridemia (Esteve et al., 2005; Popa et al., 
2007) and blockade of TNF- or IL-6 function in septic mice inhibited hypertriglyceridemia 
without affecting LPL activity (Feingold et al., 1994). 
In order to address the role of Kupffer cells in VLDL oversecretion during endotoxemia, we 
analyzed the response of rat primary hepatocytes to the direct effect of LPS-stimulated KC 
or unstimulated products. Hepatocytes were cultured for 8 h with the conditioned medium 
containing the mediators generated in 16 h by Kupffer cells after a previous 4 h culture with 
or without LPS. The exposure of hepatocytes to unstimulated KC conditioned medium 
resulted in doubled the secretion VLDL particles of normal composition. Cells cultured in 
LPS stimulated KC medium secreted further more VLDL particles that were enriched in PL 
(Bartolome et al., 2008). Regarding to apoB expression, KC products multiplied by two the 
abundance of apoB mRNA and no further increment was caused by specific LPS-triggered 
products. In any case was MTP mRNA modified. The high PL available would protect apoB 
from degradation, explaining the increase in apoB secretion in cells challenged by LPS-KC 
medium. 
There are few studies investigating the direct effect of cytokines on VLDL secretion, and 
contradictory results have been reported using different cell types. In HepG2 cells IL-6 and 
IL-1 were found to reduce apoB secretion although apoB mRNA levels were increased 
(Yokoyama et al., 1998). However, in IL-6 treated murine hepatocytes, enhanced apoB 
synthesis, which corresponded with high apoB mRNA levels, was found to be the primary 
mechanism for increased lipoprotein secretion (Sparks et al., 2010). They also found that IL-6 
did not alter the decay rate of apoB mRNA transcripts, concluding that it favours secretion 
of apoB-containing lipoproteins by increasing availability of apoB through changes in apob 
gene transcription (Sparks et al., 2010).  
Our studies in rat hepatocyte cultures, have demonstrated that the inflammatory cytokines 
TNF-α, IL-6 and IL-1β, over a wide range of concentrations, enhanced VLDL-apoB secretion 
linked to upregulation of apoB mRNA expression (Bartolome et al., 2007; Bartolome et al., 
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2008; Perez et al., 2006). IL-1β was the most potent and was the only one presenting a dose-
response effect. The effect of the three cytokines was redundant, as the increase was not 
additive when they were combined. However, none of the treatments with cytokines 
modified the amount of TG and total lipids secreted as components of VLDL, suggesting 
that these particles are lipid poor. 
We conclude that Kupffer cells play a role in the rise of VLDL secretion detected during the 
inflammatory processes and that the three cytokines TNF-α, IL-6 and IL-1β may be 
involved, nevertheless other Kupffer cells mediators are necessary to accomplish increased 
lipid association. 
6. Higher apoB availability within the hepatocytes 
As stated before, the assembly of VLDL is a complex process that depends on the 
availability of lipids and apoB (Davidson & Shelness, 2000).  
Since we have found that under LPS treatment VLDL-apoB secretion was always increased, 
and given that not always enhanced apoB secretion is linked to high levels of apoB 
transcript, we hypothesized that during the acute phase response, transcriptional or post-
transcriptional regulation affecting apoB mRNA levels might occur supplying more apoB 
for VLDL assembly. 
During the first phase of the septic response we detected elevated circulating VLDL-apoB 
and -TG after 8 h of LPS treatment without altered apoB transcript levels. Taking into 
account that at this time point of the septic response, circulating fatty acid levels were 
elevated, we propose that fatty acid uptake by the liver is increased and large amounts of 
TG are synthesized. Since the N-terminus of apoB acquires neutral lipids in the endoplasmic 
reticulum membrane (Hussain et al., 2008), more nucleation sites are expected to be 
generated in apoB leading to increased apoB secretion. This could result in an increased 
hepatic secretion of triglycerides in VLDL particles, which would accumulate in the 
circulation, even in the absence of augmented levels of hepatic apoB mRNA (Bartolome et 
al., 2010). 
In the second phase of the septic response, after 18 h of LPS challenge, enhanced VLDL-
apoB secretion is accompanied by increased apoB mRNA levels (Bartolome et al., 2010). In 
addition, hepatocytes isolated 18 h after LPS administration presented higher levels of 
apoB transcript and secreted more VLDL particles, been this effect more marked in PP 
cells. At this time point of the septic response, lipid poor VLDL particles are secreted 
(Aspichueta et al., 2005) and lipid synthesis is not modified (Aspichueta et al., 2006). 
Therefore, the increase in apob gene transcript would provide the additional apoB 
necessary to enhance VLDL-apoB secretion. Similarly, the inflammatory cytokines TNF-α 
(Bartolome et al., 2007), IL1-β (Bartolome et al., 2010) and IL-6 (Perez et al., 2006) 
augmented the levels of apoB mRNA and secretion of VLDL particles without changing 
the amounts of lipid secreted in the VLDL.  
Our hypothesis was that endotoxin-enhanced VLDL-apoB secretion was driven by higher 
transcription rates. However, we did not find a rise in transcription rate of apob gene when 
we measured the incorporation of 5’-[α-32P]-UTP into newly synthesized RNA in liver nuclei 
from 16 h LPS-treated rats (Bartolome et al., 2010). We reported that global transcription rate 
in endotoxic liver was nearly two times higher than in control rats as expected in the acute 
phase response for up-regulating the positive proteins. However, the transcription rate of 
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(Aspichueta et al., 2005) and lipid synthesis is not modified (Aspichueta et al., 2006). 
Therefore, the increase in apob gene transcript would provide the additional apoB 
necessary to enhance VLDL-apoB secretion. Similarly, the inflammatory cytokines TNF-α 
(Bartolome et al., 2007), IL1-β (Bartolome et al., 2010) and IL-6 (Perez et al., 2006) 
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phase response for up-regulating the positive proteins. However, the transcription rate of 
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apoB gene was unaffected after 16 h of LPS challenge in the treated animals. It cannot be 
discarded that transcriptional activation may occur transiently during other stages of the 
APR. 
Another aspect involved in regulating mRNA level is the modulation of mRNA stability 
through regulatory elements residing in the 3’- and 5’-untranslated region (UTR) and 
adequate RNA binding proteins. HuR is an important protein in stabilizing inflammatory 
AU-rich elements (ARE)-bearing RNAs. Human apoB mRNA has been reported to contain 
ARE sequences at 3’-UTRs and bioinformatic analysis of rat apoB transcript revealed the 
presence of AU-rich regions. Our results demonstrated the specific binding of stabilizing 
HuR protein to the rat apoB mRNA, although there were no superior binding in livers from 
LPS treated rats. Consequently, in our conditions it is not likely that apoB mRNA half-life 
was extended by HuR binding, but we can not discard a role for other stabilizing proteins or 
changes in the mRNA degradation pathway, but further analysis is need (Fig 5). 
 
 
Fig. 5. Endotoxin induce increase in apoB mRNA without altering transcription rate or HuR 
protein binding. 
7. Conclusion 
During the septic response, altered VLDL metabolism is responsible for the lipemia of 
sepsis. Entotoxin promoted changes are biphasic. In the early stage hypertriglyceridemia is 
accompanied by increased circulating fatty acids levels and a rise in large TG-rich VLDL, 
whereas the later stage is characterized by high levels of hepatic apoB transcript and TG-
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poor VLDL accumulation. In the later stage, the endotoxin induced VLDL secretion is more 
accentuated in periportal cells. Kupffer cells released products directly promote VLDL 
assembly and secretion and increase apoB mRNA levels, among these products the 
cytokines TNF–α, IL-6 and IL-1β and other mediator/s could play a role in the enhancement 
of VLD secretion. 
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1. Introduction 
Dyslipidemia is a powerful predictor of cardiovascular disease in patients at high risk 
(Turner et al., 1998), such as type 2 diabetic patients. Lowering of LDL-C is the prime target 
for treatment (2002), but even with intensification of statin therapy, a substantial residual 
cardiovascular risk remains (Barter et al., 2007; Miller et al., 2008; Fruchart et al., 2008; 
Shepherd et al., 2006). This may partly be due to atherogenic dyslipidemia. This term is 
commonly used to describe a condition of abnormally elevated plasma triglycerides and low 
high-density lipoprotein cholesterol (HDL-C), irrespective of the levels of LDL-C (Grundy, 
1995). In addition to these key components, increased levels of small, dense LDL-C particles 
are also present, which in conjunction with the former components conform the also called 
“lipid triad” (Shepherd et al., 2005). Other abnormalities include accumulation in plasma of 
triglyceride-rich lipoproteins (TLRs), including chylomicron and very-low-density 
lipoprotein (VLDL) remnants. This is reflected by elevated plasma concentrations of non-
HDL-C and apolipoprotein B-100 (apoB). Postprandially, there is also accumulation in 
plasma of TLRs and their remnants, as well as qualitative alterations in LDL and HDL 
particles. Thus, hypertriglyceridemia is associated with a wide spectrum of atherogenic 
lipoproteins not measured routinely (Taskinen, 2003). The presence of this lipid plasma 
profile with high triglyceride and low HDL-C levels have been shown to increase the risk of 
cardiovascular events independent of conventional risk factors (Bansal et al., 2007; Barter et 
al., 2007; deGoma et al., 2008). In fact, guidelines recommend modifying high triglyceride 
and low HDL-C as secondary therapeutic targets to provide additional vascular protection 
(2002). The presence of atherogenic dyslipidemia is seen in almost all patients with 
triglycerides > 2.2 mmol/l and HDL-C < 1.0 mmol/l, virtually all of whom have type 2 
diabetes or abdominal obesity and insulin resistance (Taskinen, 2003). Most of these 
alterations are also characteristic of metabolic syndrome, which is defined as the clustering 
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of multiple metabolic abnormalities, including abdominal obesity, dyslipidemia (high serum 
triglycerides and low serum HDL-C levels), glucose intolerance and hypertension (Eckel et 
al., 2005; Grundy et al., 2005).  
2. Hypertriglyceridemia is crucial in the pathogenesis of atherogenic 
dyslipidemia 
It is now recognized that the atherogenic dyslipidemia is mainly initiated by the hepatic 
overproduction of the plasma lipoproteins carrying triglycerides, the VLDL, which induce a 
sequence of lipoprotein changes leading to atherogenic lipid abnormalities in type 2 
diabetes mellitus and metabolic syndrome (Adiels et al., 2008). Under these pathological 
conditions, the presence of insulin resistance at the level of adipose tissue leads to enhanced 
lypolisis and reduced free fatty acid (FFA) uptake and esterification which results in 
increased flux into the liver of FFA, which are either oxidized or esterified for triglyceride 
production, leading to hepatic steatosis and oversecretion into plasma of larger triglyceride-
rich VLDL particles (Chan & Watts, 2011). These particles compete with chylomicrons and 
its remnants for clearance pathways regulated by lipoprotein lipase, an endothelial-bound 
enzyme, and by hepatic receptors, thereby exacerbating postprandial dyslipidemia. In 
addition, insulin resistance increases hepatic secretion of apoC-III, which is attached to 
VLDL delaying the catabolism of TRLs by inhibiting lipoprotein lipase and binding of 
remnant TRLs to hepatic clearance receptors (Chan & Watts, 2011). Finally, expansion of the 
VLDL triglyceride pool leads to cholesterol depletion and triglyceride enrichment of LDL 
and HDL through cholesteryl ester transfer protein, which facilitates the movement of 
cholesterol esters to VLDL, intermediate-density lipoprotein (IDL) and LDL from cholesterol 
ester rich HDL, leading to the accumulation in plasma of small, dense LDLs and a reduction 
in HDLs (Taskinen, 2003).  
Since residual risk remains even after achieving an optimal LDL-C concentration with 
statins (Barter et al., 2007), probably due to other risk factors, such as high triglycerides, low 
HDL-C levels, defective glucose metabolism and other non-lipid-related risk factors 
(Kannel, 1983; Castelli, 1992; Lorenzo et al., 2010; Cederberg et al., 2010), the development of 
new drugs aimed at improving risk reduction is necessary. Among the new drugs for the 
treatment of the risk factors leading to the residual risk, PPARβ/δ activators might have a 
promising future. Interestingly, PPARβ/δ agonists have been demonstrated to be effective 
raising HDL-C and lowering triglyceride concentrations (Kersten, 2008). In addition to their 
lipid-modifying properties, PPARβ/δ agonists improve insulin resistance, which may also 
confer protection against the development of dyslipidemia (Coll et al., 2010a). This review 
summarizes the effects of PPARβ/δ on dyslipidemia identified during the last few years. 
3. The PPAR family 
PPARs are members of the nuclear receptor superfamily of ligand-activated transcription 
factors that regulate the expression of genes involved in fatty acid uptake and oxidation, 
lipid metabolism and inflammation (Kersten et al., 2000). To be transcriptionally active, 
PPARs need to heterodimerize with the 9-cis retinoic acid receptor (RXR) (NR2B) (Figure 1). 
PPAR-RXR heterodimers bind to DNA-specific sequences called peroxisome proliferator-
response elements (PPREs), consisting of an imperfect direct repeat of the consensus binding 
site for nuclear hormone receptors (AGGTCA) separated by one nucleotide (DR-1). These 
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sequences have been characterized within the promoter regions of PPAR target genes. The 
binding occurs in such a way that PPAR is always oriented to the DNA’s 5’-end, while RXR 
is to the 3’-end. In the absence of ligand, high-affinity complexes are formed between PPAR-
RXR heterodimers and nuclear receptor co-repressor proteins, which block transcriptional 
activation by sequestering the heterodimer from the promoter. Binding of the ligand to 
PPAR induces a conformational change resulting in dissociation of co-repressor proteins, so 
that the PPAR-RXR heterodimer can then bind to PPREs. Moreover, once activated by the 
ligand, the heterodimer recruits co-activator proteins that promote the initiation of 
transcription (Feige et al., 2006). As a consequence of these changes in transcriptional 
activity, binding of ligands to the receptor results in changes in the expression level of 
mRNAs encoded by PPAR target genes. In a specific cellular context, the activity of PPARs 
regulating the transcription of their target genes depends on many factors (relative 
expression of the PPARs, the promoter context of the target gene, the presence of co-
activator and co-repressor proteins, etc.).  
Thus, the transcriptional activity of PPARs is modulated by co-activators and co-repressors 
(Feige et al., 2006). One of the best described PPAR co-activators is PPARγ coactivator 1 α 
(PGC-1α). Silencing mediator for retinoic and thyroid hormone receptor (SMRT) and the 
nuclear receptor co-repressor (NCoR) are co-repressors that interact with the PPARs in the 
absence of ligands (Zamir et al., 1997). Receptor-interacting protein 140 (RIP140), an 
important metabolic regulator, is another ligand-dependent co-repressor which interacts 
with PPARs.  
Finally, PPAR activity is also regulated at the post-transcriptional level by phosphorylation, 
ubiquitinylation, and sumoylation (for a detailed review see (Feige et al., 2006)). 
However, the regulation of gene transcription by PPARs extends beyond their ability to 
trans-activate specific target genes in an agonist-dependent manner. PPARs also regulate 
gene expression independently of binding to PPREs. They cross-talk with other types of 
transcription factors and influence their function without binding to DNA, through a 
mechanism termed receptor-dependent trans-repression (Daynes & Jones, 2002). Most of the 
anti-inflammatory effects of PPARs are probably explained by this mechanism (Kamei et al., 
1996; Li et al., 2000). Thus, through this DNA-binding independent mechanism, PPARs 
suppress the activities of several transcription factors, including nuclear factor κB (NF-κB), 
activator protein 1 (AP-1), signal transducers and activators of transcription (STATs) and 
nuclear factor of activated T cells (NFAT). There are three main trans-repression 
mechanisms by which ligand-activated PPAR-RXR complexes negatively regulate the 
activities of other transcription factors. First, trans-repression may result from competition 
for limiting amounts of shared co-activators. Under conditions in which the levels of specific 
co-activators are rate-limiting, activation of PPAR may suppress the activity of other 
transcription factors that use the same co-activators (Delerive et al., 1999; Delerive et al., 
2002). In the second mechanism, activated PPAR-RXR heterodimers are believed to act 
through physical interaction with other transcription factors (for example AP-1, NF-κB, 
NFAT or STATs). This association prevents the transcription factor from binding to its 
response element and thereby inhibits its ability to induce gene transcription (Desreumaux 
et al., 2001). The third trans-repression mechanism relies on the ability of activated PPAR-
RXR heterodimers to inhibit the phosphorylation and activation of certain members of the 
mitogen-activated protein kinase (MAPK) cascade (Johnson et al., 1997), preventing 
activation of downstream transcription factors. 
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sequences have been characterized within the promoter regions of PPAR target genes. The 
binding occurs in such a way that PPAR is always oriented to the DNA’s 5’-end, while RXR 
is to the 3’-end. In the absence of ligand, high-affinity complexes are formed between PPAR-
RXR heterodimers and nuclear receptor co-repressor proteins, which block transcriptional 
activation by sequestering the heterodimer from the promoter. Binding of the ligand to 
PPAR induces a conformational change resulting in dissociation of co-repressor proteins, so 
that the PPAR-RXR heterodimer can then bind to PPREs. Moreover, once activated by the 
ligand, the heterodimer recruits co-activator proteins that promote the initiation of 
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Thus, the transcriptional activity of PPARs is modulated by co-activators and co-repressors 
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(PGC-1α). Silencing mediator for retinoic and thyroid hormone receptor (SMRT) and the 
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with PPARs.  
Finally, PPAR activity is also regulated at the post-transcriptional level by phosphorylation, 
ubiquitinylation, and sumoylation (for a detailed review see (Feige et al., 2006)). 
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transcription factors and influence their function without binding to DNA, through a 
mechanism termed receptor-dependent trans-repression (Daynes & Jones, 2002). Most of the 
anti-inflammatory effects of PPARs are probably explained by this mechanism (Kamei et al., 
1996; Li et al., 2000). Thus, through this DNA-binding independent mechanism, PPARs 
suppress the activities of several transcription factors, including nuclear factor κB (NF-κB), 
activator protein 1 (AP-1), signal transducers and activators of transcription (STATs) and 
nuclear factor of activated T cells (NFAT). There are three main trans-repression 
mechanisms by which ligand-activated PPAR-RXR complexes negatively regulate the 
activities of other transcription factors. First, trans-repression may result from competition 
for limiting amounts of shared co-activators. Under conditions in which the levels of specific 
co-activators are rate-limiting, activation of PPAR may suppress the activity of other 
transcription factors that use the same co-activators (Delerive et al., 1999; Delerive et al., 
2002). In the second mechanism, activated PPAR-RXR heterodimers are believed to act 
through physical interaction with other transcription factors (for example AP-1, NF-κB, 
NFAT or STATs). This association prevents the transcription factor from binding to its 
response element and thereby inhibits its ability to induce gene transcription (Desreumaux 
et al., 2001). The third trans-repression mechanism relies on the ability of activated PPAR-
RXR heterodimers to inhibit the phosphorylation and activation of certain members of the 
mitogen-activated protein kinase (MAPK) cascade (Johnson et al., 1997), preventing 
activation of downstream transcription factors. 
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The PPAR family consists of three members, PPARα (NR1C1 according to the unified 
nomenclature system for the nuclear receptor superfamily), PPARβ/δ (NR1C2) and PPARγ 
(NR1C3) (Auwerx et al., 1999). PPARα was the first PPAR to be identified and is the 
molecular target of the fibrate hypolipidemic class of drugs. This PPAR isotype is expressed 
primarily in tissues with a high level of fatty acid catabolism such as liver, brown fat, 
kidney, heart and skeletal muscle (Braissant et al., 1996). PPARγ has a restricted pattern of 
expression, mainly in white and brown adipose tissues and macrophages, whereas other 
tissues such as skeletal muscle and heart contain limited amounts. The γ isotype is the 
molecular target for the anti-diabetic drugs, thiazolidinediones. PPARβ/δ is ubiquitously 
expressed and, for this reason, was initially thought to be a “housekeeping gene” (Kliewer et 
al., 1994). However, studies with knockout mice (Barak et al., 2002; Peters et al., 2000; Tan et 
al., 2001) and the development of specific and high-affinity ligands for this receptor have 
shown that PPARβ/δ is a potential molecular target for prevention or treatment of several 
disorders. In this review we will highlight the role of PPARβ/δ in those metabolic processes 
with potential for treating dyslipidemia. 
 
 
Fig. 1. Molecular mechanisms of Peroxisome Proliferator-Activated Receptors (PPARs). 
PPARs are ligand-activated transcription factors that regulate gene expression through two 
mechanisms: transactivation and transrepression. In transactivation PPAR-RXR 
heterodimers bind to DNA-specific sequences called peroxisome proliferator-response 
elements (PPREs), which are located in the promoter regions of genes involved in glucose 
and fatty acid metabolism. PPARs may also regulate gene expression through a DNA-
independent mechanism called transrepression. Through this mechanism, PPARs inhibit the 
activity of several transcription factors such as NF-κB, which leads to anti-inflammatory 
effects. STAT denotes signal transducers and activators of transcription. 
4. PPARβ/δ-specific features and ligands 
The crystal structure of the ligand-binding domain of the PPARβ/δ isotype, which was 
first cloned in Xenopus laevis (Dreyer et al., 1992), revealed an exceptionally large pocket of 
approximately 1300 Å3. This pocket is similar to that of PPARγ, but much larger than the 
pockets of other nuclear receptors (Takada et al., 2000; Xu et al., 1999), which may explain, 
at least in part, the great variety of natural and synthetic ligands that bind to and activate 
this nuclear receptor. Saturated (14 to 18 carbons) and polyunsaturated (20 carbons in 
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length) fatty acids have affinities for PPARβ/δ in the low micromolar range (Xu et al., 
1999; Forman et al., 1997; Yu et al., 1995; Krey et al., 1997). In addition, all-trans-retinoic 
acid (vitamin A) (Shaw et al., 2003) and fatty acids derived from VLDL (Chawla et al., 
2003) can activate PPARβ/δFinally, the availability of three synthetic ligands (GW501516, 
GW0742 and L-165041) that activate PPARβ/δ at very low concentrations both in vivo 
and in vitro with high selectivity over other PPAR isotypes (Sznaidman et al., 2003) led to 
a huge increase in experimental studies on the role of PPARβ/δ in cellular processes. The 
EC50 for these compounds assessed with recombinant human PPARβ/δ were 1.0 nM for 
GW0742, 1.1 nM for GW501516 and 50 nM for L-165041 (Berger et al., 1999; Sznaidman et 
al., 2003).  
5. Role of PPARβ/δ in lipoprotein metabolism  
Treatment of the atherogenic dyslipidemia associated with type 2 diabetes mellitus and 
metabolic syndrome requires lowering triglycerides, increasing HDL-C and increasing the 
size of the LDL-C particle. Studies using the PPARβ/δ agonist GW501516 have 
demonstrated that this drug increased HDL-C (79%), and decreased triglycerides (56%), 
LDL-C (29%) and fasting insulin levels (48%) in obese rhesus monkeys, a model for human 
obesity and its associated metabolic disorders (Oliver, Jr. et al., 2001). A decrease in small 
dense LDL was also observed in treated animals (Oliver, Jr. et al., 2001). It has been 
suggested that the increase in HDL-C levels after PPARβ/δ treatment is caused by enhanced 
cholesterol efflux stimulated by a higher expression of the reverse cholesterol transporter 
ATP-binding cassette A1 (ABCA1) in several tissues, including human and mouse 
macrophages and intestinal cells and fibroblasts (Leibowitz et al., 2000; van, V et al., 2005). 
Apart from these beneficial effects of PPARβ/δ activation on HDL levels, treatment with 
this compound also increased HDL particle size in primates (Wallace et al., 2005), an effect 
which is thought to be protective against the progression of coronary artery disease in 
humans (Rosenson et al., 2002). In addition, PPARβ/δ activation reduces cholesterol 
absorption through a mechanism that may involve, at least in part, reduced intestinal 
expression of Niemann-Pick C1-like 1 (Npc1l1), the proposed target for the inhibitor of 
cholesterol absorption ezetimibe (van, V et al., 2005). However, additional studies are 
necessary to clearly demonstrate that the effects of these drugs are mediated through 
PPARβ/δ activation.  
In obese and diabetic db/db mice, administration of a PPARβ/δ agonist modestly increased 
HDL particles, without affecting triglyceride levels (Leibowitz et al., 2000), whereas in a 
shorter treatment with GW501516 a reduction in plasma free fatty acids and triglyceride 
levels was observed in db/db mice, but not in mice exposed to a high fat diet (Tanaka et al., 
2003).  
In mice, deletion of PPARβ/δ  led to enhanced LDL and triglyceride levels (Akiyama et al., 
2004). It has been proposed that the increase in triglycerides observed in these PPARβ/δ-
null mice is caused by a combination of increased VLDL production and decreased plasma 
triglyceride clearance, as demonstrated by a decrease in postheparin LPL activity and 
increased hepatic expression of the LPL inhibitors Angptl3 and 4 (Akiyama et al., 2004). 
Recent findings obtained by our laboratory indicate that additional mechanisms can also 
contribute to the hypotriglyceridemic effect of PPARβ/δ (Barroso et al., 2011). Interestingly, 
the main factor influencing hepatic triglyceride secretion is fatty acid availability (Lewis, 
1997). In liver, fatty acids are either incorporated into triglycerides or oxidized by 
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length) fatty acids have affinities for PPARβ/δ in the low micromolar range (Xu et al., 
1999; Forman et al., 1997; Yu et al., 1995; Krey et al., 1997). In addition, all-trans-retinoic 
acid (vitamin A) (Shaw et al., 2003) and fatty acids derived from VLDL (Chawla et al., 
2003) can activate PPARβ/δFinally, the availability of three synthetic ligands (GW501516, 
GW0742 and L-165041) that activate PPARβ/δ at very low concentrations both in vivo 
and in vitro with high selectivity over other PPAR isotypes (Sznaidman et al., 2003) led to 
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EC50 for these compounds assessed with recombinant human PPARβ/δ were 1.0 nM for 
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size of the LDL-C particle. Studies using the PPARβ/δ agonist GW501516 have 
demonstrated that this drug increased HDL-C (79%), and decreased triglycerides (56%), 
LDL-C (29%) and fasting insulin levels (48%) in obese rhesus monkeys, a model for human 
obesity and its associated metabolic disorders (Oliver, Jr. et al., 2001). A decrease in small 
dense LDL was also observed in treated animals (Oliver, Jr. et al., 2001). It has been 
suggested that the increase in HDL-C levels after PPARβ/δ treatment is caused by enhanced 
cholesterol efflux stimulated by a higher expression of the reverse cholesterol transporter 
ATP-binding cassette A1 (ABCA1) in several tissues, including human and mouse 
macrophages and intestinal cells and fibroblasts (Leibowitz et al., 2000; van, V et al., 2005). 
Apart from these beneficial effects of PPARβ/δ activation on HDL levels, treatment with 
this compound also increased HDL particle size in primates (Wallace et al., 2005), an effect 
which is thought to be protective against the progression of coronary artery disease in 
humans (Rosenson et al., 2002). In addition, PPARβ/δ activation reduces cholesterol 
absorption through a mechanism that may involve, at least in part, reduced intestinal 
expression of Niemann-Pick C1-like 1 (Npc1l1), the proposed target for the inhibitor of 
cholesterol absorption ezetimibe (van, V et al., 2005). However, additional studies are 
necessary to clearly demonstrate that the effects of these drugs are mediated through 
PPARβ/δ activation.  
In obese and diabetic db/db mice, administration of a PPARβ/δ agonist modestly increased 
HDL particles, without affecting triglyceride levels (Leibowitz et al., 2000), whereas in a 
shorter treatment with GW501516 a reduction in plasma free fatty acids and triglyceride 
levels was observed in db/db mice, but not in mice exposed to a high fat diet (Tanaka et al., 
2003).  
In mice, deletion of PPARβ/δ  led to enhanced LDL and triglyceride levels (Akiyama et al., 
2004). It has been proposed that the increase in triglycerides observed in these PPARβ/δ-
null mice is caused by a combination of increased VLDL production and decreased plasma 
triglyceride clearance, as demonstrated by a decrease in postheparin LPL activity and 
increased hepatic expression of the LPL inhibitors Angptl3 and 4 (Akiyama et al., 2004). 
Recent findings obtained by our laboratory indicate that additional mechanisms can also 
contribute to the hypotriglyceridemic effect of PPARβ/δ (Barroso et al., 2011). Interestingly, 
the main factor influencing hepatic triglyceride secretion is fatty acid availability (Lewis, 
1997). In liver, fatty acids are either incorporated into triglycerides or oxidized by 
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mitochondrial -oxidation. An increase in fatty acid oxidation in liver would thus reduce the 
availability of fatty acids and subsequent hepatic triglyceride secretion. However, it was 
unknown whether the hypotriglyceridemic effect observed following PPAR/ activation 
involved increased hepatic fatty acid oxidation and the mechanisms implicated. The rate-
limiting step for mitochondrial -oxidation is the transport of fatty acid into mitochondria 
by liver carnitine palmitoyltransferase-1 (CPT1a). This fatty acid transporter is under the 
control of both PPARs and AMP-activated protein kinase (AMPK), which detects low ATP 
levels and in turn increases oxidative metabolism (Zhang et al., 2009) by reducing the levels 
of malonyl-CoA. Interestingly, PPAR/ activation can increase the activity of AMPK and 
the increase in fatty acid oxidation in human skeletal muscle cells following GW501516 
treatment is dependent on both PPAR/ and AMPK (Kramer et al., 2007). It is worth 
noting that a recent discovered protein, lipin 1, plays an important role in hepatic fatty acid 
oxidation since it determines whether fatty acids are incorporated into triglycerides or 
undergo mitochondrial -oxidation. In addition, the expression and compartmentalization 
of lipin 1 controls the secretion of hepatic triglycerides (Bou et al., 2009). Thus, in the 
cytoplasm, lipin 1 promotes triglyceride accumulation and phospholipid synthesis by 
functioning as an Mg2+-dependent phosphatidate phosphatase (phosphatidic acid 
phosphatase-1, PAP-1). In contrast, in the nucleus lipin 1 acts as a transcriptional co-
activator linked to fatty acid oxidation by regulating the induction of PGC-1α-PPARα-target 
genes (Finck et al., 2006). Lipin 1 induces PPARα gene expression and forms a complex with 
PPARα and PGC-1α leading to the induction of genes involved in fatty acid oxidation, 
including Cpt1a and Mcad (medium chain acyl-CoA dehydrogenase ) (Finck et al., 2006). 
When we examined the effects a high-fat diet (HFD) on hypertriglyceridemia and on the 
hepatic fatty acid oxidation pathway, we observed that exposure to HFD caused 
hypertriglyceridemia that was accompanied by reduced hepatic mRNA levels of PGC-1α 
and lipin 1, reduced hepatic phospho-AMPK levels and increased activity of extracellular-
signal-regulated kinase 1/2 (ERK1/2) (Figure 2). Interestingly, drug treatment reduced 
hypertriglyceridemia, and restored hepatic phosphorylated levels of AMPK and ERK1/2. 
GW501516 treatment increased nuclear lipin 1 protein levels, leading to amplification of the 
PGC-1α-PPARα signaling system, as demonstrated by the increase in PPARα levels and 
PPARα-DNA binding activity and the increased expression of PPARα-target genes involved 
in fatty acid oxidation. These effects of GW501516 were accompanied by an increase in 
plasma -hydroxybutyrate levels, demonstrating enhanced hepatic fatty acid oxidation. 
The maintenance of AMPK phosphorylation following GW501516 treatment was 
accompanied by the recovery in the expression levels of Lipin 1 and Pgc-1α and the increase 
in the mRNA levels of the Vldl receptor (Figure 2). Although we cannot rule out direct 
transcriptional activation of these genes by PPARβ/δ since it has been suggested that Lipin 
1, the Vldl receptor (Sanderson et al., 2010) and Pgc-1α (Hondares et al., 2007) might be 
PPARβ/δ-target genes, most effects of GW501516 might be the result of the increase in 
AMPK phosphorylation (Kramer et al., 2007). In fact, it has been reported that this kinase 
upregulates the expression of Lipin 1 (Higashida et al., 2008), the Vldl receptor (Zenimaru et 
al., 2008) and Pgc-1α (Lee et al., 2006b). The increase in AMPK phosphorylation following 
GW501516 treatment might involve several mechanisms. Since inhibitory crosstalk between 
ERK1/2 and AMPK has been reported (Du et al., 2008), the increase in phospho-AMPK 
levels could be the result of the inhibition by GW501516 of the phosphorylation of ERK1/2 
induced by the HFD, which is in agreement with our previous study reporting that 
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GW501516 prevents LPS-induced ERK1/2 phosphorylation in adipocytes (Rodriguez-Calvo 
et al., 2008). It is important to note that a previous study found that obesity leads to 
increased hepatic ERK1/2 activity and that caloric restriction blunts this increase and 
improves insulin sensitivity (Zheng et al., 2009). In our study, the improvement in glucose 
tolerance caused by GW501516 was also accompanied by the reduction in phospho-ERK1/2 
levels. An additional mechanism could involve SIRT1, since it has recently been reported 
that pharmacological PPARβ/δ activation increases the expression of SIRT1 (Okazaki et al., 
2010), a deacetylase which regulates AMPK activity (Ruderman et al., 2010) through LKB1 
acetylation (Lan et al., 2008), and might be essential to the regulatory loop involving PPARα, 
PGC-1α and Lipin 1 (Sugden et al., 2010). However, our findings made this possibility 
unlikely given that the increase in SIRT1 levels induced by GW501516 did not modify the 
acetylation status of LKB1. Interestingly, we showed that GW501516 increased the 
AMP/ATP ratio in liver, indicating that, in line with a previous study in skeletal muscle 
cells (Kramer et al., 2007), the underlying mechanism responsible for the increase in AMPK 
phosphorylation induced by this drug could be a modification of the cellular energy status. 
Previous studies have suggested that the reduction in ATP levels caused by GW501516 can 
be the result of a specific inhibition of one or more complexes of the respiratory chain, an 
effect on the ATP synthase system, or to mitochondrial uncoupling (Kramer et al., 2007). 
These potential changes would reduce the yield of ATP synthesis by the mitochondria, 
leading to AMPK activation.  
In agreement with the reported regulation of PGC-1α (Canto et al., 2009; Jeninga et al., 2010; 
Lee et al., 2006a) and Lipin 1 (Higashida et al., 2008) by AMPK, exposure to the HFD 
reduced both Pgc-1α and Lipin 1 expression. The reduction in Lipin 1 was likely to be the 
result of the decrease of PGC-1α, since it has been reported that genetic reduction of hepatic 
PGC-1α decreases the expression of Lipin 1 (Estall et al., 2009). In addition, it has been 
shown that physiological stimuli that increase mitochondrial fatty acid oxidation induce 
Pgc-1α gene expression, which in turn activates the expression of Lipin 1 (Finck et al., 2006). 
Interestingly, it has been reported that upregulation of Lipin 1 in liver increases PPARα 
activity by two mechanisms: transcriptional activation of the Pparα gene and direct 
coactivation of PPARα in cooperation with PGC-1α (Finck et al., 2006). Thus, Lipin 1 is 
considered to be an inducible “booster” that amplifies pathways downstream PGC-1α-
PPARα, mainly mitochondrial fatty acid oxidation (Finck et al., 2006). In agreement with 
this, GW501516 treatment prevented the reduction in PGC-1α, increased the nuclear protein 
levels of Lipin 1 and amplified the PGC-1αPPARα pathway, as demonstrated by the 
increase in the transcriptional activation of Pparα and the increase in PPARα transcriptional 
activity. These effects subsequently enhanced hepatic fatty acid oxidation, as shown by the 
increase in -hydroxybutyrate levels. The reduction in PGC-1α and Lipin 1 levels caused by 
the HFD and their restoration after GW501516 treatment observed in our study might also 
contribute to the changes of plasma triglyceride levels, since both proteins are involved in 
the control of hepatic triglyceride secretion and fatty acid oxidation (Zhang et al., 2004; Chen 
et al., 2008; Estall et al., 2009). Overall, these data implicated PGC-1α and Lipin 1 in the 
hypotriglyceridemic effect of PPARβ/δ  and complemented the findings of a previous study 
reporting that elevated plasma triglyceride levels in PPARβ/δ-null mouse were related to a 
combination of increased VLDL production and decreased plasma triglyceride clearance 
(Akiyama et al., 2004). 
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Fig. 2. A schematic of the potential effects of GW501516 (dashed lines) on liver metabolism 
is shown. Drug treatment with the PPAR/ agonist GW501516 prevents the reduction in 
phospho-AMPK levels and the subsequent increase in phospho-ERK1/2 levels caused by 
the HFD. In addition, GW501516 prevents the reduction in PGC-1α and increases Lipin 1 
protein levels in the nucleus leading to amplification of the PPARα-PGC-1α pathway, which 
subsequently induces hepatic fatty acid oxidation. This pathway is additionally increased by 
GW501516 through the enhanced synthesis of the hepatic PPARα endogenous ligand 
16:0/18:1-PC. As a result of the increase in this pathway the availability of fatty acids to be 
secreted as triglycerides might be compromised. The increase in the hepatic levels of the 
Vldl receptor can also contribute to reduce plasma triglyceride levels.  
The data reported in our study also demonstrated that PPARβ/δ activation by GW501516 
can amplify the PPARα pathway by an additional mechanism. Previous studies had 
demonstrated that hepatic fatty acid synthase (FAS) was necessary for the normal activation 
of PPARα target genes but did not identify the ligand involved in this process 
(Chakravarthy et al., 2005). Recently, this endogenous PPARα ligand was identified as 
16:0/18:1-phosphatidilcholine (PC) (Chakravarthy et al., 2009). The synthesis of this ligand 
requires FAS activity, which yields palmitate (16:0), whereas 16:0/18:1-PC is generated 
through the enzymatic activity of CEPT1 (Chakravarthy et al., 2009). Subsequent binding of 
16:0/18:1-PC to PPARα in the nucleus turns on PPARα-dependent genes and affects hepatic 
lipid metabolism. Interestingly, activation of PPARβ/δ by GW501516 induces FAS 
expression in liver as a result of increased glycolysis and the pentose phosphate shunt (Lee 
et al., 2006a). Our findings confirmed that GW501516 also increased Cept1 expression and 
the levels of 16:0/18:1-PC, contributing to further amplification of the PPARα pathway.  
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The increase in fatty acid oxidation caused by GW501516 was apparently inconsistent with 
its lack of effects on hepatic triglyceride levels observed in our study. Several reasons may 
account for this. First, similar to the effects of GW501516, which restores Lipin 1 levels, 
hepatic Lipin 1 overexpression leads to increased liver triglyceride content (Finck et al., 
2006). This apparently conflicts with the effects of Lipin 1 on fatty acid oxidation, but it has 
been explained by hepatic triglyceride sequestration secondary to diminished triglyceride 
secretion, increased fatty acid uptake, or the PAP activity of Lipin 1 (Finck et al., 2006). 
Second, in our study we reported an additional possibility, the increase caused by 
GW501516 in the expression of the Vldl receptor in liver. The huge increase of this receptor 
observed in liver after GW501516 treatment might also reduce plasma triglyceride levels by 
increasing VLDL uptake by the liver. However, this can also lead to an increase in hepatic 
triglyceride content. Third, it has been reported that GW501516 improves hyperglycemia by 
increasing glucose flux through the pentose phosphate pathway and enhancing fatty acid 
synthesis in liver (Lee et al., 2006a). In that study, GW501516 increased liver triglyceride 
content but the authors reported that although this might raise concerns that long-term drug 
treatment might cause hepatic steatosis, they did not observe signs of fatty liver with 
treatment up to 6 months. In addition, long-term GW501516 treatment has been shown to 
reduce body weight and levels of circulating and liver triglycerides (Wang et al., 2004; 
Tanaka et al., 2003). In summary, our findings indicated that PPAR/ activation by 
GW501516 amplified the PPARα-PGC1-α pathway through the restoration of AMPK 
activity, contributing to the hypotriglyceridemic effect of this drug. 
In humans, there are conflicting reports as to whether PPARβ/δ polymorphisms are 
associated with changes in plasma lipoproteins. Thus, while some studies found an 
association between a PPARβ/δ polymorphism and plasma lipids (Skogsberg et al., 2003), 
this was not confirmed in other studies (Gouni-Berthold et al., 2005). These discrepancies 
could be caused by differences in gender or the influence of gene-environment interactions, 
since a recent study reported that the association between the PPARβ/δ -87T>C 
polymorphism and plasma HDL-cholesterol might be sex-specific, women showing a 
stronger association, and that this association was only observed in subjects consuming a 
low-fat diet (Robitaille et al., 2007). The authors of this study concluded that the presence of 
the PPARβ/δ -87T>C polymorphism, which may result in enhanced PPARβ/δ activity, is 
associated with lower risk of suffering metabolic syndrome and that this association 
depends on the amount of fat consumed. In summary, the findings available at present on 
the effects of PPARβ/δ activation on lipoprotein metabolism are so promising that 
PPARβ/δ drugs are now in clinical trials for the treatment of human dyslipidemia.  
6. Role of PPARβ/δ in insulin resistance 
As stated above insulin resistance plays a crucial role in the development of 
hypertrigliceridemia, resulting in a sequence of lipoprotein changes leading to atherogenic 
dyslipidemia. Thus, those drugs, such as the PPARβ/δ ligands, which improve insulin 
resistance may also contribute to ameliorate the atherogenic dyslipidemia. 
6.1 PPARβ/δ, inflammation and insulin resistance in adipose tissue 
The expansion of adipose tissue, mainly in the form of visceral obesity, may contribute to 
enhanced inflammation in this tissue and insulin resistance through several processes. First, 
macrophages can infiltrate in adipose tissue, which contributes to the overproduction of 
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inflammatory cytokines, such as tumor necrosis factor α (TNF-α and interleukin 6 (IL-6) 
(Gustafson et al., 2009). Indeed, the infiltration of macrophages into adipose tissue correlates 
with the degree of insulin resistance (Mathieu et al., 2010). Second, as visceral fat (which is 
very sensitive to lipolytic stimuli) increases, so does the rate of lipolysis. This leads to 
increased free fatty acid (FFA) mobilization and elevated levels of circulating FFA. Several 
studies have consistently demonstrated that elevations of plasma FFA produce insulin 
resistance in diabetic patients and in nondiabetic subjects (Boden et al., 1991; Boden, 1997). 
Saturated FFA are potent activators of the Toll-like receptor-4 (TLR4) (Mathieu et al., 2006) 
and recent evidence suggests that inflammatory processes induced by obesity and a high-fat 
diet cause systemic insulin resistance via a mechanism involving this receptor (Shi et al., 
2006). TLR-4 is expressed in virtually all human cells and binds a wide spectrum of 
exogenous and endogenous ligands, including bacterial lipopolysaccharide (LPS) (Akira et 
al., 2006). In the presence of LPS, the TLR4 complex (including CD-14 and an accessory 
protein, MD-2), recruits the adaptor protein, myeloid differentiation factor-88 (MyD88), 
which in turn recruits interleukin-1 receptor-associated kinase (IRAK). This leads to the 
activation of the pro-inflammatory transcription factor NF-κB (Shoelson et al., 2006) and the 
subsequent enhanced expression of several inflammatory mediators (including IL-6 and 
monocyte chemoattractant protein-1 [MCP-1]). These observations indicate that saturated 
FFA derived from adipocytes and from high-fat diets activate TLR and the inflammatory 
pathway in adipocytes and macrophages, which contribute to the synthesis and production 
of cytokines such as TNF-α (Nguyen et al., 2007). In addition, high-fat diets raise plasma 
LPS to a concentration that is high enough to increase body weight, fasting glycemia and 
inflammation (Cani et al., 2007). Furthermore, LPS receptor-deleted mice (CD14 mutants) 
are hypersensitive to insulin, and the development of insulin resistance, obesity and 
diabetes in this animal model is delayed in response to a high-fat diet (Cani et al., 2007). 
Experiments performed in our laboratory have demonstrated that the PPARβ/δ agonist 
GW501516 inhibits LPS-induced cytokine expression and secretion by preventing NF-κB 
activation in adipocytes (Rodriguez-Calvo et al., 2008). Of note, NF-κB activation by LPS 
requires mitogen-activated protein kinase (MAPK)–extracellular signal–related kinase 
(ERK)1/2 (MEK1/2) activation, since inhibition of this pathway reduces LPS-induced 
cytokine production in adipocytes (Chung et al., 2006). In agreement with this role of 
ERK1/2 in inflammation in adipocytes, the expression of pro-inflammatory cytokines in 
these cells drops when they are exposed to LPS in the presence of the MAPK pathway 
inhibitor U0126. Interestingly, in white adipose tissue from PPARβ/δ-null mice we 
observed increased ERK1/2 phosphorylation and NF-κB activity and higher expression of 
IL-6 compared with wild-type mice (Rodriguez-Calvo et al., 2008). Moreover, in the white 
adipose tissue of a genetic model of obesity and diabetes, the Zucker diabetic fatty (ZDF) 
rat, the reduction in the expression of PPARβ/δ correlated with an increase in ERK1/2 
phosphorylation and NF-κB activity. These findings suggest that PPARβ/δ activation 
prevents LPS-induced NF-κB activation via ERK1/2, thereby reducing the production of 
pro-inflammatory cytokines involved in the development of insulin resistance.  
In addition, it has been suggested that IL-6 is another of the mediators linking obesity-
derived chronic inflammation with insulin resistance through activation of signal transducer 
and activator of transcription 3 (STAT3), with subsequent up-regulation of suppressor of 
cytokine signaling 3 (SOCS3). Recently we have demonstrated that the PPARβ/δ agonist 
GW501516 prevents both IL-6-dependent reduction in insulin-stimulated Akt 
phosphorylation and glucose uptake in adipocytes (Serrano-Marco et al., 2011). In addition, 
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this drug treatment abolished IL-6-induced SOCS3 expression in differentiated 3T3-L1 
adipocytes. This effect was associated with the capacity of the drug to prevent IL-6-induced 
STAT3 phosphorylation on Tyr705 and Ser727 residues in vitro and in vivo. Moreover, 
GW501516 prevented IL-6-dependent induction of ERK1/2, a serine-threonine-protein 
kinase involved in serine STAT3 phosphorylation. Furthermore, in white adipose tissue 
from PPARβ/δ-null mice, STAT3 phosphorylation (Tyr705 and Ser727), STAT3 DNA-binding 
activity and SOCS3 protein levels were higher than in wild-type mice. Several steps in 
STAT3 activation require its association with heat shock protein 90 (Hsp90), which was 
prevented by GW501516 as revealed in immunoprecipitation studies. Consistent with this 
finding, the STAT3-Hsp90 association was enhanced in white adipose tissue from 
PPARβ/δ-null mice compared to wild-type mice. Collectively, our findings indicate that 
PPARβ/δ activation prevents IL-6-induced STAT3 activation by inhibiting ERK1/2 and 
preventing the STAT3-Hsp90 association, an effect that may contribute to the prevention of 
cytokine-induced insulin resistance in adipocytes. 
6.2 PPARβ/δ, inflammation and insulin resistance in skeletal muscle cells 
FFAs may cause insulin resistance in skeletal muscle through several mechanisms, including 
effects on metabolism (Roden et al., 1996; Haber et al., 2003), signaling (Hirabara et al., 2007; 
Silveira et al., 2008) and mitochondrial function (Schrauwen et al., 2010; Hirabara et al., 
2010). In addition, FFAs activate pro-inflammatory pathways, linking the development of 
this pathology to a chronic low-grade systemic inflammatory response (Wellen & 
Hotamisligil, 2005). In addition to FFA-induced inflammation through TLR, an additional 
pathway leads to FFA-mediated inflammation. This pathway involves intracellular 
accumulation of fatty acid derivatives. Once fatty acids are taken up by skeletal muscle cells 
they are either stored as fatty acid derivatives or undergo β-oxidation in the mitochondria. 
In the presence of high plasma FFA, fatty acid flux in skeletal muscle cells exceeds its 
oxidation, which leads to the accumulation of fatty acid derivatives, such as diacylglycerol 
(DAG), which can then activate a number of different serine kinases that negatively regulate 
insulin action. Thus, DAG is a potent allosteric activator of protein kinase Cθ (PKCθ), which 
is the most abundant PKC isoform in skeletal muscle (Griffin et al., 1999; Cortright et al., 
2000; Itani et al., 2000). This PKC isoform inhibits the action of insulin by phosphorylating 
certain serine residues on insulin receptor substrate 1 (IRS1), including Ser307 in the rodent 
IRS-1 protein (reviewed in ref. (Gual et al., 2005)). This phosphorylation impairs insulin-
receptor signaling through several distinct mechanisms (Hotamisligil et al., 1996). PKC also 
impairs insulin sensitivity by activating another serine kinase, IκB kinase β (IKKβ) 
(Perseghin et al., 2003). In addition to phosphorylating IRS-1 in Ser307, IKKβ phosphorylates 
IκB. Thus, it activates the pro-inflammatory transcription factor NF-κB, which has been 
linked to fatty acid-induced impairment of insulin action in skeletal muscle in rodents (Kim 
et al., 2001; Yuan et al., 2001). Once activated, NF-κB regulates the expression of multiple 
inflammatory mediators, including IL-6. This cytokine correlates strongly with insulin 
resistance and type 2 diabetes (Pickup et al., 1997; Kern et al., 2001; Pradhan et al., 2001) and 
its plasma levels are 2-3 times higher in patients with obesity and type 2 diabetes than in 
lean control subjects (Kern et al., 2001). 
Accumulation of fatty acid derivatives can be attenuated by mitochondrial β-oxidation. The 
rate-limiting step for β-oxidation of long-chain fatty acids is their transport into 
mitochondria via CPT-1. The activity of this enzyme is inhibited by malonyl-CoA, the 
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product of acetyl-CoA carboxylase, which, in turn, is inhibited by AMPK. This kinase is a 
metabolic sensor that detects low ATP levels and increases oxidative metabolism (Reznick & 
Shulman, 2006), by reducing the levels of malonyl-CoA. Interestingly, activation of fatty acid 
oxidation by overexpressing CPT-1 in cultured skeletal muscle cells (Sebastian et al., 2007) 
and in mouse skeletal muscle (Bruce et al., 2009) improves lipid-induced insulin resistance. 
Hence, this approach may provide a valid therapeutic strategy to prevent this pathology. 
Activation of PPARβ/δ by its ligands (including GW501516) enhances fatty acid catabolism 
in adipose tissue and skeletal muscle, thereby delaying weight gain (for a review see (Barish 
et al., 2006)). This increase in fatty acid oxidation in human skeletal muscle cells following 
PPARβ/δ activation by GW501516 is dependent on both PPARβ/δ and AMPK (Kramer et 
al., 2007). AMPK is activated by GW501516 by modulating the ATP:AMP ratio (Kramer et 
al., 2007). Despite these data, little information was available on whether the increase in fatty 
acid oxidation attained after PPARβ/δ activation prevented fatty acid-induced 
inflammation and insulin resistance in skeletal muscle cells. However, we have recently 
reported that the PPARβ/δ ligand GW501516 prevented palmitate-induced inflammation 
and insulin resistance in skeletal muscle cells (Coll et al., 2010b). Treatment with GW501516 
enhanced the expression of two-well known PPARβ/δ-target genes involved in fatty acid 
oxidation, CPT-1 and pyruvate dehydrogenase kinase 4 (PDK-4), and increased the 
phosphorylation of AMPK. This prevented the reduction in fatty acid oxidation caused by 
palmitate exposure. In agreement with these changes, GW501516 treatment reversed the 
increase in DAG and PKCθ activation caused by palmitate. These effects were abolished in 
the presence of the CPT-1 inhibitor etomoxir, thereby implicating increased fatty acid 
oxidation in the changes. Consistent with these findings, PPARβ/δ activation by GW501516 
blocked palmitate-induced NF-κB DNA-binding activity. Likewise, drug treatment inhibited 
the increase in IL-6 expression caused by palmitate in C2C12 myotubes and human skeletal 
muscle cells, as well as the protein secretion of this cytokine. Overall, these findings indicate 
that PPARβ/δ attenuates fatty acid-induced NF-κB activation and the subsequent 
development of insulin resistance in skeletal muscle cells by reducing DAG accumulation. 
Interestingly, it has been suggested that the hypotrigliceridemic effect of GW501516 in 
humans is dependent of the increase in CPT-1 expression observed in skeletal muscle 
(Riserus et al., 2008). 
7. Conclusion 
Reduction of LDL-C, the main target of hypolipidemic therapy, has been proved effective 
reducing morbidity and mortality associated to CVD. However, a high proportion of 
patients receiving statins, the most lipid-lowering family of drugs used, do not reach 
optimal LDL-C levels. In addition, even in those patients reaching the optimal LDL-C levels 
following statin treatment, a residual risk remains, probably due to the presence of other 
risk factors, including the presence of atherogic dyslipidemia (described by the presence of 
high triglycerides, low HDL-C levels, and the presence of small dense LDL particles), 
glucose metabolism alterations and additional non-lipid-related risk factors. Several studies 
have confirmed that PPARβ/δ plays an important role in the regulation of lipoprotein 
metabolism, leading to reductions in the levels of plasma triglycerides and LDL-C and 
increases in HDL-C in different animal models. Taken together, these effects attained 
following PPARβ/δ activation on lipoprotein metabolism are so promising that this nuclear 
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receptor has been considered a therapeutic target to prevent and treat dyslipidemia. 
However, as with any drug designed for human therapy, a great deal of research will be 
needed on the efficacy and safety of PPARβ/δ activators before they reach clinical use.  
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1. Introduction 
Control of energy metabolism is crucial for optimal functioning of organs and tissues. 
Amongst all nutrients, glucose is the principal energy source for most cells and, therefore, 
minimum blood glucose levels must be guaranteed. Alterations in glycaemia can lead to 
hyperglycaemic states (producing protein glycosylation and toxicity in glucose-sensitive 
cells) or hypoglycaemic states (that can affect brain function), both harmful. Therefore, 
mechanisms must exist to keep glycaemia in a narrow physiological range (4-8 mM) 
independently of the nutritional state. To achieve control of blood glucose levels, our body 
has a complex, interorgan signaling system using nutrients (glucose, lipids, amino acids), 
hormones (insulin, glucagon, ghrelin, etc.) and the autonomic nervous system. In response 
to these signals, organs and tissues (mainly intestine, endocrine pancreas, liver, skeletal 
muscle, adipose tissue, brain and adrenal glands) adapt their function to energetic 
requirements. 
The liver plays a pivotal role in the maintenance of glucose homeostasis by continuously 
adapting its metabolism to energetic needs. In the fed state, when blood glucose levels are 
high and there is insulin, liver takes-up part glucose to replenish glycogen stores. Besides, 
when glucose stores are full, the liver has the capacity to synthesize lipids de novo from 
glucose for-long term energy storage. Lipids are packaged in very low-density lipoprotein 
(VLDL) particles and then transported to the adipose tissue. Conversely during starvation, 
when glycaemia falls and glucagon increases, the liver produces glucose to maintain 
circulating glucose levels by breaking down glycogen stores or by synthesizing glucose de 
novo through gluconeogenesis. Gluconeogenesis, as an energy-consuming pathway, is 
linked to β-oxidation of fatty acids (fuel supplier pathway). 
From this introduction on the regulation of glucose homeostasis, one can appreciate the 
close relation that exists between carbohydrate metabolism and lipid metabolism in the 
liver. Therefore, alterations in hepatic carbohydrate metabolic pathways may directly 
affect hepatic and/or blood lipid levels. Particularly, this chapter will focus on evaluating 
the incidence of glucokinase (GK) –the first enzyme of the glycolytic pathway in the liver- 
on lipidemia and on hepatic lipid content. But first, an introductory overview of the 
physiology behind the first-pass metabolism of dietary glucose in the liver will be 
presented. 
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1. Introduction 
Control of energy metabolism is crucial for optimal functioning of organs and tissues. 
Amongst all nutrients, glucose is the principal energy source for most cells and, therefore, 
minimum blood glucose levels must be guaranteed. Alterations in glycaemia can lead to 
hyperglycaemic states (producing protein glycosylation and toxicity in glucose-sensitive 
cells) or hypoglycaemic states (that can affect brain function), both harmful. Therefore, 
mechanisms must exist to keep glycaemia in a narrow physiological range (4-8 mM) 
independently of the nutritional state. To achieve control of blood glucose levels, our body 
has a complex, interorgan signaling system using nutrients (glucose, lipids, amino acids), 
hormones (insulin, glucagon, ghrelin, etc.) and the autonomic nervous system. In response 
to these signals, organs and tissues (mainly intestine, endocrine pancreas, liver, skeletal 
muscle, adipose tissue, brain and adrenal glands) adapt their function to energetic 
requirements. 
The liver plays a pivotal role in the maintenance of glucose homeostasis by continuously 
adapting its metabolism to energetic needs. In the fed state, when blood glucose levels are 
high and there is insulin, liver takes-up part glucose to replenish glycogen stores. Besides, 
when glucose stores are full, the liver has the capacity to synthesize lipids de novo from 
glucose for-long term energy storage. Lipids are packaged in very low-density lipoprotein 
(VLDL) particles and then transported to the adipose tissue. Conversely during starvation, 
when glycaemia falls and glucagon increases, the liver produces glucose to maintain 
circulating glucose levels by breaking down glycogen stores or by synthesizing glucose de 
novo through gluconeogenesis. Gluconeogenesis, as an energy-consuming pathway, is 
linked to β-oxidation of fatty acids (fuel supplier pathway). 
From this introduction on the regulation of glucose homeostasis, one can appreciate the 
close relation that exists between carbohydrate metabolism and lipid metabolism in the 
liver. Therefore, alterations in hepatic carbohydrate metabolic pathways may directly 
affect hepatic and/or blood lipid levels. Particularly, this chapter will focus on evaluating 
the incidence of glucokinase (GK) –the first enzyme of the glycolytic pathway in the liver- 
on lipidemia and on hepatic lipid content. But first, an introductory overview of the 
physiology behind the first-pass metabolism of dietary glucose in the liver will be 
presented. 
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2. Liver glucose metabolism 
After a meal rich in carbohydrates, high levels of glucose reach the liver via portal vein. 
Glucose enters passively the hepatocyte through GLUT-2, a facilitated glucose transporter, 
and then is rapidly phosphorylated by GK at the sixth carbon to obtain glucose-6-phosphate 
which cannot escape the cell. From a functional perspective, it is important to recognize that 
both GLUT2 and glucokinase are expressed in cell types in which glucose metabolism has to 
vary accordingly to extracellular glucose concentration (glucose sensors). The high Km for 
glucose of both proteins, and the absence of product inhibition by glucose-6-phosphate, 
ensure that glucose uptake and phosphorylation in these cells are proportional to 
extracellular glucose concentration throughout the physiological range of glycaemia 
The product of GK reaction, glucose-6-phosphate, is the gateway to the major pathways of 
glucose utilization: glycogen synthesis, glycolysis, oxidation of glucose and pentose 
phosphate pathway. It should be noted that hepatic glycolysis provides pyruvate 
principally for lipid synthesis rather than for oxidation. As glucose is the main substrate for 
fatty acid synthesis, hepatic glycolytic enzymes can be considered an extension of the 
lipogenic pathway. Glucose, insulin and parasympathetic nervous system orchestrate these 
glucose metabolic pathways in the fed state, with the aim of maintaining normal levels of 
blood sugar. 
2.1 Glycogen synthesis 
Two enzymes, glycogen synthase and glycogen phosphorylase, control glycogen levels. 
Both enzymes are regulated by phosphorylation and allosteric modulators. Specifically in 
the fed state, insulin activates glycogen synthase (limiting enzyme for glycogen synthesis) 
by promoting its dephosphorylation and, at the same time inhibits glycogen phosphorylase 
(important for glycogen breakdown). Meanwhile, glucose-6-phosphate binding to glycogen 
synthase favours its dephosphorylation, promoting glycogen synthase activity (Bollen, 1998; 
Agius, 2008). As a result, glucose coming from bloodstream fills hepatic glycogen stores. 
2.2 Lipogenesis de novo 
Hepatic lipogenesis is induced upon ingestion of excess carbohydrates to convert extra 
carbohydrates to triglyceride for long-time energy storage. Once inside the hepatocyte, 
glucose enters glycolytic pathway and provides pyruvate, which enters mitochondrion 
where it is converted into acetyl-CoA by pyruvate dehydrogenase. On the other side, in the 
cytoplasm glucose is also oxidized through the pentose phosphate pathway and NADPH is 
obtained. Acetyl-CoA will serve for fatty acid and also cholesterol synthesis. The initial steps 
for fatty acid synthesis are the transfer of acetyl-CoA from mitochondria to the cytoplasm 
and its conversion into malonyl-CoA under the action of the enzyme acetyl-CoA 
carboxylase. Importantly, malonyl-CoA is a regulatory molecule because it inhibits carnitine 
palmitoyltransferase-1, a rate limiting enzyme in β-oxidation of fatty acids. Therefore, 
increasing malonyl-CoA favours lipogenesis. Malonyl-CoA is elongated using NADPH 
under the action of the enzyme fatty acid synthase. Once obtained, fatty acids can be 
esterified with glycerol to form diglyceride and triglyceride. Most of the triglyceride is 
produced for export to the adipose tissue, but in order to be secreted, it must be packaged in 
very low-density lipoprotein (VLDL) particles together with cholesterol, phospholipids and 
apolipoprotein B (Figure 1). 
 

































































Fig. 1. Scheme of de novo lipogenesis from glucose. Once inside the hepatocyte,  
glucose is metabolized on one hand through glycolysis to pyruvate (GK means  
glucokinase; PFK-2, 6, phosphofructo-2-kinase/fructose-2,6-bisphosphatase; L-PK, liver-
pyruvate kinase). On the other hand, glucose is oxidized through pentose phosphate 
pathway to obtain NADPH (G6P-DH means glucose-6-phosphate dehydrogenase;  
6-PGDH, 6-phosphogluconate dehydrogenase). Pyruvate enters the mitochondrion to  
obtain citrate (PDH means, pyruvate dehydrogenase; MDH, malate dehydrogenase and EM, 
malic enzyme). De novo synthesis of fatty acids starts with citrate (ATP-CL means ATP 
citrate lyase; ACC, acetyl-CoA carboxylase) and after suffering elongation and desaturation 
reactions (ELOVL6 means elongase that catalyzes the conversion of palmitate to stearate; 
SCD-1, stearoyl-coenzyme A desaturase), fatty acids are converted to triglyceride (TAG) 
(GPAT means glycerol-3-phosphate acyltransferase; DGAT, diacylglycerol acyltransferase). 
Triglyceride can be stored in the liver but are mostly packaged into VLDL (very low-density 
lipoprotein) and secreted to bloodstream (MTP means microsomal triglyceride transfer 
protein). Original artwork. 
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In mammals, hepatic lipogenesis is controlled by several transcription factors, mainly 
SREBP-1c (sterol regulatory element binding protein 1c) and ChREBP (carbohydrate-
responsive element-binding protein), but also by PPAR-γ (peroxisome proliferator-activated 
receptor gamma), LXR-α (liver X receptor alpha) and XBP1, all of them regulated by 
nutritional and hormonal conditions.  
SREBP-1c plays a major role in the induction of lipogenic genes by insulin. SREBP-1c is a 
member of the bZIP transcription factor family that was originally identified as a mediator 
of sterol signaling (Wang, 1994), and is produced as a precursor form that reside in the 
endoplasmic reticulum in an inactive state. On one hand insulin stimulates SREBP-1c gene 
transcription, and on the other hand, induces the maturation of SREBP-1c precursor 
(Shimomura, 1998). Mature SREBP-1c moves to nucleus and activates transcription of 
several lipogenic genes with SRE (sterol regulatory elements) sequences in their promoters, 
for instance fatty acid synthase (FAS), stearoyl-Coenzyme A desaturase 1 (SCD-1), etc. 
(Figure 2) (Foretz, 1999; Ferre, 2010). 
Glucose regulates genes of glycolytic and lipogenic pathways by activating ChREBP (Iizuka, 
2008). ChREBP is a transcription factor that binds to ChoRE sequences present in the 
promoter of ACC (acetyl Coenzyme-A carboxylase), fatty acid synthase (FAS), stearoyl-
Coenzyme A desaturase 1 (SCD-1), L-pyruvate kinase (L-PK), etc. (Uyeda, 2006). Under 
basal conditions, ChREBP is phosphorylated at Ser196 and remains in the cytosol. When 
glycaemia increase, glucose enters the hepatocyte and is metabolized. Therefore there is an 
increase in some glucose metabolites such as xylulose-5P, which promotes ChREBP 
dephosphorylation (Kabashima, 2003). Then, ChREBP rapidly moves to the nucleus and will 
activate transcription of its target genes (Figure 2). 
SREBP-1c and ChREBP are also transcriptionally activated by liver X receptor apha (LXR-α), 
which could be a glucose sensor although it is controversial (Mitro, 2007; Denechaud, 2008). 
LXR-α is classically activated by oxysterols and it is important for the transcription of some 
lipogenic genes, a part form SREBP-1c and ChREBP, since their promoters contain LXRE 
(LXR response element) sequences (Chen, 2004; Cha, 2007). 
XBP1, a transcription factor best known as a key regulator of the unfolded protein response 
(UPR), has been surprisingly associated with de novo fatty acid synthesis in the liver. It 
seems to be induced by diet carbohydrates and its deletion in mice causes 
hypocholesterolemia and hypotriglyceridemia, attributed to diminished hepatic lipid 
production (Lee, 2008). But, there are still some questions about its function to answer: what 
is its binding site in the promoter regions of these genes? Does it act alone or in partnership 
with other known transcription factors such as SREBP, ChREBP and LXR?  
In summary, hepatic lipogenesis is regulated by several transcription factors that may 
probably work synergistically (Figure 2). With this complex system, carbons from glucose 
can be directed to fatty acid synthesis only when there is substrate availability and glycogen 
depots have been replenished. Altered fatty acid synthesis in the liver can lead to changes in 
lipid secretion, and consequently to dyslipidemia (Ginsberg, 2006). 
2.3 Inhibition of hepatic glucose production 
During fasting, liver produces glucose that enters bloodstream in order to maintain 
glycaemia, ensuring fuel supply for brain and red blood cells. But after a meal, when diet 
glucose arrives, hepatocytes must switch glucose production to glucose uptake. Insulin and 
high glucose levels coordinate the inhibition of glycogenolysis and gluconeogenesis (glucose 
producing pathways).  
 



























































Fig. 2. Main regulatory mechanisms of hepatic metabolism in fed state. Insulin and glucose 
direct gene transcription to switch from glucose producing pathways to glucose uptake and 
storage. Briefly, insulin signaling promotes the phosphorylation of FOXO1 that results in its 
nuclear exclusion and proteasome degradation; consequently, transcription of 
gluconeogenic genes is inhibited. Besides, insulin stimulates transcription of lipogenic genes 
through SREBP-1c activation and probably through LXR-α, as well. Finally, insulin signaling 
causes activation of glycogen synthase function. Glucose also controls allostericaly glycogen 
synthesis and promote transcription of lipogenic genes via activation of ChREBP. IR means 
insulin receptor, IRS, insulin receptor substrate; PI3K, phosphoinositide 3-kinse; AKT, 
Ser/Thr protein kinase; GSK3-β, glycogen synthase kinase 3.beta; FOXO1, forkhead box O1; 
PCK, protein kinase C; LXR, liver X receptor; SREBP-1c, sterol regulatory element binding 
protein 1c; ChREBP, carbohydrate response element binding protein; GS, glycogen synthase; 
GP, glycogen phosphorylase; GK, glucokinase; PP2A, protein phosphatase 2A); IRE, insulin 
response element; LXRE liver X receptor response element; SRE, sterol regulatory elements; 
ChORE, carbohydrate-response elements; PEPCK-C, cytosolic phosphoenolpyruvate 
carboxykinase; G6Pase, glucose-6-phosphatase; ACC, Acyl-CoA carboxylase; FAS, fatty acid 
synthase; SCD-1, stearoyl-CoA desaturase 1; ELOVL , EM, malic enzyme and L-PK, liver- 
pyruvate kinase. Original artwork. 
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Insulin directly inhibits the transcription of gluconeogenic genes by promoting the 
phosphorylation of FOXO1 (forkhead box O), a transcription factor necessary for the 
induction of gluconeogenesis in conjunction with PGC-1α (PPAR-gamma coactivator 1-
alpha) (Puigserver, 2003). In addition, SREBP-1c promotes the inhibition of some 
gluconeogenic genes. Insulin also represses glycogenolysis by phosphorylating glycogen 
synthase (Bollen, 1998). On the other hand, insulin regulates hepatic glucose production 
indirectly: a) it suppresses lipolysis in adipose tissue causing a reduction in glycerol 
(gluconeogenic substrate) availability; b) it inhibits glucagon secretion in the pancreas; and 
c) it activates hypothalamic pathways important for glucose homeostasis.  
Synergistically with insulin, glucose inhibits glycogenolysis allosterically (Bollen, 1998). 
Glucose inhibition on gluconeogenesis is mediated by glucose metabolites, specifically 
fructose-2,6-bisphosphate (Wu, 2001) and xylulose-5-phosphate (Massillon, 1998).  
3. Glucokinase regulates the fate of glucose carbons in the liver 
In order to enter the lipogenic pathway, glucose must be metabolized. The first and rate-
limiting step is the phosphorylation of glucose at the 6th carbon to obtain glucose-6-
phosphate. This reaction is catalyzed by glucokinase (GK; EC 2.7.1.1), a member of the 
hexokinase family. However, GK differs from other hexokinases in its particular kinetic 
properties: affinity for glucose that is within the physiological plasma concentration range 
(S0.5 for glucose of 8 mM), positive cooperativity for glucose although it is a monomeric 
enzyme, and lack of inhibition by glucose-6-phosphate (Table 1). 
 
 HEXOKINASES 1-3 GLUCOKINASE 
Molecular weight 100 KDa 50 KDa 
Substrates Hexoses Glucose 
S0.5 for glucose < 0.5 mM 8 mM 
Kinetic  Hyperbolic Sigmoidal 
Product inhibition Yes No 
Table 1. Hexokinase family kinetic properties 
As a result of its kinetic characteristics, intracellular glucose phosphorylation rate inside the 
hepatocyte correlates with glycaemia. Hence, GK can be considered an intracellular glucose 
sensor. Consequently, apart from hepatocytes, GK is expressed in glucosensitive cells of the 
pancreas, hypothalamus, anterior pituitary gland, and entero-endocrine K and L cells of the 
gut (Schuit, 2001; Zelent, 2006; Vieira, 2007; Iynedjian, 2009), all of them crucial in the control 
of the whole-body glucose homeostasis. 
Liver contains 99.9% of the body GK. Therefore, is not surprising that this enzyme 
influences intermediary metabolism and energy storage. GK reaction controls the flux of 
glucose through several metabolic pathways: glycolysis, glucose oxidization, glycogenesis, 
triglyceride synthesis, phospholipids and cholesterol synthesis, glycogenolysis and 
gluconeogenesis. For that reason, GK is an enzyme highly regulated in the liver, both at the 
transcriptional and the post-transcriptional level.  
3.1 Regulation of GK activity in the liver 
Gck gene has two distinct promoters and one of them directs gene transcription specifically 
in the liver (Postic, 1995). Hepatic GK expression responds to nutritional changes; it is 
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activated by insulin and inhibited by glucagon. Insulin induction of Gck gene expression is 
through the PI3-kinase/Akt signaling. However, no IRE (insulin response element) has been 
described in Gck promoter, and it is not clear which transcription factor mediates insulin-
directed Gck expression. SREBP-1c is a candidate to mediate insulin-directed expression of 
Gck, although controversial results exist (Foretz, 1999; Gregory, 2006). Probably, SREBP-1c is 
not essential for rapid induction of GK transcription, but it can have a role for long-term 
expression. Other candidates to mediate insulin-dependent expression of Gck gene are the 
complex HIF-α/HNF-4/p300 (Roth, 2004), and ERR-α -estrogen-related receptor alpha- 
(Zhu, 2010). 
GK can be modulated by covalent modifications such as nitrosylation and phosphorylation. 
However, the physiological importance of these modifications is still not determined. More 
importantly, protein interaction affects GK activity and even intracellular distribution. It has 
been described that GK in the liver can interact with GKRP (glucokinase regulatory protein), 
BAD (Bcl-xL/Bcl-2-Associated Death Promoter), PFK-2 (6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase), GKAP (glucokinase-associated protein), etc. (Massa, 2010). From all GK 
protein partners, GKRP is the best studied and has high physiological relevance in the liver.  
3.1.1 Post-transcriptional regulation by GKRP 
GKRP regulation of GK affects both the activity and subcellular localization of the enzyme. 
GKRP is a competitive inhibitor with respect to glucose. Van Shaftingen et al proposed a 
mechanistic model (Van Shaftingen, 2004); GKRP exists in two conformations, one with low 
affinity for GK and the other with high affinity. Fructose-1-phosphate and fructose-6-
phosphate bind to the same binding site in the GKRP protein. When fructose-1-phosphate is 
bound to GKRP, GKRP adopts a conformation with low affinity for GK, and on the contrary, 
when the binding of fructose-6-phosphate to GKRP favours its interaction with GK.  
But, Kamata et al also described that GK can exist in different conformations with different 
affinity for glucose (Kamata, 2004); in the absence of glucose, the enzyme exists in a super-
open conformation thermodynamically stable and with low affinity for substrate. When 
glucose binds to it, there is a conformational change to an open form and next to a closed 
conformation that binds ATP. Then the catalytic cycle completes, after reaction products are 
released, GK can relax to an open or to a super-open conformation, depending on glucose 
concentrations (considering that the open conformation has higher affinity for glucose). GK 
conformation is important for GKRP protein interaction, as it can only take place when GK 
is in the super-open conformation (Anderka, 2008). From these conformational models of 
GKRP and GK, one can extrapolate the exquisite influence of carbohydrate concentration in 
regulating GKRP/GK binding and, consequently, GK phosphorylating activity. 
GKRP also plays a fundamental role in importing GK to the nucleus, as it can be deduced 
from animals null for GKRP that present GK permanently in the cytosol (Farrelly, 1999). At 
low glucose concentrations, GKRP binds to GK and the formation of GKRP/GK complex 
results in entry and sequestration of both proteins in the nucleus of hepatocytes. However, it 
is still not resolved how GK is translocated to the nucleus. On the other hand, in metabolic 
states with high glucose concentrations, accompanied or not by high fructose levels, and 
sufficient ATP, there is the dissociation of the GKRP/GK complex. GK has a nuclear export 
signal sequence. Therefore, once dissociated from the complex, GK can be exported to the 
cytoplasm (Shiota, 1999). Insulin also favours the dissociation of the complex. 
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3. Glucokinase regulates the fate of glucose carbons in the liver 
In order to enter the lipogenic pathway, glucose must be metabolized. The first and rate-
limiting step is the phosphorylation of glucose at the 6th carbon to obtain glucose-6-
phosphate. This reaction is catalyzed by glucokinase (GK; EC 2.7.1.1), a member of the 
hexokinase family. However, GK differs from other hexokinases in its particular kinetic 
properties: affinity for glucose that is within the physiological plasma concentration range 
(S0.5 for glucose of 8 mM), positive cooperativity for glucose although it is a monomeric 
enzyme, and lack of inhibition by glucose-6-phosphate (Table 1). 
 
 HEXOKINASES 1-3 GLUCOKINASE 
Molecular weight 100 KDa 50 KDa 
Substrates Hexoses Glucose 
S0.5 for glucose < 0.5 mM 8 mM 
Kinetic  Hyperbolic Sigmoidal 
Product inhibition Yes No 
Table 1. Hexokinase family kinetic properties 
As a result of its kinetic characteristics, intracellular glucose phosphorylation rate inside the 
hepatocyte correlates with glycaemia. Hence, GK can be considered an intracellular glucose 
sensor. Consequently, apart from hepatocytes, GK is expressed in glucosensitive cells of the 
pancreas, hypothalamus, anterior pituitary gland, and entero-endocrine K and L cells of the 
gut (Schuit, 2001; Zelent, 2006; Vieira, 2007; Iynedjian, 2009), all of them crucial in the control 
of the whole-body glucose homeostasis. 
Liver contains 99.9% of the body GK. Therefore, is not surprising that this enzyme 
influences intermediary metabolism and energy storage. GK reaction controls the flux of 
glucose through several metabolic pathways: glycolysis, glucose oxidization, glycogenesis, 
triglyceride synthesis, phospholipids and cholesterol synthesis, glycogenolysis and 
gluconeogenesis. For that reason, GK is an enzyme highly regulated in the liver, both at the 
transcriptional and the post-transcriptional level.  
3.1 Regulation of GK activity in the liver 
Gck gene has two distinct promoters and one of them directs gene transcription specifically 
in the liver (Postic, 1995). Hepatic GK expression responds to nutritional changes; it is 
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activated by insulin and inhibited by glucagon. Insulin induction of Gck gene expression is 
through the PI3-kinase/Akt signaling. However, no IRE (insulin response element) has been 
described in Gck promoter, and it is not clear which transcription factor mediates insulin-
directed Gck expression. SREBP-1c is a candidate to mediate insulin-directed expression of 
Gck, although controversial results exist (Foretz, 1999; Gregory, 2006). Probably, SREBP-1c is 
not essential for rapid induction of GK transcription, but it can have a role for long-term 
expression. Other candidates to mediate insulin-dependent expression of Gck gene are the 
complex HIF-α/HNF-4/p300 (Roth, 2004), and ERR-α -estrogen-related receptor alpha- 
(Zhu, 2010). 
GK can be modulated by covalent modifications such as nitrosylation and phosphorylation. 
However, the physiological importance of these modifications is still not determined. More 
importantly, protein interaction affects GK activity and even intracellular distribution. It has 
been described that GK in the liver can interact with GKRP (glucokinase regulatory protein), 
BAD (Bcl-xL/Bcl-2-Associated Death Promoter), PFK-2 (6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase), GKAP (glucokinase-associated protein), etc. (Massa, 2010). From all GK 
protein partners, GKRP is the best studied and has high physiological relevance in the liver.  
3.1.1 Post-transcriptional regulation by GKRP 
GKRP regulation of GK affects both the activity and subcellular localization of the enzyme. 
GKRP is a competitive inhibitor with respect to glucose. Van Shaftingen et al proposed a 
mechanistic model (Van Shaftingen, 2004); GKRP exists in two conformations, one with low 
affinity for GK and the other with high affinity. Fructose-1-phosphate and fructose-6-
phosphate bind to the same binding site in the GKRP protein. When fructose-1-phosphate is 
bound to GKRP, GKRP adopts a conformation with low affinity for GK, and on the contrary, 
when the binding of fructose-6-phosphate to GKRP favours its interaction with GK.  
But, Kamata et al also described that GK can exist in different conformations with different 
affinity for glucose (Kamata, 2004); in the absence of glucose, the enzyme exists in a super-
open conformation thermodynamically stable and with low affinity for substrate. When 
glucose binds to it, there is a conformational change to an open form and next to a closed 
conformation that binds ATP. Then the catalytic cycle completes, after reaction products are 
released, GK can relax to an open or to a super-open conformation, depending on glucose 
concentrations (considering that the open conformation has higher affinity for glucose). GK 
conformation is important for GKRP protein interaction, as it can only take place when GK 
is in the super-open conformation (Anderka, 2008). From these conformational models of 
GKRP and GK, one can extrapolate the exquisite influence of carbohydrate concentration in 
regulating GKRP/GK binding and, consequently, GK phosphorylating activity. 
GKRP also plays a fundamental role in importing GK to the nucleus, as it can be deduced 
from animals null for GKRP that present GK permanently in the cytosol (Farrelly, 1999). At 
low glucose concentrations, GKRP binds to GK and the formation of GKRP/GK complex 
results in entry and sequestration of both proteins in the nucleus of hepatocytes. However, it 
is still not resolved how GK is translocated to the nucleus. On the other hand, in metabolic 
states with high glucose concentrations, accompanied or not by high fructose levels, and 
sufficient ATP, there is the dissociation of the GKRP/GK complex. GK has a nuclear export 
signal sequence. Therefore, once dissociated from the complex, GK can be exported to the 
cytoplasm (Shiota, 1999). Insulin also favours the dissociation of the complex. 
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The physiological function of GKRP consists of inhibiting GK activity by sequestering it to the 
nucleus. GKRP binding also serves to stabilize GK protein and protect it from degradation. 
Thus, thanks to GKRP a big reservoir of GK exists in the nucleus of the hepatocyte at low 
glucose concentration. After a meal, this reservoir of GK can be rapidly mobilized 
(translocation is complete within 30 minutes) to the cytosol in order to promote glucose uptake 
and storage in the liver. This regulation process is much more fast and efficient than the 
synthesis de novo of GK promoted by insulin. Conversely, when glucose uptake has finished, 
GK returns to the nucleus in order to save energy because, on one hand, this translocation 
avoids the futile cycle between glucose and glucose-6-phosphate, and on the other hand, it 
ends the glucose signal generated by GK activity that activate transcription of glycolytic and 
lipogenic genes (Figure 3). The consequence of GK translocation to the nucleus in the post-














Fig. 3. Subcellular localization of GK regulated by GKRP. (A) During fasting, GK is 
sequestered in the nucleus where it remains bound to GKRP and inactive. After a meal, 
nutritional signals (i.e. insulin, glucose and fructose) induce the dissociation of the 
GK/GKRP complex and free GK translocates to the cytosol. Original artwork. 
To summarize, thanks to its kinetic properties and its subtle regulation, GK enables the liver 
to adapt its metabolism for glucose uptake or glucose production as required, and 
consequently to regulate energy homeostasis.  
3.2 GK modulation in the liver: impact on carbohydrate and lipid metabolism  
Numerous natural mutations in GK gene have been associated to disease (Gloyn, 2003 & 
Osbak, 2009), reinforcing the concept that it is a crucial enzyme in the control of whole-body 
glucose homeostasis. Mutations that cause decrease or loss of GK activity are associated to 
maturity onset diabetes of the young-2 (MODY-2) or to permanent neonatal diabetes 
mellitus (PNDM). In diabetes, as a result of impairment in insulin secretion, the capacity of 
the liver to uptake glucose is diminished. On the other hand, activating mutations of GK 
cause persistent hyperinsulinemic hypoglycemia in infancy (PHHI). The phenotype of all 
these pathologies is mainly dominated by GK function in the pancreatic β-cell, where it 
regulates glucose-dependent insulin secretion. As insulin controls hepatic GK transcription 
and influences GKRP regulation, it is difficult to elucidate which are the specific 
consequences of these mutations on hepatic GK independently of insulin.  
Some animal models have been developed to study the specific role of liver GK on 
metabolism. 
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3.2.1 Genetic suppression of hepatic GK 
A liver specific GK knock-out was obtained using the LoxP-Cre system (Postic, 1999). 
Transgenic mice showed mild hyperglycemia and hyperinsulinemia in basal conditions, 
without changes in hepatic glycogen, plasma non-esterified fatty acids, triglycerides or β-
hydroxybutyrate. In hyperglycaemic clamp studies, reduced hepatic glucose uptake and 
glycogen levels were observed in KO animals; however, results on lipid profile were not 
provided. 
3.2.2 Genetic overexpression of GK in the liver 
Several liver GK gain-of-function studies, both using transgenic animals and by means of 
adenovirus gene transfer, have been performed in healthy animals and models of diabetes 
such as streptozotocin induced type I and type II induced by ingestion of high fat/high 
carbohydrate diet. Due to heterogeneity, these studies will be examined according to the 
animal model and analysis conditions. 
a. Overexpression of GK in the liver of fed, healthy animals is summarized in Table 2 
(Ferre, 1996a, 1996b, 2003; O’Doherty, 1999; Scott, 2003).  
 




Animal model Mus musculus Rattus norvegicus 
Transgenic Adenoviral gene transfer 
PEPCK-C promoter CMV promoter 
GK activity over 
control 
x 2 x 3 x 6.4 
Age at analysis 2 months 12 months 5 days post-injection 
(Rats 200-250 g) 
Glycaemia decrease - no change Decrease 
Blood lactate - - increase Increase 
Blood triglycerides ~ increase - ~ increase Increase 
NEFA ~ increase - no change increase 
Insulin decrease increase no change decrease 
Hepatic glucose-6-P increase ~ increase - - 
Hepatic glycogen increase decrease no change no change 







- ↑ L-PK, ACC1, 
FAS, G6Pase. 
No change in 
PEPCK-K 
- 
Table 2. Hepatic GK overexpression studies in healthy fed animals. Comments: decrease, 
increase and no change are referred to control group. “~” means no statistically significant; 
“-“, no determined; “CMV”, cytomegalovirus; “PEPCK-C”, cytosolic phosphoenolpyruvate 
carboxykinase; “L-PK”, liver pyruvate kinase; “TAT”, tyrosine aminotransferase; “ACC1”, 
Acetyl-Coenzyme A carboxylase 1; “FAS”, fatty acid synthase; and “G6Pase”, glucose-6 
phosphatase. 
In these models, enhancing hepatic glucose uptake by GK overexpression results in a direct 
reduction of glycaemia. As a consequence of lower blood glucose levels, pancreatic β-cell 
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The physiological function of GKRP consists of inhibiting GK activity by sequestering it to the 
nucleus. GKRP binding also serves to stabilize GK protein and protect it from degradation. 
Thus, thanks to GKRP a big reservoir of GK exists in the nucleus of the hepatocyte at low 
glucose concentration. After a meal, this reservoir of GK can be rapidly mobilized 
(translocation is complete within 30 minutes) to the cytosol in order to promote glucose uptake 
and storage in the liver. This regulation process is much more fast and efficient than the 
synthesis de novo of GK promoted by insulin. Conversely, when glucose uptake has finished, 
GK returns to the nucleus in order to save energy because, on one hand, this translocation 
avoids the futile cycle between glucose and glucose-6-phosphate, and on the other hand, it 
ends the glucose signal generated by GK activity that activate transcription of glycolytic and 
lipogenic genes (Figure 3). The consequence of GK translocation to the nucleus in the post-
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nutritional signals (i.e. insulin, glucose and fructose) induce the dissociation of the 
GK/GKRP complex and free GK translocates to the cytosol. Original artwork. 
To summarize, thanks to its kinetic properties and its subtle regulation, GK enables the liver 
to adapt its metabolism for glucose uptake or glucose production as required, and 
consequently to regulate energy homeostasis.  
3.2 GK modulation in the liver: impact on carbohydrate and lipid metabolism  
Numerous natural mutations in GK gene have been associated to disease (Gloyn, 2003 & 
Osbak, 2009), reinforcing the concept that it is a crucial enzyme in the control of whole-body 
glucose homeostasis. Mutations that cause decrease or loss of GK activity are associated to 
maturity onset diabetes of the young-2 (MODY-2) or to permanent neonatal diabetes 
mellitus (PNDM). In diabetes, as a result of impairment in insulin secretion, the capacity of 
the liver to uptake glucose is diminished. On the other hand, activating mutations of GK 
cause persistent hyperinsulinemic hypoglycemia in infancy (PHHI). The phenotype of all 
these pathologies is mainly dominated by GK function in the pancreatic β-cell, where it 
regulates glucose-dependent insulin secretion. As insulin controls hepatic GK transcription 
and influences GKRP regulation, it is difficult to elucidate which are the specific 
consequences of these mutations on hepatic GK independently of insulin.  
Some animal models have been developed to study the specific role of liver GK on 
metabolism. 
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3.2.1 Genetic suppression of hepatic GK 
A liver specific GK knock-out was obtained using the LoxP-Cre system (Postic, 1999). 
Transgenic mice showed mild hyperglycemia and hyperinsulinemia in basal conditions, 
without changes in hepatic glycogen, plasma non-esterified fatty acids, triglycerides or β-
hydroxybutyrate. In hyperglycaemic clamp studies, reduced hepatic glucose uptake and 
glycogen levels were observed in KO animals; however, results on lipid profile were not 
provided. 
3.2.2 Genetic overexpression of GK in the liver 
Several liver GK gain-of-function studies, both using transgenic animals and by means of 
adenovirus gene transfer, have been performed in healthy animals and models of diabetes 
such as streptozotocin induced type I and type II induced by ingestion of high fat/high 
carbohydrate diet. Due to heterogeneity, these studies will be examined according to the 
animal model and analysis conditions. 
a. Overexpression of GK in the liver of fed, healthy animals is summarized in Table 2 
(Ferre, 1996a, 1996b, 2003; O’Doherty, 1999; Scott, 2003).  
 




Animal model Mus musculus Rattus norvegicus 
Transgenic Adenoviral gene transfer 
PEPCK-C promoter CMV promoter 
GK activity over 
control 
x 2 x 3 x 6.4 
Age at analysis 2 months 12 months 5 days post-injection 
(Rats 200-250 g) 
Glycaemia decrease - no change Decrease 
Blood lactate - - increase Increase 
Blood triglycerides ~ increase - ~ increase Increase 
NEFA ~ increase - no change increase 
Insulin decrease increase no change decrease 
Hepatic glucose-6-P increase ~ increase - - 
Hepatic glycogen increase decrease no change no change 







- ↑ L-PK, ACC1, 
FAS, G6Pase. 
No change in 
PEPCK-K 
- 
Table 2. Hepatic GK overexpression studies in healthy fed animals. Comments: decrease, 
increase and no change are referred to control group. “~” means no statistically significant; 
“-“, no determined; “CMV”, cytomegalovirus; “PEPCK-C”, cytosolic phosphoenolpyruvate 
carboxykinase; “L-PK”, liver pyruvate kinase; “TAT”, tyrosine aminotransferase; “ACC1”, 
Acetyl-Coenzyme A carboxylase 1; “FAS”, fatty acid synthase; and “G6Pase”, glucose-6 
phosphatase. 
In these models, enhancing hepatic glucose uptake by GK overexpression results in a direct 
reduction of glycaemia. As a consequence of lower blood glucose levels, pancreatic β-cell 
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secretes less insulin. Therefore, a decrease in insulinemia is a secondary effect of increasing 
hepatic GK activity. But, O’Doherty et al demonstrate that the influence of GK activity on 
blood glucose and insulin levels could be dose-dependent, as it occurs only with high doses 
of their transgene. In the hepatocyte, glucose-6-phosphate derived from GK activity is 
directed to glycogen synthesis and, consequently, hepatic glycogen levels are increased in 
the study by Ferre et al. However, glycogen content is not modified by GK overexpression 
in the study of O’Doherty et al, maybe for intrinsic limitations. In both animal models, 
increasing GK activity results in glucose signaling that activates transcription of glycolytic 
and lipogenic genes. Lipogenic proteins together with high availability of citrate and ATP 
(derived from augmented glucose metabolism) lead to enhanced de novo lipogenesis in the 
liver, and consequently, higher secretion of VLDL to bloodstream that could explain the 
observed increase in blood triglycerides. Augmented blood fatty acids might be explained 
by insulin levels; low levels of this hormone result in low inhibition of lipolysis in the 
adipose tissue, and consequently fatty acids raise in the bloodstream. Importantly,  
Ferre et al show that long-term GK overexpression drives to hyperinsulinemia and hepatic 
steatosis. 
b. Studies of GK overexpression in the liver of fasted, healthy mice are listed in Table 3 
(Hariharan, 1997; O’Doherty, 1999; Desai, 2001; Ferre, 2003 & Scott, 2003) 
 
 
Study variables Hariharan 
1997 
Desai 2001 Ferre 2003 O'Doherty 1999 
Scott 2003 
Animal model M. musculus M. musculus M. musculus R. norvegicus 
 Transgenic Adenovirus Transgenic Adenovirus 
Promoter apoA1-SV40 RSV PEPCK-C CMV 
GK activity over 
control 
x5 x1.5 x2 x2.1 or x3 
Age at analysis 5 weeks 3 weeks post-
injection 
12 months 4-5 days post-
injection 
Glycaemia Decrease no change - no change 
Blood lactate Decrease no change - ~ decrease 
Blood triglycerides no change no change increase increase 
NEFA ~ increase no change - no change 
Insulin Decrease decrease increase no change 
Hepatic glucose-6-P - - ~ increase - 
Hepatic glycogen - - no change increase 




- - - ↑ L-PK, ACC1 
No change: 
PEPCK-C, PFK-2 
Table 3. Hepatic GK overexpression studies in healthy fasted animals. Comments: decrease, 
increase and no change are referred to control group. “~” means no statistically significant; “-“, 
no determined; “CMV”, cytomegalovirus; "RSV", rose sarcoma virus; "apoA1-SV40", 
apolipoprotein A1 enhancer and simian vacuolating virus 40 promoter; “PEPCK-C”, cytosolic 
phosphoenolpyruvate carboxykinase; “L-PK”, liver pyruvate kinase; “ACC1”, Acetyl-
Coenzyme A carboxylase 1; “PFK-2", 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. 
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In fast state, the influence of hepatic GK overexpression on glycaemia is not clear. Hariharan 
et al showed a decrease in glycaemia, accompanied by a decrease in insulinemia that could 
explain a reduction of glycolysis in skeletal muscle, causing the observed decline in serum 
lactate. Low insulin levels can also explain the increment of blood fatty acids. Interestingly, 
20-weeks old mice were smaller than controls and presented reduced body mass index.  
On the contrary, long-term analysis of transgenic mice developed by Ferre et al showed  
that increasing GK activity in the liver lead to hepatic steatosis, hyperglycemia, 
hyperinsulinemia, obesity and insulin resistance. On the other hand, adenoviral gene 
transfer models for hepatic GK overexpression in fasting revealed induction of lipogenesis 
and consequently a tendency to increase blood triglycerides, without affecting glycaemia.  
c. Studies on hepatic GK overexpression in the context of type 1 diabetes mellitus: This is 
an autoimmune disease with specific destruction of insulin-producing β-cells in the 
pancreas, and results in loss of insulin production. As insulin stimulates the 
transcription of Gck gene in the liver, type 1 diabetic subjects do not have GK protein in 
their livers and consequently hepatic glucose metabolism is impaired. Gene therapy has 
been tested to restore liver glucose uptake capacity by increasing hepatic GK protein 
(Ferre, 1996a; Morral, 2002, 2007). In type 1 diabetic liver, all models present a similar 
phenotype. When restoring glucose signaling in diabetic hepatocytes via GK, glucose 
catabolic pathways are induced and, on the contrary, hepatic glucose production is 
inhibited. Consequently there is a reduction of diabetic hyperglycemia accompanied by 
incremented hepatic glycogen depots and de novo lipogenesis. Decreasing blood 
glucose levels forces muscle and adipose tissue to use fatty acids as energetic substrates, 
and in consequence, serum fatty acids are decreased in type 1 diabetic mice expressing 
GK in the liver. Lower blood fatty acids, together with increased glucose metabolism in 
the liver, inhibit hepatic  β-oxidation of fatty acids. Therefore, these models suggest that 
hepatic overexpression of GK in type 1 diabetes leads to normoglycaemia thanks to 
increments in hepatic glucose uptake and fatty acid oxidation in peripheral tissues. 
d. Finally, hepatic GK overexpression in the context of type 2 diabetes: type 2 diabetes is a 
complex metabolic disorder caused by two physiologic defects: insulin resistance in 
combination with insulin secretion deficiency. Type 2 diabetes is characterized by 
glucose metabolism alterations such as failure of insulin to inhibit hepatic 
gluconeogenesis and impaired skeletal muscle glucose uptake. However, lipid 
metabolism is also altered. This is often reflected by increased circulating free fatty 
acids and triglycerides together with increased fat accumulation in non-adipose tissues. 
Thus, changes in the equilibrium between glucose and fatty acid metabolism in liver 
and muscle could be responsible for glucose homeostasis alterations. Obesity, 
hyperinsulinemia, in combination with hyperglycemia, inhibits fatty acid oxidation in 
many tissues. As a result, lipogenesis is favored over fatty acid oxidation leading to an 
increase in fat accumulation and a decrease in energy expenditure. A hypothetical 
strategy for type 2 diabetes therapy is increasing glucokinase activity, with the aim of 
enhancing glucose uptake in the liver that could contribute to gluconeogenesis 
inhibition with consequent restoration of glycaemia. If glycaemia is restored, plasma 
insulin levels could be secondarily lowered and it could be able to elevate energy 
expenditure and reduce obesity.  
However, liver GK activity is increased in mild type 2 diabetes, but diminished in morbid 
obese diabetic patients. Animal diabetic models linked to obesity, show that GK deficiency in 
the liver occurs only in the case of obesity, and in severe or long-term forms of the disease. 
Although hepatic GK expression is different depending on disease stage, some strategies 
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secretes less insulin. Therefore, a decrease in insulinemia is a secondary effect of increasing 
hepatic GK activity. But, O’Doherty et al demonstrate that the influence of GK activity on 
blood glucose and insulin levels could be dose-dependent, as it occurs only with high doses 
of their transgene. In the hepatocyte, glucose-6-phosphate derived from GK activity is 
directed to glycogen synthesis and, consequently, hepatic glycogen levels are increased in 
the study by Ferre et al. However, glycogen content is not modified by GK overexpression 
in the study of O’Doherty et al, maybe for intrinsic limitations. In both animal models, 
increasing GK activity results in glucose signaling that activates transcription of glycolytic 
and lipogenic genes. Lipogenic proteins together with high availability of citrate and ATP 
(derived from augmented glucose metabolism) lead to enhanced de novo lipogenesis in the 
liver, and consequently, higher secretion of VLDL to bloodstream that could explain the 
observed increase in blood triglycerides. Augmented blood fatty acids might be explained 
by insulin levels; low levels of this hormone result in low inhibition of lipolysis in the 
adipose tissue, and consequently fatty acids raise in the bloodstream. Importantly,  
Ferre et al show that long-term GK overexpression drives to hyperinsulinemia and hepatic 
steatosis. 
b. Studies of GK overexpression in the liver of fasted, healthy mice are listed in Table 3 
(Hariharan, 1997; O’Doherty, 1999; Desai, 2001; Ferre, 2003 & Scott, 2003) 
 
 
Study variables Hariharan 
1997 
Desai 2001 Ferre 2003 O'Doherty 1999 
Scott 2003 
Animal model M. musculus M. musculus M. musculus R. norvegicus 
 Transgenic Adenovirus Transgenic Adenovirus 
Promoter apoA1-SV40 RSV PEPCK-C CMV 
GK activity over 
control 
x5 x1.5 x2 x2.1 or x3 
Age at analysis 5 weeks 3 weeks post-
injection 
12 months 4-5 days post-
injection 
Glycaemia Decrease no change - no change 
Blood lactate Decrease no change - ~ decrease 
Blood triglycerides no change no change increase increase 
NEFA ~ increase no change - no change 
Insulin Decrease decrease increase no change 
Hepatic glucose-6-P - - ~ increase - 
Hepatic glycogen - - no change increase 




- - - ↑ L-PK, ACC1 
No change: 
PEPCK-C, PFK-2 
Table 3. Hepatic GK overexpression studies in healthy fasted animals. Comments: decrease, 
increase and no change are referred to control group. “~” means no statistically significant; “-“, 
no determined; “CMV”, cytomegalovirus; "RSV", rose sarcoma virus; "apoA1-SV40", 
apolipoprotein A1 enhancer and simian vacuolating virus 40 promoter; “PEPCK-C”, cytosolic 
phosphoenolpyruvate carboxykinase; “L-PK”, liver pyruvate kinase; “ACC1”, Acetyl-
Coenzyme A carboxylase 1; “PFK-2", 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. 
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In fast state, the influence of hepatic GK overexpression on glycaemia is not clear. Hariharan 
et al showed a decrease in glycaemia, accompanied by a decrease in insulinemia that could 
explain a reduction of glycolysis in skeletal muscle, causing the observed decline in serum 
lactate. Low insulin levels can also explain the increment of blood fatty acids. Interestingly, 
20-weeks old mice were smaller than controls and presented reduced body mass index.  
On the contrary, long-term analysis of transgenic mice developed by Ferre et al showed  
that increasing GK activity in the liver lead to hepatic steatosis, hyperglycemia, 
hyperinsulinemia, obesity and insulin resistance. On the other hand, adenoviral gene 
transfer models for hepatic GK overexpression in fasting revealed induction of lipogenesis 
and consequently a tendency to increase blood triglycerides, without affecting glycaemia.  
c. Studies on hepatic GK overexpression in the context of type 1 diabetes mellitus: This is 
an autoimmune disease with specific destruction of insulin-producing β-cells in the 
pancreas, and results in loss of insulin production. As insulin stimulates the 
transcription of Gck gene in the liver, type 1 diabetic subjects do not have GK protein in 
their livers and consequently hepatic glucose metabolism is impaired. Gene therapy has 
been tested to restore liver glucose uptake capacity by increasing hepatic GK protein 
(Ferre, 1996a; Morral, 2002, 2007). In type 1 diabetic liver, all models present a similar 
phenotype. When restoring glucose signaling in diabetic hepatocytes via GK, glucose 
catabolic pathways are induced and, on the contrary, hepatic glucose production is 
inhibited. Consequently there is a reduction of diabetic hyperglycemia accompanied by 
incremented hepatic glycogen depots and de novo lipogenesis. Decreasing blood 
glucose levels forces muscle and adipose tissue to use fatty acids as energetic substrates, 
and in consequence, serum fatty acids are decreased in type 1 diabetic mice expressing 
GK in the liver. Lower blood fatty acids, together with increased glucose metabolism in 
the liver, inhibit hepatic  β-oxidation of fatty acids. Therefore, these models suggest that 
hepatic overexpression of GK in type 1 diabetes leads to normoglycaemia thanks to 
increments in hepatic glucose uptake and fatty acid oxidation in peripheral tissues. 
d. Finally, hepatic GK overexpression in the context of type 2 diabetes: type 2 diabetes is a 
complex metabolic disorder caused by two physiologic defects: insulin resistance in 
combination with insulin secretion deficiency. Type 2 diabetes is characterized by 
glucose metabolism alterations such as failure of insulin to inhibit hepatic 
gluconeogenesis and impaired skeletal muscle glucose uptake. However, lipid 
metabolism is also altered. This is often reflected by increased circulating free fatty 
acids and triglycerides together with increased fat accumulation in non-adipose tissues. 
Thus, changes in the equilibrium between glucose and fatty acid metabolism in liver 
and muscle could be responsible for glucose homeostasis alterations. Obesity, 
hyperinsulinemia, in combination with hyperglycemia, inhibits fatty acid oxidation in 
many tissues. As a result, lipogenesis is favored over fatty acid oxidation leading to an 
increase in fat accumulation and a decrease in energy expenditure. A hypothetical 
strategy for type 2 diabetes therapy is increasing glucokinase activity, with the aim of 
enhancing glucose uptake in the liver that could contribute to gluconeogenesis 
inhibition with consequent restoration of glycaemia. If glycaemia is restored, plasma 
insulin levels could be secondarily lowered and it could be able to elevate energy 
expenditure and reduce obesity.  
However, liver GK activity is increased in mild type 2 diabetes, but diminished in morbid 
obese diabetic patients. Animal diabetic models linked to obesity, show that GK deficiency in 
the liver occurs only in the case of obesity, and in severe or long-term forms of the disease. 
Although hepatic GK expression is different depending on disease stage, some strategies 
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based on increasing GK activity in the liver have been tested in some models of high fat diet 
induced type 2 diabetes (Desai, 2001 & Ferre, 2003) , in obesity models (Wu, 2005 & Torres, 
2009) and in transgenic mice with hepatic insulin resistance (Okamoto, 2007). All these studies 
have in common that the increase in hepatic GK activity produces glycaemia normalization. 
Hepatic GK, through glycolysis and glycogenesis activation, increases blood glucose clearance 
while it inhibits hepatic glucose production. On the other hand, liver GK activity results in 
increased malonyl-CoA, a lipogenic substrate and inhibitor of β-oxidation. It is difficult to 
draw clear conclusions when evaluating consequences of liver GK overexpression on lipid 
metabolism in type 2 diabetic models. Wu et al report an expected increase in hepatic and 
serum triglycerides, together with higher serum fatty acids. However, Wu et al report that, 
although hepatic fatty acid β-oxidation was decreased, muscle increased fatty acid oxidation as 
a consequence of lower glycaemia and insulinemia. Conversely, Desai et al showed no 
changes in hepatic and serum lipid levels. Otherwise, Torres et al & Okamoto et al obtained an 
increase in serum triglycerides with no changes in fatty acid levels. The most striking model is 
presented by Ferre et al: under high fat diet, liver GK-transgenic mice became insulin resistant 
faster than controls and showed hepatic steatosis. It contrasts with results obtained in GK gene 
locus transgenic mice (Shiota, 2001). Besides exhibiting a reduction of the blood glucose 
concentration, mice with a greater than normal amount of GK also exhibited a dramatic 
resistance to the development of hyperglycemia and hyperinsulinemia normally brought on 
by consumption of a high fat diet.  
Taken together, all these models have convincingly demonstrated that increasing GK protein 
in the liver leads to a direct reduction of glycaemia, but sometimes it can be accompanied with 
the risk of serious alterations in lipid metabolism deriving in hepatic steatosis and/or overt 
dyslipidemia. This aspect is essential when considering the possibility of using GK 
overexpression in the liver for diabetes therapy. At this point, it would be important to find 
out which are the causes of the different phenotypes observed in those animal models of 
hepatic GK overexpression previously described. There are several possible reasons: 
a. Species-specific results: one possibility is that GK overexpression in mouse liver may be 
more effective stimulating glucose disposal than the same degree of expression in a 
larger animal such as rat. 
b. Side-effects of gene transfer technology: when using adenoviral gene transfer, 
adenoviruses involve per se hepatic metabolic changes. When using transgenic, germ-
line manipulated animals overexpress GK throughout life, including intrauterine life, 
possibly resulting in compensatory changes in insulin secretion, insulin action, or in 
other metabolic variables that do not occur with acute manipulation of GK via 
adenovirus technology. 
c. Promoter that directs transgene expression can affect two important variables. On one 
hand, taking into account the metabolic hepatic zonation concept (Jungermann, 1995), the 
promoter determines which set of hepatocytes express the transgene. It is well known that 
physiological GK expression predominates in the perivenous area of the liver (Moorman, 
1991; Jungerman, 1995 & Jungerman, 2000). However, most studies of hepatic GK gain of 
function did not use perivenous promoters. For instance, Ferre et al used a PEPCK 
promoter that directs the transgene to the periportal area of the liver, specialized in 
gluconeogenesis. In contrast, RSV or CMV promoters are ubiquitous promoters that 
transfect both perivenous and periportal hepatocytes. On the other hand, promoter directs 
the regulation of transgene expression by nutrients and hormones. For instance, GK under 
the PEPCK promoter is expressed under glucagon signaling and is inhibited by glucose 
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and insulin. Therefore, hepatic GK transgenic mice described by Ferre et al express GK at 
the periportal area of the liver during fasting, and not in fed state.  
d. Transgene dose: Desai et al and O'Doherty et al described different metabolic impact of 
hepatic GK overexpression depending on the dose of transgene that they used. 
In our laboratory we aimed to re-examine the conclusions of these studies and the 
differentiated effects that GK activity could have on the metabolism, clearly differentiated, of 
periportal and perivenous hepatocytes. To evaluate the issue, we have developed a 
hydrodynamic gene transfer technique that served us to pursuit GK overexpression studies 
exclusively in perivenous liver (Liu, 1999; Zhang, 1999; Gomez-Valades, 2006; Budker, 2006 & 
Suda, 2007). With the injection of a plasmid for green fluorescent protein (GFP) and 
immunohistochemistry for PEPCK (periportal marker), we could visualize that hydrodynamic 
injection generate two separate populations of hepatocytes: green hepatocytes that expressed 
GFP and red hepatocytes showing PEPCK-C staining (Figure 4). We could conclude that in our 
conditions the hydrodynamic gene transfer technique delivered the transgene only in the 




Fig. 4. Visualization of liver transfection achieved with adenoviral and hydrodynamic gene 
transfer techniques. (A) Healthy mice were injected with 5.5·109 IU of an adenovirus that 
codified for the green fluorescent protein (GFP). Green fluorescence was observed in liver 
sections (200X), demonstrating a homogeneous presence of the transgene all over the liver 
acinus. (B) A plasmid for GFP was hydrodynamically injected to healthy mice and, as it can 
see appreciated in liver sections, resulted in non-homogenous green fluorescence signal. (C) 
Slices from hydrodynamically-injected mice were immunostained for PEPCK-C (red signal), 
a periportal marker. 
Our results represent the first attempt to overexpress pGK in perivenous hepatocytes. The 
first approach was the hydrodynamic injection of a plasmid with the Gck gene to healthy 
mice (Vidal-Alabró; publication pending). Forty-eight hours post-injection, increased GK in 
perivenous hepatocytes had clear effects on glucose homeostasis (Figure 5A). There was a 
reduction of glycaemia and insulinemia in the fed state, probably as a direct consequence of 
increased hepatic glucose uptake. Therefore perivenous GK gain of function reproduced 
results of periportal GK (Ferre, 1996), and liver-homogeneous GK overexpression 
(O'Doherty, 1999; Desai, 2001 & Scott, 2003). However, 16 hours-fasted mice did not show 
differences in blood glucose and insulin levels (data not shown), as Desai et al and 
O'Doherty et al had obtained with adenoviral GK transfer. Fifty days post-injection, 
perivenous GK overexpressing-mice presented blood glucose levels similar to control 
animals but accompanied by hyperinsulinism (Figure 5B). Long-term augmented GK 
activity in perivenous liver resulted in hepatic insulin resistance, since mice presented a 
phenotype very similar to liver-specific insulin receptor knock-out mice named LIRKO 
(Michael, 2000). Briefly, hyperinsulinism was probably due to reduced hepatic insulin 
clearance. Since peripheral tissues were still insulin-sensitive, hyperinsulinism inhibited 
lipolysis and induced lipogenesis in adipose tissue. Adipose tissue function together with 
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reduced hepatic lipogenesis de novo could explain the observed decrease in circulating 
triglycerides and free fatty acids. Although having increased GK activity in the liver, neither 
glycogen synthesis nor glycolysis was stimulated in those mice. Besides, gluconeogenesis 
was not inhibited in fed state. Therefore, considering the bibliography, our perivenous 
model resembled transgenic mice that expressed GK transgene under PEPCK-C promoter at 
periportal hepatocytes (Ferre, 2003). However, periportal GK overexpressing model showed 
whole-body insulin resistance linked to obesity and hepatic steatosis. It must be considered 
that their analysis was in 12 months old mice. If the study was extended to 12 months, we 
would be able to tell if hepatic insulin resistance observed in our mice model leads to 










































































































































































Fig. 5. Analysis of GK-overexpressing healthy mice. (A) Shows glycaemia and insulinemia, 
48 hours post-injection of the plasmid that contained the GK gene. Columns represent 
media ± standard error. (B) 50 days post-injection results on serum nutrients (glucose, free 
fatty acids and triglycerides) together with insulin levels are represented. (C) After 50 days 
post-injection, expression of glycolytic and gluconeogenic genes from liver were analyzed 
by Real-Time PCR. Calculations were done following ΔΔCt algorithm (Applied Biosystems), 
using β-microglobulin gene expression as a housekeeping gene. (D) The same for lipogenic 
and lipolysis genes. * p<0.05 and **p< 0.01 vs control, determined by t-Student.  
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In the context of type 1 diabetes induced with streptozotocin, perivenous liver GK gain of 
function restored hepatic glucose uptake and reduced gluconeogenesis. Therefore, typical 
increases in hepatic glucose depots (glycogen, triglyceride) occurred and resulted in a 
reduction of diabetic glycaemia, albeit small. But, perivenous GK expressing mice showed a 
significant increase in triglyceride and free fatty acid serum concentration, and hepatic 
lipids (Figure 6) (Vidal-Alabró; publication pending). Therefore our work in type 1 diabetes 
model reproduces those of periportal GK overexpression (Ferre, 1996a) and those of liver 
homogeneous GK overexpression (Morral, 2002, 2007) in terms of glycaemia. However, our 
results on lipid metabolism are more deleterious, probably because perivenous hepatocytes 










































































































































Fig. 6. Analysis of perivenous GK overexpression in type 1 diabetic mice. (A) Shows 
glycaemia, serum triglycerides and free fatty acids, 48 hours post-injection of the plasmid 
that contained the GK gene. Columns represent media ± standard error. (B) Hepatic glucose 
storage was evaluated by measuring glycogen and triglyceride levels. (C) Expression of 
lipogenic genes in the liver was analyzed by Real-Time PCR. Calculations were done 
following ΔΔCt algorithm (Applied Biosystems), using β-microglobulin gene expression as a 
housekeeping gene. (D) The same for gluconeogenic and lipolysis genes. * p<0.05, **p< 0.01 
and *** p<0.001 vs control, determined by t-Student.  
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All in all, our review of the literature together with our own results on the subject will 
convey that pGK-overexpression in the liver, independent of zonation, will result in changes 
in glycaemia but with the risk of non-desirable lipid alterations and insulin resistance. 
However, several undetermined factors influence the results obtained in GK overexpression 
studies, reinforcing the concept that hepatic GK is a key regulator of whole-body 
homeostasis, so that little changes in its activity and/or in its regulation affect glucose and 
lipid metabolism.  
4. GKRP modulates the impact of GK activity on glucose and lipid 
homeostasis 
GKRP is the best-known regulator of the hepatic GK at the post-transcriptional level. 
Therefore, impairments in GKRP should affect GK and consequently glucose metabolism, 
since GK plays a central role in glucose homeostasis. Nevertheless, mutations in the GKRP 
gene (Gckr) that caused disease or alterations in glucose metabolism have never been 
described until now. Recently, several whole-genome analysis have associated 
polymorphisms in the Gckr gene with fast hypoglycemia and increased serum triglyceride 
in humans, even though these subjects have reduced risk to type 2 diabetes (Køster, 2005; 
Sparsø, 2007; Vaxillaire, 2008; Orho-Melander, 2008 & Beer, 2009). The mechanism 
underlying this phenotype seems to be a reduction in GK inhibition by the variant 
regulatory protein (Beer, 2009). But, before exploring this issue it should be convenient to 
consider some aspects of GKRP biology. 
Although GKRP research has been focused in the liver, there are evidences that the GKRP 
protein is also present in hypothalamic neurons (Schuit, 2001; Alvarez, 2002 & Roncero, 
2009). GK/GKRP system in the hypothalamus could play a role in glucose-sensing 
important for the regulation of energy homeostasis by balancing energy intake, expenditure 
and storage. On the other hand, there is some controversy in the literature as to whether 
GKRP also regulates GK in pancreatic β-cells. The vast majority of studies state that GKRP is 
not expressed in rodent β-cells. However, it has been demonstrated that human islets 
express GKRP at very low levels (Beer, 2009). This issue should be revisited because of the 
recent publication of several genome-wide association studies that associate GK, GCKR, 
G6PC2, MTNR1B with type 2 diabetes risk linked to β-cell function (Reiling, 2009 & Bonetti, 
2011). Whether, β-cell GK function is affected directly by a hypothetic pancreatic GKRP, or 
indirectly by liver GKRP impaired activity, still needs clarification. Another question that 
remains to be resolved is whether GKRP is also expressed and functional in other GK 
expressing cells, for instance, in the gut and in the pituitary gland. 
Consequently, when considering studies of genome-wide association, mutant GKRP protein 
might affect GK activity in the brain, in the liver and perhaps in the β-cell. Therefore it is 
difficult to explain the phenotype only taking into account the hepatic GK/GKRP system. 
The same occurs with the characterization of GKRP-deficient mice (Farrelly, 2002 & 
Grimsby, 2000). GKRP knock-out mice models, whether heterozygous or homozygous, had 
normal weight. Interestingly focusing in liver analysis, those mice displayed reduced 
production of hepatic GK protein while having the same levels of GK mRNA than control 
animals, and GK protein was localized exclusively in the cytoplasm. That showed the 
importance of hepatic GKRP in stabilizing and protecting the intracellular GK pool. These 
animal models exhibited impaired postprandial glycemic control, with lower hepatic 
glycogen content and lack of inhibition of PEPCK-C gene expression, albeit with no 
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noteworthy loss in insulin secretion or changes in fasting blood glucose concentrations. 
Moreover, when challenged with a high-sucrose/high-fat diet the knock-out and normal 
mice gained body weight at a similar rate but the knock-out mice were hyperglycaemic and 
hyperinsulinemic. Importantly, no changes in plasma triglycerides and non-esterified fatty 
acids were observed in basal conditions as well as with a high-sucrose/high-fat diet. In 
summary, absence of GKRP results in decreased hepatic GK protein content, affecting 
glucose metabolism without disturbing lipid parameters.  
On the other hand, GKRP gain of function in the liver has also been assessed. In vitro 
studies with HepG2 cells simultaneously transduced with an adenoviral vector expressing 
GKRP and another adenoviral vector for GK had significantly elevated GK protein and 
activity levels compared with cells transduced with the GK adenovirus alone (Slosberg, 
2001). These data suggest that GKRP serves to stabilize and protect a pool of GK protein 
(i.e., extend half-life), and is consistent with data obtained in GKRP knock-out studies. But 
in vivo studies revealed a more complicated situation. Adenoviral-mediated hepatic 
overproduction of GKRP in mice with high-fat diet-induced diabetes resulted in 23% 
decrease in GK enzymatic activity. Although reduction of GK activity is commonly 
associated to diabetes, hepatic GKRP-expressing mice had improved fasting and glucose-
induced glycaemia with a concomitant increase in insulin sensitivity and TAG levels, and a 
decrease in leptin levels. A possible explanation for discrepancies between in vivo and in 
vitro results on GK levels when overexpressing GKRP is that GK expression in vivo is 
influenced by insulin and other physiological regulators. To understand how decreased GK 
activity improved type 2 diabetes phenotype in this model, a possibility is that GK activity 
may be applied in a more efficient manner toward metabolizing blood glucose. The 
subcellular compartmentalization by scaffolding proteins of enzymes or signaling proteins 
into clusters is often used as a means of increasing system efficiencies. 
Coming back to genome-wide studies that associate Gckr with fast hypoglycemia and high 
triglycerides, Beer et al reported that P446L-GKRP has reduced regulation by physiological 
concentrations of fructose-6-phosphate, resulting indirectly in increased GK activity (Beer, 
2009). They predicted that this increased GK activity in the liver enhanced glycolytic flux, 
promoting hepatic glucose metabolism and elevating concentrations of malonyl-CoA, a 
substrate for de novo lipogenesis, providing a mutational mechanism for the reported 
association of this variant with raised triglycerides and lower glucose levels. However, their 
predictions are conflictive with in vivo studies by Slosberg et al (Slosberg, 2001), since GKRP 
gain of function reduced hepatic GK activity and also resulted in a decrease of blood glucose 
levels accompanied by an increase of blood triglycerides. Therefore, any other 
undetermined factor/s must exist to really understand the complex physiology of the 
GK/GKRP system. Another possibility is that brain P446L-GKRP and β-cell P446L-GKRP (if 
existent) may exert determinant influences on phenotype.  
Another study that may bring light to this issue, relates to defects in glucokinase 
translocation identified in Zucker diabetic fatty (ZDF) (Fujimoto, 2004 & Shin, 2007). 
Although having normal GK protein content, GK was predominantly localized in the 
nucleus regardless of plasma glucose and insulin levels. Nevertheless, sorbitol restored GK 
translocation. Clearly, there must be two distinct mechanisms bringing about the 
dissociation of GK from GKRP. How they are related and what differentiate them are 
questions currently under investigation. Since this defect was discovered in early stage of 
diabetes, it could cause of the progression to diabetes seen in the adult ZDF rat. 
Consistently, a MODY-2 mutation in the Gck gene has been reported to increase the physical 
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substrate for de novo lipogenesis, providing a mutational mechanism for the reported 
association of this variant with raised triglycerides and lower glucose levels. However, their 
predictions are conflictive with in vivo studies by Slosberg et al (Slosberg, 2001), since GKRP 
gain of function reduced hepatic GK activity and also resulted in a decrease of blood glucose 
levels accompanied by an increase of blood triglycerides. Therefore, any other 
undetermined factor/s must exist to really understand the complex physiology of the 
GK/GKRP system. Another possibility is that brain P446L-GKRP and β-cell P446L-GKRP (if 
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Another study that may bring light to this issue, relates to defects in glucokinase 
translocation identified in Zucker diabetic fatty (ZDF) (Fujimoto, 2004 & Shin, 2007). 
Although having normal GK protein content, GK was predominantly localized in the 
nucleus regardless of plasma glucose and insulin levels. Nevertheless, sorbitol restored GK 
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dissociation of GK from GKRP. How they are related and what differentiate them are 
questions currently under investigation. Since this defect was discovered in early stage of 
diabetes, it could cause of the progression to diabetes seen in the adult ZDF rat. 
Consistently, a MODY-2 mutation in the Gck gene has been reported to increase the physical 
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interaction of GK and GKRP (García-Herrero, 2007). But, again these data are in conflict 
with other studies that reported some new GK mutations causing MODY-2 that reduced GK 
inhibition by GKRP (Veiga-da-Cunha, 1996; Gloyn, 2005 & Sagen, 2006). Once more, it is 
difficult to draw conclusions, but the importance of proper GK/GKRP function on 
metabolism and disease is reinforced, as subtle changes in its activity and/or regulation lead 
to contrary phenotypes.  
Several naturally occurring activating mutations have been described that are localized at 
the same region where synthetic GK activators bind (Kamata, 2004; Heredia, 2006 & 
Matschinsky, 2009). Both activating mutations and synthetic activators stabilize the open 
conformation of the GK protein, resulting in higher affinity for glucose and a reduction of 
the interaction between GK and GKRP, since the super-open conformation of the enzyme 
(inactive) is not possible. In humans, activation of GK by naturally occurring mutations is 
associated to persistent hyperinsulinemic hypoglycemia of the infancy (PHHI), syndrome 
with a heterogeneous phenotype even in the same family but generally with a normal lipid 
profile. On the other hand, GK activation through administration of GK activation drugs has 
been tested for their potential in the therapy of type 2 diabetes, considering principally their 
capacity to increase glucose-stimulated insulin release at the β-cell (Grimsby, 2003; 
Brocklehurst, 2004; Efanov, 2005; Leighton, 2005; Coope, 2006 & Matschinsky, 2009). Whole-
body effects of glucokinase activator drugs demonstrated a dose-dependent reduction of 
glycaemia, associated with increased insulin secretion in the pancreas and net glucose 
uptake in the liver. Besides, the administration of a GK activator prevented the development 
of diabetes in a diet-induced obesity animal model (Grimsby, 2003). Surprisingly, most in 
vivo studies with GK activators drugs do not show the lipid profile (Grimsby, 2003; 
Brocklehurst, 2004; Efanov, 2005; Leighton, 2005 & Coope, 2006), except one where 
treatment of ob/ob mice with GK activator PSN-GK1 did not produce any significant 
change blood lipids (Fyfe, 2007).  
With all this puzzling background, we intended to study the expression of an activated 
mutant form of GK with the aim to decipher the metabolic consequences in the liver of 
having a GK not regulated by GKRP, with theoretical antidiabetic properties. Particularly 
we proposed the overexpression of glucokinase A456V (identified in patients of persistent 
hyperinsulinemic hypoglycemia of the infant), with a S0.5 for glucose of 3 mM instead of 8 
mM for the wild-type enzyme (Christesen, 2002), and without GKRP regulation (Heredia, 
2006). We postulated that GK-A456V overexpression (also as a model for the liver-specific 
consequences of activating drugs on GK) could increase glucose uptake compared with the 
wild-type enzyme at equal levels of expression, whilst the metabolic fate of glucose might be 
different from that of wild-type GK due to its different capacity of interaction with other 
regulating proteins (GKRP and maybe PFK-2). 
By means of hydrodynamic gene transfer of an expression plasmid for GK-A456V in healthy 
mice, we have been able to demonstrate that the perivenous overexpression of GK-A456V 
results in a sustained improvement in blood glucose, insulinemia and glucose tolerance, in 
the absence of dyslipidemia or hepatic lipidosis nor long-term insulin resistance (Vidal-
Alabró; publication pending). Importantly, GK-A456V protein levels were similar to GK-
control group, suggesting GK-A456V stability although not being directly regulated by 
GKRP. Its mechanism of action could be explained by its lower S0.5 for glucose, so that 
glucose uptake is stimulated in later phases after ingestion (post absorptive phase) and 
during early fasting. It is tempting to speculate that glucose taken-up in perivenous liver, 
both in postprandial and post-absorptive periods, could be directed towards the glycolytic 
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and oxidative metabolism and not through the pentose phosphate pathway that would favor 
lipid biosynthesis. This hypothesis is reinforced by results published by Wu et al (Wu, 2005) in 
which adenovirus expression of wild-type GK in the liver activate the pentose phosphate 
pathway, in marked contrast to the overexpression of the kinase domain from PFK-2 that 
stimulates flux through the glycolytic pathway. Surprisingly, GK-A456V transfected animals 
showed a marked increase in glucose-6-phosphatase. GK overexpression in perivenous 
hepatocytes does not significantly affect Glc6Pase expression, suggesting that zonation is an 
important experimental variable not sufficiently addressed to date in the field. 
Transfecting GK-A456V in type 1 diabetic mice induced with streptozotocin, also caused an 
important reduction of diabetic hyperglycemia without dyslipidemia, in contrast with GK 
overexpression. Again, an induction of glucose-6-phosphatase transcription was observed in 



















































































































Fig. 7. Study of GK-A456V expression in the liver of type 1 diabetic mice. (A) Shows 
glycaemia, serum triglyceride and free fatty acid levels, 48 h post-injection of the plasmid for 
the GK-A456V gene. Columns represent media ± standard error. (B) Expression of 
gluconeogenic and lipolysis genes from liver was analyzed by Real-Time PCR. Calculations 
were done following ΔΔCt algorithm (Applied Biosystems), using β-microglobulin gene 
expression as a housekeeping gene. (C) The same for lipogenic genes. * p<0.05, # p<0.05 vs 
control and pGK, and & p<0.001 vs control and p<0.05 vs pGK-A456V, as determined by 
One-way ANOVA.  
Our results lead us to consider the physiology of glucose-6-phosphatase in the context of 
glucose and lipid metabolism. Glucose-6-phosphatase dephosphorylates glucose-6-
phosphate in the endoplasmic reticulum to obtain glucose, as the last step in the 
 
Dyslipidemia - From Prevention to Treatment 
 
252 
interaction of GK and GKRP (García-Herrero, 2007). But, again these data are in conflict 
with other studies that reported some new GK mutations causing MODY-2 that reduced GK 
inhibition by GKRP (Veiga-da-Cunha, 1996; Gloyn, 2005 & Sagen, 2006). Once more, it is 
difficult to draw conclusions, but the importance of proper GK/GKRP function on 
metabolism and disease is reinforced, as subtle changes in its activity and/or regulation lead 
to contrary phenotypes.  
Several naturally occurring activating mutations have been described that are localized at 
the same region where synthetic GK activators bind (Kamata, 2004; Heredia, 2006 & 
Matschinsky, 2009). Both activating mutations and synthetic activators stabilize the open 
conformation of the GK protein, resulting in higher affinity for glucose and a reduction of 
the interaction between GK and GKRP, since the super-open conformation of the enzyme 
(inactive) is not possible. In humans, activation of GK by naturally occurring mutations is 
associated to persistent hyperinsulinemic hypoglycemia of the infancy (PHHI), syndrome 
with a heterogeneous phenotype even in the same family but generally with a normal lipid 
profile. On the other hand, GK activation through administration of GK activation drugs has 
been tested for their potential in the therapy of type 2 diabetes, considering principally their 
capacity to increase glucose-stimulated insulin release at the β-cell (Grimsby, 2003; 
Brocklehurst, 2004; Efanov, 2005; Leighton, 2005; Coope, 2006 & Matschinsky, 2009). Whole-
body effects of glucokinase activator drugs demonstrated a dose-dependent reduction of 
glycaemia, associated with increased insulin secretion in the pancreas and net glucose 
uptake in the liver. Besides, the administration of a GK activator prevented the development 
of diabetes in a diet-induced obesity animal model (Grimsby, 2003). Surprisingly, most in 
vivo studies with GK activators drugs do not show the lipid profile (Grimsby, 2003; 
Brocklehurst, 2004; Efanov, 2005; Leighton, 2005 & Coope, 2006), except one where 
treatment of ob/ob mice with GK activator PSN-GK1 did not produce any significant 
change blood lipids (Fyfe, 2007).  
With all this puzzling background, we intended to study the expression of an activated 
mutant form of GK with the aim to decipher the metabolic consequences in the liver of 
having a GK not regulated by GKRP, with theoretical antidiabetic properties. Particularly 
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and oxidative metabolism and not through the pentose phosphate pathway that would favor 
lipid biosynthesis. This hypothesis is reinforced by results published by Wu et al (Wu, 2005) in 
which adenovirus expression of wild-type GK in the liver activate the pentose phosphate 
pathway, in marked contrast to the overexpression of the kinase domain from PFK-2 that 
stimulates flux through the glycolytic pathway. Surprisingly, GK-A456V transfected animals 
showed a marked increase in glucose-6-phosphatase. GK overexpression in perivenous 
hepatocytes does not significantly affect Glc6Pase expression, suggesting that zonation is an 
important experimental variable not sufficiently addressed to date in the field. 
Transfecting GK-A456V in type 1 diabetic mice induced with streptozotocin, also caused an 
important reduction of diabetic hyperglycemia without dyslipidemia, in contrast with GK 
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Fig. 7. Study of GK-A456V expression in the liver of type 1 diabetic mice. (A) Shows 
glycaemia, serum triglyceride and free fatty acid levels, 48 h post-injection of the plasmid for 
the GK-A456V gene. Columns represent media ± standard error. (B) Expression of 
gluconeogenic and lipolysis genes from liver was analyzed by Real-Time PCR. Calculations 
were done following ΔΔCt algorithm (Applied Biosystems), using β-microglobulin gene 
expression as a housekeeping gene. (C) The same for lipogenic genes. * p<0.05, # p<0.05 vs 
control and pGK, and & p<0.001 vs control and p<0.05 vs pGK-A456V, as determined by 
One-way ANOVA.  
Our results lead us to consider the physiology of glucose-6-phosphatase in the context of 
glucose and lipid metabolism. Glucose-6-phosphatase dephosphorylates glucose-6-
phosphate in the endoplasmic reticulum to obtain glucose, as the last step in the 
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gluconeogenic pathway. Its transcription is regulated by insulin, so that it is repressed in 
fed state and induced during fasting. However, glucose induces transcription of this 
enzyme although the physiological significance of this induction is still not resolved 
(Nordlie, 2010). Finally glucose-6-phosphatase deficiency causes severe hyperlipidemia 
and hepatic steatosis (Bandsma, 2002, 2008), therefore giving rise that this enzyme may 
also participate or influence the GK/GKRP system in the regulation of hepatic glucose 
fate. To support this hypothesis, Reiling and colleagues described combined effects of 
single-nucleotide polymorphisms in GK, GKRP and glucose-6-phosphatase on fasting 
plasma glucose and type 2 diabetes (Reiling, 2009). Therefore, it is a field that needs 
further exploration.  
5. Conclusion 
Subtle changes in GK activity or in GKRP function have consequences in glucose and lipid 
metabolism. However, further studies must be done to completely understand the 
mechanism underlying GK/GKRP biology. Our results on increasing GK protein in the liver 
of both healthy and insulin-deficient mice (lacking endogenous GK) resulted in 
dyslipidemia. On the other hand, our analysis of the metabolic consequences of GK-GKRP 
deregulation by overexpressing a GK activating mutant (GKA456V) in the liver of both 
healthy and type 1 diabetic mice demonstrates an impact on glycaemia in the absence of 
dyslipidemia or hepatic lipid deposition. These data provide novel insights into the capacity 
of the complex GK-GKRP to influence the fate of metabolized glucose in the liver, providing 
a framework for further research on GK activating drugs in the liver. 
We conclude that GKRP regulation impairment and GK-A456V altered kinetics greatly 
influence liver metabolism, in line with results in humans carrying a mutant GKRP (Køster, 
2005; Sparsø, 2007; Vaxillaire, 2008 & Orho-Melander, 2008). Besides, it suggests that 
activating GK exclusively in the liver could be a feasible strategy to funnel excess glucose 
from the diet out of circulation, widening the scope for GK synthetic activators research.  
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Dyslipidaemia is a well-described major independent risk factor for cardiovascular disease 
(Lin et al.). It is well established that the liver plays the central role in lipid metabolism and 
liver malfunction is one of the main sources of dyslipidemia (Watson et al., 2003). However, 
most of the studies so far have focused on the role of hepatocytes in lipid turnover. Indeed, 
hepatocytes do play a central role in liver lipid metabolism, but they are not alone. 
Hepatocytes do not have direct contact with the circulation. Any blood-borne lipoprotein 
particle must first pass through a filter comprised of a layer of endothelial cells, lining the 
walls of liver sinusoids, before it can contact the liver parenchyma. Likewise, lipoproteins 
remodelled or synthesized by the liver encounter the same barrier before they reach 
systemic circulation.  
2. The structure of the hepatic sinusoid 
The hepatic sinusoids are small blood vessels, comparable to capillaries in size, that perfuse 
the hepatocytes. However, unlike the capillaries in other tissues, sinusoids are formed by a 
discontinuous endothelium that lacks any significant underlying basement membrane. 
Walls of sinusoids are formed by the liver sinusoidal endothelial cells (LSECs). LSECs are 
separated from liver parenchyma by the perisinusoidal extravascular space, known as the 
space of Disse (Figure 1A). LSECs contribute only 15-20% of all liver cells but comprise 70% 
of the population of sinusoidal cells in the liver (Arias, 1990; Arii and Imamura, 2000; Blouin 
et al., 1977; Knook and Sleyster, 1976).  
The LSECs are perforated by trans-cytoplasmic pores called fenestrae, which do not have 
any intervening diaphragmatic membrane, and thus are fully patent holes through the cell 
(Figure 1A-B). This specialized lace-like morphology of the LSECs minimizes any barrier to 
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Dyslipidaemia is a well-described major independent risk factor for cardiovascular disease 
(Lin et al.). It is well established that the liver plays the central role in lipid metabolism and 
liver malfunction is one of the main sources of dyslipidemia (Watson et al., 2003). However, 
most of the studies so far have focused on the role of hepatocytes in lipid turnover. Indeed, 
hepatocytes do play a central role in liver lipid metabolism, but they are not alone. 
Hepatocytes do not have direct contact with the circulation. Any blood-borne lipoprotein 
particle must first pass through a filter comprised of a layer of endothelial cells, lining the 
walls of liver sinusoids, before it can contact the liver parenchyma. Likewise, lipoproteins 
remodelled or synthesized by the liver encounter the same barrier before they reach 
systemic circulation.  
2. The structure of the hepatic sinusoid 
The hepatic sinusoids are small blood vessels, comparable to capillaries in size, that perfuse 
the hepatocytes. However, unlike the capillaries in other tissues, sinusoids are formed by a 
discontinuous endothelium that lacks any significant underlying basement membrane. 
Walls of sinusoids are formed by the liver sinusoidal endothelial cells (LSECs). LSECs are 
separated from liver parenchyma by the perisinusoidal extravascular space, known as the 
space of Disse (Figure 1A). LSECs contribute only 15-20% of all liver cells but comprise 70% 
of the population of sinusoidal cells in the liver (Arias, 1990; Arii and Imamura, 2000; Blouin 
et al., 1977; Knook and Sleyster, 1976).  
The LSECs are perforated by trans-cytoplasmic pores called fenestrae, which do not have 
any intervening diaphragmatic membrane, and thus are fully patent holes through the cell 
(Figure 1A-B). This specialized lace-like morphology of the LSECs minimizes any barrier to 
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the bi-directional transfer of solutes and particulate substrates between the sinusoidal blood 
and hepatocytes, whilst retaining the capacity and substantial surface area to undergo 
interactions with circulating blood cells including immune cells (Cogger and Le Couteur, 
2009; Fraser et al., 1995; Wisse et al., 1996). Fenestrae are not uniformly distributed over the 
LSEC surface but are aggregated into groups of tens to hundreds in gossamer thin areas of 
cytoplasm and towards the periphery of the cell. These areas of fenestral aggregations are 
termed sieve plates (Figure 1B). Between 60-75% of fenestrae are found within sieve plates 
in rats (Vidal-Vanaclocha and Barbera-Guillem, 1985) but isolated fenestrae are also 
frequently observed on the LSEC surface. 
The LSEC becomes fenestrated at an early gestational stage (Enzan et al., 1997; Martinez-
Hernandez and Amenta, 1993; Nonaka et al., 2007; Smedsrod et al., 2009). The porosity of 
the sinusoids depends on the number and especially the size or diameter of the fenestrae. 
The diameter of fenestrae has a normal distribution curve of about 50-200nm (Cogger and 
Le Couteur, 2009). Gaps larger than about 200nm are regarded as artifacts formed during 
specimen preparation for electron microscopy (Akinc et al., 2009; Fraser et al., 1978; Fraser et 
al., 1980; Hilmer et al., 2005a).  
Fenestrae have been found in many species including such diverse species as man, rat, 
mouse, guinea pig, sheep, goat, rabbit, fowl, monkey, baboon, bat, kitten, dog, turtle and 
fish (Cogger and Le Couteur, 2009).  
The fenestrated endothelium was first suggested as a filter of chylomicrons by Wisse in 1970 
(Wisse, 1970) from their reported diameters (Fraser et al., 1968) and termed the “liver sieve” 
once sieving was confirmed (Fraser et al., 1978; Naito and Wisse, 1978). Fenestrae allow the 
transfer of a wide range of substrates including plasma and plasma molecules, such as 
plasma proteins, some lipoproteins and colloidal particles (Le Couteur et al., 2005). The 
latter also include artificial chylomicron-like nanospheres such as Intralipid, but also small 
viruses leading to hepatitis, viral vectors for DNA manipulation of hepatocytes. 
The fenestrated LSEC can be defined as an ultrafiltration system because it is a low pressure 
system with pores approximately 100nm in diameter. Specifically, the liver sieve can be 
described as a Loeb–Sourirajan ultrafiltration system, with the LSECs providing the thin 
porous layer (Baker, 2004). The transfer of fluid across an ultrafiltration system can be 
calculated using the Hagen Poiseuille equation for ultrafiltration where the flux of fluid is 
proportional to the number of pores and the radius of the pores to the power of four (Baker, 
2004; Le Couteur et al., 2006; Warren et al., 2005). Therefore small changes in the size of 
fenestrae has profound effects on the size and number of substrates and macromolecules 
that can gain passage into the space of Disse. Indeed, manipulation of fenestrae diameter 
might have a role in regulating the transfer of substrates in response to physiological 
changes, such as feeding and fasting (O'Reilly et al., 2010). 
The space of Disse is the extravascular space lying between the hepatocytes and LSECs. It 
contains some components of extracellular matrix and most components of blood plasma 
filtered through LSEC’s sieve plates. Extracellular matrix in the space of Disse contains 
fibronectin and collagen type I ,III, V, and VI. Collagen type IV is also present but unlike its 
sheet-like polymeric presentation in typical basement membranes, here it appears in the 
form of discontinuous aggregates (Martinez-Hernandez and Amenta, 1993). Of note, 
basement membrane has not been identified in liver sinusoids in any non-pathological state 
or developmental stage until old age (Enzan et al., 1997; Martinez-Hernandez and Amenta, 
1993; Nonaka et al., 2007; Smedsrod et al., 2009), where its appearance is believed to be a 
sign of age-related degeneration and – possibly – a cause of pathology.  
 




Fig. 1. A: Transmission electron micrograph showing liver sinusoidal endothelial cell (LSEC) 
perforated by fenestrae (Fen). (Hep) – hepatocyte, (SoD) - space of Disse, (SC) - stellate cells 
with lipid droplet in space of Disse. B: Scanning electron micrograph of an isolated liver 
sinusoidal endothelial cell showing fenestrae clustered into sieve plates (SP). C: Scanning 
electron micrograph of a vascular cast showing branches of the portal vein (TPV) with 
surrounding sinusoidal network (Sin). (Preparations performed by A Warren). 
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Multiple microvilli from the the sinusoidal surface of the hepatocytes protrude into the 
space of Disse and increase the available surface area for the recognition, transport and 
diffusion of substrates to and from the liver (Cogger and Le Couteur, 2009; Fraser et al., 
1995; Wisse et al., 1996).  
There are three other cell types residing in the liver sinusoids apart from the LSECs: Kupffer 
cells (resident liver macrophages), stellate cells and pit cells. Kupffer cells represent only 
20% of all the population of liver sinusoidal cells but 80-90% of all tissue macrophages in the 
body (Knook and Sleyster, 1976). They generally reside within the lumen of the liver 
sinusoids and take up bacteria and other large particles, such as cell debris, from the 
circulation by phagocytosis. In response to bacterial infection, Kupffer cells produce 
cytokines and a number of soluble pro-inflammatory factors that promote influx and 
activation of neutrophils (Smedsrod et al., 1994; Smedsrod et al., 2009) and may alter the 
porosity of the sinusoids to promote cirrhosis (Dobbs et al., 1994). Together, LSECs 
(pinocytosis) and Kupffer cells (phagocytosis) constitute the hepatic reticuloendothelial 
system (RES), the most powerful scavenger system of mammals and other terrestrial 
vertebrates (Aschoff, 1924; Kawai et al., 1998).  
3. The normal function of the LSEC in regulation of blood lipids  
Because of the LSECs fenestrae, all lipoproteins except large chylomicrons have unimpeded 
access to the hepatocytes. After delivering triglycerides to peripheral tissues, chylomicrons 
become processed into so-called “chylomicron remnants” that carry significant amounts of 
cholesterol and are highly pro-atherogenic (Fujioka and Ishikawa, 2009; Karpe et al., 1994). 
At the same time they become small enough to pass through LSECs fenestrae (Fujioka and 
Ishikawa, 2009) and can be taken up by hepatocytes, which allows liver parenchyma to be 
the major site for removal of pro-atherogenic chylomicron remnants from the blood 
(Cooper, 1997; Dietschy et al., 1993) under normal circumstances. However, fast and 
efficient blood clearance of highly atherogenic chylomicron-remnants by hepatocytes 
requires well fenestrated LSECs.  
4. Ageing of the LSEC and regulation of blood lipids  
Many important diseases, particularly cardiovascular diseases, that result in disability and 
death, occur late in life, indicating that aging itself is a key risk factor. Old age is associated 
with significant changes in the cells of the hepatic sinusoid. Previously, it has been 
considered that the liver does not undergo significant aging changes because of its large 
functional reserve, regenerative capacity and dual blood supply (Popper, 1986). Only a few 
descriptions of the aging liver have been generally established, such as an increase in the 
number of polyploid and binucleate hepatocytes (Schmucker, 1998) and “brown atrophy”, 
which is a reduction in liver mass accompanied by the deposition of the aging pigment, 
lipofuscin (Popper, 1986). Today it has become clear that age-related changes in hepatic 
structure and function are significant and influence systemic exposure to xenobiotics, 
endogenous substances associated with disease and medications (McLean and Le Couteur, 
2004). Thus, such changes in the liver have implications for many diseases of aging and the 
aging process itself.  
It has now been reported that old age is associated with substantial ultrastructural changes 
in the LSECs and space of Disse in intact livers of the rat (Jamieson et al., 2007; Le Couteur et 
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al., 2001), human (McLean et al., 2003), the mouse (Ito et al., 2007; Warren et al., 2005) and 
the non-human primate, Papio hamadryas (Cogger et al., 2003). The findings have been 
replicated in at least three separate centres around the world (Furrer et al.; Ito et al., 2007; Le 
Couteur et al., 2001; Stacchiotti et al., 2008). These changes have been termed 
‘pseudocapillarization’ because the aging sinusoids become similar to capillaries seen in 
other non-fenestrated vascular beds (Le Couteur et al., 2001). Unlike ‘capillarization’ seen in 
the hepatic sinusoid in cirrhosis of the liver, aging is not associated with any of the typical 
changes apparent on light microscopy, such as bridging fibrosis and nodular regeneration 
(Le Couteur et al., 2001; Le Couteur et al., 2008). In old age, LSEC thickness is increased by 
approximately 50% and there is a similar reduction of about 50% in the porosity and 
number of fenestrae (Figure 2). These changes are associated with perisinusoidal basal 
lamina deposition in many old livers and some scattered collagen in the space of Disse. The 
effect of aging on the diameter of fenestrae has been inconsistent between species, however 
there is a trend towards a reduction in diameter of around 5-10% (Le Couteur et al., 2008). 
Isolated LSECs typically retain some of these ultrastructural changes. Fenestrae diameter 




Fig. 2. Scanning electron micrographs of the liver sinusoid of a young (A) and old (B) rat. 
The loss of fenestrae perforating the endothelial cell surface in the old liver is apparent. 
(Preparations performed by A Warren). 
Fenestrations have a role in the transfer of lipoproteins from blood to the hepatocyte, 
therefore it is likely that pseudocapillarization of sinusoids will impair lipoprotein clearance 
by the liver and contribute to dyslipidaemia in older people (Le Couteur et al., 2002). 
Atherosclerosis increases dramatically with old age and its complications affect most older 
people (Lakatta and Levy, 2003). The clearance of chylomicron remnants is significantly 
impaired in older people (Borel et al., 1998; Krasinski et al., 1990) and in those aged 65 years 
and older, remnant-like lipoprotein cholesterol is associated with the development of 
coronary artery disease (Simons et al., 2001). To determine whether age-related 
defenestration impairs the transfer of lipoproteins across the LSECs, the multiple indicator 
dilution method was used to study lipoprotein disposition in perfused rat livers (Hilmer et 
al., 2005b). In young livers, lipoproteins (approximately 50 nm diameter) entered the entire 
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extracellular space whereas in old livers, the lipoproteins were confined to the vascular 
space. These results strongly suggest that age-related pseudocapillarization impairs the 
hepatic disposition of lipoproteins and thus plays a role in age-related dyslipidaemia.  
Matrix heparan sulfate proteoglycans bind and sequester lipoprotein remnants (Williams, 
2008). In old age, formation of basal lamina beneath LSECs leads to a change in the 
proportions of extracellular matrix components and may result in impaired passage of 
lipoproteins across the space of Disse. However, the importance of this pathway in 
lipoprotein turnover has not been studied sufficiently, especially in connection to aging.  
A reduction in caloric intake by about 40% increases maximum life expectancy and is 
associated with a delay in the onset of most age-associated disorders and pathology 
(Everitt et al., 2005). It has also been demonstrated that caloric restriction delays the onset 
of pseudocapillarization in rats. In the old caloric restricted rats, endothelial thickness was 
significantly less and fenestrae porosity was significantly greater than in the old ad 
libitum fed rats. Moreover, caloric restriction prevented the age-related increase in 
perisinusoidal collagen IV staining (Jamieson et al., 2007). The finding that caloric 
restriction influences pseudocapillarization suggests that the latter is secondary to the 
aging process and thus potentially reversible. As a consequence, modulation of LSEC 
fenestrations might be a therapeutic target for the treatment of age-related dyslipidemia 
and prevention of vascular disease. On the other hand, early onset of 
pseudocapillarization and dyslipidemia occur in a transgenic mouse model of Werner 
syndrome, a rare premature aging syndrome in humans. 
Another hallmark of old age - the reduction in liver size as a fraction of body weight - is 
usually in the order of 25-35% (Le Couteur and McLean, 1998) and is associated with a 
decrease in the number of hepatocytes. In addition, several studies have shown that the total 
hepatic blood flow is reduced by about 30-50% (Le Couteur and McLean, 1998). Liver 
perfusion, which is the blood flow per mass of liver, is also reduced in old age but to a lesser 
extent than total blood flow. Mechanisms for these changes remain unclear; however, a 
recent study using high resolution in vivo microscopy has shown how pseudocapillarization 
might contribute to these phenomena. There was a 14% reduction in the numbers of 
perfused sinusoids with old age and a 35% reduction in sinusoidal blood flow (Ito et al., 
2007). Narrower sinusoids with thickened LSECs and swollen stellate cells with abundant 
lipid droplets were also observed. It was concluded that these changes caused age-related 
reduction in hepatic perfusion and hepatic blood flow by blocking the sinusoids (Ito et al., 
2007). The clearance of highly extracted substrates from the circulation is dependent on 
blood flow, therefore the age-related reduction in hepatic blood flow has a dramatic effect 
on the liver’s overall function (Le Couteur and McLean, 1998), including the clearance of 
lipoproteins.  
It is reasonable to conclude that pseudocapillarization, in combination with a reduction in 
hepatic blood flow, are two major factors contributing to age-related dyslipidemia.  
5. Scavenger function of LSEC in clearance of oxidized lipoproteins 
Another unique feature of LSECs is extraordinary endocytic activity. LSECs are rich in 
coated pits and vesicles and other organelles associated with endocytosis. Although 
LSECs constitute only 2.8 % of the total liver volume, they contain about 15% of the total 
lysosomal volume and about 45% of the pinocytic vesicle volume of the liver (Blouin et 
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al., 1977). Moreover, specific activities of several lysosomal enzymes are higher in LSECs 
than in other liver cells (Knook and Sleyster, 1980). LSECs express a set of high-affinity 
endocytic receptors for soluble macromolecular waste products, generated during normal 
tissue turnover, blood clotting, inflammatory processes and pathological conditions 
(McCourt et al., 1999; Skogh et al., 1985; Smedsrod, 2004; Smedsrod et al., 1994; Smedsrod 
et al., 2006; Smedsrod et al., 1997; Smedsrod et al., 1990). Connective tissue 
macromolecules including hyaluronan, chondroitin sulphate, collagen α-chain, 
Procollagen Propeptides (PICP, PINP and PIIINP), products released during cell death 
such as lysosomal enzymes and metabolic byproducts including oxidized low density 
lipoproteins (oxLDLs), advanced glycation end products, and immune complexes and 
microbial CpG motifs are exclusively cleared from the blood circulation by mannose 
receptor-mediated or scavenger receptor-mediated endocytosis in LSECs (Elvevold et al., 
2008; Malovic et al., 2007; Martin-Armas et al., 2006; Skogh et al., 1985; Smedsrod, 2004; 
Smedsrod et al., 1997; Smedsrod et al., 1990). 
LSECs express several different scavenger receptors including scavenger receptors –A, 
scavenger receptors-B, and scavenger receptors-H (Hughes et al., 1995; Malerod et al., 2002). 
However, stabilin-1 and stabilin-2 have been recognised as the main scavenger receptors on 
LSECs (Hansen et al., 2005; Hansen et al., 2002; McCourt et al., 1999; Politz et al., 2002; Zhou 
et al., 2000). Following receptor mediated endocytosis in LSECs most of the ligands are 
rapidly degraded intra-lysosomally. Thus, LSECs represent a major site of scavenging and 
degradation of harmful waste macromolecules from the circulation and have therefore been 
termed ‘scavenger endothelial cells’ (Seternes et al., 2002). 
LSEC endocytosis of oxLDL may also be implicated in the development of atherosclerosis. 
Atherosclerosis begins as a progressive, chronic inflammatory condition characterized by 
thickening of the arterial intima through proliferation of intimal smooth muscle cells, 
which has been shown to be precipitated by cholesterol-rich LDL and triglycerides 
derived from chylomicron remnants (Fischer-Dzoga et al., 1976). This may then advance 
to a complex plaque, which can ultimately lead to serious cardiovascular complications, 
such as myocardial infarction and stroke from occluded arteries. The oxidative 
modification of LDL has been suggested to play an important role in the development of 
these events (Steinberg, 1997, 2009). LDL can undergo in vivo oxidation in the arterial 
walls (Yla-Herttuala et al., 1989) and in plasma (Avogaro et al., 1988; Holvoet et al., 
1998b). The process starts within the LDL particle with oxidation of polyunsaturated fatty 
acids which generates a great number of various intermediate and end-products. 
Formation of free and organic radicals launches a chain reaction that causes fragmentation 
of both lipid and protein constituents of LDL. Formation of reactive aldehydes, such as 
malondialdehyde, 4-hydroxynonenal and glyoxal results in chemical modification of side 
chain amino groups of the lysine residues of apoB-100, which in turn leads to an increased 
net negative surface charge of the molecule (Baynes and Thorpe, 1999; Fu et al., 1996; 
Jialal and Devaraj, 1996; Oorni et al., 2000; Witztum and Steinberg, 1991; Young and 
McEneny, 2001). Therefore, the oxidative modification of LDL involves changes in both 
the protein and the lipid components of the LDL-particle. This in turn induces changes in 
surface charge and conformation, which renders LDL a ligand for scavenger receptors, 
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extent than total blood flow. Mechanisms for these changes remain unclear; however, a 
recent study using high resolution in vivo microscopy has shown how pseudocapillarization 
might contribute to these phenomena. There was a 14% reduction in the numbers of 
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al., 1977). Moreover, specific activities of several lysosomal enzymes are higher in LSECs 
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chain amino groups of the lysine residues of apoB-100, which in turn leads to an increased 
net negative surface charge of the molecule (Baynes and Thorpe, 1999; Fu et al., 1996; 
Jialal and Devaraj, 1996; Oorni et al., 2000; Witztum and Steinberg, 1991; Young and 
McEneny, 2001). Therefore, the oxidative modification of LDL involves changes in both 
the protein and the lipid components of the LDL-particle. This in turn induces changes in 
surface charge and conformation, which renders LDL a ligand for scavenger receptors, 
and reduces or abolishes its affinity to the LDL receptor (Berliner and Heinecke, 1996; Li 
et al., 2011). 
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In arterial intima, oxLDLs are taken up by macrophages via scavenger receptors. This 
induces foam cell formation and subsequent atheroma development (Henriksen et al., 1981, 
1983; Steinbrecher et al., 1984). Oxldls are commonly present in atherosclerotic lesions of 
experimental animals and humans (Palinski et al., 1989; Yla-Herttuala et al., 1989). OxLDL 
has also been identified in plasma of healthy individuals (Avogaro et al., 1988; Ehara et al., 
2001; Itabe and Takano, 2000). In patients with cardiovascular disease, plasma levels of 
oxLDL have been reported to be approximately fourfold higher than in healthy subjects 
(Ehara et al., 2001; Holvoet et al., 1998b). In addition to cardiovascular disease, increased 
levels of oxLDL are associated with ageing (Brinkley et al., 2009) and certain age-related 
pathologies, such as Alzheimer’s disease (Kankaanpaa et al., 2009), glomerulosclerosis (Lee, 
1999), and diabetes mellitus (Lopes-Virella et al., 1999). 
Therefore, timely clearance and maintenance of low circulatory levels of oxLDLs appear to 
be important for the prevention of atherosclerosis (Holvoet et al., 1998b; Itabe, 2003). 
Previously, it has been shown that intravenously injected radiolabeled oxLDLs are rapidly 
removed from blood by uptake in Kupffer cells and LSECs (Ling et al., 1997; Van Berkel et 
al., 1991). However, a recent study demonstrated that Kupffer cells are only active in uptake 
of heavily oxidized LDL (Li et al., 2011). which is mainly present in atherosclerotic plaques 
(Yla-Herttuala et al., 1989) or formed as an artifact during in vitro oxLDL preparation. At the 
same time, LSECs hold an exclusive role in the uptake of mildly oxidized LDL from the 
circulation (Li et al., 2011). Mildly oxidized LDL is the major form of oxLDL found in the 
blood (Chang et al., 1997; Holvoet et al., 1998a; Holvoet et al., 1998b), and has 
proatherogenic properties (Berliner et al., 1990; Watson et al., 1997; Witztum and Steinberg, 
1991). Both stabilin-1 and stabilin-2 are involved in the endocytic uptake of oxLDL by 
LSECs. Stabilin-1, however, appears to be more important for the uptake of mildly oxidized 
LDL, which represents physiological blood-borne oxLDL, while stabilin-2 is important for 
uptake when there is greater LDL modification (Li et al., 2011). 
The morphological changes in the LSEC in old age might also affect its role in endocytosis. 
Recently, in vivo microscopy was used to examine the real time uptake of scavenger receptor 
ligands by LSECs (Ito et al., 2007). Endocytosis was clearly diminished in old mice, 
particularly in the pericentral zone which may indicate hypoxic liver damage. The effect of 
old age on clearance of oxLDL by LSEC has not been examined yet. However, involvement 
of stabilin 1 and 2, the two major LSEC scavenger receptors, in the process of oxLDL uptake 
(Li et al., 2011) makes it likely that oxLDL clearance would be diminished in old age. This 
change would increase the level of oxLDL in the circulation, thereby promoting its 
extrahepatic concentration and increasing the risk of the development of atherosclerosis. 
6. Conclusions  
Age-related changes in morphology and function of LSECs apparently contribute to 
dyslipidemia and, as a consequence, to the development of cardiovascular disease. Old age 
is associated with reduced fenestrae in the LSEC which impedes the hepatic uptake of 
chylomicron remnants and possibly other lipoproteins. In addition, aging is associated with 
reduced LSEC endocytic capacity which will impact on circulating levels of oxLDL. Thus the 
LSEC is a novel therapeutic target for the treatment of age-related dyslipidemia and has 
great potential for the prevention of atherosclerosis and cardiovascular events. 
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1. Introduction  
There are extensive epidemiological data demonstrating that high blood cholesterol levels 
increase cardiovascular risk, and that this risk is dependent on the levels of the different 
blood cholesterol fractions. Moreover, the reduction of total blood cholesterol has been 
clearly related to a reduction in the risk of stroke, coronary disease and overall 
cardiovascular death. However, the traditional cholesterol measurements tend to be most 
accurate at predicting risk for those at the lower and higher ends of the risk spectrum. 
Recent data has shown LDL-Cholesterol/HDL-Cholesterol ratio and even Total-
Cholesterol/HDL-Cholesterol ratio, to be accurate predictors of cardiovascular risk. In fact, 
changes in ratios have been shown to be better indicators of successful CHD risk reduction 
than changes in absolute levels of lipids or lipoproteins. In the Helsinki Study, the LDL-
C/HDL-C ratio had more prognostic value than LDL-C or HDL-C alone (Manninen, 
Tenkanen, Koskinen et al, 1992). The ratio was especially accurate at predicting risk among 
those who also had elevated triglyceride levels. The PROSPER trial, a retrospective analysis 
of 6,000 patients, found that the ratio of LDL-C/HDL-C was the most powerful measure of 
cardiovascular disease risk in elderly people (Packard, Ford, Robertson et al, 2005). The 
PROCAM Study, which included almost 11,000 men aged 36 to 65 who were studied for 4 to 
14 years, found a continuous and graded relationship between the LDL-C/HDL-C ratio and 
CVD mortality (Cullen, Schulte, Assmann et al, 1997). In addition, comparison of individual 
LDL-C/HDL-C ratios from subjects in the Framingham Study clearly indicates that these 
ratios are significantly more robust predictors of CVD than the individual levels of LDL-C 
or HDL-C (Kannel, 2005). 
2. Theoretical framework 
2.1 Cardiovascular risk – Generalities 
Cardiovascular diseases are an unavoidable topic when discussing health related issues, 
particularly in developed societies. Cardiovascular disease is the leading cause of mortality 
in these countries (World Health Organization, 2002), assuming a progressively more 
important role in developing countries and even in less developed countries. In the latter, 
we may consider the presence of a double-frontier of health risk. These countries show 
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coexistence of important mortality indexes related to diseases whose prevalence is a 
demonstration to their stage of development (perinatal, nutritional and infectious health 
problems), with a more consistent presence of coronary disease, with increased percentage 
reaching 137% for males and 120% for females by the year 2010 (Yusuf, Reddy, Ounpuu et 
al, 2001). 
In epidemiological terms, coronary heart disease and cerebrovascular disease represent the 
most significant expressions of cardiovascular disease, and were the main causes of 
mortality and morbidity worldwide, accounting for one third of total mortality in the year 
2001 (American Heart Association, 2003). According to the World Health Organization, 
every year 16 million deaths occur from cardiovascular disease, and this number is expected 
to rise to 20 million in the first decade of the XXI century (World Health Organization, 2002). 
The singular importance of coronary heart disease is extraordinarily important and it is 
estimated that mortality by this disease had risen to 7.2 million individuals by the year 2001 
(World Health Organization, 2002). However, in recent years, there has been a trend 
towards a decline in this disease in Western countries, with a concomitant increase in other 
lands, notably in Russia and Eastern European countries. In fact, in Western countries, the 
number of deaths from coronary per 100,000 inhabitants was 151 in 1972, dropping to 44 in 
2004, in men aged 64 or less. Similar reductions were also observed in females (36 to 11 
women per 100,000). Paradoxically, in Russia, there was a marked increase of this rate, from 
169/100.000, in the year 1980, to 242/100.000 deaths, in the year 2005 (Allender, 
Scarborough, Black et al, 2008). 
The onset of cardiovascular disease is consistently related to the presence of a group of 
cardiovascular risk factors, whose manipulation can be crucial to its prevention (see Table 1). 
 
Reversible 
   Smoking 
   Arterial hypertension 
   Hyperlipidemia 
   Obesity 
   Sedentarism 
   Alcohol 
   Stress 
Irreversible 
   Family history 
   Male gender 
   Age 
Partially Reversible 
   Diabetes 
   Menopause 
Table 1. Conventional cardiovascular risk factors. 
Concerning reversible risk factors in which intervention could be decisive, we  
should highlight the relative importance of smoking, arterial hypertension and 
hypercholesterolaemia. Although the global fight against all reversible risk factors constitute 
a therapeutic imperative, the elimination of hypercholesterolemia would result in the single 
most important benefit against the incidence of coronary heart disease as well as other 
atherosclerotic vascular problems (Wilson, D'Augustine, Levy et al, 1998). 
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Regarding arterial hypertension, it always presents itself as a major risk factor, given its very 
high incidence and prevalence. Despite all the research carried out and considering all the 
remarkable therapeutic advances, the control of blood pressure levels only provides a 
reduction of about 40% in mortality from cerebrovascular disease and a more modest 20% 
reduction in mortality from coronary heart disease (Kaplan, 2002).  
Diabetes is another important risk factor, with the particularity of becaming the major 
epidemy of this century given its substantial and consistent epidemiological growth. The 
high cardiovascular risk that diabetes provides is well illustrated by the prognostic 
similarity between a diabetic patient without clinical manifestations of coronary heart 
disease and a patient with a history of acute coronary events (Hafnner, Lethe, Ronnema et al, 
1988).  
Obesity is undoubtedly a major risk factor for cardiovascular disease (Higgins, Kannel, 
Garrison et al, 1988), now becoming a public health problem, given the alarming increase of 
its prevalence in industrialized countries. The pathogenic mechanisms involved in this 
situation are complex and not just related to the metabolic overload involved, but also 
determined by its close associations with arterial hypertension, type 2 diabetes, 
dyslipidemia, and inflammation (Higgins, Kannel, Garrison et al, 1988). 
Smoking is consensually assumed as a relevant contributer to cardiovascular disease, both 
in the active as well as the passive form. Some studies indicate that smokers have a 
reduced life expectancy of about ten years (although this number is dose-dependent) and 
that this habit cancells the natural cardioprotection in women (Silva, 2000). In fact, the 
differences in cardiovascular risk amongst men and women are well known, largely 
documented by the classic time lag between genders, with a higher risk in males until the 
fifth decade of life, with a progressive increase in women of cardiovascular risk until the 
eighth decade of life, when the risk is similar in men and women. The explanation for this 
is closely linked to the production and subsequent estrogen deficiency (as a consequence 
of menopause) seen in different phases of a woman’s life. But other factors must not be 
overlooked. For instance, If we consider only the lipid profile changes induced by 
menopause, on average a 10% increase in LDL-cholesterol, an 8% reduction in HDL-
cholesterol and an elevation in triglycerides are expected. Nonetheless, these changes can 
be normalized by hormonal replacement therapy (Stampfer, Colditz, Willet et al, 1991). 
Oral contraception, by contrast, tends to cause an adverse impact on lipid profile. At 
present, the worrying rate of young women with acute coronary events, a situation rarely 
seen before, has directed special attention to factors that could be blamed for this 
surprising finding. The association of hormonal contraception with smoking has emerged 
as very common in this population, likely to concur not only for atherogenic metabolic 
features but also for potentially thrombotic coagulation disorders (Mosca, Grundy, 
Judelson et al, 1999). 
The cardiovascular impact of alcohollic intake must also be considered. The cardiovascular 
impact of this behaviour is closely related to the amount of alcohol consumed. A moderate 
intake may confer some cardiovascular protection, particularly by raising HDL-cholesterol 
and reducing platelet aggregation, yet it may lead to a higher incidence of arterial 
hypertension and cerebrovascular disease. Patterns of high alcoholic consumption are an 
unusually hazardous behaviour, particularly for the heart, greatly increasing the risk of 
sudden death (Silva, 2000). 
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2.2 Cardiovascular risk – Dislipidemia 
Lipids are a very heterogeneous group of compounds, and their influence on metabolism 
goes far beyond the misdeeds attributed to him. Lipids constitute an important source of 
energy storage, represented by triglycerides, and assume a great importance in the 
constitution of the brain (17% of its dry weight), the formation of hormones, lipoproteins, 
bile acids, vitamins, and in the structure of cell membranes. Cholesterol and Triglycerides 
are transported between various components of the organism by specific proteins called 
apoproteins. These constitute the protein fraction of lipoproteins whose lipid component 
includes phospholipids, cholesterol and Triglycerides. Lipoproteins are usually divided into 
six classes according to their composition, size, density and function: Quilomicra, VLDL 
(very low density lipoproteins), IDL (intermediate density lipoprotein), LDL (low density 
lipoprotein), HDL (high density lipoprotein) and Lipoprotein (a). The interaction of 
lipoproteins with a high number of enzymes, transport proteins and receptors, constitutes a 
complex metabolism where equilibrium is determined by intrinsic and extrinsic factors, and 
its unbalance leads to the pathophysiological cascade of atherosclerosis, with its well known 
clinical consequences (Silva, 2000). In very one-dimensional terms, fat from the diet is 
transported to the intestinal wall and integrated into large lipoprotein particles rich in 
triglycerides - the Quilomicra - which, when secreted by the lymphatic system eventually 
reach the bloodstream. The liver, in its turn, synthesizes other lipoproteins with high 
content of triglycerides, the VLDL. The extracellular lipoprotein-lipase degrades 
triglycerides of Quilomicra and VLDL into free fatty acids, which are deposited in tissues. 
Lipoproteins, by reducing their concentration in triglycerides, are converted into IDL, which 
are usually hydrolyzed by the hepatic lipase, and are than converted into LDL, which bind 
to specific liver or peripheral receptors. Meanwhile, in another cycle - the reverse transport 
of cholesterol - HDL particles pick up cholesterol deposited in the arterial wall and provide 
transportation to the liver, where it is subsequently excreted in the bile (Eckardstein, 
Hersberger & Roher, 2005). 
The disorder of lipid metabolism is a key player for the occurrence of cardiovascular disease 
and particularly heart disease. For many years, cholesterol has been directly related to 
cardiovascular prognosis. This relationship is very consistent, as an increase of 2 to 3% in the 
incidence of coronary heart disease is expected for every 1% increase in total cholesterol 
(Carlson, Bottiger & Ahfeldt, 1979). A review of internationally published studies showed, 
however, that this association may be even stronger. Thus, a 10% increase in total 
cholesterol relates to a 38% increase in the risk of coronary-related mortality (Law, Wald & 
Thompson, 1994). More recently, several clinical studies on the primary and secondary 
prevention of coronary heart disease emphasized the importance of the LDL fraction (ILIB 
International Lipid Information Bureau, 2003) allowing the potential for the discrimination 
of cardiovascular risk. In fact, the risk of each patient may best be defined by the magnitude 
of the LDL-cholesterol rather than its total cholesterol, which is why international standards 
for the treatment of dyslipidemia have been oriented to listing the risk thresholds and 
treatment goals depending on the plasma levels of this lipoprotein. In practical terms, the 
determination of LDL-cholesterol may be derived by the Friedewald formula, where LDL 
Cholesterol = Total Cholesterol - HDL Cholesterol - VLDL cholesterol, VLDL cholesterol are 
derived from triglycerides/5. 
For many years it was difficult to classify unequivocally Triglycerides as an independent 
risk factor for the occurrence of coronary heart disease, a situation presumably related to the 
wide fluctuations observed in their concentrations throughout the day, with the 
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heterogeneity of triglyceride-rich lipoproteins (Quilomicra and VLDL) and its inseparable 
association with other risk factors. However, several studies have demonstrated a clear 
correlation between their levels and the occurrence of coronary heart disease, indicating that 
the presence of high levels of Triglycerides leads to a 13% increase in the risk of 
cardiovascular disease in men and 37% in women (Castelli, 1986; Criqui, Heiss, Cohn et al, 
1993; Hokanson & Austin, 1996; Assman, Schulte & von Eckardstein, 1996). With regard to 
HDL-cholesterol, its inverse relationship with the risk of coronary heart disease is well 
accepted. In fact, this risk is 2 to 3% lower for each 1mg/dl elevation of HDL-Cholesterol 
(Gordon, Probstfiel, Garrison et al, 1989). The protective properties of this fraction derive not 
only from its involvement in reverse cholesterol transport, but are also a consequence of its 
anti-inflammatory capacity and protection against LDL-cholesterol oxidation (Ansell, 
Navab, Watson et al, 2004). On the other hand, it is recognized that individuals with very 
low levels of HDL-cholesterol have a higher cardiovascular risk. This population is often 
characterized for having concomitant hypertriglyceridemia, obesity, a sedentary lifestyle, 
active tobacco intoxication and decreased glucose tolerance (World Health Organization, 
1999). In fact, an increased occurrence of cardiovascular events is expected for levels of 
HDL-cholesterol below 40 mg/dl (1.0 mmol/L) in men and less than 46 mg/dl (1.2 
mmol/L) in women (UK HDL-C Consensus Group, 2004). 
Recent evidence further stresses the importance of determining the non-HDL-cholesterol, 
defined by the concentration of LDL-cholesterol + VLDL-cholesterol. This parameter can 
better translate the risk of cardiovascular mortality than LDL-cholesterol, as it expresses 
more accurately the lipoprotein atherogenicity (Cui, Blumenthal, Flaws et al, 2001). 
In recent years, a large number of risk factors for vascular disease have emerged from the 
international literature (see Table 2), demonstrating the relevance of more complex lipid 
disorders for the pathophysiology of atherosclerosis. Other emerging risk factors are related 
to inflammatory markers, as well as by the presence of metabolic changes, subtle changes in 
coagulation, hormonal disturbances and psychological or behavioral disorders (ILIB 
International Lipid Information Bureau, 2003). 
 
Lipidic 
   Lipoproteic remnants 
   Lipoprotein (a) 
   Small and dense LDL 
   HDL subspecies 
   apolipoprotein B 
   Apolipoprotein A-1 
Inflammatory 
   High-sensitivity CRP 
   Homocysteine 
   Interleukin-6 
   Cell adhesion molecule-1  
   Selectin-CD40 
Metabolic 
   Postprandial hyperinsulinemia   
   (insulin resistance) 
Coagulation 
   Fibrinogen 
   Von Willebrand Factor 
   Factor VII 
   Plasminogen activator inhibitor (PAI-1) 
 
Psychological / Behavioral 
   Alcoholism 
   Depression 
   Social Isolation 
   Loss and social support 
   Low socioeconomic status 
Hormonal 
   Loss of estrogen production (menopause) 
Table 2. Emerging cardiovascular risk factors. 
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2.2 Cardiovascular risk – Dislipidemia 
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are usually hydrolyzed by the hepatic lipase, and are than converted into LDL, which bind 
to specific liver or peripheral receptors. Meanwhile, in another cycle - the reverse transport 
of cholesterol - HDL particles pick up cholesterol deposited in the arterial wall and provide 
transportation to the liver, where it is subsequently excreted in the bile (Eckardstein, 
Hersberger & Roher, 2005). 
The disorder of lipid metabolism is a key player for the occurrence of cardiovascular disease 
and particularly heart disease. For many years, cholesterol has been directly related to 
cardiovascular prognosis. This relationship is very consistent, as an increase of 2 to 3% in the 
incidence of coronary heart disease is expected for every 1% increase in total cholesterol 
(Carlson, Bottiger & Ahfeldt, 1979). A review of internationally published studies showed, 
however, that this association may be even stronger. Thus, a 10% increase in total 
cholesterol relates to a 38% increase in the risk of coronary-related mortality (Law, Wald & 
Thompson, 1994). More recently, several clinical studies on the primary and secondary 
prevention of coronary heart disease emphasized the importance of the LDL fraction (ILIB 
International Lipid Information Bureau, 2003) allowing the potential for the discrimination 
of cardiovascular risk. In fact, the risk of each patient may best be defined by the magnitude 
of the LDL-cholesterol rather than its total cholesterol, which is why international standards 
for the treatment of dyslipidemia have been oriented to listing the risk thresholds and 
treatment goals depending on the plasma levels of this lipoprotein. In practical terms, the 
determination of LDL-cholesterol may be derived by the Friedewald formula, where LDL 
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derived from triglycerides/5. 
For many years it was difficult to classify unequivocally Triglycerides as an independent 
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heterogeneity of triglyceride-rich lipoproteins (Quilomicra and VLDL) and its inseparable 
association with other risk factors. However, several studies have demonstrated a clear 
correlation between their levels and the occurrence of coronary heart disease, indicating that 
the presence of high levels of Triglycerides leads to a 13% increase in the risk of 
cardiovascular disease in men and 37% in women (Castelli, 1986; Criqui, Heiss, Cohn et al, 
1993; Hokanson & Austin, 1996; Assman, Schulte & von Eckardstein, 1996). With regard to 
HDL-cholesterol, its inverse relationship with the risk of coronary heart disease is well 
accepted. In fact, this risk is 2 to 3% lower for each 1mg/dl elevation of HDL-Cholesterol 
(Gordon, Probstfiel, Garrison et al, 1989). The protective properties of this fraction derive not 
only from its involvement in reverse cholesterol transport, but are also a consequence of its 
anti-inflammatory capacity and protection against LDL-cholesterol oxidation (Ansell, 
Navab, Watson et al, 2004). On the other hand, it is recognized that individuals with very 
low levels of HDL-cholesterol have a higher cardiovascular risk. This population is often 
characterized for having concomitant hypertriglyceridemia, obesity, a sedentary lifestyle, 
active tobacco intoxication and decreased glucose tolerance (World Health Organization, 
1999). In fact, an increased occurrence of cardiovascular events is expected for levels of 
HDL-cholesterol below 40 mg/dl (1.0 mmol/L) in men and less than 46 mg/dl (1.2 
mmol/L) in women (UK HDL-C Consensus Group, 2004). 
Recent evidence further stresses the importance of determining the non-HDL-cholesterol, 
defined by the concentration of LDL-cholesterol + VLDL-cholesterol. This parameter can 
better translate the risk of cardiovascular mortality than LDL-cholesterol, as it expresses 
more accurately the lipoprotein atherogenicity (Cui, Blumenthal, Flaws et al, 2001). 
In recent years, a large number of risk factors for vascular disease have emerged from the 
international literature (see Table 2), demonstrating the relevance of more complex lipid 
disorders for the pathophysiology of atherosclerosis. Other emerging risk factors are related 
to inflammatory markers, as well as by the presence of metabolic changes, subtle changes in 
coagulation, hormonal disturbances and psychological or behavioral disorders (ILIB 
International Lipid Information Bureau, 2003). 
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As we have seen, each stated factor conveys a certain risk to the affected population. 
However, in everyday clinical practice a large majority of patients have associations of these 
factors and, as such, have cardiovascular risks that express the magnitude of individual risk 
factors present in an exponential, rather than additive, trend (Yusuf, Giles, Croft et al, 1998; 
American Heart Association, 2002). 
An alternative option, with very promising results in the context of cardiovascular risk 
stratification and assessment of the effectiveness of lipid-lowering interventions, is the use 
of lipid ratios, just as the LDL-Cholesterol/HDL-Cholesterol ratio and the Total-
Cholesterol/HDL-Cholesterol ratio, which have the added advantage of being easy to use in 
clinical practice (Gotto, Whitney & Stein, 2000). Changes in these relations have in fact been 
shown to better indicate the reduction in cardiovascular risk compared with the absolute 
levels of conventionally used lipid measures (Natarajan, Glick, Criqui et al, 2003; Kannel, 
2005). On the other hand, the estimated LDL-Cholesterol/HDL-Cholesterol ratio translates, 
albeit imperfectly, an approach to the relationship of plasma apolipoproteins (apo) A-1 and 
apo B (Walldius & Jungner, 2005), thus enriching the lipid characterization of each patient, 
with the possibility of a better discrimination of cardiovascular risk, particularly among 
groups at intermediate cardiovascular risk (Gotto, Whitney, Stein et al, 2000). 
Several large studies have demonstrated that the LDL-Cholesterol/HDL-Cholesterol ratio is 
an excellent predictor of risk of coronary disease and an excellent way to monitor the impact of 
lipid-lowering therapies (Manninen, Tenkanen, Koskinen et al, 1992; Kannel, 2005; Cullen, 
Schulte, Assmann et al, 1997; Stampfer, Sacks, Salvini et al, 1991; Gaziano, Hennekens, 
O'Donnell et al, 1997). In the Helsinki Study, a clinical trial with a 5-year follow-up, involving 
more than 4000 middle-aged men with hyperlipidemia, the LDL-Cholesterol/HDL-
Cholesterol ratio had a superior prognostic value compared with isolated values of LDL-
Cholesterol and HDL-Cholesterol. The predictive ability of this ratio was particularly strong in 
patients with concomitant elevation of triglycerides. It was further shown that the LDL-
Cholesterol/HDL-Cholesterol ratio together with the fasting triglyceride concentration, 
allowed the identification of a particular subgroup of patients that had a remarkable 70% 
reduction in the risk of coronary heart disease with gemfibrozil (lipid-lowering agent) therapy. 
In the PROSPER trial, a retrospective analysis of 6,000 patients, the LDL-Cholesterol/HDL-
Cholesterol ratio was the stronger predictor of cardiovascular events in elderly patients 
(Packard, Ford, Robertson et al, 2005). From this study has emerged the recommendation of 
pharmacological intervention whenever the LDL-Cholesterol/HDL-Cholesterol ratio values 
exceed 3.3 units. Another study (PROCAM study) involving about 11,000 men aged between 
36 and 65, followed over 4 to 14 years, has documented an extremely important and linear 
relationship between the LDL-Cholesterol/HDL-Cholesterol ratio and cardiovascular 
mortality (Cullen, Schulte, Assmann et al, 1997). In this study, cardiovascular mortality peaked 
for LDL-Cholesterol/HDL-Cholesterol values between 3.7 and 4.3 units. In line with these 
results is the Physician's Health Study, involving 15,000 men (40 to 84 years), where there was 
a 53% increase in the risk of an acute coronary event for each one-unit increase in the LDL-
Cholesterol/HDL-Cholesterol ratio (Stampfer, Sacks, Salvini et al, 1991). In another mixed 
study, involving men and women under the age of 76, the LDL-Cholesterol/HDL-Cholesterol 
ratio showed a strong relationship with the risk of coronary events (Gaziano, Hennekens, 
O'Donnell et al, 1997), aspect reinforced in an analysis of patients from the Framingham Heart 
Study, where a clear superiority of LDL-Cholesterol/HDL-Cholesterol ratio in predicting 
cardiovascular events compared to the levels of isolated LDL-cholesterol and HDL-cholesterol 
was depicted (Kannel, 2005). 
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Another point that reinforces the superiority of the lipid ratios in the stratification of 
cardiovascular risk arises from the effect of dietary cholesterol on plasma lipid levels. 
Several studies have demonstrated that these ratios are not affected by dietary cholesterol 
(Greene, Zerner, Wood et al, 2005; Herron, Vega-Lopez, Earl et al, 2002). On the contrary, 
some studies have shown that dietary cholesterol interferes with LDL-cholesterol and HDL-
cholesterol, with little variation in the ratio (McNamara, 2000). On average, the predicted 
change in the LDL-Cholesterol/HDL-Cholesterol ratio per 100 milligrams/day increase in 
dietary cholesterol is quite small, around 0.01 (McNamara, 2000). 
2.3 Cardiovascular risk – Atherogenesis 
To understand the sequence of events that occur at the vascular level, resulting in 
devastating clinical manifestations that are all too familiar, we must look a little closer at the 
physiology of this system. 
One of the most important organs we have without doubt is the vascular endothelium. The 
endothelium is the inner portion of our vessels, which can be compared to a thin membrane 
that carpets the blood vessels, and its integrity is fundamental for the maintenance of several 
potentially unstable equilibria. In this sense, a huge amount of vascular wall or circulating 
factors are present in close relation to the endothelium, endlessly alternating between defense 
and aggression, aggression, with Nitric Oxide as the key protector. As the most egregious 
examples of interaction near the endothelium vicinity, we have the following associations: 
vasodilation/vasoconstriction; anti-trombotic/pro-trombotic; anti-inflamatory/pro-inflamatory, 
among others. The relative hegemony of each of these interacting factors will determine the 
final maintenance of endothelial integrity or, conversely, its dysfunction and destruction 
(Houston, 2002). Endothelial dysfunction is thus the initial phase of a cascade of events that 
flow until the onset of clinically overt disease. In a very simplified overview, once the 
endothelial barrier is compromised, an association of events takes place, mainly with a lipid 
flooding process of the vascular wall, with the mobilization of inflammatory cells, the 
expression of chemotactic factors, growth and proliferation of smooth muscle and 
connective tissue, among others. The histologic consequence of these processes ranges from 
an initial lipid streak that evolves for an atherosclerotic plaque that may progress to 
calcification, progressively reducing the vascular lumen (Silva, 2000). 
Curiously, most clinical cases are not determined directly by the extreme portion of the 
atherosclerotic continuum. In other words, cardiovascular events do not usually stem from 
progressive and insidious arterial occlusion, with consequent ischemia of downstream 
areas. Of course, cardiovascular events tend to be characterized by their acute nature, that is, 
by their sudden and unpredictable occurrence. As such, the implicit pathophysiology 
should express facts that support real-life events. In fact, one of the most important factors 
in the emergence of cardiovascular events is related to the so-called "atherosclerotic plaque 
stability". Thus, plaques with a small lipid core, with small inflammation infiltrate, and 
fitted with a thick, tough outer layer will be less susceptible to disruption by various 
harmful factors, such as blood pressure, sympathetic activity and other vasoconstrictor 
stimuli. In contrast, plaques with a rich lipid core, inflammatory activity and a significant 
weak fibrous cap will present a higher risk of fracture and exposure of their internal 
contents (Ridolfi & Hutchins, 1977). This in turn will lead to the activation of several factors 
that promote clotting and platelet aggregation in-sito (Falk, 1991), which may also lead to a 
sudden reduction of the vascular lumen, or even its complete occlusion by thrombosis. 
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As we have seen, each stated factor conveys a certain risk to the affected population. 
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Cholesterol and HDL-Cholesterol. The predictive ability of this ratio was particularly strong in 
patients with concomitant elevation of triglycerides. It was further shown that the LDL-
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allowed the identification of a particular subgroup of patients that had a remarkable 70% 
reduction in the risk of coronary heart disease with gemfibrozil (lipid-lowering agent) therapy. 
In the PROSPER trial, a retrospective analysis of 6,000 patients, the LDL-Cholesterol/HDL-
Cholesterol ratio was the stronger predictor of cardiovascular events in elderly patients 
(Packard, Ford, Robertson et al, 2005). From this study has emerged the recommendation of 
pharmacological intervention whenever the LDL-Cholesterol/HDL-Cholesterol ratio values 
exceed 3.3 units. Another study (PROCAM study) involving about 11,000 men aged between 
36 and 65, followed over 4 to 14 years, has documented an extremely important and linear 
relationship between the LDL-Cholesterol/HDL-Cholesterol ratio and cardiovascular 
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calcification, progressively reducing the vascular lumen (Silva, 2000). 
Curiously, most clinical cases are not determined directly by the extreme portion of the 
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areas. Of course, cardiovascular events tend to be characterized by their acute nature, that is, 
by their sudden and unpredictable occurrence. As such, the implicit pathophysiology 
should express facts that support real-life events. In fact, one of the most important factors 
in the emergence of cardiovascular events is related to the so-called "atherosclerotic plaque 
stability". Thus, plaques with a small lipid core, with small inflammation infiltrate, and 
fitted with a thick, tough outer layer will be less susceptible to disruption by various 
harmful factors, such as blood pressure, sympathetic activity and other vasoconstrictor 
stimuli. In contrast, plaques with a rich lipid core, inflammatory activity and a significant 
weak fibrous cap will present a higher risk of fracture and exposure of their internal 
contents (Ridolfi & Hutchins, 1977). This in turn will lead to the activation of several factors 
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Thus, the atherosclerotic process brings with it a wide array of metabolic, inflammatory and 
coagulation phenomena, decisively contributing to its clinical expression. Herein lies the 
justification of the diverse therapeutic targets that aimed for in these patients. 
The importance of hypercholesterolemia as a key-player in this cascade of events is 
unquestioned and widely demonstrated in the published literature. A perfect expression of 
the interaction between research and practice is surely the publication of recommendations 
and guidelines that assist clinicians in the rationalization of therapeutic means available. 
These emerge as regular updates of successive collections of published scientific data, 
outlined in an admirably succinct way so they can be strategically combined and applied to 
the most varied health systems worldwide. Regarding the core topic of this paper, we have 
to address the most relevant recommendations published by the European Society  
of Cardiology and the National Cholesterol Education Program (NCEP). These 
recomendations were prepared according to an individual-risk perspective, and the 
therapeutic goals are defined according to the expected individual risk at long-term. Table 3 
sumarizes the NCEP guidelines, revealing a clear therapeutic aggressiveness increase based 
on individual risk, as well as the adoption of progressively reduced target LDL-cholesterol 
values. 
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Table 3. Hypercholesterolemia treatment algorithm of the second Report of the Third 
National Cholesterol Education Program – NCEP (2001). 
These recommendations also included some secondary therapeutic goals, including the 
attempt to reduce non-HDL cholesterol in patients with triglycerides above 200 mg/dl for 
values 30 mg/dL higher than the individual target for LDL-cholesterol. Another objective 
lies in promoting an increase in HDL-cholesterol. Although these objectives are based on a 
very interventionist philosophy, recent studies may impose additional requirements on 
these recommendations. In fact, the Heart Protection Study (Heart Protection Study 
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Collaborative Group, 2002) showed that a reduction of 30% compared to the more restrictive 
goal (LDL cholesterol <100 mg/dl) was related to an additional 30% reduction in the 
relative risk of coronary heart disease. The PROVE IT study (Cannon, Braunwald, McCabe 
et al, 2004), enrolled patients who had had acute coronary events and showed that larger 
reductions of LDL-cholesterol, to levels lower than 100 mg/dl, could significantly provide 
aditional benefit in terms of future cardiovascular mortality and morbidity. 
According to these results one has to consider more challenging treatment goals. The aim is 
to reach values of LDL-cholesterol <70mg/dl in patients with very high cardiovascular risk, 
such as those combining several primary risk factors (with primary relevance for diabetics), 
in patients with primary risk factors that are poorly controlled (with special care to the ones 
that maintain smoking habits), in patients with multiple risk factors of the so-called 
metabolic syndrome (triglycerides ≥ 200 mg/dl, non-HDL-cholesterol> 130 mg/dl, HDL-
cholesterol<40 mg/dl) and in patients with history of acute coronary events. 
The establishment of a therapeutic basis grounded in the control of cardiovascular risk 
factors has demonstrated its strong validity, and is further reinforced for its effectiveness in 
terms of cost-benefit. Improved control of risk factors almost certainly contributed to the 
50% reduction in cardiovascular mortality observed in the United States of America 
between 1980 and 1990, with 43% attributable to the verified pharmacological advances 
(Hunink, Glodman, Tosteson et al, 1997). In the Netherlands, similar results were observed, 
and primary prevention was responsible for a 40% decline in mortality from coronary heart 
disease between 1978 and 1985 (Grobee & Bots, 1996). The adoption of dietary measures in 
Finland, relying on an increase in the consumption of fruits and vegetables and a reduction 
of saturated fats intake, has resulted in a 65% reduction in mortality from coronary heart 
disease in a time horizon of 20 years (Pekka, Pirjo & Ulla, 2002). 
Despite the promising results indicated by these data, only 35% of Americans with a formal 
indication for dietary or pharmacological therapy, according to the recommendations of the 
NCEP (2001), are complying with it (Hoerger, Bala, Bray et al, 1988). In Canada, a study 
carried out between 1988 and 1993, including patients at high cardiovascular risk admitted 
to hospitals, showed very low percentages in relation to lipid dosing prescription (28%) and 
early dietary (22%) or pharmacological (8%) therapy (The Clinical Quality Improvement 
Network (CQIN) Investigators, 1995). 
In Europe, results have fallen below expectations. An important follow-up study - 
EUROASPIRE - between 1995 and 1996, envolving nine European countries, showed that 
86% of the enrolled patients had hypercholesterolaemia. Nevertheless, only 32% were on 
medication, and among those treated only 21% had achieved the target lipid levels 
(EUROASPIRE Study Group, 1997; EUROASPIRE I and II Group, 2001). 
In Asia and the Pacific, the outlook is not encouraging either. In patients hospitalized for 
acute coronary events, quite small rates of lipid profile dosing (1 to 58%) were observed, as 
well as for the prescription of diet (1 to 32%) or pharmacological (6 to 60%) therapy to 
patients with high Cholesterol levels (Asian-Pacific CHD Risk Factor Collaborative Group, 
1998). 
The control of risk factors in clinical practice is thus a vaguely realized desideratum. The 
EUROASPIRE study has clarified some trends from 1995 to 2000. If the positive results have 
raised expectations, with an improvement seen in the control of hypercholesterolemia and 
hypertension, they are still accompanied by other rather disappointing indicators, such as 
those of smoking habits, obesity and diabetes, whose prevalence has been steadily 
increasing (EUROASPIRE Study Group, 1997; EUROASPIRE I and Group II, 2001). In the 
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Thus, the atherosclerotic process brings with it a wide array of metabolic, inflammatory and 
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Table 3. Hypercholesterolemia treatment algorithm of the second Report of the Third 
National Cholesterol Education Program – NCEP (2001). 
These recommendations also included some secondary therapeutic goals, including the 
attempt to reduce non-HDL cholesterol in patients with triglycerides above 200 mg/dl for 
values 30 mg/dL higher than the individual target for LDL-cholesterol. Another objective 
lies in promoting an increase in HDL-cholesterol. Although these objectives are based on a 
very interventionist philosophy, recent studies may impose additional requirements on 
these recommendations. In fact, the Heart Protection Study (Heart Protection Study 
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Collaborative Group, 2002) showed that a reduction of 30% compared to the more restrictive 
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United States of America the results are also somewhat disappointing. In survivors of acute 
myocardial infarction or stroke, the control percentages for some primary risk factors are 
below expectations, particularly for smoking habits (18%), control of hypercholesterolemia 
(46%), diabetes (48%) and hypertension (53%) (Qureshi et al, 2001).  
As in almost all chronic conditions, the real picture lags far behind the expectations and 
available resources. Regarding hypercholesterolemia, the current situation is even less 
understandable, given its clear and strong association with the prevailing causes of death 
and incapacity, and the public awareness of the problem and in consideration of the 
demonstrated effectiveness of the available lipid-lowering drugs, that may have a quite 
favorable impact upon the prognosis of patients. 
3. Original research data 
3.1 Aim 
Given the demonstrated role-playing of blood cholesterol in the atherosclerotic continuum, 
we designed two studies to ascertain the usefulness of the LDL-cholesterol/HDL-
cholesterol, Triglycerides/HDL-cholesterol and Total-cholesterol/HDL-cholesterol ratios in 
predicting cardiovascular risk, through its relation to cardiovascular events and peripheral 
arterial disease (PAD) in two different clinical and experimental settings. 
3.2 Study 1 – Usefulness of the lipidic ratios predicting peripheral artery disease in 
hypertensive patients: A retrospective analysis 
The importance of the lipidic profile is well established in atherosclerotic processes related 
to coronary artery disease. Its relation with atherosclerosis in other vascular territories, 
particularly the inferior limbs has also received strong support from several experimental 
settings and in different clinical contexts. In order to address wether the lipid ratios can 
predict the occurrence of obstructive peripheral artery disease (PAD) we conducted a cross-
sectional study in a sample of hypertensive patients. The study population consisted of 920 
Portuguese nationals, aged between 20 and 91 years (mean 64.23 + 12.30 years). 
3.2.1 Methods 
A total of 920 hypertensive patients (51.3% female, age 64.22 ± 12.01 years) were 
consecutively included in the study. None of the patients were taking drugs or were in 
situations known to affect lipoprotein metabolism. Total cholesterol, triglycerides and HDL 
cholesterol were measured. LDL cholesterol was obtained by Friedewald’s formula  
(if triglycerides <3.39 mmol/l) or by ultracentrifugation. The LDL-Cholesterol/HDL-
Cholesterol, Total Cholesterol/HDL-Cholesterol and Triglycerides/HDL-Cholesterol ratios 
were calculated in all patients. Blood pressure and heart rate were measured in standard 
conditions. Ankle-Brachial index (ABI) was estimated bilaterally as the ratio of ankle (left 
and right) systolic blood pressure and brachial (highest upper limb) systolic blood pressure. 
The normal range for ABI was 0.9-1.3 mmHg, and individuals with ABI<0.9 were classified 
as having peripheral arterial disease. 
All data was processed using STATA for Windows, version 11.1. The distribution of the 
variables was tested for normality using the Kolmogorov-Smirnov test, and for 
homogeneity of variance by Levene’s test. Simple descriptive statistics were used to 
characterize the sample and the distribution of variables. Logistic regression analysis was 
used to determine the influence of the lipidic parameters on the occurrence of PAD.  
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Groups were compared using the χ2 test for categorical variables and the Student’s t test (2 
groups) or ANOVA with the post-hoc Tukey test (3 groups) for quantitative variables. A 
value of P≤0.05 was taken as the criterion of statistical significance for a 95% confidence 
interval. 
3.2.2 Results 
The general characteristics of the studied population are summarized in Table 4. Mean age 















Age, years  64.23±12.30 63.23±12.30 69.88±8.15 <0.01 
Sex, men:women 49:51 48:52 52:48 0.462 
Body Mass Index, Kg/m2 28.79±11.85 28.92±12.53 27.94±5.31 0.416 
CV events history, no:yes 88:12 90:10 75:25 <0.01 
Tobacco Consumption, 
no:yes  
89:11 89:11 88:12 0.856 
Dyslipidemia, no:yes 40:60 42:58 26:74 <0.01 
Diabetes, no:yes 66:34 68:32 54:46 <0.01 
SBP, mmHg  150.14±20.69 148.97±19.60 157.81±25.59 <0.01 
DBP, mmHg  86.28±10.91 86.59±10.63 84.20±12.43 0.025 
Heart Rate, bpm 70.52±10.48 69.12±9.42 71.22±9.21 0.791 
Plasma Glucose, mg/dl 112.42±39.65 111.35±39.10 119.61±42.60 0.035 
Plasma Creatinine, mg/dl 0.88±0.22 0.87±0.21 0.96±0.26 <0.01 
eGFR, ml/min/1.73m2 84.73±23.28 85.86±23.40 76.94±20.88 <0.01 
ABI 1.09±0.14 1.12±0.12 0.8±0.10 <0.01 
PAD – peripheral artery disease; CV – cardiovascular events; SBP – systolic blood pressure; DBP – 
diastolic blood pressure; eGFR – estimated Glomerular Filtration Rate; ABI – Ankle-Brachial Index 
Table 4. Characteristics of the study population, in general and stratified for the presence or 
absence of peripheral artery disease. 
Mean body mass index was 28.79±11.85, indicating an overwheighted population. With 
regard to cardiovascular risk factors, all patients were hypertensive, 60% had dyslipidemia 
and 34% were diabetic; 11% were smokers and 12% had a personal history of cardiovascular 
events (mainly Stroke). About 37% were medicated for cardiovascular pathologies, with 
13.6% of the patients undertaking statins. This factor was controlled in all the multivariable 
analysis. Peripheral artery disease (PAD) was encountered in 117 patients (12.7%). Patients 
with PAD were older, and had a worst metabolic and hemodynamic profile. The proportion 
of patients with a personal history of cardiovascular events was also greater in patients with 
PAD (25% versus 10%, p<0.01). The Ankle-Brachial Index (ABI) was also significantly lower 
 
Dyslipidemia - From Prevention to Treatment 
 
288 
United States of America the results are also somewhat disappointing. In survivors of acute 
myocardial infarction or stroke, the control percentages for some primary risk factors are 
below expectations, particularly for smoking habits (18%), control of hypercholesterolemia 
(46%), diabetes (48%) and hypertension (53%) (Qureshi et al, 2001).  
As in almost all chronic conditions, the real picture lags far behind the expectations and 
available resources. Regarding hypercholesterolemia, the current situation is even less 
understandable, given its clear and strong association with the prevailing causes of death 
and incapacity, and the public awareness of the problem and in consideration of the 
demonstrated effectiveness of the available lipid-lowering drugs, that may have a quite 
favorable impact upon the prognosis of patients. 
3. Original research data 
3.1 Aim 
Given the demonstrated role-playing of blood cholesterol in the atherosclerotic continuum, 
we designed two studies to ascertain the usefulness of the LDL-cholesterol/HDL-
cholesterol, Triglycerides/HDL-cholesterol and Total-cholesterol/HDL-cholesterol ratios in 
predicting cardiovascular risk, through its relation to cardiovascular events and peripheral 
arterial disease (PAD) in two different clinical and experimental settings. 
3.2 Study 1 – Usefulness of the lipidic ratios predicting peripheral artery disease in 
hypertensive patients: A retrospective analysis 
The importance of the lipidic profile is well established in atherosclerotic processes related 
to coronary artery disease. Its relation with atherosclerosis in other vascular territories, 
particularly the inferior limbs has also received strong support from several experimental 
settings and in different clinical contexts. In order to address wether the lipid ratios can 
predict the occurrence of obstructive peripheral artery disease (PAD) we conducted a cross-
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cholesterol were measured. LDL cholesterol was obtained by Friedewald’s formula  
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were calculated in all patients. Blood pressure and heart rate were measured in standard 
conditions. Ankle-Brachial index (ABI) was estimated bilaterally as the ratio of ankle (left 
and right) systolic blood pressure and brachial (highest upper limb) systolic blood pressure. 
The normal range for ABI was 0.9-1.3 mmHg, and individuals with ABI<0.9 were classified 
as having peripheral arterial disease. 
All data was processed using STATA for Windows, version 11.1. The distribution of the 
variables was tested for normality using the Kolmogorov-Smirnov test, and for 
homogeneity of variance by Levene’s test. Simple descriptive statistics were used to 
characterize the sample and the distribution of variables. Logistic regression analysis was 
used to determine the influence of the lipidic parameters on the occurrence of PAD.  
Dyslipidemia and Cardiovascular Risk: 
Lipid Ratios as Risk Factors for Cardiovascular Disease 
 
289 
Groups were compared using the χ2 test for categorical variables and the Student’s t test (2 
groups) or ANOVA with the post-hoc Tukey test (3 groups) for quantitative variables. A 
value of P≤0.05 was taken as the criterion of statistical significance for a 95% confidence 
interval. 
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Mean body mass index was 28.79±11.85, indicating an overwheighted population. With 
regard to cardiovascular risk factors, all patients were hypertensive, 60% had dyslipidemia 
and 34% were diabetic; 11% were smokers and 12% had a personal history of cardiovascular 
events (mainly Stroke). About 37% were medicated for cardiovascular pathologies, with 
13.6% of the patients undertaking statins. This factor was controlled in all the multivariable 
analysis. Peripheral artery disease (PAD) was encountered in 117 patients (12.7%). Patients 
with PAD were older, and had a worst metabolic and hemodynamic profile. The proportion 
of patients with a personal history of cardiovascular events was also greater in patients with 
PAD (25% versus 10%, p<0.01). The Ankle-Brachial Index (ABI) was also significantly lower 
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in patients with PAD, as expected. Interestingly, patients with PAD also had a significantly 
lower estimated glomerular filtration rate (76.94±20.88 ml/min/1.73m2 versus 85.86±23.40 
ml/min/1.73m2 in patients without PAD). 
Regarding the overall and the comparative lipidic profile (depicted in table 5), significant 
differences amongst patients with and without PAD were only observed for the three 
considered lipidic ratios, expressing higher values when PAD was present, and for the 














Plasma Total Cholesterol, 
mg/dl  
196.61±41.15 197.06±41.18 193.68±40.98 0.400 
Plasma LDL-Cholesterol, 
mg/dl 
116.31±37.62 116.17±41.18 193.68±40.98 0.763 
Plasma HDL-Cholesterol, 
mg/dl 
54.46±21.47 54.96±21.56 51.14±20.65 0.073 
Plasma Triglicerides, 
mg/dl 
134.84±67.88 134.20±41.18 139.09±66.02 0.460 
LDL-Colesterol/HDL-
Colesterol Racio 
2.55±2.45 2.48±2.11 3.04±2.03 <0.01 
Total Cholesterol/HDL-
Colesterol Racio 
4.15±2.95 4.06±2.48 4.80±2.05 <0.01 
Triglicerídeos/HDL-
Colesterol Racio 
2.97±2.98 2.88±2.44 3.59±2.33 <0.01 
Table 5. Lipid profile of the study population. 
Figure 1 further ilustrates the differences in the lipidic ratios among patients with and 
without PAD, with all three considered ratios presenting significant differences between the 
considered groups. 
A multivariable logistic regression analysis was also performed considering PAD as the 
dependent variable (dichotomized in normal/abnormal), and forcing each lipidic parameter 
(either individual lipis or lipid ratios) in a model adjusted for the conventional Framingham 
cardiovascular risk factors (age, sex, diabetes, blood pressure, smoking status and body 
mass index). The observed Odds Ratios (OR) with 95% confidence intervals is depicted in 
figure 2. Although there’s an appreciable tendency of association with PAD in all lipid 
variables, it reaches statistical significancy only for the lipidic ratios. In fact, the OR for LDL-
cholesterol, Total-cholesterol, HDL-cholesterol and Triglycerides were respectively 1.004 
(IC: 0.999-1.010, p=0.1), 1.001 (IC: 0.996-1.007, p=0.4), 0.993 (IC: 0.980-1.004, p=0.2) and 1.001 
(IC: 0.998-1.004, p=0.2). For the LDL-cholesterol/HDL-cholesterol ratio, the multiadjusted 
OR was 1.06 (IC: 0.999-1.120, p=0.052), with a marginally significant association with PAD. 
For the Total-cholesterol/HDL-cholesterol and the Triglycerides/HDL-cholesterol ratios, 
the adjusted OR were respectively 1.051 (IC: 1.011-1.200, p=0.01) and 1.050 (IC: 1.002-1.110, 
p=0.04). A further analysis showed that the association of the lipid ratios with PAD was 
tendencially linear, particularly for the Total-cholesterol/HDL-cholesterol ratio. 
Dyslipidemia and Cardiovascular Risk: 





PAD – peripheral artery disease 




OR – Odds Ratio 
Fig. 2. Adjusted Odds Ratios for Peripheral Artery Disease for the individual lipidic 
variables and for the lipidic ratios. The Odds Ratios are multi-adjusted to conventional 
Framingham cardiovascular risk factors. 
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3.3 Study 2 – Usefulness of the lipidic ratios in a low-to-moderate cardiovascular risk 
population: A sub-analysis of the EDIVA (Estudo de Distensibilidade Vascular) project 
The EDIVA project was an epidemiological study assessing cardiovascular risk through 
sequential Pulse Wave Velocity measurement (Maldonado, Pereira, Polónia et al, 2011), but 
since serum lipids were available for all the included patients, we re-analyzed the EDIVA 
database aiming to address the delineated objective: to ascertain the usefulness of The LDL-
Cholesterol/HDL-Cholesterol, Total Cholesterol/HDL-Cholesterol and Triglycerides/HDL-
Cholesterol ratios in the general population. The study population consisted of 2200 
Portuguese nationals (1290 men and 910 women), aged between 18 and 91 years (mean 
46.33±13.76 years). Of these, 668 had low cardiovascular risk, and 1532 were patients with 
hypertension, diabetes and/or dyslipidemia. Individuals defined as having low 
cardiovascular risk were those who had had no chronic disease, had never been prescribed 
chronic pharmacological therapy, and had a normal physical exam, electrocardiogram, 
blood and urine tests, these characteristics having remained unchanged for at least two 
annual assessments. The patient group was under pharmacological therapy for at least one 
of the above pathologies. 
3.3.1 Methods 
The study’s aims were explained to all participants and their informed consent was 
obtained. The methodology used to collect the data was approved by the Portuguese Data 
Protection Commission and the study was approved by the Ethics Committees of the 
hospitals involved. Mean follow-up was 2 years. 
This was a prospective, multicenter, observational study monitoring the occurrence of major 
adverse cardiovascular events (MACE) – death, stroke, transient ischemic attack, myocardial 
infarction, unstable angina, peripheral arterial disease, revascularization or renal failure. 
Follow-up of the patients consisted of annual assessments including, blood pressure (BP) 
measurement, laboratory tests, including serum lipids, and clinical observation. Total 
cholesterol, triglycerides and HDL cholesterol were measured. LDL cholesterol was 
obtained by Friedewald’s formula (if triglycerides <3.39 mmol/l) or by ultracentrifugation. 
The LDL-Cholesterol/HDL-Cholesterol, Total Cholesterol/HDL-Cholesterol and 
Triglycerides/HDL-Cholesterol ratios were calculated in all patients. At each consultation, 
the subjects’ weight and height were measured and body mass index (BMI) was calculated 
in kg/m2. Blood pressure and heart rate were measured in standard conditions, in a supine 
position and after a 10-minute resting period, by an experienced operator and using a 
clinically validated (class A) sphygmomanometer (Colson MAM BP 3AA1-2®; Colson, 
Paris) (Pereira & Maldonado, 2005).Three measurements were taken and the arithmetic 
mean was used in the analysis. All participants underwent routine fasting laboratory tests. 
At the first consultation they filled out a questionnaire concerning relevant personal and 
family history, smoking habits, alcohol consumption and medication. 
Data from the sample subjects were processed using STATA for Windows, version 11.1. The 
distribution of the variables was tested for normality using the Kolmogorov-Smirnov test, 
and for homogeneity of variance by Levene’s test. Simple descriptive statistics were used to 
characterize the sample and the distribution of variables. Cox proportional hazards analysis 
was used to determine the influence of the lipidic parameters on the occurrence of the 
specified cardiovascular events. C-Statistics was calculated to address the reliability of the 
lipidic parameters as prognostic variables.  
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Groups were compared using the χ2 test for categorical variables and the Student’s t test (2 
groups) or ANOVA with the post-hoc Tukey test (3 groups) for quantitative variables. A 
value of P≤0.05 was taken as the criterion of statistical significance for a 95% confidence 
interval. 
3.3.2 Results 
The general characteristics of the study population are summarized in Table 6. Mean age 
was 46.33±13.77, indicating a relatively young sample, with similar proportions of men and 
women (59% and 41%, respectively). With regard to cardiovascular risk factors, 52% of the 
patients were hypertensive, 33% had dyslipidemia and 11% were diabetic; 17% were 
smokers and 15% had a family history of cardiovascular events. About 37% were medicated 
for cardiovascular pathologies, with 13.6% of the patients undertaking statins. This factor 
was controlled in all the multivariable analysis. Mean follow-up is currently 21.42±10.76 
months. A total of 50 non-fatal MACE (2.2% of the sample) were recorded, including 27 
cases of stroke, 19 of coronary events, 2 of renal failure and 2 of occlusive peripheral arterial 
disease. 
 
 No MACE MACE  
 Total Low Risk 
Patients 




N,%  2200 32% 66% 2%  
Age, years  46.33±13.77 40.00±13.42 49.03±13,14 50.00±10,21 0.360 
Sex, men:women* 59:41 60:40 58:42 46:54 0.104 
Body Mass Index, 
Kg/m2  
27.18±5.50 25.90±4.21 27.71±4.45 28.59±5.75 0.348 
Waist, cm  89.82±11,05 86.83±10,30 90.63±11,00 90.00±13,06 0.917 
Family History, 
no:yes*  
85:15 92:8 83:17 60:40 0.020 
Tobacco Consumption, 
no:yes*  
83:17 78:22 85:15 78:22 0.243 
Hypertension, no:yes* 48:52 100:0 26:74 14:86 0.109 
Dyslipidemia, no:yes* 67:33 100:0 53:47 60:40 0.311 
Diabetes, no:yes* 89:11 100:0 85:15 86:14 0.941 
SBP, mmHg  142.51±21.05 129.17±14.33 147.83±14.33 161.08±17.34 <0.001 
DBP, mmHg  84.52±12.29 77.43±10.11 87.32±11.87 92.08±10.07 <0.001 
PP, mmHg  57.99±15.29 51.74±11.90 60.05±15.86 66.20±12.93 <0.001 
MAP, mmHg  103.85±14.02 94.68±1.26 107.48±13.52 117.14±11.43 <0.001 
Heart Rate, bpm 70.56±12.24 68.21±12.58 71.49±11.87 78.20±13.01 0.001 
Plasma Glucose, mg/dl 100.44±31.54 90.86±9.16 103.70±3.75 110.32±39.64 0.406 
Plasma Creatinine, 
mg/dl 
1.31±5.08 0.90±1.77 1.43±5.99 1.53±2.92 0.996 
MACE – major acute cardiovascular events; SBP – systolic blood pressure; DBP – diastolic blood 
pressure; PP – pulse pressure; MAP – mean blood pressure 
Table 6. General characteristics of the study cohort, depending on the presence of MACE 
and conventional cardiovascular risk factors. 
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3.3 Study 2 – Usefulness of the lipidic ratios in a low-to-moderate cardiovascular risk 
population: A sub-analysis of the EDIVA (Estudo de Distensibilidade Vascular) project 
The EDIVA project was an epidemiological study assessing cardiovascular risk through 
sequential Pulse Wave Velocity measurement (Maldonado, Pereira, Polónia et al, 2011), but 
since serum lipids were available for all the included patients, we re-analyzed the EDIVA 
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distribution of the variables was tested for normality using the Kolmogorov-Smirnov test, 
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characterize the sample and the distribution of variables. Cox proportional hazards analysis 
was used to determine the influence of the lipidic parameters on the occurrence of the 
specified cardiovascular events. C-Statistics was calculated to address the reliability of the 
lipidic parameters as prognostic variables.  
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Groups were compared using the χ2 test for categorical variables and the Student’s t test (2 
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was controlled in all the multivariable analysis. Mean follow-up is currently 21.42±10.76 
months. A total of 50 non-fatal MACE (2.2% of the sample) were recorded, including 27 
cases of stroke, 19 of coronary events, 2 of renal failure and 2 of occlusive peripheral arterial 
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Regarding the lipidic profile, patients with MACE presented higher levels of the different 
lipidic parameters, as illustrated in table 7, in particular the lipidic ratios were significantly 
higher in patients with MACE (5.76±1.74  versus 6.75±1.98 for Total Cholesterol/HDL-
Cholesterol ratio, 3.24±1.32 versus 4.51±1.49 for LDL-Cholesterol/HDL-Cholesterol ratio, 
3.17±1.34 versus 4.35±1.67 for Triglycerides/HDL-Cholesterol ratio, p-value<0.01). So, 
overall, the patients with MACE were characterized by an unfavorable metabolic profile 
compared to the asymptomatic patients.  
 





Plasma Total Cholesterol, mg/dl 221.37±34.01 238.43±36.12 <0,01 
Plasma LDL-Cholesterol, mg/dl 141.37±31.22 163.26±41.12 <0,01 
Plasma HDL-Cholesterol, mg/dl 41.22±11.07 36.19±7.28 <0,01 
Plasma Triglicerides, mg/dl 156.37±34.01 181.43±36.12 <0,01 
LDL-Colesterol/HDL-Colesterol Ratio 2.98±2.32 4.51±1.49 <0,01 
Total Cholesterol/HDL-Colesterol Ratio 4.76±2.11 6.75±1.98 <0,01 
Triglicerídeos/HDL-Colesterol Ratio 3.17±2.32 4.35±1.67 <0,01 
MACE – major acute cardiovascular events; SBP – systolic blood pressure; DBP – diastolic blood 
pressure; PP – pulse pressure; MAP – mean blood pressure 
Table 7. Lipid profile of the study cohort, stratified for the presence or absence of of MACE. 
In the multivariable model analysis, adjusting for all conventional Framingham 
cardiovascular risk factors (age, sex, diabetes, blood pressure, smoking status and body 
mass index), the lipids ratios were associated with MACE, with stronger associations than 
the ones observed for the individual lipidic variables. Overall, the Total-Cholesterol/HDL-
Cholesterol was found to be the best single predictor of MACE. In figure 3 we plot the 
hazard ratios for quintiles of the lipid ratios. A linear increase of the hazard ratios across 
quintiles of the Total-Cholesterol/HDL-Cholesterol is clearly depicted, while for the other 
ratios only the upper-extreme quintiles showed an important association with 
cardiovascular events. 
Comparative data of risk association for those in the extreme quintiles of each lipidic 
variable is presented in figure 4. Of note, one can see that the combination of two individual 
lipidic components into a single variable provides stronger association with cardiovascular 
risk, as expressed by the depicted hazard ratios for the lipid ratios. On the other hand, the 
lipid ratio with the strongest association was the Total-Cholesterol/HDL-Cholesterol ratio, 
in line with the data depicted in figure 3.  
The ROC curve analysis provided the Areas-Under-the-Curve (AUC, equivalent to the C-
statistics) for the different lipid parameter considered in the analysis. The parameters with 
the biggest AUC were the Total-cholesterol/HDL-cholesterol ratio (AUC=0.703, IC:0.65-
0.77) and the LDL-cholesterol/HDL-cholesterol (AUC=0.701, IC:0.64-0.79). 
Dyslipidemia and Cardiovascular Risk: 





Fig. 3. Adjusted Hazard Ratios for major acute cardiovascular events distributed according 
to quintiles of the lipid ratios. A) Hazard ratios for quintiles of the LDL-Cholesterol/HDL-
Cholesterol ratio; B) Hazard ratios for quintiles of the Triglycerides/HDL-Cholesterol ratio; 
C) Hazard ratios for quintiles of the Total-Cholesterol/HDL-Cholesterol ratio. The hazard 
ratios are multi-adjusted to conventional Framingham cardiovascular risk factors. 
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Fig. 4. Adjusted Hazard Ratios for major acute cardiovascular events amongst those in the 
extreme quintiles of each considered lipidic parameter. The hazard ratios are multi-adjusted 
to conventional Framingham cardiovascular risk factors. 
4. Discussion and conclusions 
As previously mentioned, cardiovascular disease, as an expression of atherosclerotic 
processes, is the leading cause of death in industrialized countries. The key role played by 
cholesterol in essential pathophysiologic processes that lead to the occurrence of clinically 
significant cardiovascular events is well recognized. In contemporary clinical practice, this 
notion is well entrenched, and the individual cardiovascular risk definition incorporates, 
among other factors, the lipid profile, including the Total Cholesterol, LDL Cholesterol, 
HDL Cholesterol and triglycerides. A practical evidence of the aforementioned is the fact 
that the major cardiovascular risk tables currently available (e.g. the Framingham score or 
the EuroSCORE), incorporate lipid parameters in the definition of thresholds of risk. On the 
other hand, therapeutic decisions and monitoring have been largely centered on the 
conventional lipid profile. Even the international recommendations (such as those issued by 
the National Cholesterol Education Program - NCEP, 2001) recommend target levels of LDL 
and HDL -cholesterol to determine cardiovascular risk and evaluate the effectiveness of 
lipid-lowering therapies. However, some studies have indicated important limitations of 
these parameters in the prediction of cardiovascular risk, particularly in patients with 
intermediate cardiovascular risk (Gotto, Whitney, Stein et al, 2000). 
However, more recent evidence has suggested other lipidic components to optimize the 
definition of cardiovascular risk in clinical practice. In fact, several studies have expressed 
the superiority of the levels of apolipoprotein (apo) B, apo A-1 and its ratio, both in 
predicting cardiovascular events and in the evaluation of treatment efficacy (Packard & 
Marcovina, 2006; Yusuf , Hawken, Ounpuu, et al, 2004; Meisinger, Loewel, Mraz et al, 2005; 
Barter, Ballantyne, Carmena et al, 2006; Kim, Chang, Choi et al, 2005). In fact, considering 
that each lipidic particle contains one molecule of the atherogenic apo B, then its levels are a 
direct measure of the number of potentially atherogenic particles in the different 
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conventional lipid components (Walldius & Junger, 2006). In contrast, the concentration of 
apo A-1 translates the number of anti-atherogenic particles contained in the HDL-
cholesterol, thus enclosing the conceptual framework of apoB/apoA-1 ratio as a measure of 
the ratio of atherogenic particles versus anti-atherogenic particles transported in the blood. 
Despite the growing enthusiasm about the potential of these emerging parameters for their 
best performance in the definition of cardiovascular risk, there still remain some questions 
that limit their dissemination in clinical practice. The central question is very practical, and 
focuses on the cost-benefit relation associated with a change in the traditional clinical 
approach. In fact, it is not yet clear whether the superiority of these new lipid parameters 
over the more conventional ones for risk stratification is enough to justify the additional cost 
inherent to their laboratory determination (Pischon, Girman, Sacks et al, 2005). Furthermore, 
despite the current literature supporting apolipoproteins as better predictors of 
cardiovascular events, its use may not be the most practical operational perspective. 
Moreover, it is not yet clear whether the replacement of conventional parameters for 
emerging ones will translate into clear clinical benefit, or if, conversely, it will confuse the 
various protagonists over the clinical decision frame. 
In contrast to this line of argument, several studies have also emerged affirming quite 
clearly the advantages of using lipid ratios, based on conventional parameters, such as those 
studied in this work. This is based on the fact that, on the one hand, they add cardiovascular 
risk discriminative capacity to the individual lipid parameters, and on the other, they are 
more favorable than the apolipoproteins considering cost and immediate operationalization 
(Gotto, Whitney & Stein, 2000). As mentioned earlier, several studies have shown fairly 
consistently that changes in these ratios are favorable indicators of cardiovascular disease 
risk, above the absolute levels of individual lipids (Natarajan, Glick, Criqui et al, 2003; 
Kannel, 2005). Accumulating evidence in this regard is quite broad, spreading over several 
clinical frameworks (Manninen, Tenkanen, Koskinen et al, 1992; Kannel, 2005; Cullen, 
Schulte, Assmann et al, 1997; Stampfer, Sacks, Salvini et al, 1991; Gaziano, Hennekens, 
O'Donnell et al, 1997; Packard, Ford, Robertson et al, 2005). The results presented here clearly 
fall into this line, reinforcing the belief in the superiority of the lipid ratios, particularly the 
Total-Cholesterol/HDL-Cholesterol and the LDL-Cholesterol/HDL-Cholesterol ratios, over 
the classic lipid parameters, predicting peripheral arterial disease in hypertensive patients 
(in a high cardiovascular risk) and predicting future major cardiovascular events (including 
stroke and myocardial infarction) in a low-to-intermediate cardiovascular risk population. 
One of the curious aspects extracted from the second presented study was the existence of a 
linear relationship for the Total-Cholesterol/HDL-Cholesterol ratio with the risk of MACE, 
something not apparent in the LDL-Cholesterol/HDL-Cholesterol ratio. This same result 
was reproduced in the Quebec Cardiovascular Study, in which more than 2.000 middle-
aged men were followed for 5 years, monitoring the occurrence of major cardiovascular 
events (Lemieux, Lamarche, Couillard et al, 2001). The lipid parameters with better 
performance in predicting risk in this study were the Total-Cholesterol/HDL-Cholesterol 
ratio and the LDL-Cholesterol/HDL-Cholesterol ratio, although only the first stated ratio 
expressed a linear relationship with risk. One possible explenation for this result is 
metabolic in nature. In fact, it is well documented that patients with dyslipidemia showing 
high triglycerides and low HDL-cholesterol (generally patients with abdominal obesity and 
insulin resistance), often have marginal or even normal levels of LDL-Cholesterol 
(Lamarche, Després, Moorjani et al, 1996). Moreover, LDL-Cholesterol concentrations are 
often estimated indirectly from 3 measurements (Total-Cholesterol, Triglycerides and HDL-
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Cholesterol), which may include a variation that can reach 25% (Schectman & Sasse, 1993), 
with a potential and quite significant impact in the LDL-Cholesterol/HDL-Cholesterol ratio, 
eventually under-estimated. By contrast, the two components included in the Total-
Cholesterol/HDL-Cholesterol ratio are measured directly. Supporting the superiority of 
these ratios over the isolated lipid parameters, is their unique ability to reflect the 
bidirectional cholesterol traffic (in and outward) through the arterial intima in a way that 
the individual LDL and HDL-Cholesterol levels cannot reach (Kannel, 2005). Consistent 
with this assumption, another recent cohort prospective study, involving over 15.000 
women followed over a period of 10 years, demonstrated that the Total-Cholesterol/HDL-
Cholesterol ratio alongside the non-HDL Cholesterol were predictors of future 
cardiovascular events, as good or better than apolipoprotein fractions (Ridker, Rifai, Cook et 
al, 2005). 
Of course, there are still unresolved issues, such as the definition of a cut-off in these ratios 
from which lipid-lowering therapy should be considered. The current guidelines of the 
NCEP (2001) recommend a cut-off of 2.5 for the ratio LDL-cholesterol/HDL-cholesterol. 
However, recent studies suggest that the risk of cardiovascular events begins to have 
significant expression for values between 3.3-3.7 (Cullen, Assmann & Schulte, 1997), in line 
with the results we reported here. 
Given all the data currently available, as long as the fundamental reservations to the routine 
use of apolipoproteins are not exceeded, the use of lipid ratios in clinical practice is strongly 
advised, both in risk stratification and therapeutic decision and in monitoring its 
effectiveness. 
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Cholesterol), which may include a variation that can reach 25% (Schectman & Sasse, 1993), 
with a potential and quite significant impact in the LDL-Cholesterol/HDL-Cholesterol ratio, 
eventually under-estimated. By contrast, the two components included in the Total-
Cholesterol/HDL-Cholesterol ratio are measured directly. Supporting the superiority of 
these ratios over the isolated lipid parameters, is their unique ability to reflect the 
bidirectional cholesterol traffic (in and outward) through the arterial intima in a way that 
the individual LDL and HDL-Cholesterol levels cannot reach (Kannel, 2005). Consistent 
with this assumption, another recent cohort prospective study, involving over 15.000 
women followed over a period of 10 years, demonstrated that the Total-Cholesterol/HDL-
Cholesterol ratio alongside the non-HDL Cholesterol were predictors of future 
cardiovascular events, as good or better than apolipoprotein fractions (Ridker, Rifai, Cook et 
al, 2005). 
Of course, there are still unresolved issues, such as the definition of a cut-off in these ratios 
from which lipid-lowering therapy should be considered. The current guidelines of the 
NCEP (2001) recommend a cut-off of 2.5 for the ratio LDL-cholesterol/HDL-cholesterol. 
However, recent studies suggest that the risk of cardiovascular events begins to have 
significant expression for values between 3.3-3.7 (Cullen, Assmann & Schulte, 1997), in line 
with the results we reported here. 
Given all the data currently available, as long as the fundamental reservations to the routine 
use of apolipoproteins are not exceeded, the use of lipid ratios in clinical practice is strongly 
advised, both in risk stratification and therapeutic decision and in monitoring its 
effectiveness. 
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1. Introduction 
Four non-communicable diseases (NCDs) including cardiovascular disease (CVD), cancer, 
chronic respiratory disease, and diabetes were announced by World Health Organization 
(WHO) as the major causes of mortality in the world in 2008(Alwan, 2008). According to 
WHO prediction, in the next 10 years, mortality rate caused by NCDs will increase by 17 
percent with the highest mortality rate in the regions of Africa (27 percent) and Eastern 
Mediterranean (EMRO, 25 percent) (Alwan, 2008). Fortunately more than 80 percent of heart 
disease, stroke, and type 2 diabetes mellitus incidence and almost one third of cancers could 
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2008). 
Dyslipidemia, as a risk factor of CVD, is manifested by elevation or attenuation of plasma 
concentration of lipoproteins. Several methods have been used to classify the lipoproteins in 
respect to their density, physical, and chemical properties. Based on these classifications, 
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those aged 60 years, the risk of CHD decreased by 27 percent, which manifested a calculated 
relative risk of 0.73. With three times reduction in serum cholesterol (1.80 mmol/l or 
70mg/dl), the relative risk of CHD was 0.39 (0.73)3 and risk reduction reached to 61 percent. 
The expected benefits of total cholesterol and LDL reduction seem to be in both primary and 
secondary prevention of CHD. Protective effects of HDL against initial coronary events in 
secondary prevention (Barter et al., 2007; Rosenson, 2007) was even observed in levels of 
higher than 75 mg/dl with long lifetime protection (Longevity Syndrome) and 
emancipation of the relative risk of coronary disease. Based on these observations, current 
attempt for stroke prevention is mostly focused on intensive treatment with lipid-lowering 
drugs (Gorelick et al., 1997).  
In spite of a decline in cardiac events and coronary mortality rates, many people who are 
under appropriate treatment are still exposed to these events. In a population-based study 
regarding hypercholesterolemia awareness (Nieto et al., 1995), only 42% of population were 
informed of their hypercholesterolemia and only 4% were under lipid-lowering drug 
treatment. Need assessment to better understand the role of lipids and its subgroups 
including; VLDL, Small dense LDL, lipoprotein (a), and subgroups of HDL in pathogenesis 
of CVD calls for a general awareness regarding these topics. In this context, the major 
challenges would be: 1 – to identify those who need treatment (with or without past history 
of coronary artery disease), 2 – to develop more effective treatment strategies for patients 
with coronary artery disease (whether individuals were treated with lipid-lowering drugs or 
people who have not received adequate treatment), 3 – to adequately treat other high risk 
individuals such as diabetic, hypertensive, and old subjects. 
1.1 Objective 
Main objective of this chapter is to express the relationship between lipid disorders and 
CVD according to the top epidemiological studies in the world. Other minor objectives 
include; evaluation of role of dyslipidaemia in the incidence of CVD, and also assessment of 
the role of different types of lipoproteins in this area. 
1.2 Expected outcomes  
- To increase general awareness regarding the relationship between lipid disorders and 
CVD  
- To reduce the morbidity and mortality of CVD (by primary or secondary prevention) 
2. World epidemiological evidences of association between dyslipidemia and 
CVD 
CVD is widespread among general population. Reports received from late 1990s indicate 
that the ultimate cause of death in adults is CVD (Murray & Lopez, 1997). It has been 
predicted that CVD will become the ultimate cause of disability in the world between years 
2000-2025 (Murray & Lopez, 1997). Common lifestyle determinants such as western diet, 
physical inactivity, tobacco consumption and also increase in life expectancy are linked to 
elevation of CVD prevalence (Critchley et al., 1999).  
According to data published from the autopsy studies in 1960s, the origin of early lesions of 
atherosclerosis in adults is mostly caused by consumption of Western diet. The prevalence 
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and severity of fibroid plaques and calcified lesions as signs of CVD were significantly 
lower in Asia, underdeveloped countries and consumers of Mediterranean diet (Eggen et al., 
1964).  
2.1 Total and LDL cholesterol 
Two decades after World War II, large population studies had been performed in different 
countries in order to determine risk factors of heart disease. The most famous studies 
include the Framingham Study, Chicago and Tecumseh in USA (Butler et al., 1985; Dawber 
et al., 1951; Dyer et al., 1981; Keys, 1970) and Seven Country Studies including studies in 
England, Sweden and Norway (Fager et al., 1981; Keys et al., 1984; Miller et al., 1977) in 
European countries. The major finding of these cohort studies was that in addition to serum 
cholesterol levels, other factors also are involved in development of coronary heart disease. 
Among the main risk factors, dyslipidemia, especially increase in LDL levels and decrease in 
HDL concentrations were considered as the important factors. Table-1 demonstrates the 
Population Attributable Factors (PARs) with its 99 percent confidence interval (CI) 
associated with lipids by sex and geographic region (Labarthe, 2011; Yusuf et al., 2004). In 
some countries, PAR estimation in women is based on small numbers which makes them 
less reliable. 
 
Region Lipids in men % (CI 99%) 
Lipids in women 
% (CI 99%) 
Lipids in both 
sexes % (CI 99%) 
West Europe 36.7 (10.7-73.8) 47.9 (20.3-76.8) 44.6 (23.5-67.8) 
Central & eastern Europe 38.7 (20.0-61.4) 26.8 (5.9-68.2) 35.0 (19.2-54.9) 
Middle East 72.7 (58.8-83.2) 63.3 (32.0-86.3) 70.5 (57.8-80.7) 
Africa 73.7 (55.2-86.4) 74.6 (49.1-90.0) 74.1 (59.7-84.6) 
South Asia 60.2 (42.5-75.6) 52.1 (19.0-83.5) 58.7 (42.7-73.1) 
China 41.3 (32.4-50.7) 48.3 (36.9-59.9) 43.8 (36.7-51.2) 
Southeast Asia and Japan 68.7 (51.2-82.1) 64.5 (29.5-88.7) 67.7 (52.0-80.2) 
Australia & New Zealand 48.7 (17.5-80.9) 14.9 (0.0-99.6) 43.4 (16.0-75.6) 
South America 41.6 (20.2-66.6) 59.3 (30.5-82.9) 47.6 (29.6-66.2) 
North America 60.0 (22.2-88.8) 32.2 (1.1-95.1) 50.5 (18.2-82.4) 
Overall adjusted for age, 
sex & smoking 
53.8 (48.3-59.2) 52.1 (44.0-60.2) 54.1 (49.6-58.6) 
Overall adjusted for risk 
factors 
49.5 (43.0-55.9) 47.1 (37.4-57.0) 49.2 (43.8-54.5) 
Legend: CI: Confidence Interval. 
Table 1. Population Attributable Factors (PARs) associated with lipids in men & women by 
geographic region. 
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relative risk of 0.73. With three times reduction in serum cholesterol (1.80 mmol/l or 
70mg/dl), the relative risk of CHD was 0.39 (0.73)3 and risk reduction reached to 61 percent. 
The expected benefits of total cholesterol and LDL reduction seem to be in both primary and 
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secondary prevention (Barter et al., 2007; Rosenson, 2007) was even observed in levels of 
higher than 75 mg/dl with long lifetime protection (Longevity Syndrome) and 
emancipation of the relative risk of coronary disease. Based on these observations, current 
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In spite of a decline in cardiac events and coronary mortality rates, many people who are 
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regarding hypercholesterolemia awareness (Nieto et al., 1995), only 42% of population were 
informed of their hypercholesterolemia and only 4% were under lipid-lowering drug 
treatment. Need assessment to better understand the role of lipids and its subgroups 
including; VLDL, Small dense LDL, lipoprotein (a), and subgroups of HDL in pathogenesis 
of CVD calls for a general awareness regarding these topics. In this context, the major 
challenges would be: 1 – to identify those who need treatment (with or without past history 
of coronary artery disease), 2 – to develop more effective treatment strategies for patients 
with coronary artery disease (whether individuals were treated with lipid-lowering drugs or 
people who have not received adequate treatment), 3 – to adequately treat other high risk 
individuals such as diabetic, hypertensive, and old subjects. 
1.1 Objective 
Main objective of this chapter is to express the relationship between lipid disorders and 
CVD according to the top epidemiological studies in the world. Other minor objectives 
include; evaluation of role of dyslipidaemia in the incidence of CVD, and also assessment of 
the role of different types of lipoproteins in this area. 
1.2 Expected outcomes  
- To increase general awareness regarding the relationship between lipid disorders and 
CVD  
- To reduce the morbidity and mortality of CVD (by primary or secondary prevention) 
2. World epidemiological evidences of association between dyslipidemia and 
CVD 
CVD is widespread among general population. Reports received from late 1990s indicate 
that the ultimate cause of death in adults is CVD (Murray & Lopez, 1997). It has been 
predicted that CVD will become the ultimate cause of disability in the world between years 
2000-2025 (Murray & Lopez, 1997). Common lifestyle determinants such as western diet, 
physical inactivity, tobacco consumption and also increase in life expectancy are linked to 
elevation of CVD prevalence (Critchley et al., 1999).  
According to data published from the autopsy studies in 1960s, the origin of early lesions of 
atherosclerosis in adults is mostly caused by consumption of Western diet. The prevalence 
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and severity of fibroid plaques and calcified lesions as signs of CVD were significantly 
lower in Asia, underdeveloped countries and consumers of Mediterranean diet (Eggen et al., 
1964).  
2.1 Total and LDL cholesterol 
Two decades after World War II, large population studies had been performed in different 
countries in order to determine risk factors of heart disease. The most famous studies 
include the Framingham Study, Chicago and Tecumseh in USA (Butler et al., 1985; Dawber 
et al., 1951; Dyer et al., 1981; Keys, 1970) and Seven Country Studies including studies in 
England, Sweden and Norway (Fager et al., 1981; Keys et al., 1984; Miller et al., 1977) in 
European countries. The major finding of these cohort studies was that in addition to serum 
cholesterol levels, other factors also are involved in development of coronary heart disease. 
Among the main risk factors, dyslipidemia, especially increase in LDL levels and decrease in 
HDL concentrations were considered as the important factors. Table-1 demonstrates the 
Population Attributable Factors (PARs) with its 99 percent confidence interval (CI) 
associated with lipids by sex and geographic region (Labarthe, 2011; Yusuf et al., 2004). In 
some countries, PAR estimation in women is based on small numbers which makes them 
less reliable. 
 
Region Lipids in men % (CI 99%) 
Lipids in women 
% (CI 99%) 
Lipids in both 
sexes % (CI 99%) 
West Europe 36.7 (10.7-73.8) 47.9 (20.3-76.8) 44.6 (23.5-67.8) 
Central & eastern Europe 38.7 (20.0-61.4) 26.8 (5.9-68.2) 35.0 (19.2-54.9) 
Middle East 72.7 (58.8-83.2) 63.3 (32.0-86.3) 70.5 (57.8-80.7) 
Africa 73.7 (55.2-86.4) 74.6 (49.1-90.0) 74.1 (59.7-84.6) 
South Asia 60.2 (42.5-75.6) 52.1 (19.0-83.5) 58.7 (42.7-73.1) 
China 41.3 (32.4-50.7) 48.3 (36.9-59.9) 43.8 (36.7-51.2) 
Southeast Asia and Japan 68.7 (51.2-82.1) 64.5 (29.5-88.7) 67.7 (52.0-80.2) 
Australia & New Zealand 48.7 (17.5-80.9) 14.9 (0.0-99.6) 43.4 (16.0-75.6) 
South America 41.6 (20.2-66.6) 59.3 (30.5-82.9) 47.6 (29.6-66.2) 
North America 60.0 (22.2-88.8) 32.2 (1.1-95.1) 50.5 (18.2-82.4) 
Overall adjusted for age, 
sex & smoking 
53.8 (48.3-59.2) 52.1 (44.0-60.2) 54.1 (49.6-58.6) 
Overall adjusted for risk 
factors 
49.5 (43.0-55.9) 47.1 (37.4-57.0) 49.2 (43.8-54.5) 
Legend: CI: Confidence Interval. 
Table 1. Population Attributable Factors (PARs) associated with lipids in men & women by 
geographic region. 
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In parallel to these large population studies, a series of case studies were also performed. In 
one study, serum lipid levels were evaluated in 500 men with a prior history of myocardial 
infarction. Overall 30 percent of study population had abnormal blood lipid levels 
(Goldstein et al., 1973). High levels of cholesterol in 8 percent, triglycerides in7 percent and 
concomitant high cholesterol and triglycerides in15 percent were reported by this study. 
In normal individuals from different communities, plasma levels of lipids vary due to 
differences in genetic background and diet. For example, the average cholesterol levels, 
according to age, in western and Chinese men are 202 mg/dl and165 mg/dl, respectively 
(Caroll et al., 2005; Wu et al., 2004). Based on results of the National Health and Nutrition 
Examination Surveys (NHANES) from 1999 to 2004, the percentage of adults with 
triglyceride levels above 150 and 200 mg/dl in the United States, were 33 and 18 percent, 
respectively (Ford et al., 2009). In the United States, the NHANES from 2005 to 2008 found 
that 98.8 million adults have total cholesterol levels ≥ 200 mg/dl, 33.6% of them having a 
total cholesterol level ≥ 240 mg/dl (American Heart Association [AHA], 2011). 
Table-2 shows the prevalence of high levels of total cholesterol (cholesterol ≥ 200 mg/dl), 
LDL (LDL cholesterol ≥130 mg/dl), and HDL (HDL cholesterol≤ 40 mg/dl) in adults aged 
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Legend: M: Male; F: Female; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein. 
Table 2. Proportion of USA adults aged ≥ 20 years with dyslipidemia by ethnicity and 
gender 
In MONICA5 project designed for more than 30 countries in different regions of WHO 
coverage except the US, the percentage of hypercholesterolemia for individuals aged 
between 35-64 years and total cholesterol levels between 5.2-7.8 mmol/l (approximately 200-
300 mg/dl) was found to be lowest (20%) among the men in China-Beijing and highest 
(76%) in France-Strasbourg. The lowest percent of women with hypercholesterolemia (5%) 
was in Australia-Perth population and the highest percent (76%) was observed in Germany-
Bremen (WHO MONICA project, 2008). However, these figures were different when the 
total cholesterol level >7.8 mmol/l was considered as hypercholesterolemia. None of the 
China-Beijing’s men had the serum cholesterol levels >7.8 mmol/l (0%) while 15% of 
Switzerland-Ticino men had hypercholesterolemia (highest percent). for women these 
figures were 0% in China-Beijing and 14% in Lithuania-Kaunas (WHO MONICA project, 
2008).  
                                                 
5 Multinational MONItoring of trends and determinants in CArdiovascular disease 
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The WHO MONICA project showed (WHO MONICA project, 1989) that the average of total 
cholesterol in 30 studied areas varied from 158 mg/dl (in the Beijing, China) to 246 mg/dl 
(Loczamburk, Germany) for men and from 162 mg/dl (Beijing, China) to 246 mg/dl 
(Glasgow, UK) in women. In addition, there was a difference in prevalence of 
hypercholesterolemia in different regions, from 2 percent in Beijing, China to nearly 50 
percent in Lille, France (WHO MONICA project, 1989). An intermediate reduction in 
cholesterol level of MONICA project study populations during 5-6 year follow-up was 
observed. The mean annual decrease in total serum cholesterol was 0.4-3 mg/dl (Dobsn et 
al., 1996). 
The highest incidence of hyperlipidemia is shown in patients with premature coronary 
artery disease, which occurs before age 55 years in men and 65 years in women. Prevalence 
of dyslipidemia in these patients is equal to 80-88 percent, compared to 40-48 percent in age-
matched controls without CHD (Genest et al., 1992; Roncaglioni et al., 1992). In these 
conditions, 12.5 percent of patients with a prior history of premature coronary disease and 
58.5 percent of age-matched controls without prior history of coronary disease have normal 
lipid profiles.  
MRFIT6 study performed in more than 350,000 middle-aged men demonstrated (Stamler et 
al., 1986) that a sigmoid relationship (curvilinear) between total serum cholesterol level and 
prevalence of coronary artery disease especially in total cholesterol more than 240 mg/dl is 
presented (Figure-1). 
The strongest association was found in population from United States and Finland, the 
intermediate association was observed in European population, and the least correlation 
was related to Japanese men and rural area of Greece. The relationship between serum 
cholesterol and incidence of CVD become stronger when the number of risk factors was 
increased (Kannel, 1983).  
 
 
Fig. 1. Association between plasma cholesterol and coronary risk among MRFIT study 
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Similar results were obtained from Framingham and Migration studies (Kannel et al., 
1971, 1979). The Migration study is one of the strong studies evaluating the relationship 
between increased serum cholesterol and risk of CVD. This study was done in 1960 and 
compared Japanese men residing in Japan with immigrated Japanese to Honolulu and San 
Francisco. In Japanese men living in their native country, the mean total cholesterol levels 
and CHD rate were lower compared to immigrated population. In immigrated Japanese, 
those who live in Hawaii had lower lipid levels than those in San Francisco. Considering 
race similarity in this study, the reason for observed differences in rate of CHD and 
cholesterol levels can be related to differences in dietary cholesterol and fat consumption 
(Kagen et al., 1974). 
However the results of other studies on immigrants were not always similar to the 
Migration study. In one study (Kushi et al., 1985), diet produced no effect on cholesterol 
levels or heart disease mortality. In General, the importance of age, sex and race on levels of 
cholesterol has been shown in population-based studies. 
Invention of ultracentrifuge has facilitated measurement of the various lipid parameters. 
LRCP (Lipid Research Clinics Program) was one of the first surveys during 1970 that was 
conducted to determine the total cholesterol, HDL cholesterol, LDL cholesterol and 
triglyceride levels in American adults (Heiss et al., 1980). In another study, difference in 
distribution of cholesterol and its components in the blood in accordance to age were 
described (Glueek & Stein, 1979). In both sexes, the slope of total cholesterol curve is 
increased by increase in age until the end of middle-age. After that, by increasing the age, 
slope of the curve is downward until reaching the old age. Mean total cholesterol in men 
and women aged between 20 -50 years is similar, however, the levels of HDL cholesterol in 
women after puberty is higher than men (Rifkind & Segal, 1983).  
Among patients with a prior history of myocardial infarction, an elevated total cholesterol 
following recovery was a major independent risk factor for reinfarction, death from heart 
disease and total mortality. Cardiovascular mortality is varied in different populations. The 
highest and lowest mortality rate was found in Finland and Japan, respectively, with a 
direct relationship to serum cholesterol levels (Rosenson, 2011). 
2.2 HDL cholesterol 
The negative relationship between low HDL cholesterol and the risk of heart disease is well 
stablished in the general population (Abbott et al., 1988; Abbott et al., 1998; Castelli, 1983; 
Gordon et al, 1989; Harper & Jacobson, 1999; Rosenson, 2005) (figure-2). In the Framingham 
Heart study, the protective role of HDL has been well described (Kannel et al., 1971).  
Based on results of this study, by each 5 mg /dl decrease in serum levels of HDL (compared 
to mean normal values for men and women), the risk of myocardial infarction was increased 
by 25 percent.  
Predictive role of HDL against coronary events was also well documented in patients with 
known heart disease. The results of Lipid and Care clinical trial showed that low levels of 
HDL cholesterol is a stronger predictor of heart disease incidence in presence of serum LDL 
cholesterol < 125 mg/dl than LDL cholesterol ≥ 125 mg/dl (Sacks et al., 2002). They also 
found that in serum LDL<125 mg/dl, each 10 mg /dl increase in HDL level, will cause 29 
percent reduction in the incidence of cardiovascular events , while with the serum LDL 
cholesterol ≥ 125 mg/dl, this attenuation will be lowered to 10 percent. This association was 
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also seen in post hoc analysis of TNT7 study, in which 10000 known cases of CVD were 





Legend: CHD: Coronary heart disease; L M H HDL: Low, middle, high, high density lipoprotein; CVD: 
Cardiovascular disease; FHS: Framingham Heart Study; LRCF: Lipid Research Clinics Prevalence 
Mortality Follow-up Study; CPPT: Lipid Research Clinics Coronary Primary Prevention Trial; MRFIT: 
Multiple Risk Factor Intervention Trial. 
Fig. 2. Inverse association between HDL and CVD events. 
As mentioned previously, the cardioprotective effect of HDL was shown to be present at 
serum levels higher than 60 mg/dl (Castelli et al., 1983). These effects are more prominent 
when the serum levels of HDL cholesterol reach 75 mg/dl and higher (Table-3).  
In assessment of 18 relatives with familial hyperalfa–lipoproteinemia, the life long of these 
men and women were found to be 5 and 7 years, respectively, more than general population 
(Glueck et al., 1976). 
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In the Lipid Research Clinics study, the Framingham heart Study and the HHS8 the ratio of 
LDL to HDL was shown to be the best predictor of cardiovascular events (Manninen et al., 
1992; Kinosian et al., 1994). In HHS study, the risk of new coronary events such as 
myocardial infarction and sudden cardiac death in patients with LDL/HDL ≥ 5 and a 
concomitant serum triglycerides ≥ 200 mg /dl, was fourfold more than patients with lower 
LDL/HDL ratio and triglycerides levels. Overall, among men, an LDL/HDL ratio of ≥ 6.4 
had 2–14 percent higher predictive value than serum total cholesterol or LDL levels. Among 
women the predictive value of LDL/HDL ≥ 5.6 was 25–45 percent greater than serum total 
cholesterol or LDL level (Kinosian et al., 1994). 
 
HDL (mg/dl) Multiplier for cardiovascular risk 
men women 
30 1.82 ---- 
35 1.49 ---- 
40 1.22 1.94 
45 1.00 1.55 
50 0.82 1.25 
55 0.67 1.00 
60 0.55 0.80 
65 0.45 0.64 
70 ---- 0.52 
75 Longevity syndrome Longevity syndrome 
Legend: HDL: High Density Lipoprotein. 
Table 3. Inverse relation between plasma HDL-cholesterol levels and cardiovascular risk in 
men and women.  
2.3 Triglycerides 
The relationship between hypertriglyceridemia and CVD was determined in the population-
based Stockholm prospective study (Carlson et al., 1979). In this study, 3,486 subjects were 
followed for 14.5 years. An independent relation between hypertriglyceridemia and CVD 
was observed in this study, which was stronger than the relationship between 
hypercholesterolemia and CVD. Meta-analysis of several large population–based 
prospective studies showed similar results (Hokanson & Austin, 1996). Based on this study, 
the univariate risk ratio (RR) of triglyceride, independent of HDL and other CVD risk 
factors, among men was 1.32 (95 percent CI, 1.26 to 1.39) and among women was 1.76 (95 
percent CI, 1.50 to 2.07).  
As mentioned previously in the HHS study, not only there is an interaction between 
triglycerides and total cholesterol/HDL ratio, but also an inverse association between 
triglycerides and HDL levels exists (Rosenson, 2011). Additionally, hypertriglyceridemia is 
associated with increased mortality in patients with known CHD and also reduces the 
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event–free survival after coronary artery bypass graft surgery (CABG) (Haim et al., 1999; 
Sprecher et al., 2000). 
Nevertheless, because hypertriglyceridemia is an independent risk factor for CVD, 
measurement of triglycerides as a part of routine cholesterol screening is recommended by 
NECP ATPIII guidelines (Haim et al., 1999). Fasting triglyceride measurement is important 
for evaluating the risk of heart disease especially in cases who are suffering from diabetes, 
glucose intolerance, insulin resistance syndrome, obesity and low HDL. Although, 
triglyceride measurement is commonly done after 8–12 hours fasting, an association 
between nonfasting triglyceride levels and CVD is also present (Nordestgaard et al., 2007; 
Bansal et al., 2007).  
2.4 Non-HDL cholesterol 
Non–HDL cholesterol is defined as the difference between total and HDL cholesterols. Thus 
it includes LDL, Lp (a), IDL and VLDL (Ballantyne et al., 2000). In both LRCP study and the 
Women’s Health Study non-HDL cholesterol has been suggested as a better tool for risk 
assessment of CVD than LDL levels (Cobbaert et al., 1997; Ridker et al., 2005). In the LRCP 
study in which the patients were followed for an average of 19 years, a 30 mg/dl difference 
in non–HDL and LDL concentrations, produced 19 and 15 percent, increase in mortality risk 
of CVD among men, respectively, and 11 and 8 percent, among women, respectively, 
(Cobbaert et al., 1997).  
2.5 Lipoprotein (a) 
Lipoprotein (a), also called Lp (a), is established as an independent risk factor for CVD. Lp 
(a) is a modified form of LDL with a structure similar to plasminogen (Steyrer et al., 1994) 
that could interfere with fibrinolysis by competing with plasminogen for binding to cells 
(Loscalzo et al., 1990; Palabrica et al., 1995). Lp (a) also binds to macrophages to promote 
foam cell formation and deposition of cholesterol in atherosclerotic plaques (Zioncheck et 
al., 1991). Thus, Lp (a) accelerates atherosclerosis process by impairing fibrinolysis and 
increasing LDL oxidation (Stein & Rosenson, 1997). Evidences of association between Lp (a) 
excess [Lp (a) levels above the 95th percentile] and CVD mostly come from 2 large meta-
analyses that found positive continuous correlation between Lp (a) and risk of CVD events 
(Bennet et al., 2008; Emerging et al., 2009). The 24 cohort studies in the meta-analysis (Bennet 
et al., 2008) found a risk ratio of 1.13 (95 percent CI, 1.09 to 1.18) between the top and third 
bottom baseline Lp (a) levels after adjustment for multiple traditional cardiovascular risk 
factors. Lp (a) excess concentration is usually detected in patients with premature CHD. In 
one study 18.6 percent of patients with premature CHD had excess levels of Lp (a), while 
12.7 percent of them had no dyslipidemia (Genest et al., 1992).  
LP (a) increases the risk of cerebrovascular disease, peripheral vascular disease, myocardial 
infarction (MI), re–stenosis after angioplasty, and failure after CABG (Rosengren et al., 1990; 
Schaefer et al., 1994). 12 years and more follow–up of patients in the Framingham Heart study 
showed that Lp (a) can increase the risk of premature coronary heart disease by two-times 
(Bostom et al., 1996), and augment the risk of MI, intermittent claudication, cerebrovascular 
disease, and coronary artery stenosis. In the 4S9 study an association between increased Lp (a) 
levels and overall mortality rate was also observed (Bostom et al., 1994).  
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event–free survival after coronary artery bypass graft surgery (CABG) (Haim et al., 1999; 
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2.6 Apolipoproteins & atherogenic lipoprotein phenotype 
There are limited prospective studies about the relationship between apolipoproteins (apo 
A-I and apo B) and the CVD risk. The QCS10 was studied 2155 men aged between 45-76 
years and reported a direct correlation between apo B levels and prevalence of ischemic 
heart disease over the future 5 years, [ relative risk (RR) 1.4; 95 percent CI, 1.2 to 1.7] 
(Lamarche et al., 1996), independent of other risk factors of CVD. For apo A–I, a negative 
correlation (RR = 0.85; 95 percent CI, 0.7 to 1.0) was reported. 
Since the measurement of apo B and apo A–I is an indicator of total atherogenic (lDL, VLDL, 
and LDL) and antiatherogenic particles (HDL), some studies (Lamarche et al., 1996; 
Meisinger et al., 2005; Yusuf et al., 2004; Walldius et al., 2001, 2005) proposed that 
measurements of apo B and apo A are more important predictors of the CVD than above 
measurements. The AMORIS11 study evaluated this relationship in 175,553 subjects with 65 
months follow up (Walldius et al., 2001). In the multivariate analysis the apo B concentration 
was significantly higher than LDL levels and served as a better predictor of CVD than LDL. 
The results regarding the role of apolipoproteins in prediction of CVD risk are conflicting. 
Two studies; Women’s Health Study and the Framingham Study obtained a similar 
predictive value for apo B/A–I ratio versus total cholesterol/ HDL ratio (Ridker et al., 2005; 
Ingelsson & Schaefer, 2007). However, in contrast to Health Professionals Follow-up Study 
(Pischon et al., 2005; Sniderman, 2005) and AMORIS study, apo A–I and apo B did not have 
any predictive value for CHD risk in ARIC12 study (Sharrett et al., 2001). The explanation for 
these disparate results is not clear. However, it seems apolipoproteins have a potential role 
in CHD risk stratification. Standardization of laboratory methods and measurements to the 
same reference system, and establishing threshold and target values for diagnosis could 
help recognize the full potential of apolipoproteins (Srinivasan & Berenson, 2001; Denke, 
2005).  
Apo E is important in plasma lipid metabolism and Apo E gene affects plasma levels of 
LDL. Three major apo E isoforms are E2, E3, and E4, which are encoded by three common 
alleles at the APO E locus. The less common and the most common isoforms in society are 
E2 and E3, respectively. E4 allele is associated with higher plasma total cholesterol and LDL 
cholesterol levels and with risk of heart attack. In contrast, subjects with E2 allele have lower 
risk of heart attack compared to people with E4 isoform (Song et al., 2004). 
Some clinical researches have focused on the relationship between small dense LDL 
particles and risk of CVD. This status, also called atherogenic lipoprotein phenotype, is 
usually associated with increased triglyceride, VLDL and LDL levels (Krauss, 1994). The 
Physician's Health Study showed that small dense LDL particles can increase three times the 
risk of CVD more than LDL cholesterol (Zambon et al., 1996). In QCS study, during 5 year 
follow up, 114 cases from a total of 2103 were diagnosed with heart disease. In this study, in 
multivariate analysis small dense LDL was more important predictor of CVD [odds ratio 
(OR) = 3.7; 95 percent CI, 1.4 to 9.7) than LDL (OR = 1.8; 95 percent CI, 1.2 to 2.9) (Lamarche 
et al., 1997). The Familial atherosclerosis Treatment Study (FATS) found that LDL subclasses 
were the most important predictor of coronary progression (Zambon et al., 1999). In the 
Pravastatin Limitation of Atherosclerosis in the Coronaries (PLAC–I) study showed that 
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small LDL particle size (≤ 20.5 nm) could increase rate of coronary progression with OR= 5.0 
and 95 percent CI, 1 to 9. High numbers of small LDL particles (>30 mg/dl) was the most 
important lipoprotein predictor in multivariate analysis (OR = 9.1; 95 percent CI, 2.1 to 39) 
(Otvos et al., 2002).  
In the FATS13 study 95 percent variance in regression of atherosclerosis in coronary arteries 
were related to changes in lipid profile. Adding the LDL density to the equation showed 
that almost 45 percent of the variance was related to changes in LDL density (Lamarche et 
al., 1997). In contrast, the CHS14 reported that LDL particle concentration and not LDL size 
acted as a significant predictor of MI and angina in women, in which by every 100 nmol/l 
increase in LDL particle number, the OR of MI and angina increased by 11 percent (Kuller et 
al., 2002). 
In Women’s Health Study which assessed LDL particle size and concentration by NMR15 , 
the LDL particle concentration was a strong predictor of CVD after adjustment for 
traditional risk factors (Blake et al., 2002). 
EPIC16- Norfolk prospective Population Study examined NMR-measured LDL particle size 
and concentration (EI Harchaoui et al., 2007) and found that LDL particle concentration did 
not increase the prediction of CHD. After LDL particle concentration adjustment, LDL size 
was no longer associated with CHD. 
Recently, some scientists from the University of Warwick in UK discovered a modified form 
of LDL, MGmin-LDL, also called super-sticky LDL, or very-bad LDL, that promotes CVD 
(Rabbani et al., 2011). High levels of this lipid are more common in diabetics and elderly 
patients. Diabetic subjects present almost four times more serum levels of MGmin-LDL than 
normal subjects. This may explain the high frequency of CVD in diabetics and elderly 
patients. Rabbani et al (Rabbani et al., 2011) found that secondary to hyperglycemia, LDL is 
glycated with methylglyoxal (MG) and makes a type of LDL with smaller, stickier and more 
atherogenic LDL than normal LDL. The MGmin-LDL can help to build fatty plaques. When 
these plaques grow, the wall of arteries become narrower and the blood flow reduces. 
Plaque rapture, an event that would eventually happen, triggers the blood clot cascades that 
could cause a heart attack or stroke. In elderly, the activity of the enzyme for detoxification 
of MGmin-LDL is reduced. They (Rabbani et al., 2011) also showed that metformin can 
block the glycation processes which might explain the cardioprotective effects of this drug. 
This discovery could lead to invention of new treatments for CVD prevention especially in 
type 2 diabetics and the elderly subjects.   
3. Summary 
The relationships described above can be summarized in the figure-3 (Ridker et al.,  
2005). This figure shows the adjusted Hazard ratios of future cardiovascular events among 
patients who are in the extreme quintiles of each measured marker. Black bars present 95 
percent CI. 
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patients. Rabbani et al (Rabbani et al., 2011) found that secondary to hyperglycemia, LDL is 
glycated with methylglyoxal (MG) and makes a type of LDL with smaller, stickier and more 
atherogenic LDL than normal LDL. The MGmin-LDL can help to build fatty plaques. When 
these plaques grow, the wall of arteries become narrower and the blood flow reduces. 
Plaque rapture, an event that would eventually happen, triggers the blood clot cascades that 
could cause a heart attack or stroke. In elderly, the activity of the enzyme for detoxification 
of MGmin-LDL is reduced. They (Rabbani et al., 2011) also showed that metformin can 
block the glycation processes which might explain the cardioprotective effects of this drug. 
This discovery could lead to invention of new treatments for CVD prevention especially in 
type 2 diabetics and the elderly subjects.   
3. Summary 
The relationships described above can be summarized in the figure-3 (Ridker et al.,  
2005). This figure shows the adjusted Hazard ratios of future cardiovascular events among 
patients who are in the extreme quintiles of each measured marker. Black bars present 95 
percent CI. 
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Fig. 3. Adjusted Hazard ratios for future cardiovascular events. 
Today, interventional studies have investigated the effects of augmentation of HDL levels. 
The clinical trials which deal with this matter will be discussed in a separate part.  
In assessment of dyslipidemia two points should be stipulated: 
1. Decline of coronary events could be possible by modifying the serum lipid levels in 
order to prevent or delay the reduction of vessel diameter, and also to stabilize 
atheroma plaques. Small plaques are mostly filled with lipid and are prone to 
disposable rupture, thrombosis, acute, serious and ultimately fatal atherosclerosis. 
Reduction of LDL leads to removal of fatty deposits from the inside of the atheroma 
plaque and makes them more stable. In addition, lowering the lipids levels can return 
the normal activity of vessel wall endothelium and its ability to produce nitric oxide, 
the main mediator of coronary vasodilation (Krauss, 1994). 
2. During lipid-lowering drug therapy the cost-effectiveness of the treatment should be 
considered. This depends on the price of drugs as well as patient’s risk. For example, at 
least cost-effectiveness includes patients with intermediate elevation of serum 
cholesterol, who, without any other risk factors, are under- lipid lowering agent 
therapy. In 4S study which was performed in patients with high risk of CVD, cost per 
year of life gain, was depended on age, sex and baseline levels of lipid. The range of this 
cost was varied from 3,800 $ U.S. for men aged 70 years and the mean serum cholesterol 
309 mg/dl, to 27,400 $ U.S. for women aged 35 years and the average serum cholesterol 
213 mg/dl (Johannessonet al., 1997). In other studies these figures were different from 
19,000 $ U.S. to 56,000 $ U.S. which depends on drug dose and formulation used. Also, 
these costs were three folds, two folds and 1.3 folds more in women at age 40, 60 and 70 
years, respectively, when compared with the men at age 40 years (Martens & Guibert, 
1994; Thorvik et al., 1996). 
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1. Introduction  
Bipolar disorder (previously also labeled manic-depressive illness) is typically referred to as 
an episodic, yet lifelong and clinically severe affective (or mood) disorder, affecting 
approximately 3.5% of the population (Marmol, 2008; Simon, 2003; Wittchen et al., 2003; 
Woods, 2000). The term bipolar disorder, however, encompasses several phenotypes of 
mood disorders, i.e. mania, hypomania or cyclothymia that may present with a puzzling 
variety of other symptoms and disorders. According to the Fourth Edition of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV) (American Psychiatric Association, 
2004), the diagnostic classificatory system used in most epidemiological studies, bipolar 
disorder is defined by a set of specific symptom criteria. Bipolar type I requires the presence 
or the history of at least one manic or mixed episode. Although, typically, patients with a 
manic episode also experience major depressive episodes, bipolar disorder can be diagnosed 
even if only one manic episode and no past major depressive episodes are present. Bipolar 
disorder type II differs from type I only by presence of hypomanic but no manic episodes. 
Hypomanic episodes differ from mania by a shorter duration (at least 4 days instead of 1 
week), and less severe impairment (not severe enough to cause marked impairment in social 
or occupational functioning, psychiatric hospitalization, or psychotic features). The DSM-IV 
also includes “cyclothymia” as a bipolar spectrum disorder with hypomanic as well as 
depressive episodes that do not meet criteria for major depression (American Psychiatric 
Association, 2004). 
Bipolar disorder is a chronic disease that is associated with a potentially devastating impact 
on patients’ wellbeing and social, occupational, and general functioning (Revicki et al., 
2005). The disorder ranks as the sixth leading cause of disability in the world, with an 
economic burden that in the US alone that was estimated more than a decade ago at $7 
billion in direct medical costs and $38 billion (1991 values) in indirect costs (Wyatt et al., 
1991). 
A number of reviews and studies have shown that people with severe mental illness, 
including bipolar disorder, have an excess mortality, being two or three times as high as that 
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in the general population. This mortality gap, which translates to a 13-30 year shortened life 
expectancy in severe mental illness patients, has widened in recent decades, even in 
countries where the quality of the health care system is generally acknowledged to be good. 
About 60% of this excess mortality is due to physical illness especially cardiovascular 
disease. Additionally, several studies have found that after suicide and accidents, 
cardiovascular and all vascular diseases are the main leading causes of death in these 
patients (De Hert et al., 2011; Garcia-Portilla et al., 2009). 
Patients with bipolar disorder, especially type I, are known to suffer a considerable number 
of associated pathologies that may manifest at earlier ages and with higher frequency than 
in the general population. The most recent studies have explored cardiovascular risk and the 
association with metabolic and endocrine disorders fundamentally, obesity and metabolic 
syndrome which are clearly associated with the development of cardiovascular disease 
(Angst et al., 2002; Sicras et al., 2008). 
Cardiovascular disease, i.e. coronary heart disease, stroke, and peripheral vascular disease, 
are potentially preventable diseases. Thanks to epidemiological, experimental and clinical 
studies, the primary determinants of cardiovascular disease have been identified, as well as 
the efficacy of specific interventions. The prevalence of cardiovascular disease is increasing 
in less urbanized, developed populations across the world, as their lifestyles change to a so 
called “western style”, with increasing consumption of dietary saturated fat, cholesterol and 
salt, cigarette smoking, decreased physical activity and the rise in cardiovascular risk factors 
including obesity and diabetes. Other known factors that contribute to cardiovascular 
disease risk are stress and high alcohol intake. Among all these factors, 
hypercholesterolemia is the leading cause of death from cardiovascular disease. As a result, 
public health agencies have attempted to reduce the prevalence of hypercholesterolemia 
through screening and by increasing public awareness and strategies for reducing it 
(Muntoni et al., 2009). 
The exact mechanisms increasing the incidence of cardiovascular risk in bipolar patients 
remain to be clarified, but they possibly include industrialisation, stress, lack of exercise, 
dietary lipids (that is, omega-3 fatty acid deficiency) and increasing incidence of smoking 
and alcohol consumption and other factors (Ezzaher et al., 2010).  
This study aims to investigate the principal factors predisposing to the cardiovascular risk in 
Tunisian bipolar I patients (cigarette smoking, hypertension, diabetes, obesity, lipid profile, 
hyperhomocysteinemia and metabolic syndrome) and to determine the association between 
these factors and the clinical and therapeutic characteristics of bipolar I disorder.  
2. Patients and methods 
2.1 Subjects 
This study was approved by the local ethical committee and all subjects were of Tunisian 
origin. Our samples included 130 patients with bipolar I disorder (37.9 ± 12.1 years) from the 
psychiatry department of the University Hospital of Monastir, Tunisia, 45 women (37.5 ± 
13.4 years) and 85 men (38.1 ± 11.4 years). Consensus on the diagnosis, according to the 
Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria 
(American Psychiatric Association, 2004), was made by psychiatrists. The exclusion criteria 
were age < 18 years, other psychiatric illnesses, epilepsy or mental retardation. The control 
group consisted of 175 volunteer subjects without psychiatric pathology. The mean age was 
40.1 ± 14.0 years, and there were 73 women (42.0 ± 14.4 years) and 102 men (38.8 ± 13.6 
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years). All subjects were questioned about their age, gender, previous treatments and 
cigarette and alcohol consumption habits.  
The clinical and socio-demographic characteristics are shown in table 1. Differences between 
patients and controls for body mass index (BMI) (p < 0.001) and smoking status (p =0.025) 
were noted. Therefore, these variables were considered as potential confounder factors for 
this analysis.  
 
 Patients (n = 130) 
Controls 
(n = 175) p 
Gender: Men/Women (ratio) 85/45 (1.89) 102/73 (1.39) 0.143 
Age (years) (mean ± SD) 37.9 ± 12.1 40.1 ± 14.0 0.840 
BMI (kg/m²) (M ± ET) 27.1 ± 4.6 25.3 ± 4.1 < 0.001 
 Nombre % Nombre % p 
BMI (kg/m²) 
< 25 47 36.2 89 50.9 
< 0.001 [25-30[ 40 30.7 72 41.1 
≥ 30 43 33.1 14 8 
Cigarette smoking
Yes 68 52.3 69 39.4 0.025 No 62 47.7 106 60.6 
Alcoholic beverages
Yes  17 13.1 12 6.9 0.067 No 113 86,9 163 93.1 
Illness episode 
Depressive 21 16.2 - - - 
Euthymic  73 56.1 - - - 
Manic 36 27.7 - - - 
Treatment 
Valproic acid 64 49.3 - - - 
Lithium 12 9.2 - - - 
Carbamazepine 10 7.7 - - - 
Valproic acid and lithium 6 4.6 - - - 
Antipsychotics 38 29.2 - - - 
Antipsychotics: Haloperidol, Risperidone, Chlorpromazine, Olanzapine; BMI: body mass index 
Table 1. Sociodemographic and therapeutic characteristics of studied population. 
2.2 Samples 
After a 12 h overnight fasting, venous blood for each patient was drawn in tubes containing 
lithium heparinate and immediately centrifuged. The plasma samples were stored at -20°C 
until the biochemical analysis. 
2.3 Biochemical analysis 
The methods of dosage and the normal values of the different biological parameters are 
shown in table 2. 
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< 25 47 36.2 89 50.9 
< 0.001 [25-30[ 40 30.7 72 41.1 
≥ 30 43 33.1 14 8 
Cigarette smoking
Yes 68 52.3 69 39.4 0.025 No 62 47.7 106 60.6 
Alcoholic beverages
Yes  17 13.1 12 6.9 0.067 No 113 86,9 163 93.1 
Illness episode 
Depressive 21 16.2 - - - 
Euthymic  73 56.1 - - - 
Manic 36 27.7 - - - 
Treatment 
Valproic acid 64 49.3 - - - 
Lithium 12 9.2 - - - 
Carbamazepine 10 7.7 - - - 
Valproic acid and lithium 6 4.6 - - - 
Antipsychotics 38 29.2 - - - 
Antipsychotics: Haloperidol, Risperidone, Chlorpromazine, Olanzapine; BMI: body mass index 
Table 1. Sociodemographic and therapeutic characteristics of studied population. 
2.2 Samples 
After a 12 h overnight fasting, venous blood for each patient was drawn in tubes containing 
lithium heparinate and immediately centrifuged. The plasma samples were stored at -20°C 
until the biochemical analysis. 
2.3 Biochemical analysis 
The methods of dosage and the normal values of the different biological parameters are 
shown in table 2. 
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Folate ≥ 3.7 µg/L 
Insulin < 17µU/mL 
Table 2. Methods of dosage of the studied parameters. 
2.4 Clinical evaluation 
Body mass index (BMI) was calculated as weight (kg) divided by height (m²). Obesity was 
defined when BMI ≥ 30 kg/m² and overweight when BMI ≥ 25 kg/m² (World Health 
Organization, 1997). 
2.5 Criteria for metabolic syndrome 
Metabolic syndrome (MS) was defined according to the National Cholesterol Education 
Program (NCEP) Adult Treatment Panel (ATP) III modified criteria and required fulfillment 
of at least three of the following five components: body mass index (BMI) ≥ 28.5 kgm2, 
triglycerides ≥ 1.7 mmol/L, high-density lipoprotein cholesterol (c-HDL) < 1.1 mmol/L (in 
men) and < 0.9 mmol/L (in women), blood pressure ≥ 130 ⁄85 mmHg and fasting glucose (≥ 
6.1 mmol/L) (National Cholesterol Education Program, 2002). 
2.6 HOMA-IR determination 
Insulin resistance (IR) was estimated using the Homeostasis Model of Assessment equation: 
HOMA-IR = [fasting insulin (mU/L) × fasting glucose (mmol/L)]/22.5. IR was defined as 
the upper quartile of HOMA-IR. Values above 2.5 were taken as abnormal and reflect 
insulin resistance (Ozdemir et al., 2007). Bipolar patients with diabetes (n = 21) were 
excluded in the HOMA-IR analysis. 
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2.7 Statistical analysis  
Statistical analyses were performed using SPSS 17.0 (SPSS, Chicago, IL, USA). Quantitative 
variables were presented as mean ± SD and comparisons were performed using the 
Student's t test. Qualitative variable comparisons were performed using the Chi-squared test 
(χ2) and Fisher’s exact test (when n < 5). Comparisons between patients and controls in 
biological parameters were performed using analysis of variance (ANOVA) after adjustment 
for potential confounder factors. Odd ratios (ORs) and their 95% condence interval (CI) 
were calculated and adjusted for potential confounder factors by binary logistic regression. 
The statistical significance level was set at p < 0.05. All variables with a p value < 0.25 
between the two studied groups (patients and controls) were considered as potential 
confounder factors for this analysis. 
3. Results 
Table 3 shows the comparisons of biological variables between bipolar I patients and controls. 
 
Biological variables Patients (n = 130) 
Controls 
(n = 175) p p
* 
Triglycerides (mmol/L) 1.95 ± 1.55 1.23 ± 0.81 < 0.001 < 0.001 
Cholesterol (mmol/L) 4.42 ± 0.99 4.37 ± 1.26 0.707 0.856 
c-LDL (mmol/L) 2.14 ± 1.10 2.37 ± 1.38 0.118 0.047 
c-HDL (mmol/L) 
Men (85/102) 1.04 ± 0.37 0.98 ± 0.29 0.192 0.017 
Women (45/73) 1.17 ± 0.36 1.21 ± 0.48 0.542 0.702 
ApoA1 (g/L) 1.20 ± 0.23 1.40 ± 0.67 < 0.001 0.028 
ApoB (g/L) 0.82 ± 0.28 0.83 ± 0.24 0.784 0.777 
ApoB/Apo A1 0.71 ± 0.26 0.65 ± 0.25 0.086 0.314 
Lp(a) (mg/L) 243 ± 223 87 ± 129 < 0.001 < 0.001 
Homocysteine (µmol/L) 15.8 ± 8.9 11.5 ± 5.0 < 0.001 < 0.001 
Vitamin B12 (ng/L) 356 ± 198 360 ± 190 0.837 0.819 
Folate (µg/L) 3.3 ± 0.9 5.1 ± 2.8 < 0.001 <0.001 
Uric acid (µmol/L) 
Men (85/102) 311 ± 99 250 ± 107 0.001 0.005 
Women (45/73) 246 ± 97 197 ± 73 0.012 0.408 
* Lipid profile parameters, folatemia, vitamin B12 and uric acid were adjusted for gender, BMI, cigarette 
smoking, alcoholic beverages, diabetes and hypertension 
*Hcys was adjusted for gender, BMI, cigarette smoking, alcoholic beverages, diabetes, hypertension, 
folatemia and vitamin B12 
Table 3. Comparisons of biological variables between bipolar I patients and controls. 
Compared with controls, patients had significantly higher triglycerides (1.95 ± 1.55 Vs 1.23 ± 
0.81 mmol/L; p < 0.001), Lp(a) (243 ± 223 Vs 87 ± 129 mg/L; p < 0.001), homocysteine levels 
(15.8 ± 8.9 Vs 11.5 ± 5.0 µmol/L; p < 0.001) and uric acid (311 ± 99 Vs 250 ± 107 µmol/L;  
p = 0.001 in men; 246 ± 97 Vs 197 ± 73 µmol/L; p = 0.012 in women), and significantly lower 
ApoA1 (1.20 ± 0.23 Vs 1.40 ± 0.67 g/L; p < 0.001) and folate (3.3 ± 0.9 Vs 5.1 ± 2.8 µg/L;  
p < 0.001) levels. After adjustment for potential confounder factors, these differences 
remained significant for all of these parameters except for uric acid which is remained 
significantly higher only for men (table 3). 
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Insulin < 17µU/mL 
Table 2. Methods of dosage of the studied parameters. 
2.4 Clinical evaluation 
Body mass index (BMI) was calculated as weight (kg) divided by height (m²). Obesity was 
defined when BMI ≥ 30 kg/m² and overweight when BMI ≥ 25 kg/m² (World Health 
Organization, 1997). 
2.5 Criteria for metabolic syndrome 
Metabolic syndrome (MS) was defined according to the National Cholesterol Education 
Program (NCEP) Adult Treatment Panel (ATP) III modified criteria and required fulfillment 
of at least three of the following five components: body mass index (BMI) ≥ 28.5 kgm2, 
triglycerides ≥ 1.7 mmol/L, high-density lipoprotein cholesterol (c-HDL) < 1.1 mmol/L (in 
men) and < 0.9 mmol/L (in women), blood pressure ≥ 130 ⁄85 mmHg and fasting glucose (≥ 
6.1 mmol/L) (National Cholesterol Education Program, 2002). 
2.6 HOMA-IR determination 
Insulin resistance (IR) was estimated using the Homeostasis Model of Assessment equation: 
HOMA-IR = [fasting insulin (mU/L) × fasting glucose (mmol/L)]/22.5. IR was defined as 
the upper quartile of HOMA-IR. Values above 2.5 were taken as abnormal and reflect 
insulin resistance (Ozdemir et al., 2007). Bipolar patients with diabetes (n = 21) were 
excluded in the HOMA-IR analysis. 
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2.7 Statistical analysis  
Statistical analyses were performed using SPSS 17.0 (SPSS, Chicago, IL, USA). Quantitative 
variables were presented as mean ± SD and comparisons were performed using the 
Student's t test. Qualitative variable comparisons were performed using the Chi-squared test 
(χ2) and Fisher’s exact test (when n < 5). Comparisons between patients and controls in 
biological parameters were performed using analysis of variance (ANOVA) after adjustment 
for potential confounder factors. Odd ratios (ORs) and their 95% condence interval (CI) 
were calculated and adjusted for potential confounder factors by binary logistic regression. 
The statistical significance level was set at p < 0.05. All variables with a p value < 0.25 
between the two studied groups (patients and controls) were considered as potential 
confounder factors for this analysis. 
3. Results 
Table 3 shows the comparisons of biological variables between bipolar I patients and controls. 
 
Biological variables Patients (n = 130) 
Controls 
(n = 175) p p
* 
Triglycerides (mmol/L) 1.95 ± 1.55 1.23 ± 0.81 < 0.001 < 0.001 
Cholesterol (mmol/L) 4.42 ± 0.99 4.37 ± 1.26 0.707 0.856 
c-LDL (mmol/L) 2.14 ± 1.10 2.37 ± 1.38 0.118 0.047 
c-HDL (mmol/L) 
Men (85/102) 1.04 ± 0.37 0.98 ± 0.29 0.192 0.017 
Women (45/73) 1.17 ± 0.36 1.21 ± 0.48 0.542 0.702 
ApoA1 (g/L) 1.20 ± 0.23 1.40 ± 0.67 < 0.001 0.028 
ApoB (g/L) 0.82 ± 0.28 0.83 ± 0.24 0.784 0.777 
ApoB/Apo A1 0.71 ± 0.26 0.65 ± 0.25 0.086 0.314 
Lp(a) (mg/L) 243 ± 223 87 ± 129 < 0.001 < 0.001 
Homocysteine (µmol/L) 15.8 ± 8.9 11.5 ± 5.0 < 0.001 < 0.001 
Vitamin B12 (ng/L) 356 ± 198 360 ± 190 0.837 0.819 
Folate (µg/L) 3.3 ± 0.9 5.1 ± 2.8 < 0.001 <0.001 
Uric acid (µmol/L) 
Men (85/102) 311 ± 99 250 ± 107 0.001 0.005 
Women (45/73) 246 ± 97 197 ± 73 0.012 0.408 
* Lipid profile parameters, folatemia, vitamin B12 and uric acid were adjusted for gender, BMI, cigarette 
smoking, alcoholic beverages, diabetes and hypertension 
*Hcys was adjusted for gender, BMI, cigarette smoking, alcoholic beverages, diabetes, hypertension, 
folatemia and vitamin B12 
Table 3. Comparisons of biological variables between bipolar I patients and controls. 
Compared with controls, patients had significantly higher triglycerides (1.95 ± 1.55 Vs 1.23 ± 
0.81 mmol/L; p < 0.001), Lp(a) (243 ± 223 Vs 87 ± 129 mg/L; p < 0.001), homocysteine levels 
(15.8 ± 8.9 Vs 11.5 ± 5.0 µmol/L; p < 0.001) and uric acid (311 ± 99 Vs 250 ± 107 µmol/L;  
p = 0.001 in men; 246 ± 97 Vs 197 ± 73 µmol/L; p = 0.012 in women), and significantly lower 
ApoA1 (1.20 ± 0.23 Vs 1.40 ± 0.67 g/L; p < 0.001) and folate (3.3 ± 0.9 Vs 5.1 ± 2.8 µg/L;  
p < 0.001) levels. After adjustment for potential confounder factors, these differences 
remained significant for all of these parameters except for uric acid which is remained 
significantly higher only for men (table 3). 
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Table 4 reports the association between bipolar I disorder and cigarette smoking, alcoholic 
beverages, obesity, diabetes, hypertension, lipid profile parameters, hyperhomocysteinemia, 
hypofolatemia, hypovitamin B12 and, hyperuricemia. 
 
Parameters Patients(n = 130)
Controls
(n = 175) OR IC 95% p OR
* p* 
Cigarette 
smoking 52.3% 39.4% 1.68 1.06-2.66 0.025 - - 
Alcoholic 
beverages 13.1% 6.9% 2.04 0.94-4.44 0.067 - - 
Obesity (BMI ≥ 
30 kg/m²) 33.1% 8% 5.68 
2.94-
10.96 < 0.001 8.69 < 0.001 
Diabetes ≥ 6.1 
mmol/L 16.1% 9.7% 1.79 0.90-3.55 0.092 1.60 0.325 
Hypertension  
(≥ 130/85 mm 
Hg) 
5.4% 16% 0.34 0.15-0.78 0.008 0.43 0.136 
Hypercholesterol
emia (≥ 5.17 
mmol/L) 
26.2% 26.9% 0.96 0.57-1.61 0.891 0.99 0.987 
Hypertriglycerid
emia (≥ 1.7 
mmol/L)  
53.1% 17.7% 4.10 2.44-6.90 < 0.001 3.71 < 0.001 
HyperLDL  
(≥ 3.4 mmol/L) 13.1% 26.9% 0.39 0.22-0.73 0.002 0.48 < 0.001 
¥HypoHDL 59.2% 58.3% 1.00 0.63-1.59 0.975 0.78 0.359 
HyperLp(a) 




39.2% 18% 2.80 1.66-4.72 < 0.001 1.95 0.038 
Hypovitamin 
B12  
(< 187 ng/L) 
21.2% 14.9% 0.69 0.34-1.38 0.296 0.62 0.215 
Hypofolatemia 
(< 3.7 µg/L) 66.2% 36.2% 3.44 2.13-5.54 < 0.001 3.69 < 0.001 
£Hyperuricemia 10.8% 4.4% 2.05 0.71-5.91 0.176 1.58 0.439 
* Lipid profile parameters, folatemia, vitamin B12 and uric acid were adjusted for gender, BMI, cigarette 
cigarette smoking, alcoholic beverages, diabetes and hypertension; * Hcys was adjusted for gender, 
BMI, cigarette smoking, alcoholic beverages, diabetes, hypertension, folatemia and vitamin B12; 
*Diabetes was adjusted for gender, BMI, cigarette smoking, alcoholic beverages, hypertension and 
dyslipidemia; *Obesity was adjusted for gender, cigarette smoking, alcoholic beverages, hypertension, 
diabetes and dyslipidemia; *Hypertension was adjusted for gender, cigarette smoking, alcoholic 
beverages, diabetes and dyslipidemia; \ c-HDL <1.1 mmol/L (in men) and < 0 .9 (in women); £ uric 
acid: 210-420 µmol/L (in men) and 150-360 µmol/L ( in women)  
Table 4. Association between bipolar I disorder and cigarette smoking, alcoholic beverages, 
obesity, diabetes, hypertension, lipid profile parameters, hyperhomocysteinemia, 
hypofolatemia, hypovitamin B12, and hyperuricemia. 
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We showed significant association between bipolar I disorder and some cardiovascular risk 
factors: obesity (33.1% Vs 8%, OR = 5.68, IC 95% = 2.94-10.96; p < 0.001), hyperLp(a) (47.7% 
Vs 14.8%, OR = 5.25, IC 95% = 3.04-9.07; p < 0.001), hypertriglyceridemia (53.1% Vs 17.7%, 
OR = 4.10, IC 95% = 2.44-6.90; p < 0.001), hypofolatemia (66.2% Vs 36.2%, OR = 3.44, IC 95% 
= 2.13-5.54; p < 0.001), hyperhomocysteinemia (39.2% Vs 18%, OR = 2.80, IC 95% = 1.66-4.72; 
p < 0.001) and cigarette smoking (52.3% Vs 39.4%, OR = 1.68, IC 95% = 1.06-2.66;  
p = 0,025). After adjustment for potential confounder factors, these associations remained 
significant (table 4). 
Alcoholic beverage, diabetes and hyperuricemia were not significantly associated with this 
illness but we showed that they were more frequents in patients than controls (13.1% Vs 
6.9%, p = 0.067; 16.1% Vs 9.7%, p = 0.325; 10.8% Vs 4.4%, p = 0.439; respectively). 
Additionally, the risk of diabetes and hyperuricemia were respectively multiplied by 1.5 in 
patients (16.1% Vs 9.7%, OR = 1.60, IC 95% = 0.62-4.12; p = 0.325; 10.8% Vs 4.4%, OR = 1.58, 
IC 95% = 0.49-5.08; p = 0.439) and the risk of alcoholic beverage by two (13.1% Vs 6.9%, OR = 
2.04, IC 95% = 0.94-4.44; p = 0.067) (table 4).  
On the contrary, this disease was not associated with hypertension (5.4% Vs 16%, OR = 0.43, 
IC 95% = 0.14-1.29; p = 0.136) nor with hyperLDL (13.1% Vs 26.9%, OR = 0.48, IC 95% = 2.53-
7.95; p < 0.001) (table 4). 
Fig.1. illustrates the receiver Operating Characteristic (ROC) of three index of atherogenicity 
as predictive factors of cardiovascular risk. 
 
 
TG: triglycerides; CT: cholesterol 
Fig. 1. Receiver Operating Characteristic (ROC) of three index of atherogenicity as predictive 
factors of cardiovascular risk. 
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Table 4 reports the association between bipolar I disorder and cigarette smoking, alcoholic 
beverages, obesity, diabetes, hypertension, lipid profile parameters, hyperhomocysteinemia, 
hypofolatemia, hypovitamin B12 and, hyperuricemia. 
 
Parameters Patients(n = 130)
Controls
(n = 175) OR IC 95% p OR
* p* 
Cigarette 
smoking 52.3% 39.4% 1.68 1.06-2.66 0.025 - - 
Alcoholic 
beverages 13.1% 6.9% 2.04 0.94-4.44 0.067 - - 
Obesity (BMI ≥ 
30 kg/m²) 33.1% 8% 5.68 
2.94-
10.96 < 0.001 8.69 < 0.001 
Diabetes ≥ 6.1 
mmol/L 16.1% 9.7% 1.79 0.90-3.55 0.092 1.60 0.325 
Hypertension  
(≥ 130/85 mm 
Hg) 
5.4% 16% 0.34 0.15-0.78 0.008 0.43 0.136 
Hypercholesterol
emia (≥ 5.17 
mmol/L) 
26.2% 26.9% 0.96 0.57-1.61 0.891 0.99 0.987 
Hypertriglycerid
emia (≥ 1.7 
mmol/L)  
53.1% 17.7% 4.10 2.44-6.90 < 0.001 3.71 < 0.001 
HyperLDL  
(≥ 3.4 mmol/L) 13.1% 26.9% 0.39 0.22-0.73 0.002 0.48 < 0.001 
¥HypoHDL 59.2% 58.3% 1.00 0.63-1.59 0.975 0.78 0.359 
HyperLp(a) 




39.2% 18% 2.80 1.66-4.72 < 0.001 1.95 0.038 
Hypovitamin 
B12  
(< 187 ng/L) 
21.2% 14.9% 0.69 0.34-1.38 0.296 0.62 0.215 
Hypofolatemia 
(< 3.7 µg/L) 66.2% 36.2% 3.44 2.13-5.54 < 0.001 3.69 < 0.001 
£Hyperuricemia 10.8% 4.4% 2.05 0.71-5.91 0.176 1.58 0.439 
* Lipid profile parameters, folatemia, vitamin B12 and uric acid were adjusted for gender, BMI, cigarette 
cigarette smoking, alcoholic beverages, diabetes and hypertension; * Hcys was adjusted for gender, 
BMI, cigarette smoking, alcoholic beverages, diabetes, hypertension, folatemia and vitamin B12; 
*Diabetes was adjusted for gender, BMI, cigarette smoking, alcoholic beverages, hypertension and 
dyslipidemia; *Obesity was adjusted for gender, cigarette smoking, alcoholic beverages, hypertension, 
diabetes and dyslipidemia; *Hypertension was adjusted for gender, cigarette smoking, alcoholic 
beverages, diabetes and dyslipidemia; \ c-HDL <1.1 mmol/L (in men) and < 0 .9 (in women); £ uric 
acid: 210-420 µmol/L (in men) and 150-360 µmol/L ( in women)  
Table 4. Association between bipolar I disorder and cigarette smoking, alcoholic beverages, 
obesity, diabetes, hypertension, lipid profile parameters, hyperhomocysteinemia, 
hypofolatemia, hypovitamin B12, and hyperuricemia. 
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We showed significant association between bipolar I disorder and some cardiovascular risk 
factors: obesity (33.1% Vs 8%, OR = 5.68, IC 95% = 2.94-10.96; p < 0.001), hyperLp(a) (47.7% 
Vs 14.8%, OR = 5.25, IC 95% = 3.04-9.07; p < 0.001), hypertriglyceridemia (53.1% Vs 17.7%, 
OR = 4.10, IC 95% = 2.44-6.90; p < 0.001), hypofolatemia (66.2% Vs 36.2%, OR = 3.44, IC 95% 
= 2.13-5.54; p < 0.001), hyperhomocysteinemia (39.2% Vs 18%, OR = 2.80, IC 95% = 1.66-4.72; 
p < 0.001) and cigarette smoking (52.3% Vs 39.4%, OR = 1.68, IC 95% = 1.06-2.66;  
p = 0,025). After adjustment for potential confounder factors, these associations remained 
significant (table 4). 
Alcoholic beverage, diabetes and hyperuricemia were not significantly associated with this 
illness but we showed that they were more frequents in patients than controls (13.1% Vs 
6.9%, p = 0.067; 16.1% Vs 9.7%, p = 0.325; 10.8% Vs 4.4%, p = 0.439; respectively). 
Additionally, the risk of diabetes and hyperuricemia were respectively multiplied by 1.5 in 
patients (16.1% Vs 9.7%, OR = 1.60, IC 95% = 0.62-4.12; p = 0.325; 10.8% Vs 4.4%, OR = 1.58, 
IC 95% = 0.49-5.08; p = 0.439) and the risk of alcoholic beverage by two (13.1% Vs 6.9%, OR = 
2.04, IC 95% = 0.94-4.44; p = 0.067) (table 4).  
On the contrary, this disease was not associated with hypertension (5.4% Vs 16%, OR = 0.43, 
IC 95% = 0.14-1.29; p = 0.136) nor with hyperLDL (13.1% Vs 26.9%, OR = 0.48, IC 95% = 2.53-
7.95; p < 0.001) (table 4). 
Fig.1. illustrates the receiver Operating Characteristic (ROC) of three index of atherogenicity 
as predictive factors of cardiovascular risk. 
 
 
TG: triglycerides; CT: cholesterol 
Fig. 1. Receiver Operating Characteristic (ROC) of three index of atherogenicity as predictive 
factors of cardiovascular risk. 
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The specificity and sensibility of three index of atherogenicity as predictive factors of 
cardiovascular risk are shown in table 5. 
 
Parameters AUC  (95% CI) Cut off Specificity Sensibility p 
TG/HDL 0.65  [0.59-0.71] 1.12 0.63 0.62 < 10
-3 
CT/HDL 0.52  [0.44-0.57] 3.93 0.53 0.57 0.661 
ApoB/ApoA1 0.56  [0.49-0.62] 0.66 0.54 0.55 0.070 
TG: triglycerides; CT: cholesterol; AUC; Area under the curve 
Table 5. Specificity and sensibility of three index of atherogenicity as predictive factors of 
cardiovascular risk 
Fig. 2. Illustrates the Receiver Operating Characteristic (ROC) of Lp(a) and homocysteine as 
predictive factors of cardiovascular risk. 
 
 
Fig. 2. Receiver Operating Characteristic (ROC) of Lp(a) and homocysteine as predictive 
factors of cardiovascular risk. 
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Table 6 reports the specificity and sensibility of Lp(a) and homocysteine as predictive factors 
of cardiovascular risk. 
 
Parameters AUC (95% CI) Cut off Specificity Sensibility p 
Lp(a) (mg/L) 0.80 [0.75-0.85] 168 0.75 0.74 < 10-3 
Homocysteine (µmol/L) 0.52 [0.44-0.57] 13.4 0.60 0.62 < 10-3 
AUC; Area under the curve 
Table 6. Specificity and sensibility of Lp(a) and homocysteine as predictive factors of 
cardiovascular risk. 
TG/HDL ratio and Lp(a) were found as the best predictive factors of cardiovascular risk in 
terms of sensibility (0.62, 0.74; respectively) and specificity (0.63, 0.75; respectively) at 
threshold of 1.12 and 168 mg/L, respectively (tables 5, 6; fig 1, 2). 
The prevalence of metabolic syndrome (modified NCEP-ATP III) and its profile in bipolar I 
patients are shown in table 7. 
 
 N % 
Total of the association of 5 criteria 2 5.9 
     Diabetes, Obesity, Hypertriglyceridemia, Low c-HDL 1  
     Diabetes, Obesity, Low c-HDL, High blood pressure 1  
     Diabetes, Hypertriglyceridemia, Low c-HDL, High blood pressure 1  
Total of the association of 4 criteria 3 8.8 
     Obesity, Hypertriglyceridemia, Low c-HDL 15  
     Diabetes, Low c-HDL, Hypertriglyceridemia 6  
     Obesity, Hypertriglyceridemia, Diabetes 4  
     Obesity, Hypertriglyceridemia, High blood pressure 2  
     Diabetes , High blood pressure, Obesity 1  
     Hypertriglyceridemia, Low c-HDL, High blood pressure 1  
Total of the association of 3 criteria 29 85.3 
At least three or more criteria 34 100 
Table 7. Prevalence of metabolic syndrome (modified NCEP-ATP III) and its profile in 
bipolar I patients. 
The prevalence of metabolic syndrome in bipolar I patients was 26.1% (N = 34). The highest 
prevalence of this syndrome was obtained by the association between obesity, low c-HDL 
and hypertrilyceridemia (44.1 %) (Table 7). 
Table 8 reports the Prevalence of the components of metabolic syndrome in the total sample 
of bipolar I patients. 
 
Criteria N (%) 
c-HDL <  1.1 mmol/L (men) and < 0 .9 (women) 77(59.2) 
TG  ≥ 1.7 mmol/L 69(53.1) 
BMI  ≥  28.5 kg/m² 44 (33.8) 
Fasting blood glucose ≥ 6.1 mmol/L 21 (16.1) 
Blood pressure  ≥ 130/85 mm Hg 7(5.4) 
Table 8. Prevalence of the components of metabolic syndrome in the total sample (N=130). 
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The specificity and sensibility of three index of atherogenicity as predictive factors of 
cardiovascular risk are shown in table 5. 
 
Parameters AUC  (95% CI) Cut off Specificity Sensibility p 
TG/HDL 0.65  [0.59-0.71] 1.12 0.63 0.62 < 10
-3 
CT/HDL 0.52  [0.44-0.57] 3.93 0.53 0.57 0.661 
ApoB/ApoA1 0.56  [0.49-0.62] 0.66 0.54 0.55 0.070 
TG: triglycerides; CT: cholesterol; AUC; Area under the curve 
Table 5. Specificity and sensibility of three index of atherogenicity as predictive factors of 
cardiovascular risk 
Fig. 2. Illustrates the Receiver Operating Characteristic (ROC) of Lp(a) and homocysteine as 
predictive factors of cardiovascular risk. 
 
 
Fig. 2. Receiver Operating Characteristic (ROC) of Lp(a) and homocysteine as predictive 
factors of cardiovascular risk. 
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Table 6 reports the specificity and sensibility of Lp(a) and homocysteine as predictive factors 
of cardiovascular risk. 
 
Parameters AUC (95% CI) Cut off Specificity Sensibility p 
Lp(a) (mg/L) 0.80 [0.75-0.85] 168 0.75 0.74 < 10-3 
Homocysteine (µmol/L) 0.52 [0.44-0.57] 13.4 0.60 0.62 < 10-3 
AUC; Area under the curve 
Table 6. Specificity and sensibility of Lp(a) and homocysteine as predictive factors of 
cardiovascular risk. 
TG/HDL ratio and Lp(a) were found as the best predictive factors of cardiovascular risk in 
terms of sensibility (0.62, 0.74; respectively) and specificity (0.63, 0.75; respectively) at 
threshold of 1.12 and 168 mg/L, respectively (tables 5, 6; fig 1, 2). 
The prevalence of metabolic syndrome (modified NCEP-ATP III) and its profile in bipolar I 
patients are shown in table 7. 
 
 N % 
Total of the association of 5 criteria 2 5.9 
     Diabetes, Obesity, Hypertriglyceridemia, Low c-HDL 1  
     Diabetes, Obesity, Low c-HDL, High blood pressure 1  
     Diabetes, Hypertriglyceridemia, Low c-HDL, High blood pressure 1  
Total of the association of 4 criteria 3 8.8 
     Obesity, Hypertriglyceridemia, Low c-HDL 15  
     Diabetes, Low c-HDL, Hypertriglyceridemia 6  
     Obesity, Hypertriglyceridemia, Diabetes 4  
     Obesity, Hypertriglyceridemia, High blood pressure 2  
     Diabetes , High blood pressure, Obesity 1  
     Hypertriglyceridemia, Low c-HDL, High blood pressure 1  
Total of the association of 3 criteria 29 85.3 
At least three or more criteria 34 100 
Table 7. Prevalence of metabolic syndrome (modified NCEP-ATP III) and its profile in 
bipolar I patients. 
The prevalence of metabolic syndrome in bipolar I patients was 26.1% (N = 34). The highest 
prevalence of this syndrome was obtained by the association between obesity, low c-HDL 
and hypertrilyceridemia (44.1 %) (Table 7). 
Table 8 reports the Prevalence of the components of metabolic syndrome in the total sample 
of bipolar I patients. 
 
Criteria N (%) 
c-HDL <  1.1 mmol/L (men) and < 0 .9 (women) 77(59.2) 
TG  ≥ 1.7 mmol/L 69(53.1) 
BMI  ≥  28.5 kg/m² 44 (33.8) 
Fasting blood glucose ≥ 6.1 mmol/L 21 (16.1) 
Blood pressure  ≥ 130/85 mm Hg 7(5.4) 
Table 8. Prevalence of the components of metabolic syndrome in the total sample (N=130). 
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The prevalence of individual diagnostic components, in the total sample, was as follows: 
59.2% for low c-HDL, 53.1% for hypertriglyceridemia, 33.8% for obesity (BMI ≥ 28.5 kg/m²), 
16.1% for high fasting glucose and 5.4% for hypertension (Table 8). 
Table 9 reports the characteristics of patients with or without metabolic syndrome. 
 
 With MS [N= 34 (26.1%)] 
Without MS 
[N= 96 (73.9%)] p values 
Variables N (% ) N (%)  
Gender 
Men 21 (24.7) 64 (75.3) 0.60 Women 13 (28.9) 32 (71.1) 
Illness episode 
Depressive 4 (19) 17 (81) 0.651a 
 Euthymic 19 (26) 54 (74) Manic 11 (30.5) 25 (69.5) 
Treatment    




Mood stabilizers 24 (26.1) 68 (74.9) 
Lithium 4 (33.3) 8 (66.7) 
Valproic acid 17 (26.6) 47 (73.4) 
Carbamazepine 2 (20) 8 (80) 
Lithium and valproic acid 1 (16.7) 5 (83.3) 
 Mean ± SD Mean ± SD p 
Age (years) 40.4 ± 8.8 37.0 ± 12.7 0.11 
HOMA-IR 6.0 ± 4.3* 2.4 ± 1.7** < 0.001 
Uric acid (µmol/L) 335 ±117 272 ± 92 < 0.001 
* n = 23 (11 diabetic patients were excluded);  
** n = 86 (10 diabetic patients were excluded 
aStatistical analysis was detected using Fisher’s exact test 
Table 9. Characteristics of patients with or without metabolic syndrome.  
We found that gender was not associated with metabolic syndrome, 24.7% in men and 
28.9% in women. As to age, we found that patients with metabolic syndrome were older 
than metabolic syndrome free patients (40.4 ± 8.8 years Vs 37.0 ± 12.7 years), but this 
difference was not significant (table 9).  
Our present data showed that there is no difference in metabolic syndrome prevalence 
between patients receiving antipsychotic and mood stabilizers treatment. However, we 
noted that patients treated with lithium had the highest prevalence of metabolic syndrome 
(table 9). 
Our study failed to show any significant association between metabolic syndrome and illness 
episode, whereas, manic patients had the highest prevalence of this disorder (30.5%) (table 9). 
Patients with metabolic syndrome had significantly higher levels of uric acid (p < 0.001) 
than metabolic syndrome free patients (table 9).  
Concerning HOMA-IR analysis, after diabetic patients exclusion (n = 21), we noted that 
patients with metabolic syndrome had significantly higher levels of HOMA-IR (p < 0.001) 
than metabolic syndrome free patients (table 9). 
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The variations of lipid profile parameters according to the illness episode and therapeutic 
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AVP: valproic acid; Li: lithium 
Table 10. Variations of lipid profile parameters according to the illness episode and 
therapeutic characteristics of bipolar I patients. 
Our study failed to show any significant association between lipid profile parameters, 
illness episode and treatment, while euthymic patients were found to have the highest levels 
of Lp(a) and depressive patients had the highest levels of ApoB/ApoA1 ratio (table 10). 
Additionally, we showed that women taking lithium had the lowest c-HDL values and 
patients taking carbamazepine had the highest values of Lp(a) (table 10).  
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28.9% in women. As to age, we found that patients with metabolic syndrome were older 
than metabolic syndrome free patients (40.4 ± 8.8 years Vs 37.0 ± 12.7 years), but this 
difference was not significant (table 9).  
Our present data showed that there is no difference in metabolic syndrome prevalence 
between patients receiving antipsychotic and mood stabilizers treatment. However, we 
noted that patients treated with lithium had the highest prevalence of metabolic syndrome 
(table 9). 
Our study failed to show any significant association between metabolic syndrome and illness 
episode, whereas, manic patients had the highest prevalence of this disorder (30.5%) (table 9). 
Patients with metabolic syndrome had significantly higher levels of uric acid (p < 0.001) 
than metabolic syndrome free patients (table 9).  
Concerning HOMA-IR analysis, after diabetic patients exclusion (n = 21), we noted that 
patients with metabolic syndrome had significantly higher levels of HOMA-IR (p < 0.001) 
than metabolic syndrome free patients (table 9). 
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The variations of lipid profile parameters according to the illness episode and therapeutic 
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Table 10. Variations of lipid profile parameters according to the illness episode and 
therapeutic characteristics of bipolar I patients. 
Our study failed to show any significant association between lipid profile parameters, 
illness episode and treatment, while euthymic patients were found to have the highest levels 
of Lp(a) and depressive patients had the highest levels of ApoB/ApoA1 ratio (table 10). 
Additionally, we showed that women taking lithium had the lowest c-HDL values and 
patients taking carbamazepine had the highest values of Lp(a) (table 10).  
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Table 11 reports the variations of uric acid, homocysteine, folate and vitamin B12 














(n = 85) 
Women 
(n = 45) 
Patients 
 (n = 130) 311 ± 99 246 ± 97 15.8 ± 8.9 3.3 ± 0.9 356 ± 198 
Illness episode 
Depressive 
 (n = 21) 228 ± 79 205 ± 128 15.2 ± 6.7 3.4 ± 1.3 481 ± 299
a 
Euthymic 
 (n = 73) 309 ± 110 271 ± 95 16.1 ± 10.1 3.4 ± 0.7 322 ± 165 
Manic 
 (n = 36) 327 ± 87 217 ± 57 15.5 ± 7.7 3.3 ± 1.2 352 ± 158 
Treatment 
Valproic acid  
 (n = 64) 328 ± 91 279 ± 109 16.3 ± 10.0 3.5 ± 0.9 361 ± 91 
Lithium 
(n = 12) 331 ± 79 219 ± 88 17.1 ± 12.7 2.8 ± 0.6 399 ± 79 
Carbamazepine 
(n = 10) 278 ± 160 207± 61 16.9 ± 9.4 3.2 ± 0.8 240 ± 160
* 
AVP and Li 
 (n = 6) 343 ± 76 288 15.5 ± 2.9 3.0 ± 0.8 518 ± 236
* 
Antipsychotics 
 (n = 38) 269 ± 96 218 ± 83 14.2 ± 5.9 3.4 ± 1.5 338 ± 233 
AVP: valproic acid; Li: lithium; *Carb Vs AVP/Li, p = 0.04; aF 2-130 = 5.688, p = 0.004 
Table 11. Variations of uric acid, homocysteine, folate and vitamin B12 concentrations 
according to the illness episode and therapeutic characteristics of bipolar I patients. 
We found a significant association between vitamin B12 values and illness episode (F 2-130 = 
5.688, p = 0.004). Manic patients had lower values of this parameter than depressive 
patients. Moreover, we showed that vitamin B12 was significantly associated with the 
therapeutic characteristics. Indeed, patients taking carbamazepine had significantly lower 
values of this parameter than those taking valproic acid and lithium (p = 0.04) (table 11).  
In patients, there was no significant change in homocysteine, folate and uric acid values in 
relation to illness episodes and the treatment, whereas the lowest values of uric acid were 
seen in depressive patients (both in men and women) compared to manic patients and in 
men taking antipsychotics and women taking carbamazepine compared to the other groups 
(table 11). 
The distribution of BMI according to the illness episode and therapeutic characteristics is 
shown in table 12. 
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Our study failed to show any significant association between the BMI and to the illness 
episode and, therapeutic characteristics. However, we found that obesity was more frequent 
in depressive patients than in those with manic episode (38.1% Vs 27.8%). In addition, 
obesity and overweight were more frequent (72% and 52%; respectively) in patients taking 
valproic acid or lithium (table 12). 
 
BMI (kg/m²) BMI ≥ 30 
n = 43 (%) 
25 ≤ BMI < 30 
n = 40 (%) 
BMI  
< 25 
n = 47 (%) Characteristics 
Illness episode 
Depressive 
 (n = 21) 8 (38.1) 4 (19.1) 9 (42.8) 
Euthymic 
 (n = 73) 25 (34.2) 23 (31.5) 25 (34.3) 
Manic 
 (n = 36) 10 (27.8) 13 (36.1) 13 (36.1) 
Treatment 
Valproic acid  
(n = 64) 25 (39.1) 17 (26.6) 22 (34.3) 
Lithium 
(n = 12) 6 (50) 4 (33.3) 2 (16.7) 
Carbamazepine 
 (n = 10) 2 (20) 5 (50) 3 (30) 
AVP and Li  
(n = 6) 2 (33.3) 3 (50) 1 (16.7) 
Antipsychotics  
(n = 38) 8 (21.1) 11 (28.9) 19 (50) 
AVP: valproic acid; Li: lithium 
Table 12. Distribution of BMI according to the illness episode and therapeutic characteristics. 
4. Discussion 
Our study showed that patients had significantly higher levels of triglycerides and Lp(a), 
and significantly lower levels of ApoA1 than control subjects. Furthermore, bipolar I 
disorder was showed to have significant association with hyperLp(a) (47.7% Vs 14.8%, OR = 
4.48, IC 95% = 2.53-7.95; p < 0.001) and hypertriglyceridemia (53.1% Vs 17.7%, OR = 3.71, IC 
95% = 2.13-6.46; p < 0.001).  
In patients, the TG/HDL ratio and Lp(a) were found as the best predictive factors of 
cardiovascular risk in terms of sensibility (0.62, 0.74; respectively) and specificity (0.63, 0.74; 
respectively) at threshold of 1.12 and 168 mg/L, respectively. These results reflect a high 
risk of cardiovascular disease and may explain the high rates of morbidity and mortality in 
this population. Several studies have found mortality rates between 1.5 and 2.5 times higher 
in bipolar patients than the general population. After suicide and accidents, cardiovascular 
and all vascular diseases are the leading causes of death in these patients, with standardized 
mortality ratios ranging from 1.47 to 2.6. (Garcia-Portilla et al., 2009; Sicras et al., 2008). 
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Table 11 reports the variations of uric acid, homocysteine, folate and vitamin B12 
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5.688, p = 0.004). Manic patients had lower values of this parameter than depressive 
patients. Moreover, we showed that vitamin B12 was significantly associated with the 
therapeutic characteristics. Indeed, patients taking carbamazepine had significantly lower 
values of this parameter than those taking valproic acid and lithium (p = 0.04) (table 11).  
In patients, there was no significant change in homocysteine, folate and uric acid values in 
relation to illness episodes and the treatment, whereas the lowest values of uric acid were 
seen in depressive patients (both in men and women) compared to manic patients and in 
men taking antipsychotics and women taking carbamazepine compared to the other groups 
(table 11). 
The distribution of BMI according to the illness episode and therapeutic characteristics is 
shown in table 12. 
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Our study failed to show any significant association between the BMI and to the illness 
episode and, therapeutic characteristics. However, we found that obesity was more frequent 
in depressive patients than in those with manic episode (38.1% Vs 27.8%). In addition, 
obesity and overweight were more frequent (72% and 52%; respectively) in patients taking 
valproic acid or lithium (table 12). 
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4. Discussion 
Our study showed that patients had significantly higher levels of triglycerides and Lp(a), 
and significantly lower levels of ApoA1 than control subjects. Furthermore, bipolar I 
disorder was showed to have significant association with hyperLp(a) (47.7% Vs 14.8%, OR = 
4.48, IC 95% = 2.53-7.95; p < 0.001) and hypertriglyceridemia (53.1% Vs 17.7%, OR = 3.71, IC 
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In patients, the TG/HDL ratio and Lp(a) were found as the best predictive factors of 
cardiovascular risk in terms of sensibility (0.62, 0.74; respectively) and specificity (0.63, 0.74; 
respectively) at threshold of 1.12 and 168 mg/L, respectively. These results reflect a high 
risk of cardiovascular disease and may explain the high rates of morbidity and mortality in 
this population. Several studies have found mortality rates between 1.5 and 2.5 times higher 
in bipolar patients than the general population. After suicide and accidents, cardiovascular 
and all vascular diseases are the leading causes of death in these patients, with standardized 
mortality ratios ranging from 1.47 to 2.6. (Garcia-Portilla et al., 2009; Sicras et al., 2008). 
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The exact mechanisms increasing the incidence of cardiovascular risk in bipolar patients 
remain to be clarified, but they possibly include industrialisation, stress, lack of exercise, 
dietary lipids (that is, omega-3 fatty acid deficiency), increasing incidence of smoking and 
alcohol consumption and other factors (Ezzaher et al., 2010). These hypotheses will be, in 
part, justified later in this study.  
Several investigators have been hypothesized that abnormalities in fatty acid composition 
may play a role in psychiatric disorders (Horrobin & Bennett, 1999). Maes et al. (1996, 1999) 
reported that patients with major depression had a significantly elevated ratio of 
ecosapentaenoic acid (EPA; 20: 5n-3)/docosahexaenoic acid (DHA; 22: 6n-3), lower level of 
EPA and total n-3 Omega-3 polyunsaturated fatty acids, in both serum cholesteryl esters 
and phospholipids when compared to patients with minor depression and normal controls. 
Similar findings were revealed in terms of fatty acid compositions of the erythrocyte 
membrane (Adams et al., 1996; Edwards et al., 1998; Peet et al., 1998; Chiu et al., 2003). 
Moreover, many prospective and case-control studies have shown a positive association 
between serum triglycerides and coronary artery disease risk and demonstrated the 
importance of fasting triglycerides level as an independent risk factor. A number of clinical 
trials including the Framingham Heart Study have concluded that a low HDL cholesterol 
level predicts the risk for coronary artery disease independently of other risk factors. Each 1 
mg/dL decrease in HDL cholesterol has been shown to increase risk for coronary artery 
disease by 2% in men and 3% in women. The Veterans Affairs High-Density Lipoprotein 
Cholesterol Interventional Trial, investigating the impact of fibrate therapy on 
cardiovascular risk, demonstrated that 6% increase in HDL cholesterol was associated with 
a 22% decrease in coronary events (Kabakci et al., 2008). In addition, Lp(a) has been shown 
to be an independent risk factor for atherosclerosis (Hakim et al., 2008) and has been found 
to exert a broad variety of pro-atherogenic and pro-thrombotic properties (von Eckardstein 
et al., 2001). Elevated plasma Lp(a) has been shown also to be associated with premature 
cardiovascular disease, premature cerebrovascular disease and premature peripheral 
vascular disease (Valentine et al., 1996). 
The underlying mechanism for the altered lipid status in bipolar patients is unclear. A 
possible explanation might be found in the patient’s nutritional status, the decrease in 
physical activity and the medications used (Ezzaher et al., 2010). Additionally, Chung et al. 
(2007) reported that bipolar disorder is associated with perturbations in lipid profile which 
play an important role in the pathophysiology of mood disorders, particularly in bipolar 
disorders. Indeed, cholesterol is one component of circulating lipoprotein particles that, 
besides handling cholesterol, carries micronutrients such as vitamins A and E as well as 
triglycerides and phospholipids. The latter compounds give rise to substrates such as fatty 
acids and choline, which are used in both the structural lipids of neuronal membranes and 
intercellular communication. Therefore, higher levels of one or more compounds of 
lipoprotein particles circulating in the bloodstream may produce subtle but measurable 
enhancements of mental processes by influencing the supply of fat-soluble micronutrients, 
specific fatty acids, or structural lipids (Ezzaher et al., 2010). 
Our study failed to found any significant association between lipid profile parameters and 
illness episode, while euthymic patients were found to have the highest levels of Lp(a). 
Additionally, depressive patients had the highest levels of ApoB/Apo A1 ratio. However, 
some authors (Sagud et al., 2009) showed that serum cholesterol and LDL values were 
significantly lower in manic patients and others (Chung et al., 2007) showed that there 
was no difference in mean serum level of cholesterol or triglycerides among patients with 
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manic, mixed, or depressive episode. These differences could be due to ethnicity and 
eating habits. 
About therapeutic characteristics, any significant association was shown between lipid 
profile parameters and treatment, while, women taking lithium had the lowest c-HDL 
values and patients taking carbamazepine had the highest values of Lp(a). The 
mechanism(s) by which these drugs exert weight gain are not well known, but are 
presumed to involve increased energy intake (e.g., overeating), decreased energy 
expenditure (e.g., reduced resting metabolic rate, reduced physical activity, or reduced diet-
induced thermogenesis), or a combination of the two (Malhotra & McElroy, 2002). 
Additionally, we found that the prevalence of metabolic syndrome was 26.1% among 
patients, 24.7% in men and 28.8% in women. These prevalences were definitely higher than 
those reported in the Tunisian general population (13% in men and 18% in women) using a 
previous criteria (Bouguerra et al., 2006).  
Compared with other studies, the prevalence of metabolic syndrome in our patients is 
included between those in Spanish patients (22.4%), Italian patients (25.3%) and US patients 
(30%) (Garcia-Portilla et al., 2008; Salvi et al., 2008; Fagiolini et al., 2005). The increasing 
prevalence of metabolic syndrome is important because it confers greater cardiovascular 
morbidity and mortality. Prospective observational studies have demonstrated an 
association between metabolic syndrome and development of type II diabetes (Hanson et 
al., 2002; Resnick et al., 2003; Klein et al., 2002; Sattar et al., 2003), cardiovascular disease 
(Lakka et al., 2002; Kip et al., 2004), and stroke (Kurl et al.,2006). 
Our study showed that the highest prevalence of metabolic syndrome was obtained by the 
association between obesity, low c-HDL and hypertriglyceridemia. Moreover, the most 
individual components of this syndrome, in the total sample of patients, was low c-HDL 
(59.2%), hypertriglyceridemia (53.1%) and obesity (BMI ≥ 28.5 kg/m²) (33.8%), confirming in 
part the higher risk of dyslipidemia and obesity in bipolar I patients and in other hand the 
higher risk of cardiovascular disease in this population.  
We found no significant difference in the prevalence of metabolic syndrome among gender 
and age. This is in line with results reported by Yumru et al., (2007).  
We noted that there was no significant change in the prevalence of metabolic syndrome in 
relation to illness episode; however, manic patients had the highest prevalence. This may 
explain the high risk of cardiovascular disease in manic patients compared with depressive 
one (Murray et al., 2009). Additionally, Angst et al. (2002) showed that individuals with 
bipolar I disorder are at greater risk for cardiovascular mortality than individuals with 
bipolar II disorder. However, the difference in cardiovascular mortality between the two 
bipolar subtypes reflects the manic symptom burden, which predicts cardiovascular 
mortality independently of diagnosis and cardiovascular risk factors at intake. The results 
suggest that mania, either directly (through factors intrinsic to illness) or indirectly (through 
other mediators or associated variables), may itself influence cardiovascular disease. 
Our study failed to show any significant association between metabolic syndrome and 
treatment. However, we noted that patients treated with lithium had the highest prevalence 
of metabolic syndrome. The increased risk to develop metabolic syndrome during treatment 
with lithium is in part related to its propensity to induce weight gain. According to Casey, 
lithium has been shown to stimulate appetite and increase calorie intake through different 
mechanisms. 
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manic, mixed, or depressive episode. These differences could be due to ethnicity and 
eating habits. 
About therapeutic characteristics, any significant association was shown between lipid 
profile parameters and treatment, while, women taking lithium had the lowest c-HDL 
values and patients taking carbamazepine had the highest values of Lp(a). The 
mechanism(s) by which these drugs exert weight gain are not well known, but are 
presumed to involve increased energy intake (e.g., overeating), decreased energy 
expenditure (e.g., reduced resting metabolic rate, reduced physical activity, or reduced diet-
induced thermogenesis), or a combination of the two (Malhotra & McElroy, 2002). 
Additionally, we found that the prevalence of metabolic syndrome was 26.1% among 
patients, 24.7% in men and 28.8% in women. These prevalences were definitely higher than 
those reported in the Tunisian general population (13% in men and 18% in women) using a 
previous criteria (Bouguerra et al., 2006).  
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included between those in Spanish patients (22.4%), Italian patients (25.3%) and US patients 
(30%) (Garcia-Portilla et al., 2008; Salvi et al., 2008; Fagiolini et al., 2005). The increasing 
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association between obesity, low c-HDL and hypertriglyceridemia. Moreover, the most 
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(59.2%), hypertriglyceridemia (53.1%) and obesity (BMI ≥ 28.5 kg/m²) (33.8%), confirming in 
part the higher risk of dyslipidemia and obesity in bipolar I patients and in other hand the 
higher risk of cardiovascular disease in this population.  
We found no significant difference in the prevalence of metabolic syndrome among gender 
and age. This is in line with results reported by Yumru et al., (2007).  
We noted that there was no significant change in the prevalence of metabolic syndrome in 
relation to illness episode; however, manic patients had the highest prevalence. This may 
explain the high risk of cardiovascular disease in manic patients compared with depressive 
one (Murray et al., 2009). Additionally, Angst et al. (2002) showed that individuals with 
bipolar I disorder are at greater risk for cardiovascular mortality than individuals with 
bipolar II disorder. However, the difference in cardiovascular mortality between the two 
bipolar subtypes reflects the manic symptom burden, which predicts cardiovascular 
mortality independently of diagnosis and cardiovascular risk factors at intake. The results 
suggest that mania, either directly (through factors intrinsic to illness) or indirectly (through 
other mediators or associated variables), may itself influence cardiovascular disease. 
Our study failed to show any significant association between metabolic syndrome and 
treatment. However, we noted that patients treated with lithium had the highest prevalence 
of metabolic syndrome. The increased risk to develop metabolic syndrome during treatment 
with lithium is in part related to its propensity to induce weight gain. According to Casey, 
lithium has been shown to stimulate appetite and increase calorie intake through different 
mechanisms. 
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HOMA-IR is significantly higher in patients with metabolic syndrome than others. This 
increase in HOMA-IR values reflects an insulin resistance and is associated with two to 
three fold increases in cardiovascular disease independent of classical risk factors (Toalson 
et al., 2004). In addition, uric acid levels were significantly higher in patients with metabolic 
syndrome. According to Vuorinen-Markkola et al. (1994), hyperuricemia forms another 
consistent feature of the metabolic syndrome what led to the suggestion of uric acid being a 
new component of the syndrome. 
In addition, Chien et al., (2008) reported that metabolic syndrome induces high oxidative 
stress and the accompanying hyperuricemia worsens this stress. Furthermore, uric acid 
stimulates vascular smooth muscle proliferation, induces endothelial dysfunction, decreases 
endothelial nitric oxid production, and consequently, makes peripheral tissue resistant to 
insulin effects and results in endothelial dysfunction (Chien et al., 2008). High levels of uric 
acid are associated with increased renal glomerular pressure and sodium reabsorption, 
enhanced by high insulin concentrations (Alkerwi et al., 2009). In addition, hyperuricemia 
was associated with insulin resistance markers, including triglycerides, microalbuminuria 
and impaired glucose tolerance. These disturbances contribute to increase cardiovascular 
risk (Chien et al., 2008). This insulin- resistance causes steatosis, which is associated with 
hyper secretion of hepatic enzymes (Fromenty et al., 2004). 
In men, uric acid was significantly higher in patients than controls. Additionally, the risk 
of hyperuricemia in bipolar I patients was approximately multiplied by 1.5 (10.8% Vs 
4.4%, OR = 1.58, IC 95% = 0.49-5.08; p = 0.439). Many, but not all, epidemiological studies 
have suggested that high plasma uric acid is a risk factor for cardiovascular diseases. This 
raised level of plasma uric acid, parallel to an increased risk of cardiovascular diseases, 
could be either primary or secondary to the underlying causes of the cardiovascular 
diseases. However, the specific role of plasma uric acid in this constellation remains 
uncertain, although it may be involved in the platelet adhesiveness, aggregation, or 
inflammation and it may be implicated in the genesis of hypertension. In contrast, there is 
some evidence that the increase of plasma uric acid is protective against the 
cardiovascular diseases, since uric acid acts as an endogenous antioxidant, and the higher 
plasma uric acid levels found in cardiovascular diseases patients suggest that any 
protective antioxidant effect of uric acid is hidden by other negative effects in these 
pathogeneses (Haj mouhamed et al., 2010). 
Additionally, Torres et al. (2007), reported that hyperuricemia which implicated in the 
oxidative stress plays an important role in the pathophysiology of bipolar disorders. The 
idea that the purinergic system might be involved in bipolar disorder dates back to 
Kraepelin, who was the first to describe an association between manic symptoms, uric acid 
excretion, hyperuricemia, and gout. In fact, the purinergic system modulates sleep, motor 
activity, cognition, attention, behavior, and mood. Even in the absence of a psychiatric 
diagnosis, individuals with higher uric acid levels are more likely to show higher drive, 
disinhibition, hyperthymia, or irritable temperament (Lorenzi et al., 2010). Similarly, 
diseases characterized by purinergic turnover dysfunction and uric acid overproduction 
(e.g., Lesch–Nyhan syndrome) are associated with impulsive/aggressive behavior, 
disinhibition, and increased sexual drive (Salvadore et al., 2010).  
Among clinical and therapeutic characteristics, we found that there was no significant 
change in uric acid values in relation to illness episodes and the treatment. This finding is 
not in agreement with the previous studies that reported that plasma uric acid levels were 
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higher only during the manic phase of bipolar disorder but not during the depressive or 
euthymic phases (De Berardis et al., 2008). Additionally, lithium was found to low uric acid 
plasma levels and to have uricosuric effects in mania. Carbamazepine and phenytoin 
similarly decreased uric acid levels; in contrast, valproate appeared to have the opposite 
effect. However, it is important to note that the effect of these drugs on uric acid levels in 
relationship to clinical improvement in patients with bipolar disorder has not been 
systematically evaluated (Salvadore et al., 2010). 
Compared with controls, patients had significantly higher levels of homocysteine and 
significantly lower levels of folatemia. Additionally, significant associations were showed 
between bipolar I disorder and hyperhomocysteinemia (39.2% Vs 18%, OR = 1.95, IC 95% = 
1.04-3.69; p = 0.038) and hypofolatemia (66.2% Vs 36.2%, OR = 3.69, IC 95% = 2.20-6.19; p < 
0.001). Homocysteine is an intermediary metabolite of the essential amino acid methionine. 
Folate and vitamin B12 are required for remethylation of homocysteine to methionine 
(Hankey & Eikelboom, 1999).  
According to Reynolds (2006), hyperhomocysteinaemia has long been identified as a risk 
factor for vascular disease and the lowering of homocysteine concentrations by the 
treatment with folic acid, or possibly vitamin B12 and vitamin B6 which might reduce the 
risk of both cardiovascular and cerebrovascular diseases. Moreover, the association between 
increased circulating homocysteine concentrations and premature vascular thrombotic 
events in individuals with hereditary homocystinuria is well established. This process may 
include platelet activation, smooth muscle cell proliferation, and enhanced leukocyte 
binding to the endothelium. In recent years, a relationship between milder degrees of 
hyperhomocysteinaemia and vascular disease has emerged, and this has been the subject of 
intense research. Hyperhomocysteinemia can be caused by a wide range of disorders, the 
most important of which are genetic defects of the enzymes involved in homocysteine 
metabolism and/or deficiencies of their co-factors: folate (former vitamin B9), vitamin B12 
and vitamin B6 (Haj mouhamed et al., 2011).  
Our study showed a significant association between bipolar I disorder and 
hyperhomocysteinemia. The exact mechanisms underlying the hyperhomocysteinemia in 
this disease are not completely understood and controversed among studies. Several 
hypotheses have been postulated including nutritional folate and vitamin B deficiency, 
and/or reduced glomerular filtration rate in bipolar patients (Vuksan-Ćusa et al., 2011). En 
effect, we found a significant association between this disease and hypofolatemia. 
Furthermore, some authors (Atmaca et al., 2005) showed that at a high concentration, 
homocysteine is considered to be a neurotoxic substance, causing activation of NMDA (N-
methyl D-aspartate) receptors and leading to excitotoxicity. By impairing the neural 
plasticity and promoting neuronal degeneration, homocysteine could contribute to the 
pathogenesis of neurodegenerative and psychiatric disorders (Ipcioglu et al., 2008). 
Additionally, homocysteine is a methyl donor when activated to S-adenosylmethionine. So 
aberrant DNA methylation due to hyperhomocysteinemia also may be involved in the 
pathogenesis of bipolar disorder as well as schizophrenia (Mill et al., 2008). 
In the other hand, folate appears to influence the synthesis rate of tetrahydrobiopterin, a 
cofactor in the hydroxylation of phenylalanine and tryptophan, rate-limiting steps in the 
biosynthesis of dopamine, norepinephrine, and serotonin, neurotransmitters postulated to 
play a role in the monoamine hypothesis of affective disorders. In addition, methyl 
tetrahydrofolate has been shown to bind to presynaptic glutamate receptors, where it may 
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higher only during the manic phase of bipolar disorder but not during the depressive or 
euthymic phases (De Berardis et al., 2008). Additionally, lithium was found to low uric acid 
plasma levels and to have uricosuric effects in mania. Carbamazepine and phenytoin 
similarly decreased uric acid levels; in contrast, valproate appeared to have the opposite 
effect. However, it is important to note that the effect of these drugs on uric acid levels in 
relationship to clinical improvement in patients with bipolar disorder has not been 
systematically evaluated (Salvadore et al., 2010). 
Compared with controls, patients had significantly higher levels of homocysteine and 
significantly lower levels of folatemia. Additionally, significant associations were showed 
between bipolar I disorder and hyperhomocysteinemia (39.2% Vs 18%, OR = 1.95, IC 95% = 
1.04-3.69; p = 0.038) and hypofolatemia (66.2% Vs 36.2%, OR = 3.69, IC 95% = 2.20-6.19; p < 
0.001). Homocysteine is an intermediary metabolite of the essential amino acid methionine. 
Folate and vitamin B12 are required for remethylation of homocysteine to methionine 
(Hankey & Eikelboom, 1999).  
According to Reynolds (2006), hyperhomocysteinaemia has long been identified as a risk 
factor for vascular disease and the lowering of homocysteine concentrations by the 
treatment with folic acid, or possibly vitamin B12 and vitamin B6 which might reduce the 
risk of both cardiovascular and cerebrovascular diseases. Moreover, the association between 
increased circulating homocysteine concentrations and premature vascular thrombotic 
events in individuals with hereditary homocystinuria is well established. This process may 
include platelet activation, smooth muscle cell proliferation, and enhanced leukocyte 
binding to the endothelium. In recent years, a relationship between milder degrees of 
hyperhomocysteinaemia and vascular disease has emerged, and this has been the subject of 
intense research. Hyperhomocysteinemia can be caused by a wide range of disorders, the 
most important of which are genetic defects of the enzymes involved in homocysteine 
metabolism and/or deficiencies of their co-factors: folate (former vitamin B9), vitamin B12 
and vitamin B6 (Haj mouhamed et al., 2011).  
Our study showed a significant association between bipolar I disorder and 
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this disease are not completely understood and controversed among studies. Several 
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and/or reduced glomerular filtration rate in bipolar patients (Vuksan-Ćusa et al., 2011). En 
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Furthermore, some authors (Atmaca et al., 2005) showed that at a high concentration, 
homocysteine is considered to be a neurotoxic substance, causing activation of NMDA (N-
methyl D-aspartate) receptors and leading to excitotoxicity. By impairing the neural 
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pathogenesis of neurodegenerative and psychiatric disorders (Ipcioglu et al., 2008). 
Additionally, homocysteine is a methyl donor when activated to S-adenosylmethionine. So 
aberrant DNA methylation due to hyperhomocysteinemia also may be involved in the 
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In the other hand, folate appears to influence the synthesis rate of tetrahydrobiopterin, a 
cofactor in the hydroxylation of phenylalanine and tryptophan, rate-limiting steps in the 
biosynthesis of dopamine, norepinephrine, and serotonin, neurotransmitters postulated to 
play a role in the monoamine hypothesis of affective disorders. In addition, methyl 
tetrahydrofolate has been shown to bind to presynaptic glutamate receptors, where it may 
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potentially modulate the release of other neurotransmitters, including the monoamines 
(Atmaca et al., 2005). 
Moreover, some studies showed that lower folatemia in patients with psychiatric disorders 
can be due to their nutritional status (Reif et al., 2005). Indeed, poor appetite as a symptom 
of bipolar disorder could lead to decreased intake of B vitamins which could then lead to 
elevated homocysteine concentrations (Tolmunen et al., 2004). 
We found a significant association between vitamin B12 values and illness episode. Manic 
patients had lower values of this parameter than depressive patients. This can be explained 
by the eating habits of bipolar patients. Indeed, Parikh et al. (2000) found that manic episode 
is often associated with weight loss. 
About therapeutic characteristics, we showed that only vitamin B12 was significantly 
associated with the medication use. Indeed, patients taking carbamazepine had significantly 
lower values of this parameter than those taking valproic acid and lithium. These findings 
are not in agreement with others studies. In fact, Derkes and Westphal (2005) showed that 
carbamazepine can cause elevated homocysteine concentrations. Although, according to 
Ozbek et al (2008), homocysteine, folate and vitamin B12 were not related to drug usage. 
Additionally, Osher et al (2008) reported that there were no significant differences in 
homocysteine levels between patients receiving versus not receiving lithium, neuroleptic or 
valproate. However, Sener et al. (2006) suggested that carbamazepine, as enzyme inducer, 
can directly modulate the activity of different liver enzymes. Liver enzyme induction may 
cause depletion of the cofactor involved, folic acid, pyridoxal 5’-phosphate and vitamin B12, 
leading to the alterations in homocysteine status.  
Our study showed that bipolar I patients are so much more likely to be smokers than 
controls (52.3% Vs 39.4%, OR = 1.68, IC 95% = 1.06-2.66; p = 0.025). An association between 
smoking and bipolar I disorder has been established and prevalence rates for lifetime and 
current smoking have been shown to be as high as 82.5% and 68.8% respectively (Lasser et 
al., 2000). The possible explanations for the high rates of smoking include an increased 
genetic vulnerability, a greater susceptibility to addiction because of a greater subjective 
experience of reward or pleasure, or that tobacco helps relieve some of the symptoms 
related to a behavioural disorder. For example, cigarette smoking may be an attempt to self-
medicate symptoms of depression, anxiety, boredom or loneliness. Other possible 
explanations for continuing to smoke include increased withdrawal symptoms and reduced 
side effects from psychiatric medication (Williams & Ziedonis, 2004). Additionally, it has 
been reported that nicotine stimulates the brain to release dopamine, which is associated 
with pleasurable feelings, and smokers quickly develop regular smoking patterns. 
Eventually, smokers need increasing levels of nicotine to feel ‘normal’. In the other hand, 
cigarette smoking is known to contribute to many diseases, including cancer, chronic 
obstructive pulmonary disease, stroke, cardiovascular diseases, and peptic ulcers. 
Investigators have attempted to elucidate the mechanisms of the pathogenesis associated 
with cigarette smoking, but the conclusions were not consistent. A basic hypothesis is that 
free radicals cause oxidative damage to macromolecules such as lipids, proteins, and DNA. 
Therefore, these radicals play an important role in the pathogenesis of these diseases (Haj 
mouhamed et al., 2010). 
In this study, the prevalence of obesity is higher in patients with bipolar I disorder than in 
controls. Moreover, the risk of obesity in these patients is approximately multiplied by nine 
(33.1% Vs 8%, OR = 8.69, IC 95% = 3.61-20.87; p < 0.001).  
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In bipolar I patients, the prevalences of obesity and overweight were respectively 33.1 % and 
30.7 %. These findings were similar to those reported by Elmslie et al (2000) and Fagiolini et 
al (2002) (36 % and 32 %). However, higher values were reported by McElroy et al (2004) (44 
% and 20 %).  
For this population, we found that the prevalence of obesity greatly exceeded that found in 
controls (12.3%) and in the general population (20%) (Haddad et al., 2006). Obesity in 
patients with bipolar I disorder thus constitutes a major public health problem and suggests 
that the development and testing of specific interventions that target the obesity epidemic in 
this particular population are urgently needed. Bipolar disorder and obesity both have 
tremendous impact on the physical and mental well-being of affected individuals. 
Therefore, both illnesses should be treated with a coordinated intensive and multifaceted 
treatment (Fagiolini et al., 2003). 
Moreover, the risk of obesity in these patients is approximately multiplied by nine (33.1% Vs 
8%, OR = 8.69, IC 95% = 3.61-20.87; p < 0.001). This could be one of the missing factors in 
understanding the relationship between psychiatric disorders and increased cardiovascular 
risk. In fact, some studies have reported that psychiatric disorders, particularly bipolar 
disorder, are significantly associated with adverse cardiovascular events and coronary heart 
disease (Garcia-Portilla et al., 2009). The mechanisms through which obesity leads to 
coronary heart disease remain hotly debated, but the accumulation, particularly, of visceral 
fat is widely favoured as the primary mechanism, leading, through the release of fatty acids 
and other mediators, to insulin resistance, dyslipidaemia, and a pro-inflammatory state. 
However, obesity in general, and central obesity in particular (ie. excessive visceral intra-
abdominal fat) have been under-recognised as risk factors for coronary heart disease in the 
population, where most attention has been placed on smoking and cholesterol (Pinkney, 
2001).  
According to Raji et al (2009), the cardiovascular afflictions including obesity, diabetes, 
hypertension and stroke increase the risk for cognitive decline and dementia, but it is 
unknown whether these factors, specifically obesity and type 2 diabetes mellitus, are 
associated with specific patterns of brain atrophy. Obesity and type 2 diabetes mellitus may 
amplify the risk for dementia by worsening cerebral atrophy even in cognitively intact 
individuals, raising their vulnerability to future Alzheimer’s disease neuropathology. 
The same authors, mostly in subjects younger than 65 years, suggest also that increased 
body tissue fat content (adiposity) is correlated with atrophy in the temporal cortex, frontal 
lobes, putamen, caudate, precuneus, thalamus, and white matter. It is unknown, but of great 
interest, whether high tissue fat content, as measured by BMI, is associated with differences 
in brain structure in cognitively normal elderly (Raji et al., 2009). 
Additionally, some studies showed that obesity has psychosocial consequences, including 
discrimination and stigmatization, which may contribute to the severity of bipolar disorder 
by negatively impacting patients’ general physical health and functioning, quality of life, 
self-esteem, and psychological well-being. Obese patients have an increased risk of sleep 
apnea, which causes sleep disruptions and may lead to mood destabilization in patients 
with bipolar disorder. Obesity may also impact effectiveness of pharmacotherapies by 
altering the distribution and elimination of medications. Truncal obesity, which is most 
common, increases the risk of type 2 diabetes mellitus, dyslipidemia, hypertension, stroke, 
ischemic heart disease, and early death (Cheymol, 2000; Fagiolini et al., 2003; Plante & 
Winkelman, 2008).  
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risk. In fact, some studies have reported that psychiatric disorders, particularly bipolar 
disorder, are significantly associated with adverse cardiovascular events and coronary heart 
disease (Garcia-Portilla et al., 2009). The mechanisms through which obesity leads to 
coronary heart disease remain hotly debated, but the accumulation, particularly, of visceral 
fat is widely favoured as the primary mechanism, leading, through the release of fatty acids 
and other mediators, to insulin resistance, dyslipidaemia, and a pro-inflammatory state. 
However, obesity in general, and central obesity in particular (ie. excessive visceral intra-
abdominal fat) have been under-recognised as risk factors for coronary heart disease in the 
population, where most attention has been placed on smoking and cholesterol (Pinkney, 
2001).  
According to Raji et al (2009), the cardiovascular afflictions including obesity, diabetes, 
hypertension and stroke increase the risk for cognitive decline and dementia, but it is 
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associated with specific patterns of brain atrophy. Obesity and type 2 diabetes mellitus may 
amplify the risk for dementia by worsening cerebral atrophy even in cognitively intact 
individuals, raising their vulnerability to future Alzheimer’s disease neuropathology. 
The same authors, mostly in subjects younger than 65 years, suggest also that increased 
body tissue fat content (adiposity) is correlated with atrophy in the temporal cortex, frontal 
lobes, putamen, caudate, precuneus, thalamus, and white matter. It is unknown, but of great 
interest, whether high tissue fat content, as measured by BMI, is associated with differences 
in brain structure in cognitively normal elderly (Raji et al., 2009). 
Additionally, some studies showed that obesity has psychosocial consequences, including 
discrimination and stigmatization, which may contribute to the severity of bipolar disorder 
by negatively impacting patients’ general physical health and functioning, quality of life, 
self-esteem, and psychological well-being. Obese patients have an increased risk of sleep 
apnea, which causes sleep disruptions and may lead to mood destabilization in patients 
with bipolar disorder. Obesity may also impact effectiveness of pharmacotherapies by 
altering the distribution and elimination of medications. Truncal obesity, which is most 
common, increases the risk of type 2 diabetes mellitus, dyslipidemia, hypertension, stroke, 
ischemic heart disease, and early death (Cheymol, 2000; Fagiolini et al., 2003; Plante & 
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Dyslipidemia - From Prevention to Treatment 
 
340 
In addition, obesity was more frequent in depressive patients than in those with manic 
episode (38.1% Vs 27.8%). Previous studies reported that patients who had depressive 
symptomatology were more likely to have excessive caloric and cholesterol intake, to smoke 
and to be inactive than non-depressed subjects. Another explanation might involve 
biological mechanisms: it is ascertained that hypothalamic–pituitary- adrenal (HPA) axis 
dysregulation and high cortisol blood levels lead to increased visceral fat. HPA axis 
dysregulation has been a common finding in both unipolar and bipolar disorders; recently, 
some studies reported that increased cortisol blood levels correlated to the amount of intra-
abdominal fat in major depression (Maina et al., 2008). 
About therapeutic characteristics, we found that obesity and overweight were more 
frequent (72% and 52%; respectively) in patients taking valproic acid or lithium. These 
findings are in line with those reported by De Hert et al. (2011). Moreover, Casey et al. 
(2005) reported that lithium have been shown to stimulate appetite through different 
mechanisms. The “carbohydrate craving” that is thought to be one of the mechanisms of 
increased calorie intake in people taking lithium is well known. In addition, it is believed 
that valproate also stimulates weight gain through a variety of mechanisms, especially the 
development of insulin resistance and diabetes mellitus type 2. In this line, our study found 
that this type of diabetes is frequent in patients (16.2%). Additionally, the risk of diabetes is 
multiplied by 1.5 in patients (16.2% Vs 9.7%, OR = 1.60, IC 95% = 0.62-4.12; p = 0.325).  
Previous studies suggested that patients with both bipolar disorder and comorbid diabetes 
have more lifetime psychiatric hospitalizations than patients with bipolar patients without 
diabetes. The association between these two disorders underscores the importance of 
screening for diabetes in patients with bipolar illness, particularly because early detection 
and initiation of treatment to control glycemia may prevent diabetes-related complications. 
Moreover, other studies have demonstrated cerebrovascular lesions involving small 
intraparenchymal cerebral vessels and focal infarctions in patients with diabetes. These 
lesions predominantly occur in areas providing blood supply to the base of the pons, 
thalamus, and basal ganglia. Diabetes has been implicated as a risk factor for subcortical 
white-matter lesions observed on magnetic resonance imaging (MRI) scans; similar MRI 
findings have been noted in patients with bipolar disorder. Cerebral microvascular disease 
may lead to greater frequency of manic episodes, another reason to minimize diabetes-
related complications in patients with comorbid bipolar disorder (Cassidy et al., 1999; 
Holman et al., 2008). 
Alcoholic beverage was not significantly associated with this illness but we showed that it 
was more frequent in patients than controls (13.1% Vs 6.9%, OR = 2.04, IC 95% = 0.94-4.44; p 
= 0.067). It has been well documented that bipolar disorder and alcoholism commonly co-
occur. In fact, the lifetime prevalence of alcohol abuse and drug abuse in people with bipolar 
disorder are known to be three to nine times more frequent that of the general population 
(Merikangas et al., 2007; Regier et al., 1990; ten Have et al., 2002).  
Additionally, some studies showed that the feelings of depression and anxiety associated 
with bipolar can be a factor that leads to alcoholism. People with bipolar disorder may use 
alcohol or other drugs to self medicate these feelings, especially in instances where the 
person has not been diagnosed. However, alcohol makes the symptoms of bipolar disorder 
worse. Anyone who shows symptoms of bipolar disorder should seek the advice of medical 
professionals (Le Strat, 2010). 
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Some studies have shown that alcohol directly contributes to heart disease and stroke. 
Heavy drinking raises levels of triglycerides circulating in the bloodstream leading to 
diabetes and blocked or narrowed arteries that carry blood to the heart. If coronary arteries 
are clogged with fats, blood cannot flow freely, resulting in heart disease or stroke. 
Additionally, alcohol directly contributes to heart failure by damaging the heart muscle and 
arteries. Cardiomyopathy, or an enlargement of the heart muscle, results from long-term 
alcohol use. An enlarged heart no longer works efficiently and fails to provide enough 
oxygenated blood to other organs of the body. Furthermore, alcohol is associated with 
cardiac arrhythmia (irregular heartbeat), sudden cardiac death, stroke and atrial fibrillation 
(Pearson, 1996).  
In our patients, hypertension was not associated with bipolar disorder (5.4% Vs 16%, OR = 
0.43, IC 95% = 0.14-1.29; p = 0.136). De Heart et al. (2010) explained the decrease of 
hypertension frequency in individuals with a mental illness by changes in lifestyle of 
patients such as reducing salt intake. 
Several methodological limitations should be considered when interpreting these findings. 
First, larger sample sizes of groups would be beneficial. Second, our work is a cross-
sectional study that does not permit to follow up biological parameters. Third the sample of 
bipolar patients may not be representative of more heterogeneous populations. Finally, the 
diagnosis of controls was made by psychiatrists but without formal use of structured 
instruments to exclude psychiatric disorders in controls. 
5. Conclusion 
Our results demonstrate that Tunisian bipolar I patients are exposed to higher 
cardiovascular risk. In fact, they had perturbations in lipid profile: significantly higher 
values of triglycerides and Lp(a), and significantly lower values of ApoA1, significantly 
hyperhomocysteinemia and hyperuricemia (in men), significantly hypofolatemia and high 
prevalence of metabolic syndrome. Obesity, hyperLp(a), hypertriglyceridemia, 
hypofolatemia, hyperhomocysteinemia and cigarette smoking were the main cardiovascular 
risk factors associated with bipolar I disorder. Indeed, the risk of obesity was increased 
approximately for nine once, hyperLp(a), hypertriglyceridemia and hypofolatemia 
approximately for four once and the other factors approximately for tow once. The 
TG/HDL ratio and Lp(a) were found as the best predictive factors of cardiovascular risk in 
terms of sensibility and specificity at threshold of 1.12 and 168 mg/L, respectively.  
Our findings noted a significant association between vitamin B12 values and illness episode. 
Manic patients had lower values of this parameter than depressive patients. Moreover, we 
showed that vitamin B12 was significantly associated with the therapeutic characteristics. 
Indeed, patients taking carbamazepine had significantly lower values of this parameter than 
those taking valproic acid and lithium. Additionally, there was no significant change in 
homocysteine, folate, uric acid values and metabolic syndrome in relation to illness episode 
and the treatment, whereas the patients with metabolic syndrome had significant higher 
levels of HOMA-IR and uric acid than metabolic syndrome free.  
Therefore, bipolar I patients require specific care, particularly for lipid profile, vitamin 
status and weight; the effectiveness of this care will be evaluated during follow-up period 
Clinicians should track the effects of treatment on physical and the biological parameters, 
and should facilitate access to appropriate medical care. 
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In addition, obesity was more frequent in depressive patients than in those with manic 
episode (38.1% Vs 27.8%). Previous studies reported that patients who had depressive 
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and to be inactive than non-depressed subjects. Another explanation might involve 
biological mechanisms: it is ascertained that hypothalamic–pituitary- adrenal (HPA) axis 
dysregulation and high cortisol blood levels lead to increased visceral fat. HPA axis 
dysregulation has been a common finding in both unipolar and bipolar disorders; recently, 
some studies reported that increased cortisol blood levels correlated to the amount of intra-
abdominal fat in major depression (Maina et al., 2008). 
About therapeutic characteristics, we found that obesity and overweight were more 
frequent (72% and 52%; respectively) in patients taking valproic acid or lithium. These 
findings are in line with those reported by De Hert et al. (2011). Moreover, Casey et al. 
(2005) reported that lithium have been shown to stimulate appetite through different 
mechanisms. The “carbohydrate craving” that is thought to be one of the mechanisms of 
increased calorie intake in people taking lithium is well known. In addition, it is believed 
that valproate also stimulates weight gain through a variety of mechanisms, especially the 
development of insulin resistance and diabetes mellitus type 2. In this line, our study found 
that this type of diabetes is frequent in patients (16.2%). Additionally, the risk of diabetes is 
multiplied by 1.5 in patients (16.2% Vs 9.7%, OR = 1.60, IC 95% = 0.62-4.12; p = 0.325).  
Previous studies suggested that patients with both bipolar disorder and comorbid diabetes 
have more lifetime psychiatric hospitalizations than patients with bipolar patients without 
diabetes. The association between these two disorders underscores the importance of 
screening for diabetes in patients with bipolar illness, particularly because early detection 
and initiation of treatment to control glycemia may prevent diabetes-related complications. 
Moreover, other studies have demonstrated cerebrovascular lesions involving small 
intraparenchymal cerebral vessels and focal infarctions in patients with diabetes. These 
lesions predominantly occur in areas providing blood supply to the base of the pons, 
thalamus, and basal ganglia. Diabetes has been implicated as a risk factor for subcortical 
white-matter lesions observed on magnetic resonance imaging (MRI) scans; similar MRI 
findings have been noted in patients with bipolar disorder. Cerebral microvascular disease 
may lead to greater frequency of manic episodes, another reason to minimize diabetes-
related complications in patients with comorbid bipolar disorder (Cassidy et al., 1999; 
Holman et al., 2008). 
Alcoholic beverage was not significantly associated with this illness but we showed that it 
was more frequent in patients than controls (13.1% Vs 6.9%, OR = 2.04, IC 95% = 0.94-4.44; p 
= 0.067). It has been well documented that bipolar disorder and alcoholism commonly co-
occur. In fact, the lifetime prevalence of alcohol abuse and drug abuse in people with bipolar 
disorder are known to be three to nine times more frequent that of the general population 
(Merikangas et al., 2007; Regier et al., 1990; ten Have et al., 2002).  
Additionally, some studies showed that the feelings of depression and anxiety associated 
with bipolar can be a factor that leads to alcoholism. People with bipolar disorder may use 
alcohol or other drugs to self medicate these feelings, especially in instances where the 
person has not been diagnosed. However, alcohol makes the symptoms of bipolar disorder 
worse. Anyone who shows symptoms of bipolar disorder should seek the advice of medical 
professionals (Le Strat, 2010). 
 
Cardiovascular Risk in Tunisian Patients with Bipolar I Disorder 
 
341 
Some studies have shown that alcohol directly contributes to heart disease and stroke. 
Heavy drinking raises levels of triglycerides circulating in the bloodstream leading to 
diabetes and blocked or narrowed arteries that carry blood to the heart. If coronary arteries 
are clogged with fats, blood cannot flow freely, resulting in heart disease or stroke. 
Additionally, alcohol directly contributes to heart failure by damaging the heart muscle and 
arteries. Cardiomyopathy, or an enlargement of the heart muscle, results from long-term 
alcohol use. An enlarged heart no longer works efficiently and fails to provide enough 
oxygenated blood to other organs of the body. Furthermore, alcohol is associated with 
cardiac arrhythmia (irregular heartbeat), sudden cardiac death, stroke and atrial fibrillation 
(Pearson, 1996).  
In our patients, hypertension was not associated with bipolar disorder (5.4% Vs 16%, OR = 
0.43, IC 95% = 0.14-1.29; p = 0.136). De Heart et al. (2010) explained the decrease of 
hypertension frequency in individuals with a mental illness by changes in lifestyle of 
patients such as reducing salt intake. 
Several methodological limitations should be considered when interpreting these findings. 
First, larger sample sizes of groups would be beneficial. Second, our work is a cross-
sectional study that does not permit to follow up biological parameters. Third the sample of 
bipolar patients may not be representative of more heterogeneous populations. Finally, the 
diagnosis of controls was made by psychiatrists but without formal use of structured 
instruments to exclude psychiatric disorders in controls. 
5. Conclusion 
Our results demonstrate that Tunisian bipolar I patients are exposed to higher 
cardiovascular risk. In fact, they had perturbations in lipid profile: significantly higher 
values of triglycerides and Lp(a), and significantly lower values of ApoA1, significantly 
hyperhomocysteinemia and hyperuricemia (in men), significantly hypofolatemia and high 
prevalence of metabolic syndrome. Obesity, hyperLp(a), hypertriglyceridemia, 
hypofolatemia, hyperhomocysteinemia and cigarette smoking were the main cardiovascular 
risk factors associated with bipolar I disorder. Indeed, the risk of obesity was increased 
approximately for nine once, hyperLp(a), hypertriglyceridemia and hypofolatemia 
approximately for four once and the other factors approximately for tow once. The 
TG/HDL ratio and Lp(a) were found as the best predictive factors of cardiovascular risk in 
terms of sensibility and specificity at threshold of 1.12 and 168 mg/L, respectively.  
Our findings noted a significant association between vitamin B12 values and illness episode. 
Manic patients had lower values of this parameter than depressive patients. Moreover, we 
showed that vitamin B12 was significantly associated with the therapeutic characteristics. 
Indeed, patients taking carbamazepine had significantly lower values of this parameter than 
those taking valproic acid and lithium. Additionally, there was no significant change in 
homocysteine, folate, uric acid values and metabolic syndrome in relation to illness episode 
and the treatment, whereas the patients with metabolic syndrome had significant higher 
levels of HOMA-IR and uric acid than metabolic syndrome free.  
Therefore, bipolar I patients require specific care, particularly for lipid profile, vitamin 
status and weight; the effectiveness of this care will be evaluated during follow-up period 
Clinicians should track the effects of treatment on physical and the biological parameters, 
and should facilitate access to appropriate medical care. 
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1. Introduction 
Almost most mental illness, such as schizophrenia, bipolar disorder, and depression are 
associated with undue medical morbidity and mortality. It represents a major health 
problem, with 20 to 30 years shorter lifetime mortality are primarily due to premature 
cardiovascular disease (myocardial infarction, stroke…). The cardiovascular events are 
strongly linked to non modifiable risk factors such as age, gender, personal and/or family 
history, but also to crucial modifiable risk factors, such as overweight and obesity, 
dyslipidemia, diabetes, hypertension and smoking. 
Although these classical risk factors exist in the general population epidemiological studies 
suggest that patients with severe mental illness have an increased prevalence of these risk 
factors. 
Another point is the causes of increased metabolic and cardiovascular risk in this population 
are related to poverty, poor diet, sedentary and compared to the general population. The 
increased morbidity and mortality limited behaviour access to medical care, but also to the 
use of psychotropic medication. Over recent years it has become apparent that antipsychotic 
drugs can have a negative impact on some of the modifiable risk factors. 
2. Epidemiological studies 
Results of most research on the physical health of people with mental health illness suggest 
the morbidity and the mortality from certain physical disease is high in these populations. 
Patients with schizophrenia are a medically vulnerable population due to underdiagnosed 
medical problems, and minimal or not utilization of primary care services. Not only there is 
increased medical morbidity among these patients, there is also increased mortality. 
Medical comorbidity in patients with bipolar disorder, is associated with an intensification 
of bipolar depressive symptoms and other indices of bipolar severity, as well as premature 
mortality. Somatic health issues remain underrecognized and suboptimally treated. 
2.1 Mortality 
An increasing number of studies have found higher rates of mortality in schizophrenia 
patients due to natural causes (Mortensen & Juel, 1993; Ruschena et al, 1998). Such increased 
rates of mortality due to natural causes highlight the failure to detect and manage physical 
health conditions in this group. In meta-analysis deaths due to natural causes accounted for 
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59% of the excess mortality in schizophrenia (Brown, 1997). Respiratory and cardiovascular 
diseases are the most common causes of natural death. The standard mortality ratio (SMR) 
for respiratory disease was 226 (95%CI, 209-244) and for cardiovascular disease 110 (95%CI, 
105-115) (Brown, 1997). However, another study found an SMR of 1.78 for men and 0.86 for 
women with schizophrenia for ischemic heart disease (Lawrence et al, 2003). Analysis of 
standardized mortality ratios for deaths from natural causes showed an increased risk of 
death in patients with a wide range of psychiatric conditions, including substance misuse, 
schizophrenia, bipolar disorder and unipolar depression. The Standardized mortality ratios 
(SMR) showed that in schizophrenia it is 1.57 for all cause mortality, and cardiovascular and 
cancer deaths accounted for the largest number of deaths with SMRs of 1.04 and 1.00 
respectively (Harris & Barraclough, 1998). Depression confers a 24% increased risk of dying 
within the next 6 years (Wulsin, 2000). A study published through the Centers for Disease 
Control and Prevention (CDC) compared the mortality of public mental health patients in 8 
states with the mortality of the states’ general population, for 1997 through 2000. In all the 
study states, mental health had a higher risk of death than the general population and died 
at much younger ages compared with their cohorts. In all states studied, cardiac disease was 
found to be the leading cause of death in mentally ill patients. And this population had lost 
decades of potential years of life, with average exceeding 25 years (Colton & Manderscheid, 
2006). 
Another indicator of the medical care is avoidable mortality. These indicators are calculated 
by selecting the number of avoidable causes of death considered amenable to health care 
(Rustein et al, 1976). A follow-up study of 30045 psychiatric in-patients born between 1912-
1970 was conducted to specifically address avoidable mortality. The standardized rate ratios 
(SRR) for male patients with schizophrenia are 3.74 (95%CI, 2.38-5.89) and 3.99 (95%CI, 2.47-
6.44) for females (Ringback Weitoft et al, 1998). 
2.2 Morbidity 
A study list some of the common physical conditions found in people with psychosis. 
These include diabetes, hyperlipidemia, cardiovascular disease, obesity, malignant 
neoplasms, HIV/AIDS, hepatitis, osteoporosis, hyperprolactinemia, irritable bowel 
syndrome and helicobacter pylori infection (Lambert et al, 2003). The prevalence of 
physical illness in medically screened chronic psychiatric samples has been variously 
reported to be 12-53% (Lyketsos et al, 2002). Another study estimate that 35% of 
psychiatric patients have undiagnosed physical disorder (Felker et al, 1996).Some studies 
have attempted to establish whether medical comorbidity exacerbates patient’ psychiatric 
condition (Bartsch et al, 1998). 
Not only do patients with mental illness die of natural causes at high rate, when medical 
conditions occur, these patients are much more likely to underdiagnosed and undertreated. 
Several studies have shown that the detection rate of physical illness among patient with 
mental illness is very poor. A study estimated that 45% of patients in California’s public 
mental-health system had physical disease and, of these, 47% were undetected by the 
treating physician (Koran, 1989). Another study of psychiatric clinic patients revealed 
remarkably similar findings: 43% of patients had physical illnesses and, of these, 48% had 
not been diagnosed by the referring doctor, non-psychiatrist physicians had missed 33% and 
psychiatrists had missed 50% (Koranyi, 1979). Hall et al found that 46% of patients admitted 
to a research ward had an unrecognized physical illness that either caused or exacerbated 
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their psychiatric illness; 80% had physical illnesses requiring treatment, and 4% had 
precancerous conditions or illnesses (Hall et al, 1981). 
Research indicates that 25% to 80% of patients with schizophrenia and other mental illness 
have a serious medical comorbidity, yet less than half of these medical conditions are 
diagnosed (Cradock-O’Leary et al, 2002). 
3. Causes of poor physical health in mental illness 
A number of reasons exist to explain the poor detection of physical health problems in 
patient with mental illness. Some patients are unaware of any physical health problems, 
usually a consequence of cognitive deficits associated with their mental illness (Goldman, 
1999). Often there is a reluctance to seek medical help and when it sought patient with 
mental health find it difficult to describe their problems to a medical practitioner, or present 
with atypical medical symptoms. Patient with schizophrenia have been shown to have a 
high tolerance for pain and subsequently are less likely to report this symptom (Dworkin, 
1994). Another complexity concerns the effects of psychiatric illness on perceived physical 
health. For example, depression can lead to an increase in perceived physical symptoms and 
worsening of subjective health outcomes. 
The management of medical conditions is a complex and problematic issue, arising largely 
because of the separation of medical and psychiatric health care services. The stigma of 
mental illness is one obvious barrier preventing psychiatric patients from receiving 
adequate physical health care, as some physicians may be uncomfortable in working with 
this patient. Another concern is managing physical conditions where patients that have an 
increased prevalence with psychiatric illness and where there is a general lack of treatment 
compliance. The challenging task of managing physical illness with this patient requires 
skill, patience and experience as patients often present late with complications. (Table 1) 
 
System-Related Barriers 
        Lack of insurance coverage 
        Lack of access to health care 
        Stigmatization by health care providers 
        Lack of understanding of benefits of preventive services by health care workers 
        Lack of integration of medical and mental health systems 
Patients–Barriers 
        Poverty 
        Non compliance 
        Pour communication skills 
        Denials of illness Related 
Table 1. Barriers to health care for patients with mental illness. Adapted from Goldman. 
3.1 Lifestyle risk factors 
In recent years, there is a growing concern about physical illness in patients with mental 
illnesses, specifically the risk of cardiovascular disease. Those patients are more likely to be 
overweight, to smoke, to have hypertension, hyperglycemia or diabetes, and dyslipidemia 
(Table 2). 
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Estimated prevalence, % (RR)
Modifiable risk factors Schizophrenia Bipolar disorder 
Overweight 45–55% (1,5–2) 21–49% (1-2) 
Smoking 50–80% (2-3) 54-68% (2-3) 
Diabetes 10-15% (2) 8-17% (1,5-2) 
Hypertension 19-58% (2-3) 35-61% (2-3) 
Dyslipidemia 25-69% (≤5) 25-38% (≤3) 
Metabolic syndrome 37-63% (2-3) 30-49% (1,5-2) 
Table 2. Estimation prevalence and relative risk 5 (RR) of modifiable cardiovascular disease 
risk factors in schizophrenia and bipolar disorder compared to the general population. 
Adapted from Correll, 2007 
3.1.1 Obesity 
Excessive body weight increases the risk of morbidity from number conditions, including 
hypertension, dyslipidemia, type II diabetes, coronary heart disease. Excess abdominal fat is 
associated with dyslipidemia, hypertension and glucose intolerance. Risk of comorbid diseases 
has been shown to rise as BMI increases above 25 kg/m2. In psychiatric practice, weight gain 
is a long recognized and commonly encountered problem. A study of patients with 
schizophrenia reported 51% of males and 59% of females to be clinically obese, compared with 
33% of people with other psychiatric disorders. This study provided an estimate of mean 
weight gain in patients who received standard doses of antipsychotics over 10-week period. 
The mean increases were 4.45 kg with clozapine, 4.15 with olanzapine, 2.92 kg with sertindole, 
2.10 kg with risperidone, and 0.04 kg with ziprasidone (Allison & Casey, 2001). It is important 
to note that substantial weight gain is associated with both atypical (eg, clozapine, olanzapine) 
and conventional (eg, thioridazine, chlorpromazine) antipsychotics. 
3.1.2 Smoking 
The prevalence of smoking greatly exceeds that in the general population (Table 1) Heavy 
cigarette smoking is intimately associated with schizophrenia and it may have implications 
for the underlying neurobiology of the disease. Smoking is a good example of how behavior 
and treatment interact to increase morbidity at a number of levels. It is a risk factor for 
respiratory and ischemic heart disease and stroke. Cigarette smoking induces hepatic 
microsomal enzymes, which increase the metabolism of psychotropic medication, reducing 
plasma levels of antipsychotics notably olanzapine and clozapine. It may influence the 
patient’s behavior and the treatment outcome. Therefore smokers usually require greater 
levels of antipsychotic medication than non-smokers to achieve similar blood levels. 
3.1.3 Diabetes 
It is another risk factor for coronary atherosclerosis that is associated with metabolic 
abnormalities that result in changes in the transport, composition and metabolism of 
lipoproteins. 
3.1.4 Hypertension 
Is a cardiovascular risk factor as it produces structural changes within the arteries. The seq 
uel of hypertension are greatly affected by comorbidities such as dyslipidemia, smoking, 
diabetes, lack of physical activity, sodium intake, and stress. 
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Other risk factors are attributable to unhealthy lifestyle, including social scale such as 
unemployment, poorer financial standing, poor diet and sedentary behaviour. 
Concerning diet, a study (Mc Creadle, 2003) examined in detail the dietary intake of 102 
people with schizophrenia in Scotland. Their fruit and vegetable consumption averaged 16 
portions per week, less than half the recommended intake. 
Brown et al, 1999 and Mc Creadle, 2003 found that patients with schizophrenia tended to 
take only small amounts of exercice. Factors such as features of the illness, sedative 
medication and lack of opportunity and general motivation may be relevant. 
3.2 Medication 
Psychotropic medication is associated with a host of physical complications and side effects. 
Old antipsychotic medication was associated with neurologic side effects, including 
involuntary movement disorders, such as akathisia, parkinsonism, tardive dyskinisia. New 
antipsychotics are more commonly use. Despite the low propensity of new antipsychotics 
towards extra pyramidal side effects other adverse effects associated with them include 
excessive weight gain, metabolic disturbances. Medical conditions attributed to the use of 
typical and atypical antipsychotic medication include diabetes, hyperlipidemia, and 
cardiovascular disease: specifically hypertension and cardiac arrhythmias, obesity (Meyer, 
2002; Davidson, 2002). 
4. The metabolic syndrome 
Much attention has been focused on the metabolic syndrome which brings together a series 
of abnormal clinical and metabolic findings which are predictive of cardiovascular risk. The 
most commonly used definition for the metabolic syndrome are the Adult Treatment Panel 
III (ATP III) of the National Cholesterol Education Program (NCEP), (Jama, 2001) and the 
adapted ATP-III-A proposed by the American to Heart Association following the American 
Diabetes Association lowering of the threshold for impaired fasting glucose 100mg/dl. 
(Quindy et al, 2005 ; Alberti et al, 2006). 
Another recent definition, by the International Diabetes Federation (Alberti et al, 2006; 
Sarafidis &, Nilsson, 2006) stressed the importance of waist circumference, using 
ethnic/race specific criteria (Table 3). 
 
 ATP III
3 out of 5 criteria 
required
ATP III A
3 out of 5 criteria 
required
IDF 
waist + 2 criteria 
required 
Waist (cm) M>102, F>88 M>102, F>88 M≥94,F≥80 
Blood pressure ≥130/85* ≥130/85* ≥130/85* 
HDL cholesterol (mg/dl) M<40, F<50 M<40,F<50 M<40,F<50 
Triglycerides (mg/dl) ≥150 ≥150 ≥150 
Fasting glucose (mg/dl) ≥110** ≥100** ≥100** 
*or treated with antihypertensive medication  
**or treated with insulin or hypoglycemic medication 
Table 3. Definitions of metabolic syndrome: The metabolic syndrome has been shown to be 
an important risk factor for the development of both type 2 diabetes and cardiovascular 
disease. 
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In the study, the clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), one 
third of patients met the NCEP criteria for metabolic syndrome at baseline (Mc Eoy et al, 
2005 ; Meyer et al, 2005). 
And from this study, 88% of patients with dyslipidemia were not receiving treatment, as 
were 62% of the hypertensive patients and 38% those with diabetes (Nasrallah et al, 2006). 
The presence of the metabolic syndrome increases the risk for the distribution of fat within 
the body is a key factor. Abdominal fat distribution, particularly visceral adiposity, increases 
the risk of dyslipidemia, glucose intolerance, and cardiovascular disease. Multiple organ 
systems are affected, including adipose, muscle, hepatic, nervous, and adrenal tissues, and 
the most important site of impact is the vasculature. The concept of insulin resistance is 
central to the metabolic syndrome. Insulin resistance is a major contributor to glucose 
intolerance, and the lipoprotein abnormalities seen in the metabolic syndrome are also 
predictable, at least in part, from the known effects of insulin to inhibit lipolysis in 
adipocytes. With resistance to insulin, unchecked lipolysis leads to increased delivery of free 
fatty acids to the liver for triglyceride synthesis and packaging into very low-density 
lipoprotein (VLDL) particles. Higher VLDL levels contribute to lower HDL levels because of 
the reciprocal exchanges between these lipoproteins mediated by cholesterol ester transfer 
protein. Is has been shown that blood pressure is related to insulin resistance independent 
of differences in age, gender, and degree of obesity(Zavaroni et al,1992). Visceral obesity is 
the primary determinant of insulin resistance and, as such, represents the fundamental 
pathophysiologic change leading to the metabolic syndrome. The risk of insulin resistance 
increases with adiposity, particularly the amount of visceral adiposity. Insulin resistance is 
associated with impaired glucose control, increase plasma triglycerides, reduced high-
density lipoprotein (HDL) cholesterol, increased blood pressure, increased risk of blood 
clotting, and increases in markers of inflammation, all which are associated with an increase 
risk for cardiovascular disease. Thus, markers of insulin resistance, such as elevated fasting 
plasma Triglycerides, can be a key point for monitoring and evaluating a patient’s risk. 
5. Effects of antipsychotics treatment 
Antipsychotic treatment is associated with metabolic side effects that include various 
degrees of weight gain, dyslipidemia and susceptibility to type 2 diabetes (Newcomer, 
2005). 
Elevated blood lipids, particularly triglycerides, are associated with some typical 
antipsychotic agents. Shortly after their introduction, phenothiazines were found to elevate 
serum triglyceride and total cholesterol levels. Then much was written on the effects of 
specific atypical drugs on lipid profiles. Both clozapine and olanzapine have been shown to 
cause significant hypertriglyceridemia compared with typicals. Studies have also reported a 
significant association between weight gain and triglyceride change for patients under 
atypical antipsychotic therapy (Meyer, 2001). 
The atypical antipsychotics vary in their propensity to induce weight gain (Table 4): 
clozapine and olanzapine produce the most weight gain, quetiapine and risperidone 
produce intermediate weight gain, and ziprasidone and aripiprazole produce the least 
weight gain (Allison et al, 1999; American Diabetes Association [ADA], 2004). The 
differences in weight gain associated with these agents reflect their order of risk for insulin 
resistance, glucoregulatory dysfunction, and dyslipidemia (Haupt & Newcomer 2002; ADA, 
2004). 
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Antipsychotic Weight Risk for diabetes Worsening lipid 
proli B 
Clozapine +++ + + 
Olanzapine +++ + + 
Risperidone ++ D D 
Quetiapine ++ D D 
Ziprasidone +/- - - 
Aripiprazole +/- - - 
aAdapted with the permission from the American Diabetes Association Abbreviation:  
D = discrepant results  
Symbols: + = increased effect, - = no effect 
Table 4. Atypical antipsychotic drugs and metabolic disturbancesa 
Metabolic disturbances related to atypical antipsychotics may result from a direct alteration 
of insulin sensitivity and/or insulin secretion. Antipsychotic affinity at both histamine and 
muscarinie acetylcholine receptors correlates with weight gain and metabolic liability 
(Matsui-Sakata, 2005) and impaired parasympathic regulation of β all activity may 
contribute to metabolic risk (Silvestre &-Prous, 2005). Certain antipsychotic agents may 
directly impair glucose transporter function. Direct attenuation of glucose transporter 
function by antipsychotic agents would result in elevations in circulating glucose and a 
compensatory hypersecretion of insulin, which overtime may further reduce insulin 
sensitivity, triggering the cascade of events leading to metabolic syndrome and type 2 
diabetes (Dwyer & Donohoe, 2003). 
Some antipsychotic drugs increase appetite and this leads to adiposity. Affinity of the 
antipsychotic drugs for histamine-1 (H1) receptors closely correlates with weight-gaining 
potential and appears to involve H1 receptor-linked activation of hypothalamic AMP-
kinase. Also, 5-HT2C receptor antagonism may contribute to weight gain. The H1 and 
5HT2C blocking effects of antipsychotic medications may interfere with leptin-mediated 
appetite suppression (Reynolds,2006; Matsui-Sakata et al,2005). 
Adiposity alone does not explain the potential side effects of atypical antipsychotic 
medications. Animal and human studies describe the adverse effect of clozapine and 
olanzapine on insulin and glucose metabolism (Hasnain & Vieweg, 2008). Significant insulin 
resistance has also been documented in non-obese patients receiving clozapine or 
olanzapine versus those receiving risperidone (Henderson et al, 2006). Diminished or 
inefficient insulin release from pancreatic beta cells as well peripheral insulin resistance may 
underlie the diabetogenic effect of some antipsychotic medications. Blocking muscarinic 
type 3 and 5-HT1A receptors may be a factor to diminished pancreatic beta-cells 
responsiveness and blocking 5HT2A receptor may suppress glucose uptake in muscle 
(Nasrallah, 2008). Some antipsychotic medications may impair and/or alter the action of 
insulin on adipocytes leading to progressive lipid accumulation (Vestri et al, 2007). The 
impaired effect of insulin on adipocytes may explain weight gain independent dyslipidemia 
(De leon et al, 2007, Birkenaes et al, 2008). 
Another study examine whether patients taking selective serotonin reuptake inhibitors 
(SSRIs) are more likely to have elements of the metabolic syndrome compared with those 
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taking no psychotropic drugs. Patients taking SSRIs had a significantly increased prevalence 
of obesity, abdominal fat, and hypercholesterolemia. The associations with this factors were 
significant after adjustment for age, gender , and several covariates. The individuals SSRIs 
might display differences in their side effect profile, the study performed analysis of the 
various SSRIs. Paroxetine was strongly associated with general and abdominal obesity but 
not with hypercholesterolemia, whereas citalopram was associated with neither obesity nor 
dyslipidemia. Patients taking sertraline, fluoxetine, or fluvoxamine, SSRIs treatment was 
significantly associated with abdominal obesity and with hypercholesterolemia. SSRIs 
induce transcriptional activation of cholesterol and fatty acid biosynthesis. The lipogenic 
effect could represent a common mechanism for explaining in part the lipid disturbances 
(Reader et al, 2006). 
Weight gain is a major side effect of the main mood stabilizers. Chronic treatment with 
lithium is associated with increased weight, reaching more than 10kg in 20% of patients 
(Garland et al, 1998).Valproic acid leads to unequivocal weight gain. Lamotrigene, another 
anticonvulsant that acts as a mood stabilizer, is not associated with significant weight gain 
(Zimmermann et al, 2003). 
With regard to mood stabilizers, additional factors could be involved. An insulin-like action 
cause by lithium at the treatment stage could increase fat deposition. In addition, edema 
secondary to sodium retention and subclinical hypothyroidism also contribute to weight 
gain (Garland et al, 1998). The mechanism by which the valproic acid causes weight gain is 
still little explored; an action in the sense of inhibiting oxidation of fatty acids might be 
involved (Isojärvi et al, 1998). 
Studies are not in accordance. A controlled study, with children undergoing anticonvulsant 
treatment, did not find significant changes in HDL and triglycerides levels associated with 
use of carbamazepine or valproic acid. But, in the group taking carbamazepine, there were 
was significant increase in total cholesterol levels (Fanzoni et al, 1992). 
Another study assessed 101 patients undergoing anticonvulsant therapy for at least 3 
months. Compared with controls paired for gender and age, patients taking valproic acid 
presented significantly lower total cholesterol and LDL levels; patients taking 
carbamazepine presented significantly increased HDL and apolipoprotein A levels 
(Calandre et al, 1991). 
6. Screening and monitoring  
Identification of treatable pathology in a high-risk population, that is, screening for diabetes, 
dyslipidemia, hypertension is important and facilitates preventive strategies and early 
diagnosis. Another goal is to track metabolic disturbance in relation to antipsychotic treatment. 
Dyslipidemia is a general term that defines an increase in the serum concentration of various 
lipoproteins. Lipoproteins are usually classified into three major categories: 
- Low-density lipoproteins (LDLs) are cholesterol-rich particles whose concentration is 
directly correlated with the risk of myocardial infarction and death. 
- Very-low-density lipoproteins (VLDLs) are triglyceride-rich particles whose 
concentration is strongly correlated with the level of insulin resistance and inversely 
proportional to the serum concentration of high-density lipoproteins (HDLs). 
- HDL particles are antiatherogenic lipid particles, and high serum levels of HDL are 
protective against coronary artery disease.  
 




In the general population, lipid screening with a fasting lipid profile (total chol, LDL, HDL 
and triglyceride) is recommended for all adults aged 20 years and older, repeteated every 5 
years in asymptomatic individuals (Expert Panel on Detection, Evaluation and Treatment, of 
High Blood Cholesterol in Adults, 2001). Adequate fasting, about 10 to 12 hours is necessary 
to obtain valid LDL and triglyceride levels-Target LDL levels are determined by a 
Framingham assessment based on age, sex, chol, HDL, systolic blood pressure, and smoking 
status (Wilson et al, 1998). Patients on antipsychotic treatment frequently have a metabolic 
dyslipidemia with elevations of triglyceride and reduced HDL (Cohn et al, 2004), along with 
associated features of the metabolic syndrome. Some SSRIs induced metabolic disturbance 
particularly hypercholesterolemia. 
Treatment of metabolic dyslipidemia is a secondary goal for intervention following 
achievement of LDL targets. Clinical trials show that LDL-lowering therapy reduces risk for 
coronary heart disease (CHD). For these reasons, ATP III continues to identify elevated LDL 
cholesterol as the primary goal of cholesterol-lowering therapy. Those with diabetes or 
established cardiovascular disease are considered high risk and are treated to the most 
stringent LDL targets. Risk determinants in addition to LDL cholesterol include the presence 
or absence of CHD, other clinical forms of atherosclerotic disease , and the major risk factors 
other than LDL. Other major risk factors are cigarette smoking, hypertension, low HDL 
cholesterol, family history of premature CHD, diabetes and age. These major risks are 
commonly observed in patients with mental illness.  
A variety of medical conditions and drugs can exacerbate hyperlipidemias. Elevations of the 
serum LDL cholesterol level can occur in response to hypothyroidism and nephrotic 
syndrome. Hypertriglyceridemia and decreased HDL levels are commonly seen with insulin 
resistance, diabetes, and the metabolic syndrome. This fact is usually seen in patients with 
mental illness. Individuals are characterized by their coronary risk profile according to the 
National Cholesterol Education Program Adult Treatment Panel III guidelines, as shown in 
Table 5. 
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To monitor for antipsychotic – associated metabolic disturbances, patients should be 
assessed before antipsychotic treatment is initiated. The results of such an assessment can 
also influence antipsychotic choice, particularly when patients have existing metabolic 
pathology or elevated risk factors. The frequency of subsequent assessments is different  
as it is reflected in the various antipsychotic monitoring guidelines: Mount Sinai  
(Chobarian et al, 2003), Australia (Lambert et al, 2004) ADA-APA(ADA,2004) Belgium (De 
Nayer, 2005), United Kingdom (Expert Consensus Meeting, 2004), Canada (Canadian 
Diabetes Association, 2005), France (Saravane et al, 2009) (Table 6).To summarize these 
recommendations, there are many aeras of general agreement about the importance of 
baseline monitoring before starting treatment and that patients should be followed more 
closely for the first 3 to 4 months of treatment, with subsequent ongoing reevaluation. The 
utility of the following tests and measures was emphasized: fasting plasma glucose, fasting 
lipid profile, weight and height, waist circumference, and blood pressure.  
A recent study characterizes associations between the combined warnings and 
recommendations and baseline metabolic testing and Second-Generation Antipsychotic 
Drugs (SGA). A total of 109451 patients receiving Medicaid who began taking SGA was 
compared to a control cohort of 203527 patients who began taking albuterol but did nor 
receive antipsychotic medication. The main outcome measures was the monthly rates of 
baseline serum glucose and lipid testing for SGA-treated and propensity-matched 
albuterol-treated patients and monthly share of new prescriptions for each SGA drug. In a 
Medicaid-receiving patients, baseline glucose and lipid testing for SGA was infrequent 
and showed little change following the monitoring recommendations. Initial testing rates 
for SGA-treated patients were low: glucose, 27%; lipids, 10%. The warning was not 
associated with an increase in glucose testing among SGA-treated patients and was 
associated with only a marginal increase in lipid testing rates: 1.7%; P=. 02.(Morrato, 
2010). 
The important question is given the risks in patients with mental illness, how should they be 
monitored and how should they be treated? 
Current studies indicate that patients with mental illness do not receive adequate evaluation 
and effective treatment of their cardio-metabolic problems. Effective communication 
between the primary care physician and the psychiatrist is very important for the mentally 
ill because of their impaired capacity to care for themselves. Such communication will 
improve monitoring, help early detection of metabolic disorders, and limit duplication of 
clinical or laboratory workup. Monitoring for metabolic side effects is primarily the 
responsibility of the physician prescribing antipsychotic medication and in most cases that 
would be a psychiatrist. 
If the primary care physician observes that the patient is being prescribed such drugs 
without being monitored effectively, he/she should discuss this with the psychiatrist. The 
psychiatrist may not have the expertise to manage any abnormalities that are detected and 
in such situations the primary care physician will most likely take over both monitoring and 
management. Liaison should extend to any healthcare professionals involved in the care of 
patients with mental illness.  
Given the serious health risks, patients taking antipsychotic drugs should receive 
appropriate baseline screening and ongoing monitoring. 
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Table 6. Recommended guidelines to monitor and initial workup. 
6.2.1 Baseline monitoring 
The recommendations are that baseline screening measures be obtained before or as soon as 
clinically feasible after, the initiation of any antipsychotic medication. We have to consider 
ethnicity, dietary habits, physical activity, support system, smoking, and alcohol and drug 
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ethnicity, dietary habits, physical activity, support system, smoking, and alcohol and drug 
 
Dyslipidemia - From Prevention to Treatment 
 
360 
abuse. Keep in mind that psychotropic medications other than antipsychotic drugs such as 
some antidepressants and mood stabilizers may link to weight gain. The baseline 
assessments include: 
- Personal and family history of obesity, diabetes, dyslipidemia, hypertension or 
cardiovascular disease 
- Weight and height, so that BMI can be calculated 
- Waist circumference at the level of the umbilicus 
- Blood pressure 
- Fasting plasma glucose 
- Fasting lipid profile 
If any abnormalities are identified, first, patients should be informed of their condition and 
supported in making lifestyle changes to adopt a healthier diet and increase physical 
activity. Psychiatrists should not hesitate to refer the patient to the appropriate health care 
professional or specialist knowledgeable about these disorders. 
Even for patients free of metabolic disorders, monitor potential risk factors. Weight gain 
may not be dose-dependent and patients with low body mass index at baseline may be 
particularly vulnerable to weight gain. Glucose and lipid metabolism abnormalities may 
occur without weight gain.  
6.2.2 Follow-up monitoring 
The patient’s weight should be reassessed at 4, 8, and 12 weeks after initiating or changing 
SGA therapy and quarterly thereafter at the time of routine visits. If a patient gains > 5% of 
his or her initial weight at any time during therapy, one should consider switching the 
medication. When switching, consideration should be given to all aspects of the individual’s 
condition, the comparative risks and benefits of changing medications, and the individual’s 
response to medication in managing the primary symptoms of the mental illness. In some 
cases, cost and availability may also be a consideration. 
Fasting plasma glucose, lipid profile, and blood pressure should also be assessed 3 months 
after initiation of medication. Thereafter, blood pressure, plasma glucose values, lipid 
profile should be obtained annually or more frequently in those who have a higher baseline 
risk for the development of diabetes, dyslipidemia or hypertension. 
7. Treatment 
With all the risk factors and in the case of dyslipidemia and to reduce the global mortality of 
patients with mental illness we should consider lipid goal of therapy for these patients. The 
benefits and risks of different therapeutic agents used in the treatment of dyslipidemia  and 
its comorbidities should be considered in the context of the patient’s psychiatric condition 
and treatment. 
7.1 Drugs 
ATP III recommends a multifaceted lifestyle approach to reduce risk for coronary heart 
disease (CHD). This approach is designated therapeutic lifestyle changes (TLC). Some 
patients whose short-term or long-term risk for CHD is high will require LDL-lowering 
drugs in addition to TLC. When drugs are prescribed, attention to TLC should always be 
maintained and reinforced. Available drugs are: 
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- HMG-CoA reductase inhibitors: statins, their side effects are myopathy and increased 
liver enzymes 
- Bile acid sequestrants , their side effects including gastrointestinal distress, constipation 
and decreased absorption of some drugs 
- Nicotinic acid side effects are essentially flushing, hyperglycemia, hyperuricemia 
(gout), upper gastrointestinal distress and hepatotoxicity 
- Fibric acids, with their side effects including dyspepsia, gallstones, myopathy, 
unexplained non-CHD deaths in WHO study 
All these drugs reduced major coronary events, CHD deaths but we have to be carefull with 
their side effects and contraindications when prescribing these drugs. 
Beyond the underlying risk factor, therapies directed against the lipid and nonlipid risk 
factors of the metabolic syndrome will reduce CHD risk. 
The management of dyslipidemia in mental health is defined, as recommended by the 
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes by: 
The lifestyle interventions with diet, increased physical activity and smoking cessation. 
They are the firs-line treatments to decrease the risk for cardiovascular disease in patient 
with metabolic syndrome. 
7.2 Diet 
Interventions that address nutrition and weight management should become a routine part 
of psychiatric care. Patients with mental illness did not know the components of a healthy 
diet. The healthy eating behavior includes: 
- Cutting down fast food 
- Increased healthy food items like fruits, vegetables, fish and decreased high glycemic 
index food items and monounsaturated fats 
- Decreased processed fat free food 
- Consume 4-6, but small meals 
- Minimizing intake of soft drinks with sugar and with artificial sweetener 
The lifestyle changes should be gradual and adapted individually for each patient. There are 
various educational and psychosocial programs that address the issues of health and 
wellness exist, like ‘ The Healthy Living’ program (Vreeland, 2007; Hoffmann et al, 2006). 
7.3 Physical activity 
Patients who developed psychosis are more likely to be physically inactive (OR=3.3,95%  
CI 1.4-7.9) and to have poor cardio respiratory fitness (OR=2.2, 95% CI 0.6-7.8) compared 
with those who did not develop psychosis (Koivukangas et al, 2010). Modern guidelines on 
managing the physical health risks associated with schizophrenia include a 
recommendation about the importance of physical activity levels and fitness. This 
recommendation includes: 
- To advise patients to engage at least 30 minutes of moderately vigorous activity on 
most days of the week 
- Reduce sedentary behaviors such as TV watching, video/computer games 
- Treating/reducing sedation and extra pyramidal effects of medications  
Some studies showed that physical activity, with and without diet, resulted in modest 
weight loss, reduction of blood pressure and decreases in fasting plasma concentrations of 
glucose and insulin (Vancampfort et al, 2009). 
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In the general population there are many studies evaluating the impact of lipid lowering in 
primary and secondary prevention of coronary heart disease and stroke, but there are some 
concerns about its value in primary prevention, especially in vulnerable population (Vrecer 
et al, 2003). 
Whether a low or lowered serum cholesterol level is associated with harm has been the 
subject of debate for a long time; ever since the unexpected finding of an increased risk of 
noncardiovascular mortality in early trials of lipid-lowering therapy. Subsequent research 
has generated conflicting evidence regarding the relation between cholesterol and violent 
behavior, mental illness , with positive studies imputing alterations in central serotoninergic 
activity as a potential underlying mechanism. A case-control study studied a cohort of 94441 
individuals, 458 had newly diagnosed depression and 105 had a recorded diagnosis of 
suicide risk. Compared with matched control subjects, and even after adjustment for 
potential confounders, neither dyslipidemia nor its treatment was associated with an 
increase risk of depression. Similarly, no association was found between treatment and 
suicide risk. (Yang, 2003).  
A 3-month study demonstrated that statins prescribed to patients with schizophrenia  
and severe dyslipidemia whilst taking antipsychotic medication led to a significant 
improvement in lipid profiles (Hanssens et, 2007). An earlier study with rosuvastatin 
proved effective in managing dyslipidemia in schizophrenic patients on antipsychotics. This 
study showed improvement in lipid profiles but not benefits in terms of high-density 
lipoprotein, waist measurement, BMI or glucose homeostasis (De Hert et al, 2006). 
This last study supports the view that statins can be safely used in the short term to control 
abnormal lipids levels. However, there are no long-term data on its impact on either relapse 
or all-cause mortality, and again this is a priority for research. 
The presence of metabolic syndrome is an indication for more aggressive lipid-lowering 
measures. Medications that raise HDL, nicotinic acid or fibrates, may be particularly 
beneficial in patients with metabolic syndrome, but they have not been as widely studied as 
medications that lower LDL-cholesterol in patients with mental illness. 
The preferred initial management is still very much a lifestyle modification approach 
including exercise and diet.  
8. Conclusion 
Despite the availability of published clinical guidelines, patients with mental illness 
receiving medications remain vulnerable to the cardio-metabolic complications of these 
drugs. Implementation of a coordinated metabolic monitoring and management program 
for patient with mental illness will require a review of current practice and the introduction 
of new procedures, both of which will require time and effort on the part of the health care 
community. 
Involvement of patient with mental illness in their treatment program will require the 
provision of information about their condition and medication and the development of 
approaches that empower, encourage, and support patients in their decisions on treatment 
and well-being. 
The evaluation of new therapies should include detailed assessments of physical health and 
future risk estimates in addition to standard psychiatric outcomes. Psychiatrists have to 
arrange the appropriate examination and investigation of patients at risk of developing 
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significant physical morbidity, working very closely with general practitioners and with 
other specialists when appropriate. We have to weight up the risk of metabolic disturbance 
and its potential impact on future cardiovascular risk when selecting an antipsychotic drug. 
We have to take a careful medical history and be prepared to monitor weight and other 
metabolic risk, such as glucose and lipid profile. The lipid area is significantly understudied 
in patients taking antipsychotic medications. Lipids may be more important than diabetes 
because dyslipidemia appears to occur at a higher prevalence in this patient population. 
Lipid levels are a significant problem because physicians are seeing hypertriglyceridemia. 
Knowing what we know about what causes and contributes to cardiovascular disease, we 
are obliged to play detective and figure out why psychiatric patients are dying sooner and 
more often of cardiovascular disease than the general population. 
The big challenge for all is to ensure that the physical health of patients with mental illness 
is given the priority it deserves, helping them to face their future with the lowest possible 
morbidity and mortality odds stacked against them. 
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1. Introduction 
The pioneering work of Hans Selye (1936) led to the use of the word “stress” in a biological 
context gaining popularity world-wide. Stress is as an organic response to stressors that can 
be aversive stimuli or unknown situations capable of compromising homeostasis. During 
the stress reaction, the sympathetic nervous system and hypothalamic–pituitary–adrenal 
axis are stimulated. Consequently, serum concentrations of classical stress hormones, 
namely catecholamines and glucocorticoids, are increased and act on cells and tissues 
inducing adaptive changes in order to protect the organism and allow its survival. In 
addition, the stress reaction can also modulate immune system activities and the secretion of 
other hormones (gonadotrophins, estrogen, testosterone, thyroid, angiotensins). 
Considering that organic homeostatic systems are subject to frequent environmental and 
internal variations, Sterling and Eyer (1988) proposed the term alostasis to describe the 
adaptative processes that actively maintain stability through physiological changes. 
The terms eustress and efficient allostasis describe facile adaptation, such as a quick peak 
stress response to mobilize energy to deal with an acute stressor, and a rapid return to 
baseline, when the stressor terminates. On the other hand, distress or allostatic load refers to 
an imbalance in systems that promote adaptation (Epel, 2009; Korte et al., 2005). This 
imbalance can simply be the result of too much repeated stress, but it can also be the result 
of adaptative systems that are out of balance and fail to shut-off or, alternatively, systems 
that fail to return to normal (Epel, 2009). Therefore the shut-off of the stress response is 
particularly important, because, when systems do not shut off in time, they can cause 
damage or promote pathology (McEwen, 1998). 
The classical stress hormones, glucocorticoids (cortisol) and catecholamines (epinephrine 
and norepinephrine), are catabolic and modulate the breakdown of glycogen, triglycerides 
and proteins into molecules that can be rapidly metabolized in order to generate energy 
(Black, 2002). These responses enable energy substrates to be directed to organs and tissues 
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with the greatest demand during the stress reaction, and support the fight or flight reaction 
to a stressor. 
During acute stress, there is a rapid and transient increase in blood concentrations of total 
cholesterol, low-density lipoprotein (LDL), apoprotein B, triglycerides, and free fatty acids 
(Stoney, 2007). This increase persists as along as the stressor is maintained (Black, 2002), and 
disappears in stress-free periods (Stoney et al., 1999). In chronic stress situations, it has been 
shown that dyslipidemia is maintained and may persist even after the stressor is no longer 
present (Neves et al., 2009). 
2. Dyslipidemia induced by stress: Physiological mechanisms  
Many studies have shown the effect of stress on lipid metabolism. Stress associated with a 
major disaster, such as an earthquake or loss of job and income is associated with increased 
total cholesterol, LDL, and triglycerides in the bloodstream (Stoney, 2007). The perception of 
increased stress during a period of high workload is associated with elevated cholesterol in 
the bloodstream and ingestion of foods that increase cholesterol (McCann et al., 1990). Acute 
psychological stress in healthy men and women reduces the clearance rate of exogenous fat 
(Stoney et al., 2002). Chronic psychological stress increased the plasma cholesterol level in 
medical students (O’Donnell et al., 1987). In a more recent study, Yoo et al., 2011, showed 
high prevalence of hypercholesterolemia in stressed female law enforcement officers in 
comparison with the general female population. Moreover, elevated basal cortisol 
concentrations and lower circadian cortisol variability can induce dyslipidemia in patients 
with depressive and anxiety disorders (Venn et al., 2009; Vogelzangs et al., 2007). These 
patients presented hypercortisolism, increased serum levels of total cholesterol, LDL, and 
triglycerides and decreased serum levels of HDL (Venn et al., 2009). 
In animal studies, it has been shown that electric shock stress increases plasma cholesterol 
concentrations (Berger et al., 1980), and unpredictable immobilization stress decreases HDL, 
increases blood LDL, and very-low-density lipoprotein (VLDL) concentrations in rats 
(Bryant et al., 1988). Chronic mild unpredictable stress increases triglycerides, total 
cholesterol, VLDL, and LDL concentrations in the bloodstream of stressed rats compared 
with control rats and this effect was observed 15 days after the stress protocol had ended 
(Neves et al., 2009). 
The stressful modern lifestyle exerts a strong influence on lipid metabolism (Black, 2002) 
and may transform adaptative responses to pathophysiological changes. Acute increases in 
blood lipids are necessary for the individual to survive and adapt to the stressor. However 
prolonged changes in lipid metabolism induced by chronic stress can result in 
cardiovascular diseases such as atherosclerosis, coronary heart disease, and stroke (Brindley 
et al., 1993). 
The negative effects of sustained stress-induced dyslipidemia are related to a bidirectional 
relationship between stress hormones and insulin. Catecholamines directly stimulate free 
fatty acid and glycerol secretion in the bloodstream from fat depots, a process that may 
result from increased blood flow through adipose tissue or from adipose-β2 adrenoceptor 
stimulation (Stoney, 2007). Stress-induced high glucocorticoid concentration exerts a 
permissive effect on these lipolytic actions of catecholamines (Brindley et al., 1993). Since 
insulin regulates triglyceride synthesis and hepatic VLDL production, insulin resistance 
results in unregulated triglyceride synthesis and VLDL production (Stoney, 2007) and 
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triglycerides are secreted by the liver in large quantities within the VLDL particles (Black, 
2003). Therefore both catecholamines and glucocorticoids antagonize the actions of 
insulin, contributing to insulin resistance (Kyrou & Tsigos, 2009; Lafontan & Langin, 
2009). 
Moreover, hyperinsulinemia acts centrally to stimulate sympathetic nervous system activity, 
resulting in increased secretion of catecholamines (Black, 2003), and the absence of 
satisfactory insulin action facilitates the actions of cortisol and glucagon, which in turn 
stimulate phosphatidate phosphohydrolase activity to synthesize hepatic triglyceride 
(Brindley et al., 1993). 
The cortisol also induces apoprotein B (apo B) secretion from the liver in the proportion of 
one apo B molecule per VLDL particle (Brindley et al., 1993), consequently increasing the 
VLDL concentrations in the bloodstream. As each VLDL particle is metabolized to 
intermediate-density lipoprotein (IDL) or LDL, the action of the cortisol that stimulates apo 
B secretion also results in increased LDL particles in the blood. Furthermore, in the presence 
of stress-induced insulin resistance, high levels of glucocorticoids suppress the hepatic LDL 
receptors, which delay LDL clearance (Stoney, 2007). 
Contributing to all these processes, it has been shown that perilipin, which coats the 
surface of lipid droplets to restrict lipase access to the triglyceride core within the droplet, 
may suffer phosphorylation and/or down-regulation by glucocorticoid action, thereby 
facilitating the lipolysis of triglycerides in fatty acids and glycerol (Xu et al., 2001). This 
sets off a vicious cycle, leading to more and more triglycerides being produced by the 
liver and secreted in VLDL particles, as a result of the stimulation of glucocorticoids and 
fatty acids. 
In addition, norepinephrine and cortisol inhibit lipoprotein lipase activity, leading to 
diminished triglyceride clearance, decrease in HDL concentration, and increase in VLDL, 
IDL, and LDL concentrations in the bloodstream (Stoney, 2007). Norepinephrine also 
diminishes hepatic triglyceride lipase activity, which in turn promotes high concentrations 
of lipoproteins rich in triglycerides in the blood (Stoney, 2007). 
In the context of stress-induced dyslipidemia, changes in food ingestion must also be 
considered. During acute stress, transient dyslipidemia and food intake inhibition are 
mediated by β-adrenergic activation and increased hypothalmic corticotrophin releasing 
hormone (CRH) levels which act as catabolic signals. On the other hand, chronic activation 
of the hypothalamic-pituitary-adrenal axis has been associated with overeating and obesity 
(Dallman et al., 2004; Nishitani & Sakakibara, 2006). Many studies have supported this 
relationship. Lemieux & Coe, 1995, related that approximately 50% of women with 
posttraumatic stress disorder as a result of childhood sexual abuse were overweight, and 
also showed high concentrations of norepinephrine, epinephrine, and dopamine in urine. 
Changes in sleep-wake cycles associated with stress, resulting in sleep loss, induce 
decreased leptin levels, increased ghrelin levels, and increased hunger and appetite (Pejovic 
et al., 2010; Spiegel et al., 2004). In addition, the parent’s lifestyle can influence metabolism, 
and individuals exposed to maternal stress during intrauterine life can exhibit deregulation 
of body weight control mechanisms and blood lipid profile (De Moura, 2008). The 
relationship between excessive glucocorticoids and visceral fat accumulation has also been 
discussed by Björntorp & Rosmond, 1999. 
Thus, the typical response to chronic stress is not by way of avoiding food but by 
increasing the intake of sugar- and fat-rich comfort foods, which make people feel better 
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(Stoney, 2007; Torres & Nowson, 2007). Dallman et al., 2003, suggested that people or 
animals eat comfort food in an attempt to reduce activity in the ‘chronic stress-response 
network’ with its attendant anxiety. They suggested the following mechanism: first, in the 
periphery, glucocorticoids stimulate accretion of mesenteric energy stores; second, as the 
abdominal energy-generated (unidentified) signal increases, the negative input to 
catecholaminergic cells in the nucleus tractus solitarius reduces the synthesis of enzymes 
required for norepinephrine synthesis; third, the decreased noradrenergic signal to the 
hypothalamic paraventricular nucleus (PVN), in turn, decreases CRH synthesis and 
secretion. Thus, there is a powerful metabolic feedback control of CRH in the PVN, which 
may indirectly decrease glucocorticoid-action in the central nucleus of the amygdala; and 
thereby control anxiety (Korte et al., 2005). Consequently, all these mechanisms can lead 
to obesity and dyslipidemia due to overeating. In addition, it has been proposed that 
when chronic stress, to which animals and humans cannot easily adapt, is combined with 
high-fat high-sugar diets, it stimulates the sympathetic nerves to upregulate the 
expression of neuropeptide Y, an adrenergic cotransmitter and stress mediator. Stress and 
hypercaloric diets also increase glucocorticoid concentration in visceral fat, which in turn 
upregulates the expression of neuropeptide Y and its receptor Y2R, resulting in  
fat growth, hyperinsulinemia and hyperlipidemia (Bartolomucci et al., 2009; Kuo et al., 
2008). 
Some studies have also shown that glucocorticoid actions in the target tissues depend not 
only on circulating hormone levels, but also on intracellular glucocorticoid receptors and 
activities of both 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) and 2 (Bose et al., 
2009). The effects of glucocorticoid are enhanced by the enzyme 11β-HSD1 in the stromal 
cells of visceral fat, since this enzyme catalyzes the conversion of inactive cortisone to active 
glucocorticoid in local tissue. It has been shown that transgenic knockout mice, which 
overexpress 11β-HSD1 in adipose tissue, present accumulation of visceral adipose tissue, 
hypertension, dyslipidemia and glucose intolerance (Masuzaki et al., 2001; Masuzaki & 
Flier, 2003). Therefore 11β-HSD1 plays an important role in the development of metabolic 
disease associated with stress (Bose et al., 2009; Walker & Stewart, 2003). 
In addition, cytokines such as interleukin 6 (IL-6), tumor necrosis factor (TNF)-α, and 
leptin released from fatty cells also contribute to dyslipidemia induced by stress. IL-6 
increases the activity of 11β-HSD1 with consequent expansion of visceral fat. TNF-α 
induces lipolysis in adipose tissue. Both IL-6 and TNF-α decrease lipoprotein lipase 
activity, contributing to the increase in triglyceride levels induced by stress (Black, 2003). 
Moreover, TNF-α induces insulin resistance because it depresses insulin receptor activity 
(Yudkin et al., 2000). TNF-α also induces IL-6 synthesis, and stimulates leptin synthesis, 
which acts centrally to decrease appetite and increase thermogenesis to decrease fat 
storage (Black, 2003). Leptin increases the activity of sympathetic nervous system 
centrally (Mohamed-Ali et al., 1998), which in turn stimulates increased release of TNF-α 
and IL-6 from adipocytes (Black, 2003). This sympathetic nervous system hyperactivity 
induced by high levels of leptin in the bloodstream would provide an additional effect of 
catecholamines on the genesis of insulin resistance and dyslipidemia associated with 
stress in obese individuals.  
Therefore, dyslipidemia induced by stress involves complex interactions among stress 
hormones, insulin, adipose tissue metabolism and cytokines. Figure 1 indicates the 
physiological mechanisms of dyslipidemia induced by stress.  
 





































Fig. 1. Schematic representation of physiological mechanisms of dyslipidemia induced by 
stress. Hypothalamic-pituitary-adrenal axis (HPA), low-density lipoprotein (LDL), very-
low-density lipoprotein (VLDL), free fatty acids (FFA), neuropeptide Y (NPY), tumor 
necrosis factor (TNF-α), interleukin 6 (IL-6). Solid arrows show stimulatory effects; dashed 
arrows indicate inhibitory effects. 
3. Stress, dyslipidemia and atherosclerosis: Putative mechanisms 
Atherogenic dyslipidemia is a major underlying cause of the development of 
atherosclerosis, which is an inflammatory disease (Mullick et al., 2006; Sheril et al., 2009). 
Since the stress-induced atherogenic lipid profile potentiates the effects of dietary and 
genetic factors in atherogenesis (Brindley et al., 1993), stress has been recognized as a risk 
factor for atherosclerosis (Kyrou & Tsigos, 2009; Shively et al., 2009). However, despite the 
association between dyslipidemia and atherosclerosis, many individuals develop severe 
atherosclerotic lesions associated with low serum lipid concentration, and others develop far 
more severe atherosclerosis than would be expected on the basis of a modest elevation of 
serum lipids (Kaplan et al., 1983). In this context, other effects of stress, not related 
specifically to dyslipidemia, are also involved in atherogenesis (Bierhaus et al., 2003; Gu et 
al., 2009) and approximately 40% of cases without known causal factor, have been attributed 
to stressful situations (Black, 2002). 
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stress. Hypothalamic-pituitary-adrenal axis (HPA), low-density lipoprotein (LDL), very-
low-density lipoprotein (VLDL), free fatty acids (FFA), neuropeptide Y (NPY), tumor 
necrosis factor (TNF-α), interleukin 6 (IL-6). Solid arrows show stimulatory effects; dashed 
arrows indicate inhibitory effects. 
3. Stress, dyslipidemia and atherosclerosis: Putative mechanisms 
Atherogenic dyslipidemia is a major underlying cause of the development of 
atherosclerosis, which is an inflammatory disease (Mullick et al., 2006; Sheril et al., 2009). 
Since the stress-induced atherogenic lipid profile potentiates the effects of dietary and 
genetic factors in atherogenesis (Brindley et al., 1993), stress has been recognized as a risk 
factor for atherosclerosis (Kyrou & Tsigos, 2009; Shively et al., 2009). However, despite the 
association between dyslipidemia and atherosclerosis, many individuals develop severe 
atherosclerotic lesions associated with low serum lipid concentration, and others develop far 
more severe atherosclerosis than would be expected on the basis of a modest elevation of 
serum lipids (Kaplan et al., 1983). In this context, other effects of stress, not related 
specifically to dyslipidemia, are also involved in atherogenesis (Bierhaus et al., 2003; Gu et 
al., 2009) and approximately 40% of cases without known causal factor, have been attributed 
to stressful situations (Black, 2002). 
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The atherogenic effects of stress include changes in nitric oxide (NO) and cytokine 
production, vascular smooth muscle mitogenesis, occurrence of insulin resistance, 
neuropeptide Y (NPY) actions and modulation of the renin-angiotensin system activity. 
These effects are directly and indirectly related to stress-induced dyslipidemia, as will be 
pointed out below. 
The healthy endothelium provides a smooth barrier that limits the activation of 
proinflammatory factors, blocks the transfer of Apo-B 100-containing atherogenic lipid 
particles into subendothelial space, inhibits the release of chemokines and cytokines, and 
prevents platelet and monocyte adhesion to the vascular wall (Cersosimo & DeFronzo, 
2006). A high amount of NO is produced by endothelial nitric oxide synthase (eNOS). It is a 
vasodilator, has antithrombogenic properties, is an inhibitor of smooth muscle cell 
proliferation and of leukocyte- and monocyte-adhesion (Badimón & Martínez-González, 
2002; Sudano et al., 2006). Decrease in NO bioavailability is a key feature of endothelial 
dysfunction resulting in lower responses to vasodilator agents (Codoñer-Franch et al., 2011), 
and represents an early stage of atherosclerosis (Badimón & Martínez-González, 2002). 
Endothelial dysfunction contributes to the development and progression of atherosclerosis 
by favoring coagulation, inflammatory cell adhesion, imbalance between vasoconstriction 
and vasodilation, and by enhancing transendothelial transport of atherogenic particles 
(Cersosimo & DeFronzo, 2006). 
High stress-induced glucocorticoid levels reduce the expression of guanosine triphosphate 
cyclohydrolase 1 messenger ribonucleic acid (mRNA), necessary for tetrahydrobiopterin 
cofactor (BH4) synthesis, which stabilizes eNOS (Mitchell et al., 2004). If BH4 levels decrease, 
endothelial eNOS becomes uncoupled and transfers electrons to molecular oxygen 
generating superoxide anions (Rizzo et al., 2009), which react avidly with NO to form 
peroxynitrites (Förstermann & Münzel, 2006), resulting in diminished NO bioavailability, 
and favoring the traffic of oxidized lipids across the endothelium. Associated with this 
injurious effect of glucorticoids, the high LDL levels induced by stress also decrease eNOS 
mRNA expression (Liao et al., 1995). 
Considering dyslipidemia induced by stress, it has been reported that before structural 
changes appear, chronic elevations of cholesterol in the bloodstream are frequently 
associated with impaired endothelium-dependent NO production due to increased 
interaction between caveolin and eNOS (Feron et al., 1999). Caveolin proteins are expressed 
in the majority of the cell types that play a role in atherogenesis, including endothelial cells, 
macrophages, and smooth muscle cells (Frank & Lisanti, 2004). High levels of LDL-
cholesterol increase the caveolin concentration in endothelial cells (Feron et al., 1999), 
strengthen the calveolin-eNOS complex, and reduce the interaction between Ca2+-
calmodulin and eNOS. These effects decrease eNOS translocation from caveolae to the 
cytoplasm and considerably diminish NO production (Feron et al., 1999; Frank & Lisanti, 
2004). In addition, lipid peroxidation induced by stress also impairs nitric oxide production 
(NO), stimulates inflammatory response, and increases the traffic of inflammatory 
molecules and oxidized LDL to sub-endothelial space, leading to vascular endothelial 
dysfunction (Black, 2002; Black, 2003; Black & Garbutt, 2002; Rizzo et al., 2009). 
Insulin resistance is also involved in the atherogenic effects of stress. Insulin stimulates NO 
production by the endothelium (Muniyappa & Quon, 2007). During chronic stress cortisol-
induced insulin resistance (Black, 2002; Kyrou & Tsigos, 2009) decreases this effect, and 
endothelial dysfunction may occur. In addition, insulin resistance is associated with 
inhibition of the phosphatidylinositol 3-kinase pathway and over-stimulation of the 
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mitogen-activated protein kinase pathway in endothelial cells. Impairment of the 
phosphatidylinositol 3-kinase pathway reduces eNOS activity, and accentuates free fatty 
acid-evoked oxidative stress. These effects decrease NO bioavailability and promote an 
imbalance between vasoconstriction and vasodilation (Cersosim & DeFronzo, 2006; 
Muniyappa & Quon, 2007) predisposing the individual to atherosclerosis and arterial 
hypertension. In addition insulin resistance increases the reactive oxygen species, reducing 
eNOS activity (Muniyappa et al., 2008). 
Morphological changes in blood vessels are also associated with atherosclerosis. The 
increase in intima media thickness (IMT) in the carotid artery has been used as a marker of 
target organ damage in human hypertension (Sierra & de la Sierra, 2008). In experimental 
studies, the IMT of the aorta observed in stressed rats (Okruhlicová et al., 2008) was related 
to the atherogenic effects of stress. In healthy blood vessels, NO produced by the 
endothelium maintains the mitogenic quiescence of smooth muscle cells. Decreased NO 
bioavailability induced by stress-related glucocorticoid levels or -insulin resistance results in 
the loss of this effect and consequently vessel wall hypertrophy may occur (Costa & 
Assreuy, 2005). In fact, it has been observed that rats submitted to chronic mild 
unpredictable stress presented higher IMT and lower relaxation response to acetylcholine in 
the thoracic aorta, in comparison with non stressed animals. These effects were observed 15 
days after the end of the stress protocol and were associated with insulin resistance and 
dyslipidemia. However, in this study, the dyslipidemia induced by the hypercaloric diet 
alone, did not promote morphological or functional changes in the thoracic aorta, or insulin 
resistance evidencing the role of stress in pro-atherogenic effects (Neves et al., 2011). 
NPY, a hormone known as orexigenic peptide, may also be involved in the atherogenic 
effects of stress. Some stressors such as cold and aggression, increase the release of NPY 
from sympathetic nerves (Kuo et al., 2007). The peripheral actions of NPY are stimulatory, 
synergizing with glucocorticoids and catecholamines to potentiate the stress response. It 
causes prolonged vasoconstriction, potentiating the effect of norepinephrine, induces 
hyperlipidemia, and vascular remodeling via smooth muscle cell proliferation, in addition 
to stimulating monocyte migration and activation (Kuo et al., 2007). NPY upregulates its Y2 
receptors in a glucocorticoid-dependent manner in abdominal fat, consequently leading to 
abdominal obesity, hyperinsulinemia and dyslipidemia (Kuo et al., 2008). In blood vessels, 
Y1 and Y5 receptor activation promotes pro-atherogenic responses (Zukowska, 2005). 
In addition to all the above-mentioned mechanisms, the inflammatory process also forms 
part of the stress response (Black, 2003), and is pathophysiologically linked to 
atherosclerosis (van Oostrom et al., 2004). In the atherogenic process, the high level of 
catecholamines induced by stress stimulates endothelial permeability to the traffic of 
oxidized LDL. Once trapped in the endothelium of an artery, LDL can undergo progressive 
oxidation, cross the endothelial barrier, and be internalized by macrophages expressing 
scavenger receptors, leading to lipid peroxide formation and accumulation of cholesterol 
esters, culminating in foam cells formation (Ross, 1999; Singh & Mehta, 2003). Oxidized LDL 
upregulates the expression of adhesion molecules and secretion of chemokines, which 
contributes to the recruitment of circulating monocytes and leukocytes (Cersosimo & 
DeFronzo, 2006; Steinberg, 2002). One of the initial steps in the formation of atherosclerosis 
is the adhesion of monocytes to the endothelium, their entry into sub-endothelial space, 
followed by their differentiation into macrophages (Lamharzi et al., 2004). These cells are 
then responsible for taking up LDL and other particles, thereby starting the atherogenesis 
process (Lamharzi et al., 2004). In foam cell formation, the macrophages in the endothelial 
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mitogen-activated protein kinase pathway in endothelial cells. Impairment of the 
phosphatidylinositol 3-kinase pathway reduces eNOS activity, and accentuates free fatty 
acid-evoked oxidative stress. These effects decrease NO bioavailability and promote an 
imbalance between vasoconstriction and vasodilation (Cersosim & DeFronzo, 2006; 
Muniyappa & Quon, 2007) predisposing the individual to atherosclerosis and arterial 
hypertension. In addition insulin resistance increases the reactive oxygen species, reducing 
eNOS activity (Muniyappa et al., 2008). 
Morphological changes in blood vessels are also associated with atherosclerosis. The 
increase in intima media thickness (IMT) in the carotid artery has been used as a marker of 
target organ damage in human hypertension (Sierra & de la Sierra, 2008). In experimental 
studies, the IMT of the aorta observed in stressed rats (Okruhlicová et al., 2008) was related 
to the atherogenic effects of stress. In healthy blood vessels, NO produced by the 
endothelium maintains the mitogenic quiescence of smooth muscle cells. Decreased NO 
bioavailability induced by stress-related glucocorticoid levels or -insulin resistance results in 
the loss of this effect and consequently vessel wall hypertrophy may occur (Costa & 
Assreuy, 2005). In fact, it has been observed that rats submitted to chronic mild 
unpredictable stress presented higher IMT and lower relaxation response to acetylcholine in 
the thoracic aorta, in comparison with non stressed animals. These effects were observed 15 
days after the end of the stress protocol and were associated with insulin resistance and 
dyslipidemia. However, in this study, the dyslipidemia induced by the hypercaloric diet 
alone, did not promote morphological or functional changes in the thoracic aorta, or insulin 
resistance evidencing the role of stress in pro-atherogenic effects (Neves et al., 2011). 
NPY, a hormone known as orexigenic peptide, may also be involved in the atherogenic 
effects of stress. Some stressors such as cold and aggression, increase the release of NPY 
from sympathetic nerves (Kuo et al., 2007). The peripheral actions of NPY are stimulatory, 
synergizing with glucocorticoids and catecholamines to potentiate the stress response. It 
causes prolonged vasoconstriction, potentiating the effect of norepinephrine, induces 
hyperlipidemia, and vascular remodeling via smooth muscle cell proliferation, in addition 
to stimulating monocyte migration and activation (Kuo et al., 2007). NPY upregulates its Y2 
receptors in a glucocorticoid-dependent manner in abdominal fat, consequently leading to 
abdominal obesity, hyperinsulinemia and dyslipidemia (Kuo et al., 2008). In blood vessels, 
Y1 and Y5 receptor activation promotes pro-atherogenic responses (Zukowska, 2005). 
In addition to all the above-mentioned mechanisms, the inflammatory process also forms 
part of the stress response (Black, 2003), and is pathophysiologically linked to 
atherosclerosis (van Oostrom et al., 2004). In the atherogenic process, the high level of 
catecholamines induced by stress stimulates endothelial permeability to the traffic of 
oxidized LDL. Once trapped in the endothelium of an artery, LDL can undergo progressive 
oxidation, cross the endothelial barrier, and be internalized by macrophages expressing 
scavenger receptors, leading to lipid peroxide formation and accumulation of cholesterol 
esters, culminating in foam cells formation (Ross, 1999; Singh & Mehta, 2003). Oxidized LDL 
upregulates the expression of adhesion molecules and secretion of chemokines, which 
contributes to the recruitment of circulating monocytes and leukocytes (Cersosimo & 
DeFronzo, 2006; Steinberg, 2002). One of the initial steps in the formation of atherosclerosis 
is the adhesion of monocytes to the endothelium, their entry into sub-endothelial space, 
followed by their differentiation into macrophages (Lamharzi et al., 2004). These cells are 
then responsible for taking up LDL and other particles, thereby starting the atherogenesis 
process (Lamharzi et al., 2004). In foam cell formation, the macrophages in the endothelial 
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space also have VLDL receptors, which bind the apolipoprotein (apo) E-containing 
lipoproteins, including VLDL, intermediate density lipoprotein, and β-migrating VLDL. The 
LDL-receptor-related protein in macrophages is also capable of binding apo E-containing 
lipoproteins, lipoprotein lipase, and lipoprotein lipase-triglyceride-rich lipoprotein complex 
(Nakazato, 1996), leading to a sequence in the development of atherosclerosis. 
In addition, high levels of free fatty acids also may amplify monocyte inflammation via toll-
like receptors in the presence of high glucose levels (Dasu & Jialal, 2011). Lamharzi et al., 
2004, showed that free fatty acids in concert with glucose stimulate machrophage 
proliferation involving glucose-dependent oxidation of LDL in atherosclerotic lesions. Toll 
like receptors are expressed by machrophages in murine and human lipid-rich 
atherosclerotic plaques and upregulated by oxidized LDL (Xu et al., 2001). Recently Gu et 
al., 2009, showed the importance of toll-like receptor 4 in atherosclerosis induced by chronic 
mild stress in aortas from apolipoprotein-E-knockout-mice. Toll-like receptor 4 is present in 
T cells, monocytes, and macrophages, and is a key signaling receptor of innate immunity. 
Toll-like receptor 4 plays an important role in atherogenesis because it recognizes pathogen-
associated molecular patterns and activates inflammatory cells via the nuclear factor kB 
(NF-kB) pathway (Bierhaus et al., 2003; Gu et al., 2009). During the stress reaction, 
glucocorticoids and catecholamines can induce cytokine production by endothelial cells and 
macrophages (Black, 2003; Chae et al., 2001) and activation of the NF-kB pathway leads to 
the synthesis of the following proinflammatory chemokines: interleukin 1-β, inteleukin 6, 
TNF-α, monocyte chemoattractant protein-1, intercellular adhesion molecule-1. Interleukin 
1-β and inteleukin 6 influences smooth muscle cell proliferation and/or migration (Gu et al., 
2009), and inhibits eNOS activity (Muniyappa et al., 2008). TNF-α increases endothelin-1 
secretion, decreases NO production in endothelial cells, inducing vasoconstriction 
(Muniyappa & Quon, 2007), and can induce interleukin 6 production (Black, 2003). 
Monocyte chemoattractant protein-1 is correlated with neointimal proliferation and plays a 
role in the transition from the stable state of lesion to the more complex state of 
atherosclerosis (Tellez et al., 2011). Intercellular adhesion molecule-1 may contribute to 
accelerating atherosclerosis in insulin-resistant states (Muniyappa et al., 2008). 
Hypertriglyceridemia associated with stress may also increase NF-kB, consequently 
activating proinflammatory molecules (Fitch et al., 2011). 
In addition, the accumulation of macrophages may also be associated with increased plasma 
concentration of C-reactive protein (CRP) (Ross, 1999). CRP is the principal down-stream 
mediator of inflammatory acute phase response, which is primarily derived via interleukin 
6-dependent hepatic biosynthesis (Pradhan et al., 2001). CRP interacts with oxidized LDL to 
form proatherogenic oxidized LDL/CRP complexes, perpetuating vascular inflammation, 
triggering an autoimmune response, and accelerating atherogenesis (Matsuura et al., 2009; 
Sitia et al., 2010). 
Activation of the renin-angiotensin system (RAS) by stress also plays a role in the 
pathogenesis of endothelial dysfunction, hypertension and atherosclerosis. Lipid 
accumulation in blood vessels enhances the expression of RAS components, which in turn 
stimulates accumulation of oxidized LDL in blood vessels (Singh & Mehta, 2003). Activation 
of the angiotensin II-type 1 receptor (AT1R) leads to vasoconstriction and neurohumoral 
activation, and is associated with reduced NO bioavailability, vascular cell apoptosis, 
increased oxidized LDL receptor expression, and proinflammatory cytokine production (Sitia 
et al., 2010). According Nickening et al., 1999, LDL-cholesterol can accumulate in vascular 
smooth muscle cells, and this effect is mediated via AT1R. Angiotensin II increases LDL uptake 
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by arterial wall macrophages (Keidar et al., 1994). Angiotensin II binds LDL and the 
angiotensin II-modified LDL is taken up by macrophages via scavenger receptors, leading to 
cellular cholesterol accumulation (Keidar et al., 1996). In atherogenic dyslipidemia, 
hypercholesterolemia increases AT1R density and its functional responsiveness to 
vasoconstrictors, whereas the administration of statins reduces AT1R expression and 
deregulates its functions. Moreover, the localization of angiotensin-converting enzyme in 
atherosclerotic lesions suggests a capacity for local generation of angiotensin II and 
proinflammatory substances (Sitia et al., 2010). There is also evidence that 
hypercholesterolemia increases plasma angiotensinogen and angiotensin peptide production 
(Sitia et al., 2010), and that AT1R antagonism improves hypercholesterolemia-associated 























































Fig. 2. Schematic representation of putative mechanisms involved in the relations between 
among stress, dyslipidemia, and atherosclerosis. Hypothalamic-pituitary-adrenal axis (HPA), 
neuropeptide Y (NPY), low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), 
free fatty acids (FFA), endothelial nitric oxide synthase (eNOS), nitric oxide (NO), endothelin 1 
(ET-1). Solid arrows show stimulatory effects; dashed arrows indicate inhibitory effects. 
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mediator of inflammatory acute phase response, which is primarily derived via interleukin 
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by arterial wall macrophages (Keidar et al., 1994). Angiotensin II binds LDL and the 
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Fig. 2. Schematic representation of putative mechanisms involved in the relations between 
among stress, dyslipidemia, and atherosclerosis. Hypothalamic-pituitary-adrenal axis (HPA), 
neuropeptide Y (NPY), low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), 
free fatty acids (FFA), endothelial nitric oxide synthase (eNOS), nitric oxide (NO), endothelin 1 
(ET-1). Solid arrows show stimulatory effects; dashed arrows indicate inhibitory effects. 
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Atherosclerosis is an inflammatory disease and stress contributes to its development.  
Therefore, if we can block or minimize the stress components that directly or indirectly 
induce atherogenesis, it will be possible to preserve the protective components of vascular 
function and structure, thereby developing new preventive and therapeutic possibilities. 
Figure 2 illustrates the putative mechanisms of the relations between stress, dyslipidemia, 
and atherosclerosis. 
4. Reduction of dyslipidemia induced by stress: Physical exercise and 
nutritional intervention 
The role of stress in the etiology of chronic degenerative diseases is increasingly recognized 
(Gerber & Pühse, 2009; Holmes et al., 2010; Tsatsoulis & Fountoulakis, 2006; Yin et al., 2005). 
Moreover, it has been reported that obese people have an exaggerated response to stress, 
which may further increase the risk of weight gain, leading to the development of insulin 
resistance, hyperlipidemia, diabetes mellitus, hypertension and atherosclerosis in both men 
and women. This burden of chronic degenerative diseases is strongly influenced by several 
lifestyle factors, including the way an individual perceives a stressful situation, i.e., “mental 
fitness” and also his/her general physical condition or “physical fitness” (McEwen, 1998). 
Tsatsoulis & Fountoulakis, 2006, demonstrated that stress-mediated allostatic load, in the 
presence of physical inactivity, is associated with an increased risk of mental and physical 
illness, and direct evidence for this notion has been provided by several studies. A strong 
inverse association between physical activity and the metabolic syndrome has been 
demonstrated, and several years ago this association was shown to be much steeper in unfit 
individuals (Kriska et al., 1993; Lindgärde & Saltin, 1981). Evidence for this view was also 
provided by the MacArthur studies of successful aging based on a large cohort of elderly 
men and women (Seeman et al., 1997), showing that subjects with low levels of physical and 
mental fitness had higher prevalence of cardiometabolic disease when compared with those 
with high fitness levels. Moreover, a strong association between physical inactivity, 
excessive food consumption, high-fat diet and increasing incidence of insulin resistance, 
Type 2 diabetes, (Hawley, 2004; Steanovv et al., 2011), development of obesity (Venables & 
Jeukendrup, 2009; Vessby, 2000) and depression (Win et al., 2011) has also been described in 
the literature. Considering that stress, physical inactivity, and aging (associated with 
declining physical activity and metabolic rate, coupled with an energy intake not matched to 
the declining need), in addition to a high-fat diet, are the very features of our current 
lifestyle, the incidence of this “stress-induced/exercise deficient” phenotype is becoming 
increasingly prevalent in modern society (Davy et al., 1996, Hawley, 2004, Poehlman et al., 
1995, Schiut et al., 1998, Tsatsoulis & Fountoulakis, 2006). 
Based on the above mentioned findings, it is reasonable to assume that physical inactivity may 
potentiate the stress-related allostatic load and comorbidities, since the energy substrate that is 
mobilized during stress is not oxidized but is stored in visceral fat depots. This adaptation 
creates a vicious cycle, in which perceived stress is also associated with decreased participation 
in several health behaviors including exercise, social behaviors, stress management/rest, and 
safety/environmental behaviors, as shown by Padden et al., 2011, in the study on health 
behavior of military spouses during deployment separation. In this context, physical exercise 
practiced as a non-pharmacological alternative, either with or without the association of 
pharmacological therapies, is very important, and a great deal of attention should be given to 
the barriers imposed, especially by mood disorders, including depression. Individuals in this 
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condition are at disadvantage, since most of the time they lack the energy and motivation to 
exercise, and this overwhelming feeling of lethargy seems very difficult to shift (Chaput et al., 
2011). In this situation, when psychological stress is not accompanied by physical activity 
(such as the fight or flight reaction) and by effective use and fast clearance of free fatty acids, 
triggered by stimulation of the sympathetic nervous system, these are converted into 
triglycerides by the liver and then circulate in the blood within the VLDL (Howard et al., 
1993). In fact, this maladaptative situation can lead to the development of dyslipidemia, 
reflected by elevated plasma triglyceride and reduced HDL concentration, overproduction of 
VLDL-apolipoprotein (apo) B-100, decreased catabolism of apoB containing particles, and 
increased catabolism of HDL apoA-I particles (Watts et al., 2008; Watts et al., 2009). 
While physical inactivity may potentiate the stress-induced allostatic load, there is 
accumulating evidence suggesting that the adoption of an active lifestyle, including exercise 
training, may play a protective role in stress system dysregulation, reducing vulnerability to 
stress, and possibly delaying or preventing the future development of comorbidities, such as 
dyslipidemia, hypertension and insulin resistance (Roberts & Barnard, 2005; Tsatsoulis & 
Fountoulakis, 2006). In addition, physical activity may induce favorable changes in 
traditional and emerging coronary heart disease biomarkers among individuals with, or at 
high risk of coronary heart disease (Chainani-Wu et al., 2011). Assuming that the stress 
response is a neuroendocrine mechanism that occurs in anticipation of physical action, it is 
reasonable to assume that physical activity should provide the vehicle to prevent or combat 
the somatic and emotional consequences of stress. Thus, physical activity may promote 
physical and psychological benefits that are involved in both the indirect action of exercise 
in reducing stress, and a direct effect on various metabolic functions of the body (McMurray 
& Hanckney, 2005). 
The first rationale for using exercise as a stress reduction strategy was based on the cross-
stressor adaptation, a promising hypothesis first presented in the 1990s (Sothmann et al., 1996), 
which has not received strong support since the publication of recent meta-analyses (Forcier et 
al., 2006; Hamer et al., 2006; Jackson & Dishman, 2006). According to Chaput et al., 2011, the 
key question now is whether physical activity, which seems to modulate the level of stress, 
may interact in the relationship between stress and obesity. Different possible mechanisms 
have been proposed, suggesting that exercise training might protect against stress induced 
obesity. Regular exercise has been demonstrated to have positive effects on plasma lipid and 
lipoprotein profiles (Durstine et al., 2002) and these results may have a significant independent 
effect on HDL cholesterol (Thompson et al., 1988). During physical activity, exercise increases 
lipid oxidation and lipolysis to ensure an adequate oxygen supply (McMurray & Hanckney, 
2005), increases the ability of muscle tissue to take up and oxidize nonesterified fatty acids, and 
increases muscle lipoprotein lipase activity (Eriksson et al., 1997). Although studies indicate 
that exercise training changes gene expression in adipose tissue in different ways, affecting 
some types of adipose tissue more than others (Company et al., 2010), the lowering of plasma 
triglycerides proves the effects of exercise on VLDL kinetics. Moreover, it is important to 
highlight that a single 90-min bout of whole body resistance exercise (Tsekouras et al., 2009) or 
2h of cycling (Magkos et al., 2006) was proven to be enough to decrease fasting plasma VLDL-
triglyceride concentrations by increasing VLDL-triglyceride removal from plasma. These 
results may be due to the increase in blood flow and hepatic insulin sensitivity associated with 
an increase in lipoprotein lipase activity. 
In addition to its possible direct effect modulating the stress response, exercise training 
improves insulin sensitivity, which might counteract the insulin resistance state produced 
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improves insulin sensitivity, which might counteract the insulin resistance state produced 
 
Dyslipidemia - From Prevention to Treatment 
 
378 
by chronic hypercortisolemia (Tsatsoulis & Fountoulakis, 2006). Insulin secretion could then 
be reduced, and thereby, its deleterious impact on energy intake may be diminished. 
Moreover, exercise training improves glucose tolerance among non-diabetic, non-obese 
subjects with hypertriglyceridemia (Lampman & Schteingart, 1991) and enhances the 
oxidative capacity of skeletal muscle (Tsatsoulis & Fountoulakis, 2006). Together, these 
beneficial adaptations could prevent stress-induced fat deposition by routing the energy 
mobilized in response to the stressor toward oxidation rather than storage. 
Apart from the protective effects of exercise on the physical and metabolic aspects related to 
stress, a number of psychological and cognitive benefits have also been reported in the 
literature. These include improvements in depression and anxiety scores and general 
improvement in mood, cognitive functioning (Callaghan, 2004; Tsatsoulis & Fountoulakis, 
2006), well-being and self esteem, leading to a decrease in body fat, triglycerides, LDL/HDL 
cholesterol ratio in stressed patients (De Geus & Stubbe, 2007). Physical activity can improve 
mental health by reducing depressive symptoms in young men (McGale et al., 2011) and in 
patients with metabolic syndrome (Rubenfire et al., 2011). Moreover exercise induces the 
elevation of circulating brain derived neurotrophic factor, which is known to improve the 
health and survival of nerve cells, suggesting that exercise influences brain health (Yarrow 
et al., 2010). Using animal models, exercise has also been shown to induce antidepressant 
responses (Greenwood et al., 2003). In rats, swimming exercise induces a remission of 
anhedonic symptoms suggesting that exercise training might induce biological alterations 
similar to those provided by antidepressant drugs. In addition, exercise plays an important 
role in hippocampal protection from damage caused by exposure to glucocorticoids (Sigwalt 
et al., 2011). In this context, physical activity was able to stimulate the proliferation of 
hippocampal cells (Ehninger & Kempermann, 2003), promote alterations in synaptic 
plasticity, neurogenesis and synaptogenesis (Castrén, 2005), and may also be linked to 
increased levels of brain testosterone (Mukai et al., 2006). 
Another beneficial effect of exercise is related to feeding behavior. Stressful situations have 
been shown to affect feeding behavior (Wallis & Hetherington, 2009) that result in increased 
energy intake through the stimulation provided by ingesting palatable foods that may serve 
as feedback signals that reduce the perception and discomfort of stress, thereby contributing 
to the development of dyslipidemia and obesity (Dallman et al., 2005). Moreover 
glucorticoids are associated with high neuropeptide Y secretion, which has an orexigenic 
activity and increases the intake of sugar- and fat-rich- comfort foods (Kuo et al., 2008) and 
can lead to a state of leptin resistance and elevated levels of this hormone (Zakrzewska et al., 
1997). In this context, it has been demonstrated that physical activity has the potential to 
modulate appetite control by improving the sensitivity of the physiological satiety signalling 
system, by adjusting macronutrient preferences or food choices and by altering the hedonic 
response to food (Blundell et al., 2003). Indeed, dietary modification, associated with 
physical activity has been shown to exert significantly favorable effects on the treatment and 
prevention of stress-induced comorbidities, improving glycemia, blood pressure, body 
weight, fat distribution, and lipid profile, which in turn suggest that chronic degenerative 
diseases are largely preventable (Dagogo et al., 2010). Although exercise cannot change total 
cholesterol and LDL-cholesterol unless dietary fat intake is reduced, this result may be 
dependent on the amount of energy expenditure during exercise (Durstine et al., 2002). 
Furthermore, depending on the time that the exercise is performed (before or after ingestion 
of fatty foods), its acute responses related to improvement in lipoprotein metabolism may be 
different (Hashimoto et al., 2011). In a review of several studies realized by Leon & Sanchez 
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2001, one of proposals evaluated was the effects of aerobic exercise training on blood lipids 
and the relationship between these effects and diet. The results showed that majority of 
physically active individuals had an increase in HDL cholesterol, but this could be changed if 
there was a concomitant reduction in fat intake. The association between low-fat diet and 
exercise reduces LDL and HDL-cholesterol levels. Furthermore, reductions in total cholesterol, 
LDL-cholesterol and triglyceride levels were less frequently observed. As regards body weight 
loss, there was considerable variability between the groups, ranging from 7.2 Kg in the group 
that was not exposed to dietary intervention to 17.9 Kg in the group that underwent dietary 
intervention. In addition, Rubenfire et al., 2011, demonstrated that the association between 
changes in diet and exercise was effective in reducing cardiovascular risk in patients with 
metabolic syndrome. In this study, the nutritional component was based on a Mediterranean 
food pattern, and all the participants were provided with the information needed to optimize 
their nutritional choices in order to improve blood lipid and glucose levels, decrease body 
weight and blood pressure, and decrease insulin resistance (Rubenfire et al., 2011). It has also 
been proposed that high-fiber diets protect against obesity and cardiovascular disease by 
lowering insulin levels (Ludwig et al., 1999). In obese men, the implementation of a high-fiber 
and low-fat diet associated with regular physical activity resulted in significant reductions in 
inflammation and dyslipidemia by reducing serum lipids, insulin, oxidative stress, leukocyte-
endothelial interactions (Roberts & Barnard, 2005). 
Dietary fat influences glucose and lipid metabolism by altering cell membrane function, 
enzyme activity, insulin signaling, and gene expression (Risérus et al., 2009; Yamazaki et al., 
2011) and dietary fructose consumption appears to induce dyslipidemia, obesity (Stanhope 
et al., 2009) and hypertension (Cunha et al., 2007; Farah et al., 2006). A combination of social 
stress and high-fat diet resulted in a significant imbalance in lipid regulation associated with 
changes in the expression of hepatic genes, responsible for its regulation (Chuang et al., 
2010). Therefore, clinical strategies based on low fat and sugar intake associated with 
increase in physical exercise have been used, and have contributed to reducing the risks of 
developing coronary and metabolic diseases. 
5. Conclusion 
Dyslipidemia induced by stress is part of the body’s response to cope with stressors. The 
mobilization of lipids, glucose and proteins, allows the organs and tissues to maintain 
homeostasis and adapt to the stressor. Any deficiency in the activation of this mobilization 
of energetic fuels can compromise the survival of the individual. Therefore, the increase in 
blood lipids induced by stress is adaptive and it should return to normal levels when the 
stressor ends. However, when the stressor is maintained over a long period, the 
dyslipidemia induced by stress persists and may have deleterious effects, contributing to the 
occurrence of insulin resistance, obesity, hypertension and atherosclerosis. Considering that 
physical inactivity may potentiate these effects, the association of physical exercise and 
control of hypercaloric food consumption have been used in the treatment of dyslipidemia. 
Knowledge about the physiological mechanisms involved in the adaptive role of transient 
dyslipidemia induced by acute stress, and in the deleterious effects of sustained 
dyslipidemia induced by chronic stress is very important in the improvement and 
development of preventive and therapeutic approaches because in modern society we are 
continuously exposed to stressors. 
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1. Introduction 
The aim of this chapter is to achieve a synthesis of the major studies existing in the literature 
on correlations between lipid metabolism and malignant hemopathies. We will expose the 
fundamental research data and their impact on clinical treatment. The purpose of this 
review is to help the clinicians to understand better the pathological disorders of the lipid 
metabolism and use the existing therapeutic arsenal to improve the treatment outcomes. The 
research and the recognition of the presence of dyslipidemia is useful, as well as monitoring 
them during oncological therapy. The treatment of dyslipidemia may not be only an option 
when a patient with malignant hemopathy has acquired multidrug resistance. It can 
contribute to reversing this resistance, but it can also have adverse effects that must be 
recognized, followed and treated. 
There are numerous studies in literature, but the connection between blood levels of various 
lipid fractions and hematologic malignancies is still unknown (Cvetkovic et al., 2009). 
Various epidemiological studies have found that between blood lipids and various 
neoplastic diseases there are correlations, thus the question is whether in the pathogenesis of 
cancer are not involved various lipid disorders (Moschovi M et al., 2004). At the same time it 
is believed that in patients with metabolic syndrome (MS), blood lipid levels may have 
correlations with the risk of cancer (Ulmer H et al., 2009). 
2. The lipid profile evolution under cancer treatment 
Cvetkovic & al. studied 47 patients with malignant non-Hodgkin's lymphoma (NHL) and 
found that before the treatment, compared with patients in the control group, blood levels of 
phospholipids, cholesterol (CH) and high density lipoprotein-cholesterol (HDL-cholesterol) 
had significantly lower values. After chemotherapy (3 or 6 cycles) the blood lipid levels 
reached even lower values in patients where the disease progressed, as opposed to those 
who achieved complete remission or whose disease was stationary, cases in which lipids 
increased progressively. (Cvetkovic et al., 2009). 
In an other study conducted in Poland on the lipid levels of 238 patients with different 
hematological malignant diseases Kuliszkiewicz-Janus M et al. found that HDL-cholesterol 
values were significantly different from those of patients in the control group when the 
disease was in active phase, but in the remission phase the difference was statistically 
significant only in patients with NHL and acute leukemia (Kuliszkiewicz-Janus et al., 2008).  
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In a health investigation conducted on 156,153 subjects, with 5079 incident cancers in men 
and 4738 cancers in women, and a mean of 10.6 years of survey, there was an inverse 
association between serum triglyceride (TG) levels and NHL (2). But in the study conducted 
by Kuliszkiewicz-Janus M et al., the TG value increased in the active disease period in all the 
hematological malignancies besides NHL (Kuliszkiewicz-Janus et al., 2008). 
Mihăilă R and al. made a cross-sectional research on all the patients with chronic 
lymphocytic leukemia (CLL) existing in a county department of hematology and a group of 
volunteer subjects from the medical staff with no malignant pathology. They found an 
augmentation of TG values in the patients with CLL (p <0.00001), an argument for a 
possible link between the MS and chronic lymphoproliferations. Hypercholesterolemia 
present in the patients with CLL from the above study may have consequences regarding 
the multiple drug resistance, subject to further future study. (Mihăilă et al., 2010) 
Nearly all the children with ALL when diagnosed and during chemotherapy revealed a 
predictable model of serum dyslipidemia that consisted of very low levels of HDL-
cholesterol, and elevated TG, and low-density lipoprotein cholesterol (LDL-cholesterol), that 
regained normal values during the remission period (Moschovi et al., 2004). 
In patients with secondary hemophagocytic syndrome an augmentation of TG was observed 
when diagnosed or during the disease period and TG values decreased when the disease 
improved under treatment (Okamoto et al., 2009). In patients with aggressive T cell 
lymphoma, fasting TG level was higher in those with hemophagocytic syndrome group 
than in the patients who had no hemophagocytic syndrome (Tong et al., 2008). 
3. The consequences of treatments with antineoplastic drugs 
In children with acute lymphoblastic leukemia (ALL), treated with asparaginase 
dyslipidemia was frequently observed (Cohen et al., 2010). 
A child heterozygote for apolipoprotein E 3/4 and with ALL who received pegasparaginase, 
presented an important aumentation of serum TG value, which normalized after continuous 
insulin infusion (Lawson et al., 2011). Another patient with a heterozygote type of familial 
lipoprotein lipase defect syndrome developed an important increase of serum TG value that 
was treated by three plasma exchanges with frozen plasma (Nakagawa et al., 2008).  
An adult patient with ALL also had an acute pancreatitis because of an important 
hypertriglyceridemia that appeared after asparaginase administration (Kfoury-Baz et al., 
2008), as well as a 10 years old boy who had been previously treated with asparaginase and 
corticosteroids (Ridola et al., 2008), both successfully treated by plasmapheresis sessions 
(Kfoury-Baz et al., 2008; Ridola et al., 2008).  
In a group of children and adolescent patients recently diagnosed with ALL during 
treatment a progresive increase of serum CH values to 274+/-124 mg/dl was observed. In 
this group of patients the average value of TG during tratment was 459+/-526 mg/dl. Two 
patients had hypertriglyceridemia-related complications: a thrombosis of saggital sinus and 
an infarct of the left frontal lobe. The observed dyslipidemia disappeared in all children after 
the asparaginase administration (Cohen et al., 2010).  
A prospective study assessed the lipid levels in children with ALL. At diagnosis, there was a 
significantly low level of total CH and HDL-cholesterol and at the same time a high level of 
TG. The patients were treated with the ALLIC 2002 protocol (including L-asparaginase), 
during which the values of total CH and HDL-cholesterol augmented, but they still 
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remained lower than for the control group. The main serum TG level was significantly 
higher as compared to that of witnesses (Zalewska-Szewczyk et al., 2008).  
A retrospective analysis showed that imatinib mesylate, used for the treatment of patients 
with chronic myeloid leukemia, led to a diminishing of serum CH and TG values 
(Franceschino et al., 2008). In a Romanian patient with chronic myeloid leukemia who 
received usual-dose of imatinib mesylate, a rapid and sustained normalization of serum CH, 
TG, low- and high-density lipoproteins and glucose values was found (Gologan et al., 2009).  
In some types of leukemia it was found that Kit receptor tyrosine kinase is overexpressed in 
a pathological manner, also that CH depletion was able to prevent Kit-mediated activation 
of the phosphatidylinositol 3-kinase downstream target Akt, which inhibits cell proliferation 
(Jahn et al., 2007).  
The treatment of cutaneous lymphomas with T cells using bexarotene can produce a serum 
TG augmentation, as in the three cases reported. The treatment with fenofibrate is 
recommended, but if adverse effects occure or a statin is needed to reduce 
hypertriglyceridemia, omega-3 fatty acids may be a therapeutic solution during the 
bexarotene administration. (Musolino et al., 2009) 
4. Is the metabolic syndrome a risk factor for some malignant hemopathies? 
The main risk factors for excess weight and obesity are high caloric diet and sedentary 
lifestyle. A study conducted in a county hospital in Transylvania examined the presence of 
MS in all 56 patients with NHL existing in its records and a control group of 64 consecutive 
patients with non-cancerous diseases in the same hospital (control group). Patients with 
NHL had significantly more frequently arterial hypertension, significantly higher body 
mass index values, and a significantly higher number of components of the MS as compared 
to those of the control group. This observation advocates the idea that excess weight may be 
a risk factor for this type of neoplasia. (Mihăilă et al., 2009) 
In a group of 170 non-Hispanic white pediatric cancer survivors, among males, body 
adiposity was more important in survivors than in witnesses, as was trunk fat. The 
survivors had higher values of CH, TG, LDL-cholesterol than the witnesses, and the first 
watched TV more hours than controls (Miller TL et al., 2010). It was observed that the young 
survivors of ALL, disease which they had in their childhood, especially those who received 
cranial radiotherapy, are likely to develop hyperlipidemia, insulin resistance, obesity, 
arterial hypertension and even MS soon after the treatment (Trimis et al., 2007).  
After an average period of 37 months after the end of type ALL-BFM 90 chemotherapy 
protocol, out of 52 patients almost half were overweight, nearly 6% - obese, more than half 
had at least one risk factor for MS, and about 6% had MS (Kourti et al., 2005).  
It was found that the consequences of treatment performed for ALL during childhood may 
become manifest when subjects reach adulthood. Cranial irradiation favors more the 
appearance of MS: 60% of those who had been so treated had at least two of the five 
components of MS when they become adults, and only 20% of those who had not been 
irradiated. The pathogenetic mechanism that explains the metabolic effects of cranial 
irradiation implies growth hormone (GH) deficiency, lower level of insulin-like growth factor 
1, fasting hyperinsulinemia, abdominal obesity and hyperlipidemia, especially in women 
(Gurney et al., 2006). In another study, ALL survivors who received cranial irradiation 
developed more frequently MS than those nonirradiated (23% towards 7%), probably because 
of higher prevalence of excess weight and arterial hypertension (van Waas et al., 2010).  
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In a study conducted on a group of 184 adults who had ALL in their childhood, the overall 
prevalence of MS has been even higher - 9.2%. Peripheral stem cell allografts after total body 
irradiation favored the occurrence of hypertriglyceridemia, low HDL-cholesterol and 
increased fasting glucose level (Oudin et al., 2011).  
In Sweden a group of adults was analysed; they survived after ALL during childhood and 
were submitted to radio-and chemotherapy. Those who received treatment for 5 years with 
GH compared with those not treated so for 8 years, showed significant changes in HDL-
cholesterol, glucose and apolipoprotein B / apolipoprotein A1 ratio, and MS was 
significantly less frequent. (Follin et al., 2010) 
Another study conducted in Sweden on adults who had childhood leukemia, found an 
augmentation of total body fat, especially of trunk adiposity and an evolution towards an 
unfavorable lipid spectrum. These observations were correlated with low levels of 
endocrine secretion of GH, a consequence of previous cranial irradiation. (Jarfelt et al., 2005) 
An interesting combination of diseases was described in a 54 years old woman: after being 
diagnosed with chronic neutrophilic leukemia a liver biopsy was made. The 
histopathological diagnosis was of nonalcoholic steatohepatitis (NASH) with neutrophilic 
infiltrate. The authors consider that the leukemia cells that infiltrated the liver contributed to 
the emergence of NASH. The administration of cytosine arabinoside contributed to a 
significant decrease in fat degeneration. (Yoshida et al., 2004)  
There are few studies on the metabolism of chylomicrons in patients with cancer. The study 
of a group of patients with Hodgkin and nonHodgkin lymphoma, as compared to a healthy 
control group, led to the observation that after an intravenous administration of a 
chylomicron-like emulsion, the levels of CH, TG and VLDL were significantly higher in 
patients with lymphoma because of the profound disturbance of the chylomicrons lipolysis 
and their removal deficit. (Gonçalves et al., 2003) 
A very interesting observation was achieved in a line of promyelocytic leukemia NB4 cells: 
the administration of peroxisome proliferator-activated receptor gamma ligands was able 
not only to induce differentiation but also to favor lipogenesis in NB4 cells. This fact 
suggests a close link between differentiation and lipogenesis process in human myeloid cells 
thus stimulated. (Yasugi et al., 2006). 
5. Cholesterol metabolism disorder  
It is known that cell membranes contain lipid rafts, belonging to CH-rich microdomains. 
These components of the cell membrane are involved in intracellular signal transduction 
processes mediated by the receptor and in the self-renewal of ES cells. (Lee et al., 2010) The 
administration of methyl-beta-cyclodextrin, that is a CH-sequestering agent useful for the 
lipid raft destruction, is able to restore the activity of large conductance background K(+) 
channels. This favors the activation by stretch. (Nam et al., 2007) The depletion of CH from 
the cell membranes leads to lipid rafts destruction, that are responsible for bloking the 
translocation of leukemia inhibitory factor receptor and gp 130 (Port et al., 2007).  
A group of Russian researchers studied the role of membrane CH in a line of human 
leukaemia K562 cells regarding the regulation of mechanosensitive cation channels activated 
by stretch. They consider that the above-mentioned suppression of this channel activation in 
leukemia cell line by methyl-beta-cyclodextrin is produced by F-actin rearrangement due to 
lipid raft destruction. (Morachevskaya et al., 2007) 
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In the regulation of lipid and CH metabolism liver X receptors are also involved, they are 
nuclear receptors. They can modulate the proliferation and survival of both normal and 
malignant B and T lymphocytes. (Geyeregger et al., 2009) 
The correlation between increasing CH in lipid domains and the possible cancerosus cell 
transformation is very interesting (Ajith et al., 2008). It is believed that CH is important for 
cell proliferation, because low serum CH values may be the result of high cellular CH need 
of cancerous cells. Low serum CH values correlate with elevated levels of CH in 
lymphocytes. Evidence of low levels of CH in the culture medium is due to the development 
of lymphoma cells, which would consume more CH for their own proliferation. The 
experimental administration of mevastatin in vitro, which inhibits CH synthesis, did not 
determine a significant variation of the concentration of CH in the culture medium, while 
cell growth diminished. (Pugliese et al., 2010) 
Low serum CH levels are also frequently found in acute leukemia patients. These patients 
have significantly lower serum values of CH, HDL-cholesterol, and LDL-cholesterol. A 
possible explanation for the low levels of HDL-cholesterol in the patients with acute 
leukemia could be an increased expression of a possible selective site for HDL-cholesteryl 
ester. (Gonçalves et al., 2005) 
Malignant, proliferative cells have an intense metabolism of CH, while decreased intake of 
CH is responsible for decreasing cell proliferation. In a human line of promyelocytic HL-60 
cells, an inhibition of cell cycle progression from G2 phase can be obtained by an enzymatic 
inhibition of CH synthesis at a stage before 7-dehydrocholesterol production. Drugs such as 
zaragozic acid or SKF 104976 can induce the expression of antigen 11c, a cluster of 
differentiation. These products have a comparable action to all-trans retinoic acid, which 
induces monocyte differentiation. (Sánchez-Martín et al., 2007) 
Chronic lymphocytic leukemia (CLL) is a heterogenous malignant hemopathy. In these 
patients, in the presence of UM-IGHV, which is a negative prognostic factor, there are 
increased levels of CH and lactate and low levels of glycerol and 3-hydroxybutyrate. 
(MacIntyre et al., 2010) 
CD5 antigen is responsible for CH synthesis and even for adipogenesis. It is known that 
malignant cells from CLL are undergoing a process of continuous stimulation due to CD5 
activation and cell survival. (Gary-Gouy et al., 2007) A continuous activation of an 
antiapoptotic pathway explains the CLL cells survival. Apolipoprotein E4-very low density 
lipoproteins is responsible for the high level of apoptosis in CLL cells. Lipoprotein lipase is 
the enzyme that metabolizes very low density lipoproteins to low-density lipoprotein. It was 
observed that an increase of lipoprotein lipase mRNA levels is present in CLL patients with 
shorter survival. (Weinberg et al., 2008) 
CH synthesis is also increased in patients with T-ALL who are glucocorticoid resistant 
(Beesley et al., 2009). 
The growth of a promyelocytic leukemia cell line – HL-60 can be experimentally supressed 
by sodium cholesteryl sulfate, cholesteryl bromide, and cholesteryl-5alpha. The first two are 
responsible for the cell arrest in S and G2/M phases, and the last product – in the G2/M 
phase. (Ishimaru et al., 2008) 
It was found that in xenotransplanted severely combined immunodeficient mice the most 
abundant bone marrow CH amounts are located in leukemia-rich sites. In vitro, in leukemic 
cells CH is able to stimulate FLT-1 expression and VEGF production. Human leukemic cells 
from patients with AML are significantly richer in CH than normal cells and this CH 
augmentation represents a marker of aggressive evolution. (Casalou et al., 2011) 
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6. Experimental and clinical observations on cholesterol metabolism disorder 
ABCA1 and ApoA-I are responsible for the efflux of CH in human monocyte leukemia cell 
line derived foam cells. This decrease of the concentration of CH can be enhanced by 
administration of rosiglitazone. (Lü et al., 2010) Animals fed on alternate days have showed 
lower incidence of lymphomas, after tumor inoculation have had higher survival, and some 
types of cells have proliferated more slowly. It seems that this diet in humans would favor 
increased levels of HDL-cholesterol and lower those of triacylglycerol. (Varady et al., 2007) 
It was found that ether phospholipid edelfosine is able to accumulate and selectively destroy 
mantle cell lymphoma and CLL cells, underlining the importance of the action on lipid rafts 
and Fas/CD95 for the therapy of these lymphoproliferations. CH depletion is involved in lipid 
raft disruption and in the diminishing of drug captation. (Mollinedo et al., 2010)  
Some clinical observations on the presence of dyslipidemia in patients with malignant 
hemopathies are presented in Table 1. 
 
Author Disease Dyslipidemia 
Inamoto et al., 2005 ALL + cholestasis from 
graft versus host disease 
hypercholesterolemia 
Lim et al., 2007 NHL serum HDL-cholesterol 
decrease 
Gokhale et al., 2007 NHL serum total CH level was 
significantly higher in 
patients who completed the 
treatment for NHL than in 
those who completed ALL 
therapy 
Garg et al., 2011 intravascular large B cell 
lymphoma 
low serum levels of HDL-
cholesterol 
Helman et al., 2011 MALT + obesity hypercholesterolemia 
MALT = mucosa-associated lymphoid tissue lymphoma  
Table 1. Examples of dyslipidemia in patients with malignant hemopathies. 
7. The cholesterol and the treatment with anti-CD20 monoclonal antibodies 
It has been noted that the loss of CH is responsible for the decrease in the number of sites 
that can fix some monoclonal antibodies, including CD20. CH depletion or Shiga-like toxin 
binding have been causes of disruption of CD20 localization, but not of CD77 in lipid rafts. 
(Jarvis et al., 2007) 
DXL625 is an anti-CD20 monoclonal antibody, capable of causing independently in vitro 
apoptosis of a lymphoma B cells line. This apoptosis is inhibited by the loss of membrane 
CH or of chelation of extracellular calcium, fact that underlines the role of lipid raft and 
calcium in this process. (Bingaman et al., 2010) 
Many lymphoproliferations with B cells have indication of treatment with rituximab, an 
anti-CD20 antibody. The inhibitor therapeutic effect of rituximab occurs at the same time as 
the decrease of CH deposits from lipid rafts, with decreased B-cell receptor relocation to 
lipid rafts structures, and with the disruption of the expression of BCR immunoglobulin, 
lowering it. (Kheirallah et al., 2010) 
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The first monoclonal antibody that was approved for the treatment of B-cell 
lymphoproliferative malignancies was rituxan, a chimeric monoclonal anti-CD20 antibody.  
It has been observed that the monoclonal antibody attachment to CD20 produces a 
redistribution of these antigens to lipid rafts, which are specialized membrane 
microdomains. If rituxan is not used, the CD20 antigen affinity to lipid rafts is small. 
Intracellular calcium entry and apoptosis have been completely eliminated experimentally 
by extracting CH, which has led to the destruction of the integrity of lipid raft structures and 
to the dissociation of CD20 antigen from a fraction that is resistant to Triton X-100. From this 
it results that for the activation of caspase induced by CD20- lipid rafts appear to have an 
essential role. (Janas et al., 2005) 
In multidrug resistance two populations of P-glycoprotein (P-gp) are involved. One is 
located in the membrane regions that are resistant to detergent; it has optimal P-gp ATPase 
activity; the verapamil can activate it and the orthovanadate can inhibit it almost entirely. 
The other population is located in another part of the membrane; it has less activity than P-
gp ATPase of the first population; the verapamil can inhibit it, and its sensitivity to the 
orthovanadate is less. The first population of Pgp is surrounded by deposits of CH that may 
have the role to stimulate the P-gp ATPase activity, but the CH near the second population 
of Pgp does not seem to have such a role. (Barakat et al., 2005) 
Rituximab induced apoptosis may be diminished by depletion of membrane deposits of CH, 
which does not allow the association to the detergent-insoluble lipid rafts of the antigen 
hypercrosslinked CD20. Under the action of rituximab, the antibody-bound CD20, found in 
lipid rafts in a high-affinity structure, activates src family kinases, interfering with the 
signal-transmission mechanism, which it inhibits. (Unruh et al., 2005) 
Besides their CH-lowering effects, statins have pleiotropic effects, including the 
antileukemic ones observed in vitro and in vivo (Sassano et al., 2009), but they disrupt the 
binding (Winiarska et al., 2008) and the antitumour activity of rituximab (Ennishi et al., 
2010), as a consequence of the changing of the antigen CD20 conformation (Ennishi et al., 
2010; Winiarska et al., 2008). Statins interfere with the detection of CD20 as well as the 
antilymphomatous function of the rituximab (Winiarska et al., 2008). But in a study that 
analyzed the progression-free survival in 3 years and overall survival in a group of patients 
with diffuse large B-cell lymphoma, including some patients who were taking statins, it was 
found that there were no statistically significant differences, fact that advocates the idea that 
statins used in clinical treatment do not alter the prognosis of patients with diffuse large B-
cell lymphoma under R-CHOP treatment. (Ennishi et al., 2010) 
8. Statins as adjuvant treatment in malignant hemopathies 
After chemotherapy, the blasts of acute myeloid leukemia (AML) respond by increasing 
cellular content of CH, which increases resistance to treatment. (Kornblau et al., 2007) Statins 
are pharmacologic inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA 
reductase) - the regulatory enzyme of CH synthesis (Nonaka et al., 2009; Sassano et al., 
2007). In vitro, they block HMG-CoA reductase and by this they contribute to restore 
sensitivity to chemotherapy. (Kornblau et al., 2007) HMG-CoA regulates not only the 
synthesis of CH but also that of the higher isoprenoids, as geranylgeranyl pyrophosphate 
(Fuchs et al., 2008). By the inhibition of the prenylation processes, in vitro, statins reduce 
cellular proliferation and stimulate apoptosis of cancerous cells (Nonaka et al., 2009; Sassano 
et al., 2007). It was found that simvastatin inhibits geranylgeranylation processes of small 
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GTPases Rab5B and Rac1 in certain leukemic cells (for example, adult T-cell leukemia). 
(Nonaka et al., 2009) 
The excessive proliferation inhibition induced by simvastatin results from the induction of 
apoptosis, cell cycle arrest in phase G2 / M, and accumulation of p21 protein. Simvastatin is 
able to remove resistance to apoptosis that occurs during treatment with bortezomib, by 
reducing geranylgeranyl pyrophosphate synthesis and cell survival mechanism dependant 
on this. (Fuchs et al., 2008) In IgM secreting cell lines and cells from Waldenstrom 
macroglobulinaemia, simvastatin showed antiproliferative and cytotoxic effects and 
stimulated the apoptosis. Simvastatin had a synergistic effect with bortezomib, 
dexamethasone and fludarabine by augmenting their cytotoxicity. (Moreau et al., 2008). 
A group of 23 patients with lymphoproliferative diseases, for which statins had not been 
contraindicated, was treated for 3 days with simvastatin at a dose of 120 mg/day. Serum 
CH level and that of total lipids decreased significantly (p<0.001 and, respectively,  
p = 0.016). Serum ALT decreased unsignificantly, while that of AST increased, the growth 
was close to the statistical significance limit, but was not higher than the upper normal level. 
Flowcytometric dosage of annexine V showed that simvastatin induced early and late 
apoptosis increase (p = 0.007, respectively, p = 0.003). By its effect on apoptosis, simvastatin 
could be an adjuvant treatment for patients with lymphoproliferative disorders. (Mihăilă et 
al., 2009) 
By their CH-lowering effect, statins are promising drugs for the treatment of lymphomas (63 
Winiarska et al., 2008). A female patient suffering from NHL with large B-cells whose 
primary location was the mammary gland had hypercholesterolemia, hypertriglyceridemia 
and was hypertensive. During the treatment with R-CHOP and radiotherapy that followed 
(30 Gy), she received lovastatin (20 mg/day) and verapamil. After the first 30 days of 
treatment, both CH and TG were normalized, and after the whole treatment, the patient has 
been in complete remission that persists today. (Mihăilă et al, 2008) Lovastatin was 
administered to the patient not only because she was dyslipidemic, but also because the 
literature claims that the drug is useful in malignant lymphomas, leukemias and multiple 
myeloma by its pleiotropic effects. In 1998 the first article about a farnesyltransferase 
inhibitor (L-744, 832) was published, inhibitor that proved to be effective in mice with 
mammary carcinomas and lymphomas (Mangues et al., 1998). Lovastatin acts by inhibition 
of geranylgeranylation, followed by reduction of intracellular signaling mechanisms, which 
results in reduction of time and dose-dependency of the viability of lymphoma cells in vitro. 
This is the result of apoptosis stimulation as well as of the decrease of lymphoma cells 
proliferation, the latter by induction of G1 arrest in cell cycle (van de Donk et al., 2003). 
In a rat lymphoma model lovastatin administration during radiotherapy led to cell cycle 
arrest in different phases, which justified the continuation of the treatment with this drug in 
the female patient during radiotherapy; the experimental model mentioned, the 
combination of lovastatin with radiotherapy resulted in a synergistic action (Rozados et al., 
2005, as cited in Mihăilă et al., 2008). Lovastatin administration did not preclude the 
response to polychemoterapy that included rituximab. In fact, although it is only one case, 
the experimental findings do not always overlap with clinical outcomes. The authors 
consider that the combination of lovastatin with verapamil favored the response to 
anticancer treatment and prevented the possible multidrug resistance (Mihăilă et al., 2008). 
The combination of lovastatin + R-CHOP did not lead to adverse effects. Six years after the 
end of therapy, the patient is still in complete remission. 
 
Cholesterol and Triglycerides Metabolism Disorder in Malignant Hemopathies 
 
399 
In a cell line of acute promyelocytic leukemia (NB4) atorvastatin and fluvastatin showed to 
be potent stimulators of cell differentiation and apoptosis (Sassano et al., 2007). When to the 
treatment with idarubicin and high-dose cytarabine of patients with AML pravastatin was 
added, CR / CRp was observed in 11 of 15 new patients, out of which 8 of 10 had 
unfavorable cytogenetics, and 9 of 22 patients who received rescue medication that 
pravastatin did not influence the length of neutropenia, of thrombocytopenia or of the 
toxicity of chemotherapy. (Kornblau et al., 2007) 
Statins are active also in acute promyelocytic leukemia cells, where they augment the 
antileukemic response that depends on all-trans retinoic acid (ATRA). The c-Jun NH2-
terminal kinase pathway is required for leukemic cells differentiation induced by statins. 
Statins also intervene in modulating ATRA-dependent transcription. This was revealed by 
the selective expression of a large number of genes (400) when atorvastatin was 
administered together with ATRA. (Sassano et al., 2009) This drug combination could be a 
solution for reversing the ATRA-resistance of leukemic cells (Sassano et al., 2007). 
Unlike the subgroup of normal and AML cells CD34 (-), the CD34 (+) is more sensitive to 
lovastatin. Both populations of cells were strongly inhibited when lovastatin was added to 
chemotherapy. Leukemic cell samples from different patients with AML had heterogeneous 
sensitivity to lovastatin. Fifty percent of the patients with unfavorable treatment response 
had cytogenetic examination with poor prognosis and significantly more blasts in the 
peripheral blood. (de Jonge-Peeters et al., 2009) 
It was observed that high expression of CXCR4 correlates with a shorter survival time of 
patients with AML. In some models of cancer hypoxia it leads to the increase of CXCR4. On 
the other hand, increased pO(2) causes depletion of CH, which alters lipid rafts and leads to 
structural changes, which result in increased rejection of CXCR4 microparticles. (Fiegl et al., 
2009) Atorvastatin administred in doses of 16 mg/kg body wt showed to be effective in the 
inhibition of ascites tumor growth and induced apoptosis of a cell line of Daltons' 
Lymphoma Ascites that was transplanted into mice (Ajith et al., 2008). 
In vitro, simvastatin induced apoptosis of CLL cells, found in short term culture and 
contributed to lower BCL-2/BAX report; it was found that its effect of apoptosis induction is 
tumor-specific and does not affect normal lymphocytes. The association of simvastatin with 
fludarabine or cladribine synergistically induces DNA damages, and these lead to apoptosis. 
The proportion of cells found in apoptosis induced by simvastatin +/- chemotherapy was 
not correlated with the expression of negative prognostic markers of the disease (ZAP-70 
and CD38) or its stage in the RAI classification. (Podhorecka et al., 2010) 
The interaction of adhesion molecules, with fundamental role in cellular interaction 
processes, including those concerning EBV-transformed B cells is blocked by some statins. 
These drugs also inhibit intracellular activation of NF-kappaB and contribute to the 
emergence of transformed B-cell apoptosis. In mice with severe combined immune 
deficiency, simvastatin caused delayed emergence of the lymphomas induced by EBV. 
(Cohen et al., 2005) 
Both the simvastatin and the tipifarnib have cytotoxic effect on AML cell lines and their 
associated administration has a synergistic effect. This combination administered to 
CD34(+) AML cells resulted in the increase of the inhibitory effect only on normally 
responsive AML cells; however, the combination administred to CD34(-) AML cells had 
augmented inhibitory effect in all cells. (van der Weide et al., 2009) 
It was observed that statins are able to decrease the expression of BCL-2, an antiapoptotic 
molecule, favoring the appearance of apoptosis of CD4(+) CD28(null) T cells - a T aggressive 
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GTPases Rab5B and Rac1 in certain leukemic cells (for example, adult T-cell leukemia). 
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arrest in different phases, which justified the continuation of the treatment with this drug in 
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2005, as cited in Mihăilă et al., 2008). Lovastatin administration did not preclude the 
response to polychemoterapy that included rituximab. In fact, although it is only one case, 
the experimental findings do not always overlap with clinical outcomes. The authors 
consider that the combination of lovastatin with verapamil favored the response to 
anticancer treatment and prevented the possible multidrug resistance (Mihăilă et al., 2008). 
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and long-lasting lymphocyte subpopulation, which can infiltrate the atheromatous plaques, 
contributing to the their destabilization, which facilitates the instalation of major coronary 
accidents. (Link et al., 2011) 
9. ABC transporters and cholesterol homeostasis 
In many neoplastic diseases, increased expression of proteins on which depends the 
multidrug resistance correlates with the presence of refractory disease. A small proportion 
of AML leukemia cells is responsible for the tumor proliferation and expansion. These are 
leukemic stem cells, primitive cells, which are frequently in a quiescent state. When they 
leave the quiescent state and progress along the cell cycle, these cells are characterized by 
the ability of self-renewal and express some ATP-binding cassette (ABC) transporters. It was 
observed that when some ABC transporters have a high expression in leukemia cells, the 
prognosis of patients with AML is reserved as the response to treatment is inadequate. (de 
Jonge-Peeters et al., 2007) 
The most studied transporter is the P-glycoprotein transporter (P-gp) - an ABC transporter 
responsible for unidirectional transmembrane translocation of the substrate (Gayet et al., 
2005). P-gp is frequently involved in the emergence of multidrug resistance during 
chemotherapy (Shu & Liu, 2007). The multidrug resistance gene encodes this membrane 
transporter. Not only P-gp occurs in CH homeostasis at the cellular level, but also the 
synthesis of CH and CH-esters affects ATP-ase (Bucher et al., 2007) and the transmembrane 
transport by P-gp (Bucher et al., 2007; Shu & Liu, 2007). The lipid structure of the cell 
membranes also depends on the P-gp function (Dos Santos et al., 2007).  
The ATP-ase activity of P-gp is controlled linearly by CH of the membrane structure. On the 
other hand, the decrease of membrane CH correlates with the non-linear decrease of the 
daunorubicin efflux induced by P-gp. An effective way to raise awareness of ALL CEM 
resistant to chemotherapy cells consists of partial depletion of the CH from cell membrane 
structure, that lowers the daunorubicin efflux by P-gp. (Gayet et al., 2005) 
CH is able to increase basal activity of P-gp ATP-ase and increase P-gp sensitivity to 
progesterone and verapamil, modulators of this transporter. (Bucher et al., 2007) LDL-
cholesterol can enlarge P-gp expression. In an experiment conducted in vitro, HMG-CoA 
reductase inhibitors were added to a primitive leukemia cells line (KG1a) and the 
observation was that lovastatin caused a decrease of 26% of P-gp expression, and 
pravastatin - a decrease of 16 %. (Connelly-Smith et al., 2007) But the CH derived from LDL 
was also able to restore sensitivity to chemotherapy of a human lymphoblastic leukemia 
cell line. It seems that the mechanism explaining this return is the restoration of the 
membrane CH and the reducing of the P-gp-associated ATPase to the same level. (Shu & 
Liu, 2007) The changes of the membrane CH quantity may be responsible for P-gp 
inhibition. It was observed that disassembly of lipid rafts can be produced both by the 
decrease of the CH content and by its increase. For a normal capacity of P-gp transport it 
is necessary to maintain accurate properties of membrane structures known as lipid raft. 
(Dos Santos et al., 2007) 
In a clinical trial involving patients with CLL the P-gp expression of lymphocytes from 
peripheral blood was determined flowcytometricaly. Those patients whose lymphocytes 
expressed P-gp were treated for 6 days with 80 mg lovastatin daily, then a new sample of 
peripheral blood was examined flowcytometricaly. Lymphocytes of six of the 27 studied 
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patients expressed P-gp; about 20% of them were positive. Following the administration of 
lovastatin only 7.33% of them also expressed P-gp (p = 0.016). Compared to the proportion 
of positive lymphocytes at baseline, the decline was of 63.35%. During the study, CH 
decreased statistically significantly, with 20.43%. There was no observation of the 
appearance of possible drug adverse effects. In conclusion, the 6 days therapy with 
lovastatin was able to reduce significantly the CH and the number of lymphocytes in the 
membranes where P-gp is expressed, so that this statin could contribute through its 
pleiotropic effects to reduce multidrug resistance, especially when it is followed by 
chemotherapy. (Mihăilă et al., 2010) 
This drug efflux pump can be inhibited by verapamil, too, the research made in vitro proved 
that it can reduce multidrug resistance. In such a study conducted in two patients with 
leukemic lymphoma resistant to treatment, verapamil was able to increase the intracellular 
amount of doxorubicin (Tidefelt et al., 1994). 
It was found that verapamil was able to overcome the P-gp - mediated resistance to 
doxorubicin and vincristine in a canine cell line of B cell lymphoma (GL-1) (Uozurmi et al., 
2005, as cited in Mihăilă et al., 2008). These experimental findings were not confirmed by 
parallel administration of chemosensitizer verapamil to chemotherapy (cyclophosphamide, 
doxorubicin, vincristine, and dexamethasone) in patients with medium and high level NHL 
found in advanced stages. This drug combination did not increase the therapeutic response 
and did not extend the survival in these patients as compared to those treated only with the 
mentioned chemotherapy (without verapamil) (Gaynor et al., 2001, as cited in Mihăilă et al., 
2008), but it cannot be excluded that it could be effective in some patients who develop 
multidrug resistance. But, in metastatic breast carcinoma that has become resistant to 
anthracyclines verapamil has showed that it is able to increase the survival of patients 
(Belpomme et al., 2000, as cited in Mihăilă et al., 2008). In the case of the patient described 
above with hypertension and primary mammary NHL, the evolution has been favorable 
under the combination of verapamil to chemo- and radiotherapy, that has resulted in a 
event-free survival of 6 years (up to the present day) (Mihăilă et al., 2008).  
In another study, 45 patients with proliferative haematological disorders were included in 
one of the following two groups: A - those who had hypertension and who received 
verapamil + chemotherapy, and B - those with normal blood pressure, who received only 
chemotherapy. Group A included 7 patients with chronic lymphoproliferations and 2 with 
chronic myleoproliferations; under treatment, both systolic and diastolic pressure decreased 
significantly in all patients in the group. Initially the serum CH level was higher than in the 
patients in group B (p = 0.004), while other biological tests did not vary significantly 
between group A and B. No adverse effects were observed during the study. The fact that 
the initial blood CH was higher in in patients in group A suggests that malignant cells of 
patients in group B captured more blood CH that contributed to their proliferation. 
Although the average survival was not significantly different between group A and B, in 
group A there were more patients with stable disease (77.78% versus 44.44% - p<0.0001) 
while in group B more patients had progressive disease (30.56 % versus 11.11% - p<0.0001). 
The deaths due to progressive disease were significantly more numerous in group B. The 
authors consider that verapamil is useful not only because of its antihypertensive effect, but 
also due to its pleiotropic effects through which it could influence the evolution of neoplasia 
by inhibiting P-gp function and the efflux of drugs from lymphoma or leukemia cells. 
(Mihăilă et al., 2008) 
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Various epidemiological studies have found that between blood lipids and various 
neoplastic diseases there are some correlations.  
Some authors found that in patients with newly diagnosed NHL the blood levels of CH, 
phospholipids and HDL-cholesterol had lower values than those of controls and the values 
of CH increased progressively after chemotherapy if the disease reached complete remission 
or was stationary, unlike those with disease progression, that their blood lipid levels were 
even lower. 
Nearly all the children with ALL when diagnosed and during chemotherapy revealed a 
predictable model of serum dyslipidemia that consisted of very low levels of HDL-
cholesterol, and elevated TG, and LDL-cholesterol, that regained normal values during the 
remission period. 
In children with ALL, treated with asparaginase, hypertriglyceridemia was frequently 
observed and it can be cause of acute pancreatitis and thrombosis. 
Imatinib mesylate, used for the treatment of patients with chronic myeloid leukemia, led to 
a diminishing of serum CH and TG values and CH depletion can inhibit cell proliferation. 
The young survivors of ALL, disease which they had in their childhood, especially those 
who received cranial radiotherapy, are likely to develop hyperlipidemia, insulin resistance, 
obesity, arterial hypertension and even MS soon after the treatment. 
Cranial irradiation favors more the appearance of MS by GH deficiency, lower level of 
insulin-like growth factor 1, fasting hyperinsulinemia, abdominal obesity and 
hyperlipidemia, especially in women. 
It is believed that CH is important for cell proliferation, because low serum CH values may 
be the result of high cellular CH need of cancerous cells. Low serum CH values correlate 
with elevated levels of CH in lymphocytes. Malignant, proliferative cells have an intense 
metabolism of CH, while decreased intake of CH is responsible for decreasing cell 
proliferation. 
An increase of lipoprotein lipase mRNA levels is present in CLL patients with shorter 
survival. 
CD5 antigen is responsible for CH synthesis and even for adipogenesis. It is known that 
malignant cells from CLL are undergoing a process of continuous stimulation due to CD5 
activation and cell survival. 
The loss of CH is responsible for the decrease in the number of sites that can fix some 
monoclonal antibodies, including CD20. Statins interfere with the detection of CD20 antigen 
as well as the antilymphomatous function of the rituximab, but this effect was not showed 
in some clinical studies. 
Statins reduce cellular proliferation and stimulate apoptosis of cancerous cells. By their 
pleiotropic effects, statins can be useful in the treatment of different diseases, like NHL, 
CLL, multiple myeloma and AML, as adjuvant therapy. 
The association of simvastatin with fludarabine or cladribine synergistically induces DNA 
damages, and these lead to apoptosis. 
Statins are active also in acute promyelocytic leukemia cells, where they augment the 
antileukemic response that depends on all-trans retinoic acid. 
The ATP-ase activity of P-gp, frequently involved in the emergence of multidrug resistance 
during chemotherapy, is controlled linearly by CH of the membrane structure. The changes 
of the membrane CH quantity may be responsible for P-gp inhibition. 
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This drug efflux pump can be inhibited by statins and verapamil. 
By their pleiotropic effects, statins are useful not only for dyslipidemia treatment, but also in 
antineoplastic therapy. 
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Various epidemiological studies have found that between blood lipids and various 
neoplastic diseases there are some correlations.  
Some authors found that in patients with newly diagnosed NHL the blood levels of CH, 
phospholipids and HDL-cholesterol had lower values than those of controls and the values 
of CH increased progressively after chemotherapy if the disease reached complete remission 
or was stationary, unlike those with disease progression, that their blood lipid levels were 
even lower. 
Nearly all the children with ALL when diagnosed and during chemotherapy revealed a 
predictable model of serum dyslipidemia that consisted of very low levels of HDL-
cholesterol, and elevated TG, and LDL-cholesterol, that regained normal values during the 
remission period. 
In children with ALL, treated with asparaginase, hypertriglyceridemia was frequently 
observed and it can be cause of acute pancreatitis and thrombosis. 
Imatinib mesylate, used for the treatment of patients with chronic myeloid leukemia, led to 
a diminishing of serum CH and TG values and CH depletion can inhibit cell proliferation. 
The young survivors of ALL, disease which they had in their childhood, especially those 
who received cranial radiotherapy, are likely to develop hyperlipidemia, insulin resistance, 
obesity, arterial hypertension and even MS soon after the treatment. 
Cranial irradiation favors more the appearance of MS by GH deficiency, lower level of 
insulin-like growth factor 1, fasting hyperinsulinemia, abdominal obesity and 
hyperlipidemia, especially in women. 
It is believed that CH is important for cell proliferation, because low serum CH values may 
be the result of high cellular CH need of cancerous cells. Low serum CH values correlate 
with elevated levels of CH in lymphocytes. Malignant, proliferative cells have an intense 
metabolism of CH, while decreased intake of CH is responsible for decreasing cell 
proliferation. 
An increase of lipoprotein lipase mRNA levels is present in CLL patients with shorter 
survival. 
CD5 antigen is responsible for CH synthesis and even for adipogenesis. It is known that 
malignant cells from CLL are undergoing a process of continuous stimulation due to CD5 
activation and cell survival. 
The loss of CH is responsible for the decrease in the number of sites that can fix some 
monoclonal antibodies, including CD20. Statins interfere with the detection of CD20 antigen 
as well as the antilymphomatous function of the rituximab, but this effect was not showed 
in some clinical studies. 
Statins reduce cellular proliferation and stimulate apoptosis of cancerous cells. By their 
pleiotropic effects, statins can be useful in the treatment of different diseases, like NHL, 
CLL, multiple myeloma and AML, as adjuvant therapy. 
The association of simvastatin with fludarabine or cladribine synergistically induces DNA 
damages, and these lead to apoptosis. 
Statins are active also in acute promyelocytic leukemia cells, where they augment the 
antileukemic response that depends on all-trans retinoic acid. 
The ATP-ase activity of P-gp, frequently involved in the emergence of multidrug resistance 
during chemotherapy, is controlled linearly by CH of the membrane structure. The changes 
of the membrane CH quantity may be responsible for P-gp inhibition. 
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This drug efflux pump can be inhibited by statins and verapamil. 
By their pleiotropic effects, statins are useful not only for dyslipidemia treatment, but also in 
antineoplastic therapy. 
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1. Introduction 
Benign prostatic hyperplasia (BPH) is a common melody of the aging men characterized by 
noncancerous enlargement of the prostate gland and is often associated with lower urinary 
tract symptoms (LUTS) (Berry et al., 1984). Approximately, 60 percent of men aged over 50 
years have histological evidence of BPH and, after the age of 70, the proportion increases to 
80 percent (Berry et al., 1984). It is a chronic, progressive and highly prevalent disease, 
clinically manifests as LUTS, posing a socioeconomic burden to the patients (Saigal and 
Joyce, 2005). Recently, Stranne et al., reported that one-third of the Swedish male population 
aged over 50 years have LUTS, which is often associated with BPH (Stranne et al., 2009). 
BPH is rarely fatal, but affects the quality of life, and if left untreated, serious life-
threatening complications may arise. Prostatic growth and development are governed by 
the genetic (Sanda et al., 1994), hormonal (Marker et al., 2003) and dietary factors (Bravi et 
al., 2006). Although, its etiology is not well understood, several theories have been proposed 
to explain the pathogenesis of BPH (Alberto et al., 2009; Bosch, 1991; Srinivasan et al., 1995). 
Augmented steroidal signaling and mesenchymal-epithelial interactions are required for the 
normal as well as pathological growth of the prostate gland (Marker et al., 2003). However, 
current literature indicates that apart from steroids, peptides and lipids are also playing a 
crucial role in the pathogenesis of BPH (Cai et al., 2001; Culig et al., 1996; Escobar et al., 2009; 
Kaplan-Lefko et al., 2008; Rahman et al., 2007; Rick et al., 2011; Story, 1995; Vikram and Jena, 
2011a; Vikram et al., 2010c). Even if the effects of peptides and lipids on the growth of the 
gland is milder as compared to that of steroids, chronic change in their levels either due to 
dietary habit or genetic predispositions can significantly contribute to the initiation and/or 
progression of the disease over a period of time. Existing clinical/epidemiological and 
preclinical studies provide convincing evidence for the association between insulin-
resistance, metabolic disorder and type 2 diabetes with the BPH (Francisco and Francois, 
2010; Vikram et al., 2010a; Wang and Olumi, 2011). Previous experimental studies in our 
laboratory suggested that insulin-resistance associated secondary rise in the plasma insulin 
level plays a central role in the prostatic enlargement (Vikram and Jena, 2011b; Vikram et al., 
2010a; b; 2011a; Vikram et al., 2010c; Vikram et al., 2011b). Other peptides such as insulin-
like growth factor-I (IGF-I), IGF-I binding proteins (IGFBPs), growth hormone (GH), 
transforming growth factor-β (TGF-β) family proteins are reported to have important 
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implications in the prostatic growth (Culig et al., 1996; Ikeda et al., 2000; Rick et al., 2011; 
Vikram et al., 2010c). However, information on the role of lipids in the prostatic growth is 
scarce and there is a need of further research in this area. Nevertheless, existing in-vitro, in-
vivo and clinical/epidemiological studies suggests that apart from contributing to the 
development of insulin-resistance and secondary hyperinsulinemia, lipids has a direct role 
in the normal prostatic growth and pathogenesis of the BPH. 
2. Role of lipids in transcriptional regulation 
Lipids are conventionally known as an important constituent of the biological membranes 
and as a signaling molecule in the cytoplasm. The presence of lipids in the nucleus and 
identification of phosphotidylinositol (PtdIns)-4-kinse activity in the preparation that were 
enriched in nuclear membranes (Smith and Wells, 1983a; b), and identification of PtdIns-4-
phosphate and PtdIns-4,5-bisphosphate that were differentially metabolized from lipids in 
the cytoplasm provided early evidence for the nuclear lipid signaling (Irvine, 2003). A recent 
study by Lee et al., explores the nuclear activities of lipids, showing that dilauroyl 
phosphotidlycholine controls transcriptional program through nuclear-receptor dependent 
pathway (Ingraham, 2011; Lee et al., 2011). The study was of particular interest as 
phosphotidylcholine reversed some of the consequences of high-fat diet feeding (Lee et al., 
2011), which is known to promote the cellular proliferation, contractility and overall 
enlargement of the prostate in rodents (Vikram et al., 2010c). The nuclear signaling and 
transcriptional regulation by lipids implies that targeting nuclear lipid signaling might be of 
value in finding the answers for the diseases associated with dietary habit and sedentary 
lifestyle such as insulin-resistance, type 2 diabetes, several cancers and BPH. 
3. Insulin-resistance and BPH 
The main function of insulin includes regulation of glucose uptake, glycogenesis and tight 
control of the plasma glucose level (Vikram and Jena, 2010). Insulin-resistance is a condition 
in which normal level of insulin elicits subnormal response. It is a condition which is 
associated with a group of disorders such as obesity, dyslipidemia, elevated fasting glucose 
level, hyperinsulinemia and hypertension. In addition to the type 2 diabetes and 
cardiovascular diseases, patients with insulin-resistance syndrome are at higher risk of BPH 
(Kasturi et al., 2006). Possible implications of the diabetes, insulin-resistance and insulin-
resistance associated disorders in the pathogenesis of BPH have been previously reviewed, 
and interested readers are encouraged to read the concerned articles for more information 
(Vikram et al., 2010a; Wang and Olumi, 2011). 
4. Fatty acids, dietary fat and BPH 
Strong appetite for the sugar, fat, and salt might have been adaptive for our ancestors, as 
they had very little access to sweet, fatty and salty foods. We have inherited these appetites 
and have easy access to these foods. As a consequence many of us suffer from obesity, high 
blood level of lipids, insulin-resistance, diabetes, hypertension, heart disease, several types 
of cancer and other aging-related disorders, including BPH. Sedentary lifestyle and fat-rich 
diets are considered as major contributor to the rise in the incidences of metabolic disorders. 
Over the past 60 years in USA, the ratio of dietary intake of ω-6-FA verses ω-3-FA has 
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increased from 2:1 to 25:1 (Simopoulos, 1999), and animal fat is a major source of ω-6-FAs 
which has been found to be associated with the higher risk of LUTS and BPH (Maserejian et 
al., 2009; Suzuki et al., 2002). Considering the rise in the incidence of LUTS/BPH in the 
obese and insulin-resistant individuals, it becomes increasingly important to understand the 
role of lipids in the pathogenesis of disease. 
4.1 Evidence from in-vitro experiments 
Limited information is available on the direct role of fatty acids (FAs) in the growth of 
normal and benign prostatic cells, as most of the studies have been conducted on the 
prostate cancer cell lines. However, cancer cell lines studies have indicative value for the 
potential effects of these FAs, as like prostate cancer, BPH is also associated with the 
pathological increase in the cell proliferation. A recent report indicating dominant uptake of 
FAs by the prostate cells [non-malignant (RWPE-1) as well as malignant (LnCaP and PC-3)] 
suggests their important role in the growth and development of the gland (Liu et al., 2010). 
Pandalai et al., reported growth promoting effects of ω-6-FAs on the rat non metastatic 
epithelial cell lines (EPYP1 & EPYP2), rat metastatic cell line (Met-Ly-Lu), and human 
metastatic prostate cancer cells (PC-3, LnCaP & TSU) (Pandalai et al., 1996). Arachidonic 
acid, a ω-6-FA treatment led to accelerated growth of the PC-3 cells in-vitro (Ghosh and 
Myers, 1997). Further, Rose et al., reported concentration-dependent stimulation of PC-3 
cells by the linolenic acid (ω-6-FA) and inhibition with the eicosapentanoic acid and 
docosahexanoic acid (ω-3-FAs) (Rose and Connolly, 1991). Further, long term 
eicosapentanoic acid treatment has been found to inhibit the metastatic activities of the PC-3 
cells (Rose and Connolly, 1991). Recently, we investigated the effects of the serum of high-
fat diet-fed (saturated animal fat-lard) rats on the growth of PC-3 cells, and a significant 
acceleration in the growth was observed (Vikram and Jena, 2011a). The serum characteristics 
of these rats indicated a rise in the glucose, triglyceride, cholesterol and insulin levels. 
Although, rise in the insulin level appears to be the primary cause for the accelerated 
growth of the cells owing to the mitogenic effects of the hormone, the possibility of direct 
growth promoting effects of lipids cannot be denied. Taken together, these studies suggest 
that at least ω-6-FAs have a growth stimulating effects on the prostatic cells, and thus 
represent a potential risk factor for BPH.  
4.2 Evidence from in-vivo experiments 
The study by Cai et al., provided first evidence for the prostatic growth promoting effects of 
dietary fat in rats (Cai et al., 2001). Similarly, Rahman et al., observed enlargement of the 
ventral prostate and increased expression of alpha-adrenergic receptors in the 
hyperlipidemic rats (Rahman et al., 2007). Further, inclusion of the saturated animal fat 
(lard) in the diet induced prostatic enlargement and changed the expression of androgen 
receptor and peroxysome proliferator activated receptor γ (PPARγ) (Escobar et al., 2009). 
Polyunsaturated FAs are ligands for the PPARγ, which is involved in the regulation of cell 
differentiation and proliferation (Morales-Garcia et al., 2011; Parast et al., 2009), and 
therefore appears to represent a possible link between diet and prostatic growth (Escobar et 
al., 2009). Prostatic atrophy and increased apoptosis in the hypoinsulinemic rats (induced by 
selective β-cell toxins, either streptozotocin or alloxan) further supports the view that insulin 
plays a central role in the prostatic growth and development (Arcolino et al., 2010; Ikeda et 
al., 2000; Suthagar et al., 2009; Vikram et al., 2011b; Vikram et al., 2008; Yono et al., 2008; 
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al., 2000; Suthagar et al., 2009; Vikram et al., 2011b; Vikram et al., 2008; Yono et al., 2008; 
 




Yono et al., 2005). Increased cell proliferation and enlargement of ventral prostate in rats 
kept on the diet rich in saturated fat was observed (Vikram et al., 2010b; 2011a; Vikram et al., 
2010c). Interestingly, pioglitazone (a synthetic PPARγ receptor agonist) treatment led to 
decreased cell proliferation, increased apoptosis and restoration of prostatic weight in the 
diet-induced insulin-resistant rats (Vikram et al., 2010b; Vikram et al., 2010c). This 
observation can be explained on the basis of the restoration of insulin-sensitivity and 
secondary hyperinsulinemia as pioglitazone is known to improve the insulin-sensitivity 
(Vikram and Jena, 2010). Further, increased oxidative stress and incidence of prostatic 
adenocarcinoma and hyperplasia was observed in the rats kept on high-cholesterol diet for 
long time (80 – 100 weeks) (Homma et al., 2004). Increased expression of NADPH oxidase 
subunits, activation of NF-kB signaling and decreased expression of glutathione peroxidase 
3 clearly indicated the increased oxidative stress and activation of inflammatory response in 
ventral prostate of the HFD-fed rats (Sekine et al., 2011; Vykhovanets et al., 2011). 
Inflammation has been greatly implicated as a risk factor for the development of BPH 
(Abdel-Meguid et al., 2009; Chughtai et al.; Donnell, 2011; Kim et al., 2011a; Wang et al., 
2008). Despite a marginal decrease in the weight of the prostate in ACI/seg rats an 
significant increase in the expression of 5-α-reductase 2 mRNA level was observed in the 
high-fat diet-fed rats (Cai et al., 2006). Based on these evidences from animal studies it 
appears that (i) insulin-resistance associated secondary hyperinsulinemia, (ii) activation of 
PPARγ signaling by FAs and (iii) increased prostatic inflammation are the important nodes 
for further investigative studies. 
4.3 Evidence from clinical/epidemiological studies 
Presence of dyslipidemia in the BPH patients is a frequently noted condition under 
clinical setups (Nandeesha et al., 2006). High level of total cholesterol, LDL-cholesterol, 
triglyceride, decreased level of HDL-cholesterol increases the risk of BPH, and 
cholesterol-lowering medication may reduce the risk (Moyad and Lowe, 2008). Yang et al., 
compared FA profiles in the serum of patients with prostate cancer and BPH and 
proposed that polyunsaturated FAs have certain relation with BPH and prostate cancer 
(Yang et al., 1999). Higher serum LDL is associated with greater risk of BPH (Parsons et 
al., 2008), and physical activity, which is known to decrease the serum lipid level is 
associated with the decreased risk for BPH (Parsons and Kashefi, 2008). Hyperlipidemia is 
closely associated with the obesity, higher body mass index (BMI), and these parameters 
show a positive correlation with the BPH (Dahle et al., 2002; Hammarsten and Hogstedt, 
1999; Hammarsten et al., 1998; Parsons et al., 2006; Parsons et al., 2009). Kim et al., 
reported that the patients with more BMI tend to have larger prostate volume and higher 
International Prostate Symptom Score (Kim et al., 2011b). Several studies indicate that 
obesity and sedentary lifestyle substantially increases the risk for BPH (Dahle et al., 2002; 
Parsons, 2011; Parsons et al., 2006; Parsons et al., 2009). Recently, it has been reported that 
the central obesity is a better predictor of LUTS (Kim et al.; Lee et al., 2009). In a health 
professionals follow up study a moderate association between FAs intake and risk of BPH 
was observed (Suzuki et al., 2002). A cross-sectional study of 1545 men aged 30-79 years in 
the Boston Area Community Health Study the associations between dietary intakes of 
total energy, carbohydrates, protein, fat, cholesterol and LUTS in men was examined 
(Maserejian et al., 2009). Results indicated that high-energy intake was associated with 
higher LUTS symptoms and the storage symptoms increased with the higher fat intake 
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(Maserejian et al., 2009). Further, Kristal et al., reported significant increase in the 
symptomatic BPH with higher total fat intake and polyunsaturated fats, and showed a 
significant decrease in the symptomatic BPH with high-protein intake and alcohol 
consumption (Kristal et al., 2008). Leptin and adiponectin are closely associated with the 
obesity, and effort has been made to identify the relationship, if any, between these 
mediators and the risk of BPH. Although, no association has been observed between 
plasma leptin level and BPH (Hoon Kim et al., 2008; Lagiou et al., 1998), high plasma 
adiponectin concentrations were found to be associated with the reduced risk of 
symptomatic BPH (Schenk et al., 2009). Few independent studies indicate that obesity is 
associated with hyperinsulinemia, which in turn promotes the prostatic growth and risk 
for BPH (Becker et al., 2009; Kogai et al., 2008; Vogeser et al., 2009). In contrast, few 
reports argue that, obesity is associated with increased estrogen/androgen ratio and 
sympathetic activity, both individually hypothesized to promote the development of BPH 
(Giovannucci et al., 1994). Obesity can augment prostatic growth either by (i) promoting 
the development of insulin-resistance and secondary hyperinsulinemia or by (ii) 
increasing the estrogen/androgen ratio. In contrast, isolated report indicates an inverse 
association between obesity and BPH owing to reduced testosterone level in the obese 
people (Zucchetto et al., 2005). However, further studies investigating the relationship 
between plasma FAs level, obesity, BMI and prostatic growth are needed to shed light on 
the pathogenesis of BPH. Although, systematic clinical studies have not been performed 
to evaluate the effect of lifestyle modifications on the BPH outcomes, number of studies 
supports the view that heart-healthy lifestyle changes would have beneficial effect on the 
prostatic health and will eventually improve the quality of life of patients. 
5. Emerging mechanistic connections 
5.1 Autotaxin-lysophosphatidic acid pathway 
Lysophophatidic acid (LPA) is a small water soluble phospholipid, which binds to its G-
protein coupled receptors and activates several downstream signaling pathways 
(Berdichevets et al., 2010; Rancoule et al., 2011). It is primarily produced by the activity of 
the phospholipase autotaxin (ATX) (Van Meeteren and Moolenaar, 2007). Excessive fat 
intake is associated with adiposity, development of insulin-resistance and obesity, and these 
conditions are known to increase the expression of ATX, and therefore the LPA levels (Ferry 
et al., 2003). Recent study indicating the expression of LPA-related molecules in the prostate 
(Zeng et al., 2009) suggests that LPA might have an important role in the normal prostatic 
growth and pathogenesis of the BPH (Sakamoto et al., 2004). Kulkarni et al., proposed ATX-
LPA axis as a possible link between excessive dietary fat intake and prostatic hyperplasia 
(Kulkarni and Getzenberg, 2009). LPA is involved in the inflammatory responses and 
experimental studies indicating increased oxidative stress and NF-kB activation in the 
ventral prostate of high-fat diet-fed rodents (Sekine et al., 2011; Vykhovanets et al., 2011), 
which are known to develop prostatic enlargement (Vikram et al., 2010b; 2011a; Vikram et 
al., 2010c) supports the hypothesis. Further, clinical studies indicate that systemic 
inflammation or lower level of soluble receptors that bind to the inflammatory cytokines 
increase the BPH risk (Schenk et al., 2010). The pharmacological inhibitors of ATX such as 
S32826 (Ferry et al., 2008) and ongoing efforts of medicinal chemists (North et al., 2010; 
North et al., 2009; Parrill and Baker, 2010) in this direction might provide an answer to 
therapeutic management of the BPH. 
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5.2 PPARγ signaling 
PPARs are ligand activated transcription factors, which includes polyunsaturated FAs, 
eicosanoids, prostaglandins, docosahexaenoic acid, thiozolidinediones, and non-steroidal 
anti-inflammatory drugs. A recent study by Jiang et al., showed that conditional prostatic 
epithelial knockout of PPARγ resulted in the inflammation and focal hyperplasia which 
developed into prostatic intraepithelial neoplasia (Jiang et al.). Increased expression of 
PPARγ and overall enlargement of the prostate was observed in the rats kept on diet rich in 
saturated fat (Escobar et al., 2009). We also observed increased cell proliferation and 
prostatic enlargement in rodents kept on high-fat diet (Vikram et al., 2010b; 2011a; Vikram et 
al., 2010c). Moreover, pioglitazone (a PPARγ agonist) treatment restored prostate size in 
these rats (Vikram et al., 2010b; Vikram et al., 2010c). A recent study indicating the dominant 
uptake of FAs (as compared to glucose) by the malignant as well as non-malignant prostatic 
cells (Liu et al., 2010) underlines the possible role of PPARγ in the prostatic growth and 
development. These findings suggest that PPARγ represents a potential link between 
dietary fat and prostatic growth. However, further studies are needed to characterize its role 
in the normal and pathological growth of the prostate. 
5.3 Hyperinsulinemia: Altered insulin/IGF signaling 
Hyperinsulinemia generally develops as a compensatory response to the decreased insulin 
mediated actions under the insulin-resistant conditions (McKeehan et al., 1984). 
Experimental (Cai et al., 2001; Escobar et al., 2009; Rahman et al., 2007; Vikram et al., 2010a; 
b; 2011a; Vikram et al., 2010c) and clinical/epidemiological (Hammarsten et al., 2009; 
Hammarsten and Hogstedt, 2001; Nandeesha et al., 2006) studies indicate that the 
hyperinsulinemia is an independent contributor to the prostatic cell proliferation and 
pathogenesis of the BPH. Further, hyperinsulinemic condition can contribute to the 
augmented prostatic growth by several ways such as (i) increasing the serum level of IGF-I 
(Chokkalingam et al., 2002; Nam et al., 1997), (ii) possibility of the binding of insulin with 
the IGF-I receptor (IGF-IR) under the hyperinsulinemic conditions and (iii) binding of IGF-I 
to the insulin receptor (IR) (Belfiore and Frasca, 2008; Li et al., 2005). Further, IR has two 
isoforms, A and B, the former is having metabolic as well as mitogenic effects while B is 
mainly concerned with the metabolic effects. IR isoforms exhibit difference in the binding 
affinities to the ligand(s) and downstream signaling cascade (Giudice et al., 2011; Kosaki et 
al., 1995; Leibiger et al., 2001; Sciacca et al., 2003; Uhles et al., 2003; Vogt et al., 1991). IGF-II 
binds to the IR-A and mediates its growth promoting effects but not with IR-B (Frasca et al., 
1999; Morrione et al., 1997). This means that insulin, IGF-I and IGF-II competes to bind with 
the IR-A, while only insulin binds with the IR-B. The hybrid receptors, IR-A/IR-B and 
IR/IGF-I further complicates the molecular diversification of the insulin signaling system. 
IR-A/IR-B hybrid receptors were found to bind to both insulin and IGF-II and therefore, 
resemble IR-A homodimers rather IR-B homodimers (Blanquart et al., 2008). The IR/IGF-IR 
hybrid receptors (Pandini et al., 2002; Soos et al., 1990) are activated by both insulin as well 
as IGF-I, but the IGF-I effect is predominant, and it resembles IGF-1R homodimers rather IR 
homodimers (Langlois et al., 1995). The IGF and insulin signaling system has been 
summarized in figure 1. Prostate is known to have both isoforms of the IR (Cox et al., 2009). 
Experimental studies investigating the effect of dietary habits (particularly dietary fat) on 
the expression of IR isoforms and signaling kinetics might provide valuable insight in the 
understanding of the pathogenesis of the BPH under the insulin-resistant, obese and 
diabetic conditions. 
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5.4 Estrogen/androgen ratio  
Androgen deprivation leads to rapid apoptosis of the luminal secretory cells and atrophy of 
the prostate gland (Ikeda et al., 2000; Vikram et al., 2010c; Vikram et al., 2008). However, 
with the re-administration of the androgens prostate regains its normal size, and is capable 
of more than 15 rounds of the regression / regeneration cycle (Wang et al., 2009). Further, 
administration of either estrogen or dihydrotestosterone leads to hyperproliferation and 
induction of prostatic hyperplasia in the experimental animals. These simple experiments 
highlights the crucial role of steroidal hormones in the growth and development of the 
gland. Aromatase is a CYP450 enzyme which irreversibly converts testosterone to the 
estradiol, and obesity is associated with increased aromatase activity (Subbaramaiah et al., 
2011). Increased aromatase activity in the obese people may lead to rise in the 
estrogen/androgen ratio and hence the susceptibility for developing BPH. These aspects 
have been recently reviewed by Nicholson et al., and readers are encouraged to read the 
review (Nicholson and Ricke, 2011). 
 
 
Fig. 1. The IGF and insulin receptor signaling system. To avoid confusion, the binding 
affinity of the ligands and relative effects of hybrid receptors (metabolic and mitogenic) are 
not depicted in the figure. However, the IGF-IR/IR hybrid resembles IGF-IR homodimer 
and IR-A/IR-B resembles IR-A homodimers. Lipids are involved in nuclear signaling and 
can influence transcriptional regulation and thus growth and differentiation. IGF-I/II; 
insulin-like growth factor-I/II, IGF-IR; insulin-like growth factor-I receptor, IR-A/B; insuln 
receptor isoform-A/B. 
6. Summary  
BPH is a highly prevalent condition of prostate in the aging men population. The worldwide 
increase in the prevalence of BPH has been thought to be associated with obesity and 
lifestyle changes such as excessive intake of fat-rich diet and physical inactivity. Considering 
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6. Summary  
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the changing dietary habits and rising incidences of BPH, it becomes increasingly important 
to delineate the precise roles of lipids in the normal as well as pathological growth of the 
prostate. Although, experimental and clinical/epidemiological studies suggest that these 
conditions contribute to the pathogenesis of both insulin-resistance and BPH, the direct role 
of lipids in the pathogenesis of prostatic enlargement is far from complete understanding. 
Role of lipids in the progression of insulin-resistance and other disorders and indirect effect 
on the prostatic growth owing to compensatory rise in the plasma insulin level is essentially 
correct, but what has emerged is that the lipids might have a direct influence on the normal 
as well as pathological growth of the prostate. 
 
 
Fig. 2. Modern lifestyle associated changes including increased consumption of fat-rich diets 
and decreased physical activities contributes to the development of lipid-disorders and 
obesity. The present illustration demonstrates the possible influence of these factors on the 
prostatic growth and development. IR; insulin receptor, IGF-IR; insulin-like growth factor-1 
receptor, PPAR-α/γ; peroxisome-proliferator activated receptor alpha/gamma, ATX; 
autotaxin, LPA, lysophosphatidic acid. 
7. Conclusion  
In addition to the genetic factors, environmental factors such as physical inactivity and 
excessive intake of dietary fat contribute to the increased incidence of lipid-disorders and 
obesity worldwide. These factors directly as well as indirectly promote the prostatic growth 
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and contractility of the prostate gland, and represent important risk factors for the 
development of symptomatic LUTS / BPH (Fig. 2). ATX-LPA axis, PPARγ signaling, 
hyperinsulinemia/IGF signaling and steroidal signaling are the emerging mechanisms 
which explains the association between dietary fat intake, obesity and BPH. However, 
further mechanistic as well as epidemiology based studies are required to delineate the role 
of lipids in the pathogenesis of BPH. Future research to investigate the direct effect of 
different types of FAs on the prostatic growth and isoforms specific characterization of 
insulin and IGF-IR signaling in response to dietary habit is warranted. 
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the changing dietary habits and rising incidences of BPH, it becomes increasingly important 
to delineate the precise roles of lipids in the normal as well as pathological growth of the 
prostate. Although, experimental and clinical/epidemiological studies suggest that these 
conditions contribute to the pathogenesis of both insulin-resistance and BPH, the direct role 
of lipids in the pathogenesis of prostatic enlargement is far from complete understanding. 
Role of lipids in the progression of insulin-resistance and other disorders and indirect effect 
on the prostatic growth owing to compensatory rise in the plasma insulin level is essentially 
correct, but what has emerged is that the lipids might have a direct influence on the normal 
as well as pathological growth of the prostate. 
 
 
Fig. 2. Modern lifestyle associated changes including increased consumption of fat-rich diets 
and decreased physical activities contributes to the development of lipid-disorders and 
obesity. The present illustration demonstrates the possible influence of these factors on the 
prostatic growth and development. IR; insulin receptor, IGF-IR; insulin-like growth factor-1 
receptor, PPAR-α/γ; peroxisome-proliferator activated receptor alpha/gamma, ATX; 
autotaxin, LPA, lysophosphatidic acid. 
7. Conclusion  
In addition to the genetic factors, environmental factors such as physical inactivity and 
excessive intake of dietary fat contribute to the increased incidence of lipid-disorders and 
obesity worldwide. These factors directly as well as indirectly promote the prostatic growth 
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and contractility of the prostate gland, and represent important risk factors for the 
development of symptomatic LUTS / BPH (Fig. 2). ATX-LPA axis, PPARγ signaling, 
hyperinsulinemia/IGF signaling and steroidal signaling are the emerging mechanisms 
which explains the association between dietary fat intake, obesity and BPH. However, 
further mechanistic as well as epidemiology based studies are required to delineate the role 
of lipids in the pathogenesis of BPH. Future research to investigate the direct effect of 
different types of FAs on the prostatic growth and isoforms specific characterization of 
insulin and IGF-IR signaling in response to dietary habit is warranted. 
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1. Introduction 
Dyslipidemia is a change in serum lipids levels, which is associated with increased risk of 
cardiovascular events when are found elevated (American Heart Association, 2002, Sposito 
et al., 2007). Before introduction of antiretroviral therapy (HAART), patients with acquired 
immunodeficiency syndrome (AIDS) developed a dyslipidemia characterized by isolated 
elevation of triglycerides (TG) and decrease in total cholesterol (TC) and its fractions 
(Gkrania-Klotsas & Klotsas, 2007; Mulligan, 2003). With the advent of HAART, especially 
with the use of protease inhibitors (PI), this situation changed to a lipid profile with elevated 
TG, TC, lipoproteins of very low and low density (VLDL-C and LDL-C) and decrease in 
high density lipoprotein (HDL-C), leaving these patients at risk for developing diabetes, 
hypertension and other complications (Chen et al., 2002; Furtado et al., 2007; Garg, 2000; 
Gkrania-Klotsas & Klotsas, 2007; Kotler, 2008; Mulligan, 2003; Sattler, 2008; Segarra-
Newnham, 2002; Schering & Tovar, 2006; Yu et al., 2005). 
Studies estimate that the prevalence of dyslipidemia in patients with HIV (Human 
Immunodeficiency Virus) during use of antiretroviral therapy can vary from 33% to 82% 
and may be influenced by several factors including study type, sample type and time of 
HAART (Gkrania-Klotsas & Klotsas, 2007; Schering & Tovar, 2006; Yu et al., 2005). 
2. HIV lipodystrophy syndrome 
According to UNAIDS and World Health Organization (WHO) (2009) there was a large 
increase in the prevalence of HIV carriers in the world, reaching 33.4 million in 2008, value 
explained by the maintenance of annual incidence and the increase of the survival (Lihn et 
al. 2003; Mallewa et al., 2008). However, was noted a illness pattern change of these patients 
which ever left to be affected by a clinical feature characteristic of opportunistic diseases to 
develop HIV lipodystrophy syndrome (HIVLS) (Kramer et al., 2009; Ministry of Health of  
Brazil, 2008; Samaras et al., 2009; Stankov & Behrens, 2010). 
Body composition abnormalities have been reported in 40-50% of HIV-positive outpatients. 
This proportion is higher in patients receiving antiretroviral therapy. The rate of 
lipodystrophy can be high depending on the characteristics of the cohort (sex, age and 
possibly race), the type and duration of antiretroviral therapy (Grinspoon & Carr, 2005). 
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Body composition abnormalities have been reported in 40-50% of HIV-positive outpatients. 
This proportion is higher in patients receiving antiretroviral therapy. The rate of 
lipodystrophy can be high depending on the characteristics of the cohort (sex, age and 
possibly race), the type and duration of antiretroviral therapy (Grinspoon & Carr, 2005). 
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The HIVLS presents three distinct forms according to distribution pattern: lipoatrophy, with 
fat loss in limbs, face and buttocks; lipohypertrophy, with localized increase of abdominal, 
breast and dorsocervical subcutaneous cellular tissue, besides visceral deposit and lipoma 
formation; and the mixed form with signs of both syndromes earlier (Sattler, 2008; Mello et 
al., 2008) (Figure 1). 
 
 
Legend: A) facial lipoatrophy with facial furrows accentuated, bony prominence, and loss of Bichat’s fat 
(malar fat). B) Lipoatrophy of the lower limbs with prominent veins. C) Visceral lipohypertrophy, with 
increased waist circumference and little subcutaneous tissue. D) Dorsocervical lipohypertrophy. Photos 
of the collection of Dr. Rosana Libonati. 
Fig. 1. Morphological changes in HIV patients with lipodystrophy syndrome, Pará, Brazil. 
In addition to fat distribution alterations, metabolic changes are expressed as a mixed 
dyslipidemia with hypertriglyceridemia, total hypercholesterolemia, low density 
lipoprotein (LDL-C) elevation, reduction of high density lipoprotein (HDL-C), besides the 
induction of insulin resistance culminating in establishment of type II diabetes (Furtado et., 
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2007; Chen et al., 2002; Garg, 2000; Sattler, 2008, Yu et al., 2005). The changes in the 
concentrations of plasma lipids are more observed in patients receiving protease inhibitors 
(PI) (Yu et al., 2005). 
Prospective studies investigating body composition in patients starting HAART for the first 
time have showed increases in fat during the initial months of treatment, followed by a 
progressive declining in the following three years. In one study, the decline was estimated at 
14% per year in white men who received treatment regimens containing 
zidovudine/lamivudine or stavudine/lamivudine plus protease inhibitor or non-nucleoside 
reverse transcriptase inhibitor. In contrast, trunk fat increases initially and then remains 
stable for two or three years, resulting in relative central adiposity. These changes are 
clinically evident in 20 to 35% of patients after about 12 to 24 months of combination 
antiretroviral therapy (Grinspoon & Carr, 2005). 
The type, duration and current use or not of antiretroviral therapy are strongly associated 
with the lipoatrophy severity. Therapy based on two nucleoside analogue reverse 
transcriptase inhibitors and one protease inhibitor has strong association with severe 
lipoatrophy (Mallon et al., 2003). 
Now, the mechanism by which the protease inhibitor causes lipodystrophy remains 
unknown. Several protease inhibitors prevent preadipocytes differentiation and mild to 
moderate apoptosis in subcutaneous adipose tissue. Adipose tissue of patients with 
lipodystrophy has reduced expression of mRNA of several key factors involved in 
adipogenesis, including Sterol regulatory element binding protein (SREBP1c) and 
Peroxisome proliferator-activated receptor gamma (PPARγ). In vitro studies have shown 
that protease inhibitors can inhibit lipogenesis and adipocyte differentiation, stimulate 
lipolysis and prevent nuclear localization of SREBP-1c (Garg, 2000; Grinspoon & Carr, 2005). 
The nucleoside analog more strongly associated with lipoatrophy is stavudine, particularly 
when used in combination with didanosine. Lipoatrophy associated with nucleoside 
analogue may be due in part by mitochondrial injury caused by inhibition of the 
mitochondrial DNA polymerase γ within adipocyte and mitochondrial DNA depletion, 
although the extent and specificity of this effect remains unknown. The nucleoside analogue 
can inhibit adipogenesis and adipocyte differentiation, promote lipolysis and exert 
synergistic toxic effect with protease inhibitors in vitro and in vivo (Grinspoon & Carr, 2005). 
In nine studies assessing risk factors for lipoatrophy, were statistically significant more 
common duration and exposure to thymidine analogues, most commonly stavudine (d4T) 
(6/9), age (5/9), markers of disease severity (CD4/HIV RNA) (5/9), duration of therapy 
(3/9) and Caucasian (3/9). A prospective nonrandomized study in 40 HIV-positive patients 
starting antiretroviral therapy for the first time resulted after an average of 96 weeks, using 
multivariate analysis, that treatment with d4T is an independent factor for lipoatrophy 
(Lichtenstein, 2005). 
In eight studies assessing lipohypertrophy, the most significant risk factors were duration of 
therapy (3/8), a marker of disease severity (3/8), age (3/8) and protease inhibitor use (4/8). 
An additional study evaluating 2258 HIV-positive patients evaluated change in adipose 
tissue for both gender. Logistic regression showed that men have a significantly lower 
adjusted risk than women have (OR: 0.47, CI 95%: from 0.38 to 0.58) and a significantly 
lower risk of lipohypertrophy and mixed redistribution, while the risk of lipoatrophy was 
similar between genders. Therefore, a rigorous multivariate analysis controlling for 
numerous variables reveals multiple risk factors, suggesting that the pathogenic mechanism 
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for fat redistribution seems to be the result of complex interactions between host, disease 
and drugs factors (Lichtenstein, 2005). 
As for the diagnosis of HIVLS, there is not one standard pattern used to subjective body 
changes mentioned by the patients, anthropometric measurements and metabolic changes 
demonstrated in fasting laboratory tests (Diehl et al., 2008). Other tests that assist in 
conducting the HIVLS patients are: bone densitometry, for the investigation of 
osteopenia/osteoporosis; Dual-emission X-ray absorptiometry (DEXA), which allows an 
analysis of body composition, especially fat in the limbs, Computed Tomography, to 
observe presence of visceral fat deposits, and upper abdominal ultrasound for hepatic 
steatosis assessment (Mallon et al., 2003). 
Therefore, the main consequences of HIVLS are increased cardiovascular risk and 
consequent development of hypertension, diabetes mellitus, atheromatous disease, stroke, 
myocardial infarction (Kramer et al., 2009). Psychological disorders as well as, like stress 
and low self-esteem by stigmatizing body changes (Santos et al., 2005; Seidl & Machado, 
2008), which not cease to be risk factor for these events already mentioned by activation of 
sympathetic and glucocorticoids systems, and neuropeptide Y production potentiating the 
metabolic changes (Licht et al., 2010; Rasmusson et al., 2010). 
3. Pathophysiology of dyslipidemia secondary to antiretroviral therapy 
Since the implementation of antiretroviral therapy (HAART), in the 90s of last century, the 
treatment of AIDS has increased the mean life expectancy of HIV-infected population. Until 
then seen as a death sentence in a matter of short time, the disease have been faced like 
chronic, and with more optimism. However, despite a decrease in morbidity and mortality, 
HAART led to a problem that has become a major challenge that patients with AIDS must 
control: dyslipidemia (Cahn et al., 2010). 
The dyslipidemia associated with HAART has been characteristic of elevated total 
cholesterol (TC), low-density lipoprotein (LDL-C) and triglycerides (TG), in addition to 
decreased high-density lipoprotein (HDL-C), which results in increased predisposition to 
the development of hypertension, insulin resistance, diabetes mellitus and cardiovascular 
complications. There are evidences that cardiovascular manifestations proportions in HIV-
infected patients on HAART are higher than in general population (Almeida et al., 2009). 
This does not mean that the occurrence of dyslipidemia has emerged only with the 
implementation of antiretroviral drugs to treat AIDS. Before the existence of HAART had 
been reported lipid profile changes with high levels of triglycerides and low rate of VLDL-C 
and HDL-C (Sprinz et al., 2010; Grunfeld et al., 1992). 
Several studies investigate ways of relating to HAART the effects of dyslipidemia like type 
of drug used by the patient and how the treatment regimen it has been implemented, but is 
still lacking a precise explanation for the lipid profile origin. Protease inhibitors (PI) are 
associated with dyslipidemia and insulin resistance for a considerable time, specifically 
ritonavir, and a variety of hypotheses (albeit not conclusive) it is presented to explain this 
association (Noor, 2007; Dubé et al., 2003). 
One proposed mechanism to emergence of dyslipidemia is the lipoprotein lipase inhibition 
by PI, responsible for LDL-C increased, due to difficulty in capturing chylomicrons, 
resulting in lower hepatic clearance of triglycerides (Sprinz et al., 2010, as cited in Carr & 
Mooser, 2001). Another hypothesis is that PI has the ability to inhibit steps in lipid 
metabolism by binding to cellular retinoic acid binding protein type 1 (CRABP-1) and 
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related protein receptor LDR-c, resulting in hyperlipidemia by higher release of lipids in the 
circulation. More specifically, the PI on CRABP-1 receptor leads to a reduction of 9-cis 
retinoic acid and dimerization with the receptor activated by peroxisome proliferator-
activated receptor gamma (PPAR-γ), which is involved both in apoptosis of adipocytes and 
in differentiation between these two. (Sprinz et al., 2010; Carr et al., 1998). A third theory, 
restricted to ritonavir, antiretroviral therapy suggests it increases the activity of sterol 
regulatory element binding protein 1 (SREBP-1c), increasing lipogenesis, the rate of VLDL-C 
and apolipoprotein B liver. Thus, the increase in triglycerides caused by ritonavir that could 
be related to elevation in hepatic lipoprotein, inhibiting degradation mediated by 
apolipoprotein B and SREBP-1c in liver (Riddle et al., 2001; Liang et al., 2001). 
As regard the insulin resistance promoted by PI, this class of antiretroviral drugs has been 
related to inhibition of GLUT-4 in the transmembrane transport of glucose, leading to 
reduced glucose uptake mediated by insulin in peripheral tissue (skeletal muscle and 
adipocytes), which can lead the modification of lipid levels (Noor, 2007). The fact that some 
patients had a clinical and laboratory profile more or less flowered depending on the effects 
that PI has on the lipids metabolism may be related to genetics, suggesting that certain 
people are more prone to PI effects through manifestation of certain genes so far not 
identified (Shahmanesh et al., 2001). 
With regard to nucleoside reverse transcriptase inhibitors (NRTIs), it is speculated that can 
lead to reduced synthesis of mitochondrial DNA, leading to decreased oxidative 
phosphorylation, resulting in subcutaneous adipocyte apoptosis, dyslipidemia, and 
increased insulin resistance (Maagaard & Kvale, 2009). The reverse transcriptase inhibitor 
non-nucleoside (NNRTI), particularly Efavirenz, are also related to the onset of metabolic 
disorders, including dyslipidemia – but they have lower participation. When compared to 
patients receiving Nevirapine, patients who make use of Efavirenz have higher levels of 
triglycerides and HDL-C (Sprinz et al., 2010, as cited in Carr et al., 1998). 
The type of antiretroviral used in HAART case amends significantly the lipid profile of 
patient it might be replaced. However, make use of a change in medication or combination 
of drugs (a strategy that appears more practical than prescription of lipid, at least at first 
glance) does not always result in improving lipid metabolism, considering the dyslipidemia 
in HIV infection is related to a multifactorial framework (Sprinz et al., 2010). 
Although there are doubts considering the mechanisms linked to development of 
dyslipidemia in patients receiving HAART, and about assumptions not fully understood, 
this is still the most effective treatment in patients with AIDS and should not be proscribed 
for patients. To minimize risks that dyslipidemia implies to health, we recommend the same 
precautions, both dietary and behavioral (avoiding a sedentary lifestyle) and drug 
(statins/fibrates) for the general population. The use of fibrates is primarily indicated for 
reduction of hypertriglyceridemia, while statins are used to reverse the 
hypercholesterolemia. However, must be careful in prescribing of statins, since there is risk 
of drug interactions with HAART (Sprinz et al., 2010). 
4. Treatment of dyslipidemia secondary to antiretroviral therapy 
Hyperlipidemia is a major risk factor for developing of atherosclerosis. Epidemiological 
studies in adults show a direct association between high levels of total cholesterol and LDL 
and the incidence of mortality and morbidity in coronary artery disease (CAD) and is LDL-C a 
predictor of CAD risk at any age, besides low HDL and diabetes mellitus (Giddings, 1999). 
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Dyslipidemia in HIV infection is related to a multifactorial framework (Sprinz et al., 2010), 
so treatment should be done with non-pharmacological and pharmacological measures. 
4.1 Hypercholesterolemia 
4.1.1 Non-pharmacologic therapy 
The HIV-infected patients with dyslipidemia they should be screened before using those 
drugs as therapy, with the implementation of the change of lifestyle of these patients 
through diet, exercise, tobacco control, diabetes mellitus and hypertension (Dubé et al., 
2003). In one study, the diet associated with exercise in 11% reduced cholesterol levels of 
patients infected with HIV (Henry et al., 1998). In another study showed that diet 
accompanied by resistance exercise at least three times a week reduced the cholesterol level 
by 18% and triglycerides by 25% (Jones et al., 2001). 
The first measure to be taken will always be non-pharmacologic therapy, unless there is 
urgent need for intervention, as patients at high risk for coronary artery disease (obesity, 
diabetes, family history of cardiovascular disease) and extremely high levels of LDL-C 
greater than 220 mg / dL (Dubé et al., 2003). 
4.1.2 Pharmacological therapy 
The pharmacological treatment for dyslipidemia it is performed with HMG-CoA reductase 
inhibitors, or statins, are the main representatives of pravastatin and atorvastatin groups. 
They have been used extensively in clinical practice as first-line treatment for 
hypercholesterolemia in the general population and in HIV-infected patients, promoting 
reduction of cardiovascular risk in patients without no history of coronary artery disease 
and of progression of coronary artery stenosis with decrease of cardiovascular events 
recurrence, working in primary and secondary, respectively (Dube et al., 2003). 
In one study, patients with altered levels of total cholesterol (TC) and triglycerides (TG), 
using pravastatin 20 mg/day occurring 19% decrease in the level of TC and 37% in the level 
of TG (Baldini et al., 2000). In another study, diet was associated with therapy with 
pravastatin 40 mg/day in patients with TC levels greater than 240 mg/dL, indicating a 17% 
decline in the levels of TC and 19% in the level of LDL-C (Moyle, 2001). Therefore, Palacios 
et al., in 2002, analyzing a group of patients with TC levels greater than 240 mg/dL under 
atorvastatin 10 mg/day was found a 27% decrease in the level of TC, 41% of TG and 37% in 
the LDL-C. 
Thus, statins are the first choice in the treatment of elevated LDL-C (> 220 mg / dL) and 
patients with high total cholesterol associated with hypertriglyceridemia (TG between 200 to 
500 mg/dL), initial dose may be used 20-40 mg of pravastatin or atorvastatin 10 mg 
monitoring possible liver toxicity with laboratory tests (Dube et al., 2003). Protease 
inhibitors and non-nucleoside inhibitors of reverse transcriptase enzyme use in its 
metabolism the cytochrome P450 pathway (Smith et al., 2001), the same route used by 
simvastatin, lovastatin and atorvastatin, then the first two are proscribed to patients under 
antiretroviral therapy and the latter can be used with caution. 
Fibrates are used as second choice in the treatment of hypercholesterolemia. In patients with 
normal TG and elevated LDL-C levels, a slight decrease in LDL-C ranging from 5 to 20% in 
the studies carried out. Therefore, the therapeutic fibrates use should be reserved for 
treatment of hypertriglyceridemia (TG> 500 mg/dL) in these patients (Dube et al., 2003). 
 




4.2.1 Non-pharmacologic therapy  
The non-pharmacologic therapy should be first applied to all patients with 
hypertriglyceridemia, through modification of lifestyle; diet should be instituted to reduce 
fat intake, weight reduction, reduction or elimination of alcohol intake, smoking cessation 
control of hyperglycemia and diabetes with insulin sensitizers such as metformin. In 
studies, it has been found that diets associated with exercise and resistance training 
promotes decrease of 21% and 27%, respectively, TG levels in HIV-infected patients (Henry 
et al., 1998; Yarashesky et al., 2001). 
Patients who demonstrate extreme elevations in TG level (> 1000 mg / dL) and with a 
history of pancreatitis should be treated associating pharmacologic and non-pharmacologic 
therapy (Dube et al., 2003). 
4.2.2 Pharmacologic therapy 
Drug therapy should be instituted in all patients with TG levels greater than 500 mg/dL with the 
introduction of Gemfibrozil with starting dose of 600 mg half an hour before meals (lunch and 
dinner) or fibrates at a dose 54 to 160 mg/day (Dube et al., 2003). In a study carried out in 
patients with TG levels higher than 400 mg/dL using fibrate dose of 200 mg/day was observed 
14% and 54% decrease of TC and TG levels, respectively (Palácios et al., 2002). Therefore, in 
another study, patients with TG levels higher than 266 mg/dL, using Gemfibrozil 600 mg/day 
associated with diet, evolved with a reduction of TG values in 18% (Miller et al., 2002). 
The use of statins in general is not recommended for the treatment of hypertriglyceridemia 
(TG> 500 mg / dL) alone, is recommended when triglyceride levels are between 200 to 500 
mg/dL associated with increased total cholesterol (Dubé et al., 2003). 
5. Experience of the assistance service of metabolic diseases secondary to 
antiretroviral therapy for patients with dyslipidemia 
Assistance Service of Metabolic Diseases Secondary to Antiretroviral Therapy (HAART) of 
the João de Barros Barreto University Hospital (HUJBB), Brazilian national reference in 
transmissible infectious diseases and AIDS, actually, assist about 99 HIV carriers’ patients 
with lipodystrophy syndrome. Into this service, the authors develop a Project titled 
Lipodystrophy and Antiretroviral Therapy, financed by The State of Pará Research 
Foundation (FAPESPA), Research Program for the Unified Health System (PPSUS). One of 
the Project’s purposes was the implantation of the lipodystrophy ambulatory care. 
The HUJBB lipodystrophy ambulatory care works with team composed by an 
endocrinologist, a nutrition doctoral student, two medicine M.Sc students, four medical 
undergraduate students. The medical accompaniment is performed once a week. In the first 
service is diagnosed the clinical form of lipodystrophy and requested the proper tests (total 
cholesterol, HDL, LDL, triglycerides, fasting glucose test, oral glucose tolerance, insulin, 
abdominal ultrasonography to hepatic steatosis diagnostic and computed tomography for 
evaluation of visceral lipohypertrophy and electrocardiogram). The first patient's return is 
around 45 days and subsequently every three months for medical accompaniment. Each 
medical consultation is also performed medical history, measurement of blood pressure, 
heart auscultation, anthropometric evaluation (measurements of weight, height, skin folds) 
and bioimpedance. In addition, if need be the patient is referred to other professionals of the 
multidisciplinary team HUJBB. 
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Of the accompanied patients with lipodystrophy syndrome in this ambulatory care, 77%  
(n = 77) have dyslipidemia and presents the following profile: 67.9% were male, mean age of 
44.5 years, average time of HIV infection of 8, 3 years, average time of use of antiretroviral 
therapy for 6.9 years and body mass index of 24.5 kg/m2. Regarding risk factors, it is 
observed that 18.2% are smokers, 40.3% alcoholics, 71.4% sedentary and 45.5% had hepatic 
steatosis. Regarding the classification of nutritional status (WHO, 1995) 58.4% are eutrophic, 
thin 6.5% and 35.1% overweight/obesity. Among the co morbidities studied, it appears that 
24.7% and 21.1% are hypertensive and diabetics, respectively. When stratifying the 
lipodystrophy syndrome, according to the clinical manifestations, 35.1%, 10.4% and 54.5% of 
patients had lipoatrophy, hypertrophy and mixed syndrome, respectively. Concerning 
average serum lipid levels, there is high levels blood of cholesterol and triglycerides, low 
HDL-C, and LDL-C within the normal range. In regard to dyslipidemia classification 
(Sposito et al., 2007), have been observed that 48.7% of patients have mixed hyperlipidemia, 
32.9% hypertriglyceridemia, low HDL-C 10.5% and 7.9% isolated hypercholesterolemia 
(Table 1 and 2). In the assessment of cardiovascular risk by Framingham Risk Score was 
found that more than 30% of the sample had medium and high cardiovascular risk. 
 
Variables Total Sample n %
Male 52 67.5 
Female 25 32.5 
Smoking 77 14 18.2 
Alcoholism 77 31 40.3 
Sedentary 77 55 71.4 
Diabetes mellitus 77 17 21.1 
SH * 77 19 24.7 
Family history 
Diabetes  77 37 48.1 
Hypertension 77 55 71.4 
Dyslipidemia 72 28 38.9 
Hepatic steatosis 66 30 45.5 
Nutritional status** 76
Thinness** 05 6.6
Eutrophic 44 57.9 
Overweight/Obesity 27 35.5 
Lipodystrophy 77
Lipoatrophy  27 35.1 
Hypertrophy 8 10.4 
Mixed 42 54.5 
Classification of dyslipidemia*** 76
Mixed Hyperlipidemia 37 48.7 
Hypertriglyceridemia 25 32.9 
Low HDL 8 10.5 
Isolated hypercholesterolemia 6 7.9
Legend: SH - systemic hypertension; ** WHO, 1995; *** Sposito et al., 2007 
Table 1. Patients profile with lipodystrophy and dyslipidemia accompanied by the 
Assistance Service of Metabolic Diseases Secondary to Antiretroviral Therapy, João de 
Barros Barreto University Hospital, Pará, Brazil. 
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Variable Total Sample Mean ± SD Median 
Age (years) 77 44.5 ± 9.6 45.0
ART Time (years) 77 6.9 ± 4.1 7.0
Time of HIV (years) 77 8.3 ± 5.4 8.0
BMI (kg/m²) 76 24.5 ± 4.2 23.9
Fasting glucose (mg/dL) 72 103.4 ± 27.7 98.5
Total Cholesterol (mg/dL) 76 218.9 ± 59.7 220.0
Triglycerides (mg/dL) 76 373.3± 393.8 280.5
HDL-c (mg/dL) 60 40.8 ± 13.34 39
  Male HDL-c  36 37.4 ± 11.7 37.0
  Female HDL-c 24 46.0 ±14.2 46.5
LDL-c (mg/dL) 58 115.6 ± 45.4 117.9
Legend: ART – Antiretroviral Therapy, BMI – body mass index, SD standard deviation. 
Table 2. Distribution of mean and median values of some variables in patients with 
lipodystrophy and dyslipidemia accompanied by the Assistance Service of Metabolic Diseases 
Secondary to Antiretroviral Therapy, João de Barros Barreto University Hospital, Pará, Brazil. 
The ambulatory care authors conducted an intervention study with outpatient HIV-positive 
with lipodystrophy syndrome, in use of HAART in the period October 2006 to December 2007. 
Patients were evaluated every quarter for four visits. This study followed all the guidelines 
contained in Resolution 196/1996 of the National Committee for Ethics in Research (CONEP), 
being approved by the Ethics in Human Research of the Center for Tropical Medicine, Federal 
University of Para, according to opinion of approval No. 058/2006, to date of October 19, 2006. 
The sample consisted of patients with positive serology for HIV, use of HAART for at least 12 
months, with clinical diagnosis of lipodystrophy. We selected only adult patients, aged 20 to 
60 years, of both sexes. All were invited and agreed to participate by reading and signing the 
Free and Informed Consent Term - FICT. 
We excluded all patients with mental illness, malignant tumors, and chronic users of 
glucocorticoids, Diabetes Mellitus and dyslipidemia diagnosed before starting HAART and 
those who did not achieve at least three follow-up visits clinical and nutritional care at the 
Ambulatory care of Lipodystrophy HUJBB. 
To collect data we used a treatment protocol for metabolic evaluation, nutritional counseling 
and patient outcomes, among several details registered there were: patient identification, 
socio-economic, personal and family morbidity history, time of HIV diagnosis, time of 
HAART treatment, clinical history and biochemical tests. Among the lipodystrophy 
syndrome metabolic changes were required tests to total serum cholesterol, LDL-C, HDL-C 
and triglycerides for dyslipidemia analysis (Sposito et al., 2007). 
We studied 29 patients, 17 (59%) and 12 (41%), male and females, respectively, with an 
average age of 46.07 (± 9.04) years. In males, the average age was 47.59 (± 7.66) years, 
median 46 years, whereas in females the mean age was 43.92 (± 10.67) years, median 44. The 
most prevalent age group for both sexes was 41 to 50 years. 
In regarding to lipodystrophy syndrome classification, was observed that 11 (37.91%), 2 (6,9%) 
and 16 (55,17%) patients demonstrated lipoatrophy, lipohypertrophy and mixed syndrome, 
respectively. There is no sex association with lipoatrophy and mixed syndrome (p= 0.4138, 
OR= 0.3750, IC 95%= 0.0744 – 1.8891), whilst lipohypertrophy syndrome had predominance in 
females. It is assumed when calculating Odds Ratio to lipohypertrophy presence, was noted 
that female chance present lipohypertrophy is 2.66 times more, However, the results have not 
been significant (p=0.4130, IC 95% 0.5294 a 13.4334), data shown in Figure 2.  
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Fig. 2. Distribution of the lipodystrophy syndrome in relation to sex, Pará, Brazil 2006-2008. 
The HAART temporal analysis showed that there was a growing evolution of lipoatrophy 
and lipohypertrophy presence in association with prolonged use of HAART (p = 0.0485,  
p = 0.0393, respectively). 
Among the 29 patients, 6 were taking hypolipidemic. The lipid profile found in patient’s 
evaluation, including those who had made use hypolipidemic therapy, was no statistically 
significant changes on the total cholesterol and LDL-C, however, for the HDL-C and 
triglycerides had significant differences between the first and last clinical follow-up 
nutritional (Figure 3). 
 
 
Legend: (A) Total cholesterol, (B) LDL-C, (C) and HDL-C (D) triglycerides, distributed by quarters. 
Dependent t-test for paired samples.  
Fig. 3. HIV patients Serum lipids who did not use hypolipidemic, distributed by quarters, 
2006-2008 Para-Brazil.  
 
Dyslipidemia in Patients with Lipodystrophy in the Use of Antiretroviral Therapy 
 
437 
When analyzing only the sample of patients who were taking hypolipidemic (n = 7), there 
was no statistically significant changes in the levels of serum total cholesterol, LDL-C and 




































* Legend: Friedman test. 
Table 3. Comparison of mean only of lipid profile of patients who were taking 
hypolipidemic therapy for the clinical follow-up of four nutritional consultations, Pará, 
Brazil 2006-2008.  
In assessing relation between lipids and lipodystrophy syndrome, there was no significant 












    
Normal levels 3 (27.27) 0 (0.00) 7 (43.75) 0.3840 
Abnormal 
levels 
8 (72.73) 2 (100.00) 9 (56.25) 
LDL 
cholesterol 
    
Normal levels 9 (81.82) 1 (50.00) 14 (87.50) 0.4141 
Abnormal 
levels 
2 (18.18) 1 (50.00) 2 (12.50) 
HDL 
cholesterol 
    
Normal levels 1 (9.09) 0 (0.00) 5 (31.25) 0.2849 
Abnormal 
levels 
10 (90.91) 2 (100.00) 11 (68.75) 
Triglycerides     
Normal levels 3 (27.27) 1 (50.00) 5 (31.25) 0.3023 
Abnormal 
levels 
8 (72.73) 1 (50.00) 11 (68.75)  
Legend: N - number of patients. Test: Partitioning Chi-square. 
Table 4. Association between lipid profile and lipodystrophy syndrome, Pará, Brazil 2006-
2008.  
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Legend: (A) Total cholesterol, (B) LDL-C, (C) and HDL-C (D) triglycerides, distributed by quarters. 
Dependent t-test for paired samples.  
Fig. 3. HIV patients Serum lipids who did not use hypolipidemic, distributed by quarters, 
2006-2008 Para-Brazil.  
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When analyzing only the sample of patients who were taking hypolipidemic (n = 7), there 
was no statistically significant changes in the levels of serum total cholesterol, LDL-C and 




































* Legend: Friedman test. 
Table 3. Comparison of mean only of lipid profile of patients who were taking 
hypolipidemic therapy for the clinical follow-up of four nutritional consultations, Pará, 
Brazil 2006-2008.  
In assessing relation between lipids and lipodystrophy syndrome, there was no significant 












    
Normal levels 3 (27.27) 0 (0.00) 7 (43.75) 0.3840 
Abnormal 
levels 
8 (72.73) 2 (100.00) 9 (56.25) 
LDL 
cholesterol 
    
Normal levels 9 (81.82) 1 (50.00) 14 (87.50) 0.4141 
Abnormal 
levels 
2 (18.18) 1 (50.00) 2 (12.50) 
HDL 
cholesterol 
    
Normal levels 1 (9.09) 0 (0.00) 5 (31.25) 0.2849 
Abnormal 
levels 
10 (90.91) 2 (100.00) 11 (68.75) 
Triglycerides     
Normal levels 3 (27.27) 1 (50.00) 5 (31.25) 0.3023 
Abnormal 
levels 
8 (72.73) 1 (50.00) 11 (68.75)  
Legend: N - number of patients. Test: Partitioning Chi-square. 
Table 4. Association between lipid profile and lipodystrophy syndrome, Pará, Brazil 2006-
2008.  
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In assessing comparison of mean of lipid profile of all patients before and after the clinical 
and nutritional intervention (first and fourth visit), there was a significant difference 
between the levels of total cholesterol, LDL-C, HDL-C and triglycerides between the 
lipoatrophy and mixed syndrome (p> 0.05) (Table 5). No analysis was performed on the 
lipohypertrophy syndrome due to be there of only two patients. 
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Table 5. Comparison of mean of lipid profile of all patients, including who were taking 
hypolipidemic therapy before and after the intervention in lipodystrophy syndrome, Pará, 
Brazil 2006-2008. 
The manifestation of lipodystrophy syndrome with regard to gender did not present 
significant differences for lipoatrophy or mixed syndrome. However, the syndrome was 
related to female lipohypertrophy corroborating other studies (Galli et al., 2002; Heath et al., 
2002) and disagreeing with most published data has been shown increased risk of 
lipoatrophy syndrome among women. Tien et al. (2003) in prospective study of 
lipodystrophy syndrome risk among HIV-infected women and non-infected observed a risk 
2,1 times more of develop lipoatrophy in infected women with virus than non-infected, 
whereas it did not differ lipohypertrophy syndrome between the two groups and the most 
prevalent de form lipodystrophy was mixed syndrome (81%). Van Griensven et al. (2007) 
evaluated the lipodystrophy syndrome prevalence among patients using stavudine in 
antiretroviral therapy and found lipoatrophy syndrome prevalence in 9.8% of patients on 
stavudine and 4.9% with lipohypertrophy syndrome. The HAART temporal analysis 
showed that there was a growing evolution of the appearance of lipoatrophy and 
lipohypertrophy associated with HAART prolonged use, as demonstrated by studies of 
Lichtenstein et al. (2005) and Goujard et al. (2003). 
As regards the evaluation of metabolic changes associated with use of HAART coupled with 
the treatment of nutritional guidance, it must be pointed out that some factors may have 
affected the outcome of this work as the low adherence to medical treatment, nutrition, 
failure to follow the previous recommendations for achieving of biochemical tests and the 
small sample size of patients available for this study. This difficulty in adhering to medical 
treatment and/or diet therapy was also found by other authors (Quintaes & Garcia, 1999; 
Ceccato et al. 2004; Parenti et al., 2005; Barros et al. 2007; Chencinski & Garcia, 2006). The 
reluctance of patients to nutritional treatment may be related to low purchasing power 
(Barros et al., 2007), cultural and dietary habits proper to the Amazon region, who abuse 
food that are rich in lipids. In addition to psychosocial factors of patients, where the 
prejudice, social isolation and emotional disorders such as anxiety and depression 
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commonly observed in patients infected with HIV make it difficult to change lifestyle 
(personal and food) as suggested by Quintaes & Garcia (1999) Chencinski & Garcia (2006). 
There was also that patients profile evaluated before intervention reflected increase in serum 
total cholesterol and triglycerides, and lowering HDL-C as described in the literature (Caar 
et al. 1998; Hadigan et al. 2006; Having Hofstede et al., 2003; Abreu et al., 2006), disagreeing 
with main studies analyzed only about LDL-C, where most patients remained within 
normal range. Lipid disorders and association with lipodystrophy syndrome were common 
in all patients, especially in mixed syndrome, according to studies by Thiebaut et al. (2000) 
and Haugaard et al. (2005). 
The lipid abnormalities evolution in patients after clinical and nutritional intervention 
during study noted significant changes of lowering triglycerides and increase in HDL-C, 
regardless of hypolipidemic use. The increased levels of HDL-C have been associated with 
decreased cardiovascular risk, as has been discussed in the work of Manninen et al. (1988). 
Where was reported that for every 1% increase in HDL-C was 3% reduction in coronary 
events and Pedersen et al. (1998) who said that for each 1% increase in HDL-C there was 1% 
reduction in coronary events, both independently of changes in LDL-C levels. 
The lipid profile of patients before and after nutritional intervention clinically observed that 
patients who had shown serum levels of triglycerides, total cholesterol and fractions (LDL-C 
and HDL-C) normal at first, had increasing them at the end of treatment. These patients had 
borderline values facilitating risk of increased total cholesterol, LDL-C and triglycerides and 
decreased HDL-C associated with nutrition acceptance less than 75%. Other patients in the 
first consultation showed values above the reference levels for total cholesterol, LDL-C and 
triglycerides as well as lowering HDL-C, reaching normal values due to good acceptance to 
nutritional care. The remaining patients showed levels of total cholesterol, LDL-C fractions, 
HDL-C and triglycerides changed during the research; probably was not able to perceive the 
importance of nutritional treatment. There were also cases of patients who had their lipid 
profile within the normal range, suggesting that not only the use of HAART interfered with 
these metabolic changes, but also other factors may be implicated as genetic predisposition. 
In regarding to lipodystrophy syndrome, the cholesterol and LDL-C means demonstrated it 
more significant in lipoatrophy than mixed syndrome compared before and after 
intervention. Triglyceride levels showed independent growing in despite to lipodystrophy 
syndrome, while HDL-C showed changed levels in mixed syndrome. 
The physiopathology by which HAART determines HIV lipodystrophy syndrome, 
dyslipidemia therefore remains unknown. Second Andrade & Hutz (2002), the lipid serum 
levels are multifactorial characteristics, determinate by genetic and environmental factors, 
highlighting the genetic variability found in those genes that can affect the response to 
drugs used in hyperlipidemia treatment. 
The authors of the lipodystrophy ambulatory care are developing a research paper about a 
case-control study conducted from December 2009 to July 2012. For data collection is being 
performed a clinical, epidemiological and nutritional evaluation where are registered 
information about patient identification, socio-economic conditions, personal and family 
history of morbidity, time of HIV diagnosis, HAART treatment duration, medication used - 
HAART, viral load, CD4 counts, clinical history, biochemical tests for dyslipidemia 
classification, anthropometric analysis and, APOAI and APOAV apolipoprotein 
polymorphism evaluation. This study aims to investigate these polymorphisms in an attempt 
to discover the main causes responsible for this metabolic disorder, the dyslipidemia. 
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In assessing comparison of mean of lipid profile of all patients before and after the clinical 
and nutritional intervention (first and fourth visit), there was a significant difference 
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2,1 times more of develop lipoatrophy in infected women with virus than non-infected, 
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evaluated the lipodystrophy syndrome prevalence among patients using stavudine in 
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stavudine and 4.9% with lipohypertrophy syndrome. The HAART temporal analysis 
showed that there was a growing evolution of the appearance of lipoatrophy and 
lipohypertrophy associated with HAART prolonged use, as demonstrated by studies of 
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commonly observed in patients infected with HIV make it difficult to change lifestyle 
(personal and food) as suggested by Quintaes & Garcia (1999) Chencinski & Garcia (2006). 
There was also that patients profile evaluated before intervention reflected increase in serum 
total cholesterol and triglycerides, and lowering HDL-C as described in the literature (Caar 
et al. 1998; Hadigan et al. 2006; Having Hofstede et al., 2003; Abreu et al., 2006), disagreeing 
with main studies analyzed only about LDL-C, where most patients remained within 
normal range. Lipid disorders and association with lipodystrophy syndrome were common 
in all patients, especially in mixed syndrome, according to studies by Thiebaut et al. (2000) 
and Haugaard et al. (2005). 
The lipid abnormalities evolution in patients after clinical and nutritional intervention 
during study noted significant changes of lowering triglycerides and increase in HDL-C, 
regardless of hypolipidemic use. The increased levels of HDL-C have been associated with 
decreased cardiovascular risk, as has been discussed in the work of Manninen et al. (1988). 
Where was reported that for every 1% increase in HDL-C was 3% reduction in coronary 
events and Pedersen et al. (1998) who said that for each 1% increase in HDL-C there was 1% 
reduction in coronary events, both independently of changes in LDL-C levels. 
The lipid profile of patients before and after nutritional intervention clinically observed that 
patients who had shown serum levels of triglycerides, total cholesterol and fractions (LDL-C 
and HDL-C) normal at first, had increasing them at the end of treatment. These patients had 
borderline values facilitating risk of increased total cholesterol, LDL-C and triglycerides and 
decreased HDL-C associated with nutrition acceptance less than 75%. Other patients in the 
first consultation showed values above the reference levels for total cholesterol, LDL-C and 
triglycerides as well as lowering HDL-C, reaching normal values due to good acceptance to 
nutritional care. The remaining patients showed levels of total cholesterol, LDL-C fractions, 
HDL-C and triglycerides changed during the research; probably was not able to perceive the 
importance of nutritional treatment. There were also cases of patients who had their lipid 
profile within the normal range, suggesting that not only the use of HAART interfered with 
these metabolic changes, but also other factors may be implicated as genetic predisposition. 
In regarding to lipodystrophy syndrome, the cholesterol and LDL-C means demonstrated it 
more significant in lipoatrophy than mixed syndrome compared before and after 
intervention. Triglyceride levels showed independent growing in despite to lipodystrophy 
syndrome, while HDL-C showed changed levels in mixed syndrome. 
The physiopathology by which HAART determines HIV lipodystrophy syndrome, 
dyslipidemia therefore remains unknown. Second Andrade & Hutz (2002), the lipid serum 
levels are multifactorial characteristics, determinate by genetic and environmental factors, 
highlighting the genetic variability found in those genes that can affect the response to 
drugs used in hyperlipidemia treatment. 
The authors of the lipodystrophy ambulatory care are developing a research paper about a 
case-control study conducted from December 2009 to July 2012. For data collection is being 
performed a clinical, epidemiological and nutritional evaluation where are registered 
information about patient identification, socio-economic conditions, personal and family 
history of morbidity, time of HIV diagnosis, HAART treatment duration, medication used - 
HAART, viral load, CD4 counts, clinical history, biochemical tests for dyslipidemia 
classification, anthropometric analysis and, APOAI and APOAV apolipoprotein 
polymorphism evaluation. This study aims to investigate these polymorphisms in an attempt 
to discover the main causes responsible for this metabolic disorder, the dyslipidemia. 
 




The HAART has as one of its major collateral effect the lipodystrophy syndrome. There is 
necessity of more studies to deep into physiopathology of this syndrome; and metabolic and 
cardiovascular complications secondary to HAART. Dyslipidemia stands out as one of the 
most prevalent metabolic changes in patients with HIV, what makes it essential to feasibility 
of research in therapeutic care to clarifying of the clinical management. It is noted that 
nutritional guideline and/or hypolipidemic use, when have there been acceptance to 
treatment, takes place improvements of the lipid profile, can also there be normalization of 
those levels, in particular of the triglyceride levels. However, the adherence neither always 
takes place, what difficult the management of those patients. 
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1. Introduction 
Fenofibrate, a selective peroxisome proliferator-activated receptors alpha (PPAR-α) 
activator, has been primarily developed to treat human dyslipidemia. PPAR modulate the 
expression of genes involved in lipid metabolism through peroxisome proliferator response 
elements (Willson et al., 2000). Although fenofibrate became commercially available in 1974 
(Fournier, Inc., France), its lipid-lowering action mechanism has not been clarified until the 
late 1990’s, contributing to open new research doors. With respect to the mechanisms of 
action, the drug with pleiotropic activity may be regarded as a “21st-century agent” (Staels 
et al., 1995).  
Fenofibrate as a ligand of PPAR-α exhibits lipid-lowering effects by activating PPAR-α.  
PPAR-α activators stimulate the β-oxidation of fatty acids in the liver resulting in a 
decreased availability of fatty acids for triglyceride (TG) synthesis (Schoonjans et al., 1995, 
1996a, 1996b). In addition, fenofibrate enhances the production of apo-AI and apo-AII: the 
major component of HDL by activating PPAR-αand increases plasma level of HDL-C 
directly (Vu-Dac, 1994, 1995). Thus, the lipid-lowering action mechanism of fenofibrate 
involves potent TG-reducing and HDL-C-increasing actions. Statins, another type of lipid-
lowering agent do not show such actions, though statins can inhibit hydroxymethylglutaryl 
(HMG)-CoA reductase (Endo A, 1992).  
Furthermore, fenofibrate decreased the level of low-density lipoprotein cholesterol (LDL-C), 
especially “small dense LDL”, which may be a powerful metabolic contributor to 
arteriosclerosis (Superko, 2000). 
PPAR-α regulates the transcription of lipid-associated genes and various genes involved in 
homeostasis, suggesting the PPAR-α-mediated pleiotropic activities of fenofibrate. The 
reports on the pleiotropic activities of fenofibrate has been accumulated in a variety of large-
scale, randomized, controlled trials (RCTs).  
The studies presumably associated with the anti-aging actions of fenofibrate are reviewed in 
this article.  
2. Clinical efficacy 
The pleiotropic activities other than the lipid-lowering actions reported in clinical practice: 
the anti-inflammatory, antioxidant, and serum uric acid-reducing actions of fenofibrate are 
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reviewed in this section. These activities may be tightly associated with anti-aging actions of 
fenofibrate. Three large-scale, randomized, comparative clinical studies of fenofibrate 
(“DAIS”, “FIELD” and “ACCORD”), in which intervention was performed in patients with 
type II diabetes mellitus (DM), were published since 2000.  
2.1 Anti-aging activities 
Previous studies reported the involvement of various clinical parameters in anti-aging 
actions of fenofibrate (Schlesinger et al., 2009). In particular, chronic, systemic, silent, low-
grade inflammation, named inflammaging is the target for intensive research in aging study 
(Goto, 2008b). Ross et al. defined arteriosclerosis as “chronic vascular inflammation” 
resulting from an interaction between oxidized lipid and macrophages (Ross, 1999). 
Inflammation is involved in the onset of arteriosclerotic disorders and acute coronary 
syndrome. Furthermore, oxidative stress that can induce a vicious cycle of chronic 
inflammation has been believed to be the major driving force to promote aging (Yu & 
Chung, 2001; Romano et al., 2010).  
Uric acid has recently been considered to be a prognostic factor for the onset of DM and 
dementia that may accelerate aging (Hikita et al., 2007; Abate et al., 2004; Martinon et al., 
2006), although an excess level of uric acid is the primary incite for gouty attack (Schlesinger 
et al., 2009).  
2.1.1 Anti-inflammatory actions 
The anti-inflammatory actions of fenofibrate were reported in Nature in 1998 (Staels et al., 
1998). PPAR-α ligand: fenofibrate inhibited cyclooxygenase-2 (COX-2) expression and 
prostaglandin production by suppressing the transcription of COX-2 genes through the 
inhibition of nuclear factor κB (NF-κB: transcription factor) signals. Fenofibrate 
administration decreased the inflammatory parameters including serum levels of IL-6, 
fibrinogen, and C-reactive protein (CRP) in coronary disease patients and the patients with 



















Baseline after 6  months  
Closed circles represent fenofibrate; open circles represent statins. mean ± S.D. 
Wilcoxon signed rank test versus baseline, ** P <0.01, Mann-Whitney U test versus group 
Fig. 1. Changes in prednisolone (PSL) dosage. 
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We compared the anti-inflammatory effects of fenofibrate and statins in 44 patients with a 
chronic inflammatory disorder: rheumatoid arthritis (RA) (Goto, 2010). Japanese patients 
with RA and dyslipidemia were randomly divided into 2 groups: fenofibrate (Lipidil, Kaken 
Pharmaceutical Co., Ltd., micronized fenofibrate at 200 mg/day, n=23) and statins (n=21) 
groups. After 6-month administration, the laboratory data were compared, and pain was 
evaluated using the visual analogue scale (VAS) and dose change of prednisolone (PSL) was 
monitored. The VAS scores significantly decreased in the fenofibrate (from 49.1 to 14.7 mm, 
p<0.0001) and statin (from 47.4 to 20.2 mm, p<0.001) groups. The dose of PSL significantly 
reduced only in the fenofibrate group (from 3.58 to 2.00 mg/day, p<0.01). The reduction rate 
was also significantly better than in the statin group (Fig. 1).  
In the fenofibrate group, a significant correlation was between the rate of change in the 
ΔVAS score and that in the ΔCRP level (Fig.2. p<0.05). The results suggest that, in patients 
with RA, fenofibrate exhibits more potent anti-inflammatory effects compared to statins. 
 
 
Spearman rank correlation coefficient 
VAS visual analogue scale; HDL-C high-density lipoprotein-cholesterol; RF rheumatoid factor; CRP C-
reactive protein; ESR erythrocyte sedimentation rate; PSL prednisolone 
Fig. 2. Fenofibrate administration group: correlation between anti-inflammatory markers 
and ΔVAS. 
2.1.2 Antioxidant actions 
Oxidative stress has been considered to promote aging (Harman, 1978; Yu & Chung, 2001; 
Romano et al., 2010). As for oxidative stress markers that can be measured on clinical 
examination, serum lipids, MDA-LDL and Ox-LDL, and urinary lipids, 8-OHdG and 15-
isoprostane F2t: 8-epi-PGF2α/8-isoPGF2α, are employed (Harman, 1978; Yu& Chung, 2001). 
Coenzyme Q10 (CoQ10), also known as ubiquinone shows antioxidant actions and has been 
monitored as an in vivo marker of oxidative stress. 
CoQ10 is biosynthesized from mevalonic acid in the liver. As the pathway of CoQ10 
biosynthesis is partially overlapped with that of cholesterol synthesis, the administration of 
an HMG-CoA reductase inhibitor, statins, reduces the production of CoQ10. Therefore, 
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ΔVAS score and that in the ΔCRP level (Fig.2. p<0.05). The results suggest that, in patients 
with RA, fenofibrate exhibits more potent anti-inflammatory effects compared to statins. 
 
 
Spearman rank correlation coefficient 
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reactive protein; ESR erythrocyte sedimentation rate; PSL prednisolone 
Fig. 2. Fenofibrate administration group: correlation between anti-inflammatory markers 
and ΔVAS. 
2.1.2 Antioxidant actions 
Oxidative stress has been considered to promote aging (Harman, 1978; Yu & Chung, 2001; 
Romano et al., 2010). As for oxidative stress markers that can be measured on clinical 
examination, serum lipids, MDA-LDL and Ox-LDL, and urinary lipids, 8-OHdG and 15-
isoprostane F2t: 8-epi-PGF2α/8-isoPGF2α, are employed (Harman, 1978; Yu& Chung, 2001). 
Coenzyme Q10 (CoQ10), also known as ubiquinone shows antioxidant actions and has been 
monitored as an in vivo marker of oxidative stress. 
CoQ10 is biosynthesized from mevalonic acid in the liver. As the pathway of CoQ10 
biosynthesis is partially overlapped with that of cholesterol synthesis, the administration of 
an HMG-CoA reductase inhibitor, statins, reduces the production of CoQ10. Therefore, 
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statins, represented by atorvastatin, also inhibit CoQ10 biosynthesis in vivo, leading to the 
increase in oxidative stress (Mabuchi et al., 2005).  
The administration of standard fenofibrate at 150 mg/day to 18 Japanese type II DM with 
dyslipidemia for 12 weeks significantly decreased the triglyceride (TG) level (from 232±109 
to 145±74 mg/dL, -37%, p<0.01), and significantly improved the HDL-C level (from 45±8.7 
to 52±9.8 mg/dL, +14%, p<0.01) (Asano et al., 2006). 
The plasma ubiquinol-10 level in fenofibrate group increased significantly after 8 weeks 
(from 768±265 to 886±310 nM, p<0.05) and after 12 weeks (from 768±265 to 894±336 nM, 
p<0.05). However, total plasma CoQ10 level (ubiquinol-10 plus ubiquinone-10) as an 
oxidative stress marker, decreased in statin group, elevated in fenofibrate group after 12 
weeks administration (from 1010±296 to 1070±285 nM, +6%). In addition, plasma 
ubiquinone-10 in fenofibrate group decreased insignificantly. Fenofibrate treatment elevates 
plasma CoQ10, especially plasma ubiquinol-10 level.  
In the wild-type mice administered by diethylhexylphthalate (DEHP: PPAR-α activator), 
elevation of plasma ubiquinone was significant, but the elevation was not observed in the 
PPAR-α-null mice (Turunen et al., 2000). In addition, the expression of PPAR-α gene was 
regulated in the liver of SAMP1 (senescence accelerated mouse prone 1) mice given 
ubiquinol for long term (Schmelzer et al., 2010a, 2010b). Although the antioxidant action 
mechanisms of fenofibrate remained unclear in human, mice studies suggested the direct 
interaction between CoQ10 and PPAR-α.  
Fenofibrate not only restores the serum lipid profiles, but also suppresses oxidative stress. 
Fenofibrate with a variety of pleiotropic activities may protect the pathogenesis and 
progression of aging-associated atherosclerosis.  
2.1.3 Serum uric acid-reducing actions 
Hyperuricemia, a common co-morbidity in the patients with metabolic syndrome and 
dyslipidemia has recently been emphasized as an independent risk factor for cardiovascular 
disease (Lippi et al., 2008).  
Kodama et al. performed a meta-analysis of 11 clinical studies, and reported that a 1-mg/dL 
increase in the serum uric acid level significantly elevated the relative risk of type II DM by 
1.17-fold (Kodama et al., 2009). Schretlen et al. investigated 96 persons aged 60 to 92 years, 
and indicated that the information-processing capacity and memory were reduced in 
persons with high uric acid level, suggesting that the serum uric acid level may be a 
prognostic factor for dementia (Schretlen et al., 2007). Thus, hyperuricemia may play a role 
not only in the onset of cardiovascular disease but also in the promotion of dementia and 
aging. 
Fenofibrate has been known to reduce the serum levels of lipids and also uric acid 
(Schlesinger et al., 2009). The serum uric acid-reducing action mechanism of fenofibrate, 
independent of lipid-profile changes, involves the promotion of uric-acid excretion (Liamis 
et al., 1999).  
Urate Transporter 1 (URAT1), the target molecule of uric acid-reducing agents such as 
benzbromarone was identified which is responsible for the reabsorption of uric acid in the 
proximal uriniferous tubule (Enomoto et al., 2002). Furthermore, URAT1 inhibition was 
involved in the serum uric acid-reducing action mechanism of fenofibrate (Uetake et al., 
2010). According to their study, the single-dose administration of standard fenofibrate at 300 
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mg to healthy adults decreased the serum uric acid level by approximately 1.5 mg/dL. In 
Japan, fenofibrate has been administered to metabolic syndrome patients with 
hyperuricemia, leading to the decrease in the serum uric acid level by approximately 2 
mg/dL. 
2.2 Randomized controlled trial (RCT) 
Large-scale, randomized, controlled clinical trials of fenofibrate involving type II DM, that 
is, high-risk patients for arteriosclerosis, were conducted. The representative 3 studies were 
reviewed in this section: “DAIS” study, regarding coronary arteriosclerosis retraction, 
“FIELD” study, in which the inhibitory effects on cardiovascular events were examined, and 
“ACCORD” study, in which the inhibitory effects of lipid-intensified therapy with statins on 
cardiovascular events were investigated. 
2.2.1 Diabetes Atherosclerosis Intervention Study (DAIS) 
The DAIS is a placebo-controlled, double-blind, comparative study to verify whether the 
deterioration of coronary arteriosclerosis can be prevented by restoring abnormal lipid 
metabolism with fenofibrate in type II diabetics employing quantitative coronary 
angiography (DAIS investigators, 2001). This international, interventional study was 
conducted based on the World Health Organization (WHO)’s request and cooperation. 
This study is the first interventional study in which it was prospectively evaluated 
whether the correction of disturbance of lipid metabolism in type II DM prevents the 
deterioration of arteriosclerosis. It was carried out in Canada, Finland, Sweden, and 
France. Four-hundred and eighteen patients with type II diabetes in whom blood sugar 
control was favourable were randomly divided into fenofibrate (micronized fenofibrate, 
200 mg/day, n=207) and placebo (n=211) groups to evaluate the deterioration of coronary 
arteriosclerosis using quantitative coronary angiography after 38-month (mean duration) 
administration. 
In the fenofibrate group, a decrease in the minimum lumen diameter and an increase in the 
percent stenosiswere significantly suppressed in comparison with the placebo group (by 
40%), confirming the inhibitory effects of fenofibrate on the deterioration of coronary 
arteriosclerosis in type II DM.  
In the continuing study of DAIS, fenofibrate reduced the small dense LDL level, leading to 
the inhibition of the deterioration of diabetic nephropathy (DAIS investigators, 2003, 2005), 
confirming that fenofibrate inhibited the deterioration of macro- and micro-angiopathy in 
type II DM.  
2.2.2 Fenofibrate Intervention and Event Lowering in Diabetes Study (FIELD) 
The FIELD is a study to verify the inhibitory effects of fenofibrate on cardiovascular events 
involving approximately 10,000 patients with type II DM (FIELD investigators, 2005). It was 
conducted in Finland, Australia, and New Zealand. The subjects were 9,795 type II diabetics 
with mild dyslipidemia. They were randomly divided into fenofibrate (micronized 
fenofibrate, 200 mg/day, n=4,895) and placebo (n=4,900) groups. Each agent was 
administered for 5 years. 
In the fenofibrate group, this agent inhibited the incidence of coronary events by 11% in 
comparison with the placebo group. Unfortunately, there was no significant difference 
between two groups. This was possibly because statins were combined with the 
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statins, represented by atorvastatin, also inhibit CoQ10 biosynthesis in vivo, leading to the 
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dyslipidemia has recently been emphasized as an independent risk factor for cardiovascular 
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Kodama et al. performed a meta-analysis of 11 clinical studies, and reported that a 1-mg/dL 
increase in the serum uric acid level significantly elevated the relative risk of type II DM by 
1.17-fold (Kodama et al., 2009). Schretlen et al. investigated 96 persons aged 60 to 92 years, 
and indicated that the information-processing capacity and memory were reduced in 
persons with high uric acid level, suggesting that the serum uric acid level may be a 
prognostic factor for dementia (Schretlen et al., 2007). Thus, hyperuricemia may play a role 
not only in the onset of cardiovascular disease but also in the promotion of dementia and 
aging. 
Fenofibrate has been known to reduce the serum levels of lipids and also uric acid 
(Schlesinger et al., 2009). The serum uric acid-reducing action mechanism of fenofibrate, 
independent of lipid-profile changes, involves the promotion of uric-acid excretion (Liamis 
et al., 1999).  
Urate Transporter 1 (URAT1), the target molecule of uric acid-reducing agents such as 
benzbromarone was identified which is responsible for the reabsorption of uric acid in the 
proximal uriniferous tubule (Enomoto et al., 2002). Furthermore, URAT1 inhibition was 
involved in the serum uric acid-reducing action mechanism of fenofibrate (Uetake et al., 
2010). According to their study, the single-dose administration of standard fenofibrate at 300 
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mg to healthy adults decreased the serum uric acid level by approximately 1.5 mg/dL. In 
Japan, fenofibrate has been administered to metabolic syndrome patients with 
hyperuricemia, leading to the decrease in the serum uric acid level by approximately 2 
mg/dL. 
2.2 Randomized controlled trial (RCT) 
Large-scale, randomized, controlled clinical trials of fenofibrate involving type II DM, that 
is, high-risk patients for arteriosclerosis, were conducted. The representative 3 studies were 
reviewed in this section: “DAIS” study, regarding coronary arteriosclerosis retraction, 
“FIELD” study, in which the inhibitory effects on cardiovascular events were examined, and 
“ACCORD” study, in which the inhibitory effects of lipid-intensified therapy with statins on 
cardiovascular events were investigated. 
2.2.1 Diabetes Atherosclerosis Intervention Study (DAIS) 
The DAIS is a placebo-controlled, double-blind, comparative study to verify whether the 
deterioration of coronary arteriosclerosis can be prevented by restoring abnormal lipid 
metabolism with fenofibrate in type II diabetics employing quantitative coronary 
angiography (DAIS investigators, 2001). This international, interventional study was 
conducted based on the World Health Organization (WHO)’s request and cooperation. 
This study is the first interventional study in which it was prospectively evaluated 
whether the correction of disturbance of lipid metabolism in type II DM prevents the 
deterioration of arteriosclerosis. It was carried out in Canada, Finland, Sweden, and 
France. Four-hundred and eighteen patients with type II diabetes in whom blood sugar 
control was favourable were randomly divided into fenofibrate (micronized fenofibrate, 
200 mg/day, n=207) and placebo (n=211) groups to evaluate the deterioration of coronary 
arteriosclerosis using quantitative coronary angiography after 38-month (mean duration) 
administration. 
In the fenofibrate group, a decrease in the minimum lumen diameter and an increase in the 
percent stenosiswere significantly suppressed in comparison with the placebo group (by 
40%), confirming the inhibitory effects of fenofibrate on the deterioration of coronary 
arteriosclerosis in type II DM.  
In the continuing study of DAIS, fenofibrate reduced the small dense LDL level, leading to 
the inhibition of the deterioration of diabetic nephropathy (DAIS investigators, 2003, 2005), 
confirming that fenofibrate inhibited the deterioration of macro- and micro-angiopathy in 
type II DM.  
2.2.2 Fenofibrate Intervention and Event Lowering in Diabetes Study (FIELD) 
The FIELD is a study to verify the inhibitory effects of fenofibrate on cardiovascular events 
involving approximately 10,000 patients with type II DM (FIELD investigators, 2005). It was 
conducted in Finland, Australia, and New Zealand. The subjects were 9,795 type II diabetics 
with mild dyslipidemia. They were randomly divided into fenofibrate (micronized 
fenofibrate, 200 mg/day, n=4,895) and placebo (n=4,900) groups. Each agent was 
administered for 5 years. 
In the fenofibrate group, this agent inhibited the incidence of coronary events by 11% in 
comparison with the placebo group. Unfortunately, there was no significant difference 
between two groups. This was possibly because statins were combined with the 
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placebo/fenofibrate in 32% of patients receiving the placebo and in 16% of patients 
receiving fenofibrate, reducing the effects of fenofibrate alone. Fenofibrate decreased the 
incidence of non-fatal myocardial infarction by 24% (p<0.05) and that of total cardiovascular 
events by 11% (p<0.05), confirming its efficacy.  
In primary prevention patients without a history of cardiovascular disease, accounting for 
approximately 80%, fenofibrate significantly inhibited the incidences of coronary (by 25%) 
and total cardiovascular (by 19%) events in comparison with the placebo group. 
Furthermore, in the FIELD, fenofibrate inhibited the onset of diabetic nephropathy, 
deterioration of diabetic retinopathy, proportion of patients undergoing lower-limb 
amputation, and deterioration of diabetic neuropathy (FIELD investigators, 2005, 2007, 2009, 
2010, 2011). As fenofibrate reduced DM-associated 3 major complications (retinopathy, 
nephropathy and neuropathy), this agent may be useful for treating diabetic complications. 
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Table 1. Inhibitory effects of fenofibrate on diabetic angiopathy in a large-scale clinical study 
involving type II DM 
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2.2.3 ACCORD-Lipid & ACCORD-EYE study 
In the ACCORD-Lipid study, the inhibitory effects of 3 intensified/standard medicinal 
therapies (blood sugar, blood pressure, lipids) on compound cardiovascular events were 
investigated in approximately 10,000 type II diabetics with mild dyslipidemia and the high 
risk of cardiovascular disease (CVD) under the auspices of the National Institutes of Health 
(NIH). Lipid intervention was performed in 5,518 patients: intensified (simvastatin 20mg + 
micronized fenofibrate 200mg) and standard (simvastatin 20mg + placebo) therapies. The 
mean follow-up was 4.7 years. In the fenofibrate-combined group, the incidence of 
cardiovascular events was inhibited by 8%, although there was no significant difference. In 
patients with a pre-treatment TG level of 204 mg/dL or more and HDL-C level of 34 mg/dL 
or less, significant inhibitory effects on events were confirmed (-31% (p<0.05), NNT=20) 
(ACCORD Study Group et al., 2010). 
In the ACCORD–EYE study, the deterioration of diabetic retinopathy was evaluated in 2,856 
patients from whom informed consent was obtained (lipid intervention: 1,593 patients) 
among type II DM who participated in the ACCORD-Lipid study (ACCORD Study Group; 
ACCORD Eye Study Group et al., 2010). In the fenofibrate-combined group, intensified 
therapy significantly inhibited the deterioration of diabetic retinopathy (by 40%) in 
comparison with the simvastatin group (p=0.006). The ACCORD–EYE study, the second 
large-scale clinical study following the FIELD, demonstrated the inhibitory effects of 
fenofibrate on the deterioration of diabetic retinopathy, supporting its efficacy for diabetic 
retinopathy. 
The inhibitory effects of fenofibrate on diabetic microangiopathy are summarized below 
(Table 1). In a large-scale clinical study of lipid-lowering agents, no statin exhibited any 
inhibitory effects on diabetic microangiopathy. Only fenofibrate inhibited the complication. 
Thus, fenofibrate should be recognized as a “prophylactic drug for diabetic complications”, 
and not solely as a lipid-lowering agent. 
3. Conclusion 
Fenofibrate is a generalized, PPAR-α-mediated, serum lipid-lowering agent. In this chapter, 
the pleiotropic effects of fenofibrate other than serum lipid-lowering actions were primarily 
reviewed. Concerning to the anti-inflammatory actions, we examined the effects of 
fenofibrate in patients with a representative inflammatory disorder, RA. Although there 
were no significant changes in inflammation parameters including CRP and ESR, 
improvement in the ΔVAS and PSL dose was achieved in patients receiving fenofibrate. In 
particular, improvement in the ΔVAS was significantly correlated with a reduction in the 
ΔCRP level, suggesting that the anti-inflammatory effects of fenofibrate may contribute the 
improvement in the patient’s quality of life (QOL).  
In Japan, infectious diseases have been the major causes of death in patients with RA 
(Souen, 2007; Shinomiya et al., 2008). However, the proportion of cardiovascular events 
represented by cerebral/myocardial infarction has been increasing, probably because of the 
changes in life-style (Goto et al., 2008a). So, fenofibrate with lipid-lowering, anti-
inflammatory and anti-oxidant actions may be appropriate for reducing disturbances of 
lipid metabolism and also homeostasis in Japanese patients with RA. 
With respect to antioxidant actions, fenofibrate, but not statin increased the plasma level of 
ubiquinol-10: a family of CoQ10. As fenofibrate exhibits antioxidant actions, combination 
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represented by cerebral/myocardial infarction has been increasing, probably because of the 
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inflammatory and anti-oxidant actions may be appropriate for reducing disturbances of 
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With respect to antioxidant actions, fenofibrate, but not statin increased the plasma level of 
ubiquinol-10: a family of CoQ10. As fenofibrate exhibits antioxidant actions, combination 
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therapy with fenofibrate and statins may be useful for achieving anti-aging effects and 
reducing oxidative stress. However, the evaluation methods for antioxidant activity in 
human should be strictly reviewed in the near future. 
The serum uric acid-reducing actions of fenofibrate are regarded as one of its characteristic 
pleiotropic effects. The action mechanism may be mediated by a uric acid transporter, 
URAT1, but not by PPAR-. This may suggest that among fibrate preparations fenofibrate 
may be favorably administered to the patients with high serum TG and high uric acid levels, 
as no other fibrate preparations can reduce the serum level of uric acid. 
The large-scale clinical study of fenofibrate (FIELD) showed that early administration to 
“primary prevention” diabetics without a history of cardiovascular events inhibited the 
onset of cardiovascular events. Furthermore, the DAIS, FIELD, and ACCORD-EYE studies 
suggested that early fenofibrate administration to all diabetics with dyslipidemia should 
inhibit the deterioration of diabetic complications regardless of the duration of disease or 
risk of events. 
Fenofibrate shows pleiotropic actions, especially a variety of clinical effects that may not be 
achieved by statins. This agent may be useful for inhibiting the deterioration of 
arteriosclerosis, and may play a role as an anti-aging panacea if properly used. 
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therapy with fenofibrate and statins may be useful for achieving anti-aging effects and 
reducing oxidative stress. However, the evaluation methods for antioxidant activity in 
human should be strictly reviewed in the near future. 
The serum uric acid-reducing actions of fenofibrate are regarded as one of its characteristic 
pleiotropic effects. The action mechanism may be mediated by a uric acid transporter, 
URAT1, but not by PPAR-. This may suggest that among fibrate preparations fenofibrate 
may be favorably administered to the patients with high serum TG and high uric acid levels, 
as no other fibrate preparations can reduce the serum level of uric acid. 
The large-scale clinical study of fenofibrate (FIELD) showed that early administration to 
“primary prevention” diabetics without a history of cardiovascular events inhibited the 
onset of cardiovascular events. Furthermore, the DAIS, FIELD, and ACCORD-EYE studies 
suggested that early fenofibrate administration to all diabetics with dyslipidemia should 
inhibit the deterioration of diabetic complications regardless of the duration of disease or 
risk of events. 
Fenofibrate shows pleiotropic actions, especially a variety of clinical effects that may not be 
achieved by statins. This agent may be useful for inhibiting the deterioration of 
arteriosclerosis, and may play a role as an anti-aging panacea if properly used. 
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1. Introduction 
Statins are common lipid lowering agents to reduce elevation of cholesterol or as 
prophylaxis against other cardiac diseases. It estimated that 62.5% to 91.7% of dyslipidemic 
patients in United State of America are using statins1 These agents widely used among 
cardiovascular patients in Malaysia2. In other countries, for example in UK, it has found that 
most patients who use statins are older than 35 years old and more of them are males 
(56%)3. In Canada, about 90% of cardiac patients are using statin, while in US, at least one 
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Cross-sectional with convenient sampling study conducted for volunteer outpatients from 
the cardiac clinic of Penang Hospital in Pulau Pinang State of Malaysia. Study protocol was 
approved by Clinical Research Committee of Penang General Hospital, and signed consent 
forms were obtained from all participants. The patients included in this study were at least 
18 years old and voluntarily to participate in this study. They have to used statins and could 
understand Malay Language (the National Language of Malaysia) or English Language, 
since Malaysia is a multiracial country. Patients who allergies to statin, pregnant or lactating 
women, or changing in types or dosage of statin used were excluded from this study. These 
types of patients excluded because their conditions may affected outcomes of the study. The 
study period was 5 months, and 1900 patients presented in the cardiac clinic within this 
study period. Depending on inclusion and exclusion criteria, 500 patients voluntarily agreed 
to participate in this study. A validated questionnaire form (Cronbach’s alpha is 0.853) were 
used for reporting of ADRs. The patients were asked whether they have experience of 
common statin-related ADRs while they were on statin therapy and give their answers on 
the self-report questionnaire forms. This questionnaire form has some questions on 
demographic data and undesired symptoms that patients had during statin therapy. There 
were 27 ADRs of statin listed in the questionnaire form. They were required to tick yes or no 
on these listed ADRs. They can tick more than one ADR. In order to ensure these ADRs 
really related with statin therapy these patients had to indicate in the questionnaire form 
that these ADRs occurred while they were receiving statin therapy and these symptoms 
should continuously occurred at least for 3 months.  
3. Statistics 
Statistical Package for Social Science software (SPSS) version 18 used to analyze the data for 
this study. Odd ratio and Chi-square and logistic regression tests were used to ensure these 
ADRs were related with stain therapy and to determine their predictors. The results with p 
value less than 0.05 was considered statistically significant.  
4. Results 
Male patients (70%) were the more frequent users of statins, with mean age 60±10 years. The 
most frequent race that used statins was Chinese (37.6%), followed by Malays (34.4%), 
Indians (26.6%) and foreigners (1.4%). Small numbers of patients were cigarette smoker 
(12%) and alcohol consumers (9%).  
Higher number of patients had dyslipidemia with primary type (51.5%) based on the 
Friedewald et al18 and Stone et al19 classifications. For primary subtypes of dyslipidemia, the 
most common subtype was IIa (50.6%), while common subtype of secondary dyslipidemia 
was diabetes (86.3%). The common type of statin used was lovastatin (81%), followed by 
simvastatin (9.4%) and atorvastatin (8%). The low dose (20 mg) of statin was the common 
prescribed to these patients. The mean duration of statin therapy was 3.5 years and the most 
frequent range of duration was 1-5 years (52.5%), as shown in Table 1.  
Statistical regression analysis was used to exclude symptoms related to other medications 
and diseases. It found only few symptoms from 27 ADRs that correlated significantly with 
statins were; fatigue (59.4%), muscle pain (53.6%), joint pain (53.4%), back pain (47.8%), 
insomnia (44.8%) and visual disturbances (44.2%).  
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Demographics Variables  No (%) 
Gender  Male  351 (70%) 
Female  149 (30%) 
Race  Malay  172 (34.4%) 
Chinese  188 (37.6%) 
Indian  133 (26.6%) 
Foreign 7 (1.4%) 
Age (mean 60±10)year 28-50 year 94 (19%) 
51-65 year 258 (51%) 
66-92 year 148 (30%) 
Smoke  Yes  59 (12%) 
No  441 (88%) 
Alcohol consuming  Yes  47 (9%)  
No  453 (91%) 
Dyslipidiemia type  Primary  247 (51.5%) 
Secondary  233 (48.5%) 
Primary dyslipidemia 
subtype  
I 13 (5.3%) 
IIa 125 (50.6%) 
IIb 59 (23.9%) 
III 7 (2.8%) 
IV 32 (13%) 
V 11 (4.5%) 
Secondary 
dyslipidemia subtype 
Renal  17 (7.3%) 
Diabetes  201 (86.3%) 
Nephrotic syndrome  1 (0.4%) 
Liver  1 (0.4%) 
Drugs 2 (0.9%) 
Hypothyroidism  11 (4.7%) 
Type of statin Atorvastatin  40 (8%) 
Simvastatin  47 (9.4%) 
Lovastatin  405 (81%) 
others 8 (1.6) 
Combination therapy  Yes  35 (7%) 
No  465 (93%) 
Duration of therapy 
Mean (3.5±3.0) year 
3months or less 16 (3.2%) 
3months -1 year 133 (26.7%) 
 1-5 years 262 (52.5%) 
5-20 years 89 (17.6%) 
Table 1. Demographic data of 500 cardiac outpatients in Penang General Hospital 
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Table 2. Relationship between statin related ADRs and predictors 
In term of predictor, females significantly had joint pain (61.74%, OR = 1.864) and back pain 
(56.38%, OR = 1.73). However, there was no significant relation between gender with 
fatigue, muscle pain, insomnia and visual disturbance. Indian patients had significantly 
higher incidence of fatigue (68.42%, OR= 1.81), muscle pain (66.92%, OR =1.94), back pain 
(62.4 %, OR = 2.18), and visual disturbances (49.62 %, OR = 1.738) when compared to other 
races. No significant relationship found between smoking and statin related-ADRs. Patients 
who consumed alcohol significantly had fatigue (76.6%, OR = 3.0), back pain (65.96%, OR = 
3.584) and insomnia (59.57%, OR = 2.893). Age was without effect on incidence of statin 
related-ADRs. Patients used statins for more than 5 years significantly had fatigue (53.41%, 
OR = 1.83) and muscle pain (60.23%, OR =1.958), as shown in Table 2. 
For secondary dyslipidemia types, renal induced dyslipidemia significantly caused higher 
incidence of insomnia when compared to the other secondary subtypes (64.71%, OR = 3.7). 
For subtypes of primary dyslipidemia, subtype IIb patients had significantly back pain 
(81.82%, OR = 2.5).  
No significant relationship found between statin related-ADRs and statin types, the patients 
used simvastatin had a higher incidence of fatigue (65.96%), joint pain (57.45%), back pain 
(55.32%) and visual disturbance (53.19%). Patients used lovastatin had insomnia (45.68%), 
while patients used atorvastatin had higher incidence of muscle pain (52.17%). No 
significant relationship found between doses of statins and other ADRs except for lovastatin 
dose. Patients used 60 mg dose of lovastatin had significantly fatigue than patients used 
lower doses (72.73%, OR = 1.904). No significant relation found between the combination 
with other lipid lowering agents and incidence of ADRs (as shown in Table 2).  
5. Discussion 
After two decades of statin marketing, significant incidences of adverse drug reactions still 
presented during therapy. Number of studies of medications' ADRs always increased after 
first years of launching, but it found this matter is different with type of statin used20. Most 
of previous studies focused on serious ADRs of statin like muscle toxicity, elevation of liver 
enzymes, renal toxicity and polyneuropathy21,22. Although serious ADRs caused mortalities 
and death to patients, but their incidences are lower than other adverse reactions of statin 
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symptomatic related ADRs. Kashani A. et al. 23 found that incidences of patients 
discontinued their therapy because of symptomatic ADRs of statin (5.6%) were higher than 
patients had rhabdomyolysis (0.2%), hepatotoxicity (1.4%), and creatine kinase (CK) 
elevations (0.9%). Therefore, self-reporting of ADRs are useful to determine and predict the 
toxicities induced by medication24. There are few studies done on the common statin-related 
ADRs that use patient self-report. There was a previous study that focused on the common 
ADRs during statin therapy and their predictors in cardiac outpatients. They reported the 
use of a self-report questionnaire form is suitable approach to assess the common undesired 
symptoms found during statin therapy25. In the real-life practice, doctors are more focusing 
on dyslipidemia and its complications than statin-related ADRs of their patients. 
Furthermore, self-report approach allows the patients to express directly their unwanted 
problems associated with statin therapy. In addition, patients sometimes feel uncomfortable 
or inappropriate telling their doctor about these undesired symptoms of statin26,27. The 
finding in this study showed a higher incidence of fatigue and muscle pain in this cardiac 
outpatients setting, which consistent with previous studies8,10.  
In this study, females reported having back and joint pain significantly more than males did. 
Female patients are more sensitive to ADRs than males possibly because of pharmacokinetic 
and pharmacodynamic differences between genders28. Not all ADRs of statin related to 
gender, this finding supported by FDA, Bayer reports and previous studies29-32. When 
compared to other races, Indian patients had significantly higher incidence of some common 
ADRs (fatigue, muscle pain, back pain and visual disturbance). This is because genetics also 
has contributed in adverse drug reactions23. This result was supported by FDA reports in 
which ADRs were different among races7. Cigarette smokers had increased incidence of 
these ADRs than nonsmokers, however this finding was not statistically significant. Alcohol 
consumers had significant problems with fatigue, back pain and insomnia, and increased 
incidence of ADRs in general30. This is because alcohol causes mitochondrial dysfunction, 
which would increase the risk of muscle disorders caused by statins33. There was no 
relationship between age and ADRs, as shown in Table 2, which supported by Kucukarslan 
et al study34. There was a relationship between duration of statin used and ADRs in 
previous studies29,35,36. Their finding were consistent with this present finding, where the 
duration of statin therapy has related to fatigue, muscle pain and back pain.  
Based on our knowledge, no previous studies reported the relationship between 
dyslipidemia types and the common ADRs. Significant relationship was found in this study 
between dyslipidemia type (primary and secondary) and common ADRs. Patients who had 
secondary dyslipidemia type had increase frequency of insomnia than with primary type. 
Patients with subtype IIb and renal induced dyslipidemia were significantly more likely to 
have back pain and insomnia than other subtypes.  
Although statins differ in their pharmacokinetic properties37,38, there is no significant 
relationship found between statin types and common ADRs. However, simvastatin was 
more likely to cause fatigue, joint pain, back pain and visual disturbance than other statins. 
Although there is no significant relation found between atorvastatin and common ADRs. 
Atorvastatin found to cause muscle pain more often than other statin types, this finding also 
proved by Clearfield et al. and Golomb et al. 10,11. Patients on lovastatin therapy had higher 
incidence of insomnia than other types of statin. Higher doses for all types of statins have 
resulted in a higher incidence of ADRs. The higher dose of lovastatin (60 mg) significantly 
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associated with fatigue. The dose of statins used did not have significant relationship with 
other symptoms of common ADRs. This result is consistent with other studies12,39. Finally, 
there was no significant relationship between combination therapy and ADRs. This 
relationship could not be seen possibly due to small number of patients receiving more than 
one type of antilipidemic agent. 
The finding of this study showed that significant number of patients feel undesired effects of 
statin therapy and their predictors. Adjustment or manipulating of these preventable 
predictors such as to change type of statin used, reduce dose and duration are 
recommended to the prescribers. For example, based on the odd ratio, fatigue was the 
highest for patients who are alcohol consumers, followed by lovastatin dosage, duration and 
race. Therefore, steps needed to reduce the incidence of fatigue by avoiding or reducing the 
preventable predictors that related to these common ADRs like cessation of alcohol and 
changing in type or dose of statin used.  
6. Conclusion 
This paper explained that significant number of cardiac outpatients were experienced 
common ADRs related-statin through self-report approach and their predictors. Common 
ADRs of statin were fatigue, muscle pain, joint pain, back pain, insomnia and visual 
disturbances. The main predictors or contributing factors of common statin-related ADRs 
were gender, race, alcohol consumption, duration of statin used, renal induced-secondary 
dyslipidemia, subtype IIb of primary dyslipidemia and lovastatin dose. These predictors are 
useful in clinical practice to determine the likelihood of ADRs and to manage the common 
ADRs of statin in cardiac outpatients. Finding from this study was suggested appropriate 
dose and type of statin use and also adjustment of the preventable predictors may minimize 
common ADRs of statin in cardiac outpatients. Appropriate prospective study design with 
multicenter sites recommended determining the actual effects of these preventable 
predictors on common ADRs of statin. 
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associated with fatigue. The dose of statins used did not have significant relationship with 
other symptoms of common ADRs. This result is consistent with other studies12,39. Finally, 
there was no significant relationship between combination therapy and ADRs. This 
relationship could not be seen possibly due to small number of patients receiving more than 
one type of antilipidemic agent. 
The finding of this study showed that significant number of patients feel undesired effects of 
statin therapy and their predictors. Adjustment or manipulating of these preventable 
predictors such as to change type of statin used, reduce dose and duration are 
recommended to the prescribers. For example, based on the odd ratio, fatigue was the 
highest for patients who are alcohol consumers, followed by lovastatin dosage, duration and 
race. Therefore, steps needed to reduce the incidence of fatigue by avoiding or reducing the 
preventable predictors that related to these common ADRs like cessation of alcohol and 
changing in type or dose of statin used.  
6. Conclusion 
This paper explained that significant number of cardiac outpatients were experienced 
common ADRs related-statin through self-report approach and their predictors. Common 
ADRs of statin were fatigue, muscle pain, joint pain, back pain, insomnia and visual 
disturbances. The main predictors or contributing factors of common statin-related ADRs 
were gender, race, alcohol consumption, duration of statin used, renal induced-secondary 
dyslipidemia, subtype IIb of primary dyslipidemia and lovastatin dose. These predictors are 
useful in clinical practice to determine the likelihood of ADRs and to manage the common 
ADRs of statin in cardiac outpatients. Finding from this study was suggested appropriate 
dose and type of statin use and also adjustment of the preventable predictors may minimize 
common ADRs of statin in cardiac outpatients. Appropriate prospective study design with 
multicenter sites recommended determining the actual effects of these preventable 
predictors on common ADRs of statin. 
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Dyslipidemia has a complex pathophysiology consisting of various genetic, lifestyle, and 
environmental factors. It has many adverse health impacts, notably in the development 
of chronic non-communicable diseases. Significant ethnic differences exist due to the 
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well as changes in lifestyle and environmental factors will make dyslipidemia a global 
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